<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD001867.pub2" GROUP_ID="ADDICTN" ID="023899072215325039" MERGED_FROM="" MODIFIED="2010-10-18 09:15:57 +0200" MODIFIED_BY="Laura Amato" REVIEW_NO="" REVMAN_SUB_VERSION="5.0.25" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="11.0">
<COVER_SHEET MODIFIED="2010-10-18 09:04:48 +0200" MODIFIED_BY="Laura Amato">
<TITLE MODIFIED="2008-08-16 14:58:51 +0200" MODIFIED_BY="[Empty name]">Opioid antagonists for alcohol dependence</TITLE>
<CONTACT>
<PERSON ID="4E40049882E26AA201AFF0120850B0DA" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Susanne</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Rösner</LAST_NAME>
<SUFFIX/>
<POSITION>Psychologist</POSITION>
<EMAIL_1>susanne.roesner@med.uni-muenchen.de</EMAIL_1>
<EMAIL_2>susan.roesner@web.de</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Psychiatric Hospital</DEPARTMENT>
<ORGANISATION>University of Munich</ORGANISATION>
<ADDRESS_1>Nußbaumstr. 7</ADDRESS_1>
<ADDRESS_2/>
<CITY>Munich</CITY>
<ZIP>80336</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>0049 (0)89 5160 5387</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CONTACT>
<CREATORS MODIFIED="2010-07-20 09:41:56 +0200" MODIFIED_BY="Susanne Rösner">
<PERSON ID="4E40049882E26AA201AFF0120850B0DA" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Susanne</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Rösner</LAST_NAME>
<SUFFIX/>
<POSITION>Psychologist</POSITION>
<EMAIL_1>susanne.roesner@med.uni-muenchen.de</EMAIL_1>
<EMAIL_2>susan.roesner@web.de</EMAIL_2>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Psychiatric Hospital</DEPARTMENT>
<ORGANISATION>University of Munich</ORGANISATION>
<ADDRESS_1>Nußbaumstr. 7</ADDRESS_1>
<ADDRESS_2/>
<CITY>Munich</CITY>
<ZIP>80336</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>0049 (0)89 5160 5387</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="71686423079288857512091120102118" ROLE="AUTHOR">
<PREFIX/>
<FIRST_NAME>Andrea</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Hackl-Herrwerth</LAST_NAME>
<SUFFIX/>
<POSITION>Psychologist</POSITION>
<EMAIL_1>andrea.m.hackl@gmx.net</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT>
<ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION>
<ADDRESS_1>Möhlstr. 26</ADDRESS_1>
<ADDRESS_2/>
<CITY>München</CITY>
<ZIP>81675</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>0049 (0) 89 4140 4249</PHONE_1>
<PHONE_2/>
<FAX_1/>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="D3501EE082E26AA20080535F42019853" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Stefan</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Leucht</LAST_NAME>
<SUFFIX/>
<POSITION>Oberarzt</POSITION>
<EMAIL_1>Stefan.Leucht@lrz.tu-muenchen.de</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Klinik und Poliklinik für Psychiatrie und Psychotherapie</DEPARTMENT>
<ORGANISATION>Technische Universität München Klinikum rechts der Isar</ORGANISATION>
<ADDRESS_1>Möhlstr. 26</ADDRESS_1>
<ADDRESS_2/>
<CITY>München</CITY>
<ZIP>81675</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49-89-4140 ext: 4249</PHONE_1>
<PHONE_2/>
<FAX_1>+49-89-4140-4888</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="11551" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Simona</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Vecchi</LAST_NAME>
<SUFFIX/>
<POSITION>Research worker</POSITION>
<EMAIL_1>vecchi@asplazio.it</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Epidemiology</DEPARTMENT>
<ORGANISATION>ASL RM/E</ORGANISATION>
<ADDRESS_1>Via di Santa Costanza, 53</ADDRESS_1>
<ADDRESS_2/>
<CITY>Rome</CITY>
<ZIP>00198</ZIP>
<REGION/>
<COUNTRY CODE="IT">Italy</COUNTRY>
<PHONE_1>39 0683060421</PHONE_1>
<PHONE_2/>
<FAX_1>39 0683060374</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="17151" ROLE="AUTHOR">
<PREFIX>Dr</PREFIX>
<FIRST_NAME>Manit</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Srisurapanont</LAST_NAME>
<SUFFIX/>
<POSITION>Professor of Psychiatry and Head of Department of Psychiatry</POSITION>
<EMAIL_1>msrisura@mail.med.cmu.ac.th</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Department of Psychiatry, Faculty of Medicine</DEPARTMENT>
<ORGANISATION>Chiang Mai University</ORGANISATION>
<ADDRESS_1>P.O. Box 102</ADDRESS_1>
<ADDRESS_2>Amphur Muang</ADDRESS_2>
<CITY>Chiang Mai</CITY>
<ZIP>50200</ZIP>
<REGION/>
<COUNTRY CODE="TH">Thailand</COUNTRY>
<PHONE_1>+66 53 945422</PHONE_1>
<PHONE_2/>
<FAX_1>+66 53 217144</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
<PERSON ID="8A992A7082E26AA200D45F892BEB5B30" ROLE="AUTHOR">
<PREFIX>Prof</PREFIX>
<FIRST_NAME>Michael</FIRST_NAME>
<MIDDLE_INITIALS/>
<LAST_NAME>Soyka</LAST_NAME>
<SUFFIX/>
<POSITION>Psychiatrist; Clinical Director</POSITION>
<EMAIL_1>Michael.Soyka@privatklinik-meiringen.ch</EMAIL_1>
<EMAIL_2/>
<URL/>
<MOBILE_PHONE/>
<ADDRESS>
<DEPARTMENT>Psychiatric Hospital</DEPARTMENT>
<ORGANISATION>University of Munich</ORGANISATION>
<ADDRESS_1>Nußbaumstr. 7</ADDRESS_1>
<ADDRESS_2/>
<CITY>Munich</CITY>
<ZIP>80336</ZIP>
<REGION/>
<COUNTRY CODE="DE">Germany</COUNTRY>
<PHONE_1>+49 89 360804-73</PHONE_1>
<PHONE_2>+41 972 82 90</PHONE_2>
<FAX_1>+41 972 82 91</FAX_1>
<FAX_2/>
</ADDRESS>
<FOOTNOTE/>
</PERSON>
</CREATORS>
<DATES MODIFIED="2010-10-18 09:04:48 +0200" MODIFIED_BY="Laura Amato">
<UP_TO_DATE>
<DATE DAY="9" MONTH="10" YEAR="2010"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="31" MONTH="1" YEAR="2010"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="28" MONTH="4" YEAR="2010"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="3" YEAR="1999"/>
<REVIEW_PUBLISHED ISSUE="3" YEAR="2000"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2005"/>
</DATES>
<WHATS_NEW MODIFIED="2010-10-15 13:54:29 +0200" MODIFIED_BY="Laura Amato">
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS" MODIFIED="2010-10-08 13:50:05 +0200" MODIFIED_BY="Laura Amato">
<DATE DAY="8" MONTH="10" YEAR="2010"/>
<DESCRIPTION>
<P>conclusion changed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2010-10-08 13:49:34 +0200" MODIFIED_BY="Laura Amato">
<DATE DAY="8" MONTH="10" YEAR="2010"/>
<DESCRIPTION>
<P>New authors, new searches, new studies</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</WHATS_NEW>
<HISTORY MODIFIED="2010-10-15 13:54:29 +0200" MODIFIED_BY="Laura Amato">
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-10-15 13:54:29 +0200" MODIFIED_BY="Laura Amato">
<DATE DAY="9" MONTH="3" YEAR="2010"/>
<DESCRIPTION>
<P>comments from authors included</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2008-08-18 15:37:11 +0200" MODIFIED_BY="Susanne Rösner">
<INTERNAL_SOURCES MODIFIED="2008-08-18 15:36:39 +0200" MODIFIED_BY="Susanne Rösner">
<SOURCE MODIFIED="2008-08-16 10:50:03 +0200" MODIFIED_BY="[Empty name]">
<NAME>Ludwig Maximilian University of Munich</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION>
<P>provision of infrastructure and related services</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2008-08-16 10:50:14 +0200" MODIFIED_BY="[Empty name]">
<NAME>Technical University of Munich</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION>
<P>provision of infrastructure and related services</P>
</DESCRIPTION>
</SOURCE>
<SOURCE MODIFIED="2008-08-18 15:36:39 +0200" MODIFIED_BY="Susanne Rösner">
<NAME>Chiang Mai University</NAME>
<COUNTRY CODE="TH">Thailand</COUNTRY>
<DESCRIPTION>
<P>provision of infrastructure and related services</P>
</DESCRIPTION>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2008-08-18 15:37:11 +0200" MODIFIED_BY="Susanne Rösner">
<SOURCE MODIFIED="2008-08-18 15:37:11 +0200" MODIFIED_BY="Susanne Rösner">
<NAME>Federal Ministry of Education and Research</NAME>
<COUNTRY CODE="DE">Germany</COUNTRY>
<DESCRIPTION>
<P>financial support / salary</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2010-10-18 09:07:58 +0200" MODIFIED_BY="Laura Amato">
<SUMMARY MODIFIED="2010-08-01 11:44:25 +0200" MODIFIED_BY="[Empty name]">
<TITLE MODIFIED="2010-01-15 11:17:12 +0100" MODIFIED_BY="[Empty name]">Naltrexone and nalmefene for alcohol dependent patients</TITLE>
<SUMMARY_BODY MODIFIED="2010-08-01 11:44:25 +0200" MODIFIED_BY="[Empty name]">
<P>Alcohol dependence is a chronic disease, which can develop when alcohol is heavily used over longer periods of time. Alcohol affects various brain regions, including the opioid receptor system, which mediates euphoric and pleasurable effects of alcohol. By blocking alcohol effects at these receptors, the opioid antagonists naltrexone and nalmefene can reduce alcohol "liking" and "craving" and thus support alcohol dependent patients in cutting down their drinking. 50 studies with 7793 participants were included in the review, in most studies treatment was provided over a period of three months. The review shows that more patients who took naltrexone were able to reduce the amount and frequency of drinking than those who took an identical appearing, but inert substance (placebo). On average, one out of nine patients was helped by naltrexone. Naltrexone does not have serious side effects, but gastrointestinal symptoms like nausea, stomach pain and loss of appetite are common. Some patients also get tired from naltrexone. For injectable formulations of naltrexone, which can be advantageous for patients who have problems with taking their medication on schedule, and the second opioid antagonist nalmefene, the database is still too sparse to allow final conclusions. Nevertheless, the available studies indicate that these drugs might have comparable effects on drinking than oral naltrexone has. Naltrexone does not cause dependency and unlike disulfiram, another medicine that is sometimes used to treat alcohol dependence, it does not make patients feel sick if they drink alcohol while taking it.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2010-10-15 14:01:34 +0200" MODIFIED_BY="Laura Amato">
<ABS_BACKGROUND MODIFIED="2010-07-30 09:44:39 +0200" MODIFIED_BY="[Empty name]">
<P>Alcohol dependence belongs to the globally leading health risk factors. Therapeutic success of psychosocial programs for relapse prevention is moderate and could be increased by an adjuvant treatment with the opioid antagonists naltrexone and nalmefene.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2010-07-30 09:43:29 +0200" MODIFIED_BY="[Empty name]">
<P>To determine the effectiveness and tolerability of opioid antagonists in the treatment of alcohol dependence.</P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2010-10-08 14:43:11 +0200" MODIFIED_BY="Laura Amato">
<P>We searched the Cochrane Drugs and Alcohol Group (CDAG) Specialized Register, PubMed, EMBASE and CINAHL in January 2010 and inquired manufacturers and researchers for unpublished trials.</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2010-10-08 14:35:49 +0200" MODIFIED_BY="Laura Amato">
<P>All double-blind randomised controlled trials (RCTs) which compare the effects of naltrexone or nalmefene with placebo or active control on drinking-related outcomes.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2010-07-31 14:38:31 +0200" MODIFIED_BY="[Empty name]">
<P>Two authors independently extracted outcome data. Trial quality was assessed by one author and cross-checked by a second author. </P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2010-10-15 14:01:34 +0200" MODIFIED_BY="Laura Amato">
<P>Based on a total of 50 RCTs with 7793 patients, naltrexone reduced the risk of heavy drinking to 83% of the risk in the placebo group RR 0.83 (95% CI 0.76 to 0.90) and decreased drinking days by about 4%, MD -3.89 (95% CI -5.75 to -2.04). Significant effects were also demonstrated for the secondary outcomes of the review including heavy drinking days, MD - 3.25 (95% CI -5.51 to -0.99), consumed amount of alcohol, MD - 10.83 (95% CI -19.69 to -1.97) and gamma-glutamyltransferase, MD - 10.37 (95% CI -18.99 to -1.75), while effects on return to any drinking, RR 0.96 (95 CI 0.92 to 1.00) missed statistical significance. Side effects of naltrexone were mainly gastrointestinal problems (e.g. nausea: RD 0.10; 95% CI 0.07 to 0.13) and sedative effects (e.g. daytime sleepiness: RD 0.09; 95% CI 0.05 to 0.14). Based on a limited study sample, effects of injectable naltrexone and nalmefene missed statistical significance. Effects of industry-sponsored studies, RR 0.90 (95% CI 0.78 to 1.05) did not significantly differ from those of non-profit funded trials, RR 0.84 (95% CI 0.77 to 0.91) and the linear regression test did not indicate publication bias (P = 0.765).</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2010-08-01 11:41:50 +0200" MODIFIED_BY="[Empty name]">
<P>Naltrexone appears to be an effective and safe strategy in alcoholism treatment. Even though the sizes of treatment effects might appear moderate in their magnitudes, these should be valued against the background of the relapsing nature of alcoholism and the limited therapeutic options currently available for its treatment.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2010-10-18 09:07:58 +0200" MODIFIED_BY="Laura Amato">
<BACKGROUND MODIFIED="2010-10-08 14:46:22 +0200" MODIFIED_BY="Laura Amato">
<CONDITION MODIFIED="2010-08-01 11:45:41 +0200" MODIFIED_BY="[Empty name]">
<P>Alcohol dependence and alcohol related impairments belong to the most widespread psychiatric disorders (<LINK REF="REF-Alonso-2004" TYPE="REFERENCE">Alonso 2004</LINK>). The one year prevalence of alcohol-use disorders is estimated at 5.2% in the American Region, 5.5% in European countries and at over 10% in Eastern European Regions (<LINK REF="REF-Rehm-2009" TYPE="REFERENCE">Rehm 2009</LINK>). According to the World Health Organisation (<LINK REF="REF-WHO-2002" TYPE="REFERENCE">WHO 2002</LINK>), the misuse of alcohol belongs to the globally leading health risk factors, causing 20&#8211;30% of oesophageal cancer, liver disease, epilepsy, motor vehicle accidents, homicide and other intentional injuries. In the year 2004, 3.8% of all global deaths and 4.6% of global disability-adjusted life-years were attributable to alcohol (<LINK REF="REF-Rehm-2009" TYPE="REFERENCE">Rehm 2009</LINK>). The costs attributable to alcohol consumption are estimated at more than 1% of the gross domestic products in high-income and middle-income countries (<LINK REF="REF-Konnopka-2007" TYPE="REFERENCE">Konnopka 2007</LINK>; <LINK REF="REF-Rehm-2009" TYPE="REFERENCE">Rehm 2009</LINK>). At the same time, alcohol consumption belongs to major potentially avoidable risk factors, underscoring the need for effective strategies to reduce excessive drinking and to maintain abstinence in patients who are dependent on alcohol.</P>
</CONDITION>
<INTERVENTION MODIFIED="2010-08-01 12:38:51 +0200" MODIFIED_BY="[Empty name]">
<P>The treatment of alcohol dependence was exclusively dominated by psychosocial strategies for many decades. Even though elaborated techniques from different theoretical and therapeutical backgrounds have been developed, treatment effects obtained by an exclusive application of psychosocial treatment are limited: A considerable high proportion of patients does not respond to the interventions at all and of those who respond, only a small portion succeeds in maintaining abstinence in a long-term perspective (<LINK REF="REF-Moos-2006" TYPE="REFERENCE">Moos 2006</LINK>). With the investigation of the neurobiological mechanism of alcohol dependence, various pharmacological agents have been examined in their potential to support alcohol dependent patients in achieving abstinence or in cutting down their alcohol consumption. Some of these agents showed promising effects in first small size trials, which were not confirmed by multicenter trials. Two substances were repeatedly shown to be effective: The glutamate-antagonist <I>acamprosate </I>and the opioid antagonist <I>naltrexone. </I>
</P>
<P>Naltrexone is a competitive antagonists for mu-opioid receptors (<LINK REF="REF-Preston-1993" TYPE="REFERENCE">Preston 1993</LINK>), originally used for the treatment of opioid dependence to prevent a relapse to opioid use after heroin detoxification and to treat accidental heroin overdose. In animal models of alcohol dependence, naltrexone was shown to decrease the alcohol intake under free-choice conditions (e.g. <LINK REF="REF-Altshuler-1980" TYPE="REFERENCE">Altshuler 1980</LINK>; <LINK REF="REF-Ulm-1995" TYPE="REFERENCE">Ulm 1995</LINK>) and to prevent the development of a conditioned place preference for alcohol (<LINK REF="REF-Matsuzawa-1999" TYPE="REFERENCE">Matsuzawa 1999</LINK>; <LINK REF="REF-Middaugh-2000" TYPE="REFERENCE">Middaugh 2000</LINK>), indicating that the opioid antagonist does not only block the immediate release of endorphins and dopamine, but also influences conditioned processes induced by drinking-associated stimuli, known as "conditioned high" (<LINK REF="REF-Childress-1986" TYPE="REFERENCE">Childress 1986</LINK>).</P>
<P>Effects of naltrexone on drinking were less consistent in animal studies, which tested the effectiveness of naltrexone to suppress the "alcohol deprivation effect" - a phenomena that describes the temporary increase in voluntary alcohol intake, observed during a reinstated access to alcohol after a period of deprivation. While in the trial of <LINK REF="REF-Heyser-2003" TYPE="REFERENCE">Heyser 2003</LINK>, naltrexone was shown to diminish this effect, some evidence indicates that naltrexone given during abstinence even increased subsequent drinking (<LINK REF="REF-Sinclair-2001" TYPE="REFERENCE">Sinclair 2001</LINK>). <LINK REF="REF-Holter-1999" TYPE="REFERENCE">Holter 1999</LINK> found that the effects are mediated by the treatment regimen, with low dose and intermittent treatment causing a reduction in ethanol intake, while chronic treatment can increase the ethanol preference during and after alcohol deprivation.</P>
<P>Until today, various clinical studies have been conducted, with the majority of trials demonstrating the superiority of opioid antagonists compared to placebo. Nevertheless, patients have been shown to strongly differ in their responsiveness to naltrexone; to explain these differences, a polymorphism in the mu-opioid receptor gene (OPRM1) has been identified as a predictor of response (<LINK REF="REF-Oslin-2003" TYPE="REFERENCE">Oslin 2003</LINK>; <LINK REF="REF-Anton-2008" TYPE="REFERENCE">Anton 2008</LINK>), while a further analysis of clinical data could not find such an association (<LINK REF="REF-Gelernter-2007" TYPE="REFERENCE">Gelernter 2007</LINK>). Since its approval by the U.S. Food and Drug Administration (FDA) as an adjuvant therapy for the treatment of alcohol-dependent patients in 1994, naltrexone has been introduced to the market in many countries all over the world. In April 2006, the FDA approved a new extended-release injectable formulation of naltrexone for the treatment of alcohol dependence, while nalmefene, a newer opioid antagonist, is tested, but not yet licensed for this indication. Nalmefene has a comparable chemical structure to naltrexone, while proposed to offer a number of potential advantages (<LINK REF="REF-Mason-1999" TYPE="REFERENCE">Mason 1999</LINK>), including a more effective binding to central opiate receptors (<LINK REF="REF-DeHaven_x002d_Hudkins-1990" TYPE="REFERENCE">DeHaven-Hudkins 1990</LINK>; <LINK REF="REF-Emmerson-1994" TYPE="REFERENCE">Emmerson 1994</LINK>; <LINK REF="REF-Ingman-2005" TYPE="REFERENCE">Ingman 2005</LINK>), a higher bioavailability (<LINK REF="REF-Dixon-1987" TYPE="REFERENCE">Dixon 1987</LINK>; <LINK REF="REF-Gal-1986" TYPE="REFERENCE">Gal 1986</LINK>) and the absence of a dose-dependent association with liver toxicity (<LINK REF="REF-Mason-1999" TYPE="REFERENCE">Mason 1999</LINK>).</P>
</INTERVENTION>
<THEORY MODIFIED="2010-10-08 14:46:22 +0200" MODIFIED_BY="Laura Amato">
<P>Alcohol affects various transmitter systems in the brain, including the endogenous opioid receptors, which are assumed to mediate pleasant and euphoric effects of drinking (<LINK REF="REF-Froehlich-1993" TYPE="REFERENCE">Froehlich 1993</LINK>; <LINK REF="REF-O_x0027_Malley-2003" TYPE="REFERENCE">O'Malley 2003</LINK>; <LINK REF="REF-Gianoulakis-2004" TYPE="REFERENCE">Gianoulakis 2004</LINK>). As naltrexone and nalmefene competitively bind to these receptors, they block the endogenous opioids at these sites (<LINK REF="REF-Clintron-1995" TYPE="REFERENCE">Clintron 1995</LINK>) and thus diminish the pleasant and euphoric effects of drinking. This explains why patients given naltrexone in combination with alcohol reported a reduced "high" compared to former drinking (<LINK REF="REF-Volpicelli-1995" TYPE="REFERENCE">Volpicelli 1995</LINK>). As changes in the opioid system also have a modulator influence on the mesolimbic dopamine system, especially on dopamine neurons in the ventral tegmental area and their projections to the nucleus accumbens in the ventral striatum - the predominant pathway involved in reinforcement and motivation (<LINK REF="REF-Adcock-2006" TYPE="REFERENCE">Adcock 2006</LINK>) - naltrexone is also assumed to mediate motivational processes including reward anticipation and reinforcement.</P>
</THEORY>
<IMPORTANCE MODIFIED="2010-08-01 12:40:45 +0200" MODIFIED_BY="[Empty name]">
<P>Naltrexone has already been subject to various meta-analyses, which indicate small to moderate, but significant effects of the substance in preventing a relapse to heavy drinking in alcohol dependent patients (<LINK REF="REF-Schoechlin-2000" TYPE="REFERENCE">Schoechlin 2000</LINK>; <LINK REF="REF-Kranzler-2001" TYPE="REFERENCE">Kranzler 2001</LINK>; <LINK REF="REF-Hopkins-2002" TYPE="REFERENCE">Hopkins 2002</LINK>; <LINK REF="REF-Berglund-2003" TYPE="REFERENCE">Berglund 2003</LINK>; <LINK REF="REF-Streeton-2001" TYPE="REFERENCE">Streeton 2001</LINK>; <LINK REF="REF-Srisurapanont-2000" TYPE="REFERENCE">Srisurapanont 2000</LINK>; <LINK REF="REF-Slattery-2003" TYPE="REFERENCE">Slattery 2003</LINK>; <LINK REF="REF-Bouza-2004" TYPE="REFERENCE">Bouza 2004</LINK>; <LINK REF="REF-Srisurapanont-2005a" TYPE="REFERENCE">Srisurapanont 2005a</LINK>; <LINK REF="REF-Srisurapanont-2005b" TYPE="REFERENCE">Srisurapanont 2005b</LINK>; <LINK REF="REF-Roozen-2006" TYPE="REFERENCE">Roozen 2006</LINK>; <LINK REF="REF-Rosner-2008" TYPE="REFERENCE">Rosner 2008</LINK>). Since the last update of the Cochrane review "Opioid antagonists for alcohol dependence" (<LINK REF="REF-Srisurapanont-2000" TYPE="REFERENCE">Srisurapanont 2000</LINK>), based on 29 RCTs (<LINK REF="REF-Srisurapanont-2005a" TYPE="REFERENCE">Srisurapanont 2005a</LINK>), the primary database for opioid antagonists has been considerably extended, with some of the newer trials partly differing from the previous research in terms of the study design, the trial setting and the source of financial sponsoring. Thus, an update of the database is likely to increase the precision of estimated effects and the validity of conclusions.</P>
<P>Besides the statistical integration of primary effects, a systematic assessment of bias risks allows to discuss the demonstrated effects against the background of methodological considerations and to estimate the risk of over- or underestimating the effectiveness of opioid antagonists with the available database. Furthermore, a meta-analytic evaluation of the side effect profile of naltrexone and nalmefene and their post-treatment effectiveness appears to be overdue.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2010-08-01 12:42:10 +0200" MODIFIED_BY="[Empty name]">
<P>To determine the effects of opioid antagonists on drinking in alcohol dependent patients in comparison to placebo and other pharmacological agents in RCTs. Further objectives of the review are to determine </P>
<UL>
<LI>the stability of treatment effects (post-treatment); and </LI>
<LI>the side effect profile. </LI>
</UL>
</OBJECTIVES>
<METHODS MODIFIED="2010-10-08 14:52:29 +0200" MODIFIED_BY="Laura Amato">
<SELECTION_CRITERIA MODIFIED="2010-10-08 14:48:35 +0200" MODIFIED_BY="Laura Amato">
<CRIT_STUDIES MODIFIED="2010-10-08 14:47:40 +0200" MODIFIED_BY="Laura Amato">
<P>All double-blind randomised controlled trials (RCTs) which compare the effects of opioid antagonists (monotherapy and combined therapy) with placebo or active control in drinking-related outcomes. Randomization was required to be restricted to procedures which consider the individual patient as the unit of allocation, excluding group or cluster randomisation studies. Cross-over and multi-phase designs were only considered if medication-free periods ensured the washout of previous treatments.</P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2010-08-01 14:07:46 +0200" MODIFIED_BY="[Empty name]">
<P>Individuals with alcohol dependence according to the criteria of the <I>Diagnostic and</I> <I>Statistical Manual of Mental Disorders (</I>DSM) or the <I>International Statistical Classification of Diseases</I> (ICD) irrespective of any other characteristics. Patient samples including both, patients with alcohol dependence and alcohol abuse, were only included if patients with alcohol dependence constituted the majority of the sample (&gt; 90%).</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2010-10-08 14:48:02 +0200" MODIFIED_BY="Laura Amato">
<UL>
<LI>Opioid antagonists versus placebo control group</LI>
<LI>opioid antagonists versus active control group.</LI>
</UL>
<P>A minimum of four weeks daily treatment was required to ensure an adequate implementation of the intervention. To allow clinically relevant conclusions on treatment stability, post-treatment evaluations had to include at least 12 weeks of observation. Any dose, any mode of administration and any combination of therapies was considered.</P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2010-10-08 14:48:35 +0200" MODIFIED_BY="Laura Amato">
<P>The selection of the primary and secondary outcomes of the review was constituted in consideration of the availability of outcomes, their clinical relevance and their theoretical and conceptual foundation (<LINK REF="REF-Keller-1972" TYPE="REFERENCE">Keller 1972</LINK>).</P>
<P>The study end-points of the primary effectiveness outcomes were considered as constitutive for effectiveness conclusions, while the secondary effectiveness outcomes had only complementary value in the interpretation of results. For reasons of clarity and conciseness, post-treatment evaluations were restricted to the primary outcomes of the review. Rates of drop-out and drop-out due to side effects were discussed as potential moderators of effect sizes, but were not included in the evaluation of effectiveness.</P>
<CRIT_OUTCOMES_PRIMARY MODIFIED="2010-10-08 14:48:35 +0200" MODIFIED_BY="Laura Amato">
<UL>
<LI>Return to heavy drinking;</LI>
<LI>return to any drinking; </LI>
<LI>drinking days.</LI>
</UL>
<P>Return to <I>heavy drinking </I>is a binary variable containing the information whether a patient returned to drinking over a certain cut-off value as determined in the primary analysis (&#8805;5 (4) standard drink units (SDUs) for men (women) in most trials). Return to <I>any drinking </I>with its<I> </I>complementary event "continuous abstinence" is a binary variable containing the information whether a patient returned to drinking after detoxification, or whether a patient remained completely abstinent throughout the entire course of the study. <I>Drinking days </I>are defined as the ratio of the total sum of drinking days (including low and heavy drinking days) related to the entire duration of the study, multiplied with the factor 100.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2010-08-01 14:25:07 +0200" MODIFIED_BY="[Empty name]">
<UL>
<LI>heavy drinking days;</LI>
<LI>consumed amount per drinking day;</LI>
<LI>gamma-glutamyl transpeptidase (GGT); and</LI>
<LI>side effects</LI>
</UL>
<P>
<I>Heavy drinking days</I> are defined as the ratio of the total sum of days with heavy drinking (as predetermined by the definition of heavy drinking in the primary analysis), related to the entire duration of the study, multiplied with the factor 100. The <I>consumed amount per drinking day was</I> calculated by relating the amount of alcohol (transformed into grams alcohol) to drinking days or drinking occasions, implying the exclusion of abstinent days from the analyses. <I>Gamma-glutamyl transpeptidase</I> (GGT) levels were uniquely transformed into "units per liter". All side effects<I> </I>presented in the trial publications were extracted, while only those documented in at least three trials or for more than 200 patients and with a significant group difference in the meta-analysis, were considered as clinically relevant.</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2010-10-08 14:49:19 +0200" MODIFIED_BY="Laura Amato">
<ELECTRONIC_SEARCHES MODIFIED="2010-10-08 14:49:19 +0200" MODIFIED_BY="Laura Amato">
<P>The electronic search was conducted using the following bibliographic databases in descending order:</P>
<UL>
<LI>The Cochrane Central Register of Controlled Trials (CENTRAL) (<I>The Cochrane Library</I> issue 2 2010) which contains the Cochrane Drugs and Alcohol Group's Trials Register;</LI>
<LI>MEDLINE (from 1966 to January 2010);</LI>
<LI>EMBASE (from 1988 to January 2010);</LI>
<LI>CINAHL (from 1982 to January 2010).</LI>
</UL>
<P>Search strategies were developed and applied by the trial search coordinator (SV) of the Cochrane Drugs and Alcohol Group (CDAG). For the MEDLINE search, the Cochrane Highly Sensitive Search Strategy for identifying randomised trials in MEDLINE (sensitivity maximizing version) was applied as outlined in the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Lefebvre-2008" TYPE="REFERENCE">Lefebvre 2008</LINK>). No operators and no restrictions in language, date, gender, subset, age as well as tag terms were used. Search strategies for further databases were invariably based on the strategy developed for MEDLINE but revised for the specific requirements of each database.</P>
<P>Details of the search strategies are provided in <LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>.</P>
<P>We searched for ongoing clinical trials and unpublished studies via Internet searches on the following sites:</P>
<OL>
<LI>http://www.controlled-trials.com;</LI>
<LI>http://clinicaltrials.gov;</LI>
<LI>http://www.clinicalstudyresults.org;</LI>
<LI>http://www.centrewatch.com</LI>
</OL>
<P>For relevant trials with a completion data before 30 April 2009, the principal investigators were contacted and requested to provide reports, manuscripts or unpublished results in advance.</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2010-08-01 14:27:55 +0200" MODIFIED_BY="[Empty name]">
<P>Key informants, experts, public sponsors and the drug manufacturers were contacted with the request to indicate further studies of potential relevance. For this purpose, reference lists with identified studies and criteria of inclusion and exclusion of the review were provided. Finally, hand searching of reference lists of included studies and of current reviews was conducted to complete and to verify the preceding searches.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2010-10-08 14:52:29 +0200" MODIFIED_BY="Laura Amato">
<STUDY_SELECTION MODIFIED="2010-10-05 16:07:30 +0200" MODIFIED_BY="[Empty name]">
<P>The eligibility and relevance of trials was assessed on the base of their abstracts retrieved from the electronic searches. For studies that met the criteria of inclusion according to the abstract information, full text versions were retrieved for a closer inspection in a second step of the study selection. On their base, the relevance and eligibility of studies was assessed by one author (SR), in case of uncertainties, a second author (AH) was consulted. The process of study identification and its results are outlined as a flow diagram (<LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK>) according to the PRISMA statement (<LINK REF="REF-Moher-2009" TYPE="REFERENCE">Moher 2009</LINK>).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2010-08-01 14:31:20 +0200" MODIFIED_BY="[Empty name]">
<P>Information considered in the study tables was extracted by one author (SR) and cross-checked by a second author (AH), while outcome statistics were coded from the study reports by two authors (SR &amp; AH) parallel and independently. If necessary, extracted statistics were standardized and converted for the meta-analyses, including a) the application of the intention-to-treat (ITT) principle on binary outcome data in studies which have not considered the principle in their primary analyses; b) the pooling of outcome data provided for patients subgroups or different dosage forms and c) the standardization of units of the measurement. If the alcohol content of standard drink units (SDUs) was not specified in the trial publications, country-specific values as provided in the International Drinking Guidelines (<LINK REF="REF-ICAP-2003" TYPE="REFERENCE">ICAP 2003</LINK>) were applied. All outcome statistics and calculation steps were entered into electronic data templates (Microsoft Excel) and compared value by value. In case of disagreements, the following sequential procedures were undertaken in descending order:</P>
<OL>
<LI>comparison of published and extracted information to identify transcription and comprehension errors;</LI>
<LI>explication of the coding decisions by each author, followed by consensus discussion and arbitration; and</LI>
<LI>contact of the study investigators to obtain the information of interest.</LI>
</OL>
<P>Finally, after comparisons and corrections were concluded, data were transformed into Review Manager 5 (<LINK REF="REF-The-Nordic-Cochrane-Centre-2008" TYPE="REFERENCE">The Nordic Cochrane Centre 2008</LINK>).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2010-10-05 16:26:43 +0200" MODIFIED_BY="[Empty name]">
<P>The risk of bias was assessed in accordance with the <I>Cochrane Collaboration'</I>s <I>risk of bias assessment tool </I>(<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>).<I> The equivalence of baseline characteristics </I>was<I> </I>considered as further bias risks in the rating of the item "free of other bias"<I>. </I>
</P>
<P>Risk of bias tables were completed by one author (SR) and cross-checked by a second author (AH). Methods for bias control were only considered as applied, if these were adequately described in the study publication or the informal investigator report. Otherwise the associated bias risk was rated as "uncertain". The criteria considered as constitutive for the rating of bias risks are outlined in the appendix (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>).</P>
<P>The results of the quality assessment with the risk of bias tables are used for a qualitative description of bias risks and considered in the discussion and the authors' conclusions. The risk of publication bias is graphically illustrated and quantified with a linear regression test (see <LINK TAG="BIAS_ASSESSMENT" TYPE="SECTION">Assessment of reporting biases</LINK>), while the risk of funding bias is further explored by sensitivity analyses (see <LINK TAG="SENSITIVITY_ANALYSIS" TYPE="SECTION">Sensitivity analysis</LINK>).</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2010-08-01 14:35:28 +0200" MODIFIED_BY="[Empty name]">
<P>Treatment effects for dichotomous effectiveness outcomes were measured with the Risk Ratio (RR), relating the risk of any drinking or heavy drinking observed in the intervention group to the corresponding risk in a reference group. As Risk Differences (RD) can be calculated even when there are no events in either group, RD were used to assess the risk of side effects. Treatment effects on continuous outcomes (drinking days, heavy drinking days, consumed amount, gamma-glutamyl transpeptidase) were measured by mean differences (MD) of standardized units. All treatment effects were calculated within a 95% Confidence Interval (CI). If effects on binary outcomes reached statistical significance, the Number Needed to Treat for an Additional Beneficial Outcome (NNTB) for effectiveness outcomes and the Number Needed to Treat for an Additional Harmful Outcome (NNTH) for side effects were calculated. A P value of 0.05 and below was chosen to indicate statistical significance of effects.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2010-08-01 14:40:03 +0200" MODIFIED_BY="[Empty name]">
<P>As all identified studies eligible for the review are based on a parallel group designs and as for all repeated measurements, only one time-point (study endpoint) was included in the evaluation of effectiveness, the units of allocation invariably correspond with the unit of analysis.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2010-07-18 09:28:59 +0200" MODIFIED_BY="[Empty name]">
<P>For the analyses of binary outcome data (return to heavy drinking, return to any drinking), all randomized patients were included in the statistical analyses, with drop-outs or lost to follow up being assigned to the relapse category. For analyses of continuous effectiveness outcomes (drinking days, heavy drinking days, consumed amount per drinking day, GGT), means and standard deviations were included as provided by the study publications irrespective of the handling of missing data in the primary analysis.</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2010-08-01 14:40:40 +0200" MODIFIED_BY="[Empty name]">
<P>Inconsistency across studies was quantified with the I<SUP>2</SUP>-statistic (<LINK REF="REF-Higgins-2003" TYPE="REFERENCE">Higgins 2003</LINK>), using a variability of 50% as a threshold value for substantial heterogeneity (<LINK REF="REF-Deeks-2008" TYPE="REFERENCE">Deeks 2008</LINK>) and the Tau<SUP>2</SUP>-statistic for providing an estimate of between-study variance<B> </B>(<LINK REF="REF-Rucker-2008" TYPE="REFERENCE">Rucker 2008</LINK>) independent of the sample size.<BR/>
</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2010-10-08 14:52:29 +0200" MODIFIED_BY="Laura Amato">
<P>The risk of publication bias was graphically illustrated with the funnel plot method (<LINK REF="REF-Light-1984" TYPE="REFERENCE">Light 1984</LINK>) and quantified with a linear regression test (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>), determining the linear regression coefficient between the log Odds Ratio (OR) and its standard error for "return to any drinking". The risk of outcome reporting bias ( <LINK REF="REF-Chan-2004" TYPE="REFERENCE">Chan 2004</LINK>; <LINK REF="REF-Pocock-1987" TYPE="REFERENCE">Pocock 1987</LINK>; <LINK REF="REF-Tannock-1996" TYPE="REFERENCE">Tannock 1996</LINK>; <LINK REF="REF-Williamson-2005" TYPE="REFERENCE">Williamson 2005</LINK>) was not quantitatively analysed, but considered in the discussion of results.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2010-08-01 14:42:37 +0200" MODIFIED_BY="[Empty name]">
<P>For synthesizing aggregate outcome measures, a random-effects model (<LINK REF="REF-DerSimonian-1986" TYPE="REFERENCE">DerSimonian 1986</LINK>) was chosen according to the recommendation of <LINK REF="REF-Brockwell-2001" TYPE="REFERENCE">Brockwell 2001</LINK>, with study effects being weighting with the Mantal-Haenzel approach<B> </B>(<LINK REF="REF-Mantel-1959" TYPE="REFERENCE">Mantel 1959</LINK>). For outcomes with low effect heterogeneity (I<SUP>2 </SUP>&lt; 30%), a fixed effect model was additionally applied within the scope of sensitivity analyses.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2010-08-01 14:43:12 +0200" MODIFIED_BY="[Empty name]">
<P>Subgroup analyses were conducted for trials with extended release naltrexone.</P>
<P>As a preliminary exploration of heterogeneity indicted a low statistical power due to the high missing rates for selected design characteristics (e.g. quality of blinding, allocation concealment, handling of missing outcome data), which were foreseen as predictors in the regression model as well as the high sensitivity of the results to the presumptions of the model, the authors of the review decided to obtain the missing information from the investigators and to deliver a meta-regression at a later stage.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2010-08-01 14:44:33 +0200" MODIFIED_BY="[Empty name]">
<P>Sensitivity analyses were conducted to determine the influence of the following variables on the primary outcome "return to any drinking":</P>
<UL>
<LI>the underlying statistical model, by comparing effect sizes for low heterogeneity outcomes (I<SUP>2 </SUP>&lt; 30%) based on random effects models versus fixed effect models;</LI>
</UL>
<UL>
<LI>the funding source, by comparing effect sizes between trials that were sponsored by the pharmaceutical industry versus those that were investigator-driven and of non-profit funding.</LI>
</UL>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2010-10-18 09:05:24 +0200" MODIFIED_BY="Laura Amato">
<STUDY_DESCRIPTION MODIFIED="2010-10-08 14:54:31 +0200" MODIFIED_BY="Laura Amato">
<SEARCH_RESULTS MODIFIED="2010-07-30 12:23:36 +0200" MODIFIED_BY="[Empty name]">
<P>The study search for the review yielded 681 potentially relevant references, of which 621 were identified through bibliographic databases and 60 through other sources (personal communication: n = 3, database of ongoing trials: n = 57). 463 references were identified as duplicates and removed. From the remaining 218 screened records, 124 were excluded on the base of the information provided in the abstracts. Full-text articles were obtained for the 94 records, on whose base a further 44 studies were excluded. The steps of trial identifying and their results are outlined in <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> as flow-diagram according to the PRISMA statement (Moher 2009).</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2010-10-08 14:54:11 +0200" MODIFIED_BY="Laura Amato">
<P>A total of 50 RCTs (naltrexone: n = 47; nalmefene; n = 3) with 7793 patients was included in the review. Of the 7793 patients, 3881 have received treatment with naltrexone, 286 treatment with nalmefene and 3626 treatment with either placebo or active control.</P>
<P>
<B>Comparisons</B>
</P>
<P>44 of the 50 RCTs included in the review were based on a 2-arm design, comparing naltrexone with placebo (n = 40), nalmefene with placebo (n = 3) or naltrexone with the new generation antipsychotic drug aripiprazole (<LINK REF="STD-Martinotti-2008" TYPE="STUDY">Martinotti 2008</LINK>). In all 2-arm design trials, naltrexone and nalmefene were tested as monotherapy, with the exception of two trials which tested naltrexone combined with the 5HT-antagonist ondansetron (<LINK REF="STD-Johnson-2000" TYPE="STUDY">Johnson 2000</LINK>) and the selective serotonin reuptake inhibitor sertraline (<LINK REF="STD-O_x0027_Malley-2008" TYPE="STUDY">O'Malley 2008</LINK>) against placebo.</P>
<P>Three trials used three treatment arms, either comparing naltrexone and placebo with the glutamate antagonist acamprosate (<LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>), with the serotonin-antagonist nalmefene (<LINK REF="STD-Kranzler-2000" TYPE="STUDY">Kranzler 2000</LINK>) or the anticonvulsant drug topiramate (<LINK REF="STD-Baltieri-2008" TYPE="STUDY">Baltieri 2008</LINK>). A further three trials were based on a four-armed design, testing naltrexone monotherapy, acamprosate monotherapy, placebo and a combined treatment with naltrexone and acamprosate (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>) as well as naltrexone monotherapy, disulfiram monotherapy, placebo and combined naltrexone and disulfiram (<LINK REF="STD-Pettinati-2008b" TYPE="STUDY">Pettinati 2008b</LINK>).</P>
<P>
<B>Publication types</B>
</P>
<P>47 of the 50 RCTs were published as journal articles, one study at a time as a congress abstract (<LINK REF="STD-Auriacombe-2000" TYPE="STUDY">Auriacombe 2000</LINK>) or in book format (Zió&#322;kowski 2000), while one study was only available as unpublished dissertation (<LINK REF="STD-de-Goes-e-Castro-2004" TYPE="STUDY">de Goes e Castro 2004</LINK>).</P>
<P>
<B>Patients</B>
</P>
<P>For the inclusion in the clinical trials, a diagnosis of alcohol dependence or abuse and a minimum age of 18 years was required. Patients in the included RCTs fulfilled the criteria of alcohol dependence or alcohol abuse as diagnosed with either DSM-III-R, DSM-IV or ICD-10. Mixed samples with both, patients with alcohol dependence and alcohol abuse, were included in six studies (<LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>; <LINK REF="STD-Gastpar-2002" TYPE="STUDY">Gastpar 2002</LINK>; <LINK REF="STD-Hersh-1998" TYPE="STUDY">Hersh 1998</LINK>; <LINK REF="STD-Monti-2001" TYPE="STUDY">Monti 2001</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-Petrakis-2004" TYPE="STUDY">Petrakis 2004</LINK>); in none of these studies, alcohol abusers exceeded 10% of the entire sample. The mean age of the patient sample varied between 40 and 50 years in most studies (n = 43). 40 of the 50 RCTs were based on mixed gender samples, with men constituting the majority. Nine trials exclusively included male patients (<LINK REF="STD-Ahmadi-2002" TYPE="STUDY">Ahmadi 2002</LINK>; <LINK REF="STD-Baltieri-2008" TYPE="STUDY">Baltieri 2008</LINK>; <LINK REF="STD-Ahmadi-2002" TYPE="STUDY">Ahmadi 2002</LINK>; <LINK REF="STD-Baltieri-2008" TYPE="STUDY">Baltieri 2008</LINK>; <LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>; <LINK REF="STD-Lee-2001" TYPE="STUDY">Lee 2001</LINK>; <LINK REF="STD-Morris-2001" TYPE="STUDY">Morris 2001</LINK>; <LINK REF="STD-Oslin-1997" TYPE="STUDY">Oslin 1997</LINK>; <LINK REF="STD-Petrakis-2004" TYPE="STUDY">Petrakis 2004</LINK>; <LINK REF="STD-Volpicelli-1992" TYPE="STUDY">Volpicelli 1992</LINK>; Zió&#322;kowski 2000), while one study evaluated the effectiveness of naltrexone in alcohol-dependent women (<LINK REF="STD-O_x0027_Malley-2007" TYPE="STUDY">O'Malley 2007</LINK>).</P>
<P>Patients with concurrent major psychiatric disorders or a psychiatric condition requiring the concurrent use of psychotropic medication were excluded in most studies (n = 48). Three studies did not explicitly state psychiatric comorbidity as a criteria of exclusion (<LINK REF="STD-Ahmadi-2002" TYPE="STUDY">Ahmadi 2002</LINK>; <LINK REF="STD-Killeeen-2004" TYPE="STUDY">Killeeen 2004</LINK>; <LINK REF="STD-Oslin-2005" TYPE="STUDY">Oslin 2005</LINK>) and three further studies even defined concurrent psychiatric disorders as a criteria of inclusion (<LINK REF="STD-Brown-2009" TYPE="STUDY">Brown 2009</LINK>; <LINK REF="STD-Petrakis-2004" TYPE="STUDY">Petrakis 2004</LINK>; <LINK REF="STD-Petrakis-2005" TYPE="STUDY">Petrakis 2005</LINK>). <LINK REF="STD-Petrakis-2004" TYPE="STUDY">Petrakis 2004</LINK> included patients with concurrent schizophrenia and schizoaffective disorders, <LINK REF="STD-Brown-2009" TYPE="STUDY">Brown 2009</LINK> patients with concurrent bipolar disorders and <LINK REF="STD-Petrakis-2005" TYPE="STUDY">Petrakis 2005</LINK> examined naltrexone's effectiveness in a patient sample with axis I-diagnosis.</P>
<P>Like psychiatric comorbidity, a concurrent drug use (other than alcohol or nicotine) led to the exclusion of patients in most trials (n = 42). In contrast, <LINK REF="STD-Brown-2009" TYPE="STUDY">Brown 2009</LINK>, <LINK REF="STD-Petrakis-2005" TYPE="STUDY">Petrakis 2005</LINK> and <LINK REF="STD-Martinotti-2008" TYPE="STUDY">Martinotti 2008</LINK> did not exclude users of illegal drugs and in the studies of <LINK REF="STD-Hersh-1998" TYPE="STUDY">Hersh 1998</LINK>, <LINK REF="STD-Pettinati-2008a" TYPE="STUDY">Pettinati 2008a</LINK>; <LINK REF="STD-Pettinati-2008b" TYPE="STUDY">Pettinati 2008b</LINK> and <LINK REF="STD-Schmitz-2004" TYPE="STUDY">Schmitz 2004</LINK>; <LINK REF="STD-Schmitz-2009" TYPE="STUDY">Schmitz 2009</LINK>, a concurrent cocaine diagnosis was constitutive for patient inclusion.</P>
<P>
<B>Treatment setting and study design</B>
</P>
<P>14 of the 50 RCTs included in the review used a multi-centre trials design (<LINK REF="STD-Anton-2004" TYPE="STUDY">Anton 2004</LINK>; <LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Balldin-2003" TYPE="STUDY">Balldin 2003</LINK>; <LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>; <LINK REF="STD-Garbutt-2005" TYPE="STUDY">Garbutt 2005</LINK>; <LINK REF="STD-Gastpar-2002" TYPE="STUDY">Gastpar 2002</LINK>; <LINK REF="STD-Guardia-2002" TYPE="STUDY">Guardia 2002</LINK>; <LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Krystal-2001" TYPE="STUDY">Krystal 2001</LINK>; <LINK REF="STD-Kranzler-2004" TYPE="STUDY">Kranzler 2004</LINK>; <LINK REF="STD-Latt-2002" TYPE="STUDY">Latt 2002</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-O_x0027_Malley-2008" TYPE="STUDY">O'Malley 2008</LINK>; <LINK REF="STD-Petrakis-2005" TYPE="STUDY">Petrakis 2005</LINK>). Sample sizes varied from 20 patients (<LINK REF="STD-Galarza-1997" TYPE="STUDY">Galarza 1997</LINK>; <LINK REF="STD-Johnson-2000" TYPE="STUDY">Johnson 2000</LINK>; <LINK REF="STD-Kranzler-1998" TYPE="STUDY">Kranzler 1998</LINK>) to over 600 patients (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Garbutt-2005" TYPE="STUDY">Garbutt 2005</LINK>; <LINK REF="STD-Krystal-2001" TYPE="STUDY">Krystal 2001</LINK>), whereby most studies (n = 28) included between 80 and 200 patients. With a total of 1383 patients, the COMBINE-study (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>) was the largest trial included in the review.</P>
<P>Industry sponsorship was reported in 11 study publications (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Balldin-2003" TYPE="STUDY">Balldin 2003</LINK>; <LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>; <LINK REF="STD-Galarza-1997" TYPE="STUDY">Galarza 1997</LINK>; <LINK REF="STD-Garbutt-2005" TYPE="STUDY">Garbutt 2005</LINK>; <LINK REF="STD-Gastpar-2002" TYPE="STUDY">Gastpar 2002</LINK>; <LINK REF="STD-Guardia-2002" TYPE="STUDY">Guardia 2002</LINK>; <LINK REF="STD-Kranzler-2004" TYPE="STUDY">Kranzler 2004</LINK>; <LINK REF="STD-Latt-2002" TYPE="STUDY">Latt 2002</LINK>; <LINK REF="STD-Mason-1994" TYPE="STUDY">Mason 1994</LINK>; <LINK REF="STD-Oslin-1997" TYPE="STUDY">Oslin 1997</LINK>), four studies did not provide information on the funding sources (<LINK REF="STD-Ahmadi-2002" TYPE="STUDY">Ahmadi 2002</LINK>; <LINK REF="STD-Auriacombe-2000" TYPE="STUDY">Auriacombe 2000</LINK>; <LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>; <LINK REF="STD-de-Goes-e-Castro-2004" TYPE="STUDY">de Goes e Castro 2004</LINK>), while the remaining 39 RCTs reported a sponsoring by non-profit organizations.</P>
<P>Most studies were conducted in the United States (n = 37), eight studies in Europe (<LINK REF="STD-Auriacombe-2000" TYPE="STUDY">Auriacombe 2000</LINK>; <LINK REF="STD-Balldin-2003" TYPE="STUDY">Balldin 2003</LINK>; <LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>; <LINK REF="STD-Hein_x00e4_l_x00e4_-2001" TYPE="STUDY">Heinälä 2001</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Gastpar-2002" TYPE="STUDY">Gastpar 2002</LINK>; <LINK REF="STD-Guardia-2002" TYPE="STUDY">Guardia 2002</LINK>; Zió&#322;kowski 2000Zió&#322;kowski 2000) and three studies at a time in Australia (<LINK REF="STD-Morris-2001" TYPE="STUDY">Morris 2001</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-Latt-2002" TYPE="STUDY">Latt 2002</LINK>), Asia (<LINK REF="STD-Ahmadi-2002" TYPE="STUDY">Ahmadi 2002</LINK>; <LINK REF="STD-Lee-2001" TYPE="STUDY">Lee 2001</LINK>; <LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>) and Latin America (<LINK REF="STD-Baltieri-2008" TYPE="STUDY">Baltieri 2008</LINK>; <LINK REF="STD-Galarza-1997" TYPE="STUDY">Galarza 1997</LINK>; <LINK REF="STD-de-Goes-e-Castro-2004" TYPE="STUDY">de Goes e Castro 2004</LINK>).</P>
<P>Before treatment, patients were detoxified in most trials, whereby at least 3 to 7 days, but not more than 30 days of abstinence were required to enter randomization. Detoxification was not necessarily required in seven RCTs (<LINK REF="STD-Brown-2009" TYPE="STUDY">Brown 2009</LINK>; <LINK REF="STD-Garbutt-2005" TYPE="STUDY">Garbutt 2005</LINK>; <LINK REF="STD-Hein_x00e4_l_x00e4_-2001" TYPE="STUDY">Heinälä 2001</LINK>; <LINK REF="STD-Johnson-2000" TYPE="STUDY">Johnson 2000</LINK>; <LINK REF="STD-Oslin-2005" TYPE="STUDY">Oslin 2005</LINK>; <LINK REF="STD-Schmitz-2004" TYPE="STUDY">Schmitz 2004</LINK>; <LINK REF="STD-Schmitz-2009" TYPE="STUDY">Schmitz 2009</LINK>) and in three of these trials (<LINK REF="STD-Brown-2009" TYPE="STUDY">Brown 2009</LINK>; <LINK REF="STD-Garbutt-2005" TYPE="STUDY">Garbutt 2005</LINK>; <LINK REF="STD-Hein_x00e4_l_x00e4_-2001" TYPE="STUDY">Heinälä 2001</LINK>), the entire patient sample was actively drinking when the treatment started.</P>
<P>Seven trials started with a placebo run-in week (<LINK REF="STD-Balldin-2003" TYPE="STUDY">Balldin 2003</LINK>; <LINK REF="STD-Hein_x00e4_l_x00e4_-2001" TYPE="STUDY">Heinälä 2001</LINK>; <LINK REF="STD-Hersh-1998" TYPE="STUDY">Hersh 1998</LINK>; <LINK REF="STD-Kranzler-2000" TYPE="STUDY">Kranzler 2000</LINK>; <LINK REF="STD-Mason-1994" TYPE="STUDY">Mason 1994</LINK>; <LINK REF="STD-Monterosso-2001" TYPE="STUDY">Monterosso 2001</LINK>; <LINK REF="STD-Volpicelli-1992" TYPE="STUDY">Volpicelli 1992</LINK>; <LINK REF="STD-Volpicelli-1997" TYPE="STUDY">Volpicelli 1997</LINK>), one trial (<LINK REF="STD-Kranzler-1998" TYPE="STUDY">Kranzler 1998</LINK>) with a two-week run-in period with naltrexone, followed by a two-week washout period without medication.</P>
<P>In the course of the trial, drinking-related outcomes were repeatedly measured. In the majority of studies (n = 39), drinking was assessed with the Time Line Follow-Back method (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>), which is a semi-structured interview that uses calendar format to record the quantity and frequency of drinking. Further instruments used to assess drinking were alcohol use questionnaires (<LINK REF="STD-de-Goes-e-Castro-2004" TYPE="STUDY">de Goes e Castro 2004</LINK>; <LINK REF="STD-Volpicelli-1992" TYPE="STUDY">Volpicelli 1992</LINK>; <LINK REF="STD-Volpicelli-1997" TYPE="STUDY">Volpicelli 1997</LINK>), daily monitoring cards (<LINK REF="STD-Baltieri-2008" TYPE="STUDY">Baltieri 2008</LINK>), drinking diaries (<LINK REF="STD-Hein_x00e4_l_x00e4_-2001" TYPE="STUDY">Heinälä 2001</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>), quantity-frequency assessments (<LINK REF="STD-Guardia-2002" TYPE="STUDY">Guardia 2002</LINK>) and a patients` self-evaluation interview (<LINK REF="STD-Martinotti-2008" TYPE="STUDY">Martinotti 2008</LINK>; <LINK REF="STD-Latt-2002" TYPE="STUDY">Latt 2002</LINK>).</P>
<P>To systematically assess side effects, checklists (<LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Hersh-1998" TYPE="STUDY">Hersh 1998</LINK>; <LINK REF="STD-Johnson-2000" TYPE="STUDY">Johnson 2000</LINK>; <LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Latt-2002" TYPE="STUDY">Latt 2002</LINK>), an open ended inquiry (<LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>), a rating scale (<LINK REF="STD-Balldin-2003" TYPE="STUDY">Balldin 2003</LINK>) and the Systematic Assessment for Treatment Emergent Effects (SAFTEE; <LINK REF="REF-Levine-1986" TYPE="REFERENCE">Levine 1986</LINK>; <LINK REF="REF-Rabkin-1992" TYPE="REFERENCE">Rabkin 1992</LINK>) were used (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Kranzler-1998" TYPE="STUDY">Kranzler 1998</LINK>; <LINK REF="STD-Pettinati-2008a" TYPE="STUDY">Pettinati 2008a</LINK>; <LINK REF="STD-Pettinati-2008b" TYPE="STUDY">Pettinati 2008b</LINK>). <LINK REF="STD-Petrakis-2004" TYPE="STUDY">Petrakis 2004</LINK> and <LINK REF="STD-Petrakis-2005" TYPE="STUDY">Petrakis 2005</LINK> applied the Hopkins Symptom Checklist (HSCL; <LINK REF="REF-Derogatis-1974" TYPE="REFERENCE">Derogatis 1974</LINK>), <LINK REF="STD-Baltieri-2008" TYPE="STUDY">Baltieri 2008</LINK> the Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale (<LINK REF="REF-Lingjaerde-1987" TYPE="REFERENCE">Lingjaerde 1987</LINK>) and <LINK REF="STD-Martinotti-2008" TYPE="STUDY">Martinotti 2008</LINK> the Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar; <LINK REF="REF-Sullivan-1989" TYPE="REFERENCE">Sullivan 1989</LINK>) for the assessment of side effects.</P>
<P>The post-treatment drinking status was assessed at intervals of 3 months (<LINK REF="REF-Kiefer-2004" TYPE="REFERENCE">Kiefer 2004</LINK>; <LINK REF="REF-Anton-2001" TYPE="REFERENCE">Anton 2001</LINK>), 6 months (<LINK REF="STD-Krystal-2001" TYPE="STUDY">Krystal 2001</LINK>; <LINK REF="REF-O_x0027_Malley-1996" TYPE="REFERENCE">O'Malley 1996</LINK>), 8 months (Zió&#322;kowski 2000), 12 months (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Monti-2001" TYPE="STUDY">Monti 2001</LINK>), and 17 months (<LINK REF="STD-O_x0027_Malley-2008" TYPE="STUDY">O'Malley 2008</LINK>) after treatment was discontinued.  </P>
<P>To measure compliance, riboflavin was used in five RCTs (<LINK REF="STD-Monti-2001" TYPE="STUDY">Monti 2001</LINK>; <LINK REF="STD-Anton-1999" TYPE="STUDY">Anton 1999</LINK>; <LINK REF="STD-Schmitz-2004" TYPE="STUDY">Schmitz 2004</LINK>; <LINK REF="STD-Hersh-1998" TYPE="STUDY">Hersh 1998</LINK>; <LINK REF="STD-Kranzler-2000" TYPE="STUDY">Kranzler 2000</LINK>), while the most common method to monitor medication compliance was pill count (<LINK REF="STD-Anton-2004" TYPE="STUDY">Anton 2004</LINK>; <LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Balldin-2003" TYPE="STUDY">Balldin 2003</LINK>; <LINK REF="STD-Baltieri-2008" TYPE="STUDY">Baltieri 2008</LINK>; <LINK REF="STD-Brown-2009" TYPE="STUDY">Brown 2009</LINK>; <LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>; <LINK REF="STD-Gastpar-2002" TYPE="STUDY">Gastpar 2002</LINK>; <LINK REF="STD-Guardia-2002" TYPE="STUDY">Guardia 2002</LINK>; <LINK REF="STD-Johnson-2000" TYPE="STUDY">Johnson 2000</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Latt-2002" TYPE="STUDY">Latt 2002</LINK>; <LINK REF="STD-Lee-2001" TYPE="STUDY">Lee 2001</LINK>; <LINK REF="STD-Mason-1999" TYPE="STUDY">Mason 1999</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-Monti-2001" TYPE="STUDY">Monti 2001</LINK>; <LINK REF="STD-Monterosso-2001" TYPE="STUDY">Monterosso 2001</LINK>; <LINK REF="STD-Morris-2001" TYPE="STUDY">Morris 2001</LINK>; <LINK REF="STD-Oslin-2005" TYPE="STUDY">Oslin 2005</LINK>; <LINK REF="STD-Oslin-2008" TYPE="STUDY">Oslin 2008</LINK>; <LINK REF="STD-Petrakis-2004" TYPE="STUDY">Petrakis 2004</LINK>; <LINK REF="STD-Pettinati-2008a" TYPE="STUDY">Pettinati 2008a</LINK>; <LINK REF="STD-Pettinati-2008b" TYPE="STUDY">Pettinati 2008b</LINK>; <LINK REF="STD-Schmitz-2009" TYPE="STUDY">Schmitz 2009</LINK>;<LINK REF="STD-Volpicelli-1997" TYPE="STUDY">Volpicelli 1997</LINK>). Seven further RCTS (<LINK REF="STD-Anton-2005" TYPE="STUDY">Anton 2005</LINK>; <LINK REF="STD-Killeeen-2004" TYPE="STUDY">Killeeen 2004</LINK>; <LINK REF="STD-Krystal-2001" TYPE="STUDY">Krystal 2001</LINK>; <LINK REF="STD-Mason-1999" TYPE="STUDY">Mason 1999</LINK>; <LINK REF="STD-O_x0027_Malley-2007" TYPE="STUDY">O'Malley 2007</LINK>; <LINK REF="STD-O_x0027_Malley-2008" TYPE="STUDY">O'Malley 2008</LINK>; <LINK REF="STD-Petrakis-2005" TYPE="STUDY">Petrakis 2005</LINK>) used electronic systems (e.g. Microelective Events Monitoring System (MEMS); Electronic Microchip System (EMS)) to assess compliance, which uses medication caps containing microelectronics to record each time and date the bottle is opened and closed. Five studies report that pill counts and cap openings have been verified by the measurement of plasma naltrexone levels (<LINK REF="STD-Kranzler-1998" TYPE="STUDY">Kranzler 1998</LINK>) or 6 beta naltrexol blood levels (<LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>; <LINK REF="STD-Gastpar-2002" TYPE="STUDY">Gastpar 2002</LINK>; <LINK REF="STD-Kranzler-1998" TYPE="STUDY">Kranzler 1998</LINK>; <LINK REF="STD-Krystal-2001" TYPE="STUDY">Krystal 2001</LINK>).</P>
<P>
<B>Treatment </B>
</P>
<P>In 4 RCTs of the 47 RCTS with naltrexone included in the review, an injectable extended-release formulation was used (<LINK REF="STD-Garbutt-2005" TYPE="STUDY">Garbutt 2005</LINK>; <LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Kranzler-1998" TYPE="STUDY">Kranzler 1998</LINK>; <LINK REF="STD-Kranzler-2004" TYPE="STUDY">Kranzler 2004</LINK>). Injectable naltrexone was administered at four-week intervals at doses between 150 mg (<LINK REF="STD-Kranzler-2004" TYPE="STUDY">Kranzler 2004</LINK>) and 400 mg (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>). When naltrexone was administered orally, a daily dose of 50 mg was used in most trials, while in the trials of <LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>, <LINK REF="STD-Monterosso-2001" TYPE="STUDY">Monterosso 2001</LINK>, <LINK REF="STD-Oslin-2008" TYPE="STUDY">Oslin 2008</LINK>, <LINK REF="STD-Pettinati-2008b" TYPE="STUDY">Pettinati 2008b</LINK> and <LINK REF="STD-Schmitz-2009" TYPE="STUDY">Schmitz 2009</LINK>, the daily dose was 100 mg dose, in <LINK REF="STD-Pettinati-2008a" TYPE="STUDY">Pettinati 2008a</LINK> 150 mg. For nalmefene, which is exclusively available as oral formulation, different dose regimes were tested from 5 mg (<LINK REF="STD-Anton-2004" TYPE="STUDY">Anton 2004</LINK>) to 80 mg (<LINK REF="STD-Mason-1999" TYPE="STUDY">Mason 1999</LINK>).</P>
<P>Treatment duration varied from four weeks (<LINK REF="STD-Galarza-1997" TYPE="STUDY">Galarza 1997</LINK>; <LINK REF="STD-Kranzler-1998" TYPE="STUDY">Kranzler 1998</LINK>) up to 52 weeks (<LINK REF="STD-Auriacombe-2000" TYPE="STUDY">Auriacombe 2000</LINK>), while a duration of three months was most common (n = 34). In the study of <LINK REF="STD-Krystal-2001" TYPE="STUDY">Krystal 2001</LINK>, different treatment durations (3 months versus 12 months) were tested within one trial. Treatment was exclusively provided in outpatient settings. In two studies (<LINK REF="STD-Lee-2001" TYPE="STUDY">Lee 2001</LINK>; Zió&#322;kowski 2000), treatment started for four weeks on an inpatient base, before it was continued as outpatient treatment. Psychosocial treatment was provided in all but two trials (<LINK REF="STD-Mason-1994" TYPE="STUDY">Mason 1994</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>), whereby cognitive behavioral therapies (n = 17) and motivational therapies (n = 10) were most common.</P>
<P>
<B>Outcomes </B>
</P>
<P>The most frequently considered outcome was &#8220;return to heavy drinking&#8221;, reported for 32 RCTs, followed by "return to a any drinking" and "drinking days", available for 29 respectively 28 RCTs. The secondary outcomes of the review, "drinks per drinking day", &#8220;heavy drinking days&#8221; and GGT values were less frequently provided; anyhow, information on these outcomes was available for 18 (drinks per drinking day), 17 (heavy drinking days) and 16 trials (GGT). Besides the outcome information available from the trial publications, information on "return to any drinking&#8221; was subsequently provided by the investigators for seven RCTs (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Balldin-2003" TYPE="STUDY">Balldin 2003</LINK>; <LINK REF="STD-Brown-2009" TYPE="STUDY">Brown 2009</LINK>; <LINK REF="STD-Guardia-2002" TYPE="STUDY">Guardia 2002</LINK>; <LINK REF="STD-Killeeen-2004" TYPE="STUDY">Killeeen 2004</LINK>; <LINK REF="STD-Krystal-2001" TYPE="STUDY">Krystal 2001</LINK>; Zió&#322;kowski 2000), on GGT values for three RCTs (<LINK REF="STD-Killeeen-2004" TYPE="STUDY">Killeeen 2004</LINK>; <LINK REF="STD-Morris-2001" TYPE="STUDY">Morris 2001</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>), on drinking days for two RCTs (<LINK REF="STD-Brown-2009" TYPE="STUDY">Brown 2009</LINK>; <LINK REF="STD-Morris-2001" TYPE="STUDY">Morris 2001</LINK>) and on "heavy drinking days" (<LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>) and "consumed amount per drinking day" (<LINK REF="STD-Brown-2009" TYPE="STUDY">Brown 2009</LINK>) for one trial at a time. Post-treatment results for "return to heavy drinking" (<LINK REF="REF-Anton-2001" TYPE="REFERENCE">Anton 2001</LINK>; <LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="REF-Kiefer-2004" TYPE="REFERENCE">Kiefer 2004</LINK>; <LINK REF="STD-Monti-2001" TYPE="STUDY">Monti 2001</LINK>; <LINK REF="STD-O_x0027_Malley-1992" TYPE="STUDY">O'Malley 1992</LINK>O'Malley 1992), "return to any drinking" (<LINK REF="REF-O_x0027_Malley-1996" TYPE="REFERENCE">O'Malley 1996</LINK>; Zió&#322;kowski 2000) and "drinking days" (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>) at post-treatment, were exclusively extracted from trial publications.</P>
<P>A cut-off value for heavy drinking of five (four) standard drink units (SDU) for men (women) was chosen in most studies, while <LINK REF="STD-Killeeen-2004" TYPE="STUDY">Killeeen 2004</LINK>; <LINK REF="STD-Krystal-2001" TYPE="STUDY">Krystal 2001</LINK>; <LINK REF="STD-Mason-1999" TYPE="STUDY">Mason 1999</LINK> and <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK> considered six drinks as a critical threshold value for heavy drinking in men. <LINK REF="STD-Ahmadi-2002" TYPE="STUDY">Ahmadi 2002</LINK>, <LINK REF="STD-Hein_x00e4_l_x00e4_-2001" TYPE="STUDY">Heinälä 2001</LINK>, <LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>, <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>, <LINK REF="STD-Mason-1999" TYPE="STUDY">Mason 1999</LINK>, <LINK REF="STD-Oslin-1997" TYPE="STUDY">Oslin 1997</LINK>, <LINK REF="STD-Volpicelli-1992" TYPE="STUDY">Volpicelli 1992</LINK> and <LINK REF="STD-Volpicelli-1997" TYPE="STUDY">Volpicelli 1997</LINK> additionally assigned patients to the heavy drinking category if drinking occurred on five or more days or occasions a week or if the blood alcohol concentration (BAC) was higher than 100mg/dl. In the Brazilian trials, alcohol consumption was defined as heavy drinking if more than 90 grams alcohol were consumed per week (<LINK REF="STD-Baltieri-2008" TYPE="STUDY">Baltieri 2008</LINK>) or if drinking was above 9 SDUs per day (<LINK REF="STD-de-Goes-e-Castro-2004" TYPE="STUDY">de Goes e Castro 2004</LINK>); in the latter trial, moderate drinking (defined as drinking 5 to 9 SDU per day), was subsequently assigned to the "heavy drinking"-category for the meta-analysis to adapt the definition to the majority of trials.</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2010-10-08 14:54:31 +0200" MODIFIED_BY="Laura Amato">
<P>44 trials were excluded on the basis of their full-text versions. Reasons for exclusion was an open label study design in 17 studies (<LINK REF="STD-Buri-2007" TYPE="STUDY">Buri 2007</LINK>; <LINK REF="STD-Caputo-2003" TYPE="STUDY">Caputo 2003</LINK>, <LINK REF="STD-Caputo-2007" TYPE="STUDY">Caputo 2007</LINK>, <LINK REF="STD-Carroll-1993" TYPE="STUDY">Carroll 1993</LINK>, <LINK REF="STD-Croop-1997" TYPE="STUDY">Croop 1997</LINK>, <LINK REF="STD-De-Sousa-2004" TYPE="STUDY">De Sousa 2004</LINK>, <LINK REF="STD-Deas-2005" TYPE="STUDY">Deas 2005</LINK>, <LINK REF="STD-Galloway-2005" TYPE="STUDY">Galloway 2005</LINK>, <LINK REF="STD-Hermos-2004" TYPE="STUDY">Hermos 2004</LINK>, <LINK REF="STD-Kranzler-2008" TYPE="STUDY">Kranzler 2008</LINK>, <LINK REF="STD-Laaksonen-2008" TYPE="STUDY">Laaksonen 2008</LINK>, <LINK REF="STD-Landabaso-1999" TYPE="STUDY">Landabaso 1999</LINK>, <LINK REF="STD-Martinotti-2007" TYPE="STUDY">Martinotti 2007</LINK>, <LINK REF="STD-Nava-2006" TYPE="STUDY">Nava 2006</LINK>, <LINK REF="STD-Oslin-1999" TYPE="STUDY">Oslin 1999</LINK>, <LINK REF="STD-Rubio-2002" TYPE="STUDY">Rubio 2002</LINK>, <LINK REF="STD-Stella-2008" TYPE="STUDY">Stella 2008</LINK>), a single-blind design in three further studies (<LINK REF="STD-Ponce-2005" TYPE="STUDY">Ponce 2005</LINK>, <LINK REF="STD-Rubio-2001" TYPE="STUDY">Rubio 2001</LINK>, <LINK REF="STD-Rubio-2005" TYPE="STUDY">Rubio 2005</LINK>) and targeted treatment in one trial (<LINK REF="STD-Karhuvaara-2007" TYPE="STUDY">Karhuvaara 2007</LINK>). Ten studies were excluded as they did not meet the sample requirement "alcohol dependence", including hazardous drinkers (<LINK REF="STD-Davidson-2004" TYPE="STUDY">Davidson 2004</LINK>; <LINK REF="STD-Palfai-1999" TYPE="STUDY">Palfai 1999</LINK>), heavy drinkers (<LINK REF="STD-Ray-2007" TYPE="STUDY">Ray 2007</LINK>; <LINK REF="STD-Tidey-2008" TYPE="STUDY">Tidey 2008</LINK>), problem drinkers (<LINK REF="STD-Kranzler-1997" TYPE="STUDY">Kranzler 1997</LINK>; <LINK REF="STD-Hernandez_x002d_Avila-2006" TYPE="STUDY">Hernandez-Avila 2006</LINK>; <LINK REF="STD-Kranzler-2004b" TYPE="STUDY">Kranzler 2004b</LINK>) and healthy persons (<LINK REF="STD-Dunbar-2006" TYPE="STUDY">Dunbar 2006</LINK>; <LINK REF="STD-Mason-2002" TYPE="STUDY">Mason 2002</LINK>) or patients with hepatic impairments (<LINK REF="STD-Turncliff-2005" TYPE="STUDY">Turncliff 2005</LINK>) to test pharmacokinetic or -dynamic properties of naltrexone. A further eight studies were excluded as they did not comply with the minimum study duration of 30 days, of which three clinical trials only covered three weeks of treatment (<LINK REF="STD-Johnson-2003" TYPE="STUDY">Johnson 2003</LINK>; <LINK REF="STD-Knox-1999" TYPE="STUDY">Knox 1999</LINK>; <LINK REF="STD-Ooteman-2007" TYPE="STUDY">Ooteman 2007</LINK>) and five laboratory studies one week of treatment (<LINK REF="STD-Drobes-2000" TYPE="STUDY">Drobes 2000</LINK>; <LINK REF="STD-Drobes-2004" TYPE="STUDY">Drobes 2004</LINK>; <LINK REF="STD-Kranzler-2004a" TYPE="STUDY">Kranzler 2004a</LINK>; <LINK REF="STD-Modesto_x002d_Lowe-1997" TYPE="STUDY">Modesto-Lowe 1997</LINK>; <LINK REF="STD-Myrick-2008" TYPE="STUDY">Myrick 2008</LINK>). Other reasons for exclusion were the lack of a control group (<LINK REF="STD-Davidson-2007a" TYPE="STUDY">Davidson 2007a</LINK>; <LINK REF="STD-Farren-2009" TYPE="STUDY">Farren 2009</LINK>; <LINK REF="STD-Tucker-2004" TYPE="STUDY">Tucker 2004</LINK>) and a multiphase design, which started with open label naltrexone in both, intervention and control groups (<LINK REF="STD-Davidson-2007b" TYPE="STUDY">Davidson 2007b</LINK>; <LINK REF="STD-O_x0027_Malley-2003" TYPE="STUDY">O'Malley 2003</LINK>). Post-treatment results from two studies were excluded because of the low post-treatment duration (<LINK REF="STD-Kranzler-1998" TYPE="STUDY">Kranzler 1998</LINK>) and the non-randomised allocation (<LINK REF="STD-Latt-2002" TYPE="STUDY">Latt 2002</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2010-10-08 14:54:44 +0200" MODIFIED_BY="Laura Amato">
<ALLOCATION MODIFIED="2010-10-08 14:54:44 +0200" MODIFIED_BY="Laura Amato">
<P>
<B>Sequence generation </B>
</P>
<P>For 14 of the 50 RCTs (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Balldin-2003" TYPE="STUDY">Balldin 2003</LINK>; <LINK REF="STD-Baltieri-2008" TYPE="STUDY">Baltieri 2008</LINK>; <LINK REF="STD-Brown-2009" TYPE="STUDY">Brown 2009</LINK>; <LINK REF="STD-Garbutt-2005" TYPE="STUDY">Garbutt 2005</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Killeeen-2004" TYPE="STUDY">Killeeen 2004</LINK>; <LINK REF="STD-de-Goes-e-Castro-2004" TYPE="STUDY">de Goes e Castro 2004</LINK>; <LINK REF="STD-Latt-2002" TYPE="STUDY">Latt 2002</LINK>; <LINK REF="STD-Martinotti-2008" TYPE="STUDY">Martinotti 2008</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-Schmitz-2009" TYPE="STUDY">Schmitz 2009</LINK>; <LINK REF="STD-Volpicelli-1997" TYPE="STUDY">Volpicelli 1997</LINK>; Zió&#322;kowski 2000), the methods used for sequence generation were specified in the trial publications and considered as adequate. Seven trials (<LINK REF="STD-Baltieri-2008" TYPE="STUDY">Baltieri 2008</LINK>; <LINK REF="STD-Brown-2009" TYPE="STUDY">Brown 2009</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Latt-2002" TYPE="STUDY">Latt 2002</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-Volpicelli-1997" TYPE="STUDY">Volpicelli 1997</LINK>; Zió&#322;kowski 2000) used computer-generated randomization lists, some trials random number tables (<LINK REF="STD-Balldin-2003" TYPE="STUDY">Balldin 2003</LINK>; <LINK REF="STD-de-Goes-e-Castro-2004" TYPE="STUDY">de Goes e Castro 2004</LINK>), urn drawing (<LINK REF="STD-Killeeen-2004" TYPE="STUDY">Killeeen 2004</LINK>; <LINK REF="STD-Schmitz-2009" TYPE="STUDY">Schmitz 2009</LINK>), an interactive voice response system (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Martinotti-2008" TYPE="STUDY">Martinotti 2008</LINK>) and coin tossing (<LINK REF="STD-Garbutt-2005" TYPE="STUDY">Garbutt 2005</LINK>). For the remaining 36 RCTs, methods used for sequence generation were not specified.  </P>
<P>
<B>Allocation concealment </B>
</P>
<P>Randomization was described as centralized and conducted by an independent support unit remote from patient recruitment centres in five trials (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Balldin-2003" TYPE="STUDY">Balldin 2003</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Kranzler-2004" TYPE="STUDY">Kranzler 2004</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>), in eight trials drug containers were described as being prepared by an independent pharmacy (<LINK REF="STD-Balldin-2003" TYPE="STUDY">Balldin 2003</LINK>; <LINK REF="STD-Baltieri-2008" TYPE="STUDY">Baltieri 2008</LINK>; <LINK REF="STD-Galarza-1997" TYPE="STUDY">Galarza 1997</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Kranzler-1998" TYPE="STUDY">Kranzler 1998</LINK>; <LINK REF="STD-Latt-2002" TYPE="STUDY">Latt 2002</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-Petrakis-2005" TYPE="STUDY">Petrakis 2005</LINK>). Three of these trials additionally reported that allocation codes were provided in sealed envelopes (<LINK REF="STD-Balldin-2003" TYPE="STUDY">Balldin 2003</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>). 3 of 50 RCTs (<LINK REF="STD-Balldin-2003" TYPE="STUDY">Balldin 2003</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>) fulfilled both criteria (centralized randomisation and drug preparation, sealed envelopes) considered as relevant for an adequate allocation concealment.</P>
</ALLOCATION>
<BLINDING MODIFIED="2010-10-07 10:58:12 +0200" MODIFIED_BY="[Empty name]">
<P>In all but three trial publications (<LINK REF="STD-Ahmadi-2002" TYPE="STUDY">Ahmadi 2002</LINK>; <LINK REF="STD-Auriacombe-2000" TYPE="STUDY">Auriacombe 2000</LINK>; <LINK REF="STD-Galarza-1997" TYPE="STUDY">Galarza 1997</LINK>) placebo and active medication were reported to have identical appearance. In studies with an active control group, blinding was ensured through a double-dummy design signifying that an identically matched placebo was available for each drug, and that participants in each group took the same number of pills per day (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Johnson-2000" TYPE="STUDY">Johnson 2000</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-O_x0027_Malley-2008" TYPE="STUDY">O'Malley 2008</LINK>; <LINK REF="STD-Pettinati-2008b" TYPE="STUDY">Pettinati 2008b</LINK>). From the 50 RCTs included in the review, 21 RCTs (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Balldin-2003" TYPE="STUDY">Balldin 2003</LINK>; <LINK REF="STD-Baltieri-2008" TYPE="STUDY">Baltieri 2008</LINK>; <LINK REF="STD-Garbutt-2005" TYPE="STUDY">Garbutt 2005</LINK>; <LINK REF="STD-Hersh-1998" TYPE="STUDY">Hersh 1998</LINK>; <LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Kranzler-1998" TYPE="STUDY">Kranzler 1998</LINK>; <LINK REF="STD-Kranzler-2000" TYPE="STUDY">Kranzler 2000</LINK>; <LINK REF="STD-Kranzler-2004" TYPE="STUDY">Kranzler 2004</LINK>; <LINK REF="STD-Latt-2002" TYPE="STUDY">Latt 2002</LINK>; <LINK REF="STD-Mason-1999" TYPE="STUDY">Mason 1999</LINK>; <LINK REF="STD-Monti-2001" TYPE="STUDY">Monti 2001</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-Morris-2001" TYPE="STUDY">Morris 2001</LINK>; <LINK REF="STD-O_x0027_Malley-1992" TYPE="STUDY">O'Malley 1992</LINK>; <LINK REF="STD-O_x0027_Malley-2007" TYPE="STUDY">O'Malley 2007</LINK>; <LINK REF="STD-O_x0027_Malley-2008" TYPE="STUDY">O'Malley 2008</LINK>; <LINK REF="STD-Oslin-2008" TYPE="STUDY">Oslin 2008</LINK>; <LINK REF="STD-Petrakis-2005" TYPE="STUDY">Petrakis 2005</LINK>; Zió&#322;kowski 2000) fulfilled both criteria of adequate blinding (blinding of patients and research stuff, identically matched placebo). From those, six trials (<LINK REF="STD-Baltieri-2008" TYPE="STUDY">Baltieri 2008</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Kranzler-1998" TYPE="STUDY">Kranzler 1998</LINK>; <LINK REF="STD-Kranzler-2000" TYPE="STUDY">Kranzler 2000</LINK>; <LINK REF="STD-Mason-1999" TYPE="STUDY">Mason 1999</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>) additionally tested and confirmed the integrity of blinding by inquiries on patients and therapists. 31 RCTs (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Balldin-2003" TYPE="STUDY">Balldin 2003</LINK>; <LINK REF="STD-Baltieri-2008" TYPE="STUDY">Baltieri 2008</LINK>; <LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>; <LINK REF="STD-Garbutt-2005" TYPE="STUDY">Garbutt 2005</LINK>; <LINK REF="STD-Gastpar-2002" TYPE="STUDY">Gastpar 2002</LINK>; <LINK REF="STD-Guardia-2002" TYPE="STUDY">Guardia 2002</LINK>; <LINK REF="STD-Hersh-1998" TYPE="STUDY">Hersh 1998</LINK>; <LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>; <LINK REF="STD-Johnson-2000" TYPE="STUDY">Johnson 2000</LINK>; <LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Killeeen-2004" TYPE="STUDY">Killeeen 2004</LINK>; <LINK REF="STD-Kranzler-1998" TYPE="STUDY">Kranzler 1998</LINK>; <LINK REF="STD-Latt-2002" TYPE="STUDY">Latt 2002</LINK>; <LINK REF="STD-Lee-2001" TYPE="STUDY">Lee 2001</LINK>; <LINK REF="STD-Martinotti-2008" TYPE="STUDY">Martinotti 2008</LINK>; <LINK REF="STD-Mason-1994" TYPE="STUDY">Mason 1994</LINK>; <LINK REF="STD-Mason-1999" TYPE="STUDY">Mason 1999</LINK>; <LINK REF="STD-Monterosso-2001" TYPE="STUDY">Monterosso 2001</LINK>; <LINK REF="STD-Monti-2001" TYPE="STUDY">Monti 2001</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-Morris-2001" TYPE="STUDY">Morris 2001</LINK>; <LINK REF="STD-O_x0027_Malley-1992" TYPE="STUDY">O'Malley 1992</LINK>; <LINK REF="STD-O_x0027_Malley-2007" TYPE="STUDY">O'Malley 2007</LINK>; <LINK REF="STD-O_x0027_Malley-2008" TYPE="STUDY">O'Malley 2008</LINK>; <LINK REF="STD-Oslin-1997" TYPE="STUDY">Oslin 1997</LINK>; <LINK REF="STD-Oslin-2008" TYPE="STUDY">Oslin 2008</LINK>; <LINK REF="STD-Petrakis-2004" TYPE="STUDY">Petrakis 2004</LINK>; <LINK REF="STD-Petrakis-2005" TYPE="STUDY">Petrakis 2005</LINK>; Zió&#322;kowski 2000) have used objective outcomes for a validity check of patient-reported drinking outcomes.</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2010-08-01 17:19:55 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Binary outcomes </B>
</P>
<P>The handling of missing binary data was considered as adequate for 11 RCTs (<LINK REF="STD-Balldin-2003" TYPE="STUDY">Balldin 2003</LINK>; <LINK REF="STD-Baltieri-2008" TYPE="STUDY">Baltieri 2008</LINK>; <LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Mason-1999" TYPE="STUDY">Mason 1999</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-O_x0027_Malley-2008" TYPE="STUDY">O'Malley 2008</LINK>; <LINK REF="STD-Oslin-2008" TYPE="STUDY">Oslin 2008</LINK>; <LINK REF="STD-Pettinati-2008a" TYPE="STUDY">Pettinati 2008a</LINK>; <LINK REF="STD-Pettinati-2008b" TYPE="STUDY">Pettinati 2008b</LINK>; Zió&#322;kowski 2000) of the 40 RCTs, which provided dichotomous outcomes (return to any drinking, return to heavy drinking) for the review: In these trials, all randomized patients or at least those who received treatment, were included in the data analysis (ITT principle) and assigned to the relapse category. </P>
<P>The problem of incomplete binary outcome data was considered as inadequately addressed in four trials, which either excluded patients who dropped out early (<LINK REF="STD-Gastpar-2002" TYPE="STUDY">Gastpar 2002</LINK>; <LINK REF="STD-Krystal-2001" TYPE="STUDY">Krystal 2001</LINK>; <LINK REF="STD-Lee-2001" TYPE="STUDY">Lee 2001</LINK>) or which only considered those patients who attended at least one week of treatment (<LINK REF="STD-O_x0027_Malley-1992" TYPE="STUDY">O'Malley 1992</LINK>). For the remaining 25 trials with binary outcomes, the bias risks associated with missing data remained unclear. </P>
<P>
<B>Continuous outcomes </B>
</P>
<P>For 12 of the 26 RCTs, which provided "drinking days" as a study outcome, the handling of missing data was considered as adequate, meaning that all randomized patients or those who received on treatment dose were included in the analysis, while missing information on drinking frequency did either not occur (<LINK REF="STD-Kranzler-2000" TYPE="STUDY">Kranzler 2000</LINK>, <LINK REF="STD-Mason-1999" TYPE="STUDY">Mason 1999</LINK>) or was adequately replaced: The latter included substitutions with &#8220;worst case&#8221; scenarios, rating the complete interval from the last attendance of a patient who dropped out from a trial as non-abstinent (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Baltieri-2008" TYPE="STUDY">Baltieri 2008</LINK>; <LINK REF="STD-Kranzler-2000" TYPE="STUDY">Kranzler 2000</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-O_x0027_Malley-2007" TYPE="STUDY">O'Malley 2007</LINK>, <LINK REF="STD-O_x0027_Malley-2008" TYPE="STUDY">O'Malley 2008</LINK>), the imputation with the mean of nearby subgroup values (<LINK REF="STD-Balldin-2003" TYPE="STUDY">Balldin 2003</LINK>) and the application of a pattern mixture strategy that was applied to assess the sensitivity of the results to the underlying assumptions of handling missing data (<LINK REF="STD-Oslin-2008" TYPE="STUDY">Oslin 2008</LINK>; <LINK REF="STD-Pettinati-2008a" TYPE="STUDY">Pettinati 2008a</LINK>; <LINK REF="STD-Pettinati-2008b" TYPE="STUDY">Pettinati 2008b</LINK>).</P>
<P>The problem of missing continuous data was considered as inadequately addressed in five trials, which either excluded patients who dropped out early (<LINK REF="STD-Gastpar-2002" TYPE="STUDY">Gastpar 2002</LINK>; <LINK REF="STD-Krystal-2001" TYPE="STUDY">Krystal 2001</LINK>; <LINK REF="STD-Lee-2001" TYPE="STUDY">Lee 2001</LINK>) or which only considered those patients who attended at least one week of treatment (<LINK REF="STD-Mason-1994" TYPE="STUDY">Mason 1994</LINK>; <LINK REF="STD-O_x0027_Malley-1992" TYPE="STUDY">O'Malley 1992</LINK>). For the remaining trials, the handling of missing continuous outcome data remained unclear.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2010-08-03 09:11:32 +0200" MODIFIED_BY="[Empty name]">
<P>With the concordance between outcomes listed in the study protocol or the methods section of the trial publication, 48 of the 50 RCTs fulfilled the criteria of non-selective outcome reporting. One trial (<LINK REF="STD-Ahmadi-2002" TYPE="STUDY">Ahmadi 2002</LINK>) has explicitly listed an outcome in the method section, that was not presented in the result section, one study that was only available as a congress abstract (<LINK REF="STD-Auriacombe-2000" TYPE="STUDY">Auriacombe 2000</LINK>), outcomes were not explicitly stated. </P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2010-10-05 16:54:16 +0200" MODIFIED_BY="[Empty name]">
<P>45 of the 50 RCTs included in the review (<LINK REF="STD-Anton-1999" TYPE="STUDY">Anton 1999</LINK>; <LINK REF="STD-Anton-2004" TYPE="STUDY">Anton 2004</LINK>; <LINK REF="STD-Anton-2005" TYPE="STUDY">Anton 2005</LINK>; <LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Balldin-2003" TYPE="STUDY">Balldin 2003</LINK>; <LINK REF="STD-Baltieri-2008" TYPE="STUDY">Baltieri 2008</LINK>; <LINK REF="STD-Brown-2009" TYPE="STUDY">Brown 2009</LINK>; <LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>; <LINK REF="STD-Gastpar-2002" TYPE="STUDY">Gastpar 2002</LINK>; <LINK REF="STD-Guardia-2002" TYPE="STUDY">Guardia 2002</LINK>; <LINK REF="STD-Hersh-1998" TYPE="STUDY">Hersh 1998</LINK>; <LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Killeeen-2004" TYPE="STUDY">Killeeen 2004</LINK>; <LINK REF="STD-Kranzler-2004" TYPE="STUDY">Kranzler 2004</LINK>; <LINK REF="STD-Krystal-2001" TYPE="STUDY">Krystal 2001</LINK>; <LINK REF="STD-Mason-1994" TYPE="STUDY">Mason 1994</LINK>; <LINK REF="STD-Mason-1999" TYPE="STUDY">Mason 1999</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-Morris-2001" TYPE="STUDY">Morris 2001</LINK>; <LINK REF="STD-O_x0027_Malley-2007" TYPE="STUDY">O'Malley 2007</LINK>; <LINK REF="STD-Oslin-2008" TYPE="STUDY">Oslin 2008</LINK>; <LINK REF="STD-Petrakis-2004" TYPE="STUDY">Petrakis 2004</LINK>; <LINK REF="STD-Pettinati-2008a" TYPE="STUDY">Pettinati 2008a</LINK>; <LINK REF="STD-Pettinati-2008b" TYPE="STUDY">Pettinati 2008b</LINK>; <LINK REF="STD-Schmitz-2004" TYPE="STUDY">Schmitz 2004</LINK>; <LINK REF="STD-Schmitz-2009" TYPE="STUDY">Schmitz 2009</LINK>; <LINK REF="STD-Volpicelli-1997" TYPE="STUDY">Volpicelli 1997</LINK>) were considered as "free" of other potential sources of bias, ensuring the equivalence of baseline characteristics (age, gender, baseline drinking, drinking or treatment history). In four trials (<LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Monterosso-2001" TYPE="STUDY">Monterosso 2001</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>; <LINK REF="STD-Oslin-2005" TYPE="STUDY">Oslin 2005</LINK>), baseline imbalance was identified for selected patient characteristics and controlled in the statistical analyses of treatment effects.</P>
<P>See <LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>, <LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK>
</P>
<P>
<B>General susceptibility to bias effects </B>
</P>
<P>In 30 of the 50 RCTs, general susceptibility to bias was reduced by the inclusion of objective measures, which were assessed for a validity check of self-reported drinking outcomes. Most trials therefore used breath alcohol concentrations (<LINK REF="STD-Garbutt-2005" TYPE="STUDY">Garbutt 2005</LINK>; <LINK REF="STD-Gastpar-2002" TYPE="STUDY">Gastpar 2002</LINK>; <LINK REF="STD-Guardia-2002" TYPE="STUDY">Guardia 2002</LINK>; <LINK REF="STD-Hersh-1998" TYPE="STUDY">Hersh 1998</LINK>; <LINK REF="STD-Huang-2005" TYPE="STUDY">Huang 2005</LINK>; <LINK REF="STD-Johnson-2000" TYPE="STUDY">Johnson 2000</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Killeeen-2004" TYPE="STUDY">Killeeen 2004</LINK>; <LINK REF="STD-Kranzler-1998" TYPE="STUDY">Kranzler 1998</LINK>; <LINK REF="STD-Kranzler-2000" TYPE="STUDY">Kranzler 2000</LINK>; <LINK REF="STD-Kranzler-2004" TYPE="STUDY">Kranzler 2004</LINK>; <LINK REF="STD-Latt-2002" TYPE="STUDY">Latt 2002</LINK>; <LINK REF="STD-Mason-1994" TYPE="STUDY">Mason 1994</LINK>; <LINK REF="STD-Mason-1999" TYPE="STUDY">Mason 1999</LINK>; <LINK REF="STD-Monti-2001" TYPE="STUDY">Monti 2001</LINK>; <LINK REF="STD-Morris-2001" TYPE="STUDY">Morris 2001</LINK>; <LINK REF="STD-O_x0027_Malley-2007" TYPE="STUDY">O'Malley 2007</LINK>; <LINK REF="STD-Petrakis-2004" TYPE="STUDY">Petrakis 2004</LINK>; <LINK REF="STD-Petrakis-2005" TYPE="STUDY">Petrakis 2005</LINK>; <LINK REF="STD-Pettinati-2008b" TYPE="STUDY">Pettinati 2008b</LINK>), 11 RCTs collateral reports (<LINK REF="STD-Baltieri-2008" TYPE="STUDY">Baltieri 2008</LINK>; <LINK REF="STD-Gastpar-2002" TYPE="STUDY">Gastpar 2002</LINK>; <LINK REF="STD-Guardia-2002" TYPE="STUDY">Guardia 2002</LINK>; <LINK REF="STD-Kranzler-2000" TYPE="STUDY">Kranzler 2000</LINK>; <LINK REF="STD-Lee-2001" TYPE="STUDY">Lee 2001</LINK>; <LINK REF="STD-Martinotti-2008" TYPE="STUDY">Martinotti 2008</LINK>; <LINK REF="STD-Mason-1999" TYPE="STUDY">Mason 1999</LINK>; <LINK REF="STD-Monterosso-2001" TYPE="STUDY">Monterosso 2001</LINK>; <LINK REF="STD-Monti-2001" TYPE="STUDY">Monti 2001</LINK>; <LINK REF="STD-O_x0027_Malley-1992" TYPE="STUDY">O'Malley 1992</LINK>; <LINK REF="STD-O_x0027_Malley-2007" TYPE="STUDY">O'Malley 2007</LINK>), 5 RCTs either blood alcohol (<LINK REF="STD-Martinotti-2008" TYPE="STUDY">Martinotti 2008</LINK>; <LINK REF="STD-Oslin-1997" TYPE="STUDY">Oslin 1997</LINK>) or urine alcohol concentrations (<LINK REF="STD-Chick-2000" TYPE="STUDY">Chick 2000</LINK>; <LINK REF="STD-Guardia-2002" TYPE="STUDY">Guardia 2002</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>), 3 RCTs (<LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Lee-2001" TYPE="STUDY">Lee 2001</LINK>; <LINK REF="STD-O_x0027_Malley-2008" TYPE="STUDY">O'Malley 2008</LINK>) GGT values and one trial (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>) carbohydrate-deficient transferrin (CDT) values.</P>
<P>
<B>Publication bias </B>
</P>
<P>The plotting of the log odds ratio against its standard error showed a slight asymmetry with a gap in the bottom corner of the graph (<LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>), while the linear regression test (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>) did not indicate a considerable risk of publication bias, neither for the non-weighted regression (R<SUP>2 </SUP>= 0.20; P = 0.229; SE = 1.440; n = 29) nor for the weighted regression (R<SUP>2 </SUP>= 0.52; P = 0.765; SE = 1.221; n = 29).</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2010-10-18 09:05:24 +0200" MODIFIED_BY="Laura Amato">
<P>
<B>
<U>01 Naltrexone versus placebo</U>
</B>
</P>
<P>
<B>Treatment phase </B>
</P>
<P>Naltrexone was shown to significantly reduce the risk to return to heavy drinking to 83%, RR 0.83 (95% CI 0.76 to 0.90) of the risk in the placebo group see <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> or <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>, while its effect on return to any drinking missed statistical significance, RR 0.96 (95% CI 0.92 to 1.00) see <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK> or <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>. The corresponding NNTB for preventing heavy drinking was 9.09 (95% CI 6.66 to 14.28). Drinking days were decreased by about 4% with naltrexone compared to placebo MD -3.89 (95% CI -5.75 to -2.04) see <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK> or <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
<P>The superiority of naltrexone compared to placebo has also been shown for the secondary outcomes of the review. Naltrexone was associated with a reduction of heavy drinking days by about 3% MD -3.25 (95% CI -5.51 to -0.99) see <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK> or <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>, a decrease of the consumed amount of alcohol on drinking days by about 11 grams MD - 10.83 (95% CI -19.69 to -1.97) see <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK> or <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK> and a reduction of GGT values by about 10 units per liter MD - 10.37 (95% CI -18.99 to -1.75) see <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK> or <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>.</P>
<P>The risk difference to be affected by any side effect was 0.05 (95% CI 0.01 to 0.09), see <LINK REF="CMP-001.07" TYPE="ANALYSIS">Analysis 1.7</LINK>, Among a total of 79 single side effects reported in the included studies, 45 were considered in more than one study allowing a statistical synthesis of results. Seexteen out of these 45 showed result statistically significant in favour of placebo. These include gastrointestinal symptoms like abdominal pain RD 0.08 (95% CI 0.04 to 0.11), see <LINK REF="CMP-001.08" TYPE="ANALYSIS">Analysis 1.8</LINK>; decreased appetite RD 0.07 (95% CI 0.03 to 0.11), see <LINK REF="CMP-001.18" TYPE="ANALYSIS">Analysis 1.18</LINK>, nausea RD 0.10 (95% CI 0.07 to 0.13), see <LINK REF="CMP-001.39" TYPE="ANALYSIS">Analysis 1.39</LINK>, and vomiting RD 0.07 (95% CI 0.04 to 0.09), see <LINK REF="CMP-001.52" TYPE="ANALYSIS">Analysis 1.52</LINK> as well as symptoms associated with a decreased central nervous arousal like daytime sleepiness RD 0.09; 95% CI 0.05 to 0.14, see <LINK REF="CMP-001.17" TYPE="ANALYSIS">Analysis 1.17</LINK>, drowsiness RD 0.10 (95% CI 0.00 to 0.19), see <LINK REF="CMP-001.23" TYPE="ANALYSIS">Analysis 1.23</LINK>, fatigue RD 0.05 (95% CI 0.01 to 0.09), see <LINK REF="CMP-001.26" TYPE="ANALYSIS">Analysis 1.26</LINK>, insomnia RD 0.03 (95% CI 0.00 to 0.06), see <LINK REF="CMP-001.31" TYPE="ANALYSIS">Analysis 1.31</LINK>, lethargy RD 0.13 (95% CI 0.04 to 0.23), see <LINK REF="CMP-001.35" TYPE="ANALYSIS">Analysis 1.35</LINK>, somnolence RD 0.10 (95% CI 0.05 to 0.14); see <LINK REF="CMP-001.49" TYPE="ANALYSIS">Analysis 1.49</LINK>, and weakness RD 0.17 (95% CI 0.05 to 0.29) see <LINK REF="CMP-001.53" TYPE="ANALYSIS">Analysis 1.53</LINK>. Further side effects that appeared more often under naltrexone than placebo were blurred vision RD 0.13 (95% CI 0.04 to 0.21), see <LINK REF="CMP-001.13" TYPE="ANALYSIS">Analysis 1.13</LINK>, decreased libido RD 0.08 (95% CI 0.01 to 0.16), see <LINK REF="CMP-001.19" TYPE="ANALYSIS">Analysis 1.19</LINK>, depression RD 0.04 (95% CI 0.00 to 0.08) see <LINK REF="CMP-001.20" TYPE="ANALYSIS">Analysis 1.20</LINK>, dizziness RD 0.06 (95% CI 0.04 to 0.08), see <LINK REF="CMP-001.22" TYPE="ANALYSIS">Analysis 1.22</LINK> and nightmares RD 0.10 (95% CI 0.04 to 0.16), see <LINK REF="CMP-001.41" TYPE="ANALYSIS">Analysis 1.41</LINK>. The remaining 29 side effects considered, did not show statistically significant differences see <LINK REF="CMP-001.09" TYPE="ANALYSIS">Analysis 1.9</LINK>; <LINK REF="CMP-001.10" TYPE="ANALYSIS">Analysis 1.10</LINK>; <LINK REF="CMP-001.11" TYPE="ANALYSIS">Analysis 1.11</LINK>; <LINK REF="CMP-001.12" TYPE="ANALYSIS">Analysis 1.12</LINK>; <LINK REF="CMP-001.14" TYPE="ANALYSIS">Analysis 1.14</LINK>; <LINK REF="CMP-001.15" TYPE="ANALYSIS">Analysis 1.15</LINK>; <LINK REF="CMP-001.16" TYPE="ANALYSIS">Analysis 1.16</LINK>; <LINK REF="CMP-001.21" TYPE="ANALYSIS">Analysis 1.21</LINK>; <LINK REF="CMP-001.24" TYPE="ANALYSIS">Analysis 1.24</LINK>; <LINK REF="CMP-001.25" TYPE="ANALYSIS">Analysis 1.25</LINK>; <LINK REF="CMP-001.27" TYPE="ANALYSIS">Analysis 1.27</LINK>; <LINK REF="CMP-001.28" TYPE="ANALYSIS">Analysis 1.28</LINK>; <LINK REF="CMP-001.29" TYPE="ANALYSIS">Analysis 1.29</LINK>; <LINK REF="CMP-001.30" TYPE="ANALYSIS">Analysis 1.30</LINK>; <LINK REF="CMP-001.32" TYPE="ANALYSIS">Analysis 1.32</LINK>; <LINK REF="CMP-001.33" TYPE="ANALYSIS">Analysis 1.33</LINK>; <LINK REF="CMP-001.34" TYPE="ANALYSIS">Analysis 1.34</LINK>; <LINK REF="CMP-001.36" TYPE="ANALYSIS">Analysis 1.36</LINK>; <LINK REF="CMP-001.37" TYPE="ANALYSIS">Analysis 1.37</LINK>; <LINK REF="CMP-001.38" TYPE="ANALYSIS">Analysis 1.38</LINK>; <LINK REF="CMP-001.40" TYPE="ANALYSIS">Analysis 1.40</LINK>; <LINK REF="CMP-001.42" TYPE="ANALYSIS">Analysis 1.42</LINK>; <LINK REF="CMP-001.43" TYPE="ANALYSIS">Analysis 1.43</LINK>; <LINK REF="CMP-001.44" TYPE="ANALYSIS">Analysis 1.44</LINK>; <LINK REF="CMP-001.45" TYPE="ANALYSIS">Analysis 1.45</LINK>; <LINK REF="CMP-001.47" TYPE="ANALYSIS">Analysis 1.47</LINK>; <LINK REF="CMP-001.48" TYPE="ANALYSIS">Analysis 1.48</LINK>; <LINK REF="CMP-001.50" TYPE="ANALYSIS">Analysis 1.50</LINK>; <LINK REF="CMP-001.51" TYPE="ANALYSIS">Analysis 1.51</LINK>. Also the risk difference for experiencing serious side effects did not differ between groups RD -0.02 (CI -0.05 to 0.00), see <LINK REF="CMP-001.46" TYPE="ANALYSIS">Analysis 1.46</LINK>. Side effects lead more often to an early termination in the naltrexone than in the placebo group: Compared to placebo, the risk of dropping out due to adverse events was 60% higher in intervention groups RR 1.60; (95% CI 1.15 to 2.23), see <LINK REF="CMP-001.54" TYPE="ANALYSIS">Analysis 1.54</LINK>. The risk of dropping out irrespective of reasons was 8% lower in the naltrexone group than in the placebo group RR 0.92 (95% CI 0.83 to 1.01), see <LINK REF="CMP-001.55" TYPE="ANALYSIS">Analysis 1.55</LINK>.</P>
<P>
<B>Post-treatment results </B>
</P>
<P>Three to twelve months after treatment was discontinued, patients who were in the naltrexone group had a 14% lower risk to return to heavy drinking RR 0.86 (95% CI 0.75 to 0.99), see <LINK REF="CMP-001.56" TYPE="ANALYSIS">Analysis 1.56</LINK> and a 6% lower risk to return to any drinking RR = 0.94 (95% CI 0.79 to 1.11), see <LINK REF="CMP-001.57" TYPE="ANALYSIS">Analysis 1.57</LINK> than those who were in the placebo group.</P>
<P>
<B>Sensitivity analyses </B>
</P>
<P>If data synthesis for "return to any drinking" (I<SUP>2</SUP> = 28%) was based on a fixed-effect model, a significant effect was obtained RR 0.95 (95% CI 0.92 to 0.98) see <LINK REF="CMP-001.58" TYPE="ANALYSIS">Analysis 1.58</LINK>, meaning that the effectiveness conclusions concerning the outcome vary with the statistical model chosen for its calculation.</P>
<P>Synthesis of effects according to their sponsoring indicated a higher magnitude of effects for non-profit sponsored, investigator-driven trials RR 0.84 (95% CI 0.77 to 0.91) than for industry-sponsored studies (RR = 0.90; 95% CI 0.78 to 1.05) see <LINK REF="CMP-001.59" TYPE="ANALYSIS">Analysis 1.59</LINK> or <LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>.</P>
<P>
<B>02 Subgroup analyses: Injectable naltrexone </B>
</P>
<P>Subgroup analyses of extended-release formulations of naltrexone compared to placebo (<LINK REF="STD-Garbutt-2005" TYPE="STUDY">Garbutt 2005</LINK>; <LINK REF="STD-Johnson-2004" TYPE="STUDY">Johnson 2004</LINK>; <LINK REF="STD-Kranzler-1998" TYPE="STUDY">Kranzler 1998</LINK>; <LINK REF="STD-Kranzler-2004" TYPE="STUDY">Kranzler 2004</LINK>) indicate that injected naltrexone reduced the risk of any drinking after detoxification to 92% of the placebo group RR = 0.92 (95% CI 0.84 to 1.00), see <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>, the percentage of drinking days by about 9% MD - 8.54 (95% CI -15.77 to -1.31), see <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK> and the percentage of heavy drinking days by about 3% MD = -3.05 (95% CI -8.46 to 2.35), see <LINK REF="CMP-002.03" TYPE="ANALYSIS">Analysis 2.3</LINK>.</P>
<P>Extended-release naltrexone caused significantly more often daytime sleepiness than placebo RD 0.22 (95% CI 0.02 to 0.42) see <LINK REF="CMP-002.05" TYPE="ANALYSIS">Analysis 2.5</LINK>, decreased appetite RD 0.08 (95% CI 0.04 to 0.11), see <LINK REF="CMP-002.06" TYPE="ANALYSIS">Analysis 2.6</LINK>, dizziness RD 0.08 (95% CI 0.04 to 0.12), see <LINK REF="CMP-002.07" TYPE="ANALYSIS">Analysis 2.7</LINK>, fatigue RD 0.06 (95% CI 0.01 to 0.10), see <LINK REF="CMP-002.08" TYPE="ANALYSIS">Analysis 2.8</LINK> and vomiting RD 0.06 (95% CI 0.02 to 0.11), see <LINK REF="CMP-002.15" TYPE="ANALYSIS">Analysis 2.15</LINK>. Other seven adverse events considered did not show statistically significant differences, see <LINK REF="CMP-002.04" TYPE="ANALYSIS">Analysis 2.4</LINK>; <LINK REF="CMP-002.09" TYPE="ANALYSIS">Analysis 2.9</LINK>; <LINK REF="CMP-002.10" TYPE="ANALYSIS">Analysis 2.10</LINK>; <LINK REF="CMP-002.11" TYPE="ANALYSIS">Analysis 2.11</LINK>; <LINK REF="CMP-002.12" TYPE="ANALYSIS">Analysis 2.12</LINK>; <LINK REF="CMP-002.13" TYPE="ANALYSIS">Analysis 2.13</LINK>; <LINK REF="CMP-002.14" TYPE="ANALYSIS">Analysis 2.14</LINK>. Early drop-out due to side effects were more frequent in the extended-release naltrexone group than in the placebo group RR 1.57 (95% CI 0.92 to 2.69), see <LINK REF="CMP-002.16" TYPE="ANALYSIS">Analysis 2.16</LINK>, while the risk of dropping out irrespective of reasons slightly differed between injectable naltrexone and placebo RR 0.98 (95% CI 0.68 to 1.40), see <LINK REF="CMP-002.17" TYPE="ANALYSIS">Analysis 2.17</LINK>.</P>
<P>
<B>
<U>03 Naltrexone versus acamprosate</U> </B>
</P>
<P>Summary statistics based on the three clinical trials (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>; <LINK REF="STD-Morley-2006" TYPE="STUDY">Morley 2006</LINK>), which include naltrexone and acamprosate, did not indicate a significant difference between both substances in any of the primary outcomes. For the risk to return to heavy drinking RR 0.96 (CI 0.87 to 1.06), see <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>, the risk to return to any drinking RR 0.97 (CI 0.91 to 1.04) see <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK> a non-significant trend favouring naltrexone compared to acamprosate was found. In contrast, drinking days were non-significantly higher under naltrexone compared to acamprosate MD 3.06 (95% CI -7.42 to 13.53), see <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK>.</P>
<P>Naltrexone was associated with a higher risk of nausea RD 0.08 (95% CI 0.03 to 0.13) see <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK> and somnolence RD 0.07 (95% CI 0.01 to 0.13), see <LINK REF="CMP-003.06" TYPE="ANALYSIS">Analysis 3.6</LINK> compared to acamprosate, while acamprosate caused more often diarrhoea RD -0.27 (95% CI -0.34 to -0.20), see <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK>. Naltrexone had a 31% higher risk of terminating the study early because of adverse events than acamprosate RR 1.31 (95% CI 0.63 to 2.73), see <LINK REF="CMP-003.07" TYPE="ANALYSIS">Analysis 3.7</LINK>. In contrast, the risk of dropping out from a study irrespective of drop-out reasons was 8% lower in the naltrexone than in the acamprosate RR 0.92 (95% CI 0.77 to 1.10), see <LINK REF="CMP-003.08" TYPE="ANALYSIS">Analysis 3.8</LINK>.</P>
<P>
<B>
<U>04 Naltrexone versus apripiprazole, nefazodone or topiramate</U> </B>
</P>
<P>Summarized effects for naltrexone versus the new generation antipsychotic aripiprazole (<LINK REF="STD-Martinotti-2008" TYPE="STUDY">Martinotti 2008</LINK>), the antidepressant nefazodone (<LINK REF="STD-Kranzler-2000" TYPE="STUDY">Kranzler 2000</LINK>) and the anticonvulsant topiramate (<LINK REF="STD-Baltieri-2008" TYPE="STUDY">Baltieri 2008</LINK>), based on one study at a time, showed a non-significant superiority of active control compared to naltrexone. Patients in the naltrexone group had a non-significantly higher risk of heavy drinking (aripiprazole: RR = 1.32; 95% CI 0.73 to 2.39; nefazodone: RR = 1.08; 95% CI 0.73 to 1.59) and of any drinking (aripiprazole: RR = 1.04; 95% CI 0.68 to 1.59; nefazodone: RR = 1.04; 95% CI 0.82 to 1.32; topiramate: RR = 1.33; 95% CI 0.98 to 1.80) than in the active control group.</P>
<P>Naltrexone was also non-significantly associated with more drinking days (aripiprazole: MD = 4.30; 95% CI -15.73 to 24.33; nefazodone: MD = 4.40; 95% CI -4.99 to 13.79; topiramate: MD = 13.30; 95% CI -2.01 to 28.61) and heavy drinking days (aripiprazole: MD = 3.00; 95% CI -3.89 to 9.8; nefazodone: MD = 1.30; 95% CI -6.69 to 9.29; topiramate: MD = 13.4; 95% CI -2.27 to 29.07). In contrast, GGT values were lower in the naltrexone group compared to nefazodone (MD = -4.7; 95% CI -27.11 to 17.71) and topiramate (MD = -5.00; 95% CI -35.49 to 25.49), but this trend was again not statistically significant.</P>
<P>The only side-effects, which significantly differed between groups was decreased appetite and insomnia, which were documented more frequently in the naltrexone than in the nefazodone group (decreased appetite: RD = 0.22; 95% CI 0.07 to 0.38; NNTH = 4.54; insomnia: RD = 0.23; 95% C 0.06 to 0.41; NH = 4.35). Drop-out risks were 4%, 51% and 12% higher under naltrexone than aripiprazole (RR = 1.04; 95% CI 0.42 to 2.57), nefazodone (RR = 1.51; 95% CI 0.90 to 2.53) and topiramate (RR = 1.12; 95% CI 0.68 to 1.83).</P>
<P>
<B>
<U>Naltrexone + acamprosate versus placebo</U> </B>
</P>
<P>The combination of naltrexone and acamprosate, tested in two RCTs (<LINK REF="STD-Anton-2006" TYPE="STUDY">Anton 2006</LINK>; <LINK REF="STD-Kiefer-2003" TYPE="STUDY">Kiefer 2003</LINK>), was shown to reduce the risk to return to heavy drinking and to any drinking by about 30% (heavy drinking: RR = 0.71; 95% CI 0.38 to 1.35; any drinking: RR = 0.70; 95% CI 0.35 to 1.39) compared to placebo; drinking days were lowered by two percent (MD = -2.20; 95% CI -6.30 to 1.90) and GGT values by about nine units per liter (MD = -8.70; 95% CI -24.86 to 7.46). None of the effects reached statistical significance. Compared to placebo, the combined therapy with naltrexone and acamprosate caused significantly more often decreased appetite (RD = 0.11; 95% CI 0.05 to 0.17; NNTH = 9.09), diarrhea (RD = 0.20; 95% CI 0.13 to 0.27; NNTH = 5), nausea (RD = 0.20; 95% CI 0.14 to 0.26; NNTH = 5) and vomiting (RD = 0.09; 95% CI 0.03 to 0.14; NNTH = 11.1). The risk to drop-out due to adverse events was higher in the combined therapy group than in the placebo group (RR = 3.75; 95% CI 1.33 to 10.55), while the risk of dropping out irrespective of reasons was higher in the placebo group (RR = 0.83; 95% CI 0.28 to 2.49).</P>
<P>
<B>
<U>Naltrexone + acamprosate versus naltrexone</U> </B>
</P>
<P>When compared to naltrexone alone, effects of combined treatment with naltrexone and acamprosate turned out be lower in their magnitude than compared to placebo for most outcomes: The risk reduction for return to heavy drinking was 3% (RR = 0.97; 95% CI 0.75 to 1.26), for any drinking 12% (RR = 0.88; 0.61 to 1.28), while drinking days were decreased by about 1% (MD = -1.10; 95% CI -5.21 to 3.01). None of the primary outcomes reached statistical significance. A significant effect was demonstrated for the GGT, assessed in one trial only, which was lower in the naltrexone than in the combined treatment group (MD = 10.7; 95% CI 1.87 to 19.93). The combination of acamprosate and naltrexone induced significantly more often diarrhea (RD = 0.37; 95% CI 0.10 to 0.65; NNTH = 2.70) and nausea (RD = 0.09; 95% CI 0.02 to 0.16; NNTH = 11.1) than naltrexone alone. The risk of dropping out because of side effects (RR = 1.07; 95% CI 0.55 to 2.08) and the risk of terminating the study early irrespective of reasons (RR = 1.03; 95% CI 0.95 to 1.43) were non-significantly higher in the combined treatment group than in the naltrexone group.</P>
<P>
<B>
<U>Naltrexone + ondansetrone / sertraline versus placebo</U> </B>
</P>
<P>Combinations of naltrexone with either the 5HT-antagonist ondansetrone (<LINK REF="STD-Johnson-2000" TYPE="STUDY">Johnson 2000</LINK>) or the selective serotonin reuptake inhibitor sertraline (<LINK REF="STD-O_x0027_Malley-2008" TYPE="STUDY">O'Malley 2008</LINK>) have both been shown to significantly reduce drinking days and consumed amount per drinking day: In the trial with ondansetron (<LINK REF="STD-Johnson-2000" TYPE="STUDY">Johnson 2000</LINK>), patients drank alcohol on about 25% days less than those treated with placebo (MD = -23.80; 95% CI -58.13 to 10.53); in the trial with sertraline (<LINK REF="STD-O_x0027_Malley-2008" TYPE="STUDY">O'Malley 2008</LINK>), the effect was lower (MD = -10.6; 95% CI -12.06 to -9.14), but reached statistical significance. The same applies to consumed amount per drinking day, which reduced at about 50 grams in the ondansetron trial (MD = -50.70; 95% CI -81.53 to -19.87) and 28 grams in the sertraline trial (MD = -10.6; 95% CI -12.06 to -9.14) in comparison to placebo. For the combination with sertraline, a significant effect was also demonstrated on heavy drinking days (MD = -8.20; 95% CI -9.61 to -6.79). Effects on dichotomous outcomes (return to heavy drinking: RR = 0.79; 95% CI 0.59 to 1.05; return to any drinking: RR = 0.79; 95% CI 0.61 to 1.02) and the GGT values (MD = -7.30; 95% CI 33.79 to 19.19) in the sertraline trial slightly missed statistical significance. At the same time, sertraline was associated significantly more often with sleepiness (RR = 0.40; 95% CI 0.18 to 0.62), nausea (RR = 0.29; 95% CI 0.06 to 0.51) and dizziness (RR = 0.25; 95% CI 0.03 to 0.47).</P>
<P>
<B>
<U>Nalmefene versus placebo</U> </B>
</P>
<P>
<B>Treatment phase </B>
</P>
<P>By including data from 3 RCTs (<LINK REF="STD-Anton-2004" TYPE="STUDY">Anton 2004</LINK>; <LINK REF="STD-Mason-1994" TYPE="STUDY">Mason 1994</LINK>; <LINK REF="STD-Mason-1999" TYPE="STUDY">Mason 1999</LINK>) with 396 patients, nalmefene was shown to reduce the risk to return to heavy drinking to 85% (RR = 0.85; 95% CI 0.67 to 1.08) of the risk in the placebo group and to lower the risk to return to any drinking after detoxification to 92% (RR = 0.92; 95% CI 0.70 to 1.20). Nalmefene was furthermore associated with a 5% reduction of heavy drinking days (MD = -4.70; 95% CI -12.38 to 2.98) and a decrease of the amount of alcohol consumed per drinking day at about 4 grams (MD = -4.16; 95% CI -32.69 to 24.37). None of the effects reached statistical significance.</P>
<P>Adverse effects associated with the use of nalmefene were nausea (RD = 0.20; 95% CI 0.14 to 0.26), insomnia (RD = 0.12; 95% CI 0.05 to 0.19) and dizziness (RD = 0.15; 95% CI 0.05 to 0.25). Patients in the nalmefene group had a 43% higher risk to drop out due to adverse events than patients in the placebo group (RR = 1.43; 95% CI 0.22 to 9.24), while the risk to drop out irrespective of the reasons for termination, was lower (RR = 0.92; 95% CI 0.68 to 1.25) than in the placebo group. None of the effects on effectiveness outcomes and drop-out rates reached statistical significance.</P>
<P>
<B>Heterogeneity </B>
</P>
<P>With the exception of the effect variance for "return to any drinking", which was predominantly explained by sampling error (I<SUP>2</SUP> = 28%; <LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>), with proportions of between-study heterogeneity over 60%, I<SUP>2</SUP> statistics indicated a substantial level of heterogeneity (<LINK REF="REF-Deeks-2008" TYPE="REFERENCE">Deeks 2008</LINK>). High levels of heterogeneity for the continuous outcomes drinking days (I<SUP>2</SUP> = 94%; <LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>), heavy drinking days (I<SUP>2</SUP> = 81%; <LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>), consumed amount per drinking day (I<SUP>2</SUP> = 66%; <LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>) and GGT (I<SUP>2</SUP> = 61%; <LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>) were confirmed by &#964;<SUP>2</SUP>statistics (drinking days: &#964;<SUP>2 </SUP>=<SUP> </SUP>9.59; heavy drinking days: &#964;<SUP>2 </SUP>= 10.71; consumed amount per drinking day; &#964;<SUP>2 </SUP>= 178.98; GGT: &#964;<SUP>2 </SUP>= 139.02), while the &#964;<SUP>2</SUP>statistics indicate<SUP> </SUP>moderate heterogeneity<SUP> </SUP>for<SUP> </SUP>the binary outcome<SUP> </SUP>"return to heavy drinking" (&#964;<SUP>2 </SUP>= 0.02; <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>).</P>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2010-10-15 14:14:57 +0200" MODIFIED_BY="Laura Amato">
<SUMMARY_OF_RESULTS MODIFIED="2010-10-15 14:14:57 +0200" MODIFIED_BY="Laura Amato">
<P>A total of 50 RCTs with 7793 patients was included in the review. Two of the three primary outcomes of the review clearly support the effectiveness of naltrexone in the treatment of alcohol dependence: Added to psychosocial treatment strategies, the opioid antagonist was shown to reduce the risk to return to heavy drinking to 83% of the placebo risk and to decrease drinking days by about 4%. For the third primary outcome of the review, return to any drinking, effects slightly missed statistical significance RR 0.96 (95% CI 0.92 to 1.00), if based on a random effects model.</P>
<P>Statistical significance was obtained for all secondary outcomes of the review: Compared to placebo, heavy drinking days were reduced by about 3% with naltrexone, the consumed amount of alcohol per drinking days was lowered by almost 11 grams and gamma-glutamyltransferase (GGT) values were decreased by 10 units per liter . Post-treatment evaluations, provided from a subset of six RCTs, indicate that the therapeutic effects of naltrexone fade after treatment is discontinued; anyhow, 3 to 12 months after the end of the treatment period, effects on heavy drinking still reach statistical significance .</P>
<P>Naltrexone intake was associated with different side effects, mainly assignable to the following two categories: 1. gastrointestinal symptoms like abdominal pain, decreased appetite, nausea and vomiting and 2. symptoms of sedation reported as daytime sleepiness, drowsiness, fatigue, lethargy, insomnia, somnolence and weakness. Further side effects were blurred vision, decreased libido, depression, dizziness and nightmares. In none of the trials, analyses of side effect indicated serious safety concerns. Anyhow, in one out of 50 patients, the adverse events induced by naltrexone lead to the discontinuation of treatment, indicating that most alcohol dependent patients accept side effects as a tolerable part of the treatment.</P>
<P>Treatment effects of extended-release naltrexone and of nalmefene, the second opioid antagonist tested in review, were shown to be comparable in their magnitude with those of oral naltrexone. However, for both drugs, extended-release naltrexone and nalmefene, statistical significance was missed. Besides a more pronounced sedative component for injectable naltrexone, the tolerability of extended-release naltrexone and nalmefene appears comparable to that of oral naltrexone.</P>
<P>Meta-analytic integrations of head-to-head comparisons between naltrexone and acamprosate did not indicate a significant superiority of one or the other drug, but the corresponding study base of three RCTs is still too sparse to draw final conclusions. The same applies to the effects of combined treatments with acamprosate and naltrexone, based on two RCTs, which are promising, but need to be confirmed by further effectiveness and safety studies. Further head-to-head comparisons of naltrexone with the antipsychotic aripiprazole, the antidepressant nefazodone and the anticonvulsant topiramate, based on one RCT in each case, showed a non-significant trend in favour of the active control groups. Future research on these substance will show, if the demonstrated effects will withstand further testing.</P>
<P>The high heterogeneity of effects (I<SUP>2 </SUP>&gt; 75%) is emphasizing the diverse nature of evidence in terms of treatment characteristics, patient characteristics and features of the study designs and the need to develop theoretically well-considered models to further explore the variability of effects.</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2010-08-02 16:45:06 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Completeness of the database</B>
</P>
<P>Analyses of return to heavy drinking, return to any drinking and drinking frequency (drinking days) refer to databases with 28, 27 and 26 RCTs, indicating outcome completeness rates of 56%, 54% and 52%. For secondary and post-treatment outcomes, completeness rates are considerably lower: outcome data on drinking amount and GGT are available from 16 RCTs (32%), heavy drinking days from 15 RCTS (30%) and post-treatment results from 6 RCTs (12%).</P>
<P>
<B>Applicability of the results</B>
</P>
<P>With the trials included in the review, treatment durations, types of psychosocial interventions and intensity of co-treatments are represented with a high variability. Additionally, inclusion criteria were defined in a non-restrictive way, meaning that samples reflect a mix of different patient characteristics. In contrast, some features of the study design, including the dosing of naltrexone as well as the settings of treatment, did not considerably vary between studies: With few exceptions, patients were detoxified before treatment, dosing of oral naltrexone was 50 mg per day and treatment was realized in outpatient programs. Thus, the generalizability of the demonstrated results might be restricted, if the frame conditions in clinical practice differ from those applied in research. Further limitations in the representativity of the sample might arise from the proceeding to screen out patients with concurrent psychiatric diagnoses from trials.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2010-08-02 17:03:57 +0200" MODIFIED_BY="[Empty name]">
<P>Various features of the study design, which have been implemented in the naltrexone and nalmefene trials included in the review, ensure a high methodological quality of the primary database: To prevent selection bias, patients were randomly assigned to treatment groups, to mask treatment allocation, active medication and placebo with identical appearance were used and to reduce the general susceptibility of outcomes to bias effects, objective measures of drinking were considered (<LINK REF="REF-Wood-2008" TYPE="REFERENCE">Wood 2008</LINK>), either to validate patient-reported outcomes or as a discrete outcome criteria in the majority of studies.</P>
<P>If treatment groups differed in baseline characteristics, differences were controlled in the statistical analyses of treatment effects. Group differences in the attendance to treatment as assessed with drop-out and compliance rates, were rarely demonstrated and are likely to be rather generated by chance than by systematic factors associated with performance bias. Sensitivity analysis did not suggest a difference between the results of industry sponsored trials and investigator-driven research and the testing of publication bias with the Egger's linear regression (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>) did not indicate that non-significant trials have been omitted from publication. The side effects caused by naltrexone can potentially reveal a patient's affiliation to the verum or placebo group - a methodological limitation that was discussed to have caused an overestimation of effects for antidepressants (<LINK REF="REF-Moncrieff-2004" TYPE="REFERENCE">Moncrieff 2004</LINK>); nevertheless, as none of the trials which tested blinding integrity found evidence that treatment allocation was unmasked, the associated risk of bias appears to be rather low. </P>
<P>Nevertheless, some uncertainties persist. As specific features of the study designs were omitted from trial reports, it remains unclear whether these have not been implemented or whether they were implemented, but not reported. For example, most analyses were conducted in accordance with the ITT principle, considered as the "gold standard" in data-analyses of RCTs (<LINK REF="REF-Newell-1992" TYPE="REFERENCE">Newell 1992</LINK>), but it has not consistently been reported, how lost to follow-ups were handled in the data analyses. Additionally, poor reporting concerned the methods used for generating random sequences, the exact specification of person groups included in the blinding process and the methods applied for allocation concealment. Particularly the latter,<B> </B>unclear concealment, has repeatedly been shown to be associated with bias effects in various fields of clinical research (<LINK REF="REF-Schulz-1995" TYPE="REFERENCE">Schulz 1995</LINK>; <LINK REF="REF-Huwiler_x002d_Muntener-2002" TYPE="REFERENCE">Huwiler-Muntener 2002</LINK>; <LINK REF="REF-Pildal-2007" TYPE="REFERENCE">Pildal 2007</LINK>).</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2010-08-02 16:45:59 +0200" MODIFIED_BY="[Empty name]">
<P>To lower the risk of bias in the review process, all outcome statistics were extracted by two authors independently (SR &amp; AH). To prevent confirmation bias (<LINK REF="REF-Nickerson-1998" TYPE="REFERENCE">Nickerson 1998</LINK>)<B>, </B>at least one author has participated in each review step, who has not been involved in addiction treatment and research before.</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2010-08-02 17:50:18 +0200" MODIFIED_BY="[Empty name]">
<P>Basically, the present Cochrane review confirms most effectiveness and safety conclusions drawn from previous reviews and meta-analyses (<LINK REF="REF-Schoechlin-2000" TYPE="REFERENCE">Schoechlin 2000</LINK>; <LINK REF="REF-Kranzler-2001" TYPE="REFERENCE">Kranzler 2001</LINK>; <LINK REF="REF-Hopkins-2002" TYPE="REFERENCE">Hopkins 2002</LINK>; <LINK REF="REF-Berglund-2003" TYPE="REFERENCE">Berglund 2003</LINK>; <LINK REF="REF-Streeton-2001" TYPE="REFERENCE">Streeton 2001</LINK>; <LINK REF="REF-Srisurapanont-2000" TYPE="REFERENCE">Srisurapanont 2000</LINK>; <LINK REF="REF-Slattery-2003" TYPE="REFERENCE">Slattery 2003</LINK>; <LINK REF="REF-Bouza-2004" TYPE="REFERENCE">Bouza 2004</LINK>; <LINK REF="REF-Srisurapanont-2005a" TYPE="REFERENCE">Srisurapanont 2005a</LINK>; <LINK REF="REF-Srisurapanont-2005b" TYPE="REFERENCE">Srisurapanont 2005b</LINK>; <LINK REF="REF-Roozen-2006" TYPE="REFERENCE">Roozen 2006</LINK>; <LINK REF="REF-Rosner-2008" TYPE="REFERENCE">Rosner 2008</LINK>). With RR = 0.64 (95% CI 0.51 to 0.82) for return to heavy drinking, based on 7 RCTs with 822 patients, and RR = 0.91 (95% CI 0.81 to 1.02) for return to any drinking, based on 10 RCTs with 1014 patients, the results of the latest available update of the Cochrane review (<LINK REF="REF-Srisurapanont-2005a" TYPE="REFERENCE">Srisurapanont 2005a</LINK>; <LINK REF="REF-Srisurapanont-2005b" TYPE="REFERENCE">Srisurapanont 2005b</LINK>) have already indicated the significance of effects for the prevention of heavy drinking, but not for any drinking. Likewise, a meta-analysis of the Spanish Agency for Health Technology Assessment (<LINK REF="REF-Bouza-2004" TYPE="REFERENCE">Bouza 2004</LINK>) reported significant effects on heavy drinking rates (NNTB = 9; 95% CI 6.o to 14.0), while abstinence rates have not significantly been modified by naltrexone. With RR = 0.96 (95% CI 0.92 to 1.01) for "return to any drinking", RR = 0.83 (95% CI 0.76 to 0.90) for "return to heavy drinking" and an associated NNTB of 9.09 (95% CI 6.67 to 14.28), the magnitude of treatment effects estimated by the present Cochrane review is marginally below the results of previous reviews - a fact that can be ascribed to the inclusion of newer studies with negative results. </P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2010-10-18 09:07:58 +0200" MODIFIED_BY="Laura Amato">
<IMPLICATIONS_PRACTICE MODIFIED="2010-08-03 11:28:17 +0200" MODIFIED_BY="[Empty name]">
<P>Based on comprehensive evidence from 50 RCTs with 7793 patients, the review demonstrates the effectiveness and safety of naltrexone for the treatment of alcohol dependence. The opioid antagonist was shown to reduce the risk to return to heavy drinking to 83% of the placebo risk, to decrease drinking days by about 4% and heavy drinking days by about 3%, meaning that the drug on average avoids one additional day with heavy drinking per month. On days, on which alcohol is consumed, patients treated with naltrexone manage to refrain from about one drink they would have had under placebo. Referred to a population of alcohol dependent patients, naltrexone can be expected to prevent heavy drinking in one out of nine patients, who would otherwise have returned to a heavy drinking pattern. In contrast, statistical significance was missed for return to any drinking; the dependency of the effectiveness conclusions on the assumptions of the underlying statistical model, as indicated by the sensitivity analysis, underscores preliminary nature of this finding.</P>
<P>However, when translating research into clinical practice, it needs to be taken into consideration that the low levels of medication compliance and the high rates of patients dropping-out early from treatment in addiction treatment impede the demonstration of therapeutic effects in clinical trials. For patients, who take naltrexone regularly, therapeutic benefits are likely to exceed those demonstrated in clinical trials. Secondly, it should be kept in mind that naltrexone was added to psychosocial and psychotherapeutic interventions in most trials. Thus, strictly speaking, effect sizes rather reflect the additional benefit of adding naltrexone to psychosocial treatments than its benefit compared to placebo - a fact which often remained unconsidered in the interpretation of results. Nevertheless, despite these obstacles and restrictions, demonstrated treatment effects for naltrexone are comparable in their magnitude with those obtained in other areas of psychiatric research (<LINK REF="REF-Adams-2007" TYPE="REFERENCE">Adams 2007</LINK>; <LINK REF="REF-Arroll-2009" TYPE="REFERENCE">Arroll 2009</LINK>; <LINK REF="REF-Citrome-2008" TYPE="REFERENCE">Citrome 2008</LINK>).</P>
<P>All in all, opioid antagonists are not magic bullets in the treatment of alcohol dependence and - considering the complexity of processes involved in the development and maintenance of addiction - there will probably never be a single strategy that can "cure" alcohol dependence. But, after summarizing and appraising the available evidence, naltrexone appears to be an helpful and effective mean to support abstinence in alcohol dependent patients. Nevertheless, the principle that therapeutic decisions should be shared decisions between physicians and patients applies to pharmacological relapse prevention in a particular way; this is not only to respect a patient's` free choice of treatment, but also to ensure commitment and compliance. Patients' doubts and reservations against a therapeutic strategy which uses a substance to treat dependency from another one, should be taken seriously when informing patients about their treatment options and the associated risks and benefits. At the same time, therapeutic strategies which have been shown to work in well-controlled trials, should not kept back from patients, particularly if these concern the treatment of a disease that is known to have a high impact on health and quality and duration of life and for which alternative therapeutic options are of limited effectiveness.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2010-10-18 09:07:58 +0200" MODIFIED_BY="Laura Amato">
<P>Treatment of alcohol dependence is a complex therapeutic process and research on its effectiveness meets with particular difficulties. One of the main methodological challenges in addiction research results from the high magnitude of drop-out rates. The inclusion of all randomised patients in the data analyses according to the intention-to-treat (ITT) principle and a handling of missing data, which accounts for the close linkage between treatment attendance and consumption in patients with substance use disorders, appear to be essential means for preventing attrition bias in addiction research. Nevertheless, as even the most elaborated methods for substituting incomplete patient data are associated with error, persistent efforts should be made to validly assess the drinking status of drop-outs and to ensure the validity of self-reports by objective measures.</P>
<P>The reporting of clinical trials with opioid antagonists was clear and comprehensible in most study publications; nevertheless some deficits became apparent. A stricter adherence to methodological standards of reporting as outlined in the CONSORT statement (<LINK REF="REF-Moher-2001" TYPE="REFERENCE">Moher 2001</LINK>) would help to remove methodological remaining doubts and uncertainties.</P>
<P>Finally, the review at hand refers to gaps in knowledge, that need to be addressed by future research. Further head-to-head comparisons between naltrexone and acamprosate are needed to determine the relative effectiveness of both substances. Thereby a conceptual distinction between different achievements in drinking control such as a patient's ability to maintain continuously abstinent or his/her ability to stop drinking once started (<LINK REF="REF-Keller-1972" TYPE="REFERENCE">Keller 1972</LINK>) will help to specify differential efficacy profiles. In addition, direct comparisons between oral versus injectable naltrexone would help to further specify the advantages and disadvantages of different forms of application. The identification of patient characteristics which determine a patient's responsiveness to the available psychosocial and pharmacological interventions is indispensable for the deduction of elaborated techniques of combining therapeutic strategies and their tailoring to the individual treatment goals and therapeutic needs of patients.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2010-08-03 08:54:36 +0200" MODIFIED_BY="[Empty name]">
<P>We thank the team of the Cochrane Drugs and Alcohol Group (CDAG, Rome, Italy) for their support in the preparation of this review. We also thank Anton RF (Center for Drug and Alcohol Programs, Medical University of South Carolina, Charleston, USA), Baltieri D (Psychiatric Institute, University of Sao Paulo, Sao Paulo, Brazil), Balldin J, Mansson M (University Hospital MAS, Malmö, Sweden), Brown S (Department of Psychiatry, Southwestern Medical Center, University of Texas, Dallas, USA), Budzynski J (Department of Gastroenterology, Vascular Diseases and Internal Medicine, The Ludwik Rydygier Medical University, Bydgoszcz, Poland) Cramer JA, Krystal JH (Yale University School of Medicine, New Haven, Connecticut, USA), Chick J (Department of Psychiatry, Edinburgh University, Edinburgh, UK), de Goes e Castro LA, Laranjeira J (Unidade Pesquisa em Alcool e Outras Drogas, Department of Psychiatry, Universidade Federal de São Paulo, São Paulo, Brazil), Huang MC (Department of Psychiatry, Taipei City Psychiatric Center, Taipei City Hospital, Taipei, Taiwan), KIlleen TK (Medical University of South Carolina, Charleston, SC, USA), Latt CN (Faculty of Medicine, University of Sydney, Sydney, Australia), Morley KC (Central Clincial School of Medicine, University of Sydney, Sydney, Australia), Morris PLP (Gold Coast Integrated Mental Health Service, Queensland, Australia), Namkoong K (Yongdong Severance Hospital, Seoul, South Korea), Segura L, </P>
<P>Guardia J (Hospital de la Santa Creu i Sant Pau, Barcelona, Spain), Schmitz J (Department of Psychiatry and Behavioral Sciences, University of Texas, Houston, USA), Thomson P (CSR Incorporated, Arlington, USA) and Ziólkowski M (Department of Psychiatry Nursing, The Ludwik Rydygier Medical University, Bydgoszcz, Poland) for the disposal of unreported data and information*. Our gratitude also goes to Hesslbrock V (Alcohol Research Center, University of Connecticut Health Center, Farmington, USA) for the reference to ongoing studies and to Thomson P (CSR Incorporated, Arlington, USA), for providing advice for analyses of the COMBINE data set.</P>
<P>
<SUB>* authors of primary studies not mentioned in this section were either not requested as all relevant data and information were available from the trial publication or were unable to provide the requested data or information. </SUB>
</P>
<P>This work was financially supported by the Federal Ministry<SUP> </SUP>of Education and Research (BMBF) under the grant number 01KG0724. All responsibilities for the contents of this publications remain with the authors.<BR/>
</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2010-07-31 10:02:25 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Rösner, S.: </B>No conflict of interest known</P>
<P>
<B>Hackl-Herrwerth, A.: </B>No conflict of interest known</P>
<P>
<B>Leucht, S.: </B>Received speaker/consultancy/advisory board honoraria from SanofiAventis, BMS, EliLilly, Janssen/Johnson and Johnson, Lundbeck and Pfizer</P>
<P>
<B>Vecchi, S.: </B>No conflict of interest known</P>
<P>
<B>Srisurapanont, M.: </B>No conflict of interest known</P>
<P>
<B>Soyka, M.: </B>Reveived speaker/consultancy/advisory board honoraria from Lipha Pharmaceuticals, Forest Laboratories, Sanofi-Aventis, Essex Pharma, Eli Lilly, Prempharm and AstraZeneca</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2010-01-29 19:01:27 +0100" MODIFIED_BY="[Empty name]">
<P>SUSANNE RÖSNER: </P>
<UL>
<LI>protocol elaboration</LI>
<LI>study selection</LI>
<LI>data extraction</LI>
<LI>data management</LI>
<LI>analysis of data (MAL)</LI>
<LI>interpretation and discussion of results</LI>
<LI>writing the review</LI>
<LI>securing funding</LI>
</UL>
<P>ANDREA HACKL-HERRWERTH:</P>
<UL>
<LI>study selection</LI>
<LI>data extraction</LI>
</UL>
<P>STEFAN LEUCHT:</P>
<UL>
<LI>protocol elaboration</LI>
<LI>interpretation and discussion of results</LI>
</UL>
<P>SIMONA VECCHI: </P>
<UL>
<LI>development of search strategies</LI>
<LI>study search</LI>
</UL>
<P>MANIT SRISURAPANONT:</P>
<UL>
<LI>protocol elaboration</LI>
<LI>interpretation and discussion of results </LI>
</UL>
<P>MICHAEL SOYKA: </P>
<UL>
<LI>protocol elaboration</LI>
<LI>interpretation and discussion of results (clinical perspective)</LI>
<LI>securing funding</LI>
</UL>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2010-01-29 18:24:03 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Authors</B>
</P>
<P>Andrea Hackl-Herrwerth and Simona Vecchi Lehert have not been considered as authors in the protocol as their contribution turned out in the course of the review process.</P>
<P>
<B>Selection of outcomes </B>
</P>
<P>The selection of the primary and secondary outcomes in the protocol was mainly based on theoretical considerations concerning different compounds of drinking control (<LINK REF="REF-Keller-1972" TYPE="REFERENCE">Keller 1972</LINK>) and their clinical relevance. In the process of data extraction, limitations in the availability of outcomes became evident, which required changes in the outcome selection. Drop-out rates were considered as potential moderators of effectiveness in the review, but were not included in the evaluation of effectiveness as originally outlined in the protocol. The decision is based on the fact that various indicators of drinking behavior are available, which were assumed to be more closely related to therapeutic success than drop-out rates.</P>
<P>
<B>Assessment of heterogeneity</B>
</P>
<P>The inclusion of &#964;<SUP>2</SUP>-statistic in the assessment of heterogeneity, which was additionally applied to I<SUP>2</SUP>-statistic in the review to provide a measure of variability independent of the sample size, is based on considerations outlined by <LINK REF="REF-Rucker-2008" TYPE="REFERENCE">Rucker 2008</LINK>, which were not known to the authors at the time the protocol was elaborated.</P>
<P>
<B>Publication bias</B>
</P>
<P>Besides the graphical illustration with the funnel plot method (<LINK REF="REF-Light-1984" TYPE="REFERENCE">Light 1984</LINK>), the risk of publication bias was additionally quantified with a linear regression test (<LINK REF="REF-Egger-1997" TYPE="REFERENCE">Egger 1997</LINK>) in the review. The authors did not consider this option when writing the protocol.</P>
<P>
<B>Sensitivity analyses</B>
</P>
<P>The option to conduct a sensitivity analysis to examine the influence of the funding source on the study outcomes was not concerned in the protocol and subsequently added to the review.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2008-08-08 07:59:39 +0200" MODIFIED_BY="[Empty name]"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2010-10-15 13:07:49 +0200" MODIFIED_BY="[Empty name]">
<STUDIES MODIFIED="2010-10-15 13:07:49 +0200" MODIFIED_BY="[Empty name]">
<INCLUDED_STUDIES MODIFIED="2010-10-15 12:47:41 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Ahmadi-2002" MODIFIED="2010-10-15 09:20:34 +0200" MODIFIED_BY="[Empty name]" NAME="Ahmadi 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-10-15 09:20:34 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;15732235&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:20:34 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ahmadi J, Ahmadi N</AU>
<TI>A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence</TI>
<SO>German Journal of Psychiatry</SO>
<YR>2002</YR>
<VL>5</VL>
<PG>85-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2008-12-25 17:23:40 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anton-1999" MODIFIED="2010-01-28 10:55:33 +0100" MODIFIED_BY="[Empty name]" NAME="Anton 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-01-21 10:16:26 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;10553740&lt;/p&gt;" NOTES_MODIFIED="2010-01-21 10:16:26 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anton RF, Moak DH, Waid LR, Latham PK, Malcolm RJ, Dias JK</AU>
<TI>Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: results of a placebo-controlled trial</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1999</YR>
<VL>156</VL>
<NO>11</NO>
<PG>1758-64</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-02-01 19:38:43 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anton-2004" MODIFIED="2010-10-15 09:20:49 +0200" MODIFIED_BY="[Empty name]" NAME="Anton 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-10-15 09:20:49 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;15232334&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:20:49 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anton RF, Pettinati H, Zweben A, Kranzler HR, Johnson B, Bohn MJ, et al</AU>
<TI>A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2004</YR>
<VL>24</VL>
<NO>4</NO>
<PG>421-28</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anton-2005" MODIFIED="2010-10-15 09:21:00 +0200" MODIFIED_BY="[Empty name]" NAME="Anton 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-10-15 09:21:00 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;16012278&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:21:00 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anton RF, Moak DH, Latham P, Waid LR, Myrick H, Voronin K, et al</AU>
<TI>Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>4</NO>
<PG>349-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anton-2006" MODIFIED="2010-10-15 09:21:11 +0200" MODIFIED_BY="[Empty name]" NAME="Anton 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-10-15 09:21:11 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;16670409&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:21:11 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Anton RF, O'Malley SS, Ciraulo DA, Cisler RA, Couper D, Donovan DM, et al</AU>
<TI>Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2006</YR>
<VL>295</VL>
<NO>17</NO>
<PG>2003-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Auriacombe-2000" MODIFIED="2010-01-21 10:48:36 +0100" MODIFIED_BY="[Empty name]" NAME="Auriacombe 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-21 10:48:36 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>Auriacombe M, Robinson M, Grabot D, Tignol J</AU>
<TI>Naltrexone is ineffective to prevent relapse to alcohol in a realistic outpatient setting. A double blind one-year controlled study</TI>
<SO>Abstract CPDD</SO>
<YR>2000</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Balldin-2003" MODIFIED="2010-10-15 09:21:25 +0200" MODIFIED_BY="[Empty name]" NAME="Balldin 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-10-15 09:21:25 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;12878920&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:21:25 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Balldin J, Berglund M, Borg S, Mansson M, Bendtsen P, Franck J, et al</AU>
<TI>A 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2003</YR>
<VL>27</VL>
<NO>7</NO>
<PG>1142-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Baltieri-2008" MODIFIED="2010-10-15 09:21:35 +0200" MODIFIED_BY="[Empty name]" NAME="Baltieri 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-10-15 09:21:35 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;18855810&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:21:35 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Baltieri DA, Daro FR, Ribeiro PL, de Andrade AG</AU>
<TI>Comparing topiramate with naltrexone in the treatment of alcohol dependence</TI>
<SO>Addiction</SO>
<YR>2008</YR>
<VL>103</VL>
<NO>12</NO>
<PG>2035-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown-2009" MODIFIED="2010-10-15 09:21:51 +0200" MODIFIED_BY="[Empty name]" NAME="Brown 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-10-15 09:21:51 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Brown ES, Carmody TJ, Schmitz JM, Caetano R, Adinoff B, Swann AC</AU>
<TI>A Randomized, Double-Blind, Placebo-Controlled Pilot Study of Naltrexone in Outpatients with Bipolar Disorder and Alcohol Dependence</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2009</YR>
<VL>33</VL>
<NO>11</NO>
<PG>1863-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Chick-2000" MODIFIED="2010-10-15 09:22:21 +0200" MODIFIED_BY="[Empty name]" NAME="Chick 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-10-15 09:22:21 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;11093966&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:22:21 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Chick J, Anton R, Checinski K, Croop R, Drummond DC, Farmer R, et al</AU>
<TI>A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>6</NO>
<PG>587-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-de-Goes-e-Castro-2004" MODIFIED="2010-01-21 14:44:13 +0100" MODIFIED_BY="[Empty name]" NAME="de Goes e Castro 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-01-21 14:44:13 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="UNPUBLISHED">
<AU>de Goes e Castro, LA</AU>
<TI>Randomized, double-blind clinical trial with naltrexone and brief therapy for the in-patient treatment of alcohol dependence</TI>
<TO>Ensaio clínico duplo-cego randomizado e placebo-controlado com naltrexona associado à intervencão breve no tratamento ambulatorial da dependência álcool</TO>
<SO>Unpublished dissertation: Federal University of São Paulo</SO>
<YR>2004</YR>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galarza-1997" MODIFIED="2010-10-15 09:22:48 +0200" MODIFIED_BY="[Empty name]" NAME="Galarza 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-10-15 09:22:48 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;9577049&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:22:48 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galarza NJ, Diaz Ramirez D, Guzman F, Caballero JA, Martinez AJ</AU>
<TI>The use of naltrexone to treat ambulatory patients with alcohol dependence</TI>
<SO>Boletin da Asociacion Medica de Puerto Rico</SO>
<YR>1997</YR>
<VL>89</VL>
<NO>10-12</NO>
<PG>157-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garbutt-2005" MODIFIED="2010-10-15 09:28:46 +0200" MODIFIED_BY="[Empty name]" NAME="Garbutt 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-10-15 09:28:46 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;15811981&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:28:46 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Garbutt JC, Kranzler HR, O'Malley SS, Gastfriend DR, Pettinati HM, Silverman BL, et al</AU>
<TI>Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial</TI>
<SO>JAMA</SO>
<YR>2005</YR>
<VL>293</VL>
<NO>13</NO>
<PG>1617-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Gastpar-2002" MODIFIED="2010-10-15 09:30:05 +0200" MODIFIED_BY="[Empty name]" NAME="Gastpar 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-10-15 09:30:05 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;12454559&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:30:05 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Gastpar M, Bonnet U, Boning J, Mann K, Schmidt LG, Soyka M, et al</AU>
<TI>Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2002</YR>
<VL>22</VL>
<NO>6</NO>
<PG>592-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Guardia-2002" MODIFIED="2010-10-15 09:30:27 +0200" MODIFIED_BY="[Empty name]" NAME="Guardia 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-10-15 09:30:27 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;12351933&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:30:27 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Guardia J, Caso C, Arias F, Gual A, Sanahuja J, Ramirez M, et al</AU>
<TI>A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder: results from a multicenter clinical trial</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2002</YR>
<VL>26</VL>
<NO>9</NO>
<PG>1381-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hein_x00e4_l_x00e4_-2001" MODIFIED="2010-10-15 09:32:40 +0200" MODIFIED_BY="[Empty name]" NAME="Heinälä 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-10-15 09:32:40 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;11386491&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:32:40 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Heinala P, Alho H, Kiianmaa K, Lonnqvist J, Kuoppasalmi K, Sinclair JD</AU>
<TI>Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>3</NO>
<PG>287-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hersh-1998" MODIFIED="2009-12-21 21:55:31 +0100" MODIFIED_BY="[Empty name]" NAME="Hersh 1998" YEAR="1998">
<REFERENCE MODIFIED="2009-12-21 21:55:31 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;9768541&lt;/p&gt;" NOTES_MODIFIED="2009-12-21 21:55:31 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hersh D, Van Kirk JR, Kranzler HR</AU>
<TI>Naltrexone treatment of comorbid alcohol and cocaine use disorders</TI>
<SO>Psychopharmacology (Berl)</SO>
<YR>1998</YR>
<VL>139</VL>
<NO>1-2</NO>
<PG>44-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Huang-2005" MODIFIED="2010-01-21 11:26:38 +0100" MODIFIED_BY="[Empty name]" NAME="Huang 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-21 11:26:38 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;16109592&lt;/p&gt;" NOTES_MODIFIED="2010-01-21 11:26:38 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang MC, Chen CH, Yu JM, Chen CC</AU>
<TI>A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence in Taiwan</TI>
<SO>Addiction Biology</SO>
<YR>2005</YR>
<VL>10</VL>
<NO>3</NO>
<PG>289-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2000" MODIFIED="2010-01-29 15:46:44 +0100" MODIFIED_BY="[Empty name]" NAME="Johnson 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-01-29 15:46:44 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson BA, Ait-Daoud N, Prihoda TJ</AU>
<TI>Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: from hypotheses to preliminary clinical evidence</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2000</YR>
<VL>24</VL>
<NO>5</NO>
<PG>737-742</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-01-26 18:04:20 +0100" MODIFIED_BY="[Empty name]"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2004" MODIFIED="2010-10-15 09:33:21 +0200" MODIFIED_BY="[Empty name]" NAME="Johnson 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-10-15 09:33:21 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;15365306&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:33:21 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson BA, Ait-Daoud N, Aubin HJ, Van Den Brink W, Guzzetta R, Loewy J, et al</AU>
<TI>A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2004</YR>
<VL>28</VL>
<NO>9</NO>
<PG>1356-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kiefer-2003" MODIFIED="2010-10-15 09:34:06 +0200" MODIFIED_BY="[Empty name]" NAME="Kiefer 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-10-15 09:34:06 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;12511176&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:34:06 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, et al</AU>
<TI>Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2003</YR>
<VL>60</VL>
<NO>1</NO>
<PG>92-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Killeeen-2004" MODIFIED="2010-10-15 09:35:00 +0200" MODIFIED_BY="[Empty name]" NAME="Killeeen 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-10-15 09:35:00 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Killeen TK, Brady KT, Gold PB, Simpson KN, Faldowski RA, Tyson C, Anton RF</AU>
<TI>Effectiveness of naltrexone in a community treatment program</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2004</YR>
<VL>28</VL>
<NO>11</NO>
<PG>1710-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kranzler-1998" MODIFIED="2010-10-15 09:34:42 +0200" MODIFIED_BY="[Empty name]" NAME="Kranzler 1998" YEAR="1998">
<REFERENCE MODIFIED="2010-10-15 09:34:42 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;9726277&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:34:42 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kranzler HR, Modesto-Lowe V, Nuwayser ES</AU>
<TI>Sustained-release naltrexone for alcoholism treatment: a preliminary study</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>1998</YR>
<VL>22</VL>
<NO>5</NO>
<PG>1074-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kranzler-2000" MODIFIED="2009-12-21 22:53:20 +0100" MODIFIED_BY="[Empty name]" NAME="Kranzler 2000" YEAR="2000">
<REFERENCE MODIFIED="2009-12-21 22:53:20 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;10731624&lt;/p&gt;" NOTES_MODIFIED="2009-12-21 22:53:20 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kranzler HR, Modesto-Lowe V, Van Kirk J</AU>
<TI>Naltrexone vs. nefazodone for treatment of alcohol dependence. A placebo-controlled trial</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2000</YR>
<VL>22</VL>
<NO>5</NO>
<PG>493-503</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kranzler-2004" MODIFIED="2010-10-15 09:35:32 +0200" MODIFIED_BY="[Empty name]" NAME="Kranzler 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-10-15 09:35:32 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;15252291&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:35:32 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kranzler HR, Wesson DR, Billot L</AU>
<TI>Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2004</YR>
<VL>28</VL>
<NO>7</NO>
<PG>1051-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Krystal-2001" MODIFIED="2010-01-21 11:35:24 +0100" MODIFIED_BY="[Empty name]" NAME="Krystal 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-21 11:35:24 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;11742047&lt;/p&gt;" NOTES_MODIFIED="2010-01-21 11:35:24 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA</AU>
<TI>Naltrexone in the treatment of alcohol dependence</TI>
<SO>New England Journal of Medicine</SO>
<YR>2001</YR>
<VL>345</VL>
<NO>24</NO>
<PG>1734-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Latt-2002" MODIFIED="2010-01-21 11:39:08 +0100" MODIFIED_BY="[Empty name]" NAME="Latt 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-01-21 11:39:08 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;12064984&lt;/p&gt;" NOTES_MODIFIED="2010-01-21 11:39:08 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Latt NC, Jurd S, Houseman J, Wutzke SE</AU>
<TI>Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting</TI>
<SO>Medical Journal of Autralia</SO>
<YR>2002</YR>
<VL>176</VL>
<NO>11</NO>
<PG>530-534</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lee-2001" MODIFIED="2010-01-21 11:39:19 +0100" MODIFIED_BY="[Empty name]" NAME="Lee 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-01-21 11:39:19 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Lee A, Tan S, Lim D, Winslow RM, Wong KE, Allen J, et al</AU>
<TI>Naltrexone in the treatment of male alcoholics - an effectiveness study in Singapore.</TI>
<SO>Drug And Alcohol Review</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>2</NO>
<PG>193-199</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martinotti-2008" MODIFIED="2010-01-29 15:49:57 +0100" MODIFIED_BY="[Empty name]" NAME="Martinotti 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-01-29 15:49:57 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;18515460&lt;/p&gt;" NOTES_MODIFIED="2010-01-29 15:49:57 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martinotti G, Di Nicola M, Di Giannantonio M, Janiri L</AU>
<TI>Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial vs. naltrexone</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2008</YR>
<VL>23</VL>
<PG>1-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mason-1994" MODIFIED="2010-10-15 09:36:06 +0200" MODIFIED_BY="[Empty name]" NAME="Mason 1994" YEAR="1994">
<REFERENCE MODIFIED="2010-10-15 09:36:06 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;7847600&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:36:06 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mason BJ, Ritvo EC, Morgan RO, Salvato FR, Goldberg G, Welch B, et al</AU>
<TI>A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>1994</YR>
<VL>18</VL>
<NO>5</NO>
<PG>1162-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mason-1999" MODIFIED="2010-10-15 09:36:38 +0200" MODIFIED_BY="[Empty name]" NAME="Mason 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-10-15 09:36:38 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;10435606&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:36:38 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB</AU>
<TI>A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1999</YR>
<VL>56</VL>
<NO>8</NO>
<PG>719-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monterosso-2001" MODIFIED="2010-10-15 09:36:56 +0200" MODIFIED_BY="[Empty name]" NAME="Monterosso 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-10-15 09:36:56 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;11579624&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:36:56 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monterosso JR, Flannery BA, Pettinati HM, Oslin DW, Rukstalis M, O'Brien CP, et al</AU>
<TI>Predicting treatment response to naltrexone: the influence of craving and family history</TI>
<SO>American Journal of Addiction</SO>
<YR>2001</YR>
<VL>10</VL>
<NO>3</NO>
<PG>258-68</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Monti-2001" MODIFIED="2010-10-15 09:37:08 +0200" MODIFIED_BY="[Empty name]" NAME="Monti 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-10-15 09:37:08 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;11707638&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:37:08 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Monti PM, Rohsenow DJ, Swift RM, Gulliver SB, Colby SM, Mueller TI, et al</AU>
<TI>Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2001</YR>
<VL>25</VL>
<NO>11</NO>
<PG>1634-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Morley-2006" MODIFIED="2010-10-15 09:37:22 +0200" MODIFIED_BY="[Empty name]" NAME="Morley 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-10-15 09:37:22 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;16968347&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:37:22 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morley KC, Teesson M, Reid SC, Sannibale C, Thomson C, Phung N, et al</AU>
<TI>Naltrexone versus acamprosate in the treatment of alcohol dependence: A multi-centre, randomized, double-blind, placebo-controlled trial</TI>
<SO>Addiction</SO>
<YR>2006</YR>
<VL>101</VL>
<NO>10</NO>
<PG>1451-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Morris-2001" MODIFIED="2010-10-15 09:37:33 +0200" MODIFIED_BY="[Empty name]" NAME="Morris 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-10-15 09:37:33 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;11784454&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:37:33 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Morris PL, Hopwood M, Whelan G, Gardiner J, Drummond E</AU>
<TI>Naltrexone for alcohol dependence: a randomized controlled trial</TI>
<SO>Addiction</SO>
<YR>2001</YR>
<VL>96</VL>
<NO>11</NO>
<PG>1565-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Malley-1992" MODIFIED="2010-10-15 09:37:44 +0200" MODIFIED_BY="[Empty name]" NAME="O'Malley 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-10-15 09:37:44 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;1444726&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:37:44 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B</AU>
<TI>Naltrexone and coping skills therapy for alcohol dependence. A controlled study</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1992</YR>
<VL>49</VL>
<NO>11</NO>
<PG>881-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Malley-2007" MODIFIED="2010-10-15 09:37:55 +0200" MODIFIED_BY="[Empty name]" NAME="O'Malley 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-10-15 09:37:55 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;17374042&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:37:55 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Malley SS, Sinha R, Grilo CM, Capone C, Farren CK, McKee SA, et al</AU>
<TI>Naltrexone and cognitive behavioral coping skills therapy for the treatment of alcohol drinking and eating disorder features in alcohol-dependent women: a randomized controlled trial</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2007</YR>
<VL>31</VL>
<NO>4</NO>
<PG>625-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Malley-2008" MODIFIED="2010-10-15 12:37:30 +0200" MODIFIED_BY="[Empty name]" NAME="O'Malley 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-10-15 12:37:30 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;18482155&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 12:37:30 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Malley SS, Robin RW, Levenson AL, GreyWolf I, Chance LE, Hodgkinson CA, et al</AU>
<TI>Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings: a randomized controlled trial</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2008</YR>
<VL>32</VL>
<NO>7</NO>
<PG>1271-83</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oslin-1997" MODIFIED="2010-10-15 09:38:07 +0200" MODIFIED_BY="[Empty name]" NAME="Oslin 1997" YEAR="1998">
<REFERENCE MODIFIED="2010-10-15 09:38:07 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;9363289&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:38:07 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oslin D, Liberto JG, O'Brien J, Krois S, Norbeck J</AU>
<TI>Naltrexone as an adjunctive treatment for older patients with alcohol dependence</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>1997</YR>
<VL>5</VL>
<NO>4</NO>
<PG>324-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oslin-2005" MODIFIED="2010-01-21 11:48:36 +0100" MODIFIED_BY="[Empty name]" NAME="Oslin 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-01-21 11:48:36 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;15956269&lt;/p&gt;" NOTES_MODIFIED="2010-01-21 11:48:36 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oslin DW</AU>
<TI>Treatment of late-life depression complicated by alcohol dependence</TI>
<SO>American Journal of Geriatric Psychiatry</SO>
<YR>2005</YR>
<VL>13</VL>
<NO>6</NO>
<PG>491-500</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oslin-2008" MODIFIED="2010-01-21 11:48:50 +0100" MODIFIED_BY="[Empty name]" NAME="Oslin 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-01-21 11:48:50 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;18540910&lt;/p&gt;" NOTES_MODIFIED="2010-01-21 11:48:50 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oslin DW, Lynch KG, Pettinati HM, Kampman KM, Gariti P, Gelfand L, et al</AU>
<TI>A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2008</YR>
<VL>32</VL>
<NO>7</NO>
<PG>1299-308</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petrakis-2004" MODIFIED="2010-10-15 09:38:28 +0200" MODIFIED_BY="[Empty name]" NAME="Petrakis 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-10-15 09:38:28 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;14634716&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:38:28 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petrakis IL, O'Malley S, Rounsaville B, Poling J, McHugh-Strong C, Krystal JH</AU>
<TI>Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia</TI>
<SO>Psychopharmacology (Berl)</SO>
<YR>2004</YR>
<VL>172</VL>
<NO>3</NO>
<PG>291-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petrakis-2005" MODIFIED="2010-10-15 09:38:43 +0200" MODIFIED_BY="[Empty name]" NAME="Petrakis 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-10-15 09:38:43 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;15866552&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:38:43 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Petrakis IL, Poling J, Levinson C, Nich C, Carroll K, Rounsaville B</AU>
<TI>Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders</TI>
<SO>Biologic Psychiatry</SO>
<YR>2005</YR>
<VL>57</VL>
<NO>10</NO>
<PG>1128-37</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pettinati-2008a" MODIFIED="2010-10-15 09:38:59 +0200" MODIFIED_BY="[Empty name]" NAME="Pettinati 2008a" YEAR="">
<REFERENCE MODIFIED="2010-10-15 09:38:59 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;18079068&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:38:59 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pettinati HM, Kampman KM, Lynch KG, Xie H, Dackis C, Rabinowitz AR, et al</AU>
<TI>A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence</TI>
<SO>Addictice Behaviors</SO>
<YR>2008</YR>
<VL>33</VL>
<NO>5</NO>
<PG>651-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pettinati-2008b" MODIFIED="2010-10-15 09:39:11 +0200" MODIFIED_BY="[Empty name]" NAME="Pettinati 2008b" YEAR="">
<REFERENCE MODIFIED="2010-10-15 09:39:11 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;17664051&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:39:11 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Pettinati HM, Kampman KM, Lynch KG, Suh JJ, Dackis CA, Oslin DW, et al</AU>
<TI>Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence</TI>
<SO>Journal of Substance Abuse and Treatment</SO>
<YR>2008</YR>
<VL>34</VL>
<NO>4</NO>
<PG>378-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmitz-2004" MODIFIED="2010-10-15 09:39:21 +0200" MODIFIED_BY="[Empty name]" NAME="Schmitz 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-10-15 09:39:21 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;15370932&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:39:21 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmitz JM, Stotts AL, Sayre SL, DeLaune KA, Grabowski J</AU>
<TI>Treatment of cocaine-alcohol dependence with naltrexone and relapse prevention therapy</TI>
<SO>American Journal of Addiction</SO>
<YR>2004</YR>
<VL>13</VL>
<NO>4</NO>
<PG>333-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmitz-2009" MODIFIED="2010-10-15 09:39:32 +0200" MODIFIED_BY="[Empty name]" NAME="Schmitz 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-10-15 09:39:32 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schmitz JM, Lindsay JA, Green CE, Herin DV, Stotts AL, Moeller GF</AU>
<TI>High-dose naltrexone therapy for cocaine-alcohol dependence</TI>
<SO>American Journal of Addiction</SO>
<YR>2009</YR>
<VL>18</VL>
<NO>5</NO>
<PG>356-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Volpicelli-1992" MODIFIED="2010-10-15 09:39:52 +0200" MODIFIED_BY="[Empty name]" NAME="Volpicelli 1992" YEAR="1992">
<REFERENCE MODIFIED="2010-10-15 09:39:52 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;1345133&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:39:52 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Volpicelli JR, Alterman AI, Hayashida M, O'Brien CP</AU>
<TI>Naltrexone in the treatment of alcohol dependence</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1992</YR>
<VL>49</VL>
<NO>11</NO>
<PG>876-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Volpicelli-1997" MODIFIED="2010-10-15 09:40:05 +0200" MODIFIED_BY="[Empty name]" NAME="Volpicelli 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-10-15 09:40:05 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;9283509&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:40:05 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Volpicelli JR, Rhines KC, Rhines JS, Volpicelli LA, Alterman AI, O'Brien CP</AU>
<TI>Naltrexone and alcohol dependence. Role of subject compliance</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1997</YR>
<VL>54</VL>
<NO>8</NO>
<PG>737-42</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="MIX" ID="STD-Zi_x00f3__x0142_kowski-2000" MODIFIED="2010-10-15 12:47:41 +0200" MODIFIED_BY="[Empty name]" NAME="Zió&#322;kowski 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-10-15 12:47:41 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="BOOK">
<AU>Ziólkowski M</AU>
<SO>Ocena skuteczno&#347;ci farmakoterapii w zapobieganiu nawrotowi picia u m&#281;&#380;czyzn uzale&#380;nionych od alkoholu, Akademia Medyczna im</SO>
<YR>2000</YR>
<PB>Ludwika Rydygiera w Bydgoszczy</PB>
<CY>Wydzia Lekarski</CY>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-05-12 15:17:28 +0200" MODIFIED_BY="[Empty name]"/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2010-10-15 11:38:21 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="PUB" ID="STD-Buri-2007" MODIFIED="2010-10-15 09:59:22 +0200" MODIFIED_BY="[Empty name]" NAME="Buri 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-10-15 09:59:22 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;17517820&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 09:59:22 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Buri C, Moggi F, Giovanoli A, Strik W</AU>
<TI>Prescription procedures in medication for relapse prevention after inpatient treatment for alcohol use disorders in Switzerland</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2007</YR>
<VL>42</VL>
<NO>4</NO>
<PG>333-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caputo-2003" MODIFIED="2010-01-21 11:53:15 +0100" MODIFIED_BY="[Empty name]" NAME="Caputo 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-21 11:53:15 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;12681528&lt;/p&gt;" NOTES_MODIFIED="2010-01-21 11:53:15 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caputo F, Addolorato G, Lorenzini F, Domenicali M, Greco G</AU>
<TI>Gamma-hydroxybutyric acid versus naltrexone in maintaining alcohol abstinence: an open randomized comparative study</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2003</YR>
<VL>70</VL>
<NO>1</NO>
<PG>85-91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Caputo-2007" MODIFIED="2010-10-15 10:00:19 +0200" MODIFIED_BY="[Empty name]" NAME="Caputo 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-10-15 10:00:19 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;17611081&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 10:00:19 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Caputo F, Addolorato G, Stoppo M, Francini S, Vignoli T, Lorenzini F, et al</AU>
<TI>Comparing and combining gamma-hydroxybutyric acid (GHB) and naltrexone in maintaining abstinence from alcohol: an open randomised comparative study</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2007</YR>
<VL>17</VL>
<NO>12</NO>
<PG>781-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Carroll-1993" MODIFIED="2010-10-15 10:00:35 +0200" MODIFIED_BY="[Empty name]" NAME="Carroll 1993" YEAR="1993">
<REFERENCE MODIFIED="2010-10-15 10:00:35 +0200" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Carroll CP, O`Malley SS, McCance-Katz E, Gordon L, Rounsaville B</AU>
<TI>Pharmacologic interventions for alcohol- and cocaine abusing individuals: a pilot study of disulfiram versus naltrexone</TI>
<SO>American Journal of Addiction</SO>
<YR>1993</YR>
<VL>2</VL>
<PG>77-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Croop-1997" MODIFIED="2010-10-15 10:00:56 +0200" MODIFIED_BY="[Empty name]" NAME="Croop 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-10-15 10:00:56 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;9400350&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 10:00:56 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Croop RS, Faulkner EB, Labriola DF</AU>
<TI>The safety profile of naltrexone in the treatment of alcoholism. Results from a multicenter usage study. The Naltrexone Usage Study Group</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1997</YR>
<VL>54</VL>
<NO>12</NO>
<PG>1130-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davidson-2004" MODIFIED="2010-10-15 10:01:19 +0200" MODIFIED_BY="[Empty name]" NAME="Davidson 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-10-15 10:01:19 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;15236831&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 10:01:19 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson D, Saha C, Scifres S, Fyffe J, O'Connor S, Selzer C</AU>
<TI>Naltrexone and brief counseling to reduce heavy drinking in hazardous drinkers</TI>
<SO>Addictive Behaviors</SO>
<YR>2004</YR>
<VL>29</VL>
<NO>6</NO>
<PG>1253-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davidson-2007a" MODIFIED="2010-10-15 10:04:36 +0200" MODIFIED_BY="[Empty name]" NAME="Davidson 2007a" YEAR="2007">
<REFERENCE MODIFIED="2010-10-15 10:04:36 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;17286342&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 10:04:36 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson D, Gulliver SB, Longabaugh R, Wirtz PW, Swift R</AU>
<TI>Building better cognitive-behavioral therapy: is broad-spectrum treatment more effective than motivational-enhancement therapy for alcohol-dependent patients treated with naltrexone?</TI>
<SO>Journal of Studies on Alcohol and Drugs</SO>
<YR>2007</YR>
<VL>68</VL>
<NO>2</NO>
<PG>238-47</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Davidson-2007b" MODIFIED="2009-12-25 22:27:06 +0100" MODIFIED_BY="[Empty name]" NAME="Davidson 2007b" YEAR="2007">
<REFERENCE MODIFIED="2009-12-25 22:27:06 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;17514344&lt;/p&gt;" NOTES_MODIFIED="2009-12-25 22:27:06 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Davidson D, Wirtz PW, Gulliver SB, Longabaugh R</AU>
<TI>Naltrexone's suppressant effects on drinking are limited to the first 3 months of treatment</TI>
<SO>Psychopharmacology (Berl)</SO>
<YR>2007</YR>
<VL>194</VL>
<NO>1</NO>
<PG>1-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-De-Sousa-2004" MODIFIED="2010-10-15 10:01:38 +0200" MODIFIED_BY="[Empty name]" NAME="De Sousa 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-10-15 10:01:38 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;15525790&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 10:01:38 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>De Sousa A</AU>
<TI>A one-year pragmatic trial of naltrexone vs disulfiram in the treatment of alcohol dependence</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2004</YR>
<VL>39</VL>
<NO>6</NO>
<PG>528-31</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Deas-2005" MODIFIED="2010-10-15 10:05:09 +0200" MODIFIED_BY="[Empty name]" NAME="Deas 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-10-15 10:05:09 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;16262589&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 10:05:09 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Deas D, May MP, Randall C, Johnson N, Anton R</AU>
<TI>Naltrexone treatment of adolescent alcoholics: an open-label pilot study</TI>
<SO>Journal of Child and Adolescent Psychopharmacology</SO>
<YR>2005</YR>
<VL>15</VL>
<NO>5</NO>
<PG>723-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Drobes-2000" MODIFIED="2010-10-15 10:05:32 +0200" MODIFIED_BY="[Empty name]" NAME="Drobes 2000" YEAR="2000">
<REFERENCE MODIFIED="2010-10-15 10:05:32 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;10757131&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 10:05:32 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Drobes DJ, Anton RF</AU>
<TI>Drinking in alcoholics following an alcohol challenge research protocol</TI>
<SO>Journal of Studies on Alcohol</SO>
<YR>2000</YR>
<VL>61</VL>
<NO>2</NO>
<PG>220-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Drobes-2004" MODIFIED="2010-10-15 10:05:46 +0200" MODIFIED_BY="[Empty name]" NAME="Drobes 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-10-15 10:05:46 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;15365307&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 10:05:46 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Drobes DJ, Anton RF, Thomas SE, Voronin K</AU>
<TI>Effects of naltrexone and nalmefene on subjective response to alcohol among non-treatment-seeking alcoholics and social drinkers</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2004</YR>
<VL>28</VL>
<NO>9</NO>
<PG>1362-70</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dunbar-2006" MODIFIED="2010-10-15 10:05:55 +0200" MODIFIED_BY="[Empty name]" NAME="Dunbar 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-10-15 10:05:55 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;16499489&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 10:05:55 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dunbar JL, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, Lasseter KC</AU>
<TI>Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2006</YR>
<VL>30</VL>
<NO>3</NO>
<PG>480-90</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Farren-2009" MODIFIED="2010-10-15 11:27:07 +0200" MODIFIED_BY="[Empty name]" NAME="Farren 2009" YEAR="2009">
<REFERENCE MODIFIED="2010-10-15 11:27:07 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;18644685&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 11:27:07 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Farren CK, Scimeca M, Wu R, Malley SO</AU>
<TI>A double-blind, placebo-controlled study of sertraline with naltrexone for alcohol dependence</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>2009</YR>
<VL>99</VL>
<NO>1-3</NO>
<PG>317-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Galloway-2005" MODIFIED="2009-12-25 22:28:45 +0100" MODIFIED_BY="[Empty name]" NAME="Galloway 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-12-25 22:28:45 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;15804355&lt;/p&gt;" NOTES_MODIFIED="2009-12-25 22:28:45 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Galloway GP, Koch M, Cello R, Smith DE</AU>
<TI>Pharmacokinetics, safety, and tolerability of a depot formulation of naltrexone in alcoholics: an open-label trial</TI>
<SO>BMC Psychiatry</SO>
<YR>2005</YR>
<VL>5</VL>
<PG>18</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hermos-2004" MODIFIED="2010-10-15 11:27:53 +0200" MODIFIED_BY="[Empty name]" NAME="Hermos 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-10-15 11:27:53 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;15318122&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 11:27:53 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hermos JA, Young MM, Gagnon DR, Fiore LD</AU>
<TI>Patterns of dispensed disulfiram and naltrexone for alcoholism treatment in a veteran patient population</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2004</YR>
<VL>28</VL>
<NO>8</NO>
<PG>1229-35</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hernandez_x002d_Avila-2006" MODIFIED="2010-10-15 11:28:11 +0200" MODIFIED_BY="[Empty name]" NAME="Hernandez-Avila 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-10-15 11:28:11 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;16634855&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 11:28:11 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hernandez-Avila CA, Song C, Kuo L, Tennen H, Armeli S, Kranzler HR</AU>
<TI>Targeted versus daily naltrexone: secondary analysis of effects on average daily drinking</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2006</YR>
<VL>30</VL>
<NO>5</NO>
<PG>860-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2003" MODIFIED="2010-10-15 11:28:57 +0200" MODIFIED_BY="[Empty name]" NAME="Johnson 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-10-15 11:28:57 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;12826990&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 11:28:57 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Johnson BA, O'Malley SS, Ciraulo DA, Roache JD, Chambers RA, Sarid-Segal O, et al</AU>
<TI>Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2003</YR>
<VL>23</VL>
<NO>3</NO>
<PG>281-93</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Karhuvaara-2007" MODIFIED="2010-10-15 11:29:17 +0200" MODIFIED_BY="[Empty name]" NAME="Karhuvaara 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-10-15 11:29:17 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;17451401&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 11:29:17 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Karhuvaara S, Simojoki K, Virta A, Rosberg M, Loyttyniemi E, Nurminen T, et al</AU>
<TI>Targeted nalmefene with simple medical management in the treatment of heavy drinkers: a randomized double-blind placebo-controlled multicenter study</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2007</YR>
<VL>31</VL>
<NO>7</NO>
<PG>1179-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Knox-1999" MODIFIED="2010-10-15 11:29:37 +0200" MODIFIED_BY="[Empty name]" NAME="Knox 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-10-15 11:29:37 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;10681104&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 11:29:37 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Knox PC, Donovan DM</AU>
<TI>Using naltrexone in inpatient alcoholism treatment</TI>
<SO>Jourbnal of Psychoactive Drugs</SO>
<YR>1999</YR>
<VL>31</VL>
<NO>4</NO>
<PG>373-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kranzler-1997" MODIFIED="2010-10-15 11:29:56 +0200" MODIFIED_BY="[Empty name]" NAME="Kranzler 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-10-15 11:29:56 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;9183513&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 11:29:56 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kranzler HR, Tennen H, Penta C, Bohn MJ</AU>
<TI>Targeted naltrexone treatment of early problem drinkers</TI>
<SO>Addictive Behaviors</SO>
<YR>1997</YR>
<VL>22</VL>
<NO>3</NO>
<PG>431-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kranzler-2004a" MODIFIED="2010-10-15 11:30:21 +0200" MODIFIED_BY="[Empty name]" NAME="Kranzler 2004a" YEAR="2004">
<REFERENCE MODIFIED="2010-10-15 11:30:21 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;15065964&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 11:30:21 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kranzler HR, Armeli S, Feinn R, Tennen H</AU>
<TI>Targeted naltrexone treatment moderates the relations between mood and drinking behavior among problem drinkers</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>2004</YR>
<VL>72</VL>
<NO>2</NO>
<PG>317-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kranzler-2004b" MODIFIED="2010-10-15 11:33:42 +0200" MODIFIED_BY="[Empty name]" NAME="Kranzler 2004b" YEAR="2004">
<REFERENCE MODIFIED="2010-10-15 11:33:42 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;15065964&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 11:33:42 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kranzler HR, Armeli S, Feinn R, Tennen H</AU>
<TI>Targeted naltrexone treatment moderates the relations between mood and drinking behavior among problem drinkers</TI>
<SO>Journal of Consulting and Clinical Psychology</SO>
<YR>2004</YR>
<VL>72</VL>
<NO>2</NO>
<PG>317-27</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kranzler-2008" MODIFIED="2010-10-15 11:33:57 +0200" MODIFIED_BY="[Empty name]" NAME="Kranzler 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-10-15 11:33:57 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;19032530&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 11:33:57 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kranzler HR, Stephenson JJ, Montejano L, Wang S, Gastfriend DR</AU>
<TI>Persistence with oral naltrexone for alcohol treatment: implications for health-care utilization</TI>
<SO>Addiction</SO>
<YR>2008</YR>
<VL>103</VL>
<NO>11</NO>
<PG>1801-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Laaksonen-2008" MODIFIED="2010-01-21 12:00:57 +0100" MODIFIED_BY="[Empty name]" NAME="Laaksonen 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-01-21 12:00:57 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;17965444&lt;/p&gt;" NOTES_MODIFIED="2010-01-21 12:00:57 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Laaksonen E, Koski-Jannes A, Salaspuro M, Ahtinen H, Alho H</AU>
<TI>A randomized, multicentre, open-label, comparative trial of disulfiram, naltrexone and acamprosate in the treatment of alcohol dependence</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2008</YR>
<VL>43</VL>
<NO>1</NO>
<PG>53-61</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Landabaso-1999" MODIFIED="2010-01-21 12:01:24 +0100" MODIFIED_BY="[Empty name]" NAME="Landabaso 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-01-21 12:01:24 +0100" MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Landabaso MA, Sanz J, Calle R, Ruiz de Apodaka J, Jimenez Lerma JM, Guitierez-Fraile K</AU>
<TI>Naltrexone in the treatment of alcoholism: two-year follow-up results</TI>
<SO>European Psychiatry</SO>
<YR>1999</YR>
<VL>13</VL>
<PG>97-105</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Martinotti-2007" MODIFIED="2010-10-15 11:34:31 +0200" MODIFIED_BY="[Empty name]" NAME="Martinotti 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-10-15 11:34:31 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;17397097&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 11:34:31 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Martinotti G, Di Nicola M, Romanelli R, Andreoli S, Pozzi G, Moroni N, et al</AU>
<TI>High and low dosage oxcarbazepine versus naltrexone for the prevention of relapse in alcohol-dependent patients</TI>
<SO>Human Psychopharmacology</SO>
<YR>2007</YR>
<VL>22</VL>
<NO>3</NO>
<PG>149-56</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Mason-2002" MODIFIED="2009-12-25 22:34:06 +0100" MODIFIED_BY="[Empty name]" NAME="Mason 2002" YEAR="2002">
<REFERENCE MODIFIED="2009-12-25 22:34:06 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;12377396&lt;/p&gt;" NOTES_MODIFIED="2009-12-25 22:34:06 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Mason BJ, Goodman AM, Dixon RM, Hameed MH, Hulot T, Wesnes K, et al</AU>
<TI>A pharmacokinetic and pharmacodynamic drug interaction study of acamprosate and naltrexone</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2002</YR>
<VL>27</VL>
<NO>4</NO>
<PG>596-606</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Modesto_x002d_Lowe-1997" MODIFIED="2010-01-21 12:01:59 +0100" MODIFIED_BY="[Empty name]" NAME="Modesto-Lowe 1997" YEAR="1997">
<REFERENCE MODIFIED="2010-01-21 12:01:59 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;9476694&lt;/p&gt;" NOTES_MODIFIED="2010-01-21 12:01:59 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Modesto-Lowe V, Burleson JA, Hersh D, Bauer LO, Kranzler HR</AU>
<TI>Effects of naltrexone on cue-elicited craving for alcohol and cocaine</TI>
<SO>Drug and Alcohol Dependence</SO>
<YR>1997</YR>
<VL>49</VL>
<NO>1</NO>
<PG>9-16</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Myrick-2008" MODIFIED="2010-10-15 11:34:43 +0200" MODIFIED_BY="[Empty name]" NAME="Myrick 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-10-15 11:34:43 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;18391135&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 11:34:43 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Myrick H, Anton RF, Li X, Henderson S, Randall PK, Voronin K</AU>
<TI>Effect of naltrexone and ondansetron on alcohol cue-induced activation of the ventral striatum in alcohol-dependent people</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2008</YR>
<VL>65</VL>
<NO>4</NO>
<PG>466-75</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Nava-2006" MODIFIED="2010-10-15 11:35:00 +0200" MODIFIED_BY="[Empty name]" NAME="Nava 2006" YEAR="2006">
<REFERENCE MODIFIED="2010-10-15 11:35:00 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;17165363&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 11:35:00 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Nava F, Premi S, Manzato E, Lucchini A</AU>
<TI>Comparing treatments of alcoholism on craving and biochemical measures of alcohol consumption</TI>
<SO>Journal of Psychoactive Drugs</SO>
<YR>2006</YR>
<VL>38</VL>
<NO>3</NO>
<PG>211-17</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-O_x0027_Malley-2003" MODIFIED="2010-01-21 12:03:00 +0100" MODIFIED_BY="[Empty name]" NAME="O'Malley 2003" YEAR="2003">
<REFERENCE MODIFIED="2010-01-21 12:03:00 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;12885685&lt;/p&gt;" NOTES_MODIFIED="2010-01-21 12:03:00 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>O'Malley SS, Rounsaville BJ, Farren C, Namkoong K, Wu R, Robinson J, et al</AU>
<TI>Initial and maintenance naltrexone treatment for alcohol dependence using primary care vs specialty care: a nested sequence of 3 randomized trials</TI>
<SO>Archives of Internal Medicine</SO>
<YR>2003</YR>
<VL>163</VL>
<NO>14</NO>
<PG>1695-704</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ooteman-2007" MODIFIED="2010-10-15 11:35:29 +0200" MODIFIED_BY="[Empty name]" NAME="Ooteman 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-10-15 11:35:29 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;17379484&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 11:35:29 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ooteman W, Koeter MW, Verheul R, Schippers GM, van den Brink W</AU>
<TI>The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2007</YR>
<VL>17</VL>
<NO>8</NO>
<PG>558-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oslin-1999" MODIFIED="2010-10-15 11:35:43 +0200" MODIFIED_BY="[Empty name]" NAME="Oslin 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-10-15 11:35:43 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;10023615&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 11:35:43 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Oslin DW, Pettinati HM, Volpicelli JR, Wolf AL, Kampman KM, O'Brien CP</AU>
<TI>The effects of naltrexone on alcohol and cocaine use in dually addicted patients</TI>
<SO>Journal of Substance Abuse and Treatment</SO>
<YR>1999</YR>
<VL>16</VL>
<NO>2</NO>
<PG>163-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Palfai-1999" MODIFIED="2010-10-15 11:36:07 +0200" MODIFIED_BY="[Empty name]" NAME="Palfai 1999" YEAR="1999">
<REFERENCE MODIFIED="2010-10-15 11:36:07 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;10472515&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 11:36:07 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Palfai T, Davidson D, Swift R</AU>
<TI>Influence of naltrexone on cue-elicited craving among hazardous drinkers: the moderational role of positive outcome expectancies</TI>
<SO>Experminetal and Clinical Psychopharmacology</SO>
<YR>1999</YR>
<VL>7</VL>
<NO>3</NO>
<PG>266-73</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ponce-2005" MODIFIED="2010-10-15 11:36:23 +0200" MODIFIED_BY="[Empty name]" NAME="Ponce 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-10-15 11:36:23 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;15704026&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 11:36:23 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ponce G, Sanchez-Garcia J, Rubio G, Rodriguez-Jimenez R, Jimenez-Arriero MA, Palomo T</AU>
<TI>Efficacy of naltrexone in the treatment of alcohol dependence disorder in women</TI>
<SO>Actas Españolas de Psiquiatría</SO>
<YR>2005</YR>
<VL>33</VL>
<NO>1</NO>
<PG>13-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Ray-2007" MODIFIED="2010-10-15 11:36:33 +0200" MODIFIED_BY="[Empty name]" NAME="Ray 2007" YEAR="2007">
<REFERENCE MODIFIED="2010-10-15 11:36:33 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;17768272&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 11:36:33 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Ray LA, Hutchison KE</AU>
<TI>Effects of naltrexone on alcohol sensitivity and genetic moderators of medication response: a double-blind placebo-controlled study</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2007</YR>
<VL>64</VL>
<NO>9</NO>
<PG>1069-77</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rubio-2001" MODIFIED="2010-10-15 11:36:49 +0200" MODIFIED_BY="[Empty name]" NAME="Rubio 2001" YEAR="2001">
<REFERENCE MODIFIED="2010-10-15 11:36:49 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;11524308&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 11:36:49 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rubio G, Jimenez-Arriero MA, Ponce G, Palomo T</AU>
<TI>Naltrexone versus acamprosate: one year follow-up of alcohol dependence treatment</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2001</YR>
<VL>36</VL>
<NO>5</NO>
<PG>419-25</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rubio-2002" MODIFIED="2010-10-15 11:37:13 +0200" MODIFIED_BY="[Empty name]" NAME="Rubio 2002" YEAR="2002">
<REFERENCE MODIFIED="2010-10-15 11:37:13 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;12495798&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 11:37:13 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rubio G, Manzanares J, Lopez-Munoz F, Alamo C, Ponce G, Jimenez-Arriero MA, et al</AU>
<TI>Naltrexone improves outcome of a controlled drinking program</TI>
<SO>Journal of Substance Abuse and Treatment</SO>
<YR>2002</YR>
<VL>23</VL>
<NO>4</NO>
<PG>361-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rubio-2005" MODIFIED="2010-10-15 11:37:34 +0200" MODIFIED_BY="[Empty name]" NAME="Rubio 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-10-15 11:37:34 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;15797885&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 11:37:34 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rubio G, Ponce G, Rodriguez-Jimenez R, Jimenez-Arriero MA, Hoenicka J, Palomo T</AU>
<TI>Clinical predictors of response to naltrexone in alcoholic patients: who benefits most from treatment with naltrexone?</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2005</YR>
<VL>40</VL>
<NO>3</NO>
<PG>227-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Stella-2008" MODIFIED="2010-10-15 11:37:44 +0200" MODIFIED_BY="[Empty name]" NAME="Stella 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-10-15 11:37:44 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;18434189&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 11:37:44 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Stella L, Addolorato G, Rinaldi B, Capuano A, Berrino L, Rossi F, et al</AU>
<TI>An open randomized study of the treatment of escitalopram alone and combined with gamma-hydroxybutyric acid and naltrexone in alcoholic patients</TI>
<SO>Pharmacological Research</SO>
<YR>2008</YR>
<VL>57</VL>
<NO>4</NO>
<PG>312-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tidey-2008" MODIFIED="2010-01-21 12:07:35 +0100" MODIFIED_BY="[Empty name]" NAME="Tidey 2008" YEAR="2008">
<REFERENCE MODIFIED="2010-01-21 12:07:35 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;18028530&lt;/p&gt;" NOTES_MODIFIED="2010-01-21 12:07:35 +0100" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tidey JW, Monti PM, Rohsenow DJ, Gwaltney CJ, Miranda R Jr, McGeary JE, et al</AU>
<TI>Moderators of naltrexone's effects on drinking, urge, and alcohol effects in non-treatment-seeking heavy drinkers in the natural environment</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2008</YR>
<VL>32</VL>
<NO>1</NO>
<PG>58-66</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tucker-2004" MODIFIED="2010-10-15 11:38:00 +0200" MODIFIED_BY="[Empty name]" NAME="Tucker 2004" YEAR="2004">
<REFERENCE MODIFIED="2010-10-15 11:38:00 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;15610829&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 11:38:00 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tucker T, Ritter A, Maher C, Jackson H</AU>
<TI>A randomized control trial of group counseling in a naltrexone treatment program</TI>
<SO>Journal of Substance Abuse and Treatment</SO>
<YR>2004</YR>
<VL>27</VL>
<NO>4</NO>
<PG>277-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Turncliff-2005" MODIFIED="2010-10-15 11:38:21 +0200" MODIFIED_BY="[Empty name]" NAME="Turncliff 2005" YEAR="2005">
<REFERENCE MODIFIED="2010-10-15 11:38:21 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;16239359&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 11:38:21 +0200" NOTES_MODIFIED_BY="[Empty name]" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Turncliff RZ, Dunbar JL, Dong Q, Silverman BL, Ehrich EW, Dilzer SC, et al</AU>
<TI>Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2005</YR>
<VL>45</VL>
<NO>11</NO>
<PG>1259-67</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2008-08-08 07:59:39 +0200" MODIFIED_BY="[Empty name]"/>
<ONGOING_STUDIES MODIFIED="2010-10-15 13:07:49 +0200" MODIFIED_BY="[Empty name]">
<STUDY DATA_SOURCE="UNPUB" ID="STD-ALK21_x002d_010" MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]" NAME="ALK21-010" YEAR="">
<IDENTIFIERS MODIFIED="2008-12-06 17:11:32 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-12-06 16:18:26 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00156923"/>
<IDENTIFIER MODIFIED="2008-12-06 17:11:32 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ALK21-010"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Anton-2009" MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]" NAME="Anton 2009" YEAR="2009">
<IDENTIFIERS MODIFIED="2008-12-06 10:34:18 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-13 14:09:19 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00183196"/>
<IDENTIFIER MODIFIED="2008-12-06 10:34:18 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NIAAAANT09568-2005a"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Batki-2007" MODIFIED="2010-10-15 13:07:49 +0200" MODIFIED_BY="[Empty name]" NAME="Batki 2007" YEAR="2007">
<IDENTIFIERS MODIFIED="2008-12-06 10:54:47 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-13 14:04:06 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00145847"/>
<IDENTIFIER MODIFIED="2008-12-06 10:54:47 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="SUNY UMU IRB # 4800"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Brown" MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]" NAME="Brown" YEAR="2007">
<IDENTIFIERS MODIFIED="2008-12-06 11:30:32 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-13 19:41:03 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00223275 "/>
<IDENTIFIER MODIFIED="2008-12-06 11:30:32 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="PA-03-107"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Foa-2009" MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]" NAME="Foa 2009" YEAR="2009">
<IDENTIFIERS MODIFIED="2008-12-06 20:27:28 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-12-06 20:27:24 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00006489"/>
<IDENTIFIER MODIFIED="2008-12-06 20:27:28 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NIAAAFOA12428"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Garbutt-2009" MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]" NAME="Garbutt 2009" YEAR="2009">
<IDENTIFIERS MODIFIED="2008-12-06 20:30:03 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-13 13:58:26 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00614328"/>
<IDENTIFIER MODIFIED="2008-12-06 20:30:03 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="05-2988 GCRC 2497"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Grabowski-2007" MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]" NAME="Grabowski 2007" YEAR="">
<IDENTIFIERS MODIFIED="2008-12-06 15:36:53 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-12-06 15:36:38 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00000307"/>
<IDENTIFIER MODIFIED="2008-12-06 15:36:53 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NIDA-09262-4"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Haber-2005" MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]" NAME="Haber 2005" YEAR="2005">
<IDENTIFIERS MODIFIED="2008-12-06 18:01:43 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-12-06 18:01:34 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00120601"/>
<IDENTIFIER MODIFIED="2008-12-06 18:01:43 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="X99-0277"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Johnson" MODIFIED="2010-08-03 08:55:09 +0200" MODIFIED_BY="[Empty name]" NAME="Johnson" YEAR="2964">
<IDENTIFIERS MODIFIED="2008-12-06 16:33:33 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-12-06 16:33:26 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00027079"/>
<IDENTIFIER MODIFIED="2008-12-06 16:33:33 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NIAAAJOH12964"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Johnson-2009" MODIFIED="2009-02-13 18:30:27 +0100" MODIFIED_BY="[Empty name]" NAME="Johnson 2009" YEAR="2009">
<IDENTIFIERS MODIFIED="2008-12-06 20:34:37 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-12-06 20:31:51 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00769158"/>
<IDENTIFIER MODIFIED="2008-12-06 20:34:37 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="IRB-HSR # 13521"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lundbeck-2010" MODIFIED="2009-02-13 18:30:27 +0100" MODIFIED_BY="[Empty name]" NAME="Lundbeck 2010" YEAR="2011">
<IDENTIFIERS MODIFIED="2008-12-25 18:11:28 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-12-25 18:11:09 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00811941"/>
<IDENTIFIER MODIFIED="2008-12-25 18:11:28 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="12013A"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Lundbeck-2011" MODIFIED="2009-02-13 18:30:27 +0100" MODIFIED_BY="[Empty name]" NAME="Lundbeck 2011" YEAR="2011">
<IDENTIFIERS MODIFIED="2008-12-25 18:11:54 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-12-25 18:11:54 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00811720"/>
<IDENTIFIER MODIFIED="2008-12-25 18:11:41 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="12013A"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Mann-2008" MODIFIED="2009-02-13 18:30:27 +0100" MODIFIED_BY="[Empty name]" NAME="Mann 2008" YEAR="2008">
<IDENTIFIERS MODIFIED="2008-12-06 18:09:58 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-12-06 18:09:49 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00317031"/>
<IDENTIFIER MODIFIED="2008-12-06 18:09:58 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="PREDICT"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Mann-2010" MODIFIED="2009-02-13 18:30:27 +0100" MODIFIED_BY="[Empty name]" NAME="Mann 2010" YEAR="2008">
<IDENTIFIERS MODIFIED="2008-12-06 15:29:11 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-12-06 15:28:50 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00501631 "/>
<IDENTIFIER MODIFIED="2008-12-06 15:29:11 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="ALK21-014"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Mason" MODIFIED="2010-08-03 08:55:00 +0200" MODIFIED_BY="[Empty name]" NAME="Mason" YEAR="0518">
<IDENTIFIERS MODIFIED="2009-01-14 12:05:55 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2009-01-14 12:05:55 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00000450"/>
<IDENTIFIER MODIFIED="2008-12-06 17:16:45 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NIAAAMAS10518"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-O_x0027_Brien-2007" MODIFIED="2009-02-13 18:30:27 +0100" MODIFIED_BY="[Empty name]" NAME="O'Brien 2007" YEAR="2007">
<IDENTIFIERS MODIFIED="2008-12-06 11:25:21 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-12-06 11:25:21 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00218660"/>
<IDENTIFIER MODIFIED="2008-12-06 11:24:45 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NIDA-5186-1"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Oslin-2008b" MODIFIED="2009-02-13 18:30:27 +0100" MODIFIED_BY="[Empty name]" NAME="Oslin 2008b" YEAR="2008">
<IDENTIFIERS MODIFIED="2008-12-06 10:49:48 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-14 17:35:33 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00115037"/>
<IDENTIFIER MODIFIED="2008-12-06 10:49:48 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NIAAAOSL014851"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Petrakis-2009" MODIFIED="2009-02-13 18:30:27 +0100" MODIFIED_BY="[Empty name]" NAME="Petrakis 2009" YEAR="2009">
<IDENTIFIERS MODIFIED="2008-12-06 20:56:53 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-12-06 20:56:41 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00338962"/>
<IDENTIFIER MODIFIED="2008-12-06 20:56:53 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="HIC # 11637"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Pettinati-2009" MODIFIED="2009-02-13 18:30:27 +0100" MODIFIED_BY="[Empty name]" NAME="Pettinati 2009" YEAR="9544">
<IDENTIFIERS MODIFIED="2008-12-06 17:49:24 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-12-06 17:49:15 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00004554"/>
<IDENTIFIER MODIFIED="2008-12-06 17:49:24 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NIAAAPET09544"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Pettinati-2012" MODIFIED="2009-02-13 18:30:27 +0100" MODIFIED_BY="[Empty name]" NAME="Pettinati 2012" YEAR="2012">
<IDENTIFIERS MODIFIED="2008-12-06 17:55:27 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-12-06 17:55:25 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00777062"/>
<IDENTIFIER MODIFIED="2008-12-06 17:55:27 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="808641"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Salloum" MODIFIED="2009-02-13 18:30:27 +0100" MODIFIED_BY="[Empty name]" NAME="Salloum" YEAR="2006">
<IDENTIFIERS MODIFIED="2008-12-06 15:30:08 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-14 10:36:33 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00006204"/>
<IDENTIFIER MODIFIED="2008-12-06 15:30:08 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NIAAASAL11929"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="UNPUB" ID="STD-Salloum-2007" MODIFIED="2009-02-13 18:30:27 +0100" MODIFIED_BY="[Empty name]" NAME="Salloum 2007" YEAR="2007">
<IDENTIFIERS MODIFIED="2008-12-06 17:41:35 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-12-06 17:41:27 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00302133"/>
<IDENTIFIER MODIFIED="2008-12-06 17:41:35 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="RO1-AA015385-01"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schmitz" MODIFIED="2009-02-13 18:30:27 +0100" MODIFIED_BY="[Empty name]" NAME="Schmitz" YEAR="2007">
<IDENTIFIERS MODIFIED="2008-12-06 17:19:38 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-12-06 17:19:06 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00218569 "/>
<IDENTIFIER MODIFIED="2008-12-06 17:19:38 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="NIDA-15801-1"/>
</IDENTIFIERS>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Toneatto" MODIFIED="2009-02-13 18:30:27 +0100" MODIFIED_BY="[Empty name]" NAME="Toneatto" YEAR="2004">
<IDENTIFIERS MODIFIED="2008-12-06 10:57:52 +0100" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2008-11-13 17:22:16 +0100" MODIFIED_BY="[Empty name]" TYPE="CTG" VALUE="NCT00326807"/>
<IDENTIFIER MODIFIED="2008-12-06 10:57:52 +0100" MODIFIED_BY="[Empty name]" TYPE="OTHER" VALUE="095/2001"/>
</IDENTIFIERS>
</STUDY>
</ONGOING_STUDIES>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2010-10-15 12:35:19 +0200" MODIFIED_BY="[Empty name]">
<ADDITIONAL_REFERENCES MODIFIED="2010-10-15 12:35:19 +0200" MODIFIED_BY="[Empty name]">
<REFERENCE ID="REF-Adams-2007" MODIFIED="2010-01-29 15:17:34 +0100" MODIFIED_BY="[Empty name]" NAME="Adams 2007" TYPE="COCHRANE_REVIEW">
<AU>Adams CE, Awad G, Rathbone J, Thornley B</AU>
<TI>Chlorpromazine versus placebo for schizophrenia</TI>
<TO>CD000284</TO>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2007</YR>
<NO>1</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Adcock-2006" MODIFIED="2008-09-20 11:30:14 +0200" MODIFIED_BY="[Empty name]" NAME="Adcock 2006" TYPE="JOURNAL_ARTICLE">
<AU>Adcock RA, Thangavel A, Whitfield-Gabrieli S, Knutson B, Gabrieli JD</AU>
<TI>Reward-motivated learning: mesolimbic activation precedes memory formation</TI>
<SO>Neuron</SO>
<YR>2006</YR>
<VL>50</VL>
<NO>3</NO>
<PG>507-17</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Alonso-2004" MODIFIED="2010-10-15 11:41:49 +0200" MODIFIED_BY="[Empty name]" NAME="Alonso 2004" TYPE="JOURNAL_ARTICLE">
<AU>Alonso J, Angermeyer MC, Bernert S, Bruffaerts R, Brugha TS, Bryson H</AU>
<TI>Prevalence of mental disorders in Europe: results from the European Study of the Epidemiology of Mental Disorders (ESEMeD) project</TI>
<SO>Acta Psychiatrica Scandinavia Supplement</SO>
<YR>2004</YR>
<VL>420</VL>
<PG>21-7</PG>
<IDENTIFIERS MODIFIED="2008-09-20 11:29:11 +0200" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Altshuler-1980" MODIFIED="2010-10-15 11:41:59 +0200" MODIFIED_BY="[Empty name]" NAME="Altshuler 1980" TYPE="JOURNAL_ARTICLE">
<AU>Altshuler HL, Phillips PE, Feinhandler DA</AU>
<TI>Alteration of ethanol self-administration by naltrexone</TI>
<SO>Life Sciences</SO>
<YR>1980</YR>
<VL>26</VL>
<PG>679-88</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anton-2001" MODIFIED="2010-10-15 11:42:13 +0200" MODIFIED_BY="[Empty name]" NAME="Anton 2001" TYPE="JOURNAL_ARTICLE">
<AU>Anton RF, Moak DH, Latham PK, Waid LR, Malcolm RJ, Dias JK, et al</AU>
<TI>Posttreatment results of combining naltrexone with cognitive-behavior therapy for the treatment of alcoholism</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>2001</YR>
<VL>21</VL>
<NO>1</NO>
<PG>72-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Anton-2008" MODIFIED="2010-10-15 11:43:11 +0200" MODIFIED_BY="[Empty name]" NAME="Anton 2008" TYPE="JOURNAL_ARTICLE">
<AU>Anton RF, Oroszi G, O'Malley S, Couper D, Swift R, Pettinati H, Goldman D</AU>
<TI>An evaluation of mu-opioid receptor (OPRM1) as a predictor of naltrexone response in the treatment of alcohol dependence: results from the Combined Pharmacotherapies and Behavioral Interventions for Alcohol Dependence (COMBINE) study</TI>
<SO>Archives of General Psychiatry</SO>
<YR>2008</YR>
<VL>65</VL>
<NO>2</NO>
<PG>135-44</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Arroll-2009" MODIFIED="2010-01-29 15:18:20 +0100" MODIFIED_BY="[Empty name]" NAME="Arroll 2009" TYPE="COCHRANE_REVIEW">
<AU>Arroll B, Elley CR, Fishman T, Goodyear-Smith F A, Kenealy T, Blashki G, et al</AU>
<TI>Antidepressants versus placebo for depression in primary care</TI>
<TO>CD007954</TO>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2009</YR>
<NO>1</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE="10.1002/14651858"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Berglund-2003" MODIFIED="2010-01-17 16:26:37 +0100" MODIFIED_BY="[Empty name]" NAME="Berglund 2003" TYPE="OTHER">
<AU>Berglund MA, Franck J, Fridell M, Hakanson I, Johansson BA</AU>
<TI>Treatment of alcohol and drug abuse - an evidence-based review</TI>
<SO>Swedish Council on Technology Assessment in Health Care (SBU)</SO>
<YR>2003</YR>
<VL>156</VL>
<NO>1</NO>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Bouza-2004" MODIFIED="2010-10-15 11:44:25 +0200" MODIFIED_BY="[Empty name]" NAME="Bouza 2004" TYPE="JOURNAL_ARTICLE">
<AU>Bouza C, Magro A, Muñoz A, Amate JM</AU>
<TI>Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review</TI>
<SO>Addiction</SO>
<YR>2004</YR>
<VL>99</VL>
<NO>7</NO>
<PG>811-28</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Brockwell-2001" MODIFIED="2010-10-15 11:44:35 +0200" MODIFIED_BY="[Empty name]" NAME="Brockwell 2001" TYPE="JOURNAL_ARTICLE">
<AU>Brockwell S E, Gordon I R</AU>
<TI>A comparison of statistical methods for meta-analysis</TI>
<SO>Statistics in Medicine</SO>
<YR>2001</YR>
<VL>20</VL>
<NO>6</NO>
<PG>825-40</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Budzynski-2000" MODIFIED="2010-10-15 11:44:55 +0200" MODIFIED_BY="[Empty name]" NAME="Budzynski 2000" TYPE="JOURNAL_ARTICLE">
<AU>Budzynski J, Rybakowski J, Swiatkowski M, Torlinski L, Klopocka M, Kosmowski W</AU>
<TI>Naltrexone exerts a favourable effect on plasma lipids in abstinent patients with alcohol dependence.</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2000</YR>
<VL>35</VL>
<NO>1</NO>
<PG>91-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Carroll-1998" MODIFIED="2010-10-15 11:45:12 +0200" MODIFIED_BY="[Empty name]" NAME="Carroll 1998" TYPE="JOURNAL_ARTICLE">
<AU>Carroll KM, Nich C, Ball SA, McCance E, Rounsaville BJ</AU>
<TI>Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram</TI>
<SO>Addiction</SO>
<YR>1998</YR>
<VL>93</VL>
<PG>713&#8211;27</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chan-2004" MODIFIED="2010-10-15 11:45:29 +0200" MODIFIED_BY="[Empty name]" NAME="Chan 2004" TYPE="JOURNAL_ARTICLE">
<AU>Chan A W, Hrobjartsson A, Haahr M T, Gotzsche P C, Altman D G</AU>
<TI>Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles</TI>
<SO>JAMA</SO>
<YR>2004</YR>
<VL>291</VL>
<NO>20</NO>
<PG>2457-65</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Chaney-1989" MODIFIED="2010-10-15 11:45:50 +0200" MODIFIED_BY="[Empty name]" NAME="Chaney 1989" TYPE="BOOK_SECTION">
<AU>Chaney EF</AU>
<TI>Social skills training</TI>
<SO>Handbook of alcoholism treatment approaches: effective alternatives</SO>
<YR>1989</YR>
<PG>167-70</PG>
<ED>Hester RK, Miller WR</ED>
<PB>Pergamon Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Childress-1986" MODIFIED="2010-10-15 11:46:12 +0200" MODIFIED_BY="[Empty name]" NAME="Childress 1986" TYPE="JOURNAL_ARTICLE">
<AU>Childress AR, McLellan AT, O'Brien CP</AU>
<TI>Role of conditioning factors in the development of drug dependence</TI>
<SO>Psychiatric Clinics of North America</SO>
<YR>1986</YR>
<VL>9</VL>
<NO>3</NO>
<PG>413-25</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Citrome-2008" MODIFIED="2010-10-15 11:47:05 +0200" MODIFIED_BY="[Empty name]" NAME="Citrome 2008" TYPE="JOURNAL_ARTICLE">
<AU>Citrome L</AU>
<TI>Compelling or irrelevant? Using number needed to treat can help decide</TI>
<SO>Acta Psychiatrica Scandinavia</SO>
<YR>2008</YR>
<VL>117</VL>
<NO>6</NO>
<PG>412-19</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Clintron-1995" MODIFIED="2010-01-21 14:43:24 +0100" MODIFIED_BY="[Empty name]" NAME="Clintron 1995" TYPE="OTHER">
<AU>Clintron R</AU>
<TI>Product Announcement: ReVia TM , Naltrexone HCL</TI>
<SO>Distributed by DuPont Pharma</SO>
<YR>1995</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Deeks-2008" MODIFIED="2010-10-15 11:51:14 +0200" MODIFIED_BY="[Empty name]" NAME="Deeks 2008" TYPE="BOOK_SECTION">
<AU>Deeks J, Higgins JPT, Altman DG</AU>
<TI>Chapter 9: Analysing data and undertaking meta-analyses</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<PG>243-93</PG>
<ED>Higgins JPT, Green S</ED>
<PB>Johm Wiley &amp; Sons</PB>
<CY>Chichester (UK)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DeHaven_x002d_Hudkins-1990" MODIFIED="2010-01-21 14:44:53 +0100" MODIFIED_BY="[Empty name]" NAME="DeHaven-Hudkins 1990" TYPE="JOURNAL_ARTICLE">
<AU>DeHaven-Hudkins DL, Brostrom PA, Allen JT, Lesko LJ, Ferkany JW, Kaplita PV</AU>
<TI>Pharmacologic profile of NPC 168 (naltrexone phenyl oxime), a novel compound with activity at opioid receptors</TI>
<SO>Pharmacology Biochemistry &amp; Behavior</SO>
<YR>1990</YR>
<VL>37</VL>
<NO>3</NO>
<PG>497-504</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Derogatis-1974" MODIFIED="2010-01-21 14:47:19 +0100" MODIFIED_BY="[Empty name]" NAME="Derogatis 1974" TYPE="JOURNAL_ARTICLE">
<AU>Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L</AU>
<TI>The Hopkins Symptom Checklist (HSCL): a self-report symptom inventory</TI>
<SO>Behavioral Science</SO>
<YR>1974</YR>
<VL>19</VL>
<PG>1&#8211;15</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-DerSimonian-1986" MODIFIED="2010-01-21 14:47:36 +0100" MODIFIED_BY="[Empty name]" NAME="DerSimonian 1986" TYPE="JOURNAL_ARTICLE">
<AU>DerSimonian R, Laird NM</AU>
<TI>Meta-analysis in clinical trials</TI>
<SO>Controlled Clinical Trials</SO>
<YR>1986</YR>
<VL>7</VL>
<PG>177-188</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Dixon-1987" MODIFIED="2010-10-15 11:55:26 +0200" MODIFIED_BY="[Empty name]" NAME="Dixon 1987" TYPE="JOURNAL_ARTICLE">
<AU>Dixon R, Gentile J, Hsu HB, Hsiao J, Howes J, Garg D</AU>
<TI>Nalmefene: safety and kinetics after single and multiple oral doses of a new opioid antagonist</TI>
<SO>Journal of Clinical Pharmacology</SO>
<YR>1987</YR>
<VL>27</VL>
<NO>3</NO>
<PG>233-9</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Egger-1997" MODIFIED="2010-10-15 11:52:32 +0200" MODIFIED_BY="[Empty name]" NAME="Egger 1997" TYPE="JOURNAL_ARTICLE">
<AU>Egger M, Davey Smith G, Schneider M, Minder C</AU>
<TI>Bias in meta-analysis detected by a simple, graphical test</TI>
<SO>BMJ</SO>
<YR>1997</YR>
<VL>315</VL>
<NO>7109</NO>
<PG>629-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Emmerson-1994" MODIFIED="2010-10-15 11:53:04 +0200" MODIFIED_BY="[Empty name]" NAME="Emmerson 1994" TYPE="JOURNAL_ARTICLE">
<AU>Emmerson PJ, Liu MR, Woods JH, Medzihradsky F</AU>
<TI>Binding affinity and selectivity of opioids at mu, delta and kappa receptors in monkey brain membranes</TI>
<SO>Journal of Pharmacology and Experimental Therapeutics</SO>
<YR>1994</YR>
<VL>271</VL>
<NO>3</NO>
<PG>1630-7</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Froehlich-1993" MODIFIED="2010-01-21 15:05:30 +0100" MODIFIED_BY="[Empty name]" NAME="Froehlich 1993" TYPE="JOURNAL_ARTICLE">
<AU>Froehlich JC, Li TK</AU>
<TI>Recent developments in alcoholism:opioid peptides</TI>
<SO>Recent Developments in Alcoholism</SO>
<YR>1993</YR>
<VL>11</VL>
<PG>187-205</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Gal-1986" MODIFIED="2010-10-15 11:56:02 +0200" MODIFIED_BY="[Empty name]" NAME="Gal 1986" TYPE="JOURNAL_ARTICLE">
<AU>Gal TJ, DiFazio CA, Dixon R</AU>
<TI>Prolonged blockade of opioid effect with oral nalmefene</TI>
<SO>Clinical Pharmacology &amp; Therapeutics</SO>
<YR>1986</YR>
<VL>40</VL>
<NO>5</NO>
<PG>537-42</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Gelernter-2007" MODIFIED="2010-10-15 11:59:49 +0200" MODIFIED_BY="[Empty name]" NAME="Gelernter 2007" TYPE="JOURNAL_ARTICLE">
<AU>Gelernter J, Gueorguieva R, Kranzler HR, Zhang H, Cramer J, Rosenheck R, et al</AU>
<TI>Opioid receptor gene (OPRM1, OPRK1, and OPRD1) variants and response to naltrexone treatment for alcohol dependence: results from the VA Cooperative Study</TI>
<SO>Alcohol Clin Exp Res</SO>
<YR>2007</YR>
<VL>31</VL>
<NO>4</NO>
<PG>555-63</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Gianoulakis-2004" MODIFIED="2010-01-21 15:06:40 +0100" MODIFIED_BY="[Empty name]" NAME="Gianoulakis 2004" TYPE="JOURNAL_ARTICLE">
<AU>Gianoulakis C</AU>
<TI>Endogenous opioids and addiction to alcohol and other drugs of abuse</TI>
<SO>Current Topics in Medicinal Chemistry</SO>
<YR>2004</YR>
<VL>4</VL>
<NO>1</NO>
<PG>39-50</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Gorski-1986" MODIFIED="2010-01-06 21:52:47 +0100" MODIFIED_BY="[Empty name]" NAME="Gorski 1986" TYPE="BOOK">
<AU>Gorski TT, Miller MM</AU>
<SO>Staying Sober: Guide to RelapsePrevention</SO>
<YR>1986</YR>
<PB>Independence, MO, Herald House</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Heyser-2003" MODIFIED="2010-10-15 12:00:25 +0200" MODIFIED_BY="[Empty name]" NAME="Heyser 2003" TYPE="JOURNAL_ARTICLE">
<AU>Heyser CJ, Moc K, Koob GF</AU>
<TI>Effects of naltrexone alone and in combination with acamprosate on the alcohol deprivation effect in rats</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>28</VL>
<NO>8</NO>
<PG>1463-71</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2003" MODIFIED="2010-10-15 12:00:48 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2003" TYPE="JOURNAL_ARTICLE">
<AU>Higgins JP, Thompson SG, Deeks JJ, Altman DG</AU>
<TI>Measuring inconsistency in meta-analyses</TI>
<SO>BMJ</SO>
<YR>2003</YR>
<VL>327</VL>
<NO>7414</NO>
<PG>557-60</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2010-10-15 12:09:38 +0200" MODIFIED_BY="[Empty name]" NAME="Higgins 2008" TYPE="BOOK">
<AU>Higgins JPT, Green S (editors)</AU>
<SO>Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]</SO>
<YR>2008</YR>
<PB>The Cochrane Collaboration, 2009. Available from www.cochrane-handbook.org</PB>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Holter-1999" MODIFIED="2010-10-15 12:11:13 +0200" MODIFIED_BY="[Empty name]" NAME="Holter 1999" TYPE="JOURNAL_ARTICLE">
<AU>Holter SM, Spanagel R</AU>
<TI>Effects of opiate antagonist treatment on the alcohol deprivation effect in long-term ethanol-experienced rats</TI>
<SO>Psychopharmacology (Berl)</SO>
<YR>1999</YR>
<VL>145</VL>
<NO>4</NO>
<PG>360-9</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hopkins-2002" MODIFIED="2010-01-21 15:08:44 +0100" MODIFIED_BY="[Empty name]" NAME="Hopkins 2002" TYPE="JOURNAL_ARTICLE">
<AU>Hopkins JS, Garbutt JC, Poole CL, West SL, Carey TS</AU>
<TI>Naltrexone and acamprosate: Meta-analysis of two medical treatments for alcoholism</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2002</YR>
<VL>26 (Supplement)</VL>
<PG>130A</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Huwiler_x002d_Muntener-2002" MODIFIED="2010-10-15 12:11:43 +0200" MODIFIED_BY="[Empty name]" NAME="Huwiler-Muntener 2002" TYPE="JOURNAL_ARTICLE">
<AU>Huwiler-Muntener K, Juni P, Junker C, Egger M</AU>
<TI>Quality of reporting of randomized trials as a measure of methodologic quality</TI>
<SO>JAMA</SO>
<YR>2002</YR>
<VL>287</VL>
<NO>21</NO>
<PG>2801-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-ICAP-2003" MODIFIED="2010-01-21 15:09:13 +0100" MODIFIED_BY="[Empty name]" NAME="ICAP 2003" TYPE="OTHER">
<AU>ICAP International Center for Alcohol Policies</AU>
<TI>International Drinking Guidelines</TI>
<TO>(http://www.icap.org/)</TO>
<SO>Report Nr. 14</SO>
<YR>2003</YR>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ingman-2005" MODIFIED="2010-10-15 12:12:13 +0200" MODIFIED_BY="[Empty name]" NAME="Ingman 2005" TYPE="JOURNAL_ARTICLE">
<AU>Ingman K, Hagelberg N, Aalto S, Nagren K, Juhakoski A, Karhuvaara S</AU>
<TI>Prolonged central mu-opioid receptor occupancy after single and repeated nalmefene dosing</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>30</VL>
<NO>12</NO>
<PG>2245-53</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Kadden-1992" MODIFIED="2010-01-21 15:09:44 +0100" MODIFIED_BY="[Empty name]" NAME="Kadden 1992" TYPE="BOOK_SECTION">
<AU>Kadden R, Carroll K, Donovan D, Cooney N, Monti P, Abrams D, et al</AU>
<TI>Cognitive-Behavioral Coping Skills Therapy Manual: A Clinical Research Guide for Therapists Treating Individuals with Alcohol Abuse and Dependence</TI>
<SO>NIAAA Project MATCH Monograph Series</SO>
<YR>1992</YR>
<VL>3</VL>
<EN>Mattson ME</EN>
<PB>National Institute on Alcoholism and Alcohol Abuse</PB>
<CY>Rockville</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Keller-1972" MODIFIED="2010-01-21 15:09:52 +0100" MODIFIED_BY="[Empty name]" NAME="Keller 1972" TYPE="JOURNAL_ARTICLE">
<AU>Keller M</AU>
<TI>On the loss-of-control phenomenon in alcoholism</TI>
<SO>British Journal of Addiction</SO>
<YR>1972</YR>
<VL>67</VL>
<PG>153-166</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Kiefer-2004" MODIFIED="2010-10-15 12:13:06 +0200" MODIFIED_BY="[Empty name]" NAME="Kiefer 2004" TYPE="JOURNAL_ARTICLE">
<AU>Kiefer F, Andersohn F, Otte C, Wolf K, Jahn H, Wiedemann K</AU>
<TI>Long-term effects of pharmacotherapy on relapse prevention in alcohol dependence</TI>
<SO>Acta Neuropsychiatrica</SO>
<YR>2004</YR>
<VL>16</VL>
<PG>233-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Konnopka-2007" MODIFIED="2010-10-15 12:13:23 +0200" MODIFIED_BY="[Empty name]" NAME="Konnopka 2007" TYPE="JOURNAL_ARTICLE">
<AU>Konnopka A, Konig HH</AU>
<TI>Direct and indirect costs attributable to alcohol consumption in Germany</TI>
<SO>Pharmacoeconomics</SO>
<YR>2007</YR>
<VL>25</VL>
<NO>7</NO>
<PG>605-18</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Kranzler-2001" MODIFIED="2010-10-15 12:13:36 +0200" MODIFIED_BY="[Empty name]" NAME="Kranzler 2001" TYPE="JOURNAL_ARTICLE">
<AU>Kranzler HR, van Kirk JR</AU>
<TI>Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis</TI>
<SO>Alcoholism: Clinical and Experimental Research</SO>
<YR>2001</YR>
<VL>25</VL>
<PG>1335-41</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Lefebvre-2008" MODIFIED="2010-01-20 11:13:40 +0100" MODIFIED_BY="[Empty name]" NAME="Lefebvre 2008" TYPE="BOOK_SECTION">
<AU>Lefebvre C, Manheimer E, Glanville J</AU>
<TI>Chapter 6: Searching for Studies</TI>
<SO>Cochrane Handbook for Systematic Reviews of Interventions</SO>
<YR>2008</YR>
<PG>95-150</PG>
<ED>Higgins JPT, Green S</ED>
<PB>Johm Wiley &amp; Sons</PB>
<CY>Chichester (UK)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Levine-1986" MODIFIED="2010-01-21 15:10:32 +0100" MODIFIED_BY="[Empty name]" NAME="Levine 1986" TYPE="JOURNAL_ARTICLE">
<AU>Levine J, Schooler N R</AU>
<TI>SAFTEE: a technique for the systematic assessment of side effects in clinical trials</TI>
<SO>Psychopharmacoligal Bulletin</SO>
<YR>1986</YR>
<VL>22</VL>
<NO>2</NO>
<PG>343-81</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Light-1984" MODIFIED="2010-01-21 15:10:43 +0100" MODIFIED_BY="[Empty name]" NAME="Light 1984" TYPE="BOOK">
<AU>Light RJ, Pillemer BD</AU>
<SO>The science of reviewing research</SO>
<YR>1984</YR>
<PB>Harvard University Press</PB>
<CY>Cambridge (MA)</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Lingjaerde-1987" MODIFIED="2010-01-07 09:15:32 +0100" MODIFIED_BY="[Empty name]" NAME="Lingjaerde 1987" TYPE="JOURNAL_ARTICLE">
<AU>Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K</AU>
<TI>The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients</TI>
<SO>Acta Psychiatrica Scandinavia Supplement</SO>
<YR>1987</YR>
<VL>334</VL>
<PG>1-100</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mantel-1959" MODIFIED="2010-10-15 12:14:15 +0200" MODIFIED_BY="[Empty name]" NAME="Mantel 1959" TYPE="JOURNAL_ARTICLE">
<AU>Mantel N, Haenszel W</AU>
<TI>Statistical aspects of the analysis of data from retrospective disease</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1959</YR>
<VL>22</VL>
<PG>719&#8211;48</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Marlatt-1985" MODIFIED="2010-01-06 15:22:57 +0100" MODIFIED_BY="[Empty name]" NAME="Marlatt 1985" TYPE="BOOK">
<AU>Marlatt GA, Gordon J</AU>
<SO>Relapse prevention</SO>
<YR>1985</YR>
<PB>Guilford Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mason-1999" MODIFIED="2010-10-15 12:14:33 +0200" MODIFIED_BY="[Empty name]" NAME="Mason 1999" TYPE="JOURNAL_ARTICLE">
<AU>Mason BJ, Salvato FR, Williams LD, Ritvo EC, Cutler RB</AU>
<TI>A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1999</YR>
<VL>56</VL>
<NO>8</NO>
<PG>719-24</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Matsuzawa-1999" MODIFIED="2010-01-21 15:12:03 +0100" MODIFIED_BY="[Empty name]" NAME="Matsuzawa 1999" TYPE="JOURNAL_ARTICLE">
<AU>Matsuzawa S, Suzuki T, Misawa M, Nagase H</AU>
<TI>Different roles of mu-, delta- and kappa-opioid receptors in ethanol-associated place preference in rats exposed to conditioned fear stress</TI>
<SO>European Journal of Pharmacology</SO>
<YR>1999</YR>
<VL>368</VL>
<NO>1</NO>
<PG>9-16</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-McCrady-1985" MODIFIED="2010-10-15 12:14:54 +0200" MODIFIED_BY="[Empty name]" NAME="McCrady 1985" TYPE="BOOK_SECTION">
<AU>McCrady BS, Dean L, DuBreuil E, Swanson S</AU>
<TI>The problem drinkers project: A programmatic application of social learning-based treatment</TI>
<SO>Relapse Prevention: Maintenance Strategies in the Treatment of Addictive Behaviors</SO>
<YR>1985</YR>
<PG>417&#8211;71</PG>
<ED>Marlatt GA, Gordon JR</ED>
<PB>Guilford Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-McLellan-1980" MODIFIED="2010-01-07 10:27:49 +0100" MODIFIED_BY="[Empty name]" NAME="McLellan 1980" TYPE="JOURNAL_ARTICLE">
<AU>McLellan AT, Luborsky L, Woody GE, O'Brien CP</AU>
<TI>An improved diagnostic evaluation instrument for substance abuse patients: the Addiction Severity Index</TI>
<SO>Journal of Nervous and Mental Disorders</SO>
<YR>1980</YR>
<VL>168</VL>
<PG>26-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Middaugh-2000" MODIFIED="2010-10-15 12:15:14 +0200" MODIFIED_BY="[Empty name]" NAME="Middaugh 2000" TYPE="JOURNAL_ARTICLE">
<AU>Middaugh LD, Bandy AL</AU>
<TI>Naltrexone effects on ethanol consumption and response to ethanol conditioned cues in C57BL/6 mice</TI>
<SO>Psychopharmacology (Berl)</SO>
<YR>2000</YR>
<VL>151</VL>
<NO>4</NO>
<PG>321-7</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-MIller-1994" MODIFIED="2010-01-06 14:47:37 +0100" MODIFIED_BY="[Empty name]" NAME="MIller 1994" TYPE="BOOK">
<AU>Miller WR, Zweben A, DiClemente CC, Rychtarik RG</AU>
<SO>Motivational Enhancement Therapy manual: A clinical research guide for therapists treating individuals with alcohol abuse and dependence</SO>
<YR>1994</YR>
<PB>National Institute on Alcohol Abuse and Alcoholism</PB>
<CY>Rockville, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2001" MODIFIED="2010-10-15 12:15:53 +0200" MODIFIED_BY="[Empty name]" NAME="Moher 2001" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Jones A, Lepage L, CONSORT Group (Consolitdated Standards for Reporting of Trials)</AU>
<TI>The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials</TI>
<SO>JAMA</SO>
<YR>2001</YR>
<VL>285</VL>
<NO>15</NO>
<PG>1992-5</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Moher-2009" MODIFIED="2010-10-15 12:17:26 +0200" MODIFIED_BY="[Empty name]" NAME="Moher 2009" TYPE="JOURNAL_ARTICLE">
<AU>Moher D, Liberati A, Tetzlaff J, Altman DG</AU>
<TI>Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement</TI>
<SO>PLoS Medicine</SO>
<YR>2009</YR>
<VL>6</VL>
<NO>7</NO>
<PG>e1000097</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moncrieff-2004" MODIFIED="2010-01-29 15:20:34 +0100" MODIFIED_BY="[Empty name]" NAME="Moncrieff 2004" TYPE="COCHRANE_REVIEW">
<AU>Moncrieff J, Wessely S, Hardy R</AU>
<TI>Active placebos versus antidepressants for depression</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2004</YR>
<NO>1</NO>
<IDENTIFIERS>
<IDENTIFIER TYPE="DOI" VALUE=" 10.1002/14651858"/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Monti-1989" MODIFIED="2010-01-06 15:47:10 +0100" MODIFIED_BY="[Empty name]" NAME="Monti 1989" TYPE="BOOK">
<AU>Monti PM, Abrams DB, Kadden R, Cooney N</AU>
<SO>Treating Alcohol Dependence: A Coping Skills Therapy Guide</SO>
<YR>1989</YR>
<PB>Guildford Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Moos-2006" MODIFIED="2010-07-30 08:48:59 +0200" MODIFIED_BY="[Empty name]" NAME="Moos 2006" TYPE="JOURNAL_ARTICLE">
<AU>Moos RH, Moos BS</AU>
<TI>Rates and predictors of relapse after natural and treated remission from alcohol use disorders</TI>
<SO>Addiction</SO>
<YR>2006</YR>
<VL>101</VL>
<NO>2</NO>
<PG>212-22</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Newell-1992" MODIFIED="2010-10-15 12:19:18 +0200" MODIFIED_BY="[Empty name]" NAME="Newell 1992" TYPE="JOURNAL_ARTICLE">
<AU>Newell DJ</AU>
<TI>Intention-to-treat analysis: implications for quantitative and qualitative research</TI>
<SO>International Journal of Epidemiology</SO>
<YR>1992</YR>
<VL>21</VL>
<NO>5</NO>
<PG>837-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nickerson-1998" MODIFIED="2010-10-15 12:19:49 +0200" MODIFIED_BY="[Empty name]" NAME="Nickerson 1998" TYPE="JOURNAL_ARTICLE">
<AU>Nickerson RS</AU>
<TI>Confirmation Bias: A Ubiquitous Phenomenon</TI>
<SO>Review of General Psychology</SO>
<YR>1998</YR>
<VL>2</VL>
<PG>175-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Nowinski-1995" MODIFIED="2010-01-06 14:54:35 +0100" MODIFIED_BY="[Empty name]" NAME="Nowinski 1995" TYPE="BOOK">
<AU>Nowinski J, Baker S, Carroll, K</AU>
<SO>Twelve Step Facilitation Therapy manual. A clinical research guide for therapists treating individuals with alcohol abuse and dependence</SO>
<YR>1995</YR>
<PB>Project MATCH Monograph Series Volume I. U.S. Department of Health and Human Services</PB>
<CY>Rockville, MD</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Malley-1996" MODIFIED="2010-10-15 12:20:06 +0200" MODIFIED_BY="[Empty name]" NAME="O'Malley 1996" TYPE="JOURNAL_ARTICLE">
<AU>O'Malley SS, Jaffe AJ, Chang G, Rode S, Schottenfeld R, Meyer RE, Rounsaville B</AU>
<TI>Six-month follow-up of naltrexone and psychotherapy for alcohol dependence</TI>
<SO>Archives of General Psychiatry</SO>
<YR>53</YR>
<VL>3</VL>
<PG>217-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-O_x0027_Malley-2003" MODIFIED="2010-01-21 13:43:24 +0100" MODIFIED_BY="[Empty name]" NAME="O'Malley 2003" TYPE="JOURNAL_ARTICLE">
<AU>O'Malley SS, Froehlich JC</AU>
<TI>Advances in the use of naltrexone: an integration of preclinical and clinical findings</TI>
<SO>Recent Developments in Alcoholism</SO>
<YR>2003</YR>
<VL>16</VL>
<PG>217-45</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Oslin-2003" MODIFIED="2010-10-15 12:20:35 +0200" MODIFIED_BY="[Empty name]" NAME="Oslin 2003" TYPE="JOURNAL_ARTICLE">
<AU>Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, et al</AU>
<TI>A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients</TI>
<SO>Neuropsychopharmacology</SO>
<YR>2003</YR>
<VL>28</VL>
<NO>8</NO>
<PG>1546-52</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Park-1999" MODIFIED="2010-10-15 12:20:57 +0200" MODIFIED_BY="[Empty name]" NAME="Park 1999" TYPE="JOURNAL_ARTICLE">
<AU>Park T, Lee SY</AU>
<TI>Simple pattern-mixture models for longitudinal data with missing observations: analysis of urinary incontinence data</TI>
<SO>Statistics in Medicine</SO>
<YR>1999</YR>
<VL>18</VL>
<NO>21</NO>
<PG>2933-41</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pettinati-2004" MODIFIED="2010-01-06 14:39:07 +0100" MODIFIED_BY="[Empty name]" NAME="Pettinati 2004" TYPE="BOOK">
<AU>Pettinati HM, Weiss RD, Miller WR, Donovan D, Ernst DB, Rounsaville BJ</AU>
<SO>Medical Management Treatment Manual. A Clinical Research Guide for MedicallyTrained Clinicians Providing Pharmacotherapy as Part of the Treatment for AlcoholDependence</SO>
<YR>2004</YR>
<VL>2</VL>
<PB>COMBINE Monograph Series. Vol 2: DHHS Pub. No (NIH) 04-5289</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pildal-2007" MODIFIED="2010-10-15 12:21:19 +0200" MODIFIED_BY="[Empty name]" NAME="Pildal 2007" TYPE="JOURNAL_ARTICLE">
<AU>Pildal J, Hrobjartsson A, Jorgensen K J, Hilden J, Altman D G, Gotzsche P C</AU>
<TI>Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials</TI>
<SO>International Journal of Epidemiology</SO>
<YR>2007</YR>
<VL>36</VL>
<NO>4</NO>
<PG>847-57</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Pocock-1987" MODIFIED="2010-10-15 12:21:34 +0200" MODIFIED_BY="[Empty name]" NAME="Pocock 1987" TYPE="JOURNAL_ARTICLE">
<AU>Pocock S J, Hughes M D, Lee R J</AU>
<TI>Statistical problems in the reporting of clinical trials. A survey of three medical journals</TI>
<SO>New England Journal of Medicine</SO>
<YR>1987</YR>
<VL>317</VL>
<NO>7</NO>
<PG>426-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Preston-1993" MODIFIED="2010-10-15 12:21:46 +0200" MODIFIED_BY="[Empty name]" NAME="Preston 1993" TYPE="JOURNAL_ARTICLE">
<AU>Preston KL, Bigelow GE</AU>
<TI>Differential naltrexone antagonism of hydromorphone and pentazocine effects in human volunteers</TI>
<SO>Journal of Pharmacology and Experimental Therapeutics</SO>
<YR>1993</YR>
<VL>264</VL>
<NO>2</NO>
<PG>813-23</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Project-Match-Research-Group-1997" MODIFIED="2009-12-23 14:53:50 +0100" MODIFIED_BY="[Empty name]" NAME="Project Match Research Group 1997" TYPE="JOURNAL_ARTICLE">
<AU>Project Match Research Group</AU>
<TI>Matching alcoholism treatment to client heterogeneity: Project Match posttreatment drinking outcomes</TI>
<SO>Journal of Studies on Alcoholism</SO>
<YR>1997</YR>
<VL>58</VL>
<PG>7-29</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rabkin-1992" MODIFIED="2010-01-21 13:47:47 +0100" MODIFIED_BY="[Empty name]" NAME="Rabkin 1992" TYPE="JOURNAL_ARTICLE">
<AU>Rabkin JG, Markowitz JS, Ocepek-Welikson K, Wager SS</AU>
<TI>General versus systematic inquiry about emergent clinical events with SAFTEE: implications for clinical research</TI>
<SO>Journal of Clinical Psychopharmacology</SO>
<YR>1992</YR>
<VL>12</VL>
<NO>1</NO>
<PG>3-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Raistrick-1986" MODIFIED="2010-01-07 09:27:24 +0100" MODIFIED_BY="[Empty name]" NAME="Raistrick 1986" TYPE="JOURNAL_ARTICLE">
<AU>Raistrick D, Dunbar G, Davidson R</AU>
<TI>Development of a questionnaire to measure alcohol dependence</TI>
<SO>Bristish Journal of Addiction</SO>
<YR>1983</YR>
<VL>781</VL>
<PG>89-95</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Rehm-2009" MODIFIED="2010-10-15 12:22:33 +0200" MODIFIED_BY="[Empty name]" NAME="Rehm 2009" TYPE="JOURNAL_ARTICLE">
<AU>Rehm J, Mathers C, Popova S, Thavorncharoensap M, Teerawattananon Y, Patra J</AU>
<TI>Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders</TI>
<SO>Lancet</SO>
<YR>2009</YR>
<VL>373</VL>
<NO>9682</NO>
<PG>2223-33</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roberts-1999" MODIFIED="2010-01-06 21:20:02 +0100" MODIFIED_BY="[Empty name]" NAME="Roberts 1999" TYPE="BOOK">
<AU>Roberts L, Shaner A, Eckman T</AU>
<SO>Overcoming addictions:skills training people for people with schizophrenia</SO>
<YR>1999</YR>
<PB>W.W. Morton &amp; Company</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Roozen-2006" MODIFIED="2010-10-15 12:22:51 +0200" MODIFIED_BY="[Empty name]" NAME="Roozen 2006" TYPE="JOURNAL_ARTICLE">
<AU>Roozen HG, de Waart R, van der Windt DA, van den Brink W, de Jong CA, Kerkhof AJ</AU>
<TI>A systematic review of the effectiveness of naltrexone in the maintenance treatment of opioid and alcohol dependence</TI>
<SO>European Neuropsychopharmacology</SO>
<YR>2006</YR>
<VL>16</VL>
<NO>5</NO>
<PG>311-23</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Rosner-2008" MODIFIED="2010-01-21 13:49:51 +0100" MODIFIED_BY="[Empty name]" NAME="Rosner 2008" TYPE="JOURNAL_ARTICLE">
<AU>Rösner S, Leucht S, Lehert P, Soyka M</AU>
<TI>Acamprosate supports abstinence, naltrexone prevents excessive drinking: evidence from a meta-analysis with unreported outcomes</TI>
<SO>Journal of Psychopharmacology</SO>
<YR>2008</YR>
<VL>22</VL>
<NO>1</NO>
<PG>11-23</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Rucker-2008" MODIFIED="2010-01-21 13:53:18 +0100" MODIFIED_BY="[Empty name]" NAME="Rucker 2008" TYPE="JOURNAL_ARTICLE">
<AU>Rücker G, Schwarzer G, Carpenter J R, Schumacher M</AU>
<TI>Undue reliance on I(2) in assessing heterogeneity may mislead</TI>
<SO>BMC Medical Research Methodology</SO>
<YR>2008</YR>
<VL>8</VL>
<PG>79</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schmitz-2002" MODIFIED="2010-01-21 13:53:50 +0100" MODIFIED_BY="[Empty name]" NAME="Schmitz 2002" TYPE="JOURNAL_ARTICLE">
<AU>Schmitz JM, Averill P, Sayre S, McCleary P, Moeller FG, Swann A</AU>
<TI>Cognitive-behavioral treatment of bipolar disorder and substance abuse: a preliminary randomized study</TI>
<SO>Addictive Disorders &amp; Their Treatment</SO>
<YR>2002</YR>
<VL>1</VL>
<PG>17-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Schoechlin-2000" MODIFIED="2010-10-15 12:24:15 +0200" MODIFIED_BY="[Empty name]" NAME="Schoechlin 2000" TYPE="BOOK_SECTION">
<AU>Schoechlin C, Engel RR</AU>
<TI>Meta-analysis of pharmacotherapeutic trials</TI>
<SO>Handbook of Alcoholism</SO>
<YR>2000</YR>
<PG>339-51</PG>
<ED>Zernig G, Saria A, Kurz M, O'Malley S</ED>
<PB>Innsbruck University Press</PB>
<CY>Innsbruck</CY>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Schulz-1995" MODIFIED="2010-10-15 12:25:07 +0200" MODIFIED_BY="[Empty name]" NAME="Schulz 1995" TYPE="JOURNAL_ARTICLE">
<AU>Schulz KF</AU>
<TI>Subverting randomization in controlled trials</TI>
<SO>JAMA</SO>
<YR>1995</YR>
<VL>274</VL>
<NO>18</NO>
<PG>1456-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sinclair-2001" MODIFIED="2010-01-19 21:34:07 +0100" MODIFIED_BY="[Empty name]" NAME="Sinclair 2001" TYPE="JOURNAL_ARTICLE">
<AU>Sinclair JD</AU>
<TI>Evidence about the use of naltrexone and for different ways of using it in the treatment of alcoholism</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2001</YR>
<VL>36</VL>
<NO>1</NO>
<PG>2-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Skinner-1982" MODIFIED="2010-01-21 13:55:28 +0100" MODIFIED_BY="[Empty name]" NAME="Skinner 1982" TYPE="JOURNAL_ARTICLE">
<AU>Skinner HA, Allen BA</AU>
<TI>Alcohol dependence syndrome: measurement and validation</TI>
<SO>Journal of Abnormal Psychology</SO>
<YR>1982</YR>
<VL>91</VL>
<PG>199-209</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Skinner-1984" MODIFIED="2010-01-07 10:31:57 +0100" MODIFIED_BY="[Empty name]" NAME="Skinner 1984" TYPE="BOOK">
<AU>Skinner HA, Horn JL</AU>
<SO>Alcohol Dependence Scale: Users Guide</SO>
<YR>1984</YR>
<PB>Addiction Research Foundation</PB>
<CY>Toronto</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Slattery-2003" MODIFIED="2010-01-21 13:56:08 +0100" MODIFIED_BY="[Empty name]" NAME="Slattery 2003" TYPE="OTHER">
<AU>Slattery J, Chick J, Cochrane M, Craig J, Godfrey C, Kohli H, et al</AU>
<TI>Prevention of relapse in alcohol dependence</TI>
<SO>Health Technology Assesment Report 3</SO>
<YR>2003</YR>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Sobell-1988" MODIFIED="2010-10-15 12:25:33 +0200" MODIFIED_BY="[Empty name]" NAME="Sobell 1988" TYPE="JOURNAL_ARTICLE">
<AU>Sobell LC, Sobell MB, Riley DM, Schuller R, Pavan DS, Cancilla A, et al</AU>
<TI>The reliability of alcohol abusers' self-reports of drinking and life events that occurred in the distant past</TI>
<SO>Journal of Studies on Alcohol</SO>
<YR>1988</YR>
<VL>49</VL>
<NO>3</NO>
<PG>225-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Sobell-1992" MODIFIED="2010-10-15 12:25:46 +0200" MODIFIED_BY="[Empty name]" NAME="Sobell 1992" TYPE="JOURNAL_ARTICLE">
<AU>Sobell LC, Toneatto T, Sobell MB, Leo GI, Johnson L</AU>
<TI>Alcohol abusers' perceptions of the accuracy of their self-reports of drinking: implications for treatment</TI>
<SO>Addictive Behaviors</SO>
<YR>1992</YR>
<VL>17</VL>
<NO>5</NO>
<PG>507-11</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Srisurapanont-2000" MODIFIED="2010-10-15 12:30:53 +0200" MODIFIED_BY="[Empty name]" NAME="Srisurapanont 2000" TYPE="COCHRANE_PROTOCOL">
<AU>Srisurapanont M, Jarusuraisin N</AU>
<TI>Opioid antagonists for alcohol dependence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2000</YR>
<VL>3</VL>
<NO>3</NO>
<IDENTIFIERS MODIFIED="2010-10-15 12:28:19 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-10-15 12:28:19 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001867.pub2 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Srisurapanont-2005a" MODIFIED="2010-10-15 12:30:38 +0200" MODIFIED_BY="[Empty name]" NAME="Srisurapanont 2005a" TYPE="COCHRANE_REVIEW">
<AU>Srisurapanont M, Jarusuraisin N</AU>
<TI>Opioid antagonists for alcohol dependence</TI>
<SO>Cochrane Database of Systematic Reviews</SO>
<YR>2005</YR>
<VL>25</VL>
<NO>1</NO>
<IDENTIFIERS MODIFIED="2010-10-15 12:30:22 +0200" MODIFIED_BY="[Empty name]">
<IDENTIFIER MODIFIED="2010-10-15 12:30:22 +0200" MODIFIED_BY="[Empty name]" TYPE="DOI" VALUE="10.1002/14651858.CD001867.pub2 "/>
</IDENTIFIERS>
</REFERENCE>
<REFERENCE ID="REF-Srisurapanont-2005b" MODIFIED="2010-10-15 12:31:39 +0200" MODIFIED_BY="[Empty name]" NAME="Srisurapanont 2005b" TYPE="JOURNAL_ARTICLE">
<AU>Srisurapanont M, Jarusuraisin N</AU>
<TI>Naltrexone for the treatment of alcoholism: a meta-analysis of randomized controlled trials</TI>
<SO>International Journal of Neuropsychopharmacology</SO>
<YR>2005</YR>
<VL>8</VL>
<NO>2</NO>
<PG>267-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Stockwell-1979" MODIFIED="2010-01-07 09:39:59 +0100" MODIFIED_BY="[Empty name]" NAME="Stockwell 1979" TYPE="JOURNAL_ARTICLE">
<AU>Stockwell T, Hodgson R, Edwards G</AU>
<TI>The development of a questionnaire to measure severity of alcohol dependence</TI>
<SO>British Journal of Addiction</SO>
<YR>1979</YR>
<VL>77</VL>
<PG>79-87</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Streeton-2001" MODIFIED="2010-10-15 12:32:16 +0200" MODIFIED_BY="[Empty name]" NAME="Streeton 2001" TYPE="JOURNAL_ARTICLE">
<AU>Streeton C Whelan G</AU>
<TI>Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of randomized controlled trials</TI>
<SO>Alcohol and Alcoholism</SO>
<YR>2001</YR>
<VL>36</VL>
<PG>544-52</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Sullivan-1989" MODIFIED="2010-10-15 12:32:32 +0200" MODIFIED_BY="[Empty name]" NAME="Sullivan 1989" TYPE="JOURNAL_ARTICLE">
<AU>Sullivan JT, Sykora K, Schneideman J</AU>
<TI>Institute Withdrawal Assessment for Alcohol scale (CIWA Ar)</TI>
<SO>Bristish Journal of Addiction</SO>
<YR>1989</YR>
<VL>84</VL>
<PG>1353-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Tannock-1996" MODIFIED="2010-10-15 12:32:45 +0200" MODIFIED_BY="[Empty name]" NAME="Tannock 1996" TYPE="JOURNAL_ARTICLE">
<AU>Tannock IF</AU>
<TI>False-positive results in clinical trials: multiple significance tests and the problem of unreported comparisons</TI>
<SO>Journal of the National Cancer Institute</SO>
<YR>1996</YR>
<VL>88</VL>
<NO>3-4</NO>
<PG>206-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-The-Nordic-Cochrane-Centre-2008" MODIFIED="2010-01-21 14:34:16 +0100" MODIFIED_BY="[Empty name]" NAME="The Nordic Cochrane Centre 2008" NOTES="The Cochrane Collaboration. Review Manager (RevMan). 5.0." NOTES_MODIFIED="2010-01-21 14:34:16 +0100" NOTES_MODIFIED_BY="[Empty name]" TYPE="COMPUTER_PROGRAM">
<AU>The Nordic Cochrane Centre</AU>
<TI>Review Manager (RevMan). 5.0</TI>
<YR>2008</YR>
<PB>The Nordic Cochrane Centre</PB>
<CY>Copenhagen</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Ulm-1995" MODIFIED="2010-01-21 13:58:32 +0100" MODIFIED_BY="[Empty name]" NAME="Ulm 1995" TYPE="JOURNAL_ARTICLE">
<AU>Ulm RR, Volpicelli JR, Volpicelli LA</AU>
<TI>Opiates and alcohol self-administration in animals</TI>
<SO>Journal of Clinical Psychiatry</SO>
<YR>1995</YR>
<VL>56</VL>
<NO>7</NO>
<PG>5-14</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Volpicelli-1995" MODIFIED="2010-10-15 12:34:14 +0200" MODIFIED_BY="[Empty name]" NAME="Volpicelli 1995" TYPE="JOURNAL_ARTICLE">
<AU>Volpicelli JR, Watson NT, King AC, Sherman CE, O'Brien CP</AU>
<TI>Effect of naltrexone on alcohol "high" in alcoholics</TI>
<SO>American Journal of Psychiatry</SO>
<YR>1995</YR>
<VL>152</VL>
<NO>4</NO>
<PG>613-15</PG>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Volpicelli-2001" MODIFIED="2010-01-21 13:59:06 +0100" MODIFIED_BY="[Empty name]" NAME="Volpicelli 2001" TYPE="BOOK">
<AU>Volpicelli JR, Pettinati HM, McLellan AT, O'Brien CP</AU>
<SO>Combining medication and psychosocial treatments for addictions: The BRENDA Approach</SO>
<YR>2001</YR>
<PB>The Guilford Press</PB>
<CY>New York</CY>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-WHO-2002" MODIFIED="2010-01-21 13:59:14 +0100" MODIFIED_BY="[Empty name]" NAME="WHO 2002" TYPE="BOOK">
<AU>World Health Organization</AU>
<SO>The World Health Report: Reducing risk, promoting healthy life</SO>
<YR>2002</YR>
<PB>WHO</PB>
<CY>Geneva</CY>
<IDENTIFIERS MODIFIED="2009-02-13 18:30:26 +0100" MODIFIED_BY="[Empty name]"/>
</REFERENCE>
<REFERENCE ID="REF-Williamson-2005" MODIFIED="2010-10-15 12:34:44 +0200" MODIFIED_BY="[Empty name]" NAME="Williamson 2005" TYPE="JOURNAL_ARTICLE">
<AU>Williamson PR, Gamble C, Altman DG, Hutton JL</AU>
<TI>Outcome selection bias in meta-analysis</TI>
<SO>Statistical Methods in Medical Research</SO>
<YR>2005</YR>
<VL>14</VL>
<NO>5</NO>
<PG>515-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Wood-2008" MODIFIED="2010-10-15 12:34:57 +0200" MODIFIED_BY="[Empty name]" NAME="Wood 2008" TYPE="JOURNAL_ARTICLE">
<AU>Wood L, Egger M, Gluud LL, Schulz KF, Juni P, Altman DG, et al</AU>
<TI>Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta-epidemiological study</TI>
<SO>BMJ</SO>
<YR>2008</YR>
<VL>336</VL>
<NO>7644</NO>
<PG>601-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Woody-1983" MODIFIED="2010-10-15 12:35:19 +0200" MODIFIED_BY="[Empty name]" NAME="Woody 1983" TYPE="JOURNAL_ARTICLE">
<AU>Woody GE, Luborsky L, McLellan AT</AU>
<TI>Psychotherapy for opiate addicts. Does it help?</TI>
<SO>Archives of General Psychiatry</SO>
<YR>1983</YR>
<VL>40</VL>
<PG>639-45</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES MODIFIED="2009-12-21 22:48:51 +0100" MODIFIED_BY="[Empty name]"/>
<PENDING_REFERENCES MODIFIED="2008-08-08 07:59:39 +0200" MODIFIED_BY="[Empty name]"/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2010-10-15 14:25:03 +0200" MODIFIED_BY="Laura Amato">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2010-10-15 14:24:37 +0200" MODIFIED_BY="Laura Amato" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Financial support" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Data assessment methods" USER_DEF_3_ENABLED="YES" USER_DEF_3_NAME="Treatment adherence">
<INCLUDED_CHAR MODIFIED="2010-07-31 15:37:54 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ahmadi-2002">
<CHAR_METHODS MODIFIED="2010-07-31 15:37:16 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence </B>
</P>
<P>
<B>Allocation:</B> random; <B>blinding:</B> double-blind; <B>study duration: </B>12 weeks; <B>principle of analysis:</B> not reported; <B>setting:</B> outpatient; <B>study sites: </B>1; <B>country:</B> Iran</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 15:37:34 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence (DSM-IV); <B>required abstinence:</B> 3 to 30 days; <B>baseline characteristics:</B> 100% male; mean age: 43.0 (SD = 9.2); 87% married; 83.6% employed; <B>pre-baseline drinking: </B>no indicators reported; <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence (other than alcohol or nicotine); 2. a concurrent use of opioids, disulfiram or neuroleptic drugs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 09:55:07 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (n = 58)</LI>
<LI>placebo (n = 58)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>cognitive-behavioral techniques: a) analyses of drinking behavior cues; b) coping skills to avoid or manage high-risk situations; c) individual counselling sessions</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-29 10:36:24 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first relapse* (survival analysis)</LI>
<LI>side effects</LI>
</OL>
<P>* relapse: drinking &#8805; 5 SDU per drinking occasion or drinking on &#8805; 5 days a week</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-12-29 10:36:07 +0100" MODIFIED_BY="[Empty name]">
<P>No information provided</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-31 15:37:54 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>; weekly); <B>assessment of side-effects: </B>systematic enquiry; no further information provided; <B>assessment of compliance:</B> pill count</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-22 16:36:55 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates: </B>naltrexone: 21% (n = 12); placebo: 57% (n = 33); <B>lost to follow-up rates:</B> <I>not reported; </I>
<B>compliance rates:</B> not reported; group differences in compliance rates: <I>not reported</I>
</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-01-20 20:12:06 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-15 14:16:29 +0200" MODIFIED_BY="Laura Amato" STUDY_ID="STD-Anton-1999">
<CHAR_METHODS MODIFIED="2010-07-31 15:43:44 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics</B>
</P>
<P>
<B>Allocation: </B>random; <B>blinding: </B>double-blind; <B>study duration: </B>12 weeks (treatment); 14 weeks (post-treatment); <B>principle of analysis:</B> ITT (modified); <B>setting:</B> outpatient; <B>study sites:</B> 1; <B>country:</B> USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-15 14:16:29 +0200" MODIFIED_BY="Laura Amato">
<P>
<B>Diagnosis: </B>alcohol dependence (DSM-III-R); <B>required abstinence</B>: &#8805; 5 days; <B>baseline characteristics:</B> 69% male; mean age: 42.5 (SD = 9.2); 68% married; 82% employed full time; <B>pre-baseline drinking: </B>82% (SD = 21) drinking days; 11.8 (SD = 4.9) drinks per drinking day; ADS score (<LINK REF="REF-Skinner-1982" TYPE="REFERENCE">Skinner 1982</LINK>; <LINK REF="REF-Skinner-1984" TYPE="REFERENCE">Skinner 1984</LINK>): 17 (SD = 16.5); <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence (other than nicotine or alcohol); 2. a lifetime diagnosis of opioid dependence; 3. a concurrent major psychiatric disorder; 4. a concurrent use of psychotropic or anti seizure medications or disulfiram</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 14:56:09 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (n = 68)</LI>
<LI>placebo (n = 63)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>CBT (cognitive behavioral therapy); <B>applied manual: </B>
<LINK REF="REF-Kadden-1992" TYPE="REFERENCE">Kadden 1992</LINK> as applied in Project MATCH (<LINK REF="REF-Project-Match-Research-Group-1997" TYPE="REFERENCE">Project Match Research Group 1997</LINK>)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 10:04:42 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first relapse* (survival curve)</LI>
<LI>return to any drinking</LI>
<LI>days abstinent</LI>
<LI>drinks per drinking day</LI>
<LI>craving </LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>carbohydrate-deficient transferrin (CDT)</LI>
<LI>side effects</LI>
</OL>
<P>* relapse / heavy drinking: drinking &#8805;5 (4) SDU for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-12-23 14:54:05 +0100" MODIFIED_BY="[Empty name]">
<P>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-22 16:41:48 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>; weekly; post-treatment: week 4, 14); <B>assessment of side-effects:</B> week 1, 2, 3, 4, 8, 12; <B>assessment of compliance:</B> urinary riboflavin detection</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-22 16:41:34 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment phase / drop-out rates:</B> naltrexone: 13% (n = 9); placebo: 22% (n = 14); <B>lost to follow-up rates: </B>naltrexone: 1.5% (n = 1); placebo: 1.5% (n = 1); <B>post-treatment phase / lost to follow-up rates: </B>naltrexone: 3% (n = 2); placebo: 8% (n = 5); <B>compliance rates</B> (patients with &gt; 75% compliance): naltrexone: 69%; placebo: 67%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-12-22 09:49:30 +0100" MODIFIED_BY="[Empty name]">
<P>Posttreatment results published in <LINK REF="REF-Anton-2001" TYPE="REFERENCE">Anton 2001</LINK>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 15:54:42 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anton-2004">
<CHAR_METHODS MODIFIED="2010-07-31 15:53:55 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence</B>
</P>
<P>
<B>Allocation: </B>random; <B>blinding: </B>double-blind; <B>study duration:</B> 12 weeks; <B>principle of analysis:</B> ITT; <B>setting:</B> outpatient; <B>study sites:</B> 13; <B>country:</B> USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 15:54:42 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence (DSM-IV); <B>required abstinence</B>: 3 to 14 days; <B>baseline characteristics</B>: 70% male; mean age: 45.0 (SD = 10.5) years; 48% married; <B>pre-baseline drinking: </B>80% days drinking; 8.5 (SD = 5.1) drinks per drinking day; ADS score (<LINK REF="REF-Skinner-1982" TYPE="REFERENCE">Skinner 1982</LINK>; <LINK REF="REF-Skinner-1984" TYPE="REFERENCE">Skinner 1984</LINK>): 16 (SD = 7); <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence (other than alcohol or nicotine); 2. a concurrent major psychiatric disorder; 3. a concurrent use of psychotropic medication (except stable antidepressant treatment), disulfiram or opioids or a recent treatment with naltrexone or investigational drugs</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 14:56:25 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>5 mg nalmefene (n = 68)</LI>
<LI>20 mg nalmefene (n = 66)</LI>
<LI>40 mg nalmefene (n = 68)</LI>
<LI>placebo (n = 68)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>motivational enhancement (ME);<B> applied manual: </B>Motivating for Alcohol Reduction and Medication Management (MARMM), which is a modified version of motivational enhancement therapy (MET) as applied as applied in Project MATCH (<LINK REF="REF-Project-Match-Research-Group-1997" TYPE="REFERENCE">Project Match Research Group 1997</LINK>); <B>aim:</B> flexible</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 10:07:29 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first relapse* (survival curve)</LI>
<LI>heavy drinking days</LI>
<LI>craving</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>carbohydrate-deficient transferrin (CDT)</LI>
<LI>side effects</LI>
</OL>
<P>*relapse / heavy drinking: drinking &#8805; 5 (4) SDU for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-12-29 10:59:46 +0100" MODIFIED_BY="[Empty name]">
<P>BioTie Therapies Corporation (Espoo, Finland)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-22 16:42:18 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>; week 1, 3, 6, 9, 12); <B>assessment of side-effects:</B> adverse event recording (week 1, 3, 6, 9, 12); <B>assessment of compliance:</B> pill count</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-22 16:45:16 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates: </B>nalmefene: 24.5% (n = 50); placebo: 28% (n = 19); <B>lost to follow-up rates: </B>nalmefene: 12.7% (n = 26); placebo: 16% (n = 11); <B>compliance rates </B>(% of prescribed medication taken): 90%; no group specific values provided</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-05-26 16:48:13 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 15:56:38 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anton-2005">
<CHAR_METHODS MODIFIED="2010-07-31 15:56:15 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Naltrexone combined with either cognitive behavioral or motivational enhancement therapy for alcohol dependence</B>
</P>
<P>
<B>Allocation:</B> random; <B>blinding:</B> double-blind; <B>study duration: </B>12 weeks; <B>principle of analysis:</B> ITT; <B>setting: </B>outpatient; <B>study sites:</B> 1; <B>country: </B>USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 15:56:38 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence (DSM-IV); <B>required abstinence: </B>&#8805; 5 days; <B>baseline characteristics:</B> 76% male; mean age: 43.7 (SD = 9.5) years; 38.7% married; 85% employed full time; <B>pre-baseline drinking: </B>74% (SD = 16.3) days drinking; 12.0 (SD = 6.1) drinks per drinking day; ADS score (<LINK REF="REF-Skinner-1982" TYPE="REFERENCE">Skinner 1982</LINK>; <LINK REF="REF-Skinner-1984" TYPE="REFERENCE">Skinner 1984</LINK>): 14.7 (SD = 7); <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence (other than alcohol, nicotine or marijuana); 2. a lifetime diagnosis of opioid abuse or dependence; 3. a concurrent major psychiatric disorder or current suicidal or homicidal ideation; 4. a concurrent use of psychotropic or antiseizure medications or disulfiram or any use of an opiate antagonist in the month before study entry</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 14:58:29 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone + CBT (n = 39)</LI>
<LI>50 mg naltrexone + ME (n = 41)</LI>
<LI>placebo + CBT (n = 41)</LI>
<LI>placebo + ME (n = 39)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>a)<B> </B>group 1. + 3: cognitive behavioral therapy (CBT); <B>applied manual: </B>
<LINK REF="REF-Kadden-1992" TYPE="REFERENCE">Kadden 1992</LINK>as applied in Project Match (<LINK REF="REF-Project-Match-Research-Group-1997" TYPE="REFERENCE">Project Match Research Group 1997</LINK>); b) group 2 + 4: motivational enhancement therapy (ME); applied manual: <LINK REF="REF-MIller-1994" TYPE="REFERENCE">MIller 1994</LINK> as applied in Project Match (<LINK REF="REF-Project-Match-Research-Group-1997" TYPE="REFERENCE">Project Match Research Group 1997</LINK>)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 10:10:54 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first relapse* (survival curve)</LI>
<LI>return to heavy drinking*</LI>
<LI>days abstinent</LI>
<LI>drinks per drinking day</LI>
<LI>time to first /second /third /fourth event</LI>
<LI>craving </LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>carbohydrate-deficient transferrin (CDT)</LI>
<LI>side effects</LI>
</OL>
<P>* relapse / heavy drinking: drinking &#8805; 5 (4) SDU for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-06 10:11:00 +0100" MODIFIED_BY="[Empty name]">
<P>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 21:26:03 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>; week 2, 6, 12); <B>assessment of side-effects:</B> (week 2, 6, and 12); <B>assessment of compliance:</B> Microelective Events Monitoring System (MEMS); urinary riboflavin detection (weeks 2, 6, and 12)</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 21:35:44 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates:</B> naltrexone: 20% (n = 16); placebo: 17% (n = 14); group difference in drop-out rates: not significant; group difference in reasons for drop-out: not significant; <B>lost to follow-up rates:</B> not reported; <B>compliance rates</B> (% of electronic pill bottle cap openings): naltrexone: 85%; placebo: 80%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-06 10:11:50 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 15:59:34 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anton-2006">
<CHAR_METHODS MODIFIED="2010-07-31 15:58:09 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Combined pharmacotherapies and behavioral interventions for alcohol dependence (COMBINE study) </B>
</P>
<P>
<B>Allocation:</B> random; <B>blinding:</B> double-blind; <B>principle of analysis:</B> ITT; <B>study duration:</B> 16 weeks (treatment); 12 months (post-treatment); <B>setting:</B> outpatient; <B>study sites: </B>11; <B>country: </B>USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 15:59:34 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence (DSM-IV); <B>required abstinence:</B> 4 to 21 days; <B>baseline characteristics: </B>70% male; mean age: 44.0 years; 42% married: 71% employed; <B>pre-baseline drinking: </B>75% days drinking; 12.4 drinks per drinking day; ADS score (<LINK REF="REF-Skinner-1982" TYPE="REFERENCE">Skinner 1982</LINK>; <LINK REF="REF-Skinner-1984" TYPE="REFERENCE">Skinner 1984</LINK>): 16.8; percentage of individuals abstinent for at least 4 days: 99%; <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence (other than alcohol, nicotine, cannabis or habitual caffeine use); 2. opiate dependence or abuse (past 6 months) or chronic treatment with opiate-containing medications (past month); 3. a concurrent major psychiatric disorder irequiring medication; 4. prior use of study medication in the last 30 days</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 15:02:02 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>3000 mg acamprosate + MM (n = 152)</LI>
<LI>3000 mg acamprosate + MM + CBI (n = 154)</LI>
<LI>100 mg naltrexone + MM (n = 153)</LI>
<LI>100 mg naltrexone + MM + CBI (n = 155)</LI>
<LI>3000 mg acamprosate + 100 mg naltrexone + MM (n = 148)</LI>
<LI>3000 mg acamprosate + 100 mg naltrexone + MM + CBI (n = 157)</LI>
<LI>placebo + MM (n = 153)</LI>
<LI>placebo + CBI (n = 156)</LI>
<LI>CBI only (n = 157)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>a) group 1 to 7:<I> </I>medial management (MM); <B>applied manual: </B>
<LINK REF="REF-Pettinati-2004" TYPE="REFERENCE">Pettinati 2004</LINK>; <B>aim:</B> flexible (with recommendation to abstinence); b)<I> </I>group 2, 4, 6, 8 and 9: combined behavioural intervention (CBI); <B>applied manual: </B>integrates aspects of cognitive behavioural therapy (CBT)<B> </B>(<LINK REF="REF-Kadden-1992" TYPE="REFERENCE">Kadden 1992</LINK> as applied in Project MATCH (<LINK REF="REF-Project-Match-Research-Group-1997" TYPE="REFERENCE">Project Match Research Group 1997</LINK>), motivational enhancement (ME) <LINK REF="REF-MIller-1994" TYPE="REFERENCE">MIller 1994</LINK>, 12-step facilitation (<LINK REF="REF-Nowinski-1995" TYPE="REFERENCE">Nowinski 1995</LINK>), etc.</P>
<P>
<B>Dosing: </B>flexible dosing allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-18 12:05:08 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Return to heavy drinking*</LI>
<LI>percent days abstinent</LI>
<LI>good clinical outcome (abstinence; moderate drinking**)</LI>
<LI>time to first heavy drinking*</LI>
<LI>side effects</LI>
</OL>
<P>* relapse / heavy drinking: drinking &#8805; 5 (4) SDU for men (women)</P>
<P>** moderate drinking: &#8805; 14 (11) SDU for men (women) per week, with no more than two days on &#8805; 5 (4) SDU for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-06 10:21:58 +0100" MODIFIED_BY="[Empty name]">
<P>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</P>
<P>Active control substances and placebo were donated by Lipha Pharmaceuticals; Lipha Pharmaceuticals conducted monitoring visits to the clinical sites</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 21:36:12 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>); <B>assessment of side-effects: </B>SAFTEE<B> </B>(<LINK REF="REF-Levine-1986" TYPE="REFERENCE">Levine 1986</LINK>, <LINK REF="REF-Rabkin-1992" TYPE="REFERENCE">Rabkin 1992</LINK>); <B>assessment of compliance:</B> pill count</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 21:36:26 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment phase / drop-out rates:</B> naltrexone: 35% (n = 108); naltrexone + acamprosate: 40.7% (n = 124); acamprosate: 38.5% (n = 116); placebo: 28.5% (n = 88); <B>lost to follow-up rates</B>: naltrexone: 6.1% (n = 19); naltrexone + acamprosate: 6.2% (n = 19); acamprosate: 4.6% (n = 14); placebo: 5.8% (n = 18); </P>
<P>
<B>Posttreatment phase / drop-out rates: </B>naltrexone: 46.0% (n = 142); naltrexone + acamprosate: 53.1% (n = 162); acamprosate: 49.2 (n = 149); placebo: 38.2% (n = 118); <B>compliance rates</B> (% of prescribed medication taken): naltrexone: 85.4%; acamprosate: 84.2%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-02 08:55:24 +0100" MODIFIED_BY="[Empty name]">
<P>The COMBINE study group provided access to the COMBINE data set, which was used for the calculation of "return to any drinking" for the review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 16:02:00 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Auriacombe-2000">
<CHAR_METHODS MODIFIED="2010-07-31 16:01:39 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Naltrexone is ineffective to prevent relapse to alcohol in a realistic outpatient setting: a double-blind, one year controlled study </B>
</P>
<P>
<B>Allocation:</B> random, unclear; <B>blinding:</B> double-blind; <B>principle of analysis:</B> not reported; <B>study duration:</B> 54 weeks; <B>setting:</B> outpatient; <B>study sites: </B>not reported; <B>country: </B>France</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 16:02:00 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence; <B>required abstinence:</B> no information available; <B>baseline characteristics: </B>no information available; <B>exclusionary of psychiatric conditions: </B>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-22 17:23:41 +0200" MODIFIED_BY="[Empty name]">
<P>No information available</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-22 17:23:42 +0200" MODIFIED_BY="[Empty name]">
<P>No information available</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-07-22 17:23:42 +0200" MODIFIED_BY="[Empty name]">
<P>No information available.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-22 17:23:48 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>no information available; <B>assessment of side-effects: </B>no information available; <B>assessment of compliance: </B>no information available.</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-22 17:23:49 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates: </B>no information available</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-07 11:05:52 +0100" MODIFIED_BY="[Empty name]">
<P>Because of missing outcome data, the study was not included in the statistical analysis </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 16:02:50 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Balldin-2003">
<CHAR_METHODS MODIFIED="2010-07-31 16:02:33 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: 6-month controlled naltrexone study: combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence</B>
</P>
<P>
<B>Allocation:</B> random; <B>blinding:</B> double-blind; <B>study duration: </B>24 weeks; <B>principle of analysis:</B> ITT; <B>setting: </B>outpatient; <B>study sites: </B>10; <B>country:</B> Sweden</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 16:02:50 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence (DSM-IV); <B>required abstinence:</B> 14 to 28 days; <B>baseline characteristics:</B> 85% male; mean age: 49.7 (SD = 7.8) years; 56% married: 72% employed; <B>pre-baseline drinking:</B> 63.5% days drinking; 151 (SD = 79.1) grams alcohol per drinking day; ASI score (<LINK REF="REF-McLellan-1980" TYPE="REFERENCE">McLellan 1980</LINK>): 0.55 (SD = 0.2); <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence (other than alcohol or nicotine); 2. a concurrent major psychiatric disorder including suicide liability, intense aggressive impulses, or brain damage; 3. a concurrent use of psychotropic medications as well as disulfiram, calcium carbamide, naltrexone, acamprosate, benzodiazepines, lithium or buspirone</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-07 16:37:00 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone + CBT (n = 25)</LI>
<LI>50 mg naltrexone + ME (n = 31)</LI>
<LI>placebo + CBT (n = 30)</LI>
<LI>placebo + ME (n = 32)</LI>
</OL>
<P>
<B>Trial started with a placebo run-in week</B>
</P>
<P>
<B>Psychosocial treatment: </B>a) group 1 + 3: cognitive behavioral therapy; <B>applied manual: </B>
<LINK REF="REF-Kadden-1992" TYPE="REFERENCE">Kadden 1992</LINK> as applied in Project Match (<LINK REF="REF-Project-Match-Research-Group-1997" TYPE="REFERENCE">Project Match Research Group 1997</LINK>); <B>aim:</B> flexible; b) group 2 + 4: motivational enhancement (ME) for sobriety without teaching specific coping skills; <B>aim:</B> abstinence</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 10:25:27 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first relapse* (survival curve)</LI>
<LI>heavy drinking* days</LI>
<LI>drinking days</LI>
<LI>amount per drinking day</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>carbohydrate-deficient transferrin (CDT)</LI>
<LI>aspartate aminotransferase (AST)</LI>
<LI>alanine aminotransferase (ALT)</LI>
<LI>craving </LI>
<LI>side effects</LI>
</OL>
<P>*relapse / heavy drinking: drinking &#8805;5 (4) STD for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-19 10:45:42 +0200" MODIFIED_BY="[Empty name]">
<P>DuPont Pharma (UK); Meda AB (Sweden)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 21:36:49 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking:</B> TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>; week 2, 4, 6, 8, 10, 12, 16, 20, 24); <B>assessment of side-effects: </B>adverse clinical event forms; <B>assessment of compliance:</B> pill count</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 21:37:04 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates </B>(provided by the investigators): naltrexone: 19.6% (n = 11); placebo: 24.2% (n = 15); <B>lost to follow-up rates</B>: 9% of possible quantitative drinking data were not obtained; <B>compliance rates</B> (patients who took at least 80% of the prescribed medication): naltrexone: 80%; placebo: 85%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-07 09:12:43 +0100" MODIFIED_BY="[Empty name]">
<P>Abstinence rates and drop-out rates were subsequently provided by the investigator for the review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 16:05:15 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Baltieri-2008">
<CHAR_METHODS MODIFIED="2010-07-31 16:05:15 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Comparing topiramate with naltrexone in the treatment of alcohol dependence</B>
</P>
<P>
<B>Allocation:</B> random; <B>blinding: </B>adequate; <B>study duration:</B> 12 weeks; <B>principle of analysis:</B> ITT; <B>setting: </B>outpatient; <B>study sites:</B> 1; <B>country: </B>Brazil</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 16:05:08 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;&lt;i&gt;These values reveal that this sample was of moderate to severe alcohol dependence. &lt;/i&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-07-31 16:05:08 +0200" NOTES_MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence (ICD-10); <B>required abstinence: </B>7 days (all patients received a 1-week detoxification prior to the initiation of double-blind treatment); <B>baseline characteristics:</B> 100% male; mean age: 44.3 (SD = 8.4) years; 51.6% married; <B>pre-baseline drinking:</B> 25 drinks with 12 grams (SD = 14.5) per drinking day (&#8776;301 grams per day; SD = 174); SADQ score (<LINK REF="REF-Raistrick-1986" TYPE="REFERENCE">Raistrick 1986</LINK>): 28.8 (SD = 8.5); <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence (other than alcohol or nicotine); 2. a concurrent major psychiatric disorder that requires drug treatment; 3. previous treatment with naltrexone or topiramate (past 6 months) </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 15:17:26 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg of naltrexone (n = 49)</LI>
<LI>300 mg topiramate (n = 52)</LI>
<LI>placebo (n = 54)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>cognitive behavioral therapy (CBT) with management of high-risk situations and negative mood, drink refusal skills + motivational enhancement (ME) for sobriety and medication compliance + attendance to AA groups</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-29 17:42:53 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first relapse (survival curve)</LI>
<LI>return to any drinking</LI>
<LI>cumulative abstinence duration (CAD)</LI>
<LI>heavy drinking* weeks (&#8805; 90 grams alcohol per week)</LI>
<LI>craving</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>side effects</LI>
</OL>
<P>*relapse / heavy drinking: drinking &#8805; 90 grams alcohol per week</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-21 10:23:16 +0200" MODIFIED_BY="[Empty name]">
<P>State of São Paulo Research Foundation (FAPESP)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-22 17:31:10 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking:</B> daily monitoring card; interview (week 1, 2, 3, 4, 6, 8, 10, 12); <B>assessment of side-effects: </B>Udvalg for Kliniske Undersøgelser (UKU) Side Effect Rating Scale (<LINK REF="REF-Lingjaerde-1987" TYPE="REFERENCE">Lingjaerde 1987</LINK>); <B>assessment of compliance:</B> daily monitoring card, pill count, collateral reports (week 1, 2, 3, 4, 6, 8, 10, 12)</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-22 17:30:33 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Dropout rates: </B>naltrexone: 40.8% (n = 20); placebo: 57.4% (n = 31); topiramate: 36.5% (n = 19); <B>lost to follow-up rates: </B>naltrexone: 34.7% (n = 17); placebo: 44.4 % (n = 24); topiramate: 19.2% (n = 10); <B>compliance rates: </B>not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-06 10:28:17 +0100" MODIFIED_BY="[Empty name]">
<P>Information on the study design was subsequently provided by the investigator</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 16:09:06 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brown-2009">
<CHAR_METHODS MODIFIED="2010-07-31 16:08:05 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: A randomized, double-blind, placebo-controlled pilot study of naltrexone in outpatients with bipolar disorder and alcohol dependence</B>
</P>
<P>
<B>Allocation:</B> random; <B>blinding:</B> double-blind; <B>study duration:</B> 12 weeks; <B>principle of analysis</B>: ITT; <B>setting: </B>outpatient; <B>study sites: </B>1; <B>country: </B>USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 16:08:42 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence (DSM-IV); <B>concurrent psychiatric diagnosis: </B>bipolar<B> </B>disorder (100%); <B>required abstinence: </B>no prior detoxification required; patients were actively drinking; <B>baseline characteristics:</B> 51.2% male; mean age: 41.1 (SD = 12.1) years; 72.1% with bipolar disorder type I; 27.9% with bipolar disorder type II; <B>pre-baseline drinking:</B> 72.1% (SD = 25.9) drinking days; 9.4 (SD = 6.4) drinks per drinking day; ASI score (<LINK REF="REF-McLellan-1980" TYPE="REFERENCE">McLellan 1980</LINK>): 0.6 (SD = 0.3 ); <B>exclusionary psychiatric conditions: </B>1. a concurrent drug dependence (other than alcohol or nicotine); 2. a lifetime diagnosis of opioid dependence or a concurrent use of opioids; 3. a current mood state of depression or mania or a risk of suicide; 4. a concurrent use of acamprosate or disulfiram or a prior therapy with naltrexone<B> </B>
</P>
<P>
<B>Note:</B> Concurrent drug abuse was not a criteria of exclusion (e.g. cocaine 11.6%; cannabis abuse 11.6%)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-31 16:09:06 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (n = 20)</LI>
<LI>placebo (n = 23)</LI>
</OL>
<P>
<B>Permitted psychiatric co-medications:</B> lithium, anticonvulsants (valproate), antipsychotics, antidepressants and sedatives; <B>psychosocial treatment: </B>cognitive behavioral therapy (CBT) designed for patients with bipolar disorder and substance use; <B>applied manual: </B>
<LINK REF="REF-Schmitz-2002" TYPE="REFERENCE">Schmitz 2002</LINK>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-29 11:45:10 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Return to any drinking (interval abstinence)</LI>
<LI>days abstinent</LI>
<LI>heavy drinking days</LI>
<LI>drinks per drinking day</LI>
<LI>craving </LI>
<LI>GGT</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-12-29 11:45:31 +0100" MODIFIED_BY="[Empty name]">
<P>National Institute of Health (NIH)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-22 17:33:29 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking:</B> TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>); <B>assessment of side-effects: </B>not reported; <B>assessment of compliance:</B> pill count</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 21:38:01 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 30% (n = 6); placebo: 47.8% (n = 11); <B>lost to follow-up rates</B>: not reported; <B>compliance rates</B> (% of prescribed medication taken): naltrexone: 94.4% (SD = 6.1); placebo: 95.3% (SD = 7.4)</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-02 11:42:44 +0100" MODIFIED_BY="[Empty name]">
<P>The study was not published at the completion date of the review; the submitted manuscript was obtained from the investigator; further information (rates of continuous abstinence, drinking days, consumed amount per drinking day) were subsequently provided by the investigator for the review </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 16:26:02 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Chick-2000">
<CHAR_METHODS MODIFIED="2010-07-31 16:25:26 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: A multi-centre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse.</B>
</P>
<P>
<B>Allocation: </B>random; <B>blinding:</B> double-blind; <B>study duration: </B>12 weeks; <B>principle of analysis</B>: ITT (modified); per-protocol analysis; <B>setting:</B> outpatient; <B>study sites:</B> 6; <B>country: </B>United Kingdom</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 16:26:02 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis</B>: alcohol dependence (96.6%); alcohol abuse (3.4%); DSM-III-R; <B>required abstinence:</B> 5 to 30 days; <B>baseline characteristics: </B>65% male; mean age: 43.5 (SD=9.0) years; 53% married: 24% full time employed; <B>pre-baseline drinking: </B>24.4 (SD = 9.7) years of drinking; 10.2 (SD = 8.4) drinks per drinking day; 10 days of abstinence at beginning of treatment; <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence; 2. a concurrent major psychiatric disorder requiring medication; 3. concurrent use of opioids, disulfiram, acamprosate, antidepressants, antipsychotics, lithium, or benzodiazepines </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 11:34:53 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (n = 85)</LI>
<LI>placebo (n = 79)</LI>
</OL>
<P>* patients excluded who did not receive at least one dose of study medication</P>
<P>
<B>Psychosocial treatment: </B>centre specific treatments; patients were free to attend alternative facilities including Alcoholics Anonymous (AA) or other support groups; <B>aim:</B> flexible</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 11:35:07 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first relapse* (survival curve)</LI>
<LI>return to any drinking</LI>
<LI>return to heavy drinking</LI>
<LI>days abstinent</LI>
<LI>drinks during last four study weeks</LI>
<LI>craving</LI>
<LI>GGT</LI>
<LI>CDT</LI>
<LI>side effects</LI>
</OL>
<P>*relapse / heavy drinking: drinking &#8805;5 (4) SDU for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-06 11:35:11 +0100" MODIFIED_BY="[Empty name]">
<P>DuPont pharmaceuticals</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-22 17:34:50 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking:</B> TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>; week 2, 4, 6, 8, 10, 12); <B>assessment of side-effects: </B>week 2, 4, 6, 8, 10, 12; <B>assessment of compliance:</B> pill count, 6-beta-naltrexol</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-22 17:36:03 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 58.9% (n = 53); placebo: 57.6% (n = 49); <B>lost to follow-up rates</B>: naltrexone: 18.9% (n = 17); placebo: 18.8% (n = 16); <B>compliance rates </B>(study completers with 80% of prescribed medication taken): naltrexone: 39%; placebo: 41%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-07 09:09:42 +0100" MODIFIED_BY="[Empty name]">
<P>Subgroup analysis: compliant completers </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 16:28:01 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-de-Goes-e-Castro-2004">
<CHAR_METHODS MODIFIED="2010-07-31 16:27:00 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Double-blind, randomized clinical trial of naltrexone combined with brief intervention for the treatment of alcohol dependence </B>
</P>
<P>
<B>Allocation</B>: random; <B>blinding:</B> double-blind; <B>study duration:</B> 12 weeks; <B>principle of analysis</B>: ITT; <B>setting:</B> outpatient; <B>study sites: </B>1; <B>country:</B> Brazil</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 16:28:01 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence; <B>required abstinence: </B>5 to 30 days; <B>baseline characteristics:</B> 81.9% male; mean age: 45.9 (SD = 8.0) years; 57.7% married: 43.7% employed; <B>pre-baseline drinking:</B> not reported; SADQ score (<LINK REF="REF-Raistrick-1986" TYPE="REFERENCE">Raistrick 1986</LINK>): 21.4 (SD = 7.4); <B>exclusionary psychiatric conditions: </B>1. a drug abuse (past 30 days); 2. a lifetime diagnosis of opioid dependence; 3. a concurrent major psychiatric disorder that required inpatient treatment; 4. a previous use of naltrexone, acamprosate or disulfiram or opioid analgesics (past 30 days)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 15:17:58 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (n = 35)</LI>
<LI>Placebo (n = 36)</LI>
</OL>
<P>
<B>Psychosocial treatment:</B> eclectic therapy including cognitive behavioral therapy (CBT), motivational enhancement (ME) and a 12-step approach</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 11:49:32 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Patients who return to heavy drinking*</LI>
<LI>drinking days</LI>
<LI>days with light drinking**</LI>
<LI>days with moderate drinking***</LI>
<LI>heavy drinking days</LI>
<LI>craving </LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>carbohydrate-deficient transferrin (CDT)</LI>
<LI>side-effects</LI>
</OL>
<P>* relapse/heavy drinking: drinking &#8805; 9 SDU; ** light drinking: drinking &#8804; 4 SDU; moderate drinking: drinking 5 to 9 SDU; to comply with commonly used definitions of heavy drinking, moderate drinking was subsequently assigned to the "heavy drinking"-category</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-06 11:38:41 +0100" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-22 17:38:29 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>alcohol use questionnaire (week 4, 8, 12); <B>assessment of side-effects:</B> checklist for side-effects; <B>assessment of compliance: </B>not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-22 17:38:11 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 51.4% (n = 18); placebo: 50% (n = 18); <B>lost to follow-up rates</B>: naltrexone: 5.7% (n = 2); placebo: 8.3% (n = 3); <B>compliance rates: </B>not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-06 11:47:58 +0100" MODIFIED_BY="[Empty name]">
<P>The study was reported in the format of an unpublished dissertation, conducted at the Department of Psychiatry, University of São Paulo Medical School; Brazil, advised by Prof. Ronaldo Laranjeira</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 16:29:53 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Galarza-1997">
<CHAR_METHODS MODIFIED="2010-07-31 16:29:38 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: The use of naltrexone to treat ambulatory patients with alcohol dependence</B>
</P>
<P>
<B>Allocation:</B> random; <B>blinding: </B>double-blind; <B>study duration:</B> 4 weeks; <B>principle of analysis: </B>no information provided; <B>setting: </B>outpatient; <B>study sites</B>:1; <B>country:</B> Puerto Rico</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 16:29:53 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence (DSM-IV); <B>baseline characteristics:</B> 100% male; mean age: 55 (SD = 13) years; <B>pre-baseline drinking:</B> not reported; <B>exclusionary psychiatric conditions: </B>1. a lifetime diagnosis of drug dependence (other than caffeine or nicotine); 2. a concurrent major psychiatric disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 11:52:40 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Naltrexone* (n = 10)</LI>
<LI>placebo (n = 10)</LI>
</OL>
<P>*treatment dose was not reported</P>
<P>
<B>Psychosocial treatment: </B>standard treatment; no further information provided</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 11:52:49 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Depression</LI>
<LI>anxiety</LI>
<LI>somatization</LI>
<LI>craving</LI>
<LI>cognitive impairment</LI>
</OL>
<P>No drinking outcomes provided</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-06 11:52:52 +0100" MODIFIED_BY="[Empty name]">
<P>No information provided</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-22 17:45:29 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking:</B> TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>; week 0, 12, 24, 48); <B>assessment of side-effects: </B>not reported; <B>assessment of compliance:</B> not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-22 17:46:38 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 50% (n = 5); placebo: 40% (n = 4); <B>lost to follow-up rates</B>: naltrexone: 30% (n = 3); placebo: 30% (n = 3); <B>compliance rates:</B> not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-07 18:51:33 +0100" MODIFIED_BY="[Empty name]">
<P>The trial did not provide any of the primary or secondary outcomes of the review; accordingly none of the outcomes from trial were included in the statistical analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 16:32:45 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garbutt-2005">
<CHAR_METHODS MODIFIED="2010-07-31 16:30:54 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence</B>
</P>
<P>
<B>Allocation:</B> random; <B>blinding:</B> double-blind; <B>study duration:</B> 24 weeks; <B>principle of analysis:</B> ITT (treatment- received analysis); <B>setting: </B>outpatient; <B>study sites: </B>24; <B>country:</B> USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 16:32:45 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence (DSM-IV); <B>required abstinence: </B>no prior detoxification required; 91,2% of patients were actively drinking before at the beginning of the study; <B>baseline characteristics: </B>68% male; mean age: 45 (SD = 10.7) years; 71% employed (&#8805;20 hrs/wk); <B>pre-baseline drinking: </B>65% (SD = 25.5) heavy drinking days; 43% of patients start with the treatment goal of abstinence; <B>exclusionary psychiatric conditions: </B>1. a concurrent dependence on benzodiazepines, opiates, or cocaine (past year); 2. a lifetime diagnosis of opioid dependence; 3. a major depression; 4. a concurrent use of opiates, oral naltrexone, or disulfiram (past 2 weeks) </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 15:18:13 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>380 mg injectable naltrexone (n = 205)</LI>
<LI>190 mg injectable naltrexone (n = 210)</LI>
<LI>injectable placebo (n = 209)</LI>
</OL>
<P>Injections were administered at 4-week intervals.</P>
<P>
<B>Psychosocial treatment:</B> motivational enhancement (ME)+ bio-psychosocial feedback; <B>applied manual</B>: BRENDA intervention (<LINK REF="REF-Volpicelli-2001" TYPE="REFERENCE">Volpicelli 2001</LINK>); <B>aim: </B>flexible</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 12:05:46 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Heavy drinking* event rate</LI>
<LI>risky drinking** event rate</LI>
<LI>return to heavy drinking</LI>
<LI>median heavy drinking days</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>aspartate aminotransferase (AST)</LI>
<LI>alanine aminotransferase (ALT)</LI>
<LI>side effects</LI>
</OL>
<P>*relapse / heavy drinking: drinking &#8805;5 (4) SDU for men (women); ** risky drinking: drinking &#8805;2 (1) SDU for men (women).</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-06 12:05:49 +0100" MODIFIED_BY="[Empty name]">
<P>Alkermes</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-22 18:07:11 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>Computerized version of the TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>); <B>assessment of side-effects: </B>coded according to Medical Dictionary for Regulatory Activities; <B>assessment of compliance:</B> assessed by the number of received injections</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-22 18:08:57 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates: </B>naltrexone: 39.8% (n = 165); placebo: 38.6% (n = 81); <B>lost to follow-up rates</B>: naltrexone: 13.3% (n = 55); placebo: 13.4% (n = 28); <B>compliance rates: </B>64% of patients received all injections</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-07 09:10:44 +0100" MODIFIED_BY="[Empty name]">
<P>Subgroup analysis: gender </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 16:34:21 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Gastpar-2002">
<CHAR_METHODS MODIFIED="2010-07-31 16:33:58 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Lack of efficacy of naltrexone in the prevention of alcohol relapse: Results from a German multicenter study</B>
</P>
<P>
<B>Allocation:</B> random; <B>blinding: </B>double-blinded; <B>study duration:</B> 12 weeks; <B>principle of analysis: </B>available case analyses (subsequently transformed into ITT); <B>setting: </B>outpatient; <B>study sites: </B>7; <B>country: </B>Germany</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 16:34:21 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence (97.7%), alcohol abuse (2.3%); DSM-III-R; <B>required abstinence: </B>5 to 30 days; <B>baseline characteristics</B>: 72.5% male; mean age: 42.7 (SD = 9.7); <B>pre-baseline drinking</B>: 21.2 (SD = 9.6) years of drinking; 7.1 (SD = 5.5) drinks per drinking day; mean abstinence time at beginning: 19.5 (SD = 9.4) days; <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence (other than alcohol or nicotine); 2. a psychiatric condition requiring medication; 3. a concurrent use benzodiazepines, lithium, disulfiram, neuroleptics, or antidepressants</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-07 12:55:18 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (n = 80 + 4*)</LI>
<LI>placebo (n = 80 + 7*)</LI>
</OL>
<P>
<B>* </B>subsequently added to available case sample</P>
<P>
<B>Psychosocial treatment: </B>centre specific treatments; <B>aim:</B> abstinence</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 12:10:00 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first heavy drinking (survival curve)</LI>
<LI>time to first drink</LI>
<LI>consumed amount</LI>
<LI>craving </LI>
<LI>severity of alcohol problems</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>aspartate aminotransferase (AST)</LI>
<LI>alanine aminotransferase (ALT)</LI>
<LI>side effects</LI>
</OL>
<P>*relapse / heavy drinking: drinking &#8805;5 (4) SDU for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-06 12:10:04 +0100" MODIFIED_BY="[Empty name]">
<P>DuPont Pharmaceuticals, USA</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-22 18:10:25 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking</B>: TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>); <B>assessment of side-effects</B>: adverse clinical event data (no reference provided); <B>assessment of compliance: </B>pill count, 6-beta-naltrexol (no marker for placebo used)</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-22 18:10:50 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out-rates: </B>naltrexone: 33% (n = 28); placebo: 38% (n = 33); <B>lost to follow-up rates</B>: naltrexone: 5% (n = 4); placebo: 8% (n = 7); <B>compliance rates</B> (patients who took at least 80% of the medication): naltrexone: 80%; placebo: 80%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-06 12:10:51 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 16:36:12 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Guardia-2002">
<CHAR_METHODS MODIFIED="2010-07-31 16:35:43 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Titel: A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol-dependence disorder</B>
</P>
<P>
<B>Allocation: </B>random; <B>blinding: </B>double-blind; <B>duration:</B> 12 weeks; <B>principle of analysis: </B>ITT; <B>setting: </B>outpatient; <B>study sites: </B>7; <B>country: </B>Spain</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 16:36:12 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence (DSM-IV); <B>required abstinence: </B>5 to 30 days; <B>baseline characteristics: </B>74.5% male; mean age: 41.0 (SD = 8.0); 58% married; 45% employed; <B>pre-baseline drinking:</B> 18.4 (SD = 9.2) years of drinking; 16.6 (SD = 8.2) drinks per day: 2.4 (SD = 2.6) past alcohol detoxifications; <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence (other than alcohol or nicotine); 2. severe psychiatric disorders. 3. a concurrent use of disulfiram, cyanamide, and acamprosate </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 14:24:24 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (n = 101)</LI>
<LI>placebo (n = 101)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>supportive group therapy; individual supportive counselling</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-31 16:36:08 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first relapse (survival curve)</LI>
<LI>time to first drink</LI>
<LI>days abstinent</LI>
<LI>drinks per drinking day</LI>
<LI>craving</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>aspartate aminotransferase (AST)</LI>
<LI>alanine aminotransferase (ALT)</LI>
<LI>carbohydrate-deficient transferrin (CDT) </LI>
<LI>side effects</LI>
</OL>
<P>*relapse / heavy drinking: drinking &#8805;5 (4) SDU for men (women) per drinking occasion or drinking on &#8805; 5 days a week.</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-07-18 15:07:01 +0200" MODIFIED_BY="[Empty name]">
<P>Pharmazam/Zambón S.A.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-22 18:13:19 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>quantity-frequency assessment (weekly); <B>assessment of side-effects:</B> not reported; <B>assessment of compliance:</B> pill count</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-22 18:12:23 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out-rates:</B> naltrexone: 39.6% (n = 40); placebo: 41.6% (n = 42); <B>lost to follow-up rates</B>: not reported; <B>compliance rates</B> (% of prescribed medication taken): naltrexone: 78%; placebo: 79%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-06 14:26:18 +0100" MODIFIED_BY="[Empty name]">
<P>Rates of continuous abstinence rates were subsequently provided by the investigators for the review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 16:37:41 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hein_x00e4_l_x00e4_-2001">
<CHAR_METHODS MODIFIED="2010-07-31 16:37:12 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Targeted use of naltrexone without prior detoxi&#64257;cation in the treatment of alcohol dependence: A factorial double-blind, placebo-controlled trial</B>
</P>
<P>
<B>Allocation: </B>random; <B>blinding</B>: double-blind; <B>study duration:</B> 12 weeks; <B>principle of analysis:</B> ITT; <B>setting</B>: outpatient; <B>study sites:</B> 1; <B>country: </B>Finland</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 16:37:31 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence; <B>required abstinence: </B>no prior detoxification; patients were actively drinking; <B>baseline characteristics: </B>71.7% male; mean age: 45.5 (SD = 7.8) years; 72.7 % married: 75.2 % employed; <B>pre-baseline drinking:</B> 14 (SD = 11.6) past alcohol detoxifications; <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence; 2. a concurrent major psychiatric disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-07 16:37:40 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone + CBT (n = 34)</LI>
<LI>50 mg naltrexone + ME (n = 29)</LI>
<LI>50 mg placebo + CBT (n = 33)</LI>
<LI>50 mg of placebo + ME (n = 25)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>a) group 1 and 3: cognitive behavioral therapy (CBT); focus of the program: controlled drinking; keeping a slip-up from developing into relapse); <B>aim:</B> harm reduction; b) group 2 + 4: motivation enhancement (ME) for complete abstinence; <B>aim: </B>abstinence.</P>
<P>
<B>Trial started with a placebo run-in week</B>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-07-26 17:02:26 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first relapse (survival curve)</LI>
<LI>return to heavy drinking*</LI>
<LI>drinks per drinking day</LI>
<LI>craving</LI>
<LI>GGT</LI>
<LI>side effects</LI>
</OL>
<P>* relapse: drinking &#8805; 5 (4) SDU per drinking for men (women) or having &#8805; 5 drinking occasions per week</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-13 17:13:56 +0200" MODIFIED_BY="[Empty name]">
<P>Finnish Alcohol Research Foundation; National Public Health Institute</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-22 18:17:00 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking</B>: drinking diary (week 2, 4, 6, 8, 10, 12); <B>assessment of side-effects</B>: not reported; <B>assessment of compliance: </B>riboflavin</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-22 18:16:44 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates:</B> 16.5% (n = 20); no group specific values reported; <B>lost to follow-up rates: </B>not reported; group difference in lost to follow-up rates: not reported; <B>compliance rates </B>(% of riboflavin positive samples): not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-07-31 16:37:41 +0200" MODIFIED_BY="[Empty name]">
<P>The targeted medication period, which followed the regular medication interval, did not meet the inclusion criteria of the review and thus was not included in the data analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 16:39:23 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hersh-1998">
<CHAR_METHODS MODIFIED="2010-07-31 16:39:00 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Naltrexone treatment of comorbid alcohol and cocaine use disorders</B>
</P>
<P>
<B>Allocation:</B> random; <B>blinding:</B> double-blind; <B>study duration:</B> 7 weeks; <B>principle of analysis:</B> ITT; <B>setting: </B>outpatient; <B>study sites: </B>1; <B>country:</B> USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 16:39:23 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence (92.1%); alcohol abuse (7.9%); <B>concurrent psychiatric diagnosis: </B>cocaine dependence (95.3%); cocaine abuse (4.7%); <B>required abstinence</B>: no prior detoxification required; patients were actively consuming alcohol and cocaine; <B>baseline characteristics: </B>92% male; mean age: 35.5 (SD = 6.0) years; 82 % employed; <B>pre-baseline drinking:</B> 50.9% (SD = 28.6) days drinking; 9.2 (SD = 5.1) drinks per drinking day; <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence on another psychoactive substance; and 2. a concurrent major psychiatric disorder were excluded</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-07 16:38:42 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (n = 31)</LI>
<LI>placebo (n = 33)</LI>
</OL>
<P>
<B>Psychosocial treatment:</B> cognitive behavioral therapy (CBT) and skills training; <B>applied manual: </B>
<LINK REF="REF-Marlatt-1985" TYPE="REFERENCE">Marlatt 1985</LINK>; <LINK REF="REF-Chaney-1989" TYPE="REFERENCE">Chaney 1989</LINK>
</P>
<P>
<B>Trial started with a placebo run-in week</B>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 15:33:00 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first relapse (survival curve)</LI>
<LI>return to any drinking</LI>
<LI>return to heavy drinking*</LI>
<LI>days abstinent</LI>
<LI>drinks per drinking day</LI>
<LI>craving</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>side effects</LI>
</OL>
<P>*relapse/heavy drinking: drinking &#8805;5 (4) STD for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-13 16:57:59 +0200" MODIFIED_BY="[Empty name]">
<P>National Institute of Health (NIH)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-22 18:19:09 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>); <B>assessment of side-effects: </B>adverse event checklist; <B>assessment of compliance:</B> riboflavin</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-22 18:19:31 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates: </B>naltrexone: 35.5% (n = 11); placebo: 42.4% (n = 14); <B>lost to follow-up rates: </B>not reported; <B>compliance rates </B>(number of urine samples positive for riboflavin): naltrexone: 97.9%; placebo: 94.5%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-06 15:33:53 +0100" MODIFIED_BY="[Empty name]">
<P>Outcomes concerning the cocaine consumption were not included in the review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 16:40:49 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Huang-2005">
<CHAR_METHODS MODIFIED="2010-07-31 16:40:30 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: A double-blind, placebo-controlled study of naltrexone in the treatment of alcohol dependence in Taiwan </B>
</P>
<P>
<B>Allocation: </B>random; <B>blinding: </B>double-blind; <B>study duration:</B> 14 weeks; <B>principle of analysis: </B>not reported; <B>setting: </B>outpatient; <B>study sites: </B>1; <B>country:</B> Taiwan</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 16:40:49 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence (DSM-III-R); <B>required abstinence</B>: &#8805; 14 days; <B>baseline characteristics:</B> 100% male; mean age: 40.5 (SD = 7.8) years; 65% married; 60% with an education &lt; 9 years; <B>pre-baseline drinking:</B> age of first habitual alcohol use: 26.9 (SD = 6.9) years; <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence (other than alcohol or nicotine); 2. a concurrent major psychiatric disorder.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 15:34:42 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (n = 20)</LI>
<LI>placebo (n = 20)</LI>
</OL>
<P>
<B>Psychosocial treatment:</B> individual supportive therapy for abstinence and motivation enhancement (ME) for medication compliance; <B>aim</B>: abstinence</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-07 11:36:27 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Return to any drinking</LI>
<LI>return to heavy drinking*</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>aspartate aminotransferase (AST)</LI>
<LI>alanine aminotransferase (ALT)</LI>
</OL>
<P>* relapse: drinking &#8805; 5 (4) SDU per drinking for men (women) or having &#8805; 5 drinking occasions per week or a blood alcohol concentration (BAC) &#8805; 100mg/dl</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-06 15:40:38 +0100" MODIFIED_BY="[Empty name]">
<P>Not reported</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-22 18:36:30 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking:</B> not reported; <B>assessment of side-effects:</B> not reported; <B>assessment of compliance: </B>not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 21:42:11 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 22.5% (n = 9); placebo: 17.5% (n = 7); <B>lost to follow-up rates</B>: not reported; <B>compliance rates</B>: not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-07 19:05:52 +0100" MODIFIED_BY="[Empty name]">
<P>Information on the study design was subsequently provided by the investigators for the review</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 16:41:49 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-2000">
<CHAR_METHODS MODIFIED="2010-07-31 16:41:49 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Tilte: Combining ondansetron and naltrexone effectively treats biologically predisposed alcoholics: From hypotheses to preliminary clinical evidence</B>
</P>
<P>
<B>Allocation:</B> random; <B>blinding:</B> double-blind; <B>study duration: </B>8 weeks; <B>principle of analysis: </B>ITT; <B>setting: </B>outpatient; <B>study sites:</B> 1; <B>country:</B> USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-06 15:44:39 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence with early onset (&lt; 25 years)</P>
<P>
<B>Required abstinence: </B>no prior detoxification required</P>
<P>
<B>Baseline characteristics:</B> gender: 75% male; mean age: 38 (SD = 7.9) years; <B>pre-baseline drinking: </B>7.44 (SD = 3.5) drinks per day; MAST score: 32.9 (SD = 9.6)</P>
<P>
<B>Exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence on narcotics, amphetamines, sedative hypnotics; or 2. a concurrent use of medications with a potential effect on alcohol consumption </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 15:47:49 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (25 mg twice a day) + 8 mg ondansetron (4 micrograms/kg twice a day) (n = 10)</LI>
<LI>placebo (n = 10)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>cognitive behavioral therapy (CBT) and coping skills training; <B>applied manuals: </B>
<LINK REF="REF-Marlatt-1985" TYPE="REFERENCE">Marlatt 1985</LINK>; <LINK REF="REF-Monti-1989" TYPE="REFERENCE">Monti 1989</LINK>; <B>aim: </B>abstinence </P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 15:47:54 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Drinks per drinking day</LI>
<LI>days abstinent</LI>
<LI>side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-06 15:47:57 +0100" MODIFIED_BY="[Empty name]">
<P>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-22 18:38:31 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking</B>: TLFB interview (weekly); <B>assessment of side-effects</B>: adverse event profile (weekly); <B>assessment of compliance: </B>pill count (weekly)</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-22 18:38:53 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates: </B>not reported; <B>lost to follow-up rates</B>: not reported; <B>compliance rates</B> (% of prescribed medication taken; pill count): naltrexone: 96.6%; placebo: 95%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-01-27 11:10:17 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 16:43:14 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-2004">
<CHAR_METHODS MODIFIED="2010-07-31 16:42:57 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex®) in patients with alcohol dependence</B>
</P>
<P>
<B>Allocation:</B> random; <B>blinding: </B>double-blind; <B>study duration: </B>16 weeks; <B>principle of analysis: </B>ITT; <B>setting: </B>outpatient; <B>study sites:</B> 4; <B>country: </B>USA, Europe</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 16:43:14 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence; <B>required abstinence</B>: &#8805;5 days; <B>baseline characteristics:</B> gender: 73.3% male; mean age: 42.5 (SD=9.2) years; <B>pre-baseline drinking: </B>60.8% (SD = 34.4) days drinking: 7.9 (SD = 4.0) drinks per drinking day; ADS score (<LINK REF="REF-Skinner-1982" TYPE="REFERENCE">Skinner 1982</LINK>; <LINK REF="REF-Skinner-1984" TYPE="REFERENCE">Skinner 1984</LINK>): 17.8 (SD = 8.8); 56.7 % had a treatment goal of total abstinence; <B>exclusionary psychiatric conditions: </B>1. an axis I diagnoses, including narcotic or benzodiazepine dependence; or 2. opiate use within 2 weeks of screening or 3. receiving pharmacological treatment for alcohol dependence</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-04 20:27:52 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>400 mg injectable naltrexone (n = 20)</LI>
<LI>injectable placebo (n = 5)</LI>
</OL>
<P>Injections were administered on days 28, 56, and 84</P>
<P>
<B>Psychosocial treatment:</B> motivational enhancement (ME)+ bio-psychosocial feedback; <B>applied manual</B> (in US centres): BRENDA (<LINK REF="REF-Volpicelli-2001" TYPE="REFERENCE">Volpicelli 2001</LINK>)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-12-23 17:39:33 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Days abstinent</LI>
<LI>heavy drinking days*</LI>
<LI>drinks per drinking day</LI>
<LI>side effects</LI>
</OL>
<P>*relapse/heavy drinking: drinking &gt; 5 (4) STD for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-13 17:39:35 +0200" MODIFIED_BY="[Empty name]">
<P>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-22 18:39:16 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>); <B>assessment of side-effects: </B>adverse event checklist</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-22 18:42:35 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates:</B> naltrexone: 32% (n = 8); placebo: 20% (n = 1); <B>lost to follow-up rates</B>: naltrexone: 16% (n = 4); placebo: 0%; <B>compliance rates</B> (number of received injections): naltrexone: 80%; placebo: 80%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-01-27 20:00:55 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 17:24:15 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kiefer-2003">
<CHAR_METHODS MODIFIED="2010-07-31 17:23:44 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism</B>
</P>
<P>
<B>Allocation: </B>random; <B>blinding: </B>double-blind; <B>study duration: </B>12 weeks (treatment); 12 weeks<B> </B>(post-treatment); <B>principle of analysis:</B> ITT; <B>setting: </B>outpatient; <B>study sites:</B> 1; <B>country:</B> Germany</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 17:24:15 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence; <B>required abstinence: </B>12 to 15 days; <B>baseline characteristics:</B> 73.7% male; mean age: 46.2 (SD=9.3) years; 28% married: 61% employed; <B>pre-baseline drinking:</B> 254.9 (SD = 129.4) grams alcohol per day; 2.7 (SD = 4.0) previous detoxifications; <B>exclusionary psychiatric conditions: </B>1. a history of opioid or cocaine abuse; 2. a concurrent major psychiatric impairment or disorder requiring psychotropic medication or inpatient treatment or a history of psychosis; 3. a concurrent use of psychotropic medications or disulfiram</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 15:55:23 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (n = 40)</LI>
<LI>1998 mg acamprosate (n = 40)</LI>
<LI>50 mg of naltrexone and 1998 mg of acamprosate (n = 40)</LI>
<LI>placebo plus psychosocial treatment (n = 40)</LI>
</OL>
<P>
<B>Psychosocial treatment:</B> cognitive behavioral therapy (CBT); <B>applied manual:</B> <LINK REF="REF-Marlatt-1985" TYPE="REFERENCE">Marlatt 1985</LINK>; <B>aim: </B>abstinence</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 15:55:30 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first drink (survival curve)</LI>
<LI>time to first relapse* (survival curve)</LI>
<LI>days abstinent</LI>
<LI>craving</LI>
<LI>gamma-glutamyltransferase (GT)</LI>
<LI>carbohydrate-deficient transferrin level (CDT)</LI>
<LI>mean corpuscular volume (MCV)</LI>
<LI>side effects</LI>
</OL>
<P>* relapse: drinking &#8805; 5 (4) SDU per drinking for men (women) or having &#8805; 5 drinking days per week</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-13 17:50:26 +0200" MODIFIED_BY="[Empty name]">
<P>University of Hamburg<BR/>
</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 09:34:11 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking</B>: drinking diary (weekly); <B>assessment of side-effects: </B>adverse effect checklist, rating each adverse effect for its presumed association with the study medication; <B>assessment of compliance:</B> pill count</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 10:11:16 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates: </B>naltrexone: 45% (n = 18); naltrexone + acamprosate: 35.0% (n = 14); acamprosate: 57.5% (n = 23); placebo: 75% (n = 30); <B>lost to follow-up rates</B>: not reported; <B>compliance rates </B>(% of prescribed medication taken): 81.1%; no group specific values provided</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-28 11:15:08 +0100" MODIFIED_BY="[Empty name]">
<P>Posttreatment results published in <LINK REF="REF-Kiefer-2004" TYPE="REFERENCE">Kiefer 2004</LINK>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 17:32:19 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Killeeen-2004">
<CHAR_METHODS MODIFIED="2010-07-31 17:28:28 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Effectiveness of naltrexone in a community treatment program</B>
</P>
<P>
<B>Allocation: </B>random; <B>blinding: </B>double-blind; <B>study duration:</B> 12 weeks (treatment); 48 weeks (post-treatment); <B>principle of analysis:</B> ITT modified; <B>setting: </B>outpatient; <B>study sites: </B>1; <B>country: </B>USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 17:28:50 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence; <B>other psychiatric diagnosis</B>: axis 1 disorders: 51%; other substance abuse disorders: 35%; <B>required abstinence: </B>no prior detoxification required; 61.1% stopped drinking between study entry and treatment beginning; <B>baseline characteristics:</B> 63% male; mean age: 37.3 (SD=8.75) years; 28% married: 55% employed; <B>pre-baseline drinking:</B> 53% had previous treatments of alcohol dependence; <B>exclusionary psychiatric conditions: </B>1. a current addiction to opiates; 2. having had 10 days of outpatient treatment in the past 3 months</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-07 16:34:14 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg of naltrexone (n = 54)</LI>
<LI>placebo (n = 43)</LI>
<LI>community program alone* (n = 48)</LI>
</OL>
<P>
<B>* </B>not included in the meta-analysis</P>
<P>
<B>Psychosocial treatment: </B>eclectic therapy including cognitive behavioral therapy (CBT) + 12-step facilitation ; patients were encouraged to attend Alcoholics Anonymous (AA) self-help groups</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 16:48:48 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Return to heavy drinking*</LI>
<LI>days abstinent</LI>
<LI>heavy drinking days</LI>
<LI>drinks per day</LI>
<LI>drinks per drinking day</LI>
<LI>craving</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>side effects</LI>
</OL>
<P>*relapse/heavy drinking: drinking &#8805; 6 (4) STD for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-13 18:03:34 +0200" MODIFIED_BY="[Empty name]">
<P>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 09:44:57 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>TLFB interview (week 0, 12, 24, 48); <B>assessment of side-effects: </B>symptom checklist (week 4,8,12); <B>assessment of compliance: </B>Microelective events monitoring system (MEMS); pill count (week 4, 8, 12)</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 10:16:16 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 47% (n = 24); placebo: 33% (n = 12); <B>lost to follow-up rates</B>: naltrexone: 24% (n = 12); placebo: 33% (n = 12); <B>compliance rate</B> (% of MEMS cap openings): naltrexone: 51%; placebo: 61%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-07-31 17:32:19 +0200" MODIFIED_BY="[Empty name]">
<P>Rates of continuous abstinence and GGT values were subsequently provided by the investigator for the review</P>
<P>Study arm "community program alone" did not meet the inclusion criteria of the review and not included in the meta-analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 17:35:23 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kranzler-1998">
<CHAR_METHODS MODIFIED="2010-07-31 17:35:02 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Sustained-Release Naltrexone for Alcoholism Treatment: A Preliminary Study</B>
</P>
<P>
<B>Allocation: </B>random; <B>blinding: </B>double-blind; <B>study duration: </B>4 weeks (treatment); 4 weeks (post-treatment); <B>principle of analysis</B>: ITT; <B>setting: </B>outpatient; <B>study sites:</B> 1; <B>country: </B>USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 17:35:23 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence; <B>required abstinence</B>: &#8805; 3 days; <B>baseline characteristics: </B>74.8% male; mean age: 47.3 (SD=8.2) years; 70% married: 70% employed; <B>pre-baseline drinking: </B>20.7 (SD = 9.9) years of heavy drinking; 0.55 (SD = 0.6) previous alcohol detoxifications; ADS score (<LINK REF="REF-Skinner-1982" TYPE="REFERENCE">Skinner 1982</LINK>; <LINK REF="REF-Skinner-1984" TYPE="REFERENCE">Skinner 1984</LINK>): 13.6 (SD = 4.7); <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence (other than nicotine or alcohol); 2. a lifetime diagnosis of opioid dependence, psychoactive drug use in the preceding month; 3. a current major psychiatric disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-07 16:40:00 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>206 mg injectable naltrexone (n = 15)</LI>
<LI>injectable placebo (n = 5)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>cognitive behavioral therapy (CBT) + skills training; <B>applied manual: </B>
<LINK REF="REF-Marlatt-1985" TYPE="REFERENCE">Marlatt 1985</LINK>; <LINK REF="REF-Chaney-1989" TYPE="REFERENCE">Chaney 1989</LINK>
</P>
<P>
<B>Trial started with two-week naltrexone (oral) run-in period, followed by a two-week, no-medication washout period</B>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 16:57:20 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Drinking days</LI>
<LI>heavy drinking days*</LI>
<LI>drinks per day</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>side effects</LI>
</OL>
<P>* relapse/heavy drinking: drinking &#8805; 5 (4) STD for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-13 18:13:20 +0200" MODIFIED_BY="[Empty name]">
<P>National Institutes of Health Grants (General Clinical Research Center)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 10:21:21 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>TLFB interview; <B>assessment of side-effects: </B>SAFTEE<B> </B>(<LINK REF="REF-Levine-1986" TYPE="REFERENCE">Levine 1986</LINK>, <LINK REF="REF-Rabkin-1992" TYPE="REFERENCE">Rabkin 1992</LINK>)</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 10:21:26 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: not reported; <B>lost to follow-up rates</B>: not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-02-02 14:17:49 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 17:51:39 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kranzler-2000">
<CHAR_METHODS MODIFIED="2010-07-31 17:50:59 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title; Naltrexone vs. nefazodone for treatment of alcohol dependence (VA Cooperative Study # 425)</B>
</P>
<P>
<B>Allocation:</B> random; <B>blinding: </B>double-blind; <B>study duration:</B> 12 weeks; <B>principle of analysis:</B> ITT; <B>setting: </B>outpatient; <B>study sites:</B> 1; <B>country: </B>USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 17:51:39 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence; <B>required abstinence: </B>3 to 28 days; <B>baseline characteristics:</B> 77.6% male; mean age: 40.9 (SD=8.5) years; 44.8% married: 44.8% full time employed; <B>pre-baseline drinking:</B> 1.8 (SD = 2.9) previous alcohol treatments; MAST score: 26.5 (SD = 11.3); <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence (other than nicotine); 2. a lifetime diagnosis of opioid dependence; 3. concurrent suicidality, mania or psychosis</P>
<P>Psychiatric disorders that did not require acute intervention, such as mild major depression, were not exclusionary</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-07 16:40:48 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (n = 61)</LI>
<LI>400 mg of nefazodone (n = 59)</LI>
<LI>placebo (n = 63)</LI>
</OL>
<P>
<B>Trial started with a placebo run-in week</B>
</P>
<P>
<B>Psychosocial treatment:</B> coping skills training; <B>applied manual:</B> <LINK REF="REF-McCrady-1985" TYPE="REFERENCE">McCrady 1985</LINK>; <LINK REF="REF-Monti-1989" TYPE="REFERENCE">Monti 1989</LINK>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 17:04:20 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first relapse (survival curve)</LI>
<LI>return to any drinking</LI>
<LI>return to heavy drinking*</LI>
<LI>days abstinent</LI>
<LI>heavy drinking days</LI>
<LI>average drinks per drinking occasion</LI>
<LI>time to first drink</LI>
<LI>craving</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>side effects</LI>
</OL>
<P>* heavy drinking: drinking &#8805; 5 (4) STD for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-13 18:31:35 +0200" MODIFIED_BY="[Empty name]">
<P>National Institute of Health; General Clinical Research Center, University of Connecticut School of Medicine</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 10:26:36 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>TLFB interview; <B>assessment of side-effects: </B>SAFTEE<B> </B>(<LINK REF="REF-Levine-1986" TYPE="REFERENCE">Levine 1986</LINK>, <LINK REF="REF-Rabkin-1992" TYPE="REFERENCE">Rabkin 1992</LINK>); <B>assessment of compliance: </B>riboflavin</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 10:27:10 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 41% (n = 25); nefazodone: 27,1% (n = 17); placebo: 20.6% (n = 13); <B>lost to follow-up rates</B>: naltrexone: 1,6 % (n = 1); nefazodone: 0%; placebo: 0%; <B>compliance rates</B> (% of positive urine samples; riboflavin): naltrexone: 66.0%; nefazodone: 76.8%; placebo: 79.8%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-02-03 21:27:59 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 17:53:25 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kranzler-2004">
<CHAR_METHODS MODIFIED="2010-07-31 17:52:43 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Naltrexone Depot for Treatment of Alcohol Dependence</B>
</P>
<P>
<B>Allocation: </B>random; <B>blinding: </B>double-blind; <B>study duration:</B> 12 weeks; <B>principle of analysis:</B> ITT; <B>setting: </B>outpatient; <B>study sites: </B>29; <B>country: </B>USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 17:53:25 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence; <B>required abstinence: </B>&#8805;3 days (self-reported sobriety); <B>baseline characteristics: </B>gender: 77% male; mean age: 43.9 (SD = 9.1) years; <B>pre-baseline drinking: </B>69.7% (SD = 24.7) heavy days drinking; 5 (SD = 3.7) previous alcohol detoxifications; ADS score: 18.4 (SD = 7.5); <B>exclusionary psychiatric conditions: </B>1.a concurrent drug abuse or dependence (other than nicotine or alcohol); 2. a concurrent use of amphetamines, barbiturates, benzodiazepines, cocaine, or opiates; 3. a concurrent major psychiatric disorders4. the use of disulfiram, oral naltrexone, or antipsychotic medication (past 30 days)</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 17:09:28 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>150 mg injectable naltrexone (n = 167)</LI>
<LI>injectable placebo (n = 166)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>motivation enhancement (ME);<B> applied manual: </B>Motivating for Alcohol Reduction and Medication Management (MARMM), adapted from motivational enhancement (ME) <LINK REF="REF-MIller-1994" TYPE="REFERENCE">MIller 1994</LINK> as applied in Project MATCH (<LINK REF="REF-Project-Match-Research-Group-1997" TYPE="REFERENCE">Project Match Research Group 1997</LINK>); patients were encouraged to attend Alcoholics Anonymous (AA) or another self-help recovery program.</P>
<P>Trial started with a four day treatment with naltrexone (oral), followed by a non-medication wash-out</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 17:09:43 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first relapse (survival curve)</LI>
<LI>return to any drinking</LI>
<LI>return to heavy drinking*</LI>
<LI>days abstinent</LI>
<LI>heavy drinking days</LI>
<LI>time to first drink</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>side effects</LI>
</OL>
<P>* heavy drinking: drinking &#8805;5 (4) STD for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-13 18:44:33 +0200" MODIFIED_BY="[Empty name]">
<P>DrugAbuse Sciences, Inc. (Hayward, CA)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 10:44:47 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>TLFB; <B>assessment of side-effects: </B>not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 10:46:40 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 19.6% (n = 31); placebo: 24.8% (n = 39); group difference in drop-out rates: not significant; group difference in reasons for drop-out: not reported; <B>lost to follow-up rates</B>: not reported; <B>compliance rates:</B> between 70% and 90% of patients received week 4 and week 8 injections</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-02-04 15:01:52 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 17:55:58 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Krystal-2001">
<CHAR_METHODS MODIFIED="2010-07-31 17:55:25 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Tilte: Naltrexone in the treatment of alcohol dependence (VA Cooperative Study # 425)</B>
</P>
<P>
<B>Allocation:</B> random; <B>blinding: </B>double-blind; <B>study duration: </B>12 weeks, 12 months (treatment); 6 months (post-treatment); <B>principle of analysis:</B> available case analyses (subsequently transformed into ITT); <B>setting:</B> outpatient; <B>study sites:</B> 15; <B>country:</B> USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 17:55:43 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence; <B>required abstinence: </B>&#8805; 5 days; <B>baseline characteristics:</B> 97.6% male; mean age: 48.5 (SD = 10) years; 36.9 % married or living with partner; <B>pre-baseline drinking:</B> 68.3% (SD = 29.0) drinking days: 14.1 (SD = 9.0) drinks per drinking day; <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence (other than alcohol, nicotine or occasional marijuana use); 2. a lifetime diagnosis of opioid or marijuana dependence; 3. a concurrent major psychiatric disorder requiring psychotropic medication</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-07 12:53:49 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (3 months) (n = 196 + 13*)</LI>
<LI>50 mg naltrexone (12 months) (n = 190 + 19*)</LI>
<LI>placebo (12 months) (n = 195 + 14*)</LI>
</OL>
<P>
<B>* </B>subsequently added to available case sample </P>
<P>
<B>Psychosocial treatment: </B>individual 12-step facilitation counselling; patients were encouraged to attend Alcoholics Anonymous meetings; <B>aim: </B>abstinence</P>
<P>Dosing: naltrexone was started with 25 mg once daily for 2 days, followed by 50 mg once daily</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 17:29:07 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first relapse</LI>
<LI>return to heavy drinking*</LI>
<LI>days abstinent</LI>
<LI>drinks per drinking day</LI>
<LI>side effects</LI>
</OL>
<P>*heavy drinking: drinking &#8805;6 (4) STD for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-12-23 21:16:34 +0100" MODIFIED_BY="[Empty name]">
<P>Department of Veterans Affairs</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 10:57:46 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>TLFB interview (4-week intervals); <B>assessment of side-effects:</B> not reported; <B>assessment of compliance:</B> Microelective events monitoring system (MEMS); 6-beta-naltrexol levels</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 21:45:29 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 1.7% (n = 7); placebo: 1.4% (n = 3); <B>lost to follow-up rates</B>: naltrexone: 10% (n = 40); placebo: 11% (n = 22); <B>compliance rates </B>(% of days taking medication (MEMS, 6-beta-naltrexol levels): naltrexone: 72%; placebo: 70%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-07-31 17:55:58 +0200" MODIFIED_BY="[Empty name]">
<P>Abstinence rates and drop-out rates were subsequently provided by the investigator for the review</P>
<P>The short-term naltrexone group was switched in a double-blind fashion to matching placebo when naltrexone was discontinued at the 3 months visit; for the review, only the first three months of treatment were included with a pooled naltrexone group </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-15 14:21:03 +0200" MODIFIED_BY="Laura Amato" STUDY_ID="STD-Latt-2002">
<CHAR_METHODS MODIFIED="2010-10-15 14:20:59 +0200" MODIFIED_BY="Laura Amato">
<P>
<B>Title: Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting</B>
</P>
<P>
<B>Allocation: </B>random; <B>blinding: </B>double-blind; <B>study duration: </B>12 weeks (treatment); 12 weeks (post-treatment)*; <B>principle of analysis: </B>ITT; <B>setting: </B>outpatient; <B>study sites:</B> 4; <B>country: </B>Australia</P>
<P>* non-randomized sample</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 17:57:45 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence; <B>required abstinence:</B> not reported; mean abstinence was 11.7 days; <B>baseline characteristics:</B> 69.2% male; mean age: 44.8 (SD = 10.6); mean abstinence: 11.7 days (range: 7 to 51 days); <B>pre-baseline drinking:</B> 168.2 (SD = 80.4) grams per day; mean duration of alcohol dependence: 14.1 years; SDAQ-Score (<LINK REF="REF-Stockwell-1979" TYPE="REFERENCE">Stockwell 1979</LINK>). 23.5 (SD = 20); <B>exclusionary psychiatric conditions: </B>1. a concurrent use of either illicit or prescribed opioids; 2. a concurrent major psychiatric disorder or an untreated major depression or a recent suicide attempt</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 17:42:28 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (n = 56)</LI>
<LI>placebo (n = 51)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>supportive behavioural therapy; AA attendance allowed</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 17:43:40 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first relapse (survival curve)</LI>
<LI>return to heavy drinking</LI>
<LI>drinks per day</LI>
<LI>drinking days</LI>
<LI>craving</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>aspartate aminotransferase (AST) </LI>
<LI>alanine aminotransferase (ALT)</LI>
<LI>mean corpuscular volume (MCV)</LI>
<LI>side-effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-16 09:57:12 +0200" MODIFIED_BY="[Empty name]">
<P>Du Pont Pharma; Northern Sydney Health, Orphan Australia; Kim and Kris Morris Trust Fund for Drug &amp; Alcohol Services</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 11:00:13 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>self-reported drinking quantity and frequency (week 1, 2, 3, 4, 6, 8, 12); <B>assessment of side-effects: </B>structured checklist; <B>assessment of compliance: </B>pill count</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 21:45:49 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 41% (n = 23); placebo: 33,3% (n = 17); <B>lost to follow-up rates</B>: naltrexone: 32.1% (n = 18); placebo: 29.4% (n = 15); <B>compliance rates</B> (% of prescribed medication taken): not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-10-15 14:21:03 +0200" MODIFIED_BY="Laura Amato">
<P>Information on the study design was subsequently provided by the investigator</P>
<P>The post-treatment evaluation did not meet the inclusion criteria of the review (non-randomised sample: patients who voluntarily chose to continue taking naltrexone) and was not included in the meta-analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 18:00:22 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lee-2001">
<CHAR_METHODS MODIFIED="2010-07-31 18:00:01 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Naltrexone in the treatment of male alcoholics&#8211; an effectiveness study in Singapore</B>
</P>
<P>
<B>Allocation:</B> random; <B>blinding: </B>double-blind; <B>study duration: </B>12 weeks (treatment); <B>principle of analysis: </B>available case analyses (subsequently transformed into ITT); <B>setting: </B>inpatient (4 weeks); outpatient (8 weeks); <B>study sites:</B> 1; <B>country: </B>Singapore</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 18:00:22 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence; <B>required abstinence: </B>not reported; mean abstinence duration: 7 days; <B>baseline characteristics:</B> gender: 100% male; mean age: 45.0 (SD = 9.5) years; 74% married: 41.5% employed; <B>pre-baseline drinking:</B> not reported; ADS Score: 17.0 (SD = 7.6); <B>exclusionary psychiatric conditions: </B>1. a concurrent illicit drug abuse or dependence; 2. a concurrent major psychiatric disorder.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-07 12:57:09 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (n = 24 + 11*)</LI>
<LI>placebo (n = 15 +3*)</LI>
</OL>
<P>
<B>* </B>subsequently added to available case sample</P>
<P>
<B>Psychosocial treatment: </B>12-step primary rehabilitation programme; patients were free to attend Alcoholics Anonymous (AA) groups; <B>aim: </B>abstinence</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 17:55:40 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>return to any drinking</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-06 17:55:50 +0100" MODIFIED_BY="[Empty name]">
<P>Not supported by the pharmaceutical industry </P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 11:05:26 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>TLFB interview (week 1, 2, 3, 4, 6, 8, 10, 12); <B>assessment of side-effects: </B>comprehensive side-effects checklist (week 1, 2, 3, 4, 6, 8, 10, 12); <B>assessment of compliance: </B>pill count</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 11:05:16 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 60% (n=21); placebo: 77.8% (n=14); group difference in drop-out rates: significant; group difference in reasons for drop-out: <I>not reported </I>(reasons for study drop-out were found to be mainly due to return to drinking); <B>lost to follow-up rates</B>: naltrexone: 31.4% (n = 11); placebo: 16.7% (n = 3); <B>compliance rates </B>(% of prescribed medication taken): <I>not reported</I>
</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-06 17:56:18 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 18:08:29 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martinotti-2008">
<CHAR_METHODS MODIFIED="2010-07-31 18:08:06 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Aripiprazole in the treatment of patients with alcohol dependence: a double-blind, comparison trial versus naltrexone</B>
</P>
<P>
<B>Allocation:</B> random; <B>blinding:</B> double-blind; <B>study duration: </B>16 weeks; <B>principle of analysis: </B>ITT; <B>setting:</B> outpatient; <B>study sites:</B> 1; <B>country:</B> Italy</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 18:08:22 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence; <B>required abstinence: </B>5 to 10 days; <B>baseline characteristics </B>80% male; mean age: 40.3 (SD = 11.8) years; <B>pre-baseline drinking </B>8.5 (SD = 3.5) drinks per day; 14.8 (SD = 6.7) years of alcohol disorder; <B>exclusionary psychiatric conditions: </B>1. a concurrent severe mental disorder; 2. a regular concurrent use of anticonvulsants, antidepressants or antipsychotics</P>
<P>Illicit drug use was not a criteria of exclusion</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-31 18:08:29 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (n = 28)</LI>
<LI>5 to 15 mg aripiprazole (n = 29)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>no psychosocial treatment provided; patients were free to attend a supportive self-help group; <B>therapeutic aim:</B> abstinence; <B>dosing:</B> naltrexone started with a dose of 10 mg, aripiprazole with a dose of 5 mg; aripiprazole: flexible dosing</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-29 17:43:52 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first drink (survival curve)</LI>
<LI>return to any drinking</LI>
<LI>return to heavy drinking*</LI>
<LI>days abstinent</LI>
<LI>heavy drinking days</LI>
<LI>craving</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>aspartate aminotransferase (AST)</LI>
<LI>alanine aminotransferase (ALT)</LI>
<LI>side effects</LI>
</OL>
<P>* heavy drinking: drinking &#8805; 5 (4) SDU for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-16 10:18:05 +0200" MODIFIED_BY="[Empty name]">
<P>Not supported by any pharmaceutical company</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 11:07:40 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>participant&#8217;s self-evaluation and a family member interview (week 2, 8, 16); <B>assessment of side-effects: </B>Clinical Institute Withdrawal Assessment for Alcohol (CIWA-Ar; <LINK REF="REF-Sullivan-1989" TYPE="REFERENCE">Sullivan 1989</LINK>; week 2, 8, 16); <B>assessment of compliance: </B>not reported<B> </B>
</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 11:07:23 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 25% (n = 7); placebo: 24.1% (n = 7); <B>lost to follow-up rates</B>: not reported; <B>compliance rates</B>: not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-06 17:58:20 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-15 14:21:30 +0200" MODIFIED_BY="Laura Amato" STUDY_ID="STD-Mason-1994">
<CHAR_METHODS MODIFIED="2010-07-31 18:09:42 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: A double-blind, placebo-controlled pilot study to evaluate the efficacy and safety of oral nalmefene HCl for alcohol dependence </B>
</P>
<P>
<B>Allocation: </B>random; <B>blinding: </B>double-blind; <B>study duration: </B>12 weeks; <B>principle of analysis:</B> ITT / ITT modified; <B>setting: </B>outpatient; <B>study sites: </B>1; <B>country: </B>United States</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-15 14:21:30 +0200" MODIFIED_BY="Laura Amato">
<P>
<B>Diagnosis: </B>alcohol dependence (DSM-III-R); <B>required abstinence: </B>not reported; <B>baseline characteristics:</B> 71.4% male; mean age: 42.0 (SD = 9.4) years;<B> pre-baseline drinking:</B> 47.1% drinking days; 8.8 (SD = 4.7) drinks per drinking day; 28.4 (SD = 8.4) years of alcohol dependence; <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence (other than alcohol); 2. a lifetime diagnosis of opioid dependence; 3. a concurrent major psychiatric disorder; 4. a concurrent use of psychotropic or anti seizure medications or disulfiram</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-07 17:30:10 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>10 mg nalmefene (n = 7)</LI>
<LI>40 mg nalmefene (n = 7)</LI>
<LI>placebo (n = 7)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>no psychosocial treatment provided; patients were free to attend a supportive self-help group</P>
<P>
<B>Trial started with a 2-week run-on placebo phase, followed by a 1-week titration period</B>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 18:03:08 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Return to heavy drinking*</LI>
<LI>drinking days</LI>
<LI>drinks per drinking day</LI>
<LI>side effects</LI>
</OL>
<P>heavy drinking: drinking &#8805; 5 (4) STD for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-07-15 10:37:38 +0200" MODIFIED_BY="[Empty name]">
<P>Baker Norton Pharmaceuticals, Miami, FL.</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-28 07:47:45 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>computerized version of the TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>); <B>assessment of side-effects: </B>documentation of treatment emergent signs and symptoms; <B>assessment of compliance: </B>pill count</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 11:09:27 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 57.1% (n = 8); placebo: 71.4% (n = 5); <B>lost to follow up rates</B>: not reported; <B>compliance rates </B>(patients who took at least 75% of the prescribed medication): no group specific values provided</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-05-13 15:01:06 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 18:12:57 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mason-1999">
<CHAR_METHODS MODIFIED="2010-07-31 18:12:14 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Titel: A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence</B>
</P>
<P>
<B>Allocation:</B> random; <B>blinding:</B> double-blind; <B>study duration:</B> 12 weeks; <B>principle of analysis:</B> ITT; <B>setting:</B> outpatient; <B>study sites: </B>1; <B>country: </B>USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 18:12:57 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence; <B>required abstinence:</B> not reported; <B>baseline characteristics:</B> 67% male; mean age: 41.8 (SD = 8.8) years; 37.5% married: 70% employed; <B>pre-baseline drinking:</B> 57% drinking days: 8.0 (SD = 4.4) drinks per drinking day; days abstinent prior to random assignment: nalmefene: 13.0 days (SD = 17.4); placebo: 16.0 days (SD = 19.7); <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence of illicit drugs; 2. a concurrent major psychiatric disorder including mood and anxiety disorders; 3. a concurrent use of naltrexone, disulfiram, narcotic-containing medication, or psychotropic medications</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-03-05 11:21:09 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>80 mg of nalmefene (n = 35)</LI>
<LI>20 mg of nalmefene (n = 35)</LI>
<LI>placebo (n = 35)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>cognitive behavioral therapy (CBT); <B>applied manual:</B> <LINK REF="REF-Kadden-1992" TYPE="REFERENCE">Kadden 1992</LINK> as applied in Project Match (<LINK REF="REF-Project-Match-Research-Group-1997" TYPE="REFERENCE">Project Match Research Group 1997</LINK>); patients were free to attending self-help groups or to receive other forms of therapy outside the study</P>
<P>
<B>Dosing:</B> the dose was gradually increased during the first week</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 18:18:32 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first relapse (survival curve)</LI>
<LI>return to any drinking</LI>
<LI>return to heavy drinking</LI>
<LI>days abstinent</LI>
<LI>drinks per drinking day</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>side effects</LI>
</OL>
<P>* relapse: drinking &#8805; 6 (4) SDU per drinking for men (women) or having &#8805; 5 drinking days per week</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-17 09:30:01 +0200" MODIFIED_BY="[Empty name]">
<P>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 11:10:04 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking:</B> TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>); <B>assessment of side-effects: </B>not reported; <B>assessment of compliance:</B> medication management system (MMS); pill count</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 11:11:03 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 35.7% (n = 25); placebo: 34.3% (n = 12); <B>lost to follow-up rates</B>: naltrexone: 0%; placebo: 0%; <B>compliance rates </B>(% of prescribed medication taken): 86.1%; no group specific values provided</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-06 18:19:45 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 18:14:39 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Monterosso-2001">
<CHAR_METHODS MODIFIED="2010-07-31 18:14:22 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Predicting treatment response to naltrexone: the Influence of craving and family history</B>
</P>
<P>
<B>Allocation: </B>random; <B>blinding: </B>double-blind; <B>study duration: </B>12 weeks; <B>principle of analysis:</B> ITT; <B>setting: </B>outpatient; <B>study sites: </B>1; <B>country:</B> USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 18:14:39 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence; <B>required abstinence:</B> 3 to 28 days; <B>baseline characteristics:</B> 72.8% male; mean age: 46.2 (SD = 11.5) years; <B>pre-baseline drinking:</B> 63.1% heavy drinking days. ASI score: 0.71 (SD = 0.16); <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence (other than alcohol, nicotine or cannabis); 2. a concurrent major psychiatric disorder such as psychosis or dementia ; 3. a concurrent use of disulfiram or opioid use in the past 30 days</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-07 16:41:08 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>100 mg naltrexone (n = 121)</LI>
<LI>placebo (n = 62)</LI>
</OL>
<P>
<B>Psychosocial treatment:</B> motivational enhancement (ME) + bio-psychosocial feedback; <B>applied manual: </B>BRENDA intervention (<LINK REF="REF-Volpicelli-2001" TYPE="REFERENCE">Volpicelli 2001</LINK>)</P>
<P>
<B>Trial started with a placebo run-in week</B>
</P>
<P>
<B>Dosing:</B> Patients reporting side-effects of naltrexone were instructed to temporarily reduce their medication to a single dose per day (50 mg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-17 10:17:35 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Heavy drinking days</LI>
<LI>gamma-glutamyltransferase</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-17 09:59:28 +0200" MODIFIED_BY="[Empty name]">
<P>National Institute on Alcoholism and Alcohol Abuse (NIAAA)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 11:13:24 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking:</B> TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>); <B>assessment of side-effects:</B> not reported; <B>assessment of compliance: </B>pill count</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 11:13:57 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: 17.9% (no group specific values provided); <B>lost to follow-up rates</B>: not reported; <B>compliance rates</B> (90% of prescribed medication taken): 78.3%; no group specific values provided</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-07 18:53:52 +0100" MODIFIED_BY="[Empty name]">
<P>No binary data were available for "return to heavy drinking"; accordingly no outcomes from trial were included in the statistical analysis</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 18:17:42 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Monti-2001">
<CHAR_METHODS MODIFIED="2010-07-31 18:16:27 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes</B>
</P>
<P>
<B>Allocation:</B> random; <B>blinding:</B> double-blind; <B>study duration: </B>12 weeks (treatment); 12 months (post-treatment); <B>principle of analysis:</B> ITT / available case analysis; <B>setting: </B>outpatient; <B>study sites: </B>1; <B>country:</B> USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 18:17:15 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence (DSM-IV); <B>required abstinence:</B> 7 to 27 days; <B>baseline characteristics:</B> 76% male; mean age: 39.2 (SD = 9.3) years; 46% married or cohabiting: 84% employed; <B>pre-baseline drinking:</B> 66.1% (SD = 28.3) drinking days; 12.0 (SD = 7.5) drinks per drinking day; 19.4 (SD = 8.5) years of drinking; ADS score: 17.1 (SD = 7.3); 50% of patients were committed to total abstinence; <B>exclusionary psychiatric conditions: </B>1. a concurrent opiate abuse, opiate use (past 2 weeks), or urine screen positive for opiates; 2. a concurrent psychotic symptoms or currently suicidal, homicidal, or a symptomatic posttraumatic stress disorder; 3. a concurrent use of disulfiram</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-31 18:17:42 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (n = 64)</LI>
<LI>placebo (n = 64)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>cue exposure + coping and communication skills training (CET); <B>applied manual:</B> <LINK REF="REF-Monti-1989" TYPE="REFERENCE">Monti 1989</LINK>; <B>dosing: </B>The first two days, the dosing started with 25mg, than naltrexone was taken 25 mg twice a day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 18:24:35 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Return to heavy drinking*</LI>
<LI>heavy drinking days</LI>
<LI>drinks per drinking day</LI>
<LI>time to first drink</LI>
<LI>craving</LI>
<LI>gamma-glutamyltranspeptidase (GGT)</LI>
<LI>side effects</LI>
</OL>
<P>* relapse / heavy drinking: drinking &#8805;6 (5) SDU for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-17 10:18:01 +0200" MODIFIED_BY="[Empty name]">
<P>National Institute on Alcoholism and Alcohol Abuse (NIAAA)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 11:16:22 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>TLFB (week 1, 2, 3, 4, 6, 8, 10, 12); <B>assessment of side-effects:</B> open-ended assessment of side effect symptoms (week 1, 2, 3, 4, 6, 8, 10, 12); <B>assessment of compliance: </B>pill count, riboflavin detection</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 11:16:14 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment phase / drop-out rates</B>: not reported; <B>lost to follow-up rates</B>: 9% (n = 12; no group specific values provided); <B>compliance rates</B> (number of days on medication): 61%; no group specific values provided</P>
<P>
<B>Follow-up phase / drop-out rates</B>: not reported; <B>lost to follow-up rates</B>: 13% (n=17; no group specific values provided)</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-07 19:06:02 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 18:19:35 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Morley-2006">
<CHAR_METHODS MODIFIED="2010-07-31 18:18:51 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Naltrexone versus acamprosate in the treatment of alcohol dependence</B>
</P>
<P>
<B>Allocation: </B>random; <B>blinding:</B> double-blind; <B>study duration:</B> 12 weeks; <B>principle of analysis: </B>ITT; <B>setting:</B> outpatient; <B>study sites:</B> 3; <B>country: </B>Australia</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 18:19:35 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence (DSM-IV); <B>required abstinence:</B> 3 to 21 days; <B>baseline characteristics:</B> 70.4% male; mean age: 44.9 (SD=9.0) years; 35% married: 66% employed; <B>pre-baseline drinking:</B> 14.8 (SD = 7.9) drinks per drinking day; 15.8 (SD = 10.8 ) years of problematic drinking; ADS score: 20.5 (SD = 8.7); mean duration of abstinence: 4.8 (SD = 3.8) days; <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence (other than alcohol, nicotine or low-potency benzodiazepines); 2. a concurrent major psychiatric disorder; 3. a treatment with naltrexone or acamprosate (past 3 months before randomization</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 19:32:40 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (n = 53)</LI>
<LI>1998 mg acamprosate (n = 55)</LI>
<LI>placebo (n = 61)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>brief intervention;<B> </B>compliance training<B> </B>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 19:32:57 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Return to any drinking</LI>
<LI>return to heavy drinking*</LI>
<LI>days abstinent</LI>
<LI>drinks per drinking day</LI>
<LI>time to first drink</LI>
<LI>craving</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>side effects</LI>
</OL>
<P>*heavy drinking: drinking &#8805;6 (4) for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-17 10:35:27 +0200" MODIFIED_BY="[Empty name]">
<P>National Health and Medical Research Council of Australia, University of Sydney Sesqui Fund</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 11:19:46 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>TLFB interview (week 1, 2, 6, 12); daily monitoring cards; <B>assessment of side-effects:</B> open-ended enquiry; <B>assessment of compliance: </B>pill count</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 11:19:36 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 32.1% (n = 17); acamprosate: 25.5% (n = 14); placebo: 34.4% (n = 21); <B>lost to follow-up rates</B>: naltrexone: 3.8% (n = 2); acamprosate: 3.3% (n = 2); placebo: 1.6% (n = 1); <B>compliance rates </B>(patients who took at least 80% of the prescribed medication): 79.7% (of study completers); no group specific values provided</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-07 17:55:00 +0100" MODIFIED_BY="[Empty name]">
<P>Information on the GGT values, "heavy drinking days" and the study design was subsequently provided by the investigator</P>
<P>Subgroup analysis: Completer analyses available</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-15 14:22:04 +0200" MODIFIED_BY="Laura Amato" STUDY_ID="STD-Morris-2001">
<CHAR_METHODS MODIFIED="2010-10-15 14:22:04 +0200" MODIFIED_BY="Laura Amato">
<P>
<B>Tilte: Naltrexone for alcohol dependence: a randomised controlled trial</B>
</P>
<P>
<B>Allocation:</B> random; <B>blinding:</B> double-blind; <B>study duration:</B> 12 weeks; <B>principle of analysis</B>: ITT; <B>setting: </B>outpatient; <B>study sites: </B>1; <B>country: </B>Australia</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 18:23:16 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence; <B>required abstinence:</B> 3 to 30 days; <B>baseline characteristics:</B> 100% male; mean age: 47.5 (SD=8.0) years; 48% married; <B>pre-baseline drinking:</B> 71% (SD = 29) drinking days: 11.7 (SD = 6.4) drinks per day; 30 (SD = 8) years of drinking; 8.5. (SD = 5.5) days abstinent; <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence (other than alcohol or nicotine); 2. an acute psychotic illness, dementia or suicidal behaviour (other psychiatric disorders were included); 3. a concurrent use of opioids (including opioid analgesics) or disulfiram</P>
<P>Patients with current co-morbid psychiatric disorders (apart from acute psychotic illness, dementia or suicidal behaviour) were included in the study</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 19:46:11 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (n = 55)</LI>
<LI>placebo (n = 56)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>cognitive behavioral therapy (CBT); psycho-education and social support; <B>aim: </B>harm reduction (information provided by the investigator)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 19:46:24 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first relapse* (survival curve)</LI>
<LI>time to first drink</LI>
<LI>drinking days </LI>
<LI>heavy drinking days</LI>
<LI>drinks per drinking day (completer sample)</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-06 19:46:27 +0100" MODIFIED_BY="[Empty name]">
<P>Department of Veterans&#8217; Affairs</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 11:22:06 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>; weekly); <B>assessment of side-effects: </B>systematic enquiries about adverse experiences (weekly); <B>assesment of compliance: </B>pill count</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 11:21:57 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 30.9% (n = 17); placebo: 41.1% (n = 23); <B>lost to follow-up rates</B>: 5.4% (n = 6); no group specific values provided; <B>compliance rates</B> (80% of prescribed medication taken): naltrexone: 69%; placebo: 59%.</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-07-31 18:23:32 +0200" MODIFIED_BY="[Empty name]">
<P>Information on the GGT values, drinking days and drinks per drinking day were subsequently provided by the investigator</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 18:25:22 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x0027_Malley-1992">
<CHAR_METHODS MODIFIED="2010-07-31 18:24:54 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Tilte: Naltrexone and coping skills therapy for alcohol dependence</B>
</P>
<P>
<B>Allocation:</B> random; <B>blinding:</B> double-blind; <B>study duration:</B> 12 weeks (treatment); 6 months (post-treatment); <B>principle of analysis: </B>ITT modified (first week drop-outs excluded); <B>setting:</B> outpatient; <B>study sites: </B>1; <B>country: </B>USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 18:25:11 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence; <B>required abstinence: </B>7 to 30 days; <B>baseline characteristics:</B> 74% male; mean age: 40.5 (SD=9.7) years; 34% married: 73% employed full time; <B>pre-baseline drinking:</B> 60% drinking days: 11.2 (SD = 9.2) drinks per drinking occasion; 1.0 (SD = 1.6) previous alcohol treatments; ASI score: 7.3 (SD = 1.9); <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence (other than alcohol or nicotine); 2. a lifetime diagnosis of opioid dependence; 3. a history of psychosis; 4. a current suicidality, homocidality or psychiatric symptoms that required other psychotropic medication; 4. a concurrent use of disulfiram</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-07 13:32:19 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg of naltrexone + CBT (n = 24 + 3*)</LI>
<LI>50 mg of naltrexone + MET (n = 22 + 1*)</LI>
<LI>50 mg of placebo + CBT (n = 24 + 1*)</LI>
<LI>50 mg of placebo + MET (n = 27)</LI>
</OL>
<P>
<B>* </B>subsequently added to available case sample</P>
<P>
<B>Psychosocial treatment:</B> a) group 1 and 3: cognitive behavioral therapy (CBT); <B>applied manual: </B>
<LINK REF="REF-Marlatt-1985" TYPE="REFERENCE">Marlatt 1985</LINK> with focus on coping skills to keep a slip-up from developing into relapse; <B>aim:</B> harm reduction;<B> </B>b) group 2 and 4: motivation enhancement (ME); <B>aim</B>: abstinence; patients were free to attend self-help groups</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 19:51:42 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first relapse (survival curve)</LI>
<LI>time to first drink (survival curve)</LI>
<LI>return to any drinking</LI>
<LI>return to heavy drinking</LI>
<LI>drinking days</LI>
<LI>drinks per drinking occasion</LI>
<LI>time to first drink</LI>
<LI>craving</LI>
</OL>
<P>* relapse / heavy drinking: drinking &#8805;5 (4) STD for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-17 11:00:10 +0200" MODIFIED_BY="[Empty name]">
<P>National Institute on Alcohol Abuse and Alcoholism NIAAA)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 11:24:09 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>; weekly); <B>assessment of side-effects:</B> side effects checklist; <B>assessment of compliance:</B> riboflavin detection</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 11:28:50 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Treatment phase / drop-out rates</B>: naltrexone: 28.8% (n = 15); placebo: 40.4% (n = 21); <B>lost to follow-up rates</B>: not reported; <B>compliance rates </B>(% of prescribed medication taken): naltrexone: 92%; placebo: 78%</P>
<P>
<B>Follow-up phase / lost to follow-up rates</B>: naltrexone: 13.0% (n = 6); placebo: 21.6% (n = 11)</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-07-31 18:25:22 +0200" MODIFIED_BY="[Empty name]">
<P>Post-treatment results provided in <LINK REF="REF-O_x0027_Malley-1996" TYPE="REFERENCE">O'Malley 1996</LINK>
</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 18:27:19 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x0027_Malley-2007">
<CHAR_METHODS MODIFIED="2010-07-31 18:26:49 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Naltrexone for the treatment of alcohol drinking and eating disorder in alcohol-dependent women</B>
</P>
<P>
<B>Allocation:</B> random; <B>blinding: </B>double-blind; <B>study duration: </B>12 weeks; <B>principle of analysis:</B> ITT (modified); <B>setting:</B> outpatient; <B>study sites:</B>1; <B>country: </B>USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 18:27:19 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence; <B>other psychiatric diagnosis: </B>comorbid eating disorder (28% of the sample); <B>required abstinence: </B>3 to 5 days; <B>baseline characteristics:</B> 100% female; mean age: 40.34 (SD = 8.0) years; 52% married: 75% employed; <B>pre-baseline drinking:</B> 65.6 (SD = 25.3) drinking days; 7.1 (SD = 4.5) drinks per drinking episode; ADS score: 16.5 (SD = 8.0); <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence (other than alcohol or nicotine); 2. a concurrent psychosis or other severe psychiatric disability (e.g., suicidal, manic state); 3. a concurrent use of opioid analgesics or disulfiram.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-08 11:55:46 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (n = 57)</LI>
<LI>Placebo (n = 50)</LI>
</OL>
<P>
<B>Psychosocial treatment:</B> cognitive behavioral therapy (CBT); <B>applied manual:</B> (<LINK REF="REF-Kadden-1992" TYPE="REFERENCE">Kadden 1992</LINK> as applied in Project MATCH (<LINK REF="REF-Project-Match-Research-Group-1997" TYPE="REFERENCE">Project Match Research Group 1997</LINK>)</P>
<P>Dosing: 25 mg naltrexone daily for the first two treatment days</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 19:56:50 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first relapse* (survival curve)</LI>
<LI>time to first drink (survival curve)</LI>
<LI>drinks per drinking day</LI>
<LI>craving</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>time to the second day of drinking (non-abstinent participants)</LI>
<LI>side effects</LI>
</OL>
<P>** relapse / heavy drinking: drinking &#8805; 4 SDU</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-17 11:11:12 +0200" MODIFIED_BY="[Empty name]">
<P>Grants RO1AA10225, U10AA11787, KO5-AA014715 (SSO), KO2DA017232 (RS), K24DK070052 (CMG), P50 DA09421, K05-DA00089 (BJR)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 11:58:44 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking:</B> TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>); <B>assessment of side-effects: </B>not reported; <B>assessment of compliance:</B> Microelective events monitoring system (MEMS)</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 11:58:33 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 40.4% (n = 23); placebo: 46.0% (n = 23); <B>lost to follow-up rates</B>: naltrexone: 22.8% (n = 13); placebo: 24% (n = 12); <B>compliance rates </B>(% of days on which study medication was taken): 65%; no group specific values provided</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-06 19:58:14 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 18:29:00 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x0027_Malley-2008">
<CHAR_METHODS MODIFIED="2010-07-31 18:28:37 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Naltrexone alone and with sertraline for the treatment of alcohol dependence in Alaska natives and non-natives residing in rural settings</B>
</P>
<P>
<B>Allocation:</B> random; <B>blinding: </B>double-blind; <B>study duration: </B>16 weeks (treatment); 68 weeks (post-treatment); <B>principle of analysis:</B> ITT; <B>setting:</B> outpatient; <B>study sites: </B>5; <B>country:</B> USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 18:29:00 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence; <B>required abstinence: </B>4 to 30 days; <B>baseline characteristics:</B> 66% male; mean age: 40.0 (SD = 9.8) years; 37% married: 59% employed. Native Alaskans (n = 68); non-native Alaskans (n = 33): <B>pre-baseline drinking:</B> 57.5% (SD = 25.7) drinking days: 17.9 (SD = 11.5) drinks per drinking day; ADS score: 19.5 (SD = 8.0); <B>exclusionary psychiatric conditions: </B>1. a concurrent cocaine, opioid, or amphetamine drug abuse or dependence; 2. a concurrent major psychiatric condition that required use of psychotropic medications or could jeopardize safety (e.g. suicidality, psychosis); 3. a concurrent use of opioids or psychotropic medications</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-07-27 12:00:39 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (n = 34)</LI>
<LI>50 mg naltrexone + 100 mg sertraline (n = 33)</LI>
<LI>placebo (n = 34)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>medial management (MM); <B>applied manual: </B>
<LINK REF="REF-Pettinati-2004" TYPE="REFERENCE">Pettinati 2004</LINK> as applied in<U> Anton 2006;</U> <B>aim:</B> flexible (with recommendation to abstinence)</P>
<P>
<B>Dosing: </B>12.5 mg naltrexone for the fist treatment day, 25 mg naltrexone for the second and third treatment day</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 20:01:03 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first relapse* (survival curve)</LI>
<LI>time to first drink (survival curve)</LI>
<LI>return to any drinking</LI>
<LI>return to heavy drinking*</LI>
<LI>days abstinent</LI>
<LI>heavy drinking days</LI>
<LI>drinks per drinking day</LI>
<LI>craving</LI>
<LI>gamma-glutamyltransferase level (GGT)</LI>
<LI>carbohydrate-deficient transferrin (CDT)</LI>
<LI>side effects</LI>
</OL>
<P>* heavy drinking: drinking &#8805;5 (4) STD for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-17 11:21:38 +0200" MODIFIED_BY="[Empty name]">
<P>National Institute on Alcohol Abuse and Alcoholism (NIAAAA); National Center on Minority Health and Health Disparities</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 12:01:14 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking:</B> TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>; week 0, 8, 16); <B>assessment of side-effects: </B>not reported; <B>assessment of compliance:</B> Electronic Microchip System (EMS)</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 12:00:36 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 23.5% (n = 8 ); naltrexone + sertraline: 36.4% (n = 12); placebo: 38.2% (n = 13); <B>lost to follow-up rates: </B>naltrexone: 9% (n = 3); naltrexone + sertraline: 12% (n = 4); placebo: 9% (n = 3); <B>compliance rate</B> (% of bottle openings): naltrexone: 66%; naltrexone + sertraline: 58%; placebo: 61%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-06 20:02:27 +0100" MODIFIED_BY="[Empty name]">
<P>The report focuses on the 16-week treatment period; post-treatment results presented </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 18:31:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oslin-1997">
<CHAR_METHODS MODIFIED="2010-07-31 18:30:49 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Naltrexone as an adjunctive treatment for older patients with alcohol dependence </B>
</P>
<P>
<B>Allocation: </B>random; <B>blinding: </B>double-blind; <B>study duration:</B> 12 weeks; <B>principle of analysis: </B>ITT; <B>setting: </B>outpatient; <B>study sites: </B>1; <B>country:</B> USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 18:31:32 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;information provided by the author:&lt;/p&gt;&lt;p&gt;required abstinence &amp;#8805; 3 days&lt;/p&gt;" NOTES_MODIFIED="2010-07-31 18:31:32 +0200" NOTES_MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence (veterans; &gt; 50 years); <B>required abstinence:</B> &#8805; 3 days; <B>baseline characteristics:</B> 100% male; mean age: 57.8 (SD = 6.8) years; 15.9% married; <B>pre-baseline drinking:</B> 10.7 (SD = 7.3) drinks per drinking occasion; ASI score (<LINK REF="REF-McLellan-1980" TYPE="REFERENCE">McLellan 1980</LINK>): 0.48 (SD = 0.18); <B>exclusionary psychiatric conditions: </B>1. drug abuse or dependence other than alcohol or nicotine (past 6 weeks); 2. a diagnosis of severe dementia, seizure disorder, mental retardation or psychosis; 3. a concurrent use of psychoactive substances</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 20:04:52 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (n = 21)</LI>
<LI>placebo (n=23)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>group therapy, case management, peer support, education; <B>aim: </B>abstinence</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-07 11:25:06 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first relapse* (survival curve)</LI>
<LI>return to any drinking</LI>
<LI>return to heavy drinking</LI>
<LI>days abstinent</LI>
<LI>craving</LI>
<LI>gamma-glutamyltransferase</LI>
<LI>side effects</LI>
</OL>
<P>* relapse: drinking &#8805; 5 (4) SDU per drinking for men (women) or having &#8805; 5 drinking occasions per week or a blood alcohol concentration (BAC) &gt; 100mg/dl</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-17 11:31:26 +0200" MODIFIED_BY="[Empty name]">
<P>Dupont Merck Pharmaceuticals</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 12:04:31 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking:</B> not reported; <B>assessment of side-effects: </B>weekly checklist for selected adverse events; <B>assessment of compliance:</B> not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 12:04:14 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 14.3% (n = 3); placebo: 30.4% (n = 7); <B>lost to follow-up rates</B>: naltrexone: 14.3% (n = 3); placebo: 30.4% (n = 7); <B>compliance rate </B>(doses of medication taken): naltrexone: 26.8 (SD = 8.1); placebo: 25.6 (SD = 12.6)</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-12-29 10:02:39 +0100" MODIFIED_BY="[Empty name]">
<P>Information on drop-out rates and the study design were provided by the investigator</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 18:33:12 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oslin-2005">
<CHAR_METHODS MODIFIED="2010-07-31 18:32:47 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Treatment of late-life depression complicated by alcohol dependence </B>
</P>
<P>
<B>Allocation: </B>random; <B>blinding:</B> double-blind; <B>study duration:</B> 12 weeks (treatment); <B>principle of analysis:</B> not reported; <B>setting:</B> outpatient; <B>study sites: </B>1; <B>country:</B> USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 18:33:12 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence (DSM-IV); <B>concurrent psychiatric diagnosis: </B>major depression (100%); <B>required abstinence:</B> &#8805; 3 days; <B>baseline characteristics:</B> 79.8% male; mean age: 63.4 (SD=6.3) years; 44.6% married; <B>pre-baseline drinking:</B> 79% drinking days; 67.5% heavy drinking days; 8.4 (SD = 5.5) drinks per drinking day; 17.3 (SD = 9.9) years of drinking-to-intoxication; 48.6% had received formal treatment of alcohol dependence before; ASI score: 0.7 (SD = 0.2); <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence (other than alcohol or nicotine); 2. an opioid use during the last 30 days</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 20:07:01 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone + 100mg sertraline (n = 37)</LI>
<LI>placebo + 100mg sertraline (n = 37)</LI>
</OL>
<P>
<B>Psychosocial treatment:</B> motivational enhancement (ME)+ bio-psychosocial feedback; <B>applied manual</B>: BRENDA intervention (<LINK REF="REF-Volpicelli-2001" TYPE="REFERENCE">Volpicelli 2001</LINK>); <B>aim: </B>flexible</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 20:07:14 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to first relapse*</LI>
<LI>return to any drinking</LI>
<LI>return to heavy drinking*</LI>
<LI>side effects</LI>
</OL>
<P>* heavy drinking: drinking &#8805;4 (3) SDU for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-06 20:07:16 +0100" MODIFIED_BY="[Empty name]">
<P>National Institute of Mental Health; Department of Veterans Affairs</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 12:12:51 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>); <B>assessment of side-effects:</B> SAFTEE<B> </B>(<LINK REF="REF-Levine-1986" TYPE="REFERENCE">Levine 1986</LINK>, <LINK REF="REF-Rabkin-1992" TYPE="REFERENCE">Rabkin 1992</LINK>); <B>assessment of compliance: </B>pill count</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 12:12:55 +0200" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Systematic Assessment for Treatment Emergent effects: SAFETEE&lt;/p&gt;" NOTES_MODIFIED="2010-07-27 12:12:55 +0200" NOTES_MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 18.9% (n = 7); placebo: 10.8% (n = 4); <B>lost to follow-up rates</B>: not reported; <B>compliance rates:</B> not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-05-13 10:03:58 +0200" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 18:34:34 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oslin-2008">
<CHAR_METHODS MODIFIED="2010-07-31 18:34:14 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Tilte: A placebo-controlled randomized clinical trial of naltrexone in the context of different levels of psychosocial intervention</B>
</P>
<P>
<B>Allocation: </B>random; <B>blinding:</B> double-blind; <B>study duration: </B>24 weeks; <B>principle of analysis: </B>ITT modified (treatment received analysis); <B>setting: </B>outpatient; <B>study sites:</B> 1; <B>country: </B>USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 18:34:34 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence; <B>required abstinence</B>: &#8805; 3 days; <B>baseline characteristics:</B> 72.9% male; mean age: 41.0 (SD = 9.4) years; 34.5% married: 85% employed; <B>pre-baseline drinking:</B> 71.6 (SD = 27.4) % drinking days; 8.7 (SD = 6.6) drinks per day; ASI score (<LINK REF="REF-McLellan-1980" TYPE="REFERENCE">McLellan 1980</LINK>): 0.70 (SD = 0.18); <B>exclusionary psychiatric conditions: </B>1. a concurrent psychoactive substance dependence (other than alcohol or nicotine); 2. opioid abuse in the past 30 days; 3. concurrent severe psychiatric symptoms; 4. a concurrent use of psychotropic medications</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 20:12:20 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>100 mg naltrexone + physician visit (n = 41 +1*)</LI>
<LI>placebo * physician visit (n = 40 +1*)</LI>
<LI>100 mg naltrexone + BRENDA (n = 39 +3*)</LI>
<LI>placebo + BRENDA (n = 40 +1*)</LI>
<LI>100 mg naltrexone + CBT (n = 40 + 2*)</LI>
<LI>placebo + CBT (n = 40)</LI>
</OL>
<P>* patients excluded who did not receive at least one dose of study medication</P>
<P>Psychosocial treatment: a) group 1 and 2: physician visit; no formal psychotherapy; b) group 3 and 4: motivational enhancement (ME) + bio-psychosocial feedback; <B>applied manual</B>: BRENDA (<LINK REF="REF-Volpicelli-2001" TYPE="REFERENCE">Volpicelli 2001</LINK>); c) group 5 and 6: cognitive behavioral therapy (CBT); <B>applied manual: </B>
<LINK REF="REF-Kadden-1992" TYPE="REFERENCE">Kadden 1992</LINK> as applied in Project Match (<LINK REF="REF-Project-Match-Research-Group-1997" TYPE="REFERENCE">Project Match Research Group 1997</LINK>) </P>
<P>
<B>Dosing: </B>flexible (in case of side-effects, patients were maintained on 50 mg)</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 20:12:30 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Return to any drinking</LI>
<LI>return to heavy drinking</LI>
<LI>days abstinent</LI>
<LI>heavy drinking days</LI>
<LI>drinks per drinking day</LI>
<LI>side effects</LI>
</OL>
<P>* relapse / heavy drinking: drinking &#8805;5 (4) SDU for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-17 11:48:15 +0200" MODIFIED_BY="[Empty name]">
<P>National Institute on Alcoholism and Alcohol Abuse (NIAAA); National Institute on Mental Health; National Institute on Drug Abuse</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 12:15:45 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>; week 4, 8, 12, 16, 20, 24); <B>assessment of side-effects:</B> research physician&#8217;s probing for side effects commonly (weekly); <B>assessment of compliance:</B> pill count</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 12:15:36 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 24.2% (n = 29); placebo: 19.2% (n = 23); <B>lost to follow-up rates</B>: 77% of the patients provided complete data on drinking during the 24-week trial; <B>compliance rates</B> (80% of days on which prescribed medication was taken over 24 weeks): naltrexone: 50%; placebo: 51%<BR/>
</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-06 20:13:15 +0100" MODIFIED_BY="[Empty name]">
<P>Information on the study design were subsequently provided by the investigator</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 18:36:02 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Petrakis-2004">
<CHAR_METHODS MODIFIED="2010-07-31 18:35:37 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Tile: Naltrexone augmentation of neuroleptic treatment in alcohol abusing patients with schizophrenia</B>
</P>
<P>
<B>Allocation: </B>random; <B>blinding: </B>double-blind; <B>study duration:</B> 12 weeks; <B>principle of analysis:</B> ITT; <B>setting: </B>outpatient; <B>study sites:</B> 1; <B>country:</B> USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 18:36:02 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence (97%); alcohol abuse (3%); <B>concurrent psychiatric diagnosis</B>: schizophrenia (58%); schizoaffective disorder (42%); <B>required abstinence: </B>&#8804; 29 days; <B>baseline characteristics:</B> 100% male; mean age: 46 (SD=5.7) years; 16% employed; <B>pre-baseline drinking:</B> 39% (SD = 27.7) drinking days; 30% (SD = 26.3) heavy drinking days; 4.26 (SD = 4.2) drinks per day; <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence (other than alcohol or nicotine); 2. serious psychiatric symptoms, such as suicidal or homicidal ideation or an unstable psychotic condition</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 21:20:37 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (n = 16)</LI>
<LI>placebo (n = 15)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>skills training for schizophrenia; <B>applied manual:</B> <LINK REF="REF-Roberts-1999" TYPE="REFERENCE">Roberts 1999</LINK>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 21:20:44 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Drinking days</LI>
<LI>heavy drinking days* </LI>
<LI>drinks per day</LI>
<LI>craving</LI>
<LI>side effects</LI>
</OL>
<P>* relapse / heavy drinking: drinking &#8805; 5 (4) SDU for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-07-15 11:01:54 +0200" MODIFIED_BY="[Empty name]">
<P>National Alliance for Research on Schizophrenia and Depression (NARSAD); Department of Veterans Affairs; VA-Yale Alcoholism Research Center; VISN I Mental Illness Research and Clinical Center; National Institute on Alcohol Abuse and Alcoholism (NIAAA).</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 14:07:50 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking:</B> TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>; weekly); <B>assessment of side-effects: </B>Hopkins symptom checklist (HSCL; <LINK REF="REF-Derogatis-1974" TYPE="REFERENCE">Derogatis 1974</LINK>); <B>assessment of compliance:</B> pill count</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 14:07:39 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 25% (n = 4); placebo: 13.4% (n = 2); <B>lost to follow-up rates</B>: naltrexone: 12.5% (n = 2); placebo: 6.7% (n = 1); <B>compliance rate </B>(% of days taking medication): naltrexone: 68.4%; placebo: 77.5%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-06 21:24:38 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-15 14:23:30 +0200" MODIFIED_BY="Laura Amato" STUDY_ID="STD-Petrakis-2005">
<CHAR_METHODS MODIFIED="2010-07-31 18:37:21 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders</B>
</P>
<P>
<B>Allocation:</B> random; <B>blinding: </B>double-blind; <B>study duration:</B> 12 weeks; <B>principle of analysis: </B>ITT; <B>setting:</B> outpatient; <B>study sites:</B> 3; <B>country: </B>USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-10-15 14:23:30 +0200" MODIFIED_BY="Laura Amato">
<P>
<B>Diagnosis: </B>alcohol dependence (DSM-IV); <B>other psychiatric diagnosis: </B>comorbid axis I disorders (major depression: 70.1%; posttraumatic stress disorder: 42.9%; schizophrenia or schizoaffective disorder: 7.4%; cocaine dependence 19.7%; <B>required abstinence</B>: 3 to 29 days; <B>baseline characteristics:</B> 97.2% male; mean age: 47.0 (SD=8.2) years; <B>pre-baseline drinking:</B> 52% (SD = 4) drinking days: 19.4 (SD = 12.5) drinks per drinking day; ADS score: 21.7 (SD = 8.9); <B>exclusionary psychiatric conditions: </B>1. an unstable psychotic symptoms or serious current psychiatric symptoms, such as suicidal or homicidal ideation; 2. a psychiatric medications change (unstable regimen) for at least 2 weeks before randomisation</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 21:28:28 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (n = 59)</LI>
<LI>50 mg naltrexone + 250 mg disulfiram (n = 65)*</LI>
<LI>250 mg disulfiram (n = 66)*</LI>
<LI>placebo (n = 64)</LI>
</OL>
<P>* study arms not included in the review (open-label)</P>
<P>
<B>Psychosocial treatment: </B>supportive therapy and compliance enhancement therapy; <B>applied manual:</B> <LINK REF="REF-Carroll-1998" TYPE="REFERENCE">Carroll 1998</LINK>; <B>aim:</B> abstinence</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 21:28:54 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Return to any drinking</LI>
<LI>days abstinent</LI>
<LI>heavy drinking days*</LI>
<LI>time to first drink</LI>
<LI>craving</LI>
<LI>gamma-glutamyltransferase (GGT) </LI>
<LI>carbohydrate-deficient (CDT)</LI>
<LI>glutamic-oxaloacetic transaminase</LI>
<LI>glutamic pyruvic transaminase</LI>
<LI>side effects</LI>
</OL>
<P>* relapse / heavy drinking: drinking &#8805; 5 (4) SDU for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2010-01-06 21:29:14 +0100" MODIFIED_BY="[Empty name]">
<P>Department of Veterans Affairs; Veterans Affairs New England Mental Illness Research and Clinical Center (MIRECC)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 14:15:46 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>; weekly); <B>assessment of side-effects:</B> Hopkins symptom checklist (HSC; <LINK REF="REF-Derogatis-1974" TYPE="REFERENCE">Derogatis 1974</LINK>); <B>assessment of compliance: </B>Microelective Events Monitoring System (MEMS)</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 14:15:35 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 22% (n = 13); placebo: 37.5% (n = 24); <B>lost to follow-up rates</B>: naltrexone: 5.1% (n = 3); placebo: 15.6% (n = 10); <B>compliance rates </B>(% number of days pills taken related to the number of potential medication days): naltrexone: 82%; placebo: 86%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-07 22:39:04 +0100" MODIFIED_BY="[Empty name]">
<P>Information on the study design was subsequently provided by the investigator</P>
<P>Study arms with disulfiram did not meet the inclusion criteria of the review and were not included in the meta-analysis </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 18:40:09 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pettinati-2008a">
<CHAR_METHODS MODIFIED="2010-07-31 18:39:07 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Gender differences with high-dose naltrexone in patients with co-occurring cocaine and alcohol dependence</B>
</P>
<P>
<B>Allocation:</B> random; <B>blinding: </B>double-blind; <B>study duration:</B> 12 weeks; <B>principle of analysis:</B> ITT; <B>setting:</B> outpatient; <B>study sites: </B>1; <B>country: </B>USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 18:40:09 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence (DSM-IV); <B>concurrent psychiatric diagnosis:</B> cocaine dependence; <B>required abstinence:</B> &#8805; 3 days; <B>baseline characteristics:</B> 70.7% male; mean age: 39.1 (SD = 7.0) years; 47.8 % ever married: 70.9% employed; <B>pre-baseline drinking:</B> 57.1% (SD = 26.6) drinking days; 12.0 (SD = 7.2) drinks per drinking day; 2.0 (SD = 2.5) previous alcohol treatments; 19.7 (SD = 8.2 ) years of problematic drinking; ASI score (<LINK REF="REF-McLellan-1980" TYPE="REFERENCE">McLellan 1980</LINK>): 0.61 (SD = 0.2); <B>pre-baseline cocaine use:</B> 71.1% crack cocaine preference; 1122 US Dollars (SD = 1138) spent on cocaine during the last 30 days; <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence (other than alcohol or cocaine); 2. opiate use (past 30 days); 3. psychosis, suicidal or homicidal ideation, or mania; 4. a concurrent treatment with psychiatric medications, including antipsychotic, antidepressant, and antianxiety medications</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 21:35:30 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>150 mg naltrexone + CBT(n = 44)</LI>
<LI>placebo + CBT (n = 37)</LI>
<LI>150 mg naltrexone + BRENDA (n = 38)</LI>
<LI>placebo + BRENDA (n = 45)</LI>
</OL>
<P>
<B>Psychosocial treatment: a) </B>group 1 and 2: cognitive behavioral therapy (CBT); <B>applied manual: </B>
<LINK REF="REF-Marlatt-1985" TYPE="REFERENCE">Marlatt 1985</LINK>, adapted by <LINK REF="REF-Carroll-1998" TYPE="REFERENCE">Carroll 1998</LINK> for the treatment of concurrent cocaine and alcohol dependence; b) group 3 and 4:<B> </B>motivational enhancement (ME) + bio-psychosocial feedback; <B>applied manual</B>: BRENDA (<LINK REF="REF-Volpicelli-2001" TYPE="REFERENCE">Volpicelli 2001</LINK>) </P>
<P>
<B>Dosing:</B> ascending; starting with 50 mg naltrexone up to for the first two treatment days up to 150 mg/day of naltrexone, as tolerated</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 21:35:34 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Drinking days</LI>
<LI>heavy drinking days*</LI>
<LI>drinks per drinking day</LI>
<LI>side effects</LI>
</OL>
<P>* relapse / heavy drinking: drinking &#8805;5 (4) for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-17 18:23:46 +0200" MODIFIED_BY="[Empty name]">
<P>National Institute on Drug Abuse; Mental Health Research Education and Clinical Center at the Philadelphia Veterans Affairs Medical Center</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 14:16:23 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking:</B> TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>; weekly; extended version for cocaine self-reports; weekly); <B>assessment of side-effects </B>(weekly): SAFTEE<B> </B>(<LINK REF="REF-Levine-1986" TYPE="REFERENCE">Levine 1986</LINK>, <LINK REF="REF-Rabkin-1992" TYPE="REFERENCE">Rabkin 1992</LINK>)</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 14:18:06 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 39% (n=32); placebo: 32.9% (n=27); <B>lost to follow-up rates</B>: not reported; <B>compliance rates</B> (% of patients who took &#8805; 80% of the medication): naltrexone: 49%; placebo: 42.7%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-07 10:40:01 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 18:41:41 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pettinati-2008b">
<CHAR_METHODS MODIFIED="2010-07-31 18:41:19 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence</B>
</P>
<P>
<B>Allocation: </B>random; <B>blinding: </B>double-blind; <B>study duration:</B> 12 weeks; <B>principle of analysis:</B> ITT; <B>setting: </B>outpatient; <B>study sites: </B>1; <B>country:</B> USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 18:41:41 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence; <B>other psychiatric diagnosis:</B> cocaine dependence (100%); <B>required abstinence:</B> &#8805; 3 days; <B>baseline characteristics:</B> 40.1% male; mean age: 41.2 (SD=6.8) years; 31.5% days employed in past 30 days; <B>pre-baseline drinking:</B> 55.8% drinking days; 14.4 (SD = 12.0) drinks per drinking day; 3.6 (SD = 6.1) previous alcohol or drug treatments; <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence (other than cocaine, alcohol or nicotine); 2. a concurrent active psychosis, mania or dementia or the need for treatment with psychiatric medications.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-09-17 18:22:01 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>100 mg of naltrexone (n = 52)</LI>
<LI>100 mg of naltrexone and 250 mg disulfiram (n = 49)</LI>
<LI>250 mg disulfiram (n = 53)</LI>
<LI>placebo (n = 54)</LI>
</OL>
<P>
<B>Psychosocial treatment:</B> cognitive behavioral therapy; <B>applied manual:</B> Kadden et al. (1994) as applied in Project Match (Project Match Research Group 1997)</P>
<P>Dosing: ascending; starting with 25 mg naltrexone up to for the first two treatment days up to 100 mg/day of naltrexone in week 4</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-17 18:09:53 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>days abstinent</LI>
<LI>heavy drinking days (&#8805;5 (4) STD for men (women))</LI>
<LI>side effects</LI>
</OL>
<P>* relapse / heavy drinking: drinking &#8805; 5 (4) SDU for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-07-15 11:03:17 +0200" MODIFIED_BY="[Empty name]">
<P>National Institute on Drug Abuse (NIDA)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 14:20:01 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking:</B> TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>); <B>assessment of side-effects:</B> SAFTEE<B> </B>(<LINK REF="REF-Levine-1986" TYPE="REFERENCE">Levine 1986</LINK>, <LINK REF="REF-Rabkin-1992" TYPE="REFERENCE">Rabkin 1992</LINK>); <B>assessment of compliance:</B> pill count</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 14:20:10 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 32.7% (n = 17); disulfiram: 22.6% (n = 12); disulfiram + naltrexone: 40.8%% (n = 20); placebo: 40.7% (n = 22); <B>lost to follow-up rates</B>: not reported; <B>compliance rates</B> (% patients who took &#8805; 80% of the medication): naltrexone: 58.5%; disulfiram: 35.1%; placebo: not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-06 21:37:20 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 18:43:49 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmitz-2004">
<CHAR_METHODS MODIFIED="2010-07-31 18:43:29 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Treatment of cocaine&#8211;alcohol dependence with naltrexone and relapse prevention therapy</B>
</P>
<P>
<B>Allocation:</B> random; <B>blinding:</B> double-blind; <B>study duration:</B> 12 weeks; <B>principle of analysis:</B> not reported; <B>setting:</B> outpatient; <B>study sites: </B>1; <B>country:</B> USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 18:43:49 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence (DSM-IV); <B>concurrent psychiatric diagnosis:</B> cocaine dependence; <B>required abstinence:</B> abstinence from alcohol during the intake evaluation was encouraged, but not required; no further information required; <B>baseline characteristics:</B> 83.7% male; mean age: 35.9 (SD = 6.4) years; 41.3% employed; <B>pre-baseline drinking:</B> 59.7% drinking days; <B>pre-baseline cocaine use:</B> 48.7% day with cocaine use; <B>exclusionary psychiatric conditions: </B>1. a concurrent drug dependence (other than alcohol, cocaine, cannabis or nicotine); 2. a concurrent axis I disorder.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 21:42:39 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone + CBT (n = 20)</LI>
<LI>placebo + CBT (n = 20)</LI>
<LI>50 mg naltrexone + drug counselling (n = 20)</LI>
<LI>placebo + drug counselling (n = 20)</LI>
</OL>
<P>Psychosocial treatment: a) group 1 and 2: cognitive behavioral therapy (CBT); <B>applied manual:</B> <LINK REF="REF-Marlatt-1985" TYPE="REFERENCE">Marlatt 1985</LINK>; b) group 3 and 4: drug counselling; <B>applied manual:</B> <LINK REF="REF-Woody-1983" TYPE="REFERENCE">Woody 1983</LINK>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-09-17 20:43:27 +0200" MODIFIED_BY="[Empty name]">
<OL>
<LI>Drinking days</LI>
<LI>drinks per drinking day</LI>
<LI>side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-17 20:43:29 +0200" MODIFIED_BY="[Empty name]">
<P>National Institute on Drug Abuse (NIDA)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 14:21:45 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking:</B> TLFB interview (<LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>); modified version (weekly); <B>asssessment of side-effects:</B> side-effects<B> </B>checklist; <B>assessment of compliance: </B>riboflavin detection</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 14:21:48 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: 67% (no group specific values provided); <B>lost to follow-up rates</B>: not reported; <B>compliance rates</B> (% of urine samples positive for riboflavin): naltrexone: 93%; placebo: 83%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-02-17 22:06:00 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 18:45:40 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmitz-2009">
<CHAR_METHODS MODIFIED="2010-07-31 18:45:13 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: High-dose naltrexone therapy for cocaine-alcohol dependence </B>
</P>
<P>
<B>Allocation:</B> random;<B> blinding:</B> double-blind; <B>study duration: </B>12 weeks; <B>principle of analysis: </B>ITT; <B>setting: </B>outpatient; <B>study sites: </B>1; <B>country: </B>United States</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 18:45:40 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis: </B>alcohol dependence (DSM-IV); <B>concurrent psychiatric diagnosis:</B> cocaine dependence; <B>required abstinence: </B>no prior detoxification required; <B>baseline characteristics:</B> 87.3% male; mean age: 34.4 (SD = 4.5) years; 36% employed; <B>pre-baseline drinking:</B> 70% drinking days; 47.1% previous alcohol treatment. detoxifications; 21.7 (SD = 8.0) years of drinking; <B>pre-baseline cocaine use:</B> 81.2% crack cocaine consumption; 55% days with cocaine use during the last 30 days; <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse or dependence (other than alcohol, cocaine, cannabis or nicotine); 2. a concurrent major psychiatric disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 21:44:52 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>100 mg naltrexone + CBT (n = 20)</LI>
<LI>100 mg naltrexone + CBT + CM (n = 25)</LI>
<LI>Placebo + CBT (n = 27)</LI>
<LI>Placebo + CBT + CM (n = 14)</LI>
</OL>
<P>
<B>Psychosocial treatment:</B> a) group 1 and 3: cognitive behavioral therapy (CBT);<B> applied manual: </B>
<LINK REF="REF-Marlatt-1985" TYPE="REFERENCE">Marlatt 1985</LINK>;<B> aim: </B>abstinence; b) group 2 and 4: contingency management (CM);<B> aim: </B>abstinence</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 21:45:01 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Return to any drinking</LI>
<LI>Return to heavy drinking*</LI>
<LI>side effects</LI>
</OL>
<P>* relapse / heavy drinking: drinking &#8805; 5 (4) SDU for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-18 09:56:48 +0200" MODIFIED_BY="[Empty name]">
<P>National Institute on Drug Abuse</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 14:30:24 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking:</B> TLFB interview (week 0, 12, 24, 48; <LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>); <B>assessment of side-effects:</B> standardized reporting system; <B>assessment of compliance:</B> pill count</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 14:30:11 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: 76%; no group specific values provided; <B>lost to follow-up rates: </B>not reported; <B>compliance rates</B> (% of urine samples positive for riboflavin): 50% - 80%; no group specific values provided</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-06 21:45:50 +0100" MODIFIED_BY="[Empty name]">
<P>Information on the study design was subsequently provided by the investigators</P>
<P>The manuscript has been provided from the investigators before publication</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 18:47:12 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Volpicelli-1992">
<CHAR_METHODS MODIFIED="2010-07-31 18:46:50 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Naltrexone in the treatment of alcohol dependence </B>
</P>
<P>
<B>Allocation: </B>random; <B>blinding: </B>double-blind; <B>study duration: </B>12 weeks; <B>principle of analysis: </B>ITT; <B>setting: </B>outpatient; <B>study sites: </B>1; <B>country: </B>USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 18:47:12 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence (DSM-III-R); <B>required abstinence:</B> &#8804; 21 days; <B>baseline characteristics:</B> 100% male; mean age: 43.4 (SD=9.2) years; 44.3% married: 41.6% employed; <B>pre-baseline drinking: </B>19.9 (SD = 9.0) years of heavy drinking; <B>exclusionary psychiatric conditions: </B>1. a concurrent drug abuse of opiates, amphetamines, cocaine or barbiturates; 2. the use of narcotics within the past 30 days; 3. a concurrent major psychiatric disorder associated with psychosis, dementia, suicidality or homocidality</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 21:47:18 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (n = 35)</LI>
<LI>placebo (n = 35)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>standard rehabilitation treatment (group therapy, individual counselling, education)</P>
<P>
<B>Trial started with a placebo run-in week</B>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-29 17:44:47 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Return to any drinking</LI>
<LI>Return to heavy drinking*</LI>
<LI>drinking days</LI>
<LI>drinks per drinking day</LI>
<LI>craving</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>aspartate-aminotransferase (AST)</LI>
</OL>
<P>*relapse / heavy drinking: drinking &#8805; 5 (4) SDU per drinking for men (women) or having &#8805; 5 drinking occasions per week or a blood alcohol concentration (BAC) &#8805; 100mg/dl</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-18 10:16:06 +0200" MODIFIED_BY="[Empty name]">
<P>National Institute on Drug Abuse Research; National Institute on Alcohol Abuse and Alcoholism (NIAAA); Penn Veterans Affairs Addiction Research Center</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 14:33:27 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking:</B> alcohol use questionnaire (weekly); <B>assessment of side-effects:</B> not reported; <B>assessment of compliance:</B> not reported</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 14:33:15 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 31% (n = 11); placebo: 40.0% (n = 14); <B>lost to follow-up rates</B>: naltrexone: 5.7% (n = 2); placebo: 8.6% (n = 3); <B>compliance rates: </B>not reported</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-06 21:48:00 +0100" MODIFIED_BY="[Empty name]"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-07-31 18:48:45 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Volpicelli-1997">
<CHAR_METHODS MODIFIED="2010-07-31 18:48:19 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Naltrexone and alcohol dependence </B>
</P>
<P>
<B>Allocation</B>: random; <B>blinding: </B>double-blind; <B>study duration: </B>12 weeks; <B>principle of analysis: </B>ITT / available case analysis; <B>setting: </B>outpatient; <B>study sites: </B>1; <B>country: </B>USA</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 18:48:45 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence (DSM-III-R); <B>required abstinence:</B> &#8804; 21 days; <B>baseline characteristics:</B> 77.8% male; mean age: 41.2 (SD = 9.0) years; 44.5% married: 67.7% employed; <B>pre-baseline drinking: </B>70% (SD = 2.9) drinking days; 15.4 (SD = 9.2) years of regular drinking; <B>exclusionary psychiatric conditions: </B>1. the use of narcotics (past 30 days); 2. a concurrent major psychiatric disorder associated with psychosis, dementia, suicidality or homocidality; 3. a concurrent treatment with disulfiram</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-01-06 21:53:15 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>50 mg naltrexone (n = 48)</LI>
<LI>placebo (n = 49)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>individual psychotherapy; <B>applied manual:</B> <LINK REF="REF-Gorski-1986" TYPE="REFERENCE">Gorski 1986</LINK>
</P>
<P>
<B>Trial started with a</B> <B>placebo run-in week</B>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-06 21:55:44 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Return to any drinking</LI>
<LI>Return to heavy drinking*</LI>
<LI>drinking days</LI>
<LI>craving (10-point scale)</LI>
<LI>gamma-glutamyltransferase level (GGT)</LI>
<LI>side-effects</LI>
</OL>
<P>*relapse / heavy drinking: drinking &#8805; 5 (4) SDU per drinking for men (women) or having &#8805; 5 drinking occasions per week or a blood alcohol concentration (BAC) &#8805; 100mg/dl</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-18 11:08:50 +0200" MODIFIED_BY="[Empty name]">
<P>National Institute on Alcohlism and Alcohol Abuse (NIAAA), Pennsylvania Veterans Affairs Medical Center, National Institute on Drug Abuse Center</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 14:36:23 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>alcohol use questionnaire (weekly); <B>assessment of side-effects: </B>side-effects checklist (week 4, 8, 12); <B>assessment of compliance: </B>pill count</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 14:36:14 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: naltrexone: 27.1% (n = 13); placebo: 26.5% (n = 13); <B>lost to follow-up rates</B>: naltrexone: 0%; placebo: 0%; <B>compliance rates</B> (% patients taking medication on 90% of the study days): naltrexone: 58,3%; placebo: 46.9%</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-07 17:55:46 +0100" MODIFIED_BY="[Empty name]">
<P>Subgroup analysis: degree of compliance </P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2010-10-15 14:24:32 +0200" MODIFIED_BY="Laura Amato" STUDY_ID="STD-Zi_x00f3__x0142_kowski-2000">
<CHAR_METHODS MODIFIED="2010-07-31 18:50:21 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Title: Naltrexone exerts a favourable effect on drinking in patients with alcohol dependence</B>
</P>
<P>
<B>Allocation:</B> random; <B>blinding: </B>double-blind; <B>study duration:</B> 16 weeks (treatment); 8 months (post-treatment); <B>principle of analysis:</B> ITT; <B>setting:</B> inpatient (week 1-4); outpatient (week 5-16); <B>study sites: </B>1; <B>country:</B> Poland</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-07-31 18:50:58 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Diagnosis:</B> alcohol dependence (ICD-10); <B>required abstinence:</B> not reported; <B>baseline characteristics:</B> 100% male; mean age: 39.0 (SD = 7) years; <B>pre-baseline drinking:</B> 52.3% (SD = 30.7) drinking days; 7.5 (SD = 6.9) drinks per day; 13 (SD = 6) years of alcohol dependence; MAST score: 42 (SD = 13); <B>exclusionary psychiatric conditions: </B>a concurrent treatment with<B> </B>psychoactive medication others than benzodiazepines</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2010-10-15 14:24:32 +0200" MODIFIED_BY="Laura Amato">
<OL>
<LI>50 mg naltrexone (n = 40)</LI>
<LI>600-800 mg carbamazepine (n = 40)</LI>
<LI>500-1000 mg lithium carbonate (n = 39)</LI>
<LI>Placebo (n = 41)</LI>
</OL>
<P>
<B>Psychosocial treatment: </B>before randomisation, patients were treated with psychosocial therapy for four weeks</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2010-01-29 17:45:40 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Return to any drinking</LI>
<LI>Return to heavy drinking*</LI>
<LI>total cholesterol</LI>
<LI>HDL cholesterol</LI>
<LI>LDL cholesterol</LI>
<LI>fasting triglyceride</LI>
<LI>gamma-glutamyltransferase (GGT)</LI>
<LI>aspartat-amino-transferase (AST)</LI>
<LI>alanine-amino-transferase (ALT)</LI>
</OL>
<P>* relapse / heavy drinking: drinking &#8805; 5 (4) SDU for men (women)</P>
</CHAR_OUTCOMES>
<CHAR_USER_DEF_1 MODIFIED="2009-09-18 11:48:53 +0200" MODIFIED_BY="[Empty name]">
<P>Polish-American M. Curie-Sklodowska grant</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2010-07-27 14:38:23 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Assessment of drinking: </B>TLFB interview (week 2, 4, 6, 8, 10, 12, 14, 16, 24, 28, 42; <LINK REF="REF-Sobell-1988" TYPE="REFERENCE">Sobell 1988</LINK>; <LINK REF="REF-Sobell-1992" TYPE="REFERENCE">Sobell 1992</LINK>); <B>assessment of side-effects:</B> not reported; <B>assessment of compliance: </B>riboflavin detection</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2010-07-27 14:38:08 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Drop-out rates</B>: no information available; <B>lost to follow-up rates</B>: naltrexone: 0%; placebo: 0%; <B>compliance rates: </B>no information available<B> </B>
</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2010-01-06 22:08:00 +0100" MODIFIED_BY="[Empty name]">
<P>Rates of continuous abstinence and information on the study design was subsequently provided by the investigator</P>
<P>Published in book format; language: Polish (partly translated by the investigators for the review) </P>
<P>A publication of the trial (<LINK REF="REF-Budzynski-2000" TYPE="REFERENCE">Budzynski 2000</LINK>), which mainly concerns effects on laboratory values has additionally been used for data extraction</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2010-10-15 14:25:03 +0200" MODIFIED_BY="Laura Amato" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2010-10-15 14:25:03 +0200" MODIFIED_BY="Laura Amato" STUDY_ID="STD-Buri-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-15 14:25:03 +0200" MODIFIED_BY="Laura Amato">
<P>open trial; non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-19 10:25:49 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Caputo-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-19 10:25:49 +0200" MODIFIED_BY="[Empty name]">
<P>open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-25 22:17:24 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Caputo-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-25 22:17:24 +0100" MODIFIED_BY="[Empty name]">
<P>open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-25 22:25:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Carroll-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-25 22:25:03 +0100" MODIFIED_BY="[Empty name]">
<P>open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-10-15 14:24:53 +0200" MODIFIED_BY="Laura Amato" STUDY_ID="STD-Croop-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-10-15 14:24:53 +0200" MODIFIED_BY="Laura Amato">
<P>open trial; non-randomised</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-19 10:26:21 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Davidson-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-19 10:26:21 +0200" MODIFIED_BY="[Empty name]">
<P>sample: hazardous drinkers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-23 22:18:51 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Davidson-2007a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-23 22:18:51 +0100" MODIFIED_BY="[Empty name]">
<P>no active or placebo control group (naltrexone + broad-spectrum treatment versus naltrexone + MET)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-19 11:32:10 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Davidson-2007b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-19 11:32:10 +0200" MODIFIED_BY="[Empty name]">
<P>multiphase study, starting with open-label naltrexone treatment in the intervention and control group</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-19 10:31:33 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-De-Sousa-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-19 10:31:33 +0200" MODIFIED_BY="[Empty name]">
<P>open trial </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-19 10:31:39 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Deas-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-19 10:31:39 +0200" MODIFIED_BY="[Empty name]">
<P>open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-11 11:24:05 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Drobes-2000">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-11 11:24:05 +0200" MODIFIED_BY="[Empty name]">
<P>treatment duration: 7 days (laboratory study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-25 22:46:59 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Drobes-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-25 22:46:59 +0100" MODIFIED_BY="[Empty name]">
<P>treatment duration: 7 days (laboratory study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-29 18:11:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Dunbar-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-29 18:11:53 +0100" MODIFIED_BY="[Empty name]">
<P>sample: healthy patients (pharmacokinetic study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-25 22:28:26 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Farren-2009">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-25 22:28:26 +0100" MODIFIED_BY="[Empty name]">
<P>no active or placebo control for naltrexone (naltrexone + sertraline placebo versus naltrexone + sertraline)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-19 10:59:50 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Galloway-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-19 10:59:50 +0200" MODIFIED_BY="[Empty name]">
<P>open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-19 11:00:01 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hermos-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-19 11:00:01 +0200" MODIFIED_BY="[Empty name]">
<P>open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-19 11:00:20 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Hernandez_x002d_Avila-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-19 11:00:20 +0200" MODIFIED_BY="[Empty name]">
<P>sample: problem drinkers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-11 11:30:25 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-11 11:30:25 +0200" MODIFIED_BY="[Empty name]">
<P>treatment duration: 23 days (pharmacokinetic study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-19 11:00:54 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Karhuvaara-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-19 11:00:54 +0200" MODIFIED_BY="[Empty name]">
<P>sample: heavy drinkers </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-22 10:06:30 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Knox-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-22 10:06:30 +0200" MODIFIED_BY="[Empty name]">
<P>treatment duration: 21 days</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-19 11:04:51 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kranzler-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-19 11:04:51 +0200" MODIFIED_BY="[Empty name]">
<P>sample: problem drinkers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-11 11:26:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kranzler-2004a">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-11 11:26:32 +0200" MODIFIED_BY="[Empty name]">
<P>treatment duration: 7 days (laboratory study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-19 11:04:48 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kranzler-2004b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-19 11:04:48 +0200" MODIFIED_BY="[Empty name]">
<P>sample: problem drinkers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-25 22:32:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Kranzler-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-25 22:32:07 +0100" MODIFIED_BY="[Empty name]">
<P>open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-25 22:32:56 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Laaksonen-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-25 22:32:56 +0100" MODIFIED_BY="[Empty name]">
<P>open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-19 11:06:02 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Landabaso-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-19 11:06:02 +0200" MODIFIED_BY="[Empty name]">
<P>open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-19 11:07:26 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Martinotti-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-19 11:07:26 +0200" MODIFIED_BY="[Empty name]">
<P>open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-29 18:11:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mason-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-29 18:11:54 +0100" MODIFIED_BY="[Empty name]">
<P>sample: healthy patients (pharmacokinetic study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-25 22:34:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Modesto_x002d_Lowe-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-25 22:34:35 +0100" MODIFIED_BY="[Empty name]">
<P>treatment duration: 7 days (laboratory study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-11 11:33:41 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Myrick-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-11 11:33:41 +0200" MODIFIED_BY="[Empty name]">
<P>treatment duration: 7 days (laboratory study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-19 11:08:04 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Nava-2006">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-19 11:08:04 +0200" MODIFIED_BY="[Empty name]">
<P>open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-19 11:13:09 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x0027_Malley-2003">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-19 11:13:09 +0200" MODIFIED_BY="[Empty name]">
<P>multiphase study, starting with open-label naltrexone treatment in the intervention and control group </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-11 11:37:05 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ooteman-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-11 11:37:05 +0200" MODIFIED_BY="[Empty name]">
<P>treatment duration: 21 days</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-19 11:13:42 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oslin-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-19 11:13:42 +0200" MODIFIED_BY="[Empty name]">
<P>open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-25 22:36:33 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Palfai-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-25 22:36:33 +0100" MODIFIED_BY="[Empty name]">
<P>sample: hazardous drinkers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-19 11:14:59 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ponce-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-19 11:14:59 +0200" MODIFIED_BY="[Empty name]">
<P>single-blinded</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-19 11:15:15 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Ray-2007">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-19 11:15:15 +0200" MODIFIED_BY="[Empty name]">
<P>sample: heavy drinkers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-12-25 22:52:07 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rubio-2001">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-12-25 22:52:07 +0100" MODIFIED_BY="[Empty name]">
<P>single-blind</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-19 11:15:58 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rubio-2002">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-19 11:15:58 +0200" MODIFIED_BY="[Empty name]">
<P>open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-09-11 11:09:16 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Rubio-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-09-11 11:09:16 +0200" MODIFIED_BY="[Empty name]">
<P>single-blinded </P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-19 11:16:19 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Stella-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-19 11:16:19 +0200" MODIFIED_BY="[Empty name]">
<P>open trial</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-19 11:16:32 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tidey-2008">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-19 11:16:32 +0200" MODIFIED_BY="[Empty name]">
<P>sample: heavy drinkers</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-07-19 11:19:34 +0200" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Tucker-2004">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-07-19 11:19:34 +0200" MODIFIED_BY="[Empty name]">
<P>no active or placebo control group (naltrexone + group counselling program versus naltrexone + structured treatment program)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2010-01-29 18:11:54 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Turncliff-2005">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2010-01-29 18:11:54 +0100" MODIFIED_BY="[Empty name]">
<P>sample: hepatic impaired patients (pharmacokinetic study)</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2008-08-08 07:59:39 +0200" MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES MODIFIED="2010-01-29 17:45:58 +0100" MODIFIED_BY="[Empty name]" NOTES="&lt;p&gt;Last search: 04 12 2008; name of the principal investigator is used as a study ID. If the name of the PI is not mentioned, than the organization ID is used. &lt;/p&gt;" NOTES_MODIFIED="2010-01-29 17:45:58 +0100" NOTES_MODIFIED_BY="[Empty name]" SORT_BY="STUDY" USER_DEF_1_ENABLED="YES" USER_DEF_1_NAME="Principal investigator" USER_DEF_2_ENABLED="YES" USER_DEF_2_NAME="Collaborators" USER_DEF_3_ENABLED="YES" USER_DEF_3_NAME="Sponsor">
<ONGOING_CHAR MODIFIED="2008-12-06 16:22:25 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-ALK21_x002d_010">
<CHAR_STUDY_NAME MODIFIED="2008-12-06 16:18:53 +0100" MODIFIED_BY="[Empty name]">
<P>Long-Term Safety Study of Naltrexone Long Acting Injection in Alcohol Dependent Adults</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-12-06 16:20:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-control, parallel assignment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-06 16:20:44 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-06 16:21:11 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone (extended release) and Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-06 16:20:22 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Long-term safety</LI>
<LI>Social functioning</LI>
<LI>Healthcare utilization</LI>
<LI>Drinking behaviour</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-12-06 16:21:22 +0100" MODIFIED_BY="[Empty name]">
<P>October 2003</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-12-06 16:22:19 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-12-06 16:22:23 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-06 16:22:25 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-12-06 16:22:17 +0100" MODIFIED_BY="[Empty name]">
<P>Alkermes</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-12-06 16:21:49 +0100" MODIFIED_BY="[Empty name]">
<P>Completion date: January 2007</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-12-06 10:38:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Anton-2009">
<CHAR_STUDY_NAME MODIFIED="2008-11-13 14:09:35 +0100" MODIFIED_BY="[Empty name]">
<P>Effectiveness of Gabapentin When Used With Naltrexone to Treat Alcohol Dependence Compared to Placebo and Naltrexone Alone</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-13 14:15:11 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-control, factorial assignment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-13 14:15:23 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-13 14:15:45 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone, gabapentin, placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-06 10:37:31 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to relapse to drinking</LI>
<LI>Percent days drinking</LI>
<LI>Drinks per drinking dayRetention in the protocol</LI>
<LI>Craving for alcohol</LI>
<LI>CDT and GGT</LI>
<LI>Psychological and general health functioning</LI>
<LI>Consequences of drinking</LI>
<LI>Urinary riboflavin</LI>
<LI>Liver function tests (ALT and AST)</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-11-13 14:17:10 +0100" MODIFIED_BY="[Empty name]">
<P>January 2003</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-11-13 14:17:47 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-11-13 14:18:18 +0100" MODIFIED_BY="[Empty name]">
<P>Raymond F. Anton, MD, Medical University of South Carolina    </P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-06 10:38:12 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-12-06 10:37:28 +0100" MODIFIED_BY="[Empty name]">
<P>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-12-06 10:38:28 +0100" MODIFIED_BY="[Empty name]">
<P>completion date: April 2009 </P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-12-06 10:56:11 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Batki-2007">
<CHAR_STUDY_NAME MODIFIED="2008-11-13 14:04:20 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone Treatment of Alcohol Abuse in Schizophrenia</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-13 14:04:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-control, single group assignment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-13 14:05:43 +0100" MODIFIED_BY="[Empty name]">
<P>Patients with alcohol abuse or alcohol dependence and with schizophrenia or schizoaffective disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-13 14:06:19 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone vs. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-13 14:06:41 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Measures of Alcohol Use</LI>
<LI>Psychiatric Symptom Severity</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-11-13 14:06:54 +0100" MODIFIED_BY="[Empty name]">
<P>April 2003</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-11-13 14:07:35 +0100" MODIFIED_BY="[Empty name]">
<P>Steven L Batki, M.D.    <A HREF="mailto:batkis%40upstate.edu">batkis@upstate.edu</A>  </P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-11-13 14:08:02 +0100" MODIFIED_BY="[Empty name]">
<P>Steven L Batki, MD, State University of New York, Upstate Medical University    </P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-06 10:56:11 +0100" MODIFIED_BY="[Empty name]">
<P>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-11-13 14:08:15 +0100" MODIFIED_BY="[Empty name]">
<P>State University of New York - Upstate Medical University</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-12-06 10:55:45 +0100" MODIFIED_BY="[Empty name]">
<P>Related publication: PMID: 18701256; no NTX vs. PBO results provided: completion date: October 2007</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-12-06 11:31:17 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Brown">
<CHAR_STUDY_NAME MODIFIED="2008-11-13 17:30:40 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone for Bipolar Disorder and Alcohol Dependence</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-13 17:17:01 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-control, crossover assignment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-13 19:43:35 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients with concurrent bipolar disorder (I or II) </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-13 17:17:56 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone vs. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-13 17:18:24 +0100" MODIFIED_BY="[Empty name]">
<P>--- </P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-11-13 17:18:34 +0100" MODIFIED_BY="[Empty name]">
<P>May 2005</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-11-13 17:18:49 +0100" MODIFIED_BY="[Empty name]">
<P>----</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-11-13 17:19:01 +0100" MODIFIED_BY="[Empty name]">
<P>Edson S Brown, MD, PhD, UT Southwestern Medical Center Dallas    </P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-06 11:30:45 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-11-13 17:29:16 +0100" MODIFIED_BY="[Empty name]">
<P>University of Texas Southwestern Medical Center</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-12-06 11:31:17 +0100" MODIFIED_BY="[Empty name]">
<P>In PubMed only a open label study from the author is published (PMID: 16841344); no completion date mentioned</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-01-29 17:45:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Foa-2009">
<CHAR_STUDY_NAME MODIFIED="2008-11-13 20:14:00 +0100" MODIFIED_BY="[Empty name]">
<P>Treatment for Alcoholism and Post-Traumatic Stress Disorder (Naltrexone)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-01-29 17:45:45 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled, factorial assignment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-06 20:27:51 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients with post-traumatic stress disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-13 20:15:08 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone vs. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-13 20:16:12 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Drinking frequency and amount (TLFB)</LI>
<LI>PTSD Symptom Scale</LI>
<LI>Beck Depression Inventory</LI>
<LI>Penn Alcohol Cravings Scale</LI>
<LI>Sheehan Disability Scale</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-11-13 20:16:34 +0100" MODIFIED_BY="[Empty name]">
<P>December 2000</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-12-06 20:28:29 +0100" MODIFIED_BY="[Empty name]">
<P>Edna B. Foa, PhD <A HREF="mailto:foa%40mail.med.upenn.edu">foa@mail.med.upenn.edu</A>   </P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-11-13 20:18:15 +0100" MODIFIED_BY="[Empty name]">
<P>Edna B. Foa, PhD     University of Pennsylvania    </P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-06 20:28:27 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-11-13 20:18:23 +0100" MODIFIED_BY="[Empty name]">
<P>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-12-06 20:28:12 +0100" MODIFIED_BY="[Empty name]">
<P>Conpletion date: January 2009</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-12-06 10:41:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Garbutt-2009">
<CHAR_STUDY_NAME MODIFIED="2008-11-13 19:43:41 +0100" MODIFIED_BY="[Empty name]">
<P>Combination of Naltrexone and Baclofen for Alcohol Dependence: A Pilot Study</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-13 13:51:00 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled, parallel assignment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-13 13:51:04 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-13 13:51:23 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone, Baclofen, Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-13 13:53:38 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Retention of study</LI>
<LI>Compliance</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-11-13 13:53:53 +0100" MODIFIED_BY="[Empty name]">
<P>July 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-11-13 13:54:46 +0100" MODIFIED_BY="[Empty name]">
<P>Linda S Kalka-Juhl  <A HREF="mailto:lkjuhl%40med.unc.edu">lkjuhl@med.unc.edu</A>  </P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-11-13 13:56:09 +0100" MODIFIED_BY="[Empty name]">
<P>James C Garbutt, M.D., The University of North Carolina, Chapel Hill</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-06 10:41:53 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-11-13 13:56:23 +0100" MODIFIED_BY="[Empty name]">
<P>University of North Carolina</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-12-06 10:40:44 +0100" MODIFIED_BY="[Empty name]">
<P>Completion date: March 2009</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-01-29 17:45:47 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Grabowski-2007">
<CHAR_STUDY_NAME MODIFIED="2008-12-06 15:38:55 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone as Adjunct in Alcoholic Cocaine Dependent Patients</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-12-06 15:40:00 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-29 17:45:47 +0100" MODIFIED_BY="[Empty name]">
<P>alcohol dependent patients with concurrent cocaine dependence</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-06 15:41:36 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone, placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-06 15:39:18 +0100" MODIFIED_BY="[Empty name]">
<P>Verified abstinence from cocaine</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-12-06 15:41:46 +0100" MODIFIED_BY="[Empty name]">
<P>April 2003</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-12-06 15:42:21 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-12-06 15:42:45 +0100" MODIFIED_BY="[Empty name]">
<P>John Grabowski, Ph.D.     University of Texas      </P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-06 15:42:18 +0100" MODIFIED_BY="[Empty name]">
<P>University of Texas</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-12-06 15:42:05 +0100" MODIFIED_BY="[Empty name]">
<P>National Institute on Drug Abuse (NIDA)</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-12-06 15:43:16 +0100" MODIFIED_BY="[Empty name]">
<P>Completion date: April 2007</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-12-06 18:06:09 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Haber-2005">
<CHAR_STUDY_NAME MODIFIED="2008-12-06 18:02:15 +0100" MODIFIED_BY="[Empty name]">
<P>Trial for the Treatment of Alcohol Dependence</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-12-06 18:03:24 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-control, parallel assignment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-06 18:03:10 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-06 18:03:39 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone, acamprosate</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-06 18:05:20 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time (days) to relapse</LI>
<LI>Time (days) to lapse</LI>
<LI>Days abstinence</LI>
<LI>Drinks per drinking day</LI>
<LI>Biochemical measures of liver function</LI>
<LI>Secondary Outcome Measure </LI>
<LI>Craving</LI>
<LI>Depression</LI>
<LI>Anxiety</LI>
<LI>Stress</LI>
<LI>Global physical health</LI>
<LI>Global mental health   </LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-12-06 18:03:58 +0100" MODIFIED_BY="[Empty name]">
<P>March 2003</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-12-06 18:04:52 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-12-06 18:04:50 +0100" MODIFIED_BY="[Empty name]">
<P>Paul Haber, MBBAMDFRACP, Conjoint Associate Professor</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-06 18:05:03 +0100" MODIFIED_BY="[Empty name]">
<P>National Health and Medical Research Council, Australia<BR/>Sydney South West Area Health Service<BR/>South Eastern Area Health Service<BR/>Wentworth Area Health Services</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-12-06 18:05:13 +0100" MODIFIED_BY="[Empty name]">
<P>University of Sydney</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-12-06 18:06:09 +0100" MODIFIED_BY="[Empty name]">
<P>Completion date: June 2005</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-12-06 16:37:44 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson">
<CHAR_STUDY_NAME MODIFIED="2008-12-06 16:34:59 +0100" MODIFIED_BY="[Empty name]">
<P>Combined Pharmacotherapies for Alcoholism (Naltrexone/Ondansetron)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-12-06 16:35:21 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-06 16:35:53 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-06 16:36:37 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone, ondansetron</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-06 16:37:36 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-12-06 16:36:55 +0100" MODIFIED_BY="[Empty name]">
<P>September 2001</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-12-06 16:37:41 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-12-06 16:37:43 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-06 16:37:44 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-12-06 16:37:34 +0100" MODIFIED_BY="[Empty name]">
<P>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-12-06 16:37:11 +0100" MODIFIED_BY="[Empty name]">
<P>Completion date: August 2004</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-12-06 20:35:03 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Johnson-2009">
<CHAR_STUDY_NAME MODIFIED="2008-11-14 10:29:17 +0100" MODIFIED_BY="[Empty name]">
<P>Combining Medications for the Treatment of Alcohol Dependence: An Inpatient Preliminary Study</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-14 10:29:54 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-control, cross-over assignment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-14 10:31:28 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-06 16:26:22 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone, Topiramate, Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-14 10:32:29 +0100" MODIFIED_BY="[Empty name]">
<P>Safety and efficacy</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-11-14 10:32:41 +0100" MODIFIED_BY="[Empty name]">
<P>October 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-12-06 20:32:56 +0100" MODIFIED_BY="[Empty name]">
<P>Mindy Borszich  <A HREF="mailto:uvacare%40virginia.edu">uvacare@virginia.edu</A>    </P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-12-06 20:35:03 +0100" MODIFIED_BY="[Empty name]">
<P>Bankole Johnson, DSc,MD.PhD, University of Virginia    </P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-06 20:34:55 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-11-14 10:33:55 +0100" MODIFIED_BY="[Empty name]">
<P>University of Virginia</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-12-06 20:32:02 +0100" MODIFIED_BY="[Empty name]">
<P>Completion date: December 2009</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-12-25 18:14:28 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lundbeck-2010">
<CHAR_STUDY_NAME MODIFIED="2008-12-25 18:10:28 +0100" MODIFIED_BY="[Empty name]">
<P>Safety of Nalmefene in Patients With Alcohol Dependence (SENSE)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-12-25 18:12:22 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-control, parallel assignment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-25 18:12:22 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-25 18:12:22 +0100" MODIFIED_BY="[Empty name]">
<P>Nalmefene, placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-25 18:14:28 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Adverse events</LI>
<LI>Clinical safety laboratory tests,</LI>
<LI>Vital signs, weight,</LI>
<LI>Body mass index, electrocardiograms,</LI>
<LI>Profile of moods states and physical examination</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-12-25 18:12:22 +0100" MODIFIED_BY="[Empty name]">
<P>December 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-12-25 18:12:22 +0100" MODIFIED_BY="[Empty name]">
<P>H. Lundbeck A/S                   LundbeckClinicalTrials@lundbeck.com   </P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-12-25 18:12:22 +0100" MODIFIED_BY="[Empty name]">
<P>--</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-25 18:12:22 +0100" MODIFIED_BY="[Empty name]">
<P>--</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-12-25 18:12:22 +0100" MODIFIED_BY="[Empty name]">
<P>H. Lundbeck A/S   </P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-12-25 18:12:59 +0100" MODIFIED_BY="[Empty name]">
<P>Completion date: November 2010</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-12-25 18:17:41 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Lundbeck-2011">
<CHAR_STUDY_NAME MODIFIED="2008-12-25 18:17:41 +0100" MODIFIED_BY="[Empty name]">
<P>Efficacy of Nalmefene in Patients With Alcohol Dependence (ESENSE1/2) </P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-12-25 17:45:06 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-control, parallel assignment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-25 17:45:28 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-25 17:45:40 +0100" MODIFIED_BY="[Empty name]">
<P>Nalmefene, placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-25 17:46:46 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Heavy drinking days</LI>
<LI>Total alcohol consumption</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-12-25 17:47:03 +0100" MODIFIED_BY="[Empty name]">
<P>December 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-12-25 17:47:57 +0100" MODIFIED_BY="[Empty name]">
<P>H. Lundbeck A/S                   LundbeckClinicalTrials@lundbeck.com   </P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-12-25 17:48:27 +0100" MODIFIED_BY="[Empty name]">
<P>--</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-25 17:48:36 +0100" MODIFIED_BY="[Empty name]">
<P>--</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-12-25 17:48:53 +0100" MODIFIED_BY="[Empty name]">
<P>H. Lundbeck A/S   </P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-12-25 17:49:59 +0100" MODIFIED_BY="[Empty name]">
<P>Completion date: February 2011</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-12-06 18:18:05 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mann-2008">
<CHAR_STUDY_NAME MODIFIED="2008-12-06 18:10:16 +0100" MODIFIED_BY="[Empty name]">
<P>Individually Adapted Therapy of Alcoholism</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-12-06 18:10:39 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-control, parallel assignment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-06 18:10:39 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-06 18:11:09 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone, acamprosate, placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-06 18:18:05 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Time to relapse to heavy drinking</LI>
<LI>Percentage of days without heavy drinking</LI>
<LI>Time to first alcohol consumption</LI>
<LI>Percentage of days of complete abstinence from alcohol</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-12-06 18:13:35 +0100" MODIFIED_BY="[Empty name]">
<P>November 2002</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-12-06 18:17:06 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-12-06 18:14:43 +0100" MODIFIED_BY="[Empty name]">
<P>Karl F. Mann, MD, Central Institute of Mental Health, J5, 68159 Mannheim, Germany         </P>
<P>Michael N. Smolka, MD, Central Institute of Mental Health, J5, 68159 Mannheim, Germany</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-06 18:16:45 +0100" MODIFIED_BY="[Empty name]">
<P>BMBF Federal Ministry of Education and Research<BR/>Merck<BR/>Dupont Pharmaceuticals</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-12-06 18:17:02 +0100" MODIFIED_BY="[Empty name]">
<P>Central Institute of Mental Health, Mannheim</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-12-06 18:10:39 +0100" MODIFIED_BY="[Empty name]"/>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-12-06 15:10:36 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mann-2010">
<CHAR_STUDY_NAME MODIFIED="2008-12-06 15:04:26 +0100" MODIFIED_BY="[Empty name]">
<P>Efficacy and Safety of Vivitrol® After Enforced Abstinence</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-12-06 15:05:39 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-control, parallel assignment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-06 15:05:46 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-06 15:06:10 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone (extended-release) vs. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-06 15:08:04 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Heavy drinking days</LI>
<LI>Percent heavy drinking days</LI>
<LI>Percent days abstinent</LI>
<LI>Days to first drinking day</LI>
<LI>Days to first heavy drinking</LI>
<LI>Obsessive-Compulsive Drinking Scale scores</LI>
<LI>Gamma glutamyl-transferase levels</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-12-06 15:08:19 +0100" MODIFIED_BY="[Empty name]">
<P>July 2007</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-12-06 15:08:56 +0100" MODIFIED_BY="[Empty name]">
<P>Petra Falkenstein    falkenstein.petra@kendle.com    </P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-12-06 15:09:50 +0100" MODIFIED_BY="[Empty name]">
<P>Karl Mann, Prof, MD, University of Heidelberg  (Study Chair)</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-06 15:10:01 +0100" MODIFIED_BY="[Empty name]">
<P>Kendle International</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-12-06 15:10:15 +0100" MODIFIED_BY="[Empty name]">
<P>Alkermes</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-12-06 15:10:36 +0100" MODIFIED_BY="[Empty name]">
<P>Completion date: August 2010</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2009-01-14 12:06:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Mason">
<CHAR_STUDY_NAME MODIFIED="2008-12-06 17:16:59 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone Maintenance Treatment of Alcoholism</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-12-06 17:17:59 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-06 17:17:59 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-06 17:17:59 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone, Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-06 17:18:22 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-12-06 17:18:27 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-12-06 17:18:29 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-12-06 17:18:31 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-06 17:18:32 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-12-06 17:18:14 +0100" MODIFIED_BY="[Empty name]">
<P>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2009-01-14 12:06:45 +0100" MODIFIED_BY="[Empty name]">
<P>April 2002</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-01-29 17:45:49 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-O_x0027_Brien-2007">
<CHAR_STUDY_NAME MODIFIED="2008-12-06 11:07:55 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence - 1</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-12-06 11:08:04 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-29 17:45:49 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients with concurrent cocaine dependence</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-06 11:08:24 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone, Placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-06 11:08:55 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol and Cocaine use </P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-12-06 11:09:14 +0100" MODIFIED_BY="[Empty name]">
<P>April 1998</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-12-06 11:10:09 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-12-06 11:09:58 +0100" MODIFIED_BY="[Empty name]">
<P>Charles O'Brien, M.D., Ph.D.     University of Pennsylvania    </P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-06 11:10:39 +0100" MODIFIED_BY="[Empty name]">
<P>University of Pennsylvania</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-12-06 11:10:30 +0100" MODIFIED_BY="[Empty name]">
<P>National Institute on Drug Abuse (NIDA)</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-12-06 11:26:07 +0100" MODIFIED_BY="[Empty name]">
<P>Completion date: November 2007</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-12-06 10:50:45 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Oslin-2008b">
<CHAR_STUDY_NAME MODIFIED="2008-11-14 17:35:48 +0100" MODIFIED_BY="[Empty name]">
<P>Managing Alcoholism in People Who Do Not Respond to Naltrexone (EXTEND)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-14 17:36:16 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-control, parallel assignment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-14 17:36:16 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-14 17:36:25 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone vs. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-14 17:37:06 +0100" MODIFIED_BY="[Empty name]">
<P>Reduction in alcohol use</P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-11-14 17:37:16 +0100" MODIFIED_BY="[Empty name]">
<P>September 2003</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-11-14 17:37:23 +0100" MODIFIED_BY="[Empty name]">
<P>----</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-11-14 17:37:49 +0100" MODIFIED_BY="[Empty name]">
<P>David W. Oslin, M.D.    University of Pennsylvania    </P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-06 10:50:24 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-11-14 17:36:42 +0100" MODIFIED_BY="[Empty name]">
<P>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-12-06 10:50:45 +0100" MODIFIED_BY="[Empty name]">
<P>Cpmpletion data: September 2008</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-12-06 21:01:46 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Petrakis-2009">
<CHAR_STUDY_NAME MODIFIED="2008-11-14 17:39:28 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone &amp; SSRI in Alcoholics With Depression/PTSD</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-12-06 20:58:34 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-control, parallel assignment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-06 20:58:34 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-06 20:58:34 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone, paroxetine, desipramine, placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-06 21:00:37 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Alcohol consumption</LI>
<LI>Craving</LI>
<LI>Psychiatric and emotional distress</LI>
<LI>Psychiatric symptoms of depression and PTSD</LI>
<LI>Side effects</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-12-06 20:58:49 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-control</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-12-06 20:59:27 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients with comorbid PTSD and depression</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-12-06 20:57:49 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone, paroxetine, desipramine, placebo</P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-06 21:01:16 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-12-06 21:01:27 +0100" MODIFIED_BY="[Empty name]">
<P>Yale University</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-12-06 21:01:46 +0100" MODIFIED_BY="[Empty name]">
<P>Completion date: August 2009</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-01-29 17:45:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pettinati-2009">
<CHAR_STUDY_NAME MODIFIED="2008-12-06 17:49:37 +0100" MODIFIED_BY="[Empty name]">
<P>Sertraline for Alcohol Dependence and Depression</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2010-01-29 17:45:52 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-control, factorial assignment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-29 17:45:53 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients with concurrent cocaine dependence</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-06 17:50:25 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone, sertraline, placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-06 17:50:57 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Alcohol use</LI>
<LI>Depressive symptoms</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-12-06 17:51:10 +0100" MODIFIED_BY="[Empty name]">
<P>January 2000</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-12-06 17:52:53 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-12-06 17:52:51 +0100" MODIFIED_BY="[Empty name]">
<P>Helen Pettinati, PhD                  University of Pennsylvania         </P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-06 17:53:51 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-12-06 17:54:06 +0100" MODIFIED_BY="[Empty name]">
<P>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-12-06 17:51:28 +0100" MODIFIED_BY="[Empty name]">
<P>Completion date: April 2009</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-01-29 17:45:55 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Pettinati-2012">
<CHAR_STUDY_NAME MODIFIED="2008-11-13 15:40:35 +0100" MODIFIED_BY="[Empty name]">
<P>Extended-Release Injectable Naltrexone as a Treatment for Alcohol and Cocaine Dependence</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-13 16:43:55 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-control, single group assignment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-29 17:45:55 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients with concurrent cocaine dependence</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-13 17:02:10 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone extended-release vs. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-13 17:06:29 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Days of abstinence from drinking (TLFB)</LI>
<LI>urine assay for benzoylecgonine (BE)</LI>
<LI>craving</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-11-13 17:06:41 +0100" MODIFIED_BY="[Empty name]">
<P>November 2008</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-11-13 17:06:57 +0100" MODIFIED_BY="[Empty name]">
<P>Donna Simpson    </P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-11-13 17:09:34 +0100" MODIFIED_BY="[Empty name]">
<P>Helen Pettinati, Ph.D., University of Pennsylvania    </P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-06 17:56:43 +0100" MODIFIED_BY="[Empty name]">
<P>University of Pennsylvania<BR/>Alkermes</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-11-13 17:09:47 +0100" MODIFIED_BY="[Empty name]">
<P>National Institute on Drug Abuse (NIDA)</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-12-06 17:57:24 +0100" MODIFIED_BY="[Empty name]">
<P>Completion date: November 2012</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-12-06 17:43:35 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salloum">
<CHAR_STUDY_NAME MODIFIED="2008-11-14 10:36:54 +0100" MODIFIED_BY="[Empty name]">
<P>Drug Treatment for Depressed Alcoholics (Naltrexone/Fluoxetine)</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-12-06 15:30:33 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, controlled, parallel assignment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-14 10:45:04 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients with comorbid major depressive disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-06 17:43:35 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone + fluoxetine, fluoxetine alone</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-14 10:46:02 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Alcohol us (TLFB)</LI>
<LI>Hamilton Rating Scale for Depression</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-11-14 10:46:16 +0100" MODIFIED_BY="[Empty name]">
<P>March 2000</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-11-14 10:46:25 +0100" MODIFIED_BY="[Empty name]">
<P>----</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-11-14 10:46:51 +0100" MODIFIED_BY="[Empty name]">
<P>Ihsan M. Salloum, MD     Western Psychiatric Institute, Clinic of the University of Pittsburgh Medical Center, Pittsburgh, PA    </P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-06 15:34:43 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-11-14 10:47:30 +0100" MODIFIED_BY="[Empty name]">
<P>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-12-06 15:34:16 +0100" MODIFIED_BY="[Empty name]">
<P>not identified in PubMed; Completion date: January 2006</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-12-06 17:47:42 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Salloum-2007">
<CHAR_STUDY_NAME MODIFIED="2008-12-06 17:42:05 +0100" MODIFIED_BY="[Empty name]">
<P>Optimizing Pharmacotherapy for Bipolar Alcoholics</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-12-06 17:43:51 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, controlled, parallel assignment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-12-06 17:44:10 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients with comorbid bipolar disorder</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-06 17:44:36 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone + valproate, valproate</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-12-06 17:45:38 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Quantity of alcohol consumption</LI>
<LI>Frequency of alcohol consumption</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-12-06 17:45:51 +0100" MODIFIED_BY="[Empty name]">
<P>May 2006</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-12-06 17:47:25 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-12-06 17:46:57 +0100" MODIFIED_BY="[Empty name]">
<P>Ihsan M Salloum, MD, MPH     UPMC and University of Pittsburgh    </P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-06 17:47:16 +0100" MODIFIED_BY="[Empty name]">
<P>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-12-06 17:47:20 +0100" MODIFIED_BY="[Empty name]">
<P>University of Pittsburgh</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-12-06 17:47:42 +0100" MODIFIED_BY="[Empty name]">
<P>Completion date: March 2007</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2010-01-29 17:45:58 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Schmitz">
<CHAR_STUDY_NAME MODIFIED="2008-11-13 20:56:43 +0100" MODIFIED_BY="[Empty name]">
<P>Combined Treatment for Cocaine-Alcohol Dependence - 1</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-13 20:57:08 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-control, single group assignment</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2010-01-29 17:45:58 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patients with concurrent cocaine dependence</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-12-06 17:19:43 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone, placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-13 20:57:53 +0100" MODIFIED_BY="[Empty name]">
<P>Urine toxicology for cocaine </P>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-11-13 20:58:09 +0100" MODIFIED_BY="[Empty name]">
<P>April 2003</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-11-13 20:59:01 +0100" MODIFIED_BY="[Empty name]">
<P>----</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-11-13 20:58:49 +0100" MODIFIED_BY="[Empty name]">
<P>Joy Schmitz, Ph.D., The University of Texas Health Science Center, Houston  </P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-06 17:20:22 +0100" MODIFIED_BY="[Empty name]">
<P>The University of Texas Health Science Center, Houston</P>
</CHAR_USER_DEF_2>
<CHAR_USER_DEF_3 MODIFIED="2008-11-13 20:59:08 +0100" MODIFIED_BY="[Empty name]">
<P>National Institute on Drug Abuse (NIDA)</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-12-06 17:20:50 +0100" MODIFIED_BY="[Empty name]">
<P>only a older study was identified in PubMed PMID: 15370932; completion date: December 2007</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<ONGOING_CHAR MODIFIED="2008-12-06 10:59:53 +0100" MODIFIED_BY="[Empty name]" STUDY_ID="STD-Toneatto">
<CHAR_STUDY_NAME MODIFIED="2008-11-13 17:23:35 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone in the Treatment of Concurrent Alcohol Dependence and Pathological Gambling</P>
</CHAR_STUDY_NAME>
<CHAR_METHODS MODIFIED="2008-11-13 19:38:58 +0100" MODIFIED_BY="[Empty name]">
<P>Randomized, double-blind, placebo-controlled</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2008-11-13 19:44:43 +0100" MODIFIED_BY="[Empty name]">
<P>Alcohol dependent patient with concurrent pathological gambling</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2008-11-13 19:38:30 +0100" MODIFIED_BY="[Empty name]">
<P>Naltrexone vs. placebo</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2008-11-13 19:37:57 +0100" MODIFIED_BY="[Empty name]">
<OL>
<LI>Frequency of drinking/gambling</LI>
<LI>Amount of drinking/gambling</LI>
<LI>Gambling Urge Questionnaire</LI>
<LI>Obsessive Compulsive Drinking Scale</LI>
<LI>Readiness to Change Questionnaire</LI>
<LI>Money spent of gambling</LI>
</OL>
</CHAR_OUTCOMES>
<CHAR_STARTING_DATE MODIFIED="2008-12-06 10:59:53 +0100" MODIFIED_BY="[Empty name]">
<P>June 2001</P>
</CHAR_STARTING_DATE>
<CHAR_CONTACT_INFORMATION MODIFIED="2008-12-06 10:59:10 +0100" MODIFIED_BY="[Empty name]">
<P>---</P>
</CHAR_CONTACT_INFORMATION>
<CHAR_USER_DEF_1 MODIFIED="2008-11-13 19:45:43 +0100" MODIFIED_BY="[Empty name]">
<P>Tony Toneatto, PhD,   Centre for Addiction and Mental Health  </P>
</CHAR_USER_DEF_1>
<CHAR_USER_DEF_2 MODIFIED="2008-12-06 10:59:05 +0100" MODIFIED_BY="[Empty name]"/>
<CHAR_USER_DEF_3 MODIFIED="2008-11-13 19:46:22 +0100" MODIFIED_BY="[Empty name]">
<P>Centre for Addiction and Mental Health</P>
</CHAR_USER_DEF_3>
<CHAR_NOTES MODIFIED="2008-12-06 10:59:27 +0100" MODIFIED_BY="[Empty name]">
<P>Not identified with PubMed; completion date: June 2004</P>
</CHAR_NOTES>
</ONGOING_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2010-10-15 14:24:37 +0200" MODIFIED_BY="Laura Amato">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2010-10-15 14:24:37 +0200" MODIFIED_BY="Laura Amato" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-21 10:32:49 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ahmadi-2002">
<DESCRIPTION>
<P>Patients were stratified to dose and duration of drinking alcohol; no further details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 09:40:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anton-1999">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 09:43:13 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anton-2004">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 09:43:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anton-2005">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 09:43:56 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anton-2006">
<DESCRIPTION>
<P>Participants are randomly assigned to treatment by a stratified random block design controlling for clinical centres; the randomization was implemented via a central telephone based interactive voice response system at a coordinating centre</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 17:24:27 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Auriacombe-2000">
<DESCRIPTION>
<P>Randomized; no information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-15 14:17:15 +0200" MODIFIED_BY="Laura Amato" RESULT="YES" STUDY_ID="STD-Balldin-2003">
<DESCRIPTION>
<P>A randomisation list was used to assign the patient numbers to either of the two study medications</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 09:47:02 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baltieri-2008">
<DESCRIPTION>
<P>The random sequence was generated by a computer random generator (information provided by the investigator)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-15 14:17:47 +0200" MODIFIED_BY="Laura Amato" RESULT="YES" STUDY_ID="STD-Brown-2009">
<DESCRIPTION>
<P>Randomization was performed with computerized randomisation procedures (randomizer.org)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 09:48:56 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chick-2000">
<DESCRIPTION>
<P>Randomization was stratified according to diagnosis based on DSM-II-R criteria; no further details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 09:49:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Galarza-1997">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-15 14:18:14 +0200" MODIFIED_BY="Laura Amato" RESULT="YES" STUDY_ID="STD-Garbutt-2005">
<DESCRIPTION>
<P>The study used a dynamic randomisation procedure based on the coin principle</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:11:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gastpar-2002">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:12:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guardia-2002">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:12:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hein_x00e4_l_x00e4_-2001">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:13:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hersh-1998">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:13:16 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2005">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:13:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Johnson-2000">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-15 14:20:02 +0200" MODIFIED_BY="Laura Amato" RESULT="UNKNOWN" STUDY_ID="STD-Johnson-2004">
<DESCRIPTION>
<P>Eligible patients were randomised in a 5:1 ratio to either naltrexone or placebo; no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-18 17:26:46 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kiefer-2003">
<DESCRIPTION>
<P>Randomization was organized with a computer-generated list</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-19 10:36:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Killeeen-2004">
<DESCRIPTION>
<P>Urn randomization</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:14:44 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kranzler-1998">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:15:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kranzler-2000">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:15:22 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kranzler-2004">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:15:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Krystal-2001">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:15:49 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Latt-2002">
<DESCRIPTION>
<P>Patients were assigned by computer-generated random numbers to naltrexone or placebo (information provided by the investigator) </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:16:23 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lee-2001">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-15 14:21:22 +0200" MODIFIED_BY="Laura Amato" RESULT="YES" STUDY_ID="STD-Martinotti-2008">
<DESCRIPTION>
<P>Random assignment was achieved with an interactive voice-response central randomisation service</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:16:45 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mason-1994">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:16:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mason-1999">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:17:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Monterosso-2001">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:17:21 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Monti-2001">
<DESCRIPTION>
<P>Stratified random assignment was used to balance treatment conditions for sex and socialization scale scores; no further details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-15 14:21:54 +0200" MODIFIED_BY="Laura Amato" RESULT="YES" STUDY_ID="STD-Morley-2006">
<DESCRIPTION>
<P>Randomized; computer-generated randomisation lists (information provided by the investigator)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:18:51 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morris-2001">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:19:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Malley-1992">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:19:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Malley-2007">
<DESCRIPTION>
<P>Randomization was stratified by the presence or absence of eating disturbance and the use of antidepressant therapy was balanced across medication conditions; no further details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-15 14:22:55 +0200" MODIFIED_BY="Laura Amato" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Malley-2008">
<DESCRIPTION>
<P>Study participants were randomised to conditions in blocks of 12 within native and non-native groups and within study sites; no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:19:27 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oslin-1997">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:19:37 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oslin-2005">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-06 11:47:29 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oslin-2008">
<DESCRIPTION>
<P>Random numbers were generated in block sequences by a blinded statistician; no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:19:57 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Petrakis-2004">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:20:20 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Petrakis-2005">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:20:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pettinati-2008a">
<DESCRIPTION>
<P>Participants were stratified by gender and then randomly assigned to one of four treatment conditions; no further details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:20:35 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pettinati-2008b">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:21:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmitz-2004">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-15 14:24:03 +0200" MODIFIED_BY="Laura Amato" RESULT="YES" STUDY_ID="STD-Schmitz-2009">
<DESCRIPTION>
<P>Urn randomisation (information provided by the investigator)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:23:31 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volpicelli-1992">
<DESCRIPTION>
<P>Randomized; no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-18 11:10:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Volpicelli-1997">
<DESCRIPTION>
<P>Randomized in computer-generated blocks</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-15 14:24:37 +0200" MODIFIED_BY="Laura Amato" RESULT="YES" STUDY_ID="STD-Zi_x00f3__x0142_kowski-2000">
<DESCRIPTION>
<P>Computer randomisation (information provided by the investigator)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 09:39:00 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Goes-e-Castro-2004">
<DESCRIPTION>
<P>Seuquence was generated by a random number table</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2010-10-15 14:21:57 +0200" MODIFIED_BY="Laura Amato" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:25:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ahmadi-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:26:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anton-1999">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:26:09 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anton-2004">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:26:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anton-2005">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-30 13:13:59 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anton-2006">
<DESCRIPTION>
<P>Randomization was performed at the coordinating centre; no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 17:23:52 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Auriacombe-2000">
<DESCRIPTION>
<P>No information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-15 14:17:27 +0200" MODIFIED_BY="Laura Amato" RESULT="YES" STUDY_ID="STD-Balldin-2003">
<DESCRIPTION>
<P>The randomisation list was prepared by the manufacturer&#8217;s clinical operations staff, who delivered the trial medications labelled with consecutive numbers. The statistician who performed the randomisation knew the block size but was blinded to the randomisation code for drug treatments. Every patient received the assigned number and type of psychological therapy in a sealed black envelope, which was opened by the patient at the study site together with one of the local research staff on the randomisation day</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-01 16:22:50 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Baltieri-2008">
<DESCRIPTION>
<P>Two pharmacists from the pharmacy sector at the psychiatric institute knew which medication corresponded to the specific code. The packages containing the capsules were distributed to patients by two blinded research assistants. Medications codes were revealed to researchers only after all patients had completed the study (information provided by the investigator)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:28:01 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown-2009">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:28:12 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chick-2000">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:28:49 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Galarza-1997">
<DESCRIPTION>
<P>The pharmacy department administered the medication or placebo to the patients according to the numbers assigned; all medication or placebo were pre-packed and pre-numbers by DuPont-Pharma</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:32:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Garbutt-2005">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:33:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gastpar-2002">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:32:08 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guardia-2002">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-13 17:15:10 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hein_x00e4_l_x00e4_-2001">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-13 17:00:20 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hersh-1998">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-13 17:27:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2005">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:33:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Johnson-2000">
<DESCRIPTION>
<P>Ondansetron and naltrexone as well as their matching placebos were dispensed in two separate bottles numbered sequentially and labelled with subject identification number, study and visit numbers, and the date; no further details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-13 17:40:39 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Johnson-2004">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:34:17 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kiefer-2003">
<DESCRIPTION>
<P>Allocation codes were provided in sealed envelopes for each patient at the pharmacy of the university hospital, where formulation and blinding was conducted </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-13 18:06:41 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Killeeen-2004">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-01-29 18:11:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kranzler-1998">
<DESCRIPTION>
<P>A research pharmacist randomly assigned patients to a medication group, with double-blind conditions maintained throughout the study; no further details provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:35:47 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kranzler-2000">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 17:54:10 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kranzler-2004">
<DESCRIPTION>
<P>Patients were assigned to sequential medication kits that had been centrally randomized; no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:36:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Krystal-2001">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 17:58:19 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Latt-2002">
<DESCRIPTION>
<P>The chief pharmacist, who had no contact to the patients, packed up the active and placebo tablets (information provided by the investigator); no further information published</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-16 10:08:36 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lee-2001">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-16 10:21:25 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martinotti-2008">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 08:56:24 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mason-1994">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 09:31:43 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mason-1999">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:37:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Monterosso-2001">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 10:20:35 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Monti-2001">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-15 14:21:57 +0200" MODIFIED_BY="Laura Amato" RESULT="YES" STUDY_ID="STD-Morley-2006">
<DESCRIPTION>
<P>The randomisation was conducted by an independent support unit; prior to the start of the trial all medication packages were collated and packaged by a member of staff not involved in the study; each sealed envelope contained the medication and had a subject code, which corresponded to the allocation that was kept in a spreadsheet held by a member of staff not involved in the study; the naltrexone and naltrexone placebo were packaged similarly as were the acamprosate and acamprosate placebo<BR/>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:38:52 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morris-2001">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 11:02:52 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Malley-1992">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 11:13:40 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Malley-2007">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 11:22:54 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Malley-2008">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:39:02 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oslin-1997">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-05-12 16:01:25 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oslin-2005">
<DESCRIPTION>
<P>No detailed information provided.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-06-12 14:23:41 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oslin-2008">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:39:10 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Petrakis-2004">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-30 13:17:53 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Petrakis-2005">
<DESCRIPTION>
<P>Phamacist prepared medication (information provided by the investigator); no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:40:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pettinati-2008a">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 18:10:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pettinati-2008b">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:40:28 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmitz-2004">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-18 09:57:18 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmitz-2009">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-18 10:45:39 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volpicelli-1992">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-18 11:10:14 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volpicelli-1997">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:40:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zi_x00f3__x0142_kowski-2000">
<DESCRIPTION>
<P>No detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-12-24 10:28:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Goes-e-Castro-2004">
<DESCRIPTION>
<P>No information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2010-10-15 14:18:22 +0200" MODIFIED_BY="Laura Amato" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.03" NO="3">
<NAME>objective outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.02" NO="2">
<NAME>patient-reported outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>all outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-05 21:12:21 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ahmadi-2002">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> double-blind, including patients and research staff; <B>placebo appearance:</B> not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 10:32:26 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ahmadi-2002">
<DESCRIPTION>
<P>GGT, urine analysis and urine toxicology screens were assessed; unclear if used to validate patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-05 21:13:37 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ahmadi-2002">
<DESCRIPTION>
<P>No objective outcomes reported in the trial publication </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 15:44:26 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anton-1999">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>no detailed information provided; <B>placebo appearance: </B>identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-05 21:14:17 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anton-1999">
<DESCRIPTION>
<P>GGT, CDT were assessed; unclear if used to validate patient-reported outcomes; collateral reports (post-treatment phase)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 10:41:07 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anton-1999">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 15:54:59 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anton-2004">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind, no detailed information provided; <B>placebo appearance:</B> identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 10:32:38 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anton-2004">
<DESCRIPTION>
<P>GGT, CDT were assessed (week 6, 12); unclear if used to validate patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 10:41:38 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anton-2004">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 15:56:59 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anton-2005">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> no detailed information provided; <B>placebo appearance:</B> identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 10:37:44 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anton-2005">
<DESCRIPTION>
<P>GGT, CDT were assessed; unclear if used to validate patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 10:41:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anton-2005">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-06 10:30:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anton-2006">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind, including patients, investigators, research staff, evaluators, health care practitioners and therapists; <B>placebo appearance: </B>double-dummy design (an identically matched placebo was available for each drug, and participants in each group took the same number of pills per day) </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 10:56:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anton-2006">
<DESCRIPTION>
<P>Knowledge of the allocated interventions was adequately prevented during the study (see "Blinding (all outcomes)")</P>
<P>CDT (week 8, 16) was used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 10:43:01 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anton-2006">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-06 10:43:31 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Auriacombe-2000">
<DESCRIPTION>
<P>No information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 10:43:35 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Auriacombe-2000">
<DESCRIPTION>
<P>No information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 10:43:39 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Auriacombe-2000">
<DESCRIPTION>
<P>No information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 16:03:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Balldin-2003">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind, including patients and research stuff; <B>placebo appearance: </B>identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:01:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Balldin-2003">
<DESCRIPTION>
<P>Knowledge of the allocated interventions was adequately prevented during the study (see "Blinding (all outcomes)")</P>
<P>ALT, AST, GGT (week 12, 24) and urine samples for serum levels of CDT (each study visit) were assessed; unclear if used to validate patient-reported drinking outcomes, but </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 10:44:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Balldin-2003">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 16:05:58 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baltieri-2008">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> double-blind, including patients, health care providers and outcome assessors; <B>placebo appearance:</B> double-dummy design (an identically matched placebo was available for each drug, and participants in each group took the same number of pills per day)</P>
<P>The validity of the double-blind procedure was examined and confirmed at the end of treatment (estimations of group allocation from patients and staff members)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:02:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baltieri-2008">
<DESCRIPTION>
<P>Knowledge of the allocated interventions was adequately prevented during the study (see "Blinding (all outcomes)")</P>
<P>Collateral reports (week 1, 2, 3, 4, 6, 8, 10, 12) were used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:02:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baltieri-2008">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 16:09:50 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown-2009">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> no detailed information provided; <B>placebo appearance: </B>identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:02:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown-2009">
<DESCRIPTION>
<P>GGT was assessed; unclear if used to validate patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:03:43 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brown-2009">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-06 11:05:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Chick-2000">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>no detailed information provided; <B>placebo appearance:</B> identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:04:43 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chick-2000">
<DESCRIPTION>
<P>Urine alcohol test (week 2, 4, 6, 8, 10, 12) was used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:04:51 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chick-2000">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 16:30:02 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Galarza-1997">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind, including patients and research staff; <B>placebo appearance:</B> no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:07:24 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Galarza-1997">
<DESCRIPTION>
<P>No objective outcomes used for a validity check of patient-reported drinking outcomes </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:06:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Galarza-1997">
<DESCRIPTION>
<P>No objective outcomes reported in the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-15 14:18:22 +0200" MODIFIED_BY="Laura Amato" RESULT="YES" STUDY_ID="STD-Garbutt-2005">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind,<B> </B>including patients, all study personnel, besides staff who administered the injections (not involved in any of the safety or efficacy assessments or psychosocial treatments); <B>placebo appearance:</B> placebo appeared identical to active medication (injections were prepared in amber-coloured syringes to mask a slight colour difference between the active and placebo microspheres)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:08:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garbutt-2005">
<DESCRIPTION>
<P>Knowledge of the allocated interventions was adequately prevented during the study (see "Blinding (all outcomes)")</P>
<P>Breathalyzer test (weekly) and collateral reports (monthly) were used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:08:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garbutt-2005">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 16:34:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Gastpar-2002">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind;<B> </B>no detailed information; <B>placebo appearance:</B> no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:09:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gastpar-2002">
<DESCRIPTION>
<P>Breathalyzer test (weekly) were used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:09:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gastpar-2002">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 16:36:22 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guardia-2002">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind;<B> </B>no detailed information provided; <B>placebo appearance:</B> identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:10:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guardia-2002">
<DESCRIPTION>
<P>Urine alcohol tests, breathalyzer tests and collateral information were used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:10:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guardia-2002">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 16:37:49 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hein_x00e4_l_x00e4_-2001">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>no detailed information provided; <B>placebo appearance:</B> identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:18:58 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hein_x00e4_l_x00e4_-2001">
<DESCRIPTION>
<P>GGT was<B> </B>assessed; unclear if used to validate patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:19:07 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hein_x00e4_l_x00e4_-2001">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 16:39:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hersh-1998">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> double-blind, including patients and research evaluators; <B>placebo appearance:</B> identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:19:53 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hersh-1998">
<DESCRIPTION>
<P>Knowledge of the allocated interventions was adequately prevented during the study (see "Blinding (all outcomes)")</P>
<P>Breathalyzer test was used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:20:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hersh-1998">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 16:40:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2005">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> double-blind, including patients and research staff; <B>placebo appearance</B>: identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:20:35 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2005">
<DESCRIPTION>
<P>Knowledge of the allocated interventions was adequately prevented during the study (see "Blinding (all outcomes)")</P>
<P>Breathalyzer test (weekly) was used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:20:36 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2005">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-10-06 11:27:03 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Johnson-2000">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> double-blind; no detailed information provided; <B>placebo appearance:</B> identical to active medication; naltrexone, purchased as 25 mg tablets, were over-encapsulated in opaque size 1 gelatin capsules identical to those used for ondansetron; placebos were opaque gelatin capsules of the same size, shape, and color but contained only cornstarch</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-07 10:23:47 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-2000">
<DESCRIPTION>
<P>Breathalyzer test was used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:26:35 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-2000">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 16:43:28 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-2004">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind, including patients and research staff; <B>placebo appearance:</B> placebo had matching volume of microspheres</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:27:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-2004">
<DESCRIPTION>
<P>Knowledge of the allocated interventions was adequately prevented during the study (see "Blinding (all outcomes)")</P>
<P>GGT levels during the study were assessed as a marker of heavy drinking</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:27:53 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-2004">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 17:24:28 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kiefer-2003">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> double-blind, including patients and research staff; <B>placebo appearance: </B>double-dummy design (an identically matched placebo was available for each drug, and participants in each group took the same number of pills per day)</P>
<P>The integrity of the double-blind procedure was confirmed by obtaining a prediction from each patient at the end of the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:28:39 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kiefer-2003">
<DESCRIPTION>
<P>Knowledge of the allocated interventions was adequately prevented during the study (see "Blinding (all outcomes)")</P>
<P>Breathalyzer test, randomly registered, was used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:28:46 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kiefer-2003">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 17:33:07 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Killeeen-2004">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind,<B> </B>including outcome assessors, health care providers and patients; <B>placebo appearance:</B> no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:29:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Killeeen-2004">
<DESCRIPTION>
<P>Breathalyzer test was used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:29:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Killeeen-2004">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 17:35:31 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kranzler-1998">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> double-blind; no detailed information provided; <B>placebo appearance:</B> identical to active medication</P>
<P>The validity of the double-blind procedure was examined and confirmed at the end of treatment by estimations of group allocation from patients and staff members</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:30:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kranzler-1998">
<DESCRIPTION>
<P>Knowledge of the allocated interventions was adequately prevented during the study (see "Blinding (all outcomes)")</P>
<P>Breathalyzer test (weekly) was used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:30:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kranzler-1998">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 17:51:48 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kranzler-2000">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind, including patients and research staff; <B>placebo appearance: </B>double-dummy design (an identically matched placebo was available for each drug)</P>
<P>The validity of the double-blind procedure was examined and confirmed at the end of treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:31:31 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kranzler-2000">
<DESCRIPTION>
<P>Knowledge of the allocated interventions was adequately prevented during the study (see "Blinding (all outcomes)")</P>
<P>Breathalyzer test and collateral information were used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:30:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kranzler-2000">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-12-28 11:52:29 +0100" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kranzler-2004">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> double-blind, including patients and research staff</P>
<P>
<B>Placebo appearance: </B>the placebo formulation contained microspheres and diluent, but no naltrexone</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:32:10 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kranzler-2004">
<DESCRIPTION>
<P>Knowledge of the allocated interventions was adequately prevented during the study (see "Blinding (all outcomes)")</P>
<P>Breathalyzer test was used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:32:16 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kranzler-2004">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 17:56:03 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Krystal-2001">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> double-blind; no detailed information provided; <B>placebo appearance: </B>identical to<B> </B>active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:33:21 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Krystal-2001">
<DESCRIPTION>
<P>No objective outcomes were used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:33:04 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Krystal-2001">
<DESCRIPTION>
<P>No objective outcomes reported in the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 17:58:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Latt-2002">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind, including health care providers, outcome assessors and patients (information provided by the investigator); <B>placebo appearance: </B>identical to active medication (information provided by the investigator)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:34:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Latt-2002">
<DESCRIPTION>
<P>Knowledge of the allocated interventions was adequately prevented during the study (see "Blinding (all outcomes)")</P>
<P>Breathalyzer test was used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:33:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Latt-2002">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 18:06:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lee-2001">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind; no detailed information provided; <B>placebo appearance:</B> identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:35:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lee-2001">
<DESCRIPTION>
<P>GGT and collateral information were used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:35:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lee-2001">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 18:08:36 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martinotti-2008">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> double-blind; no detailed information provided; <B>placebo appearance:</B> identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:36:31 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martinotti-2008">
<DESCRIPTION>
<P>Blood alcohol concentration and collateral information were used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:36:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martinotti-2008">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 18:10:32 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mason-1994">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> double-blind; no detailed information provided; <B>placebo appearance:</B> identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:37:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mason-1994">
<DESCRIPTION>
<P>Breathalyzer test (weekly) was used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:37:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mason-1994">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 18:13:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mason-1999">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind; no detailed information provided; <B>placebo appearance:</B> identical to active medication; all patients received the same number of identical tablets</P>
<P>The validity of the double-blind procedure was examined and confirmed at the end of treatment by estimations of group allocation from patients and staff members</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:38:22 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mason-1999">
<DESCRIPTION>
<P>Knowledge of the allocated interventions was adequately prevented during the study (see "Blinding (all outcomes)")</P>
<P>Breathalyzer test and collateral information were used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:37:58 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mason-1999">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 18:14:53 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Monterosso-2001">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>no detailed information provided; <B>placebo appearance:</B> identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:39:03 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Monterosso-2001">
<DESCRIPTION>
<P>Collateral information was used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:39:17 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Monterosso-2001">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 18:17:50 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Monti-2001">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind, including patients and research assistants; <B>placebo appearance: </B>identical to active medication (each identical capsule contained 25 mg of either NTX or acetaminophen to provide a bitter taste)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:40:47 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Monti-2001">
<DESCRIPTION>
<P>Knowledge of the allocated interventions was adequately prevented during the study (see "Blinding (all outcomes)")</P>
<P>Breathalyzer tests and collateral information were used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:40:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Monti-2001">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 18:21:48 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morley-2006">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind, including patients, researchers and therapists; <B>placebo appearance: </B>an identically matched placebo was available for each drug, and participants in each group took the same number of pills per day</P>
<P>The validity of the double-blind procedure was examined and confirmed at the end of the trial</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:41:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morley-2006">
<DESCRIPTION>
<P>Knowledge of the allocated interventions was adequately prevented during the study (see "Blinding (all outcomes)")</P>
<P>Urine alcohol concentration was used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:41:43 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morley-2006">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 18:23:39 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morris-2001">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> double-blind, including patients, clinicians and research staff; <B>placebo appearance:</B> identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:42:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morris-2001">
<DESCRIPTION>
<P>Knowledge of the allocated interventions was adequately prevented during the study (see "Blinding (all outcomes)")</P>
<P>Breathalyzer test (weekly) was used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:42:37 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morris-2001">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 18:25:30 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Malley-1992">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind, including<B> </B>patients and research staff; <B>placebo appearance: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:43:13 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Malley-1992">
<DESCRIPTION>
<P>Collateral information was used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:43:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Malley-1992">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 18:27:28 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Malley-2007">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> double-blind, including patients and research staff; <B>placebo appearance:</B> identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:44:36 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Malley-2007">
<DESCRIPTION>
<P>Knowledge of the allocated interventions was adequately prevented during the study (see "Blinding (all outcomes)")</P>
<P>Breathalyzer test and collateral information were used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:44:43 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Malley-2007">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 18:29:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Malley-2008">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind, including patients and all study staff (besides pharmacists, who did not interact directly with participants); <B>placebo appearance:</B> double-dummy design (an identically matched placebo was available for each drug, and participants in each group took the same number of pills per day)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:45:17 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Malley-2008">
<DESCRIPTION>
<P>Knowledge of the allocated interventions was adequately prevented during the study (see "Blinding (all outcomes)")</P>
<P>GGT was used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:45:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Malley-2008">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 18:31:39 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oslin-1997">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> double-blind; no detailed information provided; <B>placebo appearance:</B> not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:46:01 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oslin-1997">
<DESCRIPTION>
<P>Blood alcohol concentration was used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:46:00 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oslin-1997">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 18:33:19 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oslin-2005">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind;<B> </B>no detailed information provided; <B>placebo appearance: </B>identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:46:43 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oslin-2005">
<DESCRIPTION>
<P>No objective outcomes were used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:47:01 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oslin-2005">
<DESCRIPTION>
<P>No objective outcomes reported in the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 18:34:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oslin-2008">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> double-blind, including patients and research staff (information provided by the investigator); <B>placebo appearance:</B> identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:47:59 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oslin-2008">
<DESCRIPTION>
<P>Knowledge of the allocated interventions was adequately prevented during the study (see "Blinding (all outcomes)")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:47:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oslin-2008">
<DESCRIPTION>
<P>No objective outcomes reported in the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 18:36:15 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Petrakis-2004">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> double-blind; no detailed information provided; <B>placebo appearance:</B> identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:48:46 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Petrakis-2004">
<DESCRIPTION>
<P>Breathalyzer test (weekly) was used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:48:59 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Petrakis-2004">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 18:37:56 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Petrakis-2005">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> double-blind, including patients, research staff (information provided by the investigator); <B>placebo appearance:</B> identical to active medication (information provided by the investigator)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:49:31 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Petrakis-2005">
<DESCRIPTION>
<P>Knowledge of the allocated interventions was adequately prevented during the study (see "Blinding (all outcomes)")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:49:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Petrakis-2005">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 18:40:25 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pettinati-2008a">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>no detailed information provided; <B>placebo appearance: </B>identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 12:04:17 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pettinati-2008a">
<DESCRIPTION>
<P>No objective measures used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 12:04:27 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pettinati-2008a">
<DESCRIPTION>
<P>No objective outcomes reported in the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 18:42:20 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pettinati-2008b">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>no detailed information provided; <B>placebo appearance: </B>double-dummy design (an identically matched placebo was available for each drug, and participants in each group took the same number of pills per day)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 19:36:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pettinati-2008b">
<DESCRIPTION>
<P>Breathalyzer test was used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 19:36:31 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pettinati-2008b">
<DESCRIPTION>
<P>No objective outcomes reported in the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 18:43:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmitz-2004">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>no detailed information provided; <B>placebo appearance:</B> identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 19:37:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmitz-2004">
<DESCRIPTION>
<P>No objective outcomes were used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 19:37:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmitz-2004">
<DESCRIPTION>
<P>No objective outcomes reported in the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 18:45:57 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmitz-2009">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind;<B> </B>no detailed information provided; <B>placebo appearance: </B>no detailed information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 19:37:49 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmitz-2009">
<DESCRIPTION>
<P>No objective outcomes were used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 19:38:09 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmitz-2009">
<DESCRIPTION>
<P>No objective outcomes were reported in the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 18:47:21 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volpicelli-1992">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind;<B> </B>no detailed information provided; <B>placebo appearance:</B> identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 19:38:31 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volpicelli-1992">
<DESCRIPTION>
<P>No objective outcomes were used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 19:38:42 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volpicelli-1992">
<DESCRIPTION>
<P>No objective outcomes were reported in the trial publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 18:48:53 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volpicelli-1997">
<DESCRIPTION>
<P>
<B>Persons blinded:</B> double-blind; no detailed information provided; <B>placebo appearance: </B>identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 19:39:07 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volpicelli-1997">
<DESCRIPTION>
<P>No objective outcomes were used for a validity check of patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-07 10:13:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Volpicelli-1997">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 18:51:07 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zi_x00f3__x0142_kowski-2000">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>double-blind, including patients, research stuff (information provided by the investigator); <B>placebo appearance: </B>identical to active medication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-07 10:14:00 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zi_x00f3__x0142_kowski-2000">
<DESCRIPTION>
<P>Knowledge of the allocated interventions was adequately prevented during the study (see "Blinding (all outcomes)")</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-07 10:13:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zi_x00f3__x0142_kowski-2000">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2010-07-31 16:28:13 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Goes-e-Castro-2004">
<DESCRIPTION>
<P>
<B>Persons blinded: </B>no detailed information provided; <B>placebo appearance</B>: identical to active placebo</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.02" MODIFIED="2010-10-06 11:06:01 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Goes-e-Castro-2004">
<DESCRIPTION>
<P>GGT and CDT were assessed; unclear if used to validate patient-reported drinking outcomes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.03" MODIFIED="2010-10-06 11:06:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Goes-e-Castro-2004">
<DESCRIPTION>
<P>Objective outcomes are less susceptible to bias due to a lack of blindness</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" MODIFIED="2010-10-15 14:20:49 +0200" MODIFIED_BY="Laura Amato" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.03" NO="3">
<NAME>Continuous outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-04.02" NO="2">
<NAME>Binary outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 15:38:16 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ahmadi-2002">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> not reported; <B>handling of missing data: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2009-12-31 15:13:48 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ahmadi-2002">
<DESCRIPTION>
<P>No continuous outcomes considered in the study </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 15:44:37 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anton-1999">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did receive one treatment dose (n = 1) were excluded from the primary analysis; <B>handling of missing data: </B>not reported; it was supposed for the meta-analysis that lost to follow-ups have been categorized as relapsers in the survival analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 15:44:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anton-1999">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did receive one treatment dose (n = 1) were excluded from the primary analysis; <B>handling of missing data: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 15:55:08 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anton-2004">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data:</B> not reported; it was supposed for the meta-analysis that lost to follow-ups have been categorized as relapsers in the survival analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 15:55:15 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anton-2004">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-10-15 14:17:02 +0200" MODIFIED_BY="Laura Amato" RESULT="UNKNOWN" STUDY_ID="STD-Anton-2005">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT; <B>handling of missing data: </B>not reported; it was supposed for the meta-analysis that lost to follow-ups have been categorized as relapses for in the survival analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 15:57:15 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anton-2005">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT; <B>handling of missing data: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 16:00:05 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anton-2006">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>not reported; it was assumed for the meta-analysis that lost to follow-ups have been classified as relapsers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 16:00:38 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anton-2006">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data (drinking days): </B>patients<B> </B>lost to follow-up were assumed to have relapsed to heavy drinking on the day after their last contact</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-22 17:24:46 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Auriacombe-2000">
<DESCRIPTION>
<P>No information available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-22 17:24:03 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Auriacombe-2000">
<DESCRIPTION>
<P>No information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 16:03:10 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Balldin-2003">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>individuals lost to follow-up were assumed to have failed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 16:03:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Balldin-2003">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>imputations were made with the mean of nearby values in these subgroups</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 16:06:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baltieri-2008">
<DESCRIPTION>
<P>
<B>Principle of analysis</B>: ITT; <B>handling of missing data:</B> drop-outs were classified as treatment failures</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 16:07:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baltieri-2008">
<DESCRIPTION>
<P>
<B>Principle of analysis</B>: ITT; <B>handling of missing data: </B>the entire week was considered a relapse period, if alcohol consumption at any day or sequence of days was reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 16:24:05 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown-2009">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT; <B>handling of missing data: </B>not reported;<B> </B>it was supposed for the meta-analysis that lost to follow-ups have been categorized as relapsers in the survival analyses.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 16:24:17 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Brown-2009">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT; <B>handling of missing data:</B> excluded from the analyses (information provided from the investigator)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 16:26:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chick-2000">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT modified version; patients who did not receive at least one dose of the study medication (naltrexone: n = 5; placebo: n = 6) were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data:</B> individuals lost to follow-up were assumed to have failed and were assigned to the heavy drinking category</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 16:26:22 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Chick-2000">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> per-protocol analyses; <B>handling of missing data:</B> the endpoint was defined as the last observation available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-01-07 11:07:58 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Galarza-1997">
<DESCRIPTION>
<P>No binary outcomes provided </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 16:30:08 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Galarza-1997">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> no information provided; <B>handling of missing data: </B>no information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-10-15 14:18:34 +0200" MODIFIED_BY="Laura Amato" RESULT="UNKNOWN" STUDY_ID="STD-Garbutt-2005">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT modified version; patients who did not receive at least one dose of the study medication (n = 3) were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data</B>: not reported; it was supposed for the meta-analysis that lost to follow-ups have been categorized as relapses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 16:33:16 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Garbutt-2005">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT modified version; patients who did not receive at least one dose of the study medication (n = 3) were excluded from the primary analysis (= treatment-received analysis); <B>handling of missing data: </B>no imputations were performed for days in which drinking data were unavailable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-10-15 14:19:03 +0200" MODIFIED_BY="Laura Amato" RESULT="NO" STUDY_ID="STD-Gastpar-2002">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>available case analysis, subsequently transformed into ITT-analyses for the meta-analysis; <B>handling of missing data: </B>individuals<B> </B>lost to follow-up excluded from the analyses and subsequently included as re lapsers in the meta-analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 16:35:00 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Gastpar-2002">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>available case analysis; <B>handling of missing data: </B>endpoint was defined as the last observation available during the treatment period</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 16:36:27 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Guardia-2002">
<DESCRIPTION>
<P>
<B>Principle of analysis</B>: ITT; <B>handling of missing data</B>: not reported; it was supposed for the meta-analysis that lost to follow-ups have been categorized as relapsers in the survival analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 16:36:34 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Guardia-2002">
<DESCRIPTION>
<P>
<B>Principle of analysis</B>: available case analysis; <B>handling of missing data:</B> missing data were not replaced</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-10-15 14:19:36 +0200" MODIFIED_BY="Laura Amato" RESULT="UNKNOWN" STUDY_ID="STD-Hein_x00e4_l_x00e4_-2001">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT; <B>handling of missing data: </B>not explicitly reported; it was assumed for the meta-analysis that lost to follow-ups have been classified as re lapsers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 16:38:03 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hein_x00e4_l_x00e4_-2001">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT; <B>handling of missing data: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 16:39:38 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hersh-1998">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT; <B>handling of missing data:</B> not reported; it was assumed for the meta-analysis that lost to follow-ups have been classified as relapsers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 16:39:43 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hersh-1998">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT; <B>handling of missing data:</B> not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 16:41:03 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2005">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> not reported; <B>handling of missing data: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 16:41:09 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Huang-2005">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> not reported; <B>handling of missing data: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-10-06 11:20:59 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Johnson-2000">
<DESCRIPTION>
<P>No binary outcomes considered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 16:42:07 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Johnson-2000">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT; <B>handling of missing data:</B> endpoint was defined as the last visit of recorded drinking data in the study for each subject</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-01-04 11:51:54 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Johnson-2004">
<DESCRIPTION>
<P>No binary outcomes considered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 16:43:33 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Johnson-2004">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data:</B> not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 17:24:46 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kiefer-2003">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>lost to follow-ups have been categorized as relapsers in the primary analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 17:24:52 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kiefer-2003">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> not reported; <B>handling of missing data: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-10-15 14:20:26 +0200" MODIFIED_BY="Laura Amato" RESULT="UNKNOWN" STUDY_ID="STD-Killeeen-2004">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT modified version; patients who did not receive at least one treatment (naltrexone: n = 3; placebo: n = 7; usual treatment: n = 2) were excluded from the primary analysis, but subsequently considered in the meta-analysis; <B>handling of missing data: </B>not reported; it was assumed for the meta-analysis that lost to follow-ups have been classified as re lapsers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 17:33:53 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Killeeen-2004">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT modified version; patients who did not receive at least one treatment (naltrexone: n = 3; placebo: n = 7; usual treatment: n = 2) were excluded from the primary analysis; <B>handling of missing data:</B> not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-10-06 11:30:03 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kranzler-1998">
<DESCRIPTION>
<P>No binary outcomes considered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 17:50:17 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kranzler-1998">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-10-15 14:20:43 +0200" MODIFIED_BY="Laura Amato" RESULT="UNKNOWN" STUDY_ID="STD-Kranzler-2000">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>not explicitly reported; it was assumed for the meta-analysis that lost to follow-ups have been classified as re lapsers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 17:51:59 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kranzler-2000">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>missings were excluded from analysis; because of the low lost to follow-up-rate (n = 1), the proceeding was considered as adequate</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-10-15 14:20:49 +0200" MODIFIED_BY="Laura Amato" RESULT="UNKNOWN" STUDY_ID="STD-Kranzler-2004">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>not explicitly reported; it was assumed for the meta-analysis that lost to follow-ups have been classified as re lapsers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 17:54:30 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Kranzler-2004">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 17:56:10 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Krystal-2001">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>available case analyses, subsequently transformed into ITT analyses for the meta-analyses; <B>handling of missing data: </B>individuals<B> </B>lost to follow-up were originally excluded from the analyses and subsequently considered as relapsers in the meta-analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 17:56:17 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Krystal-2001">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>available case analyses; <B>handling of missing data: </B>excluded from the analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 17:59:03 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Latt-2002">
<DESCRIPTION>
<P>
<B>Principle of analysis</B>: ITT; <B>handling of missing data:</B> not explicitly reported; it was assumed for the meta-analysis that lost to follow-ups have been classified as relapsers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 17:59:09 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Latt-2002">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT; <B>handling of missing data:</B> not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 18:07:12 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lee-2001">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>available case analyses, subsequently transformed into ITT analyses for the meta-analysis; <B>handling of lost to follow-up data: </B>individuals<B> </B>lost to follow-up excluded from the primary analyses and subsequently included as relapsers in the meta-analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 18:07:20 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Lee-2001">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT analyses; <B>handling of lost to follow-up data: </B>last observation carried forward</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 18:08:42 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martinotti-2008">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>not explicitly reported; it was assumed for the meta-analysis that lost to follow-ups have been classified as relapsers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 18:08:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martinotti-2008">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data:</B> not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 18:10:40 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Mason-1994">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>not reported; it was assumed for the meta-analysis that lost to follow-ups have been classified as relapsers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 18:11:01 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Mason-1994">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT modified version; patients who did not attend at least one week of treatment (n = 2) were excluded in the primary analysis; <B>handling of missing data: </B>for calculating <I>drinking days</I>, any alcohol use during a given study week resulted in that week being coded as a non-abstinent week; no further information provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 18:13:18 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mason-1999">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>none of the participants was lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 18:13:25 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mason-1999">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>none of the participants was lost to follow-up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-27 11:12:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Monterosso-2001">
<DESCRIPTION>
<P>No binary outcomes considered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2009-12-31 12:48:42 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Monterosso-2001">
<DESCRIPTION>
<P>No continuous outcomes considered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-12-31 12:48:00 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Monti-2001">
<DESCRIPTION>
<P>No binary outcomes considered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2009-12-31 12:48:18 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Monti-2001">
<DESCRIPTION>
<P>No continuous outcomes considered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 18:21:55 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morley-2006">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>patients lost to follow-up<B> </B>were assumed to have relapsed from the last date of contact<B> </B>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 18:22:03 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morley-2006">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT / available case analyses; <B>handling of missing data: </B>for the calculations of drinking days,<B> </B>individuals<B> </B>lost to follow-up<B> </B>were assumed to have relapsed from the last date of contact (drinking days); for the calculations of <I>drinks per drinking</I> <I>day</I>, individuals<B> </B>lost to follow-up (n = 4) were excluded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 18:23:47 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morris-2001">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data:</B> not reported; it was supposed for the meta-analysis that lost to follow-ups have been categorized as relapsers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 18:23:54 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Morris-2001">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> available case analysis; <B>handling of missing data: </B>data were censored for patients who dropped-out</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 18:25:54 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-O_x0027_Malley-1992">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT modified version; patients who not receive at least one week of study medication (naltrexone: n = 6; placebo: n = 1) were excluded from the primary analysis, but subsequently considered in the meta-analysis; <B>handling of missing data: </B>individuals<B> </B>lost to follow-up excluded from the analyses and subsequently included as relapsers in the meta-analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 18:26:08 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-O_x0027_Malley-1992">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT modified version; patients who not receive at least one week of study medication (naltrexone: n = 6; placebo: n = 1) were excluded from the primary analysis; <B>handling of missing data: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 18:27:37 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-O_x0027_Malley-2007">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT modified version; patients who did receive at least one dose of treatment (naltrexone: n = 4; placebo: n = 0) were excluded from the primary analysis; <B>handling of missing data: </B>not reported; it was assumed for the meta-analysis that lost to follow-ups have been classified as relapsers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 18:27:59 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Malley-2007">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT modified version; patients who did receive at least one dose of treatment (naltrexone: n = 4; placebo: n = 0) were excluded from the primary analysis; <B>handling of missing data: </B>for the calculation of days abstinent,<B> </B>individuals lost to follow-up were assumed to have failed on the day following their last recorded data point</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 18:29:16 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Malley-2008">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>individuals lost to follow-up were assumed to have failed on the day following their last recorded data point in the primary analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 18:29:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Malley-2008">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>for the calculation of percent drinking days,<B> </B>individuals lost to follow-up were assumed to have failed on the day following their last recorded data point; for the calculation of further continuous outcomes(drinks per drinking day, GGT), handling of lost to follow-ups was not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 18:31:45 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oslin-1997">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT; <B>handling of missing data:</B> not explicitly reported; it was assumed for the meta-analysis that lost to follow-ups have been classified as relapsers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 18:31:51 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Oslin-1997">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>available case analysis; <B>handling of missing data:</B> considered as censored at the time of drop out (information provided by the investigator)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 18:33:25 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oslin-2005">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> not reported; <B>handling of missing data:</B> not reported; it was supposed for the meta-analysis that lost to follow-ups have been categorized as relapsers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 18:33:32 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oslin-2005">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> not reported; <B>handling of missing data:</B> not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-10-06 11:47:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oslin-2008">
<DESCRIPTION>
<P>Blinding? (objective outcomes)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-10-06 11:47:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oslin-2008">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT modified version; patients who did not receive one dose of the treatment were excluded from the primary analysis; <B>handling of missing data: </B>handling<B> </B>was conducted against non-adherence patterns; a GEE model with a pattern mixture strategy (<LINK REF="REF-Park-1999" TYPE="REFERENCE">Park 1999</LINK>) Pwas used to assess the sensitivity of the results to the assumption that missing data were ignorable.</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-27 14:13:24 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Petrakis-2004">
<DESCRIPTION>
<P>No binary outcomes considered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 18:36:23 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Petrakis-2004">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>hierarchical linear modelling (HLM) analyses with group specific imputations have been used</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 18:38:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Petrakis-2005">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data:</B> not reported; it was assumed for the meta-analysis that lost to follow-ups have been classified as relapsers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 18:38:12 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Petrakis-2005">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 18:40:31 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pettinati-2008a">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>generalized estimating equations (GEE) models with a pattern mixture strategy (<LINK REF="REF-Park-1999" TYPE="REFERENCE">Park 1999</LINK>) was used to assess the sensitivity of the results to the assumption that missing data were ignorable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 18:40:37 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pettinati-2008a">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>generalized estimating equations (GEE) models with a pattern mixture strategy (<LINK REF="REF-Park-1999" TYPE="REFERENCE">Park 1999</LINK>) was used to assess the sensitivity of the results to the assumption that missing data were ignorable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 18:42:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pettinati-2008b">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>lost to follow-ups have been categorized as relapsers in the primary analysis; sensitivity of the results to the handling of missing data was examined with pattern-mixture analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 18:42:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pettinati-2008b">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>any alcohol use during a given study week resulted in that week being coded as a non-abstinent week; sensitivity of the results to the handling of missing data was examined with pattern-mixture analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2009-12-31 12:28:14 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmitz-2004">
<DESCRIPTION>
<P>No binary outcomes considered in the study </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 18:44:07 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmitz-2004">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> not reported; <B>handling of missing data: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 18:46:03 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmitz-2009">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>not reported; it was supposed for the meta-analysis that lost to follow-ups have been categorized as relapsers in the survival analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-10-06 19:37:49 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmitz-2009">
<DESCRIPTION>
<P>No continuous outcomes considered in the study</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 18:47:31 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volpicelli-1992">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT; <B>handling of missing data: </B>not reported; it was supposed for the meta-analysis that lost to follow-ups have been categorized as relapsers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 18:47:38 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volpicelli-1992">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT; <B>handling of missing data: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 18:49:00 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volpicelli-1997">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>ITT; <B>handling of missing data: </B>not reported; it was supposed for the meta-analysis that lost to follow-ups have been categorized as relapsers</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 18:49:06 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Volpicelli-1997">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>available case analysis; <B>handling of missing data: </B>if data were not obtained beyond the baseline period, the subject was dropped from the data analysis for that particular variable</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 18:51:14 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zi_x00f3__x0142_kowski-2000">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>none of the patients were lost to follow up</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2009-12-29 10:31:19 +0100" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zi_x00f3__x0142_kowski-2000">
<DESCRIPTION>
<P>No continuous outcomes provided</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.02" MODIFIED="2010-07-31 16:28:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Goes-e-Castro-2004">
<DESCRIPTION>
<P>
<B>Principle of analysis:</B> ITT; <B>handling of missing data: </B>lost to follow-ups<B> </B>were subsequently classified as relapsers in the meta-analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-04.03" MODIFIED="2010-07-31 16:28:53 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Goes-e-Castro-2004">
<DESCRIPTION>
<P>
<B>Principle of analysis: </B>available case analysis;<B> handling of missing data: </B>excluded from the analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2010-08-03 09:05:56 +0200" MODIFIED_BY="[Empty name]" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 15:38:27 +0200" MODIFIED_BY="[Empty name]" RESULT="NO" STUDY_ID="STD-Ahmadi-2002">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>abstinence is listed as a primary study outcome in the method section, but it is not reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-03 09:03:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anton-1999">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>primary outcomes were explicitly stated in the methods section and adequately reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 15:55:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anton-2004">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>all outcomes stated in the methods section are adequately reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 15:57:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anton-2005">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>primary outcomes were explicitly stated in the methods section and adequately reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 16:00:48 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anton-2006">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> a study protocol is available and the primary outcomes listed in the protocol are reported adequately in the study publication</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 17:24:05 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Auriacombe-2000">
<DESCRIPTION>
<P>No information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 16:03:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Balldin-2003">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> the publication provides all outcomes specified in the methods section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 16:07:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baltieri-2008">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 16:24:42 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brown-2009">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 16:26:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chick-2000">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-03 09:05:56 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Galarza-1997">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>primary outcomes were stated in the methods section and adequately reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 16:33:23 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garbutt-2005">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 16:35:12 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gastpar-2002">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>all outcomes stated in the methods section were adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 16:36:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guardia-2002">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section were adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 16:38:12 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hein_x00e4_l_x00e4_-2001">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 16:39:58 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hersh-1998">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-03 09:03:42 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2005">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>primary outcomes were stated in the methods section and adequately reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-03 09:04:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-2000">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>primary outcomes were stated in the methods section and adequately reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 16:43:39 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-2004">
<DESCRIPTION>
<P>
<B>Ooutcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 17:24:58 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kiefer-2003">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 17:34:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Killeeen-2004">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-03 09:04:24 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kranzler-1998">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>primary outcomes were stated in the methods section and adequately reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 17:52:05 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kranzler-2000">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 17:54:35 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kranzler-2004">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 17:56:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krystal-2001">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 17:59:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Latt-2002">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 18:07:28 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lee-2001">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 18:08:52 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martinotti-2008">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 18:11:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mason-1994">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>all outcomes stated in the methods section are adequately reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 18:13:33 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mason-1999">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-03 09:04:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Monterosso-2001">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>primary outcomes were stated in the methods section and adequately reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 18:18:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Monti-2001">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 18:22:13 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morley-2006">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 18:24:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morris-2001">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 18:26:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Malley-1992">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-09-17 11:16:29 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Malley-2007">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
<P>
<B>Diversity of outcomes:</B> continuous abstinence: yes; drinking frequency: yes; drinking intensity (amount per drinking day/occasion): yes; laboratory indicators: yes </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 18:29:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Malley-2008">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 18:31:59 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oslin-1997">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-08-03 09:05:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oslin-2005">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>primary outcomes were stated in the methods section and adequately reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 18:35:04 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oslin-2008">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 18:36:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Petrakis-2004">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 18:38:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Petrakis-2005">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 18:40:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pettinati-2008a">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 18:42:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pettinati-2008b">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 18:44:18 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmitz-2004">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 18:46:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmitz-2009">
<DESCRIPTION>
<P>
<B>Outcome reporting: </B>all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 18:47:43 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Volpicelli-1992">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 18:49:12 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Volpicelli-1997">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 18:51:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zi_x00f3__x0142_kowski-2000">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported in the results section</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 16:29:00 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Goes-e-Castro-2004">
<DESCRIPTION>
<P>
<B>Outcome reporting:</B> all outcomes stated in the methods section are adequately reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2010-10-15 14:20:18 +0200" MODIFIED_BY="Laura Amato" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:25:56 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ahmadi-2002">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: <I>not reported</I>; drinking history or treatment history:<I> not reported</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:38:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anton-1999">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: <I>not reported</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:41:00 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anton-2004">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: <I>not reported</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:41:10 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anton-2005">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: <I>not reported</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:41:28 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anton-2006">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>67 pretreatment characteristics were compared across groups and no evidence for baseline imbalance was found; socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 17:24:56 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Auriacombe-2000">
<DESCRIPTION>
<P>No information available </P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:41:56 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Balldin-2003">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:42:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baltieri-2008">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:42:27 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Brown-2009">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: <I>not reported</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:42:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chick-2000">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:43:12 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Galarza-1997">
<DESCRIPTION>
<P>
<B>Baseline equivalence:</B> socio-demographic variables:<I> not reported;</I> drinking frequency and intensity: <I>not reported;</I> drinking history or treatment history:<I> not reported</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:44:35 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garbutt-2005">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: <I>not reported</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:44:52 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gastpar-2002">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:45:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guardia-2002">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:45:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hein_x00e4_l_x00e4_-2001">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: <I>not reported</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:45:40 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hersh-1998">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history:<I> not reported</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:45:52 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2005">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: <I>not reported</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:46:01 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Johnson-2000">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history:<I> not reported</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:46:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-2004">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: <I>not reported</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-15 14:20:18 +0200" MODIFIED_BY="Laura Amato" RESULT="YES" STUDY_ID="STD-Kiefer-2003">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes (besides gender); drinking frequency: <I>not reported;</I> drinking intensity: yes*<I>;</I> drinking history or treatment history: yes<I>*</I> (duration of alcohol problems); *baseline differences between groups (amount of alcohol consumed per day, history of drinking problems, GGT) were considered as covariate in the MANCOVA and were shown not have a significant influence on the treatment effects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:47:10 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Killeeen-2004">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: <I>not reported;</I> drinking history or treatment history: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:47:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kranzler-1998">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: <I>not reported;</I> drinking history or treatment history: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:47:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kranzler-2000">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: <I>not reported; </I>drinking history or treatment history: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:48:01 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kranzler-2004">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:48:07 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Krystal-2001">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:48:19 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Latt-2002">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:48:27 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Lee-2001">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: <I>not reported; </I>drinking history or treatment history: <I>not reported </I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:48:49 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Martinotti-2008">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: <I>not reported;</I> drinking history or treatment history: <I>not reported</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:49:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mason-1994">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:49:40 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mason-1999">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:49:54 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Monterosso-2001">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: <I>not reported</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:50:09 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Monti-2001">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: <I>not reported</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:50:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morley-2006">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes (except age*); drinking frequency and intensity: no*; drinking history or treatment history: yes</P>
<P>* baseline imbalance was found for age and consecutive abstinent days before treatment and considered as covariates in the statistical analyses</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:50:49 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morris-2001">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:51:03 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Malley-1992">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes (except age*); drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
<P>*naltrexone-treated patients were older (42.8 years) than placebo-treated patients (38.5 years), but no other group differences were shown</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:51:15 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Malley-2007">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: <I>not reported</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:51:30 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Malley-2008">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: <I>not reported</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:51:43 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oslin-1997">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:51:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oslin-2005">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: no*; drinking history or treatment history: <I>not reported</I>
</P>
<P>* those randomized to naltrexone were significantly less depressed, had fewer drinks on a drinking day and had fewer heavy drinking before randomization than patients in the placebo group; these variables were considered as covariates in the statistical analyses and were shown not have a significant influence on the treatment effects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:52:06 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oslin-2008">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: <I>not reported</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:52:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Petrakis-2004">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes*; psychiatric comorbidity: yes; drinking history or treatment history: <I>not reported</I>
</P>
<P>
<I>* </I>baseline differences between groups ( drinking days) were entered as a covariate in the random regression analysis</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:52:32 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Petrakis-2005">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: <I>not reported</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:52:40 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pettinati-2008a">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:52:49 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pettinati-2008b">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-28 07:54:16 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmitz-2004">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: <I>not reported ; </I>
<B>equivalence of treatment attendance: </B>drop-out: yes; reasons for drop-out: <I>not reported</I>; lost to follow-up: <I>not reported</I>; compliance: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:52:57 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Schmitz-2009">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:53:10 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Volpicelli-1992">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:53:19 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Volpicelli-1997">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency: yes; drinking history or treatment history: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:53:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Zi_x00f3__x0142_kowski-2000">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency: yes; drinking history or treatment history: <I>not reported</I>
</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:43:00 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-de-Goes-e-Castro-2004">
<DESCRIPTION>
<P>
<B>Baseline equivalence: </B>socio-demographic variables: yes; drinking frequency and intensity: yes; drinking history or treatment history: yes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="NO" ID="QIT-07" LEVEL="STUDY" MODIFIED="2010-10-05 16:39:59 +0200" MODIFIED_BY="[Empty name]" NO="7">
<NAME>Susceptibility to bias reduced?</NAME>
<DESCRIPTION>
<P>Was the susceptibility to bias effects reduced by objective outcomes?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-31 15:39:28 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Ahmadi-2002">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes: </B>GGT, urine analysis and urine toxicology screens were assessed; unclear if used to validate patient-reported outcomes; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-10-05 16:39:59 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anton-1999">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes:</B> GGT, CDT were assessed; unclear if used to validate patient-reported outcomes; collateral reports (post-treatment phase); <B>laboratory assessment of drop-outs: </B>not reported (treatment phase); yes (post-treatment phase)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 14:25:04 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anton-2004">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes:</B> GGT, CDT were assessed (week 6, 12); unclear if used to validate patient-reported outcomes; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 14:25:38 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Anton-2005">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes: </B>GGT, CDT were assessed; unclear if used to validate patient-reported outcomes; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-26 16:53:17 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Anton-2006">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes: </B>CDT (week 8, 16) used as a validity check for self-reported drinking; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 17:24:08 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Auriacombe-2000">
<DESCRIPTION>
<P>No information available</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-26 16:57:08 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Balldin-2003">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes: </B>ALT, AST, GGT (week 12, 24) and urine samples for serum levels of CDT (each study visit) were assessed; unclear if used to validate patient-reported outcomes; <B>laboratory assessment of drop-outs: </B>drop-outs underwent a repeated physical examination and a laboratory evaluation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 14:23:31 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Baltieri-2008">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes:</B> collateral reports (week 1, 2, 3, 4, 6, 8, 10, 12); <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-26 16:59:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Brown-2009">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes: </B>GGT was assessed; unclear if used to validate patient-reported outcomes; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 14:28:54 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Chick-2000">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes: </B>urine alcohol test (week 2, 4, 6, 8, 10, 12); <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 14:29:22 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Galarza-1997">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes:</B> not reported; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 18:05:34 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Garbutt-2005">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes: </B>breathalyzer test (weekly; collateral reports (monthly); <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-26 17:50:11 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Gastpar-2002">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes: </B>breathalyzer test (weekly); collateral reports; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 14:48:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Guardia-2002">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes: </B>urine alcohol tests, breathalyzer test, collateral information; l<B>aboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 14:49:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Hein_x00e4_l_x00e4_-2001">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes: </B>GGT was<B> </B>assessed; unclear if used to validate patient-reported outcomes; <B>laboratory assessment of drop-outs:</B> not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 14:52:22 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Hersh-1998">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes: </B>breathalyzer test; <B>laboratory assessment of drop-outs:</B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 14:51:56 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Huang-2005">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes:</B> breathalyzer test (weekly); <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 14:53:07 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-2000">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes:</B> breathalyzer test (weekly); <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-26 17:07:56 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Johnson-2004">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes: </B>GGT levels during the study were assessed as a marker of heavy drinking;<B> laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-26 17:50:39 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kiefer-2003">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes: </B>breathalyzer test, randomly registered; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 14:54:02 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Killeeen-2004">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes:</B> breathalyzer test; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 14:54:20 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kranzler-1998">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes: </B>breathalyzer test (weekly); <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-26 17:09:22 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kranzler-2000">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes:</B> collateral information, breathalyzer test; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 14:54:49 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Kranzler-2004">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes: </B>breathalyzer test; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 14:55:06 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Krystal-2001">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes:</B> not reported;<I> </I>
<B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-26 17:51:00 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Latt-2002">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes: </B>breathalyzer test, random; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 14:55:36 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Lee-2001">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes:</B> GGT, collateral information; <B>laboratory assessment of drop-outs:<I> </I>
</B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 14:55:51 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Martinotti-2008">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes: </B>blood alcohol concentration, collateral information; <B>laboratory assessment of drop-outs:<I> </I>
</B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-26 17:51:16 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mason-1994">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes:</B> breathalyzer test (weekly); <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-26 17:51:44 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Mason-1999">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes:</B> collateral information; breathalyzer test (weekly); <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 14:57:01 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Monterosso-2001">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes:</B> collateral information; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 14:57:13 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Monti-2001">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes: </B>collateral information, breathalyzer test; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 14:57:49 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Morley-2006">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes:</B> urine alcohol concentrations, randomly selected; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 14:58:09 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Morris-2001">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes: </B>breathalyzer test (weekly); <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 14:58:26 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Malley-1992">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes: </B>collateral information; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 14:58:41 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Malley-2007">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes:</B> collateral information, breathalyzer test; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 14:58:56 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-O_x0027_Malley-2008">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes:</B> GGT; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-26 17:14:45 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Oslin-1997">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes:</B> blood alcohol concentration;<B> laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 15:00:03 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oslin-2005">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes: </B>not reported; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 15:00:09 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Oslin-2008">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes: </B>not reported; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 15:00:21 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Petrakis-2004">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes:</B> breathalyzer test (weekly); <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 15:00:42 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Petrakis-2005">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes: </B>not reported; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 15:00:53 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Pettinati-2008a">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes:</B> not reported; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 15:01:08 +0200" MODIFIED_BY="[Empty name]" RESULT="YES" STUDY_ID="STD-Pettinati-2008b">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes:</B> breathalyzer test; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 15:01:19 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmitz-2004">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes: </B>not reported; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 15:01:31 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Schmitz-2009">
<DESCRIPTION>
<P>
<B>Validation of patient-reported drinking outcomes: </B>not reported; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 15:01:43 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volpicelli-1992">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes: </B>not reported; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 15:01:54 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Volpicelli-1997">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes:</B> not reported; <B>laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 15:02:39 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-Zi_x00f3__x0142_kowski-2000">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes: </B>various laboratory indicators like Glutamat-Pyruvat-Transaminase (GPT) and aspartate aminotransferase (AspAT) were assessed; unclear if used to validate patient-reported outcomes; <B>laboratory assessment of drop-outs: </B>collateral reports</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2010-07-22 14:29:11 +0200" MODIFIED_BY="[Empty name]" RESULT="UNKNOWN" STUDY_ID="STD-de-Goes-e-Castro-2004">
<DESCRIPTION>
<P>
<B>Validation of patient-reported outcomes:</B> not reported;<B> laboratory assessment of drop-outs: </B>not reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES MODIFIED="2010-01-30 11:26:10 +0100" MODIFIED_BY="[Empty name]"/>
<ADDITIONAL_TABLES MODIFIED="2008-11-13 13:55:35 +0100" MODIFIED_BY="[Empty name]"/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2010-10-15 13:53:40 +0200" MODIFIED_BY="Laura Amato">
<COMPARISON ID="CMP-001" MODIFIED="2010-10-15 13:53:40 +0200" MODIFIED_BY="Laura Amato" NO="1">
<NAME>NTX versus PBO</NAME>
<DICH_OUTCOME CHI2="69.81113241833137" CI_END="0.9022090804505192" CI_START="0.7644607615745396" CI_STUDY="95" CI_TOTAL="95" DF="27" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8304838594100845" ESTIMABLE="YES" EVENTS_1="1180" EVENTS_2="1286" I2="61.324219985134924" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="-0.04469280617899984" LOG_CI_START="-0.1166448012509961" LOG_EFFECT_SIZE="-0.08066880371499795" METHOD="MH" MODIFIED="2010-01-31 22:18:36 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="1.193441117741667E-5" P_Q="0.0" P_Z="1.1086576413503649E-5" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="28" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.022332326423362366" TOTALS="YES" TOTAL_1="2330" TOTAL_2="2103" WEIGHT="99.99999999999999" Z="4.394817678067763">
<NAME>Return to heavy drinking</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6311701919871983" CI_START="0.20950198003228845" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="33" LOG_CI_END="-0.19985351955965688" LOG_CI_START="-0.6788118681008685" LOG_EFFECT_SIZE="-0.43933269383026263" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1236" O_E="0.0" SE="0.28134250481517004" STUDY_ID="STD-Ahmadi-2002" TOTAL_1="58" TOTAL_2="58" VAR="0.07915360501567398" WEIGHT="1.7601717357446798"/>
<DICH_DATA CI_END="0.9108199521780594" CI_START="0.44117433589720834" EFFECT_SIZE="0.6339009287925697" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="38" LOG_CI_END="-0.04056746441402639" LOG_CI_START="-0.3553897593832673" LOG_EFFECT_SIZE="-0.19797861189864682" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1241" O_E="0.0" SE="0.18492817446042564" STUDY_ID="STD-Anton-1999" TOTAL_1="68" TOTAL_2="63" VAR="0.03419842970926562" WEIGHT="3.1599200208046097"/>
<DICH_DATA CI_END="0.9902205910630894" CI_START="0.5197329647541995" EFFECT_SIZE="0.717391304347826" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="46" LOG_CI_END="-0.004268047008677679" LOG_CI_START="-0.28421973659869554" LOG_EFFECT_SIZE="-0.14424389180368663" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1230" O_E="0.0" SE="0.16444500824838956" STUDY_ID="STD-Anton-2005" TOTAL_1="80" TOTAL_2="80" VAR="0.027042160737812914" WEIGHT="3.617914400034086"/>
<DICH_DATA CI_END="1.0157058857044763" CI_START="0.8259539672896838" EFFECT_SIZE="0.915929203539823" ESTIMABLE="YES" EVENTS_1="207" EVENTS_2="226" LOG_CI_END="0.006767969062773602" LOG_CI_START="-0.08304415644374001" LOG_EFFECT_SIZE="-0.038138093690483175" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1245" O_E="0.0" SE="0.05275608709971741" STUDY_ID="STD-Anton-2006" TOTAL_1="309" TOTAL_2="309" VAR="0.0027832047260729696" WEIGHT="7.112438396459328"/>
<DICH_DATA CI_END="1.1073188942420145" CI_START="0.9243370618651896" EFFECT_SIZE="1.0116995073891626" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="58" LOG_CI_END="0.04427271036871017" LOG_CI_START="-0.0341696333088997" LOG_EFFECT_SIZE="0.005051538529905233" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1227" O_E="0.0" SE="0.04607742097209158" STUDY_ID="STD-Balldin-2003" TOTAL_1="56" TOTAL_2="62" VAR="0.002123128723439345" WEIGHT="7.3044098759321505"/>
<DICH_DATA CI_END="1.2388202070168948" CI_START="0.8065030656609786" EFFECT_SIZE="0.9995560488346282" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="53" LOG_CI_END="0.09300828073734807" LOG_CI_START="-0.09339397744164589" LOG_EFFECT_SIZE="-1.9284835214893506E-4" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1223" O_E="0.0" SE="0.10949360916040024" STUDY_ID="STD-Chick-2000" TOTAL_1="85" TOTAL_2="79" VAR="0.011988850446970482" WEIGHT="5.204736095431618"/>
<DICH_DATA CI_END="1.0279813336408024" CI_START="0.09262456760122725" EFFECT_SIZE="0.30857142857142855" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="10" LOG_CI_END="0.011985228695834653" LOG_CI_START="-1.0332738064224865" LOG_EFFECT_SIZE="-0.5106442888633259" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1247" O_E="0.0" SE="0.6139903313441727" STUDY_ID="STD-de-Goes-e-Castro-2004" TOTAL_1="35" TOTAL_2="36" VAR="0.376984126984127" WEIGHT="0.44734612503538734"/>
<DICH_DATA CI_END="1.4024453698131532" CI_START="0.6822551344180127" EFFECT_SIZE="0.9781746031746031" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="36" LOG_CI_END="0.14688595295794266" LOG_CI_START="-0.16605318729453325" LOG_EFFECT_SIZE="-0.00958361716829529" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1229" O_E="0.0" SE="0.1838220000580317" STUDY_ID="STD-Gastpar-2002" TOTAL_1="84" TOTAL_2="87" VAR="0.033790527705335006" WEIGHT="3.182886381456742"/>
<DICH_DATA CI_END="0.9172755281341353" CI_START="0.19327379083161578" EFFECT_SIZE="0.42105263157894735" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" LOG_CI_END="-0.037500192819751935" LOG_CI_START="-0.713827035102019" LOG_EFFECT_SIZE="-0.3756636139608854" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1239" O_E="0.0" SE="0.3972777350284667" STUDY_ID="STD-Guardia-2002" TOTAL_1="101" TOTAL_2="101" VAR="0.1578295987493486" WEIGHT="0.9915117632289353"/>
<DICH_DATA CI_END="1.0409448319572654" CI_START="0.7516211334361477" EFFECT_SIZE="0.8845315904139434" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="51" LOG_CI_END="0.017427713361236823" LOG_CI_START="-0.12400101728137106" LOG_EFFECT_SIZE="-0.05328665196006713" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1242" O_E="0.0" SE="0.08307593646297537" STUDY_ID="STD-Hein_x00e4_l_x00e4_-2001" TOTAL_1="63" TOTAL_2="58" VAR="0.0069016112192003196" WEIGHT="6.110455261922594"/>
<DICH_DATA CI_END="1.260162826363499" CI_START="0.6963750011818706" EFFECT_SIZE="0.9367741935483871" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="25" LOG_CI_END="0.10042666418299362" LOG_CI_START="-0.1571568277954268" LOG_EFFECT_SIZE="-0.028365081806216576" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1238" O_E="0.0" SE="0.15130581824697328" STUDY_ID="STD-Hersh-1998" TOTAL_1="31" TOTAL_2="33" VAR="0.022893450635386114" WEIGHT="3.9497976532867423"/>
<DICH_DATA CI_END="0.9534900594109206" CI_START="0.46612383638171156" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="30" LOG_CI_END="-0.02068383032168624" LOG_CI_START="-0.3314986877896763" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1222" O_E="0.0" SE="0.18257418583505539" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.03333333333333334" WEIGHT="3.209028131086283"/>
<DICH_DATA CI_END="2.176882556831785" CI_START="0.7009801940414653" EFFECT_SIZE="1.2352941176470589" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="12" LOG_CI_END="0.33783499941512735" LOG_CI_START="-0.15429425270383665" LOG_EFFECT_SIZE="0.09177037335564536" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1226" O_E="0.0" SE="0.28907915877376605" STUDY_ID="STD-Killeeen-2004" TOTAL_1="51" TOTAL_2="36" VAR="0.08356676003734825" WEIGHT="1.686819726825389"/>
<DICH_DATA CI_END="1.3396020845421344" CI_START="0.6539456472103151" EFFECT_SIZE="0.9359631147540983" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="32" LOG_CI_END="0.12697581466989097" LOG_CI_START="-0.18445834662616148" LOG_EFFECT_SIZE="-0.028741265978135234" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1244" O_E="0.0" SE="0.18293796796926262" STUDY_ID="STD-Kranzler-2000" TOTAL_1="61" TOTAL_2="63" VAR="0.03346630012472296" WEIGHT="3.2013810938657192"/>
<DICH_DATA CI_END="1.023815555803078" CI_START="0.8238254531845772" EFFECT_SIZE="0.9183927886459532" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="132" LOG_CI_END="0.010221723913303017" LOG_CI_START="-0.08416479406588406" LOG_EFFECT_SIZE="-0.03697153507629053" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1234" O_E="0.0" SE="0.055443107881773715" STUDY_ID="STD-Kranzler-2004" TOTAL_1="158" TOTAL_2="157" VAR="0.003073938211589999" WEIGHT="7.031048076581961"/>
<DICH_DATA CI_END="1.0362441863164529" CI_START="0.7328270354900073" EFFECT_SIZE="0.8714285714285714" ESTIMABLE="YES" EVENTS_1="183" EVENTS_2="105" LOG_CI_END="0.015462107024900128" LOG_CI_START="-0.13499851703187965" LOG_EFFECT_SIZE="-0.05976820500348979" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1237" O_E="0.0" SE="0.0883813153630534" STUDY_ID="STD-Krystal-2001" TOTAL_1="418" TOTAL_2="209" VAR="0.007811256905303497" WEIGHT="5.926059491568095"/>
<DICH_DATA CI_END="1.002895037476627" CI_START="0.409532610219688" EFFECT_SIZE="0.6408730158730159" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="27" LOG_CI_END="0.0012554823423941252" LOG_CI_START="-0.38771151057123887" LOG_EFFECT_SIZE="-0.19322801411442236" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1243" O_E="0.0" SE="0.2284811370551357" STUDY_ID="STD-Latt-2002" TOTAL_1="56" TOTAL_2="51" VAR="0.0522036299900077" WEIGHT="2.3965972490382033"/>
<DICH_DATA CI_END="1.4855732426693047" CI_START="0.4773519432566174" EFFECT_SIZE="0.8421052631578947" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.1718940685280875" LOG_CI_START="-0.32116130512189595" LOG_EFFECT_SIZE="-0.07463361829690421" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1231" O_E="0.0" SE="0.2896231671454623" STUDY_ID="STD-Monti-2001" TOTAL_1="64" TOTAL_2="64" VAR="0.08388157894736842" WEIGHT="1.6818199789491943"/>
<DICH_DATA CI_END="1.3123382710959026" CI_START="0.8303370936172787" EFFECT_SIZE="1.0438788942518649" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="43" LOG_CI_END="0.11804579413635513" LOG_CI_START="-0.08074556042257375" LOG_EFFECT_SIZE="0.018650116856890674" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1246" O_E="0.0" SE="0.11677102570099017" STUDY_ID="STD-Morley-2006" TOTAL_1="53" TOTAL_2="61" VAR="0.013635472443261305" WEIGHT="4.966460937938473"/>
<DICH_DATA CI_END="0.8920981246228511" CI_START="0.4927392976786826" EFFECT_SIZE="0.6630021141649048" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="43" LOG_CI_END="-0.04958737360764319" LOG_CI_START="-0.30738279984317834" LOG_EFFECT_SIZE="-0.17848508672541075" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1228" O_E="0.0" SE="0.15143030947869401" STUDY_ID="STD-Morris-2001" TOTAL_1="55" TOTAL_2="56" VAR="0.022931138628813047" WEIGHT="3.9465089093113708"/>
<DICH_DATA CI_END="1.0056817734332681" CI_START="0.49545483408011104" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="34" LOG_CI_END="0.002460579223404905" LOG_CI_START="-0.30499592988470303" LOG_EFFECT_SIZE="-0.15126767533064908" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1224" O_E="0.0" SE="0.1806014753843682" STUDY_ID="STD-O_x0027_Malley-1992" TOTAL_1="52" TOTAL_2="52" VAR="0.03261689291101055" WEIGHT="3.250868169895406"/>
<DICH_DATA CI_END="1.4041285884489532" CI_START="0.813978011065845" EFFECT_SIZE="1.069078947368421" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="32" LOG_CI_END="0.1474068817942262" LOG_CI_START="-0.08938732705398487" LOG_EFFECT_SIZE="0.029009777370120622" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1249" O_E="0.0" SE="0.13909409042767718" STUDY_ID="STD-O_x0027_Malley-2007" TOTAL_1="57" TOTAL_2="50" VAR="0.019347165991902834" WEIGHT="4.2858647680961095"/>
<DICH_DATA CI_END="1.0531862794102325" CI_START="0.586170700135986" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="28" LOG_CI_END="0.022505192614775998" LOG_CI_START="-0.23197589365480198" LOG_EFFECT_SIZE="-0.104735350520013" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1232" O_E="0.0" SE="0.14948344977644334" STUDY_ID="STD-O_x0027_Malley-2008" TOTAL_1="34" TOTAL_2="34" VAR="0.022345301757066463" WEIGHT="3.998257637431271"/>
<DICH_DATA CI_END="1.3470011349479771" CI_START="0.12523094458737097" EFFECT_SIZE="0.4107142857142857" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.1293679616483279" LOG_CI_START="-0.902288343625543" LOG_EFFECT_SIZE="-0.38646019098860757" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1240" O_E="0.0" SE="0.606000020498944" STUDY_ID="STD-Oslin-1997" TOTAL_1="21" TOTAL_2="23" VAR="0.3672360248447205" WEIGHT="0.4585399905132115"/>
<DICH_DATA CI_END="0.850023691821018" CI_START="0.31810878049848024" EFFECT_SIZE="0.52" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="25" LOG_CI_END="-0.07056896948130421" LOG_CI_START="-0.4974243432490974" LOG_EFFECT_SIZE="-0.28399665636520083" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1235" O_E="0.0" SE="0.25073695951937935" STUDY_ID="STD-Oslin-2005" TOTAL_1="37" TOTAL_2="37" VAR="0.06286902286902288" WEIGHT="2.096594356524812"/>
<DICH_DATA CI_END="1.1706677672836119" CI_START="0.7881064372899773" EFFECT_SIZE="0.9605263157894737" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="76" LOG_CI_END="0.0684336608216132" LOG_CI_START="-0.10341512514228415" LOG_EFFECT_SIZE="-0.017490732160335455" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1233" O_E="0.0" SE="0.10094482754040318" STUDY_ID="STD-Oslin-2008" TOTAL_1="120" TOTAL_2="120" VAR="0.01018985820716174" WEIGHT="5.492640489072686"/>
<DICH_DATA CI_END="0.831382895649233" CI_START="0.213241479331991" EFFECT_SIZE="0.42105263157894735" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" LOG_CI_END="-0.08019891464044512" LOG_CI_START="-0.6711283132813257" LOG_EFFECT_SIZE="-0.3756636139608854" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1248" O_E="0.0" SE="0.3471148539093527" STUDY_ID="STD-Volpicelli-1992" TOTAL_1="35" TOTAL_2="35" VAR="0.12048872180451127" WEIGHT="1.2507446928249846"/>
<DICH_DATA CI_END="1.0615484316755095" CI_START="0.41968265344480227" EFFECT_SIZE="0.6674679487179487" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="26" LOG_CI_END="0.0259398130376758" LOG_CI_START="-0.377078980916911" LOG_EFFECT_SIZE="-0.1755695839396176" MODIFIED="2010-01-09 12:19:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1225" O_E="0.0" SE="0.2367352345441289" STUDY_ID="STD-Volpicelli-1997" TOTAL_1="48" TOTAL_2="49" VAR="0.05604357127466372" WEIGHT="2.279178591139927"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="34.946622787266655" CI_END="0.9967288087120283" CI_START="0.9222909594122763" CI_STUDY="95" CI_TOTAL="95" DF="25" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9587877602790265" ESTIMABLE="YES" EVENTS_1="1823" EVENTS_2="1576" I2="28.46232910062732" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="-0.0014229890312708283" LOG_CI_START="-0.03513204843324812" LOG_EFFECT_SIZE="-0.018277518732259454" METHOD="MH" MODIFIED="2010-01-09 13:50:30 +0100" MODIFIED_BY="[Empty name]" NO="2" NOTES="&lt;p&gt;Results provided by the investigators:&lt;/p&gt;&lt;p&gt;Anton (2006)&lt;/p&gt;&lt;p&gt;Balldin (2003)&lt;/p&gt;&lt;p&gt;Brown (2009)&lt;/p&gt;&lt;p&gt;Guardia (2002)&lt;/p&gt;&lt;p&gt;Killeeen (2004)&lt;/p&gt;&lt;p&gt;Krystal (2001)&lt;/p&gt;&lt;p&gt;Ziolkowski (2000)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-01-09 13:50:30 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="0.08917348217225995" P_Q="0.0" P_Z="0.03354998070912732" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="27" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.002073605581961347" TOTALS="YES" TOTAL_1="2561" TOTAL_2="2132" WEIGHT="99.99999999999999" Z="2.125439218863727">
<NAME>Return to any drinking</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.05501916081994" CI_START="0.5977359092512923" EFFECT_SIZE="0.7941176470588235" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="42" LOG_CI_END="0.023260347181391996" LOG_CI_START="-0.22349065294792766" LOG_EFFECT_SIZE="-0.10011515288326783" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2028" O_E="0.0" SE="0.1449427589131121" STUDY_ID="STD-Anton-1999" TOTAL_1="68" TOTAL_2="63" VAR="0.021008403361344533" WEIGHT="1.6986146595177958"/>
<DICH_DATA CI_END="1.0265471364745902" CI_START="0.8769760963985553" EFFECT_SIZE="0.9488188976377953" ESTIMABLE="YES" EVENTS_1="241" EVENTS_2="254" LOG_CI_END="0.011378895879832901" LOG_CI_START="-0.057012243969972204" LOG_EFFECT_SIZE="-0.022816674045069686" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2023" O_E="0.0" SE="0.040173294089377705" STUDY_ID="STD-Anton-2006" TOTAL_1="309" TOTAL_2="309" VAR="0.0016138935579916298" WEIGHT="10.632528245883254"/>
<DICH_DATA CI_END="1.1028453044442927" CI_START="0.9658597812043965" EFFECT_SIZE="1.0320823244552058" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="59" LOG_CI_END="0.042514598443915884" LOG_CI_START="-0.015085917755609676" LOG_EFFECT_SIZE="0.013714340344153092" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2008" O_E="0.0" SE="0.033834828342754954" STUDY_ID="STD-Balldin-2003" TOTAL_1="56" TOTAL_2="62" VAR="0.0011447956089836939" WEIGHT="12.182272015226136"/>
<DICH_DATA CI_END="1.2602014296051345" CI_START="0.7761796752531707" EFFECT_SIZE="0.989010989010989" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" LOG_CI_END="0.10043996795429373" LOG_CI_START="-0.11003773371783114" LOG_EFFECT_SIZE="-0.004798882881768708" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2015" O_E="0.0" SE="0.12363564384363265" STUDY_ID="STD-Baltieri-2008" TOTAL_1="49" TOTAL_2="54" VAR="0.01528577242862958" WEIGHT="2.2585739384383383"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2004" O_E="0.0" SE="0.0" STUDY_ID="STD-Brown-2009" TOTAL_1="20" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.175392360397191" CI_START="0.8791633993381085" EFFECT_SIZE="1.0165441176470589" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="64" LOG_CI_END="0.07018286363877968" LOG_CI_START="-0.05593040042574289" LOG_EFFECT_SIZE="0.0071262316065183766" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2007" O_E="0.0" SE="0.07407955558222577" STUDY_ID="STD-Chick-2000" TOTAL_1="85" TOTAL_2="79" VAR="0.005487780555260077" WEIGHT="5.185218430946017"/>
<DICH_DATA CI_END="1.0279861075480583" CI_START="0.9474192484596005" EFFECT_SIZE="0.9868808567603748" ESTIMABLE="YES" EVENTS_1="388" EVENTS_2="198" LOG_CI_END="0.011987245538647284" LOG_CI_START="-0.023457796075372458" LOG_EFFECT_SIZE="-0.005735275268362568" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2024" O_E="0.0" SE="0.020820592899860928" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="4.3349708870173923E-4" WEIGHT="15.638545330036498"/>
<DICH_DATA CI_END="1.2720378856867658" CI_START="0.7000395431438031" EFFECT_SIZE="0.9436507936507936" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="45" LOG_CI_END="0.10450004629642128" LOG_CI_START="-0.1548774272941639" LOG_EFFECT_SIZE="-0.02518869049887133" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2027" O_E="0.0" SE="0.15235961192631112" STUDY_ID="STD-Gastpar-2002" TOTAL_1="84" TOTAL_2="87" VAR="0.023213451346336123" WEIGHT="1.5504943447311643"/>
<DICH_DATA CI_END="1.2727904259294296" CI_START="0.7568456509936812" EFFECT_SIZE="0.9814814814814815" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="54" LOG_CI_END="0.10475689983961217" LOG_CI_START="-0.120992680283971" LOG_EFFECT_SIZE="-0.00811789022217945" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2003" O_E="0.0" SE="0.13260642084303684" STUDY_ID="STD-Guardia-2002" TOTAL_1="101" TOTAL_2="101" VAR="0.017584462848800594" WEIGHT="1.9944705605392261"/>
<DICH_DATA CI_END="0.8968220243868565" CI_START="0.5506009832031952" EFFECT_SIZE="0.7027027027027027" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="37" LOG_CI_END="-0.047293734766085706" LOG_CI_START="-0.2591630174262683" LOG_EFFECT_SIZE="-0.153228376096177" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2019" O_E="0.0" SE="0.12445306540445474" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.01548856548856549" WEIGHT="2.232493841722046"/>
<DICH_DATA CI_END="1.4440589007315197" CI_START="0.7041799601497147" EFFECT_SIZE="1.0084033613445378" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="21" LOG_CI_END="0.15958490773568682" LOG_CI_START="-0.15231633842549874" LOG_EFFECT_SIZE="0.0036342846550940556" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2009" O_E="0.0" SE="0.1832123359311492" STUDY_ID="STD-Killeeen-2004" TOTAL_1="51" TOTAL_2="36" VAR="0.033566760037348264" WEIGHT="1.1000852006124768"/>
<DICH_DATA CI_END="1.3812002805549306" CI_START="0.8494424658463556" EFFECT_SIZE="1.0831667333066772" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="41" LOG_CI_END="0.14025665789305944" LOG_CI_START="-0.07086603128772812" LOG_EFFECT_SIZE="0.03469531330266566" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2010" O_E="0.0" SE="0.1240145126989608" STUDY_ID="STD-Kranzler-2000" TOTAL_1="61" TOTAL_2="63" VAR="0.015379599359960708" WEIGHT="2.2464320388540897"/>
<DICH_DATA CI_END="1.0019434233433513" CI_START="0.8377036568034879" EFFECT_SIZE="0.9161504623395278" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="141" LOG_CI_END="8.43198952887247E-4" LOG_CI_START="-0.07690958874035127" LOG_EFFECT_SIZE="-0.03803319489373202" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2018" O_E="0.0" SE="0.04567237237351468" STUDY_ID="STD-Kranzler-2004" TOTAL_1="158" TOTAL_2="157" VAR="0.0020859655982249873" WEIGHT="9.425836718212834"/>
<DICH_DATA CI_END="1.0290907543853136" CI_START="0.8059546805466064" EFFECT_SIZE="0.9107142857142857" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="140" LOG_CI_END="0.012453676405537625" LOG_CI_START="-0.09368937822206576" LOG_EFFECT_SIZE="-0.04061785090826406" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2005" O_E="0.0" SE="0.06234895570484846" STUDY_ID="STD-Krystal-2001" TOTAL_1="418" TOTAL_2="209" VAR="0.0038873922774851554" WEIGHT="6.577328106247763"/>
<DICH_DATA CI_END="1.4323366178155366" CI_START="0.5509163459038132" EFFECT_SIZE="0.8883116883116883" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.156045094843362" LOG_CI_START="-0.2589143417480933" LOG_EFFECT_SIZE="-0.051434623452365665" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2026" O_E="0.0" SE="0.2437492271361598" STUDY_ID="STD-Lee-2001" TOTAL_1="35" TOTAL_2="18" VAR="0.05941368572947521" WEIGHT="0.6376510970963475"/>
<DICH_DATA CI_END="1.1997343917933971" CI_START="0.8550434147066528" EFFECT_SIZE="1.0128301886792452" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="50" LOG_CI_END="0.0790851085922953" LOG_CI_START="-0.0680118334720021" LOG_EFFECT_SIZE="0.0055366375601465945" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2025" O_E="0.0" SE="0.08640547191017486" STUDY_ID="STD-Morley-2006" TOTAL_1="53" TOTAL_2="61" VAR="0.007465905576020018" WEIGHT="4.110005021527417"/>
<DICH_DATA CI_END="1.0602926997846036" CI_START="0.7529560979722425" EFFECT_SIZE="0.8935064935064935" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="49" LOG_CI_END="0.025425771259002097" LOG_CI_START="-0.12323034513294324" LOG_EFFECT_SIZE="-0.04890228693697058" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2006" O_E="0.0" SE="0.0873213386282726" STUDY_ID="STD-Morris-2001" TOTAL_1="55" TOTAL_2="56" VAR="0.007625016179833452" WEIGHT="4.042578391567734"/>
<DICH_DATA CI_END="0.967996988340346" CI_START="0.5215384464108057" EFFECT_SIZE="0.7105263157894737" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="38" LOG_CI_END="-0.014125993878800312" LOG_CI_START="-0.2827136710368454" LOG_EFFECT_SIZE="-0.14841983245782286" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2016" O_E="0.0" SE="0.15776973109308" STUDY_ID="STD-O_x0027_Malley-1992" TOTAL_1="52" TOTAL_2="52" VAR="0.02489128804918278" WEIGHT="1.4540179278488277"/>
<DICH_DATA CI_END="1.3647831039386018" CI_START="0.9374575840490486" EFFECT_SIZE="1.131117266851339" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="38" LOG_CI_END="0.13506363727622298" LOG_CI_START="-0.028048373125761073" LOG_EFFECT_SIZE="0.05350763207523094" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2012" O_E="0.0" SE="0.09581280232759878" STUDY_ID="STD-O_x0027_Malley-2007" TOTAL_1="57" TOTAL_2="50" VAR="0.00918009308986752" WEIGHT="3.4839602432547214"/>
<DICH_DATA CI_END="0.9673244521940851" CI_START="0.5559435374118685" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="30" LOG_CI_END="-0.014427833917195277" LOG_CI_START="-0.25496931387771726" LOG_EFFECT_SIZE="-0.13469857389745624" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2017" O_E="0.0" SE="0.14129525602833978" STUDY_ID="STD-O_x0027_Malley-2008" TOTAL_1="34" TOTAL_2="34" VAR="0.01996434937611409" WEIGHT="1.7790869813831491"/>
<DICH_DATA CI_END="1.9759691717101815" CI_START="0.34147541754166066" EFFECT_SIZE="0.8214285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.2957801646136561" LOG_CI_START="-0.4666405552629088" LOG_EFFECT_SIZE="-0.08543019532462635" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2021" O_E="0.0" SE="0.44784970489892456" STUDY_ID="STD-Oslin-1997" TOTAL_1="21" TOTAL_2="23" VAR="0.2005693581780538" WEIGHT="0.19348038557436714"/>
<DICH_DATA CI_END="1.9346302440652738" CI_START="0.7887561779696548" EFFECT_SIZE="1.2352941176470589" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="17" LOG_CI_END="0.28659797281393634" LOG_CI_START="-0.10305722610264562" LOG_EFFECT_SIZE="0.09177037335564536" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2011" O_E="0.0" SE="0.22888539266794258" STUDY_ID="STD-Oslin-2005" TOTAL_1="37" TOTAL_2="37" VAR="0.052388522976758264" WEIGHT="0.7199027985097538"/>
<DICH_DATA CI_END="1.1249039948236184" CI_START="0.8705411111680323" EFFECT_SIZE="0.9895833333333334" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="96" LOG_CI_END="0.051115459071825776" LOG_CI_START="-0.060210714573267016" LOG_EFFECT_SIZE="-0.004547627750720631" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2022" O_E="0.0" SE="0.06539354547257462" STUDY_ID="STD-Oslin-2008" TOTAL_1="120" TOTAL_2="120" VAR="0.004276315789473684" WEIGHT="6.174476260224885"/>
<DICH_DATA CI_END="1.676839534303586" CI_START="0.6393779397348134" EFFECT_SIZE="1.0354391371340523" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.22449150464493242" LOG_CI_START="-0.19424235213802046" LOG_EFFECT_SIZE="0.015124576253455991" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2020" O_E="0.0" SE="0.24596634024032676" STUDY_ID="STD-Petrakis-2005" TOTAL_1="59" TOTAL_2="64" VAR="0.060499440531220194" WEIGHT="0.6265867046220218"/>
<DICH_DATA CI_END="1.268707555567973" CI_START="0.504450373288339" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" LOG_CI_END="0.10336152623978546" LOG_CI_START="-0.29718155225589826" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2013" O_E="0.0" SE="0.23528098702858008" STUDY_ID="STD-Volpicelli-1992" TOTAL_1="35" TOTAL_2="35" VAR="0.05535714285714287" WEIGHT="0.6826907158243501"/>
<DICH_DATA CI_END="1.1889216075614926" CI_START="0.6239992058329584" EFFECT_SIZE="0.861328125" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="32" LOG_CI_END="0.07515322003009052" LOG_CI_START="-0.20481596304607497" LOG_EFFECT_SIZE="-0.06483137150799222" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2029" O_E="0.0" SE="0.16445528400874684" STUDY_ID="STD-Volpicelli-1997" TOTAL_1="48" TOTAL_2="49" VAR="0.027045540438397585" WEIGHT="1.3464487844117399"/>
<DICH_DATA CI_END="1.3261896420833033" CI_START="0.7922132451204937" EFFECT_SIZE="1.025" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="30" LOG_CI_END="0.12260563162633525" LOG_CI_START="-0.10115790084278914" LOG_EFFECT_SIZE="0.010723865391773066" MODIFIED="2009-12-22 11:41:57 +0100" MODIFIED_BY="[Empty name]" ORDER="2014" O_E="0.0" SE="0.13143980661971333" STUDY_ID="STD-Zi_x00f3__x0142_kowski-2000" TOTAL_1="40" TOTAL_2="41" VAR="0.01727642276422764" WEIGHT="2.026221257187057"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="448.6648031359122" CI_END="-2.0429233488659904" CI_START="-5.745804407391907" CI_STUDY="95" CI_TOTAL="95" DF="25" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.8943638781289485" ESTIMABLE="YES" I2="94.42791147750744" I2_Q="0.0" ID="CMP-001.03" MODIFIED="2010-02-03 11:33:25 +0100" MODIFIED_BY="[Empty name]" NO="3" NOTES="&lt;p&gt;Drinking days in %&lt;/p&gt;&lt;p&gt;Results provided by the investigators:&lt;/p&gt;&lt;p&gt;Brown (2009)&lt;/p&gt;&lt;p&gt;Morris (2001)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-02-03 11:33:25 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="-4.440892098500626E-16" P_Q="1.0" P_Z="3.745634712623698E-5" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="26" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="9.591485114262197" TOTALS="YES" TOTAL_1="2045" TOTAL_2="1837" UNITS="" WEIGHT="100.0" Z="4.122634685363093">
<NAME>Drinking days</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.7781094296756779" CI_START="-15.221890570324323" EFFECT_SIZE="-8.0" ESTIMABLE="YES" MEAN_1="10.0" MEAN_2="18.0" MODIFIED="2009-03-17 10:53:40 +0100" MODIFIED_BY="[Empty name]" ORDER="91" SD_1="18.9" SD_2="22.9" SE="3.6847057534167327" STUDY_ID="STD-Anton-1999" TOTAL_1="68" TOTAL_2="63" WEIGHT="3.8514534566558916"/>
<CONT_DATA CI_END="1.5216860276632378" CI_START="-15.12168602766324" EFFECT_SIZE="-6.800000000000001" ESTIMABLE="YES" MEAN_1="16.2" MEAN_2="23.0" MODIFIED="2009-03-17 10:53:56 +0100" MODIFIED_BY="[Empty name]" ORDER="92" SD_1="24.4" SD_2="29.1" SE="4.245836195615652" STUDY_ID="STD-Anton-2005" TOTAL_1="80" TOTAL_2="80" WEIGHT="3.2308852355495983"/>
<CONT_DATA CI_END="2.9997786485180225" CI_START="-5.199778648518018" EFFECT_SIZE="-1.0999999999999979" ESTIMABLE="YES" MEAN_1="22.1" MEAN_2="23.2" MODIFIED="2009-03-17 10:54:14 +0100" MODIFIED_BY="[Empty name]" ORDER="93" SD_1="26.1" SD_2="25.9" SE="2.091762236886265" STUDY_ID="STD-Anton-2006" TOTAL_1="309" TOTAL_2="309" WEIGHT="6.38883447895489"/>
<CONT_DATA CI_END="0.7391194822838045" CI_START="-20.5391194822838" EFFECT_SIZE="-9.899999999999999" ESTIMABLE="YES" MEAN_1="38.6" MEAN_2="48.5" MODIFIED="2009-03-17 10:54:31 +0100" MODIFIED_BY="[Empty name]" ORDER="115" SD_1="25.7" SD_2="33.1" SE="5.428221929690453" STUDY_ID="STD-Balldin-2003" TOTAL_1="56" TOTAL_2="62" WEIGHT="2.2846706212138286"/>
<CONT_DATA CI_END="7.330866320095222" CI_START="-23.930866320095216" EFFECT_SIZE="-8.299999999999997" ESTIMABLE="YES" MEAN_1="45.0" MEAN_2="53.3" MODIFIED="2009-03-17 10:54:48 +0100" MODIFIED_BY="[Empty name]" ORDER="94" SD_1="40.8" SD_2="40.0" SE="7.975078339902925" STUDY_ID="STD-Baltieri-2008" TOTAL_1="49" TOTAL_2="54" WEIGHT="1.2191346329940635"/>
<CONT_DATA CI_END="16.534892686619372" CI_START="-20.534892686619372" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="46.0" MEAN_2="48.0" MODIFIED="2009-07-20 13:29:17 +0200" MODIFIED_BY="[Empty name]" ORDER="636" SD_1="31.3" SD_2="30.5" SE="9.456751671367556" STUDY_ID="STD-Brown-2009" TOTAL_1="20" TOTAL_2="23" WEIGHT="0.9011420340877994"/>
<CONT_DATA CI_END="23.18906215516023" CI_START="-5.189062155160231" EFFECT_SIZE="9.0" ESTIMABLE="YES" MEAN_1="20.7" MEAN_2="11.7" MODIFIED="2009-03-17 10:57:02 +0100" MODIFIED_BY="[Empty name]" ORDER="103" SD_1="35.5" SD_2="24.3" SE="7.239450452703082" STUDY_ID="STD-de-Goes-e-Castro-2004" TOTAL_1="35" TOTAL_2="36" WEIGHT="1.439208649328519"/>
<CONT_DATA CI_END="2.9828631537631356" CI_START="-16.382863153763132" EFFECT_SIZE="-6.699999999999999" ESTIMABLE="YES" MEAN_1="12.7" MEAN_2="19.4" MODIFIED="2009-03-17 10:55:04 +0100" MODIFIED_BY="[Empty name]" ORDER="95" SD_1="29.0" SD_2="40.3" SE="4.940327082609846" STUDY_ID="STD-Guardia-2002" TOTAL_1="101" TOTAL_2="101" WEIGHT="2.6246169825476318"/>
<CONT_DATA CI_END="9.182704823809265" CI_START="-12.98270482380927" EFFECT_SIZE="-1.9000000000000021" ESTIMABLE="YES" MEAN_1="17.9" MEAN_2="19.8" MODIFIED="2009-03-17 10:55:17 +0100" MODIFIED_BY="[Empty name]" ORDER="96" SD_1="22.8" SD_2="22.4" SE="5.654545140231264" STUDY_ID="STD-Hersh-1998" TOTAL_1="31" TOTAL_2="33" WEIGHT="2.1468007752220184"/>
<CONT_DATA CI_END="40.150019849912475" CI_START="-53.75001984991247" EFFECT_SIZE="-6.799999999999997" ESTIMABLE="YES" MEAN_1="30.6" MEAN_2="37.4" MODIFIED="2009-03-17 10:55:32 +0100" MODIFIED_BY="[Empty name]" ORDER="97" SD_1="33.7" SD_2="51.4" SE="23.954531930304963" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" WEIGHT="0.15294971576876046"/>
<CONT_DATA CI_END="-1.1146700729080063" CI_START="-1.2853299270919922" EFFECT_SIZE="-1.1999999999999993" ESTIMABLE="YES" MEAN_1="8.8" MEAN_2="10.0" MODIFIED="2009-03-17 10:55:45 +0100" MODIFIED_BY="[Empty name]" ORDER="98" SD_1="0.2" SD_2="0.2" SE="0.043536477080734354" STUDY_ID="STD-Killeeen-2004" TOTAL_1="51" TOTAL_2="36" WEIGHT="9.301471913982164"/>
<CONT_DATA CI_END="25.478359328642412" CI_START="-40.27835932864241" EFFECT_SIZE="-7.399999999999999" ESTIMABLE="YES" MEAN_1="21.0" MEAN_2="28.4" MODIFIED="2009-03-17 10:55:58 +0100" MODIFIED_BY="[Empty name]" ORDER="99" SD_1="25.5" SD_2="34.5" SE="16.774981371077587" STUDY_ID="STD-Kranzler-1998" TOTAL_1="15" TOTAL_2="5" WEIGHT="0.3066500712539132"/>
<CONT_DATA CI_END="14.507648879397554" CI_START="-3.5076488793975535" EFFECT_SIZE="5.5" ESTIMABLE="YES" MEAN_1="21.2" MEAN_2="15.7" MODIFIED="2009-03-17 10:56:16 +0100" MODIFIED_BY="[Empty name]" ORDER="100" SD_1="28.9" SD_2="21.3" SE="4.59582367352091" STUDY_ID="STD-Kranzler-2000" TOTAL_1="60" TOTAL_2="63" WEIGHT="2.9053601469095667"/>
<CONT_DATA CI_END="-1.1900385206011528" CI_START="-16.00996147939885" EFFECT_SIZE="-8.600000000000001" ESTIMABLE="YES" MEAN_1="37.1" MEAN_2="45.7" MODIFIED="2009-03-17 10:56:32 +0100" MODIFIED_BY="[Empty name]" ORDER="101" SD_1="33.6" SD_2="33.5" SE="3.7806620620826092" STUDY_ID="STD-Kranzler-2004" TOTAL_1="158" TOTAL_2="157" WEIGHT="3.7359417134746016"/>
<CONT_DATA CI_END="1.217743799985878" CI_START="-6.617743799985877" EFFECT_SIZE="-2.6999999999999993" ESTIMABLE="YES" MEAN_1="11.3" MEAN_2="14.0" MODIFIED="2009-03-17 10:56:48 +0100" MODIFIED_BY="[Empty name]" ORDER="102" SD_1="21.0" SD_2="23.0" SE="1.9988856075359243" STUDY_ID="STD-Krystal-2001" TOTAL_1="378" TOTAL_2="187" WEIGHT="6.567481459574123"/>
<CONT_DATA CI_END="24.903996418462345" CI_START="-26.703996418462342" EFFECT_SIZE="-0.8999999999999986" ESTIMABLE="YES" MEAN_1="31.4" MEAN_2="32.3" MODIFIED="2009-03-17 10:57:21 +0100" MODIFIED_BY="[Empty name]" ORDER="104" SD_1="64.1" SD_2="71.4" SE="13.16554621513506" STUDY_ID="STD-Latt-2002" TOTAL_1="56" TOTAL_2="51" WEIGHT="0.4878146249525673"/>
<CONT_DATA CI_END="11.96134040170408" CI_START="-14.561340401704081" EFFECT_SIZE="-1.3000000000000007" ESTIMABLE="YES" MEAN_1="31.2" MEAN_2="32.5" MODIFIED="2009-03-17 10:57:37 +0100" MODIFIED_BY="[Empty name]" ORDER="105" SD_1="34.8" SD_2="37.4" SE="6.766114329808017" STUDY_ID="STD-Morley-2006" TOTAL_1="53" TOTAL_2="61" WEIGHT="1.6115166673063404"/>
<CONT_DATA CI_END="-0.3071034962174135" CI_START="-22.492896503782582" EFFECT_SIZE="-11.399999999999999" ESTIMABLE="YES" MEAN_1="24.6" MEAN_2="36.0" MODIFIED="2009-03-17 10:57:52 +0100" MODIFIED_BY="[Empty name]" ORDER="106" SD_1="28.6" SD_2="31.0" SE="5.65974507250232" STUDY_ID="STD-Morris-2001" TOTAL_1="55" TOTAL_2="56" WEIGHT="2.143766389044853"/>
<CONT_DATA CI_END="-5.060579060576954" CI_START="-6.139420939423047" EFFECT_SIZE="-5.6000000000000005" ESTIMABLE="YES" MEAN_1="4.3" MEAN_2="9.9" MODIFIED="2009-03-23 21:17:45 +0100" MODIFIED_BY="[Empty name]" ORDER="107" SD_1="1.4" SD_2="1.3" SE="0.2752198222405768" STUDY_ID="STD-O_x0027_Malley-1992" TOTAL_1="46" TOTAL_2="51" WEIGHT="9.230415518806664"/>
<CONT_DATA CI_END="-7.649953868349279" CI_START="-10.550046131650724" EFFECT_SIZE="-9.100000000000001" ESTIMABLE="YES" MEAN_1="5.2" MEAN_2="14.3" MODIFIED="2009-03-17 10:58:34 +0100" MODIFIED_BY="[Empty name]" ORDER="108" SD_1="3.1" SD_2="3.0" SE="0.7398330495297372" STUDY_ID="STD-O_x0027_Malley-2008" TOTAL_1="34" TOTAL_2="34" WEIGHT="8.801063707364817"/>
<CONT_DATA CI_END="5.344288535884056" CI_START="-6.144288535884053" EFFECT_SIZE="-0.3999999999999986" ESTIMABLE="YES" MEAN_1="18.0" MEAN_2="18.4" MODIFIED="2009-03-17 10:58:52 +0100" MODIFIED_BY="[Empty name]" ORDER="109" SD_1="22.4" SD_2="23.0" SE="2.9308133114660624" STUDY_ID="STD-Oslin-2008" TOTAL_1="120" TOTAL_2="120" WEIGHT="4.90797066763235"/>
<CONT_DATA CI_END="7.087847410308637" CI_START="-51.687847410308635" EFFECT_SIZE="-22.3" ESTIMABLE="YES" MEAN_1="22.7" MEAN_2="45.0" MODIFIED="2009-03-17 10:59:08 +0100" MODIFIED_BY="[Empty name]" ORDER="110" SD_1="26.7" SD_2="52.0" SE="14.994075218787808" STUDY_ID="STD-Petrakis-2004" TOTAL_1="16" TOTAL_2="15" WEIGHT="0.3806626081024356"/>
<CONT_DATA CI_END="2.6640234941566527" CI_START="-6.4640234941566534" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" MEAN_1="4.6" MEAN_2="6.5" MODIFIED="2009-03-17 10:59:21 +0100" MODIFIED_BY="[Empty name]" ORDER="111" SD_1="11.8" SD_2="14.0" SE="2.328626204439004" STUDY_ID="STD-Petrakis-2005" TOTAL_1="59" TOTAL_2="64" WEIGHT="5.9432961312720405"/>
<CONT_DATA CI_END="2.246154080750266" CI_START="-6.846154080750264" EFFECT_SIZE="-2.299999999999999" ESTIMABLE="YES" MEAN_1="10.8" MEAN_2="13.1" MODIFIED="2009-03-17 10:59:35 +0100" MODIFIED_BY="[Empty name]" ORDER="112" SD_1="14.6" SD_2="15.1" SE="2.3195089892517147" STUDY_ID="STD-Pettinati-2008a" TOTAL_1="82" TOTAL_2="82" WEIGHT="5.960118994192925"/>
<CONT_DATA CI_END="6.109102065426589" CI_START="-6.909102065426589" EFFECT_SIZE="-0.40000000000000036" ESTIMABLE="YES" MEAN_1="12.6" MEAN_2="13.0" MODIFIED="2009-03-17 10:59:49 +0100" MODIFIED_BY="[Empty name]" ORDER="113" SD_1="14.6" SD_2="15.1" SE="3.321031466276705" STUDY_ID="STD-Schmitz-2004" TOTAL_1="40" TOTAL_2="40" WEIGHT="4.327321948035374"/>
<CONT_DATA CI_END="-3.8128541671534184" CI_START="-5.387145832846583" EFFECT_SIZE="-4.6000000000000005" ESTIMABLE="YES" MEAN_1="6.2" MEAN_2="10.8" MODIFIED="2009-03-17 11:00:02 +0100" MODIFIED_BY="[Empty name]" ORDER="114" SD_1="1.6" SD_2="2.3" SE="0.4016123964804905" STUDY_ID="STD-Volpicelli-1997" TOTAL_1="48" TOTAL_2="49" WEIGHT="9.149450855772242"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="74.06661865248157" CI_END="-0.9875653137788918" CI_START="-5.506317434696875" CI_STUDY="95" CI_TOTAL="95" DF="14" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.2469413742378834" ESTIMABLE="YES" I2="81.0980975577033" I2_Q="0.0" ID="CMP-001.04" MODIFIED="2010-01-09 09:23:48 +0100" MODIFIED_BY="[Empty name]" NO="4" NOTES="&lt;p&gt;Results provided by the investigator &lt;/p&gt;&lt;p&gt;Morley (2006)&lt;/p&gt;" NOTES_MODIFIED="2010-01-09 09:23:48 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="3.5084413152475236E-10" P_Q="1.0" P_Z="0.004852626845774346" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="15" SUBGROUPS="NO" SUBGROUP_TEST="NO" TAU2="10.711278201983136" TOTALS="YES" TOTAL_1="868" TOTAL_2="847" UNITS="" WEIGHT="100.0" Z="2.816657335090299">
<NAME>Heavy drinking days</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-0.2808779434996005" CI_START="-20.3191220565004" EFFECT_SIZE="-10.3" ESTIMABLE="YES" MEAN_1="28.2" MEAN_2="38.5" MODIFIED="2009-03-17 11:07:42 +0100" MODIFIED_BY="[Empty name]" ORDER="116" SD_1="24.4" SD_2="31.0" SE="5.111890899797117" STUDY_ID="STD-Balldin-2003" TOTAL_1="56" TOTAL_2="62" WEIGHT="3.606860402375963"/>
<CONT_DATA CI_END="8.482046111449346" CI_START="-23.482046111449346" EFFECT_SIZE="-7.5" ESTIMABLE="YES" MEAN_1="41.7" MEAN_2="49.2" MODIFIED="2009-03-17 11:07:57 +0100" MODIFIED_BY="[Empty name]" ORDER="117" SD_1="42.5" SD_2="40.0" SE="8.154254995251794" STUDY_ID="STD-Baltieri-2008" TOTAL_1="49" TOTAL_2="54" WEIGHT="1.7212574289918399"/>
<CONT_DATA CI_END="-3.9470838895107088" CI_START="-12.452916110489294" EFFECT_SIZE="-8.200000000000001" ESTIMABLE="YES" MEAN_1="0.1" MEAN_2="8.3" MODIFIED="2009-03-17 11:09:20 +0100" MODIFIED_BY="[Empty name]" ORDER="123" SD_1="0.7" SD_2="13.0" SE="2.169895030743295" STUDY_ID="STD-de-Goes-e-Castro-2004" TOTAL_1="35" TOTAL_2="36" WEIGHT="8.617956575772414"/>
<CONT_DATA CI_END="17.861762880995872" CI_START="-45.06176288099587" EFFECT_SIZE="-13.600000000000001" ESTIMABLE="YES" MEAN_1="11.7" MEAN_2="25.3" MODIFIED="2009-03-17 11:08:11 +0100" MODIFIED_BY="[Empty name]" ORDER="118" SD_1="17.8" SD_2="35.0" SE="16.052214800456664" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" WEIGHT="0.4951340815757832"/>
<CONT_DATA CI_END="4.142215133934515" CI_START="-9.942215133934514" EFFECT_SIZE="-2.8999999999999995" ESTIMABLE="YES" MEAN_1="4.2" MEAN_2="7.1" MODIFIED="2009-03-17 11:08:23 +0100" MODIFIED_BY="[Empty name]" ORDER="119" SD_1="14.3" SD_2="17.9" SE="3.5930329278918434" STUDY_ID="STD-Killeeen-2004" TOTAL_1="51" TOTAL_2="36" WEIGHT="5.625738899814422"/>
<CONT_DATA CI_END="7.398917318921166" CI_START="-10.598917318921165" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" MEAN_1="3.7" MEAN_2="5.3" MODIFIED="2009-03-17 11:08:37 +0100" MODIFIED_BY="[Empty name]" ORDER="120" SD_1="10.7" SD_2="8.2" SE="4.591368713865906" STUDY_ID="STD-Kranzler-1998" TOTAL_1="15" TOTAL_2="5" WEIGHT="4.179879548935914"/>
<CONT_DATA CI_END="11.34693745888842" CI_START="-2.1469374588884182" EFFECT_SIZE="4.6000000000000005" ESTIMABLE="YES" MEAN_1="12.4" MEAN_2="7.8" MODIFIED="2009-03-17 11:08:50 +0100" MODIFIED_BY="[Empty name]" ORDER="121" SD_1="21.4" SD_2="16.3" SE="3.4423782845539" STUDY_ID="STD-Kranzler-2000" TOTAL_1="60" TOTAL_2="63" WEIGHT="5.890033621892973"/>
<CONT_DATA CI_END="3.4361401046187847" CI_START="-10.236140104618789" EFFECT_SIZE="-3.400000000000002" ESTIMABLE="YES" MEAN_1="26.7" MEAN_2="30.1" MODIFIED="2009-03-17 11:09:05 +0100" MODIFIED_BY="[Empty name]" ORDER="122" SD_1="30.7" SD_2="31.2" SE="3.4878906747988165" STUDY_ID="STD-Kranzler-2004" TOTAL_1="158" TOTAL_2="157" WEIGHT="5.8088244842347905"/>
<CONT_DATA CI_END="-0.41105363012395124" CI_START="-1.9889463698760488" EFFECT_SIZE="-1.2" ESTIMABLE="YES" MEAN_1="0.5" MEAN_2="1.7" MODIFIED="2009-03-17 11:09:50 +0100" MODIFIED_BY="[Empty name]" ORDER="124" SD_1="1.4" SD_2="2.9" SE="0.40253105470261547" STUDY_ID="STD-Monti-2001" TOTAL_1="64" TOTAL_2="64" WEIGHT="12.221348133629249"/>
<CONT_DATA CI_END="11.689640426932968" CI_START="-11.28964042693297" EFFECT_SIZE="0.1999999999999993" ESTIMABLE="YES" MEAN_1="24.0" MEAN_2="23.8" MODIFIED="2009-05-22 10:34:31 +0200" MODIFIED_BY="[Empty name]" ORDER="590" SD_1="28.5" SD_2="28.2" SE="5.862169161046726" STUDY_ID="STD-Morley-2006" TOTAL_1="44" TOTAL_2="50" WEIGHT="2.948034422473287"/>
<CONT_DATA CI_END="-6.0974833746577835" CI_START="-8.902516625342214" EFFECT_SIZE="-7.499999999999999" ESTIMABLE="YES" MEAN_1="3.7" MEAN_2="11.2" MODIFIED="2009-03-17 11:10:07 +0100" MODIFIED_BY="[Empty name]" ORDER="125" SD_1="3.0" SD_2="2.9" SE="0.7155828558101514" STUDY_ID="STD-O_x0027_Malley-2008" TOTAL_1="34" TOTAL_2="34" WEIGHT="11.840195110892047"/>
<CONT_DATA CI_END="2.196070350111296" CI_START="-6.196070350111296" EFFECT_SIZE="-2.0" ESTIMABLE="YES" MEAN_1="9.2" MEAN_2="11.2" MODIFIED="2009-03-17 11:10:20 +0100" MODIFIED_BY="[Empty name]" ORDER="126" SD_1="15.5" SD_2="17.6" SE="2.140891558829327" STUDY_ID="STD-Oslin-2008" TOTAL_1="120" TOTAL_2="120" WEIGHT="8.688404791242391"/>
<CONT_DATA CI_END="1.490658215186967" CI_START="-4.490658215186968" EFFECT_SIZE="-1.5000000000000002" ESTIMABLE="YES" MEAN_1="1.2" MEAN_2="2.7" MODIFIED="2009-03-17 11:10:31 +0100" MODIFIED_BY="[Empty name]" ORDER="127" SD_1="3.7" SD_2="4.7" SE="1.525874066450658" STUDY_ID="STD-Petrakis-2004" TOTAL_1="16" TOTAL_2="15" WEIGHT="10.19101868512226"/>
<CONT_DATA CI_END="2.3953486567121054" CI_START="-6.195348656712106" EFFECT_SIZE="-1.9000000000000004" ESTIMABLE="YES" MEAN_1="4.0" MEAN_2="5.9" MODIFIED="2009-03-17 11:10:43 +0100" MODIFIED_BY="[Empty name]" ORDER="128" SD_1="11.4" SD_2="12.9" SE="2.191544686837752" STUDY_ID="STD-Petrakis-2005" TOTAL_1="59" TOTAL_2="64" WEIGHT="8.565505150417428"/>
<CONT_DATA CI_END="0.3682732425862012" CI_START="-6.5682732425862005" EFFECT_SIZE="-3.0999999999999996" ESTIMABLE="YES" MEAN_1="6.0" MEAN_2="9.1" MODIFIED="2009-03-17 11:10:56 +0100" MODIFIED_BY="[Empty name]" ORDER="129" SD_1="9.9" SD_2="12.6" SE="1.7695596806591842" STUDY_ID="STD-Pettinati-2008a" TOTAL_1="82" TOTAL_2="82" WEIGHT="9.59980866262924"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="43.992888271017904" CI_END="-1.9734000880555005" CI_START="-19.686152133228006" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="MD" EFFECT_SIZE="-10.829776110641754" ESTIMABLE="YES" I2="65.9035798977494" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2010-01-09 09:23:53 +0100" MODIFIED_BY="[Empty name]" NO="5" NOTES="&lt;p&gt;Brown (2009)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-01-09 09:23:53 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="1.1024653769853288E-4" P_Q="1.0" P_Z="0.01654399897672989" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="178.98470926822137" TOTALS="YES" TOTAL_1="966" TOTAL_2="872" UNITS="" WEIGHT="99.99999999999999" Z="2.3966881129886417">
<NAME>Consumed amount per drinking day</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="-5.867318335862279" CI_START="-41.732681664137715" EFFECT_SIZE="-23.799999999999997" ESTIMABLE="YES" MEAN_1="35.0" MEAN_2="58.8" MODIFIED="2009-03-17 11:12:54 +0100" MODIFIED_BY="[Empty name]" ORDER="14" SD_1="42.2" SD_2="60.2" SE="9.14949550378906" STUDY_ID="STD-Anton-1999" TOTAL_1="68" TOTAL_2="63" WEIGHT="7.772472321155892"/>
<CONT_DATA CI_END="9.555138740566779" CI_START="-28.75513874056678" EFFECT_SIZE="-9.600000000000001" ESTIMABLE="YES" MEAN_1="49.1" MEAN_2="58.7" MODIFIED="2009-03-17 11:13:08 +0100" MODIFIED_BY="[Empty name]" ORDER="130" SD_1="59.0" SD_2="64.5" SE="9.773209554695939" STUDY_ID="STD-Anton-2005" TOTAL_1="80" TOTAL_2="80" WEIGHT="7.43828878161795"/>
<CONT_DATA CI_END="27.866971388910134" CI_START="-18.06697138891015" EFFECT_SIZE="4.8999999999999915" ESTIMABLE="YES" MEAN_1="91.1" MEAN_2="86.2" MODIFIED="2009-03-17 11:18:08 +0100" MODIFIED_BY="[Empty name]" ORDER="131" SD_1="65.2" SD_2="61.7" SE="11.718057867425463" STUDY_ID="STD-Balldin-2003" TOTAL_1="56" TOTAL_2="62" WEIGHT="6.455353518411731"/>
<CONT_DATA CI_END="0.3618614855657398" CI_START="-50.761861485565746" EFFECT_SIZE="-25.200000000000003" ESTIMABLE="YES" MEAN_1="67.2" MEAN_2="92.4" MODIFIED="2009-07-20 13:34:49 +0200" MODIFIED_BY="[Empty name]" ORDER="637" SD_1="42.0" SD_2="43.4" SE="13.042005713979666" STUDY_ID="STD-Brown-2009" TOTAL_1="20" TOTAL_2="23" WEIGHT="5.849148662889218"/>
<CONT_DATA CI_END="24.32865987714329" CI_START="-27.12865987714329" EFFECT_SIZE="-1.3999999999999986" ESTIMABLE="YES" MEAN_1="54.6" MEAN_2="56.0" MODIFIED="2009-03-17 11:18:23 +0100" MODIFIED_BY="[Empty name]" ORDER="132" SD_1="51.8" SD_2="53.2" SE="13.12710849795592" STUDY_ID="STD-Hersh-1998" TOTAL_1="31" TOTAL_2="33" WEIGHT="5.8120686164279975"/>
<CONT_DATA CI_END="-16.873273203178066" CI_START="-44.72672679682193" EFFECT_SIZE="-30.799999999999997" ESTIMABLE="YES" MEAN_1="53.2" MEAN_2="84.0" MODIFIED="2009-03-17 11:18:35 +0100" MODIFIED_BY="[Empty name]" ORDER="133" SD_1="25.2" SD_2="11.2" SE="7.105603422651731" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" WEIGHT="8.897783649284735"/>
<CONT_DATA CI_END="51.95817838142918" CI_START="-7.1581783814291775" EFFECT_SIZE="22.4" ESTIMABLE="YES" MEAN_1="65.8" MEAN_2="43.4" MODIFIED="2009-03-17 11:18:51 +0100" MODIFIED_BY="[Empty name]" ORDER="134" SD_1="92.4" SD_2="54.6" SE="15.080980372384552" STUDY_ID="STD-Killeeen-2004" TOTAL_1="54" TOTAL_2="43" WEIGHT="5.023889940041679"/>
<CONT_DATA CI_END="24.93102165235637" CI_START="-19.33102165235635" EFFECT_SIZE="2.8000000000000114" ESTIMABLE="YES" MEAN_1="128.8" MEAN_2="126.0" MODIFIED="2009-03-17 11:19:06 +0100" MODIFIED_BY="[Empty name]" ORDER="135" SD_1="112.0" SD_2="84.0" SE="11.291545062523104" STUDY_ID="STD-Krystal-2001" TOTAL_1="198" TOTAL_2="110" WEIGHT="6.662059882746707"/>
<CONT_DATA CI_END="-29.50315147257252" CI_START="-77.69684852742748" EFFECT_SIZE="-53.599999999999994" ESTIMABLE="YES" MEAN_1="69.2" MEAN_2="122.8" MODIFIED="2009-03-17 11:19:24 +0100" MODIFIED_BY="[Empty name]" ORDER="136" SD_1="47.0" SD_2="86.4" SE="12.294536388168527" STUDY_ID="STD-Monti-2001" TOTAL_1="64" TOTAL_2="64" WEIGHT="6.184681315791074"/>
<CONT_DATA CI_END="10.600074727937734" CI_START="-34.60007472793774" EFFECT_SIZE="-12.0" ESTIMABLE="YES" MEAN_1="59.0" MEAN_2="71.0" MODIFIED="2009-03-17 11:19:39 +0100" MODIFIED_BY="[Empty name]" ORDER="137" SD_1="61.0" SD_2="60.0" SE="11.530862253696618" STUDY_ID="STD-Morley-2006" TOTAL_1="51" TOTAL_2="60" WEIGHT="6.545415141255479"/>
<CONT_DATA CI_END="0.6554506861548468" CI_START="-50.255450686154845" EFFECT_SIZE="-24.799999999999997" ESTIMABLE="YES" MEAN_1="56.7" MEAN_2="81.5" MODIFIED="2009-07-22 09:36:36 +0200" MODIFIED_BY="[Empty name]" ORDER="138" SD_1="51.6" SD_2="51.6" SE="12.987713492158116" STUDY_ID="STD-O_x0027_Malley-1992" TOTAL_1="27" TOTAL_2="38" WEIGHT="5.872924634440892"/>
<CONT_DATA CI_END="1.3625372771660178" CI_START="-9.762537277166023" EFFECT_SIZE="-4.200000000000003" ESTIMABLE="YES" MEAN_1="50.4" MEAN_2="54.6" MODIFIED="2009-03-17 11:20:27 +0100" MODIFIED_BY="[Empty name]" ORDER="139" SD_1="11.9" SD_2="11.5" SE="2.838081373455127" STUDY_ID="STD-O_x0027_Malley-2008" TOTAL_1="34" TOTAL_2="34" WEIGHT="10.916483861404007"/>
<CONT_DATA CI_END="74.19009674314017" CI_START="-18.990096743140185" EFFECT_SIZE="27.599999999999994" ESTIMABLE="YES" MEAN_1="149.0" MEAN_2="121.4" MODIFIED="2009-03-17 11:21:10 +0100" MODIFIED_BY="[Empty name]" ORDER="140" SD_1="94.1" SD_2="242.8" SE="23.77089431777161" STUDY_ID="STD-Oslin-2008" TOTAL_1="120" TOTAL_2="120" WEIGHT="2.744223981700108"/>
<CONT_DATA CI_END="45.220034173209996" CI_START="-15.420034173209988" EFFECT_SIZE="14.900000000000002" ESTIMABLE="YES" MEAN_1="45.7" MEAN_2="30.8" MODIFIED="2009-03-17 11:21:28 +0100" MODIFIED_BY="[Empty name]" ORDER="141" SD_1="52.7" SD_2="31.4" SE="15.46968944958711" STUDY_ID="STD-Petrakis-2004" TOTAL_1="16" TOTAL_2="15" WEIGHT="4.8812629151946325"/>
<CONT_DATA CI_END="4.236328587399949" CI_START="-40.23632858739995" EFFECT_SIZE="-18.0" ESTIMABLE="YES" MEAN_1="63.7" MEAN_2="81.7" MODIFIED="2009-03-17 11:21:45 +0100" MODIFIED_BY="[Empty name]" ORDER="142" SD_1="54.8" SD_2="86.9" SE="11.345274077889835" STUDY_ID="STD-Pettinati-2008a" TOTAL_1="82" TOTAL_2="82" WEIGHT="6.63572657680982"/>
<CONT_DATA CI_END="57.56278271358318" CI_START="-46.56278271358318" EFFECT_SIZE="5.5" ESTIMABLE="YES" MEAN_1="65.0" MEAN_2="59.5" MODIFIED="2009-03-17 11:22:05 +0100" MODIFIED_BY="[Empty name]" ORDER="143" SD_1="134.4" SD_2="100.8" SE="26.563132345414388" STUDY_ID="STD-Schmitz-2004" TOTAL_1="40" TOTAL_2="40" WEIGHT="2.3082162008280607"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="38.22125320886906" CI_END="-1.7486710910152237" CI_START="-18.98589394630097" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="MD" EFFECT_SIZE="-10.367282518658095" ESTIMABLE="YES" I2="60.754819005988736" I2_Q="0.0" ID="CMP-001.06" MODIFIED="2010-01-09 09:23:57 +0100" MODIFIED_BY="[Empty name]" NO="6" NOTES="&lt;p&gt;Results provided by the investigators:&lt;/p&gt;&lt;p&gt;Killeen (2004)&lt;/p&gt;&lt;p&gt;Morley (2006)&lt;/p&gt;&lt;p&gt;Morris (2001)&lt;/p&gt;" NOTES_MODIFIED="2010-01-09 09:23:57 +0100" NOTES_MODIFIED_BY="[Empty name]" P_CHI2="8.367849810155814E-4" P_Q="1.0" P_Z="0.018391994203450366" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="139.02180469293887" TOTALS="YES" TOTAL_1="839" TOTAL_2="806" UNITS="" WEIGHT="99.99999999999997" Z="2.3576304053980084">
<NAME>GGT</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="0.8155985914142327" CI_START="-42.81559859141423" EFFECT_SIZE="-21.0" ESTIMABLE="YES" MEAN_1="50.0" MEAN_2="71.0" MODIFIED="2009-03-17 11:23:59 +0100" MODIFIED_BY="[Empty name]" ORDER="9" SD_1="45.0" SD_2="77.0" SE="11.130611972206065" STUDY_ID="STD-Anton-1999" TOTAL_1="68" TOTAL_2="63" WEIGHT="7.354742459950882"/>
<CONT_DATA CI_END="-14.776956098980381" CI_START="-62.22304390101961" EFFECT_SIZE="-38.49999999999999" ESTIMABLE="YES" MEAN_1="48.6" MEAN_2="87.1" MODIFIED="2009-08-26 08:41:17 +0200" MODIFIED_BY="[Empty name]" ORDER="144" SD_1="35.9" SD_2="87.5" SE="12.103816237514543" STUDY_ID="STD-Balldin-2003" TOTAL_1="56" TOTAL_2="62" WEIGHT="6.772289869138588"/>
<CONT_DATA CI_END="13.771439145144093" CI_START="-61.571439145144105" EFFECT_SIZE="-23.900000000000006" ESTIMABLE="YES" MEAN_1="63.0" MEAN_2="86.9" MODIFIED="2009-03-17 11:24:21 +0100" MODIFIED_BY="[Empty name]" ORDER="145" SD_1="63.0" SD_2="124.8" SE="19.2204751935707" STUDY_ID="STD-Baltieri-2008" TOTAL_1="49" TOTAL_2="54" WEIGHT="3.8030450827077957"/>
<CONT_DATA CI_END="46.18363810179675" CI_START="-10.783638101796754" EFFECT_SIZE="17.7" ESTIMABLE="YES" MEAN_1="48.5" MEAN_2="30.8" MODIFIED="2009-03-17 11:25:09 +0100" MODIFIED_BY="[Empty name]" ORDER="147" SD_1="62.6" SD_2="16.5" SE="14.532735461708508" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" WEIGHT="5.521216053418984"/>
<CONT_DATA CI_END="-5.66594483124419" CI_START="-33.13405516875581" EFFECT_SIZE="-19.4" ESTIMABLE="YES" MEAN_1="11.5" MEAN_2="30.9" MODIFIED="2009-03-17 11:25:22 +0100" MODIFIED_BY="[Empty name]" ORDER="148" SD_1="5.3" SD_2="44.0" SE="7.007299765244812" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" WEIGHT="10.278602924918895"/>
<CONT_DATA CI_END="48.36285649636069" CI_START="-13.162856496360689" EFFECT_SIZE="17.6" ESTIMABLE="YES" MEAN_1="53.9" MEAN_2="36.3" MODIFIED="2009-06-06 12:46:15 +0200" MODIFIED_BY="[Empty name]" ORDER="613" SD_1="85.6" SD_2="34.0" SE="15.695623357885234" STUDY_ID="STD-Killeeen-2004" TOTAL_1="36" TOTAL_2="27" WEIGHT="5.017594506626662"/>
<CONT_DATA CI_END="13.867429320119584" CI_START="-22.067429320119587" EFFECT_SIZE="-4.100000000000001" ESTIMABLE="YES" MEAN_1="29.4" MEAN_2="33.5" MODIFIED="2009-03-17 11:25:38 +0100" MODIFIED_BY="[Empty name]" ORDER="149" SD_1="21.3" SD_2="16.4" SE="9.167224225467598" STUDY_ID="STD-Kranzler-1998" TOTAL_1="15" TOTAL_2="5" WEIGHT="8.668762449049407"/>
<CONT_DATA CI_END="18.629107862416646" CI_START="-29.829107862416635" EFFECT_SIZE="-5.599999999999994" ESTIMABLE="YES" MEAN_1="42.7" MEAN_2="48.3" MODIFIED="2009-03-17 11:25:53 +0100" MODIFIED_BY="[Empty name]" ORDER="150" SD_1="72.5" SD_2="64.8" SE="12.362016880683905" STUDY_ID="STD-Kranzler-2000" TOTAL_1="61" TOTAL_2="63" WEIGHT="6.625699254179012"/>
<CONT_DATA CI_END="13.164008185031939" CI_START="-44.16400818503194" EFFECT_SIZE="-15.5" ESTIMABLE="YES" MEAN_1="47.0" MEAN_2="62.5" MODIFIED="2009-03-17 11:26:09 +0100" MODIFIED_BY="[Empty name]" ORDER="151" SD_1="78.5" SD_2="165.7" SE="14.62476270540172" STUDY_ID="STD-Kranzler-2004" TOTAL_1="158" TOTAL_2="157" WEIGHT="5.479235998677355"/>
<CONT_DATA CI_END="10.27476706488017" CI_START="-14.474767064880172" EFFECT_SIZE="-2.1000000000000014" ESTIMABLE="YES" MEAN_1="26.4" MEAN_2="28.5" MODIFIED="2009-03-17 11:26:25 +0100" MODIFIED_BY="[Empty name]" ORDER="152" SD_1="33.6" SD_2="31.7" SE="6.313772682809865" STUDY_ID="STD-Latt-2002" TOTAL_1="56" TOTAL_2="51" WEIGHT="10.80944029869189"/>
<CONT_DATA CI_END="154.4410899450053" CI_START="11.15891005499472" EFFECT_SIZE="82.80000000000001" ESTIMABLE="YES" MEAN_1="129.8" MEAN_2="47.0" MODIFIED="2009-05-22 10:39:45 +0200" MODIFIED_BY="[Empty name]" ORDER="591" SD_1="235.1" SD_2="63.2" SE="36.552248158691214" STUDY_ID="STD-Morley-2006" TOTAL_1="44" TOTAL_2="50" WEIGHT="1.310872033773096"/>
<CONT_DATA CI_END="52.07665388415121" CI_START="-160.0766538841512" EFFECT_SIZE="-54.0" ESTIMABLE="YES" MEAN_1="94.0" MEAN_2="148.0" MODIFIED="2009-03-17 11:26:43 +0100" MODIFIED_BY="[Empty name]" ORDER="153" SD_1="180.0" SD_2="362.0" SE="54.121736277232806" STUDY_ID="STD-Morris-2001" TOTAL_1="55" TOTAL_2="56" WEIGHT="0.6302269906558101"/>
<CONT_DATA CI_END="27.34192964737867" CI_START="-20.34192964737867" EFFECT_SIZE="3.5" ESTIMABLE="YES" MEAN_1="43.4" MEAN_2="39.9" MODIFIED="2009-03-17 11:26:58 +0100" MODIFIED_BY="[Empty name]" ORDER="154" SD_1="53.3" SD_2="46.8" SE="12.164473345143465" STUDY_ID="STD-O_x0027_Malley-2008" TOTAL_1="34" TOTAL_2="34" WEIGHT="6.737553834964283"/>
<CONT_DATA CI_END="15.05591334713942" CI_START="-34.255913347139426" EFFECT_SIZE="-9.600000000000001" ESTIMABLE="YES" MEAN_1="36.1" MEAN_2="45.7" MODIFIED="2009-03-17 11:27:15 +0100" MODIFIED_BY="[Empty name]" ORDER="155" SD_1="29.3" SD_2="95.9" SE="12.579778782478718" STUDY_ID="STD-Petrakis-2005" TOTAL_1="59" TOTAL_2="64" WEIGHT="6.5046432322555665"/>
<CONT_DATA CI_END="-1.4578873959646756" CI_START="-150.34211260403532" EFFECT_SIZE="-75.9" ESTIMABLE="YES" MEAN_1="51.4" MEAN_2="127.3" MODIFIED="2009-03-17 11:27:31 +0100" MODIFIED_BY="[Empty name]" ORDER="156" SD_1="36.6" SD_2="221.7" SE="37.98136761247922" STUDY_ID="STD-Volpicelli-1992" TOTAL_1="35" TOTAL_2="35" WEIGHT="1.2225878937508239"/>
<CONT_DATA CI_END="-16.00189543676479" CI_START="-26.198104563235212" EFFECT_SIZE="-21.1" ESTIMABLE="YES" MEAN_1="45.1" MEAN_2="66.2" MODIFIED="2009-03-17 11:27:59 +0100" MODIFIED_BY="[Empty name]" ORDER="157" SD_1="7.4" SD_2="15.0" SE="2.6011215529715894" STUDY_ID="STD-Volpicelli-1997" TOTAL_1="48" TOTAL_2="40" WEIGHT="13.263487117240919"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="7.203526530894306" CI_END="0.09411253429273322" CI_START="0.009607010214148191" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RD" EFFECT_SIZE="0.051859772253440704" ESTIMABLE="YES" EVENTS_1="429" EVENTS_2="359" I2="0.0" I2_Q="0.0" ID="CMP-001.07" LOG_CI_END="-1.0263525316029902" LOG_CI_START="-2.017411747557332" LOG_EFFECT_SIZE="-1.2851693948032883" METHOD="MH" MODIFIED="2010-01-29 17:27:37 +0100" MODIFIED_BY="[Empty name]" NO="7" P_CHI2="0.514841580397668" P_Q="0.0" P_Z="0.01614588897876347" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="539" TOTAL_2="482" WEIGHT="100.0" Z="2.4056009822191333">
<NAME>Side effect: Any</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.12046554744551671" CI_START="-0.035096015017160836" EFFECT_SIZE="0.04268476621417794" ESTIMABLE="YES" EVENTS_1="81" EVENTS_2="71" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 12:58:59 +0100" MODIFIED_BY="[Empty name]" ORDER="237" O_E="0.0" SE="0.0396848012743416" STUDY_ID="STD-Chick-2000" TOTAL_1="85" TOTAL_2="78" VAR="0.0015748834521839843" WEIGHT="29.50975513299637"/>
<DICH_DATA CI_END="0.17068808526660348" CI_START="-0.12190759746172539" EFFECT_SIZE="0.024390243902439046" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="52" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 12:59:08 +0100" MODIFIED_BY="[Empty name]" ORDER="238" O_E="0.0" SE="0.07464312738302496" STUDY_ID="STD-Gastpar-2002" TOTAL_1="82" TOTAL_2="82" VAR="0.005571596465518492" WEIGHT="8.341312104094113"/>
<DICH_DATA CI_END="0.48638222804925396" CI_START="-0.24638222804925397" EFFECT_SIZE="0.12" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 12:59:17 +0100" MODIFIED_BY="[Empty name]" ORDER="239" O_E="0.0" SE="0.18693314312876677" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" VAR="0.034944" WEIGHT="1.3299686652059686"/>
<DICH_DATA CI_END="0.40484841980213127" CI_START="-0.40484841980213127" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 12:59:28 +0100" MODIFIED_BY="[Empty name]" ORDER="240" O_E="0.0" SE="0.2065591117977289" STUDY_ID="STD-Kranzler-1998" TOTAL_1="15" TOTAL_2="5" VAR="0.042666666666666665" WEIGHT="1.0892443368036884"/>
<DICH_DATA CI_END="0.21453730839498947" CI_START="-0.03030623891801837" EFFECT_SIZE="0.09211553473848555" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="51" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 12:59:37 +0100" MODIFIED_BY="[Empty name]" ORDER="241" O_E="0.0" SE="0.06246123634013239" STUDY_ID="STD-Kranzler-2000" TOTAL_1="61" TOTAL_2="63" VAR="0.0039014060451378753" WEIGHT="11.912224592689114"/>
<DICH_DATA CI_END="0.1261288857504271" CI_START="-0.03984362494673341" EFFECT_SIZE="0.04314263040184685" ESTIMABLE="YES" EVENTS_1="140" EVENTS_2="132" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 12:59:48 +0100" MODIFIED_BY="[Empty name]" ORDER="242" O_E="0.0" SE="0.04234070421863118" STUDY_ID="STD-Kranzler-2004" TOTAL_1="167" TOTAL_2="166" VAR="0.0017927352337296126" WEIGHT="25.92375280106021"/>
<DICH_DATA CI_END="0.2111174239438149" CI_START="-0.25556186838825934" EFFECT_SIZE="-0.0222222222222222" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 12:59:55 +0100" MODIFIED_BY="[Empty name]" ORDER="243" O_E="0.0" SE="0.11905302750794935" STUDY_ID="STD-Lee-2001" TOTAL_1="35" TOTAL_2="18" VAR="0.014173623358808545" WEIGHT="3.2789374925836943"/>
<DICH_DATA CI_END="0.432111068478518" CI_START="0.07505874284223676" EFFECT_SIZE="0.2535849056603774" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="26" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:00:03 +0100" MODIFIED_BY="[Empty name]" ORDER="244" O_E="0.0" SE="0.09108645068293714" STUDY_ID="STD-O_x0027_Malley-2007" TOTAL_1="53" TOTAL_2="50" VAR="0.00829674149801514" WEIGHT="5.601527424721576"/>
<DICH_DATA CI_END="0.11712827820384197" CI_START="-0.11712827820384197" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:00:12 +0100" MODIFIED_BY="[Empty name]" ORDER="245" O_E="0.0" SE="0.059760423726014804" STUDY_ID="STD-Petrakis-2004" TOTAL_1="16" TOTAL_2="15" VAR="0.003571308243912833" WEIGHT="13.013277449845269"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="19.15290060592982" CI_END="0.10950066113798647" CI_START="0.04453991328255043" CI_STUDY="95" CI_TOTAL="95" DF="12" EFFECT_MEASURE="RD" EFFECT_SIZE="0.07702028721026845" ESTIMABLE="YES" EVENTS_1="142" EVENTS_2="65" I2="37.34630463082574" I2_Q="0.0" ID="CMP-001.08" LOG_CI_END="-0.9605832586529726" LOG_CI_START="-1.351250632855337" LOG_EFFECT_SIZE="-1.1133948662170248" METHOD="MH" MODIFIED="2010-01-29 17:27:37 +0100" MODIFIED_BY="[Empty name]" NO="8" P_CHI2="0.0849048245827535" P_Q="0.0" P_Z="3.3575902591705354E-6" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="13" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.001117516931539239" TOTALS="YES" TOTAL_1="892" TOTAL_2="864" WEIGHT="100.00000000000003" Z="4.647637042202701">
<NAME>Side effect: Abdominal pain</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.3321765007188406" CI_START="0.06324833588246664" EFFECT_SIZE="0.19771241830065361" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:02:57 +0100" MODIFIED_BY="[Empty name]" ORDER="246" O_E="0.0" SE="0.06860538432278475" STUDY_ID="STD-Anton-1999" TOTAL_1="68" TOTAL_2="63" VAR="0.004706698758076999" WEIGHT="4.71529000959579"/>
<DICH_DATA CI_END="0.27713922573504657" CI_START="0.05120178808983823" EFFECT_SIZE="0.1641705069124424" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:03:10 +0100" MODIFIED_BY="[Empty name]" ORDER="247" O_E="0.0" SE="0.057638160554830085" STUDY_ID="STD-Balldin-2003" TOTAL_1="56" TOTAL_2="62" VAR="0.0033221575521443707" WEIGHT="6.185783700113188"/>
<DICH_DATA CI_END="0.11461867434518948" CI_START="-0.08656437570265553" EFFECT_SIZE="0.014027149321266974" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:03:18 +0100" MODIFIED_BY="[Empty name]" ORDER="248" O_E="0.0" SE="0.05132314971977833" STUDY_ID="STD-Chick-2000" TOTAL_1="85" TOTAL_2="78" VAR="0.002634065697158783" WEIGHT="7.320341512645672"/>
<DICH_DATA CI_END="0.08173560763724942" CI_START="-0.03295511983237137" EFFECT_SIZE="0.024390243902439025" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:03:26 +0100" MODIFIED_BY="[Empty name]" ORDER="249" O_E="0.0" SE="0.029258376269739293" STUDY_ID="STD-Gastpar-2002" TOTAL_1="82" TOTAL_2="82" VAR="8.560525819416434E-4" WEIGHT="13.91532746497532"/>
<DICH_DATA CI_END="0.1380299521656463" CI_START="0.020385889418512104" EFFECT_SIZE="0.07920792079207921" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-29 15:53:08 +0100" MODIFIED_BY="[Empty name]" ORDER="250" O_E="0.0" SE="0.03001179197043812" STUDY_ID="STD-Guardia-2002" TOTAL_1="101" TOTAL_2="101" VAR="9.007076572768541E-4" WEIGHT="13.607438045875977"/>
<DICH_DATA CI_END="0.29030099594615466" CI_START="-0.13389825889825627" EFFECT_SIZE="0.07820136852394918" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:03:41 +0100" MODIFIED_BY="[Empty name]" ORDER="251" O_E="0.0" SE="0.10821608411951456" STUDY_ID="STD-Hersh-1998" TOTAL_1="31" TOTAL_2="33" VAR="0.011710720862161851" WEIGHT="2.1408136095250194"/>
<DICH_DATA CI_END="0.5167856388460081" CI_START="-0.036785638846008106" EFFECT_SIZE="0.24" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:03:49 +0100" MODIFIED_BY="[Empty name]" ORDER="252" O_E="0.0" SE="0.14121975762272057" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" VAR="0.019943019943019943" WEIGHT="1.3039964849212007"/>
<DICH_DATA CI_END="0.12796222073258817" CI_START="-0.08221058674566005" EFFECT_SIZE="0.022875816993464054" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:03:57 +0100" MODIFIED_BY="[Empty name]" ORDER="253" O_E="0.0" SE="0.053616497327518386" STUDY_ID="STD-Killeeen-2004" TOTAL_1="51" TOTAL_2="36" VAR="0.0028747287856717863" WEIGHT="6.879052042458952"/>
<DICH_DATA CI_END="0.3090197445065897" CI_START="0.027175935951385843" EFFECT_SIZE="0.16809784022898777" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:04:06 +0100" MODIFIED_BY="[Empty name]" ORDER="254" O_E="0.0" SE="0.07190025193788045" STUDY_ID="STD-Kranzler-2000" TOTAL_1="61" TOTAL_2="63" VAR="0.005169646228730682" WEIGHT="4.368085471126769"/>
<DICH_DATA CI_END="0.08978867517076536" CI_START="0.01799575596695919" EFFECT_SIZE="0.05389221556886228" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:04:15 +0100" MODIFIED_BY="[Empty name]" ORDER="255" O_E="0.0" SE="0.01831485674484316" STUDY_ID="STD-Kranzler-2004" TOTAL_1="167" TOTAL_2="166" VAR="3.35433977584127E-4" WEIGHT="18.901441117200683"/>
<DICH_DATA CI_END="0.22696315241001416" CI_START="0.03718779098621225" EFFECT_SIZE="0.1320754716981132" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:04:23 +0100" MODIFIED_BY="[Empty name]" ORDER="256" O_E="0.0" SE="0.04841297159558179" STUDY_ID="STD-Morley-2006" TOTAL_1="53" TOTAL_2="61" VAR="0.0023438158187146095" WEIGHT="7.934188370928632"/>
<DICH_DATA CI_END="0.1364854061274224" CI_START="-0.02554200990100733" EFFECT_SIZE="0.05547169811320754" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:04:30 +0100" MODIFIED_BY="[Empty name]" ORDER="257" O_E="0.0" SE="0.041334284024217106" STUDY_ID="STD-O_x0027_Malley-2007" TOTAL_1="53" TOTAL_2="50" VAR="0.0017085230357946493" WEIGHT="9.71779110430884"/>
<DICH_DATA CI_END="0.2606346158267173" CI_START="-0.09008376836909018" EFFECT_SIZE="0.08527542372881358" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="26" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:04:38 +0100" MODIFIED_BY="[Empty name]" ORDER="258" O_E="0.0" SE="0.08947061960378593" STUDY_ID="STD-Petrakis-2005" TOTAL_1="59" TOTAL_2="64" VAR="0.008004991772285362" WEIGHT="3.010451066323974"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5229850217071669" CI_END="0.0432937389511046" CI_START="-0.04921019242340142" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.0029582267361484083" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="3" I2="0.0" I2_Q="0.0" ID="CMP-001.09" LOG_CI_END="-1.3635749058543662" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-01-29 17:27:37 +0100" MODIFIED_BY="[Empty name]" NO="9" P_CHI2="0.4695711965823606" P_Q="0.0" P_Z="0.9002407540139017" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="117" TOTAL_2="100" WEIGHT="100.0" Z="0.1253572204943558">
<NAME>Side effect: Agitation</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.04039722670052318" CI_START="-0.0647874706029622" EFFECT_SIZE="-0.01219512195121951" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:05:42 +0100" MODIFIED_BY="[Empty name]" ORDER="259" O_E="0.0" SE="0.0268333240133923" STUDY_ID="STD-Gastpar-2002" TOTAL_1="82" TOTAL_2="82" VAR="7.200272776076958E-4" WEIGHT="77.34197498525293"/>
<DICH_DATA CI_END="0.12573851237943567" CI_START="-0.06859565523657854" EFFECT_SIZE="0.02857142857142857" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:05:48 +0100" MODIFIED_BY="[Empty name]" ORDER="260" O_E="0.0" SE="0.04957595372897087" STUDY_ID="STD-Lee-2001" TOTAL_1="35" TOTAL_2="18" VAR="0.0024577751881370603" WEIGHT="22.658025014747064"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.2291538418240937" CI_END="0.06353869452887743" CI_START="-0.015508382162196275" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RD" EFFECT_SIZE="0.024015156183340578" ESTIMABLE="YES" EVENTS_1="176" EVENTS_2="169" I2="0.0" I2_Q="0.0" ID="CMP-001.10" LOG_CI_END="-1.1969617124665226" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.6195145845677044" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="10" P_CHI2="0.9191646391179201" P_Q="0.0" P_Z="0.2336902892553171" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="561" TOTAL_2="557" WEIGHT="99.99999999999999" Z="1.1909065628423705">
<NAME>Side effect: Anxiety</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.21586199338409953" CI_START="-0.07793095890134091" EFFECT_SIZE="0.06896551724137931" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="10" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:08:14 +0100" MODIFIED_BY="[Empty name]" ORDER="262" O_E="0.0" SE="0.07494855890282723" STUDY_ID="STD-Ahmadi-2002" TOTAL_1="58" TOTAL_2="58" VAR="0.005617286481610562" WEIGHT="7.239171747164455"/>
<DICH_DATA CI_END="0.14891470507873067" CI_START="-0.04604894338943956" EFFECT_SIZE="0.05143288084464555" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:08:21 +0100" MODIFIED_BY="[Empty name]" ORDER="263" O_E="0.0" SE="0.04973653852979407" STUDY_ID="STD-Chick-2000" TOTAL_1="85" TOTAL_2="78" VAR="0.00247372326492569" WEIGHT="16.438581538192214"/>
<DICH_DATA CI_END="0.22528107886936416" CI_START="-0.050677904266189566" EFFECT_SIZE="0.0873015873015873" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:08:27 +0100" MODIFIED_BY="[Empty name]" ORDER="264" O_E="0.0" SE="0.07039899337750156" STUDY_ID="STD-de-Goes-e-Castro-2004" TOTAL_1="35" TOTAL_2="36" VAR="0.00495601826856551" WEIGHT="8.205074999688028"/>
<DICH_DATA CI_END="0.1519051064666009" CI_START="-0.14476224932374374" EFFECT_SIZE="0.0035714285714285865" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:08:35 +0100" MODIFIED_BY="[Empty name]" ORDER="265" O_E="0.0" SE="0.07568183857724399" STUDY_ID="STD-Morris-2001" TOTAL_1="55" TOTAL_2="56" VAR="0.005727740690432017" WEIGHT="7.099570981160615"/>
<DICH_DATA CI_END="0.08206117831956843" CI_START="-0.046589480206360875" EFFECT_SIZE="0.01773584905660377" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:08:42 +0100" MODIFIED_BY="[Empty name]" ORDER="266" O_E="0.0" SE="0.032819648611073796" STUDY_ID="STD-O_x0027_Malley-2007" TOTAL_1="53" TOTAL_2="50" VAR="0.0010771293349543583" WEIGHT="37.75266374592528"/>
<DICH_DATA CI_END="0.2256344279822518" CI_START="-0.3415764569677591" EFFECT_SIZE="-0.05797101449275366" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:08:50 +0100" MODIFIED_BY="[Empty name]" ORDER="267" O_E="0.0" SE="0.14469931320781862" STUDY_ID="STD-Oslin-1997" TOTAL_1="21" TOTAL_2="23" VAR="0.020937891242814394" WEIGHT="1.9421488593011738"/>
<DICH_DATA CI_END="0.10839929801687329" CI_START="-0.1417326313502066" EFFECT_SIZE="-0.016666666666666663" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="52" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:08:58 +0100" MODIFIED_BY="[Empty name]" ORDER="268" O_E="0.0" SE="0.0638103381848056" STUDY_ID="STD-Oslin-2008" TOTAL_1="120" TOTAL_2="120" VAR="0.004071759259259259" WEIGHT="9.986961164497176"/>
<DICH_DATA CI_END="0.1736581848827511" CI_START="-0.124877697077873" EFFECT_SIZE="0.024390243902439046" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="49" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:09:15 +0100" MODIFIED_BY="[Empty name]" ORDER="270" O_E="0.0" SE="0.07615851217559022" STUDY_ID="STD-Pettinati-2008a" TOTAL_1="82" TOTAL_2="82" VAR="0.005800118976799525" WEIGHT="7.0109771465140645"/>
<DICH_DATA CI_END="0.1330710057268524" CI_START="-0.24703111968696626" EFFECT_SIZE="-0.056980056980056926" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="28" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:09:06 +0100" MODIFIED_BY="[Empty name]" ORDER="269" O_E="0.0" SE="0.09696660969589638" STUDY_ID="STD-Pettinati-2008b" TOTAL_1="52" TOTAL_2="54" VAR="0.009402523395916306" WEIGHT="4.324849817556995"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.282548858502402" CI_END="0.13219017244237155" CI_START="-0.12064909722651192" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.005770537607929821" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="14" I2="76.64941993563856" I2_Q="0.0" ID="CMP-001.11" LOG_CI_END="-0.8788008308768308" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-2.2387837242305757" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="11" P_CHI2="0.03850573846415961" P_Q="0.0" P_Z="0.9287129132804074" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0064245390864228575" TOTALS="YES" TOTAL_1="167" TOTAL_2="160" WEIGHT="100.0" Z="0.08946431381318197">
<NAME>Side effect: Arthralgia</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.04158467670756012" CI_START="-0.16104169028222076" EFFECT_SIZE="-0.05972850678733033" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:11:05 +0100" MODIFIED_BY="[Empty name]" ORDER="271" O_E="0.0" SE="0.051691349582969844" STUDY_ID="STD-Chick-2000" TOTAL_1="85" TOTAL_2="78" VAR="0.0026719956217087963" WEIGHT="45.735865295286445"/>
<DICH_DATA CI_END="0.13005883391771328" CI_START="-0.008107614405518153" EFFECT_SIZE="0.06097560975609757" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:11:23 +0100" MODIFIED_BY="[Empty name]" ORDER="272" O_E="0.0" SE="0.03524719061499873" STUDY_ID="STD-Gastpar-2002" TOTAL_1="82" TOTAL_2="82" VAR="0.0012423644462500544" WEIGHT="54.264134704713555"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7756185313936246" CI_END="0.04447224479967293" CI_START="-0.020149845252514273" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RD" EFFECT_SIZE="0.012161199773579332" ESTIMABLE="YES" EVENTS_1="79" EVENTS_2="48" I2="0.0" I2_Q="0.0" ID="CMP-001.12" LOG_CI_END="-1.351910948367443" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.9150235772555844" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="12" P_CHI2="0.620255062268392" P_Q="0.0" P_Z="0.46070325554251923" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="752" TOTAL_2="535" WEIGHT="100.00000000000003" Z="0.7376893426307686">
<NAME>Aide effect: Back pain</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.07658669011849539" CI_START="-0.12123224064639884" EFFECT_SIZE="-0.022322775263951725" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="10" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:13:09 +0100" MODIFIED_BY="[Empty name]" ORDER="274" O_E="0.0" SE="0.05046494025534773" STUDY_ID="STD-Chick-2000" TOTAL_1="85" TOTAL_2="78" VAR="0.0025467101949758156" WEIGHT="10.67152042838725"/>
<DICH_DATA CI_END="0.07324410474405516" CI_START="-0.07324410474405516" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:13:17 +0100" MODIFIED_BY="[Empty name]" ORDER="275" O_E="0.0" SE="0.037370127880815826" STUDY_ID="STD-Gastpar-2002" TOTAL_1="82" TOTAL_2="82" VAR="0.0013965264578285283" WEIGHT="19.46061939501288"/>
<DICH_DATA CI_END="0.09797710574703888" CI_START="-0.014794074219732035" EFFECT_SIZE="0.04159151576365342" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:13:42 +0100" MODIFIED_BY="[Empty name]" ORDER="276" O_E="0.0" SE="0.028768686786159233" STUDY_ID="STD-Kranzler-2004" TOTAL_1="167" TOTAL_2="166" VAR="8.276373394001328E-4" WEIGHT="32.83717224571385"/>
<DICH_DATA CI_END="0.055489360445710685" CI_START="-0.05070467145049538" EFFECT_SIZE="0.002392344497607654" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="24" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:13:51 +0100" MODIFIED_BY="[Empty name]" ORDER="277" O_E="0.0" SE="0.027090812059265126" STUDY_ID="STD-Krystal-2001" TOTAL_1="418" TOTAL_2="209" VAR="7.339120980304248E-4" WEIGHT="37.03068793088603"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.896379977117205" CI_END="0.21326772790102488" CI_START="0.04199990202624965" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RD" EFFECT_SIZE="0.12763381496363727" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="38" I2="0.0" I2_Q="0.0" ID="CMP-001.13" LOG_CI_END="-0.6710748578880524" LOG_CI_START="-1.3767517226856418" LOG_EFFECT_SIZE="-0.8940342495446936" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="13" P_CHI2="0.3874417316089175" P_Q="0.0" P_Z="0.0034863501513808194" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="136" TOTAL_2="142" WEIGHT="100.0" Z="2.921245473403564">
<NAME>Side effect: Blurred vision</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.234685186075333" CI_START="0.029691602891619873" EFFECT_SIZE="0.13218839448347644" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:14:49 +0100" MODIFIED_BY="[Empty name]" ORDER="278" O_E="0.0" SE="0.05229524236176694" STUDY_ID="STD-Kranzler-2000" TOTAL_1="61" TOTAL_2="63" VAR="0.0027347923736759437" WEIGHT="69.80250941495733"/>
<DICH_DATA CI_END="0.2485486123978286" CI_START="-0.44854861239782856" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:14:55 +0100" MODIFIED_BY="[Empty name]" ORDER="279" O_E="0.0" SE="0.1778341924377874" STUDY_ID="STD-Petrakis-2004" TOTAL_1="16" TOTAL_2="15" VAR="0.031625" WEIGHT="6.036217246212445"/>
<DICH_DATA CI_END="0.3455604731592348" CI_START="-0.0028697951931331844" EFFECT_SIZE="0.17134533898305082" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:15:02 +0100" MODIFIED_BY="[Empty name]" ORDER="280" O_E="0.0" SE="0.08888690585662326" STUDY_ID="STD-Petrakis-2005" TOTAL_1="59" TOTAL_2="64" VAR="0.007900882032764206" WEIGHT="24.161273338830224"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="17.7729249744514" CI_END="0.3139774073174335" CI_START="-0.044824397999020604" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RD" EFFECT_SIZE="0.13457650465920645" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="46" I2="88.746928246898" I2_Q="0.0" ID="CMP-001.14" LOG_CI_END="-0.5031016010681074" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-0.8710307557698455" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="14" P_CHI2="1.3824948588392338E-4" P_Q="0.0" P_Z="0.1414926612173283" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.02181229632964633" TOTALS="YES" TOTAL_1="322" TOTAL_2="195" WEIGHT="100.0" Z="1.4702551569644267">
<NAME>Side effect: Confusion</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.08595598134596578" CI_START="0.01305391964413323" EFFECT_SIZE="0.04950495049504951" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:16:50 +0100" MODIFIED_BY="[Empty name]" ORDER="282" O_E="0.0" SE="0.018597806458913204" STUDY_ID="STD-Anton-2004" TOTAL_1="202" TOTAL_2="68" VAR="3.4587840508319375E-4" WEIGHT="37.811080050832956"/>
<DICH_DATA CI_END="0.31192859695620545" CI_START="0.053931408248062085" EFFECT_SIZE="0.18293000260213377" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:16:57 +0100" MODIFIED_BY="[Empty name]" ORDER="283" O_E="0.0" SE="0.06581681876381205" STUDY_ID="STD-Kranzler-2000" TOTAL_1="61" TOTAL_2="63" VAR="0.004331853632188482" WEIGHT="32.0463476494075"/>
<DICH_DATA CI_END="0.34148757617640113" CI_START="0.03827937297614126" EFFECT_SIZE="0.1898834745762712" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="41" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:17:06 +0100" MODIFIED_BY="[Empty name]" ORDER="284" O_E="0.0" SE="0.07735045276135875" STUDY_ID="STD-Petrakis-2005" TOTAL_1="59" TOTAL_2="64" VAR="0.005983092542387193" WEIGHT="30.142572299759543"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.832223615490317" CI_END="0.10184939388425718" CI_START="-0.03574721987540763" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RD" EFFECT_SIZE="0.03305108700442477" ESTIMABLE="YES" EVENTS_1="52" EVENTS_2="40" I2="54.711291582511166" I2_Q="0.0" ID="CMP-001.15" LOG_CI_END="-0.9920415511852286" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.480814252600115" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="15" P_CHI2="0.06543271828940678" P_Q="0.0" P_Z="0.34640898734561076" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.002776819513286745" TOTALS="YES" TOTAL_1="267" TOTAL_2="278" WEIGHT="99.99999999999999" Z="0.9415775346291514">
<NAME>Side effect: Constipation</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.047437120279443815" CI_START="-0.08069486782290565" EFFECT_SIZE="-0.016628873771730914" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:18:00 +0100" MODIFIED_BY="[Empty name]" ORDER="285" O_E="0.0" SE="0.03268733229616417" STUDY_ID="STD-Baltieri-2008" TOTAL_1="49" TOTAL_2="54" VAR="0.0010684616926398573" WEIGHT="32.04285566106039"/>
<DICH_DATA CI_END="0.08291580147846156" CI_START="-0.009745069771144484" EFFECT_SIZE="0.036585365853658534" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:18:07 +0100" MODIFIED_BY="[Empty name]" ORDER="286" O_E="0.0" SE="0.023638411720955883" STUDY_ID="STD-Gastpar-2002" TOTAL_1="82" TOTAL_2="82" VAR="5.587745086894245E-4" WEIGHT="36.93908486641802"/>
<DICH_DATA CI_END="0.24614032306823797" CI_START="-0.03901047659412915" EFFECT_SIZE="0.10356492323705441" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="10" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:18:14 +0100" MODIFIED_BY="[Empty name]" ORDER="287" O_E="0.0" SE="0.07274388762028287" STUDY_ID="STD-Kranzler-2000" TOTAL_1="61" TOTAL_2="63" VAR="0.0052916731861123445" WEIGHT="15.270980001862162"/>
<DICH_DATA CI_END="0.11812491978121853" CI_START="-0.5681249197812185" EFFECT_SIZE="-0.22499999999999998" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:18:20 +0100" MODIFIED_BY="[Empty name]" ORDER="288" O_E="0.0" SE="0.17506695147857004" STUDY_ID="STD-Petrakis-2004" TOTAL_1="16" TOTAL_2="15" VAR="0.0306484375" WEIGHT="3.6862481149723427"/>
<DICH_DATA CI_END="0.31285151831211294" CI_START="-0.025245586108723128" EFFECT_SIZE="0.1438029661016949" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="19" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:18:29 +0100" MODIFIED_BY="[Empty name]" ORDER="289" O_E="0.0" SE="0.08625084621138522" STUDY_ID="STD-Petrakis-2005" TOTAL_1="59" TOTAL_2="64" VAR="0.007439208472180025" WEIGHT="12.060831355687082"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.962451057078015" CI_END="0.11831206467140824" CI_START="-0.08392382556398044" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0171941195537139" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" I2="79.84866775514722" I2_Q="0.0" ID="CMP-001.16" LOG_CI_END="-0.9269709666733476" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.764620057861941" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="16" P_CHI2="0.025903622910515067" P_Q="0.0" P_Z="0.7389284119318681" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.004288676580973912" TOTALS="YES" TOTAL_1="167" TOTAL_2="160" WEIGHT="100.0" Z="0.33327274433762316">
<NAME>Side effect: Coughing</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.14552264114965752" CI_START="-0.01068101219038152" EFFECT_SIZE="0.067420814479638" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:19:18 +0100" MODIFIED_BY="[Empty name]" ORDER="290" O_E="0.0" SE="0.03984860297744079" STUDY_ID="STD-Chick-2000" TOTAL_1="85" TOTAL_2="78" VAR="0.0015879111592537031" WEIGHT="45.29341474650819"/>
<DICH_DATA CI_END="0.022679395632255548" CI_START="-0.0714598834371336" EFFECT_SIZE="-0.024390243902439022" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:19:25 +0100" MODIFIED_BY="[Empty name]" ORDER="291" O_E="0.0" SE="0.024015563503193876" STUDY_ID="STD-Gastpar-2002" TOTAL_1="82" TOTAL_2="82" VAR="5.767472903759377E-4" WEIGHT="54.70658525349181"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="23.56165353596322" CI_END="0.13887596509385197" CI_START="0.05068231734325247" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RD" EFFECT_SIZE="0.09477914121855222" ESTIMABLE="YES" EVENTS_1="351" EVENTS_2="182" I2="53.31397270904523" I2_Q="0.0" ID="CMP-001.17" LOG_CI_END="-0.8573729099882276" LOG_CI_START="-1.2951435361252401" LOG_EFFECT_SIZE="-1.0232872307044971" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="17" P_CHI2="0.014713309201605851" P_Q="0.0" P_Z="2.5241181438073307E-5" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.002420015085399588" TOTALS="YES" TOTAL_1="1633" TOTAL_2="1169" WEIGHT="99.99999999999999" Z="4.212632270281289">
<NAME>Side effect: Daytime sleepiness</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.34736957013589453" CI_START="0.024712596063918707" EFFECT_SIZE="0.18604108309990663" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="17" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:20:49 +0100" MODIFIED_BY="[Empty name]" ORDER="292" O_E="0.0" SE="0.0823119650710556" STUDY_ID="STD-Anton-1999" TOTAL_1="68" TOTAL_2="63" VAR="0.006775259593858679" WEIGHT="5.504954466400431"/>
<DICH_DATA CI_END="0.20082616539017867" CI_START="0.058073510985225896" EFFECT_SIZE="0.12944983818770228" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="72" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:20:59 +0100" MODIFIED_BY="[Empty name]" ORDER="293" O_E="0.0" SE="0.036417162644560686" STUDY_ID="STD-Anton-2006" TOTAL_1="309" TOTAL_2="309" VAR="0.0013262097350803862" WEIGHT="13.512154459773216"/>
<DICH_DATA CI_END="0.23436495865752782" CI_START="-0.07790237362351421" EFFECT_SIZE="0.0782312925170068" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:21:08 +0100" MODIFIED_BY="[Empty name]" ORDER="294" O_E="0.0" SE="0.07966149754387501" STUDY_ID="STD-Baltieri-2008" TOTAL_1="49" TOTAL_2="54" VAR="0.006345954190932804" WEIGHT="5.774554623643443"/>
<DICH_DATA CI_END="0.2209474594774835" CI_START="-0.042968575616246674" EFFECT_SIZE="0.08898944193061842" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:21:18 +0100" MODIFIED_BY="[Empty name]" ORDER="295" O_E="0.0" SE="0.06732675630151018" STUDY_ID="STD-Chick-2000" TOTAL_1="85" TOTAL_2="78" VAR="0.004532892114082941" WEIGHT="7.280345755100681"/>
<DICH_DATA CI_END="0.1269835451758224" CI_START="0.014366544176803428" EFFECT_SIZE="0.0706750446763129" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:21:27 +0100" MODIFIED_BY="[Empty name]" ORDER="296" O_E="0.0" SE="0.02872935469409833" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="8.253758211393098E-4" WEIGHT="15.597371741373887"/>
<DICH_DATA CI_END="0.16819396706246126" CI_START="-0.021852503647827135" EFFECT_SIZE="0.07317073170731707" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:21:34 +0100" MODIFIED_BY="[Empty name]" ORDER="297" O_E="0.0" SE="0.048482133398713115" STUDY_ID="STD-Gastpar-2002" TOTAL_1="82" TOTAL_2="82" VAR="0.0023505172588906137" WEIGHT="10.610884648114293"/>
<DICH_DATA CI_END="0.5167856388460081" CI_START="-0.036785638846008106" EFFECT_SIZE="0.24" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:21:41 +0100" MODIFIED_BY="[Empty name]" ORDER="298" O_E="0.0" SE="0.14121975762272057" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" VAR="0.019943019943019943" WEIGHT="2.2635375006582477"/>
<DICH_DATA CI_END="0.27270487622300826" CI_START="0.008340875410978665" EFFECT_SIZE="0.14052287581699346" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:21:49 +0100" MODIFIED_BY="[Empty name]" ORDER="299" O_E="0.0" SE="0.06744103537036882" STUDY_ID="STD-Killeeen-2004" TOTAL_1="51" TOTAL_2="36" VAR="0.004548293251827337" WEIGHT="7.264254961987793"/>
<DICH_DATA CI_END="0.49989776378562273" CI_START="-0.0998977637856227" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:21:56 +0100" MODIFIED_BY="[Empty name]" ORDER="300" O_E="0.0" SE="0.15301187478503583" STUDY_ID="STD-Kranzler-1998" TOTAL_1="15" TOTAL_2="5" VAR="0.023412633825231483" WEIGHT="1.9595190795369732"/>
<DICH_DATA CI_END="0.26790866672049374" CI_START="-0.07899375649410809" EFFECT_SIZE="0.09445745511319281" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="24" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:22:05 +0100" MODIFIED_BY="[Empty name]" ORDER="301" O_E="0.0" SE="0.08849714228193065" STUDY_ID="STD-Kranzler-2000" TOTAL_1="61" TOTAL_2="63" VAR="0.007831744192068276" WEIGHT="4.937646997488258"/>
<DICH_DATA CI_END="0.0557726294568206" CI_START="-0.0031410505094521812" EFFECT_SIZE="0.02631578947368421" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:22:13 +0100" MODIFIED_BY="[Empty name]" ORDER="302" O_E="0.0" SE="0.015029276157872381" STUDY_ID="STD-Krystal-2001" TOTAL_1="418" TOTAL_2="209" VAR="2.258791418295912E-4" WEIGHT="19.131365076664903"/>
<DICH_DATA CI_END="0.2790451501325473" CI_START="-0.01930489039228761" EFFECT_SIZE="0.12987012987012986" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:22:21 +0100" MODIFIED_BY="[Empty name]" ORDER="303" O_E="0.0" SE="0.0761111027748933" STUDY_ID="STD-Morris-2001" TOTAL_1="55" TOTAL_2="56" VAR="0.005792899965610372" WEIGHT="6.163410689257865"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="23.172900232036625" CI_END="0.10675887095252798" CI_START="0.028212236334174468" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RD" EFFECT_SIZE="0.06748555364335122" ESTIMABLE="YES" EVENTS_1="210" EVENTS_2="112" I2="52.530758386503315" I2_Q="0.0" ID="CMP-001.18" LOG_CI_END="-0.9715960278189598" LOG_CI_START="-1.5495624867231557" LOG_EFFECT_SIZE="-1.1707891848645327" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="18" P_CHI2="0.016708496151548125" P_Q="0.0" P_Z="7.573852219959126E-4" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.001927312602344401" TOTALS="YES" TOTAL_1="1189" TOTAL_2="952" WEIGHT="100.00000000000003" Z="3.367916531634767">
<NAME>Side-effect: Decreased appetite</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.12992180708859685" CI_START="0.012473014917875627" EFFECT_SIZE="0.07119741100323623" ESTIMABLE="YES" EVENTS_1="63" EVENTS_2="41" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:23:50 +0100" MODIFIED_BY="[Empty name]" ORDER="304" O_E="0.0" SE="0.029961977132524447" STUDY_ID="STD-Anton-2006" TOTAL_1="309" TOTAL_2="309" VAR="8.97720073689918E-4" WEIGHT="14.212664863119246"/>
<DICH_DATA CI_END="0.024534555105694876" CI_START="-0.09860862917976895" EFFECT_SIZE="-0.037037037037037035" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:23:57 +0100" MODIFIED_BY="[Empty name]" ORDER="305" O_E="0.0" SE="0.031414654875498105" STUDY_ID="STD-Baltieri-2008" TOTAL_1="49" TOTAL_2="54" VAR="9.868805409466567E-4" WEIGHT="13.77782483095581"/>
<DICH_DATA CI_END="0.14820375456583493" CI_START="0.014390513910786495" EFFECT_SIZE="0.08129713423831071" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:24:06 +0100" MODIFIED_BY="[Empty name]" ORDER="306" O_E="0.0" SE="0.03413665804845145" STUDY_ID="STD-Chick-2000" TOTAL_1="85" TOTAL_2="78" VAR="0.0011653114227169054" WEIGHT="12.98290459055745"/>
<DICH_DATA CI_END="0.2219615407107018" CI_START="-0.10132662007578114" EFFECT_SIZE="0.060317460317460325" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:24:48 +0100" MODIFIED_BY="[Empty name]" ORDER="312" O_E="0.0" SE="0.0824729850488424" STUDY_ID="STD-de-Goes-e-Castro-2004" TOTAL_1="35" TOTAL_2="36" VAR="0.006801793262866581" WEIGHT="4.599697067698037"/>
<DICH_DATA CI_END="0.1093061033801852" CI_START="0.04511829276900484" EFFECT_SIZE="0.07721219807459502" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:24:13 +0100" MODIFIED_BY="[Empty name]" ORDER="307" O_E="0.0" SE="0.016374742372177654" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="2.6813218775519033E-4" WEIGHT="18.288431953697785"/>
<DICH_DATA CI_END="0.19084772390645396" CI_START="-0.2240833055291324" EFFECT_SIZE="-0.01661779081133921" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:24:20 +0100" MODIFIED_BY="[Empty name]" ORDER="308" O_E="0.0" SE="0.10585169745681791" STUDY_ID="STD-Hersh-1998" TOTAL_1="31" TOTAL_2="33" VAR="0.011204581854489712" WEIGHT="3.0575361981333278"/>
<DICH_DATA CI_END="0.2930321759859651" CI_START="-0.4530321759859651" EFFECT_SIZE="-0.08000000000000002" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:24:26 +0100" MODIFIED_BY="[Empty name]" ORDER="309" O_E="0.0" SE="0.19032603605392512" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" VAR="0.036224" WEIGHT="1.052421002400043"/>
<DICH_DATA CI_END="0.141900901786986" CI_START="-0.04059371224450235" EFFECT_SIZE="0.05065359477124183" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:24:33 +0100" MODIFIED_BY="[Empty name]" ORDER="310" O_E="0.0" SE="0.04655560394756807" STUDY_ID="STD-Killeeen-2004" TOTAL_1="51" TOTAL_2="36" VAR="0.0021674242589228153" WEIGHT="9.805573352376767"/>
<DICH_DATA CI_END="0.3833835014809769" CI_START="0.08500057346047504" EFFECT_SIZE="0.23419203747072598" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:24:40 +0100" MODIFIED_BY="[Empty name]" ORDER="311" O_E="0.0" SE="0.07611949259632021" STUDY_ID="STD-Kranzler-2000" TOTAL_1="61" TOTAL_2="63" VAR="0.0057941771531212485" WEIGHT="5.199934717703364"/>
<DICH_DATA CI_END="0.15399163634597723" CI_START="-0.0030482401195621595" EFFECT_SIZE="0.07547169811320754" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:24:54 +0100" MODIFIED_BY="[Empty name]" ORDER="313" O_E="0.0" SE="0.04006192912325173" STUDY_ID="STD-O_x0027_Malley-2007" TOTAL_1="53" TOTAL_2="50" VAR="0.0016049581650764454" WEIGHT="11.366977589080431"/>
<DICH_DATA CI_END="0.43809289346937347" CI_START="-0.2547595601360401" EFFECT_SIZE="0.09166666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:25:01 +0100" MODIFIED_BY="[Empty name]" ORDER="314" O_E="0.0" SE="0.17675132274637323" STUDY_ID="STD-Petrakis-2004" TOTAL_1="16" TOTAL_2="15" VAR="0.031241030092592593" WEIGHT="1.2105290584194792"/>
<DICH_DATA CI_END="0.3797152639092662" CI_START="0.049310159819547394" EFFECT_SIZE="0.2145127118644068" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="34" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:25:09 +0100" MODIFIED_BY="[Empty name]" ORDER="315" O_E="0.0" SE="0.08428856517158276" STUDY_ID="STD-Petrakis-2005" TOTAL_1="59" TOTAL_2="64" VAR="0.007104562218684154" WEIGHT="4.445504775858292"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.263050728050041" CI_END="0.1592819177209805" CI_START="0.008217943056119906" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RD" EFFECT_SIZE="0.08374993038855019" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="36" I2="11.623722119419691" I2_Q="0.0" ID="CMP-001.19" LOG_CI_END="-0.7978335241344268" LOG_CI_START="-2.0852368723828096" LOG_EFFECT_SIZE="-1.077015545268802" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="19" P_CHI2="0.3225412292540797" P_Q="0.0" P_Z="0.02976453832012885" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="5.759905780569823E-4" TOTALS="YES" TOTAL_1="190" TOTAL_2="198" WEIGHT="99.99999999999999" Z="2.173209696533659">
<NAME>Side-effect: Decreased libido</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.2154485029761603" CI_START="0.03455149702383968" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:26:22 +0100" MODIFIED_BY="[Empty name]" ORDER="316" O_E="0.0" SE="0.0461480433771266" STUDY_ID="STD-Balldin-2003" TOTAL_1="56" TOTAL_2="62" VAR="0.002129641907537158" WEIGHT="54.89045572577041"/>
<DICH_DATA CI_END="0.18608702309937356" CI_START="-0.08852604748961748" EFFECT_SIZE="0.04878048780487804" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="21" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:26:37 +0100" MODIFIED_BY="[Empty name]" ORDER="318" O_E="0.0" SE="0.07005564203095156" STUDY_ID="STD-Pettinati-2008a" TOTAL_1="82" TOTAL_2="82" VAR="0.004907792980368828" WEIGHT="27.08228699736354"/>
<DICH_DATA CI_END="0.18224811647300637" CI_START="-0.16088059510548508" EFFECT_SIZE="0.010683760683760646" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:26:29 +0100" MODIFIED_BY="[Empty name]" ORDER="317" O_E="0.0" SE="0.08753444305228232" STUDY_ID="STD-Pettinati-2008b" TOTAL_1="52" TOTAL_2="54" VAR="0.0076622787204732555" WEIGHT="18.027257276866038"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.085900835977582" CI_END="0.08119368432261231" CI_START="0.0030772624018474623" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RD" EFFECT_SIZE="0.04213547336222989" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="14" I2="0.0" I2_Q="0.0" ID="CMP-001.20" LOG_CI_END="-1.0904777511838675" LOG_CI_START="-2.5118354693633584" LOG_EFFECT_SIZE="-1.3753521227241192" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="20" P_CHI2="0.5547704329503504" P_Q="0.0" P_Z="0.034482583743275834" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="242" TOTAL_2="225" WEIGHT="100.00000000000003" Z="2.114382820689973">
<NAME>Side-effect: Depression</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.09894681097346505" CI_START="-0.12639779136562188" EFFECT_SIZE="-0.01372549019607841" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:27:32 +0100" MODIFIED_BY="[Empty name]" ORDER="319" O_E="0.0" SE="0.057486924279368495" STUDY_ID="STD-Chick-2000" TOTAL_1="85" TOTAL_2="78" VAR="0.0033047464631018467" WEIGHT="12.016842389389886"/>
<DICH_DATA CI_END="0.10824429747115806" CI_START="-0.029812924922138453" EFFECT_SIZE="0.0392156862745098" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:27:37 +0100" MODIFIED_BY="[Empty name]" ORDER="320" O_E="0.0" SE="0.03521932634534978" STUDY_ID="STD-Killeeen-2004" TOTAL_1="51" TOTAL_2="36" VAR="0.001240400948220249" WEIGHT="32.01595213303327"/>
<DICH_DATA CI_END="0.11010942995062585" CI_START="-0.029688768026716175" EFFECT_SIZE="0.04021033096195484" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:27:45 +0100" MODIFIED_BY="[Empty name]" ORDER="321" O_E="0.0" SE="0.03566346093092842" STUDY_ID="STD-Morley-2006" TOTAL_1="53" TOTAL_2="61" VAR="0.0012718824455718578" WEIGHT="31.22349673293365"/>
<DICH_DATA CI_END="0.15399163634597723" CI_START="-0.0030482401195621595" EFFECT_SIZE="0.07547169811320754" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:27:52 +0100" MODIFIED_BY="[Empty name]" ORDER="322" O_E="0.0" SE="0.04006192912325173" STUDY_ID="STD-O_x0027_Malley-2007" TOTAL_1="53" TOTAL_2="50" VAR="0.0016049581650764454" WEIGHT="24.74370874464321"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="28.574442758448313" CI_END="0.0348887947346451" CI_START="-0.051030243522365994" CI_STUDY="95" CI_TOTAL="95" DF="11" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.008070724393860447" ESTIMABLE="YES" EVENTS_1="202" EVENTS_2="189" I2="61.50406118856773" I2_Q="0.0" ID="CMP-001.21" LOG_CI_END="-1.4573140333932224" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="21" P_CHI2="0.0026416180391347632" P_Q="0.0" P_Z="0.7127131041843063" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="12" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.003027985334620238" TOTALS="YES" TOTAL_1="1246" TOTAL_2="1048" WEIGHT="100.00000000000001" Z="0.3682147626885137">
<NAME>Side effect: Diarrhea</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.021880205428179103" CI_START="-0.1254400759783409" EFFECT_SIZE="-0.0517799352750809" ESTIMABLE="YES" EVENTS_1="92" EVENTS_2="108" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:29:27 +0100" MODIFIED_BY="[Empty name]" ORDER="323" O_E="0.0" SE="0.03758239502576669" STUDY_ID="STD-Anton-2006" TOTAL_1="309" TOTAL_2="309" VAR="0.0014124364158727728" WEIGHT="10.819281472655891"/>
<DICH_DATA CI_END="0.014604474002984119" CI_START="-0.12571558511409522" EFFECT_SIZE="-0.05555555555555555" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:29:34 +0100" MODIFIED_BY="[Empty name]" ORDER="324" O_E="0.0" SE="0.035796591218998426" STUDY_ID="STD-Baltieri-2008" TOTAL_1="49" TOTAL_2="54" VAR="0.0012813959429000751" WEIGHT="11.14827620997405"/>
<DICH_DATA CI_END="0.11461867434518948" CI_START="-0.08656437570265553" EFFECT_SIZE="0.014027149321266974" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:29:40 +0100" MODIFIED_BY="[Empty name]" ORDER="325" O_E="0.0" SE="0.05132314971977833" STUDY_ID="STD-Chick-2000" TOTAL_1="85" TOTAL_2="78" VAR="0.002634065697158783" WEIGHT="8.484941676831264"/>
<DICH_DATA CI_END="0.08104516410798174" CI_START="-0.01714938962247995" EFFECT_SIZE="0.0319478872427509" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="18" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:29:49 +0100" MODIFIED_BY="[Empty name]" ORDER="326" O_E="0.0" SE="0.025050091354996265" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="6.275070768936586E-4" WEIGHT="13.142462729389432"/>
<DICH_DATA CI_END="0.04039722670052318" CI_START="-0.0647874706029622" EFFECT_SIZE="-0.01219512195121951" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:29:55 +0100" MODIFIED_BY="[Empty name]" ORDER="327" O_E="0.0" SE="0.0268333240133923" STUDY_ID="STD-Gastpar-2002" TOTAL_1="82" TOTAL_2="82" VAR="7.200272776076958E-4" WEIGHT="12.81803925076163"/>
<DICH_DATA CI_END="0.09961579614974223" CI_START="-0.2657937042631342" EFFECT_SIZE="-0.083088954056696" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:30:02 +0100" MODIFIED_BY="[Empty name]" ORDER="328" O_E="0.0" SE="0.09321842219938221" STUDY_ID="STD-Hersh-1998" TOTAL_1="31" TOTAL_2="33" VAR="0.008689674237342276" WEIGHT="4.099980246127002"/>
<DICH_DATA CI_END="-0.10341159568963931" CI_START="-0.3965884043103607" EFFECT_SIZE="-0.25" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:30:08 +0100" MODIFIED_BY="[Empty name]" ORDER="329" O_E="0.0" SE="0.07479137650825796" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.00559375" WEIGHT="5.572216138783086"/>
<DICH_DATA CI_END="0.29348363671577504" CI_START="-0.017657459250253332" EFFECT_SIZE="0.13791308873276087" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:30:17 +0100" MODIFIED_BY="[Empty name]" ORDER="330" O_E="0.0" SE="0.07937418708207641" STUDY_ID="STD-Kranzler-2000" TOTAL_1="61" TOTAL_2="63" VAR="0.006300261574940467" WEIGHT="5.150182369920752"/>
<DICH_DATA CI_END="0.2122428047087972" CI_START="0.019121253441527555" EFFECT_SIZE="0.11568202907516238" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:30:25 +0100" MODIFIED_BY="[Empty name]" ORDER="331" O_E="0.0" SE="0.04926660713936271" STUDY_ID="STD-Morley-2006" TOTAL_1="53" TOTAL_2="61" VAR="0.0024271985790243053" WEIGHT="8.806700843893434"/>
<DICH_DATA CI_END="0.10992694412947004" CI_START="-0.03671939695965873" EFFECT_SIZE="0.03660377358490566" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:30:31 +0100" MODIFIED_BY="[Empty name]" ORDER="332" O_E="0.0" SE="0.03741046831621815" STUDY_ID="STD-O_x0027_Malley-2007" TOTAL_1="53" TOTAL_2="50" VAR="0.0013995431396387622" WEIGHT="10.850787985937847"/>
<DICH_DATA CI_END="0.2485486123978286" CI_START="-0.44854861239782856" EFFECT_SIZE="-0.09999999999999998" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:30:38 +0100" MODIFIED_BY="[Empty name]" ORDER="333" O_E="0.0" SE="0.1778341924377874" STUDY_ID="STD-Petrakis-2004" TOTAL_1="16" TOTAL_2="15" VAR="0.031625" WEIGHT="1.3863790467683172"/>
<DICH_DATA CI_END="0.07658873992784603" CI_START="-0.1449648083039144" EFFECT_SIZE="-0.03418803418803418" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:30:46 +0100" MODIFIED_BY="[Empty name]" ORDER="334" O_E="0.0" SE="0.05651980086862476" STUDY_ID="STD-Pettinati-2008b" TOTAL_1="52" TOTAL_2="54" VAR="0.003194487890228996" WEIGHT="7.720752028957314"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="20.239813141041893" CI_END="0.08445572021579785" CI_START="0.03501503787082358" CI_STUDY="95" CI_TOTAL="95" DF="15" EFFECT_MEASURE="RD" EFFECT_SIZE="0.059735379043310714" ESTIMABLE="YES" EVENTS_1="185" EVENTS_2="68" I2="25.88864385519797" I2_Q="0.0" ID="CMP-001.22" LOG_CI_END="-1.0733709301779393" LOG_CI_START="-1.4557453996007017" LOG_EFFECT_SIZE="-1.2237683762014513" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="22" P_CHI2="0.16292497061725486" P_Q="0.0" P_Z="2.178186730174294E-6" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="16" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="5.763149392650918E-4" TOTALS="YES" TOTAL_1="1557" TOTAL_2="1098" WEIGHT="100.00000000000001" Z="4.736147883672525">
<NAME>Side effect: Dizziness</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.1937313360416314" CI_START="0.013165215682506573" EFFECT_SIZE="0.10344827586206898" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:32:31 +0100" MODIFIED_BY="[Empty name]" ORDER="335" O_E="0.0" SE="0.0460636322359511" STUDY_ID="STD-Ahmadi-2002" TOTAL_1="58" TOTAL_2="58" VAR="0.0021218582147689534" WEIGHT="5.89580242830266"/>
<DICH_DATA CI_END="0.08834515370600651" CI_START="-0.04374953768181906" EFFECT_SIZE="0.022297808012093724" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:32:41 +0100" MODIFIED_BY="[Empty name]" ORDER="336" O_E="0.0" SE="0.033698244567188895" STUDY_ID="STD-Baltieri-2008" TOTAL_1="49" TOTAL_2="54" VAR="0.001135571686910076" WEIGHT="9.29261061468635"/>
<DICH_DATA CI_END="0.07985578260383781" CI_START="-0.12661294700806103" EFFECT_SIZE="-0.023378582202111614" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:32:48 +0100" MODIFIED_BY="[Empty name]" ORDER="337" O_E="0.0" SE="0.05267156214106428" STUDY_ID="STD-Chick-2000" TOTAL_1="85" TOTAL_2="78" VAR="0.002774293458379996" WEIGHT="4.74776337476965"/>
<DICH_DATA CI_END="0.12029800217534456" CI_START="0.03929155221446348" EFFECT_SIZE="0.07979477719490402" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:32:57 +0100" MODIFIED_BY="[Empty name]" ORDER="338" O_E="0.0" SE="0.020665290433867563" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="4.2705422871609815E-4" WEIGHT="15.854479429084064"/>
<DICH_DATA CI_END="0.1455536739970377" CI_START="7.877894175964684E-4" EFFECT_SIZE="0.07317073170731708" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:33:05 +0100" MODIFIED_BY="[Empty name]" ORDER="339" O_E="0.0" SE="0.036930751208016074" STUDY_ID="STD-Gastpar-2002" TOTAL_1="82" TOTAL_2="82" VAR="0.0013638803847883809" WEIGHT="8.199120797951442"/>
<DICH_DATA CI_END="0.3700139555397254" CI_START="-0.08066889200111352" EFFECT_SIZE="0.14467253176930595" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:33:11 +0100" MODIFIED_BY="[Empty name]" ORDER="340" O_E="0.0" SE="0.11497222681022909" STUDY_ID="STD-Hersh-1998" TOTAL_1="31" TOTAL_2="33" VAR="0.013218612937702762" WEIGHT="1.1531699169007577"/>
<DICH_DATA CI_END="0.3389173589085932" CI_START="-0.4189173589085933" EFFECT_SIZE="-0.04000000000000001" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:33:18 +0100" MODIFIED_BY="[Empty name]" ORDER="341" O_E="0.0" SE="0.19332873557751315" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" VAR="0.037376" WEIGHT="0.4191548225448777"/>
<DICH_DATA CI_END="0.18953366617328457" CI_START="0.006544765199264446" EFFECT_SIZE="0.09803921568627451" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:33:42 +0100" MODIFIED_BY="[Empty name]" ORDER="342" O_E="0.0" SE="0.046681699872398986" STUDY_ID="STD-Killeeen-2004" TOTAL_1="51" TOTAL_2="36" VAR="0.0021791811029767353" WEIGHT="5.773151399844712"/>
<DICH_DATA CI_END="0.27295208038765423" CI_START="-0.002330170421481925" EFFECT_SIZE="0.13531095498308615" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:33:49 +0100" MODIFIED_BY="[Empty name]" ORDER="343" O_E="0.0" SE="0.07022635440766448" STUDY_ID="STD-Kranzler-2000" TOTAL_1="61" TOTAL_2="63" VAR="0.004931740853390897" WEIGHT="2.888114505801723"/>
<DICH_DATA CI_END="0.06199698641992757" CI_START="-0.014150096467774459" EFFECT_SIZE="0.023923444976076555" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="10" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:33:56 +0100" MODIFIED_BY="[Empty name]" ORDER="344" O_E="0.0" SE="0.019425633197431305" STUDY_ID="STD-Krystal-2001" TOTAL_1="418" TOTAL_2="209" VAR="3.7735522512114526E-4" WEIGHT="16.680710404496057"/>
<DICH_DATA CI_END="0.12573851237943567" CI_START="-0.06859565523657854" EFFECT_SIZE="0.02857142857142857" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:34:03 +0100" MODIFIED_BY="[Empty name]" ORDER="345" O_E="0.0" SE="0.04957595372897087" STUDY_ID="STD-Lee-2001" TOTAL_1="35" TOTAL_2="18" VAR="0.0024577751881370603" WEIGHT="5.24305316109895"/>
<DICH_DATA CI_END="0.0729853140851057" CI_START="-0.06308738646370143" EFFECT_SIZE="0.004948963810702131" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:34:11 +0100" MODIFIED_BY="[Empty name]" ORDER="346" O_E="0.0" SE="0.034713061470040066" STUDY_ID="STD-Morley-2006" TOTAL_1="53" TOTAL_2="61" VAR="0.00120499663662278" WEIGHT="8.930439822469511"/>
<DICH_DATA CI_END="0.19640649994708986" CI_START="0.021775318234728294" EFFECT_SIZE="0.10909090909090909" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:34:18 +0100" MODIFIED_BY="[Empty name]" ORDER="347" O_E="0.0" SE="0.044549589454150704" STUDY_ID="STD-Morris-2001" TOTAL_1="55" TOTAL_2="56" VAR="0.0019846659205333757" WEIGHT="6.211641829602278"/>
<DICH_DATA CI_END="0.35459389280674686" CI_START="0.030021491808637724" EFFECT_SIZE="0.1923076923076923" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:34:25 +0100" MODIFIED_BY="[Empty name]" ORDER="348" O_E="0.0" SE="0.08280060336779012" STUDY_ID="STD-O_x0027_Malley-1992" TOTAL_1="52" TOTAL_2="52" VAR="0.006855939918070096" WEIGHT="2.140386213725547"/>
<DICH_DATA CI_END="0.21114305817445977" CI_START="0.013007885221766616" EFFECT_SIZE="0.1120754716981132" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:34:32 +0100" MODIFIED_BY="[Empty name]" ORDER="349" O_E="0.0" SE="0.050545615765278884" STUDY_ID="STD-O_x0027_Malley-2007" TOTAL_1="53" TOTAL_2="50" VAR="0.0025548592730912094" WEIGHT="5.080488901179282"/>
<DICH_DATA CI_END="0.22639305089076822" CI_START="-0.1675695214790035" EFFECT_SIZE="0.02941176470588236" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:34:39 +0100" MODIFIED_BY="[Empty name]" ORDER="350" O_E="0.0" SE="0.10050250297385518" STUDY_ID="STD-O_x0027_Malley-2008" TOTAL_1="34" TOTAL_2="34" VAR="0.01010075310400977" WEIGHT="1.4899123775421506"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.556241151804653" CI_END="0.19031081803669178" CI_START="0.003970032691093112" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RD" EFFECT_SIZE="0.09714042536389245" ESTIMABLE="YES" EVENTS_1="131" EVENTS_2="108" I2="38.98943148393847" I2_Q="0.0" ID="CMP-001.23" LOG_CI_END="-0.7205365239562533" LOG_CI_START="-2.4012059170396833" LOG_EFFECT_SIZE="-1.0125999991460088" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="23" P_CHI2="0.16128112586746257" P_Q="0.0" P_Z="0.041005050171773604" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.00427227343354006" TOTALS="YES" TOTAL_1="243" TOTAL_2="252" WEIGHT="100.0" Z="2.0434789389023837">
<NAME>Side effect: Drowsiness</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.4279467671830166" CI_START="0.08779614200251565" EFFECT_SIZE="0.2578714545927661" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:35:59 +0100" MODIFIED_BY="[Empty name]" ORDER="351" O_E="0.0" SE="0.0867747131742128" STUDY_ID="STD-Kranzler-2000" TOTAL_1="61" TOTAL_2="63" VAR="0.0075298508464668994" WEIGHT="19.14694483782907"/>
<DICH_DATA CI_END="0.16177740255389167" CI_START="-0.08515402593051503" EFFECT_SIZE="0.03831168831168831" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:36:05 +0100" MODIFIED_BY="[Empty name]" ORDER="352" O_E="0.0" SE="0.06299386887518604" STUDY_ID="STD-Morris-2001" TOTAL_1="55" TOTAL_2="56" VAR="0.003968227515864132" WEIGHT="27.422437536984315"/>
<DICH_DATA CI_END="0.19173288680031308" CI_START="-0.4167328868003132" EFFECT_SIZE="-0.11250000000000004" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:36:12 +0100" MODIFIED_BY="[Empty name]" ORDER="353" O_E="0.0" SE="0.15522371288455467" STUDY_ID="STD-Petrakis-2004" TOTAL_1="16" TOTAL_2="15" VAR="0.024094401041666665" WEIGHT="7.966200717535805"/>
<DICH_DATA CI_END="0.20865477729615722" CI_START="-0.037044607804631716" EFFECT_SIZE="0.08580508474576276" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="52" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:36:20 +0100" MODIFIED_BY="[Empty name]" ORDER="354" O_E="0.0" SE="0.06267956631826767" STUDY_ID="STD-Petrakis-2005" TOTAL_1="59" TOTAL_2="64" VAR="0.0039287280338461145" WEIGHT="27.554515562173055"/>
<DICH_DATA CI_END="0.3051132897837044" CI_START="-0.05297653764695226" EFFECT_SIZE="0.12606837606837606" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:36:28 +0100" MODIFIED_BY="[Empty name]" ORDER="355" O_E="0.0" SE="0.09135112437147404" STUDY_ID="STD-Pettinati-2008b" TOTAL_1="52" TOTAL_2="54" VAR="0.008345027923932519" WEIGHT="17.909901345477753"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.5504610476731395" CI_END="-8.308656133477269E-4" CI_START="-0.11413688767249286" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.0574838766429203" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="13" I2="35.50305559106087" I2_Q="0.0" ID="CMP-001.24" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="24" P_CHI2="0.21306787319215215" P_Q="0.0" P_Z="0.046733380760274564" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="6.307398772384462E-4" TOTALS="YES" TOTAL_1="167" TOTAL_2="160" WEIGHT="100.0" Z="1.988708558721721">
<NAME>Side effect: Dyspepsia</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="-0.013975154429867742" CI_START="-0.16973525280995128" EFFECT_SIZE="-0.09185520361990951" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:39:33 +0100" MODIFIED_BY="[Empty name]" ORDER="364" O_E="0.0" SE="0.039735449122713304" STUDY_ID="STD-Chick-2000" TOTAL_1="85" TOTAL_2="78" VAR="0.0015789059169837374" WEIGHT="37.81178240045941"/>
<DICH_DATA CI_END="0.0157413631774717" CI_START="-0.08891209488478878" EFFECT_SIZE="-0.03658536585365854" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:39:40 +0100" MODIFIED_BY="[Empty name]" ORDER="365" O_E="0.0" SE="0.026697801308532606" STUDY_ID="STD-Gastpar-2002" TOTAL_1="82" TOTAL_2="82" VAR="7.127725947098853E-4" WEIGHT="62.1882175995406"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="13.220877420341308" CI_END="0.08165328762960783" CI_START="-0.03032558115680403" CI_STUDY="95" CI_TOTAL="95" DF="7" EFFECT_MEASURE="RD" EFFECT_SIZE="0.025663853236401902" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="96" I2="47.05343845613471" I2_Q="0.0" ID="CMP-001.25" LOG_CI_END="-1.088026324452691" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.5906781369839544" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="25" P_CHI2="0.06690623812919694" P_Q="0.0" P_Z="0.368978817297256" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0024056657471468166" TOTALS="YES" TOTAL_1="503" TOTAL_2="360" WEIGHT="100.0" Z="0.8983878582272863">
<NAME>Side effect: Dry mouth</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.12300487790728509" CI_START="0.02580117916901075" EFFECT_SIZE="0.07440302853814793" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:37:50 +0100" MODIFIED_BY="[Empty name]" ORDER="356" O_E="0.0" SE="0.024797317579558786" STUDY_ID="STD-Anton-2004" TOTAL_1="202" TOTAL_2="68" VAR="6.149069591414952E-4" WEIGHT="27.016350663533867"/>
<DICH_DATA CI_END="0.3389173589085932" CI_START="-0.4189173589085933" EFFECT_SIZE="-0.04000000000000001" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:37:56 +0100" MODIFIED_BY="[Empty name]" ORDER="357" O_E="0.0" SE="0.19332873557751315" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" VAR="0.037376" WEIGHT="2.0513181111235217"/>
<DICH_DATA CI_END="0.24403221809599923" CI_START="-0.09206760711499479" EFFECT_SIZE="0.07598230549050222" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="20" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:38:05 +0100" MODIFIED_BY="[Empty name]" ORDER="358" O_E="0.0" SE="0.0857413268463366" STUDY_ID="STD-Kranzler-2000" TOTAL_1="61" TOTAL_2="63" VAR="0.0073515751293703226" WEIGHT="8.363517153110756"/>
<DICH_DATA CI_END="0.06323280653297525" CI_START="-0.08612176415747261" EFFECT_SIZE="-0.011444478812248686" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:38:11 +0100" MODIFIED_BY="[Empty name]" ORDER="359" O_E="0.0" SE="0.0381013559097355" STUDY_ID="STD-Morley-2006" TOTAL_1="53" TOTAL_2="61" VAR="0.001451713322160336" WEIGHT="21.155517767778544"/>
<DICH_DATA CI_END="0.024528157246653644" CI_START="-0.10452815724665365" EFFECT_SIZE="-0.04" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:38:18 +0100" MODIFIED_BY="[Empty name]" ORDER="360" O_E="0.0" SE="0.032923134177792815" STUDY_ID="STD-O_x0027_Malley-2007" TOTAL_1="53" TOTAL_2="50" VAR="0.0010839327640889496" WEIGHT="23.385169146259727"/>
<DICH_DATA CI_END="0.23726897666745414" CI_START="-0.23726897666745414" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:38:25 +0100" MODIFIED_BY="[Empty name]" ORDER="361" O_E="0.0" SE="0.12105782480647682" STUDY_ID="STD-O_x0027_Malley-2008" TOTAL_1="34" TOTAL_2="34" VAR="0.014654996946875637" WEIGHT="4.7832169770507456"/>
<DICH_DATA CI_END="0.2030683439424097" CI_START="-0.3114016772757431" EFFECT_SIZE="-0.054166666666666696" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:38:31 +0100" MODIFIED_BY="[Empty name]" ORDER="362" O_E="0.0" SE="0.1312447640049069" STUDY_ID="STD-Petrakis-2004" TOTAL_1="16" TOTAL_2="15" VAR="0.017225188078703706" WEIGHT="4.1569690326115465"/>
<DICH_DATA CI_END="0.31357287918452187" CI_START="-0.00425084528621672" EFFECT_SIZE="0.15466101694915257" ESTIMABLE="YES" EVENTS_1="46" EVENTS_2="40" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:38:40 +0100" MODIFIED_BY="[Empty name]" ORDER="363" O_E="0.0" SE="0.08107897057744212" STUDY_ID="STD-Petrakis-2005" TOTAL_1="59" TOTAL_2="64" VAR="0.006573799469897726" WEIGHT="9.087941148531288"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.632436795029217" CI_END="0.09170927267309051" CI_START="0.01169656368399298" CI_STUDY="95" CI_TOTAL="95" DF="6" EFFECT_MEASURE="RD" EFFECT_SIZE="0.051702918178541744" ESTIMABLE="YES" EVENTS_1="89" EVENTS_2="65" I2="0.0" I2_Q="0.0" ID="CMP-001.26" LOG_CI_END="-1.0375867508385785" LOG_CI_START="-1.9319417102435383" LOG_EFFECT_SIZE="-1.2864849440806838" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="26" P_CHI2="0.5917427436654563" P_Q="0.0" P_Z="0.011309287552807253" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="7" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="454" TOTAL_2="428" WEIGHT="99.99999999999997" Z="2.5329940407184823">
<NAME>Side effect: Fatigue</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.18953366617328457" CI_START="0.006544765199264446" EFFECT_SIZE="0.09803921568627451" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:40:36 +0100" MODIFIED_BY="[Empty name]" ORDER="366" O_E="0.0" SE="0.046681699872398986" STUDY_ID="STD-Killeeen-2004" TOTAL_1="51" TOTAL_2="36" VAR="0.0021791811029767353" WEIGHT="19.119144323272188"/>
<DICH_DATA CI_END="0.24082803600099356" CI_START="-0.10811921476758224" EFFECT_SIZE="0.06635441061670566" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="33" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:40:43 +0100" MODIFIED_BY="[Empty name]" ORDER="367" O_E="0.0" SE="0.08901879154949457" STUDY_ID="STD-Kranzler-2000" TOTAL_1="61" TOTAL_2="63" VAR="0.007924345248932367" WEIGHT="5.257731295840877"/>
<DICH_DATA CI_END="0.09862307259647689" CI_START="-0.02770466844093257" EFFECT_SIZE="0.03545920207777216" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:40:51 +0100" MODIFIED_BY="[Empty name]" ORDER="368" O_E="0.0" SE="0.03222705673008957" STUDY_ID="STD-Kranzler-2004" TOTAL_1="167" TOTAL_2="166" VAR="0.0010385831854844113" WEIGHT="40.11626473129054"/>
<DICH_DATA CI_END="0.07157848085241514" CI_START="-0.18268959196352624" EFFECT_SIZE="-0.05555555555555555" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:40:58 +0100" MODIFIED_BY="[Empty name]" ORDER="369" O_E="0.0" SE="0.06486549620849553" STUDY_ID="STD-Lee-2001" TOTAL_1="35" TOTAL_2="18" VAR="0.004207532598374348" WEIGHT="9.902259112729702"/>
<DICH_DATA CI_END="0.21947049797191653" CI_START="-0.0388333188812886" EFFECT_SIZE="0.09031858954531397" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:41:04 +0100" MODIFIED_BY="[Empty name]" ORDER="370" O_E="0.0" SE="0.06589504166675324" STUDY_ID="STD-Morley-2006" TOTAL_1="53" TOTAL_2="61" VAR="0.004342156516263145" WEIGHT="9.595250161598443"/>
<DICH_DATA CI_END="0.18451078813507302" CI_START="-0.0403598447388466" EFFECT_SIZE="0.07207547169811321" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:41:11 +0100" MODIFIED_BY="[Empty name]" ORDER="371" O_E="0.0" SE="0.05736601147971863" STUDY_ID="STD-O_x0027_Malley-2007" TOTAL_1="53" TOTAL_2="50" VAR="0.0032908592730912095" WEIGHT="12.660546853230606"/>
<DICH_DATA CI_END="0.3068524021808205" CI_START="-0.13038181394552634" EFFECT_SIZE="0.08823529411764708" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:41:18 +0100" MODIFIED_BY="[Empty name]" ORDER="372" O_E="0.0" SE="0.11154139044778233" STUDY_ID="STD-O_x0027_Malley-2008" TOTAL_1="34" TOTAL_2="34" VAR="0.012441481783024629" WEIGHT="3.3488035220376124"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.924041137797499" CI_END="0.04506938331239037" CI_START="-0.1584154538095769" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.056673035248593254" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="24" I2="48.026059300128765" I2_Q="0.0" ID="CMP-001.27" LOG_CI_END="-1.3461183843709625" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="27" P_CHI2="0.16541210818395347" P_Q="0.0" P_Z="0.27494378547478426" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.003194935177051341" TOTALS="YES" TOTAL_1="141" TOTAL_2="146" WEIGHT="100.0" Z="1.0917482555737852">
<NAME>Side effect: Fever</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.009745069771144484" CI_START="-0.08291580147846156" EFFECT_SIZE="-0.036585365853658534" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:42:59 +0100" MODIFIED_BY="[Empty name]" ORDER="374" O_E="0.0" SE="0.023638411720955883" STUDY_ID="STD-Gastpar-2002" TOTAL_1="82" TOTAL_2="82" VAR="5.587745086894245E-4" WEIGHT="71.78723918129172"/>
<DICH_DATA CI_END="0.048475628437462254" CI_START="-0.2640476623357674" EFFECT_SIZE="-0.10778601694915255" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="21" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:43:08 +0100" MODIFIED_BY="[Empty name]" ORDER="375" O_E="0.0" SE="0.07972679427743913" STUDY_ID="STD-Petrakis-2005" TOTAL_1="59" TOTAL_2="64" VAR="0.006356361725757101" WEIGHT="28.212760818708272"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6918280488455995" CI_END="0.031376558392110815" CI_START="-0.05712028187400732" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.012871861740948249" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="49" I2="0.0" I2_Q="0.0" ID="CMP-001.28" LOG_CI_END="-1.5033946946969894" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="28" P_CHI2="0.4291651979970502" P_Q="0.0" P_Z="0.5685736889651902" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="555" TOTAL_2="347" WEIGHT="100.0" Z="0.5701533602866168">
<NAME>Side effect: Flue-like symptoms</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.02408213463310354" CI_START="-0.12164311024285965" EFFECT_SIZE="-0.04878048780487806" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:55:36 +0100" MODIFIED_BY="[Empty name]" ORDER="405" O_E="0.0" SE="0.03717549047467844" STUDY_ID="STD-Gastpar-2002" TOTAL_1="82" TOTAL_2="82" VAR="0.0013820170920329073" WEIGHT="36.87957791012906"/>
<DICH_DATA CI_END="0.06770972512312277" CI_START="-0.05814034713269216" EFFECT_SIZE="0.004784688995215308" ESTIMABLE="YES" EVENTS_1="74" EVENTS_2="36" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:55:45 +0100" MODIFIED_BY="[Empty name]" ORDER="406" O_E="0.0" SE="0.03210520020992841" STUDY_ID="STD-Krystal-2001" TOTAL_1="418" TOTAL_2="209" VAR="0.001030743880519587" WEIGHT="49.44798410354382"/>
<DICH_DATA CI_END="0.1397969760330554" CI_START="-0.09953723577331515" EFFECT_SIZE="0.020129870129870123" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:43:56 +0100" MODIFIED_BY="[Empty name]" ORDER="376" O_E="0.0" SE="0.061055767783032816" STUDY_ID="STD-Morris-2001" TOTAL_1="55" TOTAL_2="56" VAR="0.0037278067795756278" WEIGHT="13.672437986327123"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="23.08524041557496" CI_END="0.03774887214342368" CI_START="-0.016005503081259254" CI_STUDY="95" CI_TOTAL="95" DF="21" EFFECT_MEASURE="RD" EFFECT_SIZE="0.01087168453108221" ESTIMABLE="YES" EVENTS_1="493" EVENTS_2="416" I2="9.032786222005765" I2_Q="0.0" ID="CMP-001.29" LOG_CI_END="-1.4230960196428677" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.9637031582253395" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="29" P_CHI2="0.33945054870456437" P_Q="0.0" P_Z="0.4278970564394182" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="3.562340465342933E-4" TOTALS="YES" TOTAL_1="2043" TOTAL_2="1590" WEIGHT="100.00000000000001" Z="0.7927953787254922">
<NAME>Side effect: Headache</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.2731009644510382" CI_START="0.002761104514479029" EFFECT_SIZE="0.13793103448275862" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:46:22 +0100" MODIFIED_BY="[Empty name]" ORDER="378" O_E="0.0" SE="0.06896551724137931" STUDY_ID="STD-Ahmadi-2002" TOTAL_1="58" TOTAL_2="58" VAR="0.0047562425683709865" WEIGHT="3.6782405608997126"/>
<DICH_DATA CI_END="0.07548818706255522" CI_START="-0.2305409774094631" EFFECT_SIZE="-0.07752639517345394" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="40" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:46:28 +0100" MODIFIED_BY="[Empty name]" ORDER="379" O_E="0.0" SE="0.07807009896251597" STUDY_ID="STD-Chick-2000" TOTAL_1="85" TOTAL_2="78" VAR="0.006094940352017037" WEIGHT="2.914960546690332"/>
<DICH_DATA CI_END="0.11962602445790363" CI_START="-0.27518158001345916" EFFECT_SIZE="-0.07777777777777778" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="10" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:47:44 +0100" MODIFIED_BY="[Empty name]" ORDER="390" O_E="0.0" SE="0.10071807634873774" STUDY_ID="STD-de-Goes-e-Castro-2004" TOTAL_1="35" TOTAL_2="36" VAR="0.010144130903390162" WEIGHT="1.7908824065901774"/>
<DICH_DATA CI_END="0.08785384768117906" CI_START="-0.037309084897988856" EFFECT_SIZE="0.0252723813915951" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="34" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:46:36 +0100" MODIFIED_BY="[Empty name]" ORDER="380" O_E="0.0" SE="0.031929906255022324" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="0.001019518913454514" WEIGHT="13.668819474499879"/>
<DICH_DATA CI_END="0.09568084344632537" CI_START="-0.09568084344632537" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:46:42 +0100" MODIFIED_BY="[Empty name]" ORDER="381" O_E="0.0" SE="0.048817653896216284" STUDY_ID="STD-Gastpar-2002" TOTAL_1="82" TOTAL_2="82" VAR="0.0023831633319307613" WEIGHT="6.864618838955258"/>
<DICH_DATA CI_END="0.12229071083996251" CI_START="0.00804490336661945" EFFECT_SIZE="0.06516780710329098" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:46:48 +0100" MODIFIED_BY="[Empty name]" ORDER="382" O_E="0.0" SE="0.029144874185061412" STUDY_ID="STD-Guardia-2002" TOTAL_1="93" TOTAL_2="99" VAR="8.494236912630591E-4" WEIGHT="15.597228186791266"/>
<DICH_DATA CI_END="0.06900008024578821" CI_START="-0.3974458280463746" EFFECT_SIZE="-0.16422287390029322" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:46:55 +0100" MODIFIED_BY="[Empty name]" ORDER="383" O_E="0.0" SE="0.11899348966905225" STUDY_ID="STD-Hersh-1998" TOTAL_1="31" TOTAL_2="33" VAR="0.014159450583618845" WEIGHT="1.2954896259273077"/>
<DICH_DATA CI_END="0.5154272876744013" CI_START="-0.27542728767440133" EFFECT_SIZE="0.12" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:47:00 +0100" MODIFIED_BY="[Empty name]" ORDER="384" O_E="0.0" SE="0.20175232340669588" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" VAR="0.040704000000000004" WEIGHT="0.45798372289558575"/>
<DICH_DATA CI_END="0.1257465292508508" CI_START="-0.20090992794366128" EFFECT_SIZE="-0.037581699346405234" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:47:07 +0100" MODIFIED_BY="[Empty name]" ORDER="385" O_E="0.0" SE="0.08333226012598612" STUDY_ID="STD-Killeeen-2004" TOTAL_1="51" TOTAL_2="36" VAR="0.0069442655777050164" WEIGHT="2.575839986233172"/>
<DICH_DATA CI_END="0.32992667741821347" CI_START="-0.19659334408488016" EFFECT_SIZE="0.06666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:47:13 +0100" MODIFIED_BY="[Empty name]" ORDER="386" O_E="0.0" SE="0.13431880015556824" STUDY_ID="STD-Kranzler-1998" TOTAL_1="15" TOTAL_2="5" VAR="0.018041540075231483" WEIGHT="1.0221301080845648"/>
<DICH_DATA CI_END="0.17415768494425848" CI_START="-0.17675981869393315" EFFECT_SIZE="-0.001301066874837331" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="29" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:47:21 +0100" MODIFIED_BY="[Empty name]" ORDER="387" O_E="0.0" SE="0.08952141631330578" STUDY_ID="STD-Kranzler-2000" TOTAL_1="61" TOTAL_2="63" VAR="0.008014083978740209" WEIGHT="2.246619399025661"/>
<DICH_DATA CI_END="0.11024381481087862" CI_START="-0.06472040380157194" EFFECT_SIZE="0.02276170550465334" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="33" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:47:30 +0100" MODIFIED_BY="[Empty name]" ORDER="388" O_E="0.0" SE="0.04463454940818964" STUDY_ID="STD-Kranzler-2004" TOTAL_1="167" TOTAL_2="166" VAR="0.0019922430008721217" WEIGHT="8.007282367253037"/>
<DICH_DATA CI_END="0.06568114806805662" CI_START="-0.04175770309198008" EFFECT_SIZE="0.01196172248803827" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="24" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:47:38 +0100" MODIFIED_BY="[Empty name]" ORDER="389" O_E="0.0" SE="0.027408373829187847" STUDY_ID="STD-Krystal-2001" TOTAL_1="418" TOTAL_2="209" VAR="7.512189559605092E-4" WEIGHT="16.980331272959923"/>
<DICH_DATA CI_END="-0.015173083810319232" CI_START="-0.3339178252805899" EFFECT_SIZE="-0.17454545454545456" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:47:51 +0100" MODIFIED_BY="[Empty name]" ORDER="391" O_E="0.0" SE="0.08131392821105093" STUDY_ID="STD-Latt-2002" TOTAL_1="55" TOTAL_2="50" VAR="0.006611954921111946" WEIGHT="2.6986809541056274"/>
<DICH_DATA CI_END="0.024677717123447962" CI_START="-0.22944109479124875" EFFECT_SIZE="-0.10238168883390039" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:47:58 +0100" MODIFIED_BY="[Empty name]" ORDER="392" O_E="0.0" SE="0.06482741874829166" STUDY_ID="STD-Morley-2006" TOTAL_1="53" TOTAL_2="61" VAR="0.004202594221566358" WEIGHT="4.124945653947735"/>
<DICH_DATA CI_END="0.19342097694757404" CI_START="-0.14666773019432727" EFFECT_SIZE="0.023376623376623384" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:48:05 +0100" MODIFIED_BY="[Empty name]" ORDER="393" O_E="0.0" SE="0.08675891746595285" STUDY_ID="STD-Morris-2001" TOTAL_1="55" TOTAL_2="56" VAR="0.007527109759864019" WEIGHT="2.385398799470516"/>
<DICH_DATA CI_END="0.20144739683285545" CI_START="-0.10861720815361015" EFFECT_SIZE="0.04641509433962265" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:48:11 +0100" MODIFIED_BY="[Empty name]" ORDER="394" O_E="0.0" SE="0.07909956699006095" STUDY_ID="STD-O_x0027_Malley-2007" TOTAL_1="53" TOTAL_2="50" VAR="0.00625674149801514" WEIGHT="2.843639557550656"/>
<DICH_DATA CI_END="0.2885418684648643" CI_START="-0.2388524274710755" EFFECT_SIZE="0.0248447204968944" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-22 12:32:43 +0200" MODIFIED_BY="[Empty name]" ORDER="1025" O_E="0.0" SE="0.1345418334459099" STUDY_ID="STD-Oslin-1997" TOTAL_1="21" TOTAL_2="23" VAR="0.018101504946986955" WEIGHT="1.0188094467148157"/>
<DICH_DATA CI_END="0.10976057626414809" CI_START="-0.14309390959748142" EFFECT_SIZE="-0.016666666666666663" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="59" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:48:19 +0100" MODIFIED_BY="[Empty name]" ORDER="395" O_E="0.0" SE="0.064504880665184" STUDY_ID="STD-Oslin-2008" TOTAL_1="120" TOTAL_2="120" VAR="0.00416087962962963" WEIGHT="4.163038656925188"/>
<DICH_DATA CI_END="0.43809289346937347" CI_START="-0.2547595601360401" EFFECT_SIZE="0.09166666666666667" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:48:26 +0100" MODIFIED_BY="[Empty name]" ORDER="396" O_E="0.0" SE="0.17675132274637323" STUDY_ID="STD-Petrakis-2004" TOTAL_1="16" TOTAL_2="15" VAR="0.031241030092592593" WEIGHT="0.5951438950155731"/>
<DICH_DATA CI_END="0.11219167617586281" CI_START="-0.18536240788317995" EFFECT_SIZE="-0.03658536585365857" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="52" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:48:42 +0100" MODIFIED_BY="[Empty name]" ORDER="398" O_E="0.0" SE="0.07590804892490663" STUDY_ID="STD-Pettinati-2008a" TOTAL_1="82" TOTAL_2="82" VAR="0.005762031891586019" WEIGHT="3.073570034677703"/>
<DICH_DATA CI_END="0.2841709616282886" CI_START="-0.08901426647159358" EFFECT_SIZE="0.09757834757834749" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="29" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:48:34 +0100" MODIFIED_BY="[Empty name]" ORDER="397" O_E="0.0" SE="0.09520206265102818" STUDY_ID="STD-Pettinati-2008b" TOTAL_1="52" TOTAL_2="54" VAR="0.009063432733010295" WEIGHT="1.9963465047863422"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.560972290600743" CI_END="0.1644701212108596" CI_START="-0.10786072019986699" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RD" EFFECT_SIZE="0.02830470050549631" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="46" I2="56.14970070917549" I2_Q="0.0" ID="CMP-001.30" LOG_CI_END="-0.783912987512494" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.5481414360628514" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="30" P_CHI2="0.10223463583724024" P_Q="0.0" P_Z="0.6837012783782727" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.008124466101950978" TOTALS="YES" TOTAL_1="182" TOTAL_2="185" WEIGHT="100.0" Z="0.407417634349367">
<NAME>Side effect: Increased libido</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.14876392341741215" CI_START="-0.1243736795149731" EFFECT_SIZE="0.012195121951219523" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="22" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:53:09 +0100" MODIFIED_BY="[Empty name]" ORDER="402" O_E="0.0" SE="0.06967924030412288" STUDY_ID="STD-Pettinati-2008a" TOTAL_1="82" TOTAL_2="82" VAR="0.004855196529359702" WEIGHT="37.1855387515636"/>
<DICH_DATA CI_END="0.0749857708939346" CI_START="-0.24592594183410554" EFFECT_SIZE="-0.08547008547008547" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:53:00 +0100" MODIFIED_BY="[Empty name]" ORDER="401" O_E="0.0" SE="0.08186673715929241" STUDY_ID="STD-Pettinati-2008b" TOTAL_1="52" TOTAL_2="54" VAR="0.006702162653108668" WEIGHT="32.55330363580575"/>
<DICH_DATA CI_END="0.3438720680074676" CI_START="-0.002885673449644466" EFFECT_SIZE="0.17049319727891157" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:53:17 +0100" MODIFIED_BY="[Empty name]" ORDER="403" O_E="0.0" SE="0.08846023299210927" STUDY_ID="STD-Volpicelli-1997" TOTAL_1="48" TOTAL_2="49" VAR="0.007825212821018257" WEIGHT="30.261157612630658"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.790582084467106" CI_END="0.059006130245693886" CI_START="0.0012697405720848084" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RD" EFFECT_SIZE="0.030137935408889347" ESTIMABLE="YES" EVENTS_1="190" EVENTS_2="123" I2="12.10623134533396" I2_Q="0.0" ID="CMP-001.31" LOG_CI_END="-1.2291028664328436" LOG_CI_START="-2.896285003155198" LOG_EFFECT_SIZE="-1.5208865022283578" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="31" P_CHI2="0.320608286101539" P_Q="0.0" P_Z="0.04073953288784635" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="3.5758406920412424E-4" TOTALS="YES" TOTAL_1="1162" TOTAL_2="918" WEIGHT="100.0" Z="2.046171168780847">
<NAME>Side effect: Insomnia</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.2205088690423626" CI_START="-0.013612317318224654" EFFECT_SIZE="0.10344827586206898" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:57:08 +0100" MODIFIED_BY="[Empty name]" ORDER="407" O_E="0.0" SE="0.05972588991616818" STUDY_ID="STD-Ahmadi-2002" TOTAL_1="58" TOTAL_2="58" VAR="0.0035671819262782403" WEIGHT="5.527507052783304"/>
<DICH_DATA CI_END="0.09015785717438658" CI_START="-0.14536147708388886" EFFECT_SIZE="-0.027601809954751144" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:57:15 +0100" MODIFIED_BY="[Empty name]" ORDER="408" O_E="0.0" SE="0.060082566852253896" STUDY_ID="STD-Chick-2000" TOTAL_1="85" TOTAL_2="78" VAR="0.0036099148395555584" WEIGHT="5.467971691852304"/>
<DICH_DATA CI_END="0.06768316886787376" CI_START="-0.04185737766478386" EFFECT_SIZE="0.012912895601544946" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="25" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:57:22 +0100" MODIFIED_BY="[Empty name]" ORDER="409" O_E="0.0" SE="0.027944530459921575" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="7.808967826254847E-4" WEIGHT="19.05536811241839"/>
<DICH_DATA CI_END="0.049651144143456886" CI_START="-0.07404138804589591" EFFECT_SIZE="-0.012195121951219516" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:57:28 +0100" MODIFIED_BY="[Empty name]" ORDER="410" O_E="0.0" SE="0.03155479722204686" STUDY_ID="STD-Gastpar-2002" TOTAL_1="82" TOTAL_2="82" VAR="9.957052277244963E-4" WEIGHT="16.03069777451814"/>
<DICH_DATA CI_END="0.16462644988590108" CI_START="-0.25846809211464006" EFFECT_SIZE="-0.04692082111436949" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:57:34 +0100" MODIFIED_BY="[Empty name]" ORDER="411" O_E="0.0" SE="0.10793426444002463" STUDY_ID="STD-Hersh-1998" TOTAL_1="31" TOTAL_2="33" VAR="0.011649805440209165" WEIGHT="1.8067350695624167"/>
<DICH_DATA CI_END="0.1483412693852491" CI_START="-0.18428898180354975" EFFECT_SIZE="-0.01797385620915032" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:57:46 +0100" MODIFIED_BY="[Empty name]" ORDER="412" O_E="0.0" SE="0.08485621516837652" STUDY_ID="STD-Killeeen-2004" TOTAL_1="51" TOTAL_2="36" VAR="0.007200577252701812" WEIGHT="2.8702975229803966"/>
<DICH_DATA CI_END="0.32992667741821347" CI_START="-0.19659334408488016" EFFECT_SIZE="0.06666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:57:53 +0100" MODIFIED_BY="[Empty name]" ORDER="413" O_E="0.0" SE="0.13431880015556824" STUDY_ID="STD-Kranzler-1998" TOTAL_1="15" TOTAL_2="5" VAR="0.018041540075231483" WEIGHT="1.1790871973171482"/>
<DICH_DATA CI_END="0.3660421220245139" CI_START="0.02063495317715147" EFFECT_SIZE="0.1933385376008327" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="25" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:58:01 +0100" MODIFIED_BY="[Empty name]" ORDER="414" O_E="0.0" SE="0.0881156928320852" STUDY_ID="STD-Kranzler-2000" TOTAL_1="61" TOTAL_2="63" VAR="0.007764375323278391" WEIGHT="2.671051487973757"/>
<DICH_DATA CI_END="0.09236391897617728" CI_START="-0.14633217294443124" EFFECT_SIZE="-0.026984126984126982" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:58:08 +0100" MODIFIED_BY="[Empty name]" ORDER="415" O_E="0.0" SE="0.06089297910660931" STUDY_ID="STD-Lee-2001" TOTAL_1="35" TOTAL_2="18" VAR="0.003707954904477958" WEIGHT="5.336112102476009"/>
<DICH_DATA CI_END="0.13700654038690524" CI_START="-0.0188500294063918" EFFECT_SIZE="0.05907825549025672" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:58:14 +0100" MODIFIED_BY="[Empty name]" ORDER="416" O_E="0.0" SE="0.03976005962932834" STUDY_ID="STD-Morley-2006" TOTAL_1="53" TOTAL_2="61" VAR="0.0015808623417277452" WEIGHT="11.191525129716542"/>
<DICH_DATA CI_END="0.10992694412947004" CI_START="-0.03671939695965873" EFFECT_SIZE="0.03660377358490566" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:58:20 +0100" MODIFIED_BY="[Empty name]" ORDER="417" O_E="0.0" SE="0.03741046831621815" STUDY_ID="STD-O_x0027_Malley-2007" TOTAL_1="53" TOTAL_2="50" VAR="0.0013995431396387622" WEIGHT="12.346386540129343"/>
<DICH_DATA CI_END="0.31777779719796606" CI_START="-0.25152520920624766" EFFECT_SIZE="0.0331262939958592" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:58:27 +0100" MODIFIED_BY="[Empty name]" ORDER="418" O_E="0.0" SE="0.14523302746754613" STUDY_ID="STD-Oslin-1997" TOTAL_1="21" TOTAL_2="23" VAR="0.02109263226738901" WEIGHT="1.0113730966686587"/>
<DICH_DATA CI_END="0.22073767785801268" CI_START="0.029262322141987332" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="14" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:58:34 +0100" MODIFIED_BY="[Empty name]" ORDER="419" O_E="0.0" SE="0.04884665157787554" STUDY_ID="STD-Oslin-2008" TOTAL_1="120" TOTAL_2="120" VAR="0.0023859953703703704" WEIGHT="7.907251165257832"/>
<DICH_DATA CI_END="0.11014283101551602" CI_START="-0.085752587113077" EFFECT_SIZE="0.01219512195121951" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 13:58:42 +0100" MODIFIED_BY="[Empty name]" ORDER="420" O_E="0.0" SE="0.04997423923954498" STUDY_ID="STD-Pettinati-2008a" TOTAL_1="82" TOTAL_2="82" VAR="0.002497424587571277" WEIGHT="7.598636056345764"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.135461215892837" CI_END="0.1427823722865732" CI_START="-0.0271336024260962" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0578243849302385" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="124" I2="41.5826568660313" I2_Q="0.0" ID="CMP-001.32" LOG_CI_END="-0.845325406644063" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.2378889780614342" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="32" P_CHI2="0.16214276413052708" P_Q="0.0" P_Z="0.18220479485386545" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0028770193475966825" TOTALS="YES" TOTAL_1="622" TOTAL_2="385" WEIGHT="100.00000000000001" Z="1.3339971369154338">
<NAME>Side effect: Injection pain</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.05888605238114977" CI_START="-0.038294595645114726" EFFECT_SIZE="0.010295728368017523" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="19" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:02:04 +0100" MODIFIED_BY="[Empty name]" ORDER="421" O_E="0.0" SE="0.024791437187829227" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="6.14615357838082E-4" WEIGHT="53.81253451671644"/>
<DICH_DATA CI_END="0.42467604254355296" CI_START="-0.10467604254355292" EFFECT_SIZE="0.16" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:02:11 +0100" MODIFIED_BY="[Empty name]" ORDER="422" O_E="0.0" SE="0.1350412786312829" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" VAR="0.018236146934371786" WEIGHT="8.899362160873162"/>
<DICH_DATA CI_END="0.42455683077684775" CI_START="-0.5578901641101812" EFFECT_SIZE="-0.06666666666666671" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:02:16 +0100" MODIFIED_BY="[Empty name]" ORDER="423" O_E="0.0" SE="0.2506288387532744" STUDY_ID="STD-Kranzler-1998" TOTAL_1="15" TOTAL_2="5" VAR="0.06281481481481482" WEIGHT="2.860229364907656"/>
<DICH_DATA CI_END="0.2156101269708158" CI_START="0.01647990982306627" EFFECT_SIZE="0.11604501839694104" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="103" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:02:25 +0100" MODIFIED_BY="[Empty name]" ORDER="424" O_E="0.0" SE="0.050799458234555145" STUDY_ID="STD-Kranzler-2004" TOTAL_1="167" TOTAL_2="166" VAR="0.0025805849569243127" WEIGHT="34.427873957502754"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3684873561194562" CI_END="0.15690195625139386" CI_START="-0.14595526088277327" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.005473347684310304" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="28" I2="0.0" I2_Q="0.0" ID="CMP-001.33" LOG_CI_END="-0.8043716416017873" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-2.261746963225777" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="33" P_CHI2="0.5438302162387934" P_Q="0.0" P_Z="0.9435231953132117" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="75" TOTAL_2="79" WEIGHT="100.00000000000003" Z="0.07084238861880278">
<NAME>Side effect: Irregular heartbeat</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.24872229222329606" CI_START="-0.4237222922232961" EFFECT_SIZE="-0.08750000000000002" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:04:17 +0100" MODIFIED_BY="[Empty name]" ORDER="426" O_E="0.0" SE="0.17154513801037907" STUDY_ID="STD-Petrakis-2004" TOTAL_1="16" TOTAL_2="15" VAR="0.029427734375" WEIGHT="20.284432139882906"/>
<DICH_DATA CI_END="0.19873546101584222" CI_START="-0.14047274915143543" EFFECT_SIZE="0.029131355932203395" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="22" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:04:27 +0100" MODIFIED_BY="[Empty name]" ORDER="427" O_E="0.0" SE="0.08653429676333563" STUDY_ID="STD-Petrakis-2005" TOTAL_1="59" TOTAL_2="64" VAR="0.007488184516325039" WEIGHT="79.71556786011712"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.023661751796153" CI_END="0.08445384366731214" CI_START="-0.05197198597235379" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RD" EFFECT_SIZE="0.01624092884747917" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="11" I2="70.07081768833206" I2_Q="0.0" ID="CMP-001.34" LOG_CI_END="-1.073380580012249" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.7893891363141092" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="34" P_CHI2="0.018366109214193793" P_Q="0.0" P_Z="0.6407494816391871" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0029882988262297096" TOTALS="YES" TOTAL_1="306" TOTAL_2="288" WEIGHT="100.0" Z="0.4666511569049928">
<NAME>Side effect: Irritability</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.11295152322178667" CI_START="-0.16374517401543745" EFFECT_SIZE="-0.02539682539682539" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:06:00 +0100" MODIFIED_BY="[Empty name]" ORDER="430" O_E="0.0" SE="0.07058718920851922" STUDY_ID="STD-de-Goes-e-Castro-2004" TOTAL_1="35" TOTAL_2="36" VAR="0.004982551280359292" WEIGHT="15.196108699514305"/>
<DICH_DATA CI_END="0.24954391266271944" CI_START="-0.007713847303242288" EFFECT_SIZE="0.12091503267973858" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:05:46 +0100" MODIFIED_BY="[Empty name]" ORDER="428" O_E="0.0" SE="0.06562818551646309" STUDY_ID="STD-Killeeen-2004" TOTAL_1="51" TOTAL_2="36" VAR="0.004307058734183295" WEIGHT="16.603148460403148"/>
<DICH_DATA CI_END="-0.0018277984563954408" CI_START="-0.058413165399026246" EFFECT_SIZE="-0.030120481927710843" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:05:55 +0100" MODIFIED_BY="[Empty name]" ORDER="429" O_E="0.0" SE="0.014435307839574849" STUDY_ID="STD-Kranzler-2004" TOTAL_1="167" TOTAL_2="166" VAR="2.0837811242329108E-4" WEIGHT="37.89119356499661"/>
<DICH_DATA CI_END="0.09996266284322952" CI_START="-0.024490964730021977" EFFECT_SIZE="0.03773584905660377" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:06:07 +0100" MODIFIED_BY="[Empty name]" ORDER="431" O_E="0.0" SE="0.031748957775481035" STUDY_ID="STD-O_x0027_Malley-2007" TOTAL_1="53" TOTAL_2="50" VAR="0.0010079963198292778" WEIGHT="30.30954927508594"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.006495421280887131" CI_END="0.23220462797939107" CI_START="0.03673738599413097" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.134471006986761" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="13" I2="0.0" I2_Q="0.0" ID="CMP-001.35" LOG_CI_END="-0.634129128758158" LOG_CI_START="-1.4348917486483994" LOG_EFFECT_SIZE="-0.8713713428956255" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="35" P_CHI2="0.9357646978116159" P_Q="0.0" P_Z="0.007003016847289204" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="113" TOTAL_2="114" WEIGHT="100.0" Z="2.6967007666559306">
<NAME>Side effect: Lethargy</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.2672956683023673" CI_START="0.008566400663149953" EFFECT_SIZE="0.13793103448275862" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:08:12 +0100" MODIFIED_BY="[Empty name]" ORDER="434" O_E="0.0" SE="0.06600357702489452" STUDY_ID="STD-Ahmadi-2002" TOTAL_1="58" TOTAL_2="58" VAR="0.0043564721800811845" WEIGHT="57.076436674651625"/>
<DICH_DATA CI_END="0.2790451501325473" CI_START="-0.01930489039228761" EFFECT_SIZE="0.12987012987012986" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:08:19 +0100" MODIFIED_BY="[Empty name]" ORDER="435" O_E="0.0" SE="0.0761111027748933" STUDY_ID="STD-Morris-2001" TOTAL_1="55" TOTAL_2="56" VAR="0.005792899965610372" WEIGHT="42.923563325348375"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.174750712464913" CI_END="0.3692186427881907" CI_START="-0.07788407117186705" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RD" EFFECT_SIZE="0.14566728580816185" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="24" I2="67.61002843462785" I2_Q="0.0" ID="CMP-001.36" LOG_CI_END="-0.43271637845969635" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-0.8366379718282102" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="36" P_CHI2="0.04562157019024693" P_Q="0.0" P_Z="0.20155876599760214" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.025599224751023997" TOTALS="YES" TOTAL_1="108" TOTAL_2="111" WEIGHT="99.99999999999999" Z="1.2771232425809222">
<NAME>Side effect: Lightheadedness</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.37611196828399984" CI_START="-0.03398098099172228" EFFECT_SIZE="0.1710654936461388" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:09:55 +0100" MODIFIED_BY="[Empty name]" ORDER="436" O_E="0.0" SE="0.10461747065519647" STUDY_ID="STD-Hersh-1998" TOTAL_1="31" TOTAL_2="33" VAR="0.010944815166290896" WEIGHT="35.59933473954823"/>
<DICH_DATA CI_END="0.4514324002289414" CI_START="0.14809921569611717" EFFECT_SIZE="0.2997658079625293" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:10:02 +0100" MODIFIED_BY="[Empty name]" ORDER="437" O_E="0.0" SE="0.07738233634022809" STUDY_ID="STD-Kranzler-2000" TOTAL_1="61" TOTAL_2="63" VAR="0.005988025977472186" WEIGHT="41.18571511442969"/>
<DICH_DATA CI_END="0.1752884402123886" CI_START="-0.5086217735457219" EFFECT_SIZE="-0.16666666666666663" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="10" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:10:09 +0100" MODIFIED_BY="[Empty name]" ORDER="438" O_E="0.0" SE="0.17447009719380227" STUDY_ID="STD-Petrakis-2004" TOTAL_1="16" TOTAL_2="15" VAR="0.030439814814814815" WEIGHT="23.21495014602206"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.262574231151885" CI_END="0.35076802643106236" CI_START="-0.4595925376942442" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.05441225563159091" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="21" I2="80.9978927407715" I2_Q="0.0" ID="CMP-001.37" LOG_CI_END="-0.4549800007604159" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="37" P_CHI2="0.021788821816435155" P_Q="0.0" P_Z="0.7923914642983593" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.07076521422428349" TOTALS="YES" TOTAL_1="98" TOTAL_2="97" WEIGHT="100.0" Z="0.2632064443328814">
<NAME>Side effect: Muscle stiffness</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.044758466893657645" CI_START="-0.6280918002269908" EFFECT_SIZE="-0.29166666666666663" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="10" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:14:01 +0100" MODIFIED_BY="[Empty name]" ORDER="442" O_E="0.0" SE="0.17164863039015144" STUDY_ID="STD-Petrakis-2004" TOTAL_1="16" TOTAL_2="15" VAR="0.029463252314814815" WEIGHT="42.63922838857137"/>
<DICH_DATA CI_END="0.24181049354432047" CI_START="0.0020919454800697734" EFFECT_SIZE="0.12195121951219512" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:14:10 +0100" MODIFIED_BY="[Empty name]" ORDER="443" O_E="0.0" SE="0.061153814548410075" STUDY_ID="STD-Pettinati-2008a" TOTAL_1="82" TOTAL_2="82" VAR="0.0037397890338213315" WEIGHT="57.36077161142863"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.797185366435617" CI_END="0.12946525885157048" CI_START="-0.06906421719084341" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RD" EFFECT_SIZE="0.03020052083036353" ESTIMABLE="YES" EVENTS_1="100" EVENTS_2="63" I2="77.26545574871356" I2_Q="0.0" ID="CMP-001.38" LOG_CI_END="-0.8878467560093288" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.5199855672480667" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="38" P_CHI2="0.01229467701378728" P_Q="0.0" P_Z="0.5509723454826149" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0055228601617741705" TOTALS="YES" TOTAL_1="650" TOTAL_2="438" WEIGHT="100.00000000000001" Z="0.5963037259940024">
<NAME>Side effect: Nasal problems</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.3618077896485054" CI_START="0.042020408297339606" EFFECT_SIZE="0.2019140989729225" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:14:55 +0100" MODIFIED_BY="[Empty name]" ORDER="444" O_E="0.0" SE="0.08157991266003045" STUDY_ID="STD-Anton-1999" TOTAL_1="68" TOTAL_2="63" VAR="0.0066552821496181965" WEIGHT="21.062638530106064"/>
<DICH_DATA CI_END="0.06928804968836724" CI_START="-0.0387121576032805" EFFECT_SIZE="0.015287946042543368" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="24" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:15:03 +0100" MODIFIED_BY="[Empty name]" ORDER="445" O_E="0.0" SE="0.027551579555425403" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="7.590895359989351E-4" WEIGHT="40.831878925101236"/>
<DICH_DATA CI_END="0.019402864572753434" CI_START="-0.11687057974481894" EFFECT_SIZE="-0.048733857586032756" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:15:11 +0100" MODIFIED_BY="[Empty name]" ORDER="446" O_E="0.0" SE="0.034764272556148966" STUDY_ID="STD-Kranzler-2004" TOTAL_1="167" TOTAL_2="166" VAR="0.0012085546463582123" WEIGHT="38.105482544792714"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="53.40150706358931" CI_END="0.13491433332287964" CI_START="0.06608435815000666" CI_STUDY="95" CI_TOTAL="95" DF="24" EFFECT_MEASURE="RD" EFFECT_SIZE="0.10049934573644315" ESTIMABLE="YES" EVENTS_1="616" EVENTS_2="317" I2="55.057448151376434" I2_Q="0.0" ID="CMP-001.39" LOG_CI_END="-0.8699419083536264" LOG_CI_START="-1.1799013237674716" LOG_EFFECT_SIZE="-0.9978367655467496" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="39" P_CHI2="5.119274229301585E-4" P_Q="0.0" P_Z="1.0433520091608364E-8" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="25" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0033140196738564117" TOTALS="YES" TOTAL_1="2391" TOTAL_2="1943" WEIGHT="99.99999999999999" Z="5.723526635555107">
<NAME>Side effect: Nausea</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.3434272933032711" CI_START="0.035883051524315146" EFFECT_SIZE="0.18965517241379312" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:17:12 +0100" MODIFIED_BY="[Empty name]" ORDER="447" O_E="0.0" SE="0.07845660537765635" STUDY_ID="STD-Ahmadi-2002" TOTAL_1="58" TOTAL_2="58" VAR="0.006155438927385296" WEIGHT="3.255921328826552"/>
<DICH_DATA CI_END="0.1857892066597896" CI_START="0.0472205020780745" EFFECT_SIZE="0.11650485436893204" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="65" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-22 10:43:50 +0200" MODIFIED_BY="[Empty name]" ORDER="449" O_E="0.0" SE="0.03534980889310399" STUDY_ID="STD-Anton-2006" TOTAL_1="309" TOTAL_2="309" VAR="0.0012496089887789738" WEIGHT="6.755986192447633"/>
<DICH_DATA CI_END="0.05589623799710255" CI_START="-0.1224117330840262" EFFECT_SIZE="-0.03325774754346183" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:17:35 +0100" MODIFIED_BY="[Empty name]" ORDER="450" O_E="0.0" SE="0.04548756316126196" STUDY_ID="STD-Baltieri-2008" TOTAL_1="49" TOTAL_2="54" VAR="0.002069118402349796" WEIGHT="5.727479361620201"/>
<DICH_DATA CI_END="0.2799602633037117" CI_START="0.022000521010013763" EFFECT_SIZE="0.15098039215686274" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-22 10:33:14 +0200" MODIFIED_BY="[Empty name]" ORDER="451" O_E="0.0" SE="0.06580726593153025" STUDY_ID="STD-Chick-2000" TOTAL_1="85" TOTAL_2="78" VAR="0.004330596249383142" WEIGHT="4.033140780623724"/>
<DICH_DATA CI_END="0.31108179391923785" CI_START="-0.020605603443047377" EFFECT_SIZE="0.14523809523809522" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:19:01 +0100" MODIFIED_BY="[Empty name]" ORDER="461" O_E="0.0" SE="0.08461568681327643" STUDY_ID="STD-de-Goes-e-Castro-2004" TOTAL_1="35" TOTAL_2="36" VAR="0.007159814454882482" WEIGHT="2.943698730880631"/>
<DICH_DATA CI_END="0.24244535469068648" CI_START="0.12059148164989111" EFFECT_SIZE="0.1815184181702888" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-22 11:36:05 +0200" MODIFIED_BY="[Empty name]" ORDER="452" O_E="0.0" SE="0.031085742901901043" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="9.663234117630911E-4" WEIGHT="7.203117043539648"/>
<DICH_DATA CI_END="0.12214222592068623" CI_START="-1.910064084911095E-4" EFFECT_SIZE="0.06097560975609756" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-22 11:38:56 +0200" MODIFIED_BY="[Empty name]" ORDER="453" O_E="0.0" SE="0.0312080306817182" STUDY_ID="STD-Gastpar-2002" TOTAL_1="82" TOTAL_2="82" VAR="9.739411790310646E-4" WEIGHT="7.190320362057654"/>
<DICH_DATA CI_END="0.5154272876744013" CI_START="-0.27542728767440133" EFFECT_SIZE="0.12" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-22 11:43:47 +0200" MODIFIED_BY="[Empty name]" ORDER="454" O_E="0.0" SE="0.20175232340669588" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" VAR="0.040704000000000004" WEIGHT="0.7004361500282312"/>
<DICH_DATA CI_END="0.17980539735825762" CI_START="-0.029805397358257588" EFFECT_SIZE="0.07500000000000001" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:18:12 +0100" MODIFIED_BY="[Empty name]" ORDER="455" O_E="0.0" SE="0.053473124090518596" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.002859375" WEIGHT="4.994304408041812"/>
<DICH_DATA CI_END="0.32992667741821347" CI_START="-0.19659334408488016" EFFECT_SIZE="0.06666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:18:30 +0100" MODIFIED_BY="[Empty name]" ORDER="457" O_E="0.0" SE="0.13431880015556824" STUDY_ID="STD-Kranzler-1998" TOTAL_1="15" TOTAL_2="5" VAR="0.018041540075231483" WEIGHT="1.443737021856323"/>
<DICH_DATA CI_END="0.33110821616836345" CI_START="0.038915203035383594" EFFECT_SIZE="0.18501170960187352" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:18:37 +0100" MODIFIED_BY="[Empty name]" ORDER="458" O_E="0.0" SE="0.07454040365990422" STUDY_ID="STD-Kranzler-2000" TOTAL_1="61" TOTAL_2="63" VAR="0.005556271777781462" WEIGHT="3.4758510924159003"/>
<DICH_DATA CI_END="0.10502086469060119" CI_START="-0.03439104000262773" EFFECT_SIZE="0.03531491234398673" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="17" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:18:46 +0100" MODIFIED_BY="[Empty name]" ORDER="459" O_E="0.0" SE="0.03556491491499136" STUDY_ID="STD-Kranzler-2004" TOTAL_1="167" TOTAL_2="166" VAR="0.0012648631729105745" WEIGHT="6.733479161623967"/>
<DICH_DATA CI_END="0.07100409539789578" CI_START="-0.004018449464881432" EFFECT_SIZE="0.03349282296650717" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:18:54 +0100" MODIFIED_BY="[Empty name]" ORDER="460" O_E="0.0" SE="0.019138755980861247" STUDY_ID="STD-Krystal-2001" TOTAL_1="418" TOTAL_2="209" VAR="3.662919804949521E-4" WEIGHT="8.377500366244629"/>
<DICH_DATA CI_END="0.12573851237943567" CI_START="-0.06859565523657854" EFFECT_SIZE="0.02857142857142857" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:19:08 +0100" MODIFIED_BY="[Empty name]" ORDER="462" O_E="0.0" SE="0.04957595372897087" STUDY_ID="STD-Lee-2001" TOTAL_1="35" TOTAL_2="18" VAR="0.0024577751881370603" WEIGHT="5.341806659700686"/>
<DICH_DATA CI_END="0.21236978593766126" CI_START="-0.008843649222535999" EFFECT_SIZE="0.10176306835756263" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:19:33 +0100" MODIFIED_BY="[Empty name]" ORDER="464" O_E="0.0" SE="0.056433035735631014" STUDY_ID="STD-Morley-2006" TOTAL_1="53" TOTAL_2="61" VAR="0.003184687522339007" WEIGHT="4.744299335454442"/>
<DICH_DATA CI_END="0.3276783746651627" CI_START="0.006087859101071069" EFFECT_SIZE="0.16688311688311688" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="10" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:19:50 +0100" MODIFIED_BY="[Empty name]" ORDER="465" O_E="0.0" SE="0.08203990433006846" STUDY_ID="STD-Morris-2001" TOTAL_1="55" TOTAL_2="56" VAR="0.006730545902486786" WEIGHT="3.0695018114907353"/>
<DICH_DATA CI_END="0.34998303070299175" CI_START="0.03463235391239286" EFFECT_SIZE="0.19230769230769232" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:19:57 +0100" MODIFIED_BY="[Empty name]" ORDER="466" O_E="0.0" SE="0.08044807947443035" STUDY_ID="STD-O_x0027_Malley-1992" TOTAL_1="52" TOTAL_2="52" VAR="0.0064718934911242604" WEIGHT="3.1506321088721636"/>
<DICH_DATA CI_END="0.2644116845753035" CI_START="-0.05837394872624688" EFFECT_SIZE="0.1030188679245283" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:20:05 +0100" MODIFIED_BY="[Empty name]" ORDER="467" O_E="0.0" SE="0.08234478690619884" STUDY_ID="STD-O_x0027_Malley-2007" TOTAL_1="53" TOTAL_2="50" VAR="0.006780663930627297" WEIGHT="3.054262366234887"/>
<DICH_DATA CI_END="0.35326257300058994" CI_START="-0.1179684553535311" EFFECT_SIZE="0.11764705882352944" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="16" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:20:13 +0100" MODIFIED_BY="[Empty name]" ORDER="468" O_E="0.0" SE="0.12021420599335786" STUDY_ID="STD-O_x0027_Malley-2008" TOTAL_1="34" TOTAL_2="34" VAR="0.014451455322613476" WEIGHT="1.735490452034038"/>
<DICH_DATA CI_END="0.18433788141516058" CI_START="-0.2464496826573966" EFFECT_SIZE="-0.031055900621118016" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:20:19 +0100" MODIFIED_BY="[Empty name]" ORDER="469" O_E="0.0" SE="0.10989680613280511" STUDY_ID="STD-Oslin-1997" TOTAL_1="21" TOTAL_2="23" VAR="0.012077307998191351" WEIGHT="2.0031938042756816"/>
<DICH_DATA CI_END="0.21568842583781628" CI_START="-0.032355092504482943" EFFECT_SIZE="0.09166666666666667" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="44" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:20:27 +0100" MODIFIED_BY="[Empty name]" ORDER="470" O_E="0.0" SE="0.06327757048058914" STUDY_ID="STD-Oslin-2008" TOTAL_1="120" TOTAL_2="120" VAR="0.0040040509259259265" WEIGHT="4.213106694152413"/>
<DICH_DATA CI_END="0.38470063226764967" CI_START="-0.3097006322676497" EFFECT_SIZE="0.03749999999999998" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:20:33 +0100" MODIFIED_BY="[Empty name]" ORDER="471" O_E="0.0" SE="0.17714643483570308" STUDY_ID="STD-Petrakis-2004" TOTAL_1="16" TOTAL_2="15" VAR="0.031380859375" WEIGHT="0.8886559941254265"/>
<DICH_DATA CI_END="0.329147310645296" CI_START="-0.020354937763940067" EFFECT_SIZE="0.15439618644067798" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:20:41 +0100" MODIFIED_BY="[Empty name]" ORDER="472" O_E="0.0" SE="0.08916037518190774" STUDY_ID="STD-Petrakis-2005" TOTAL_1="59" TOTAL_2="64" VAR="0.00794957250257855" WEIGHT="2.737298345791271"/>
<DICH_DATA CI_END="0.41267303850068" CI_START="0.12391232735297858" EFFECT_SIZE="0.2682926829268293" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="22" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:21:03 +0100" MODIFIED_BY="[Empty name]" ORDER="474" O_E="0.0" SE="0.0736648003293451" STUDY_ID="STD-Pettinati-2008a" TOTAL_1="82" TOTAL_2="82" VAR="0.0054265028075622815" WEIGHT="3.52745643040993"/>
<DICH_DATA CI_END="0.30184029625802394" CI_START="-0.05112804554577316" EFFECT_SIZE="0.1253561253561254" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="14" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:20:50 +0100" MODIFIED_BY="[Empty name]" ORDER="473" O_E="0.0" SE="0.09004459892833908" STUDY_ID="STD-Pettinati-2008b" TOTAL_1="52" TOTAL_2="54" VAR="0.008108029796165444" WEIGHT="2.699323997251426"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.8112782861305119" CI_END="0.033124400655812763" CI_START="-0.025546991476818347" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.0037887045894972097" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-001.40" LOG_CI_END="-1.479851970994097" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-2.4215092559424263" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="40" P_CHI2="0.3677426521024666" P_Q="0.0" P_Z="0.800168289340722" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="110" TOTAL_2="100" WEIGHT="100.00000000000001" Z="0.25312931135807143">
<NAME>Side effect: Nervousness</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.11502115813698353" CI_START="-0.052929654869009676" EFFECT_SIZE="0.03104575163398693" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:33:56 +0100" MODIFIED_BY="[Empty name]" ORDER="475" O_E="0.0" SE="0.04284538244854696" STUDY_ID="STD-Killeeen-2004" TOTAL_1="51" TOTAL_2="36" VAR="0.0018357267971622557" WEIGHT="12.203616888275223"/>
<DICH_DATA CI_END="0.0313081989551585" CI_START="-0.0313081989551585" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:34:45 +0100" MODIFIED_BY="[Empty name]" ORDER="476" O_E="0.0" SE="0.01597386441899626" STUDY_ID="STD-Petrakis-2005" TOTAL_1="59" TOTAL_2="64" VAR="2.551643444764747E-4" WEIGHT="87.7963831117248"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.607123307254213" CI_END="0.15996990974959732" CI_START="0.04260786642336501" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RD" EFFECT_SIZE="0.10128888808648116" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="7" I2="0.0" I2_Q="0.0" ID="CMP-001.41" LOG_CI_END="-0.795961700210803" LOG_CI_START="-1.370510212426126" LOG_EFFECT_SIZE="-0.9944381963714556" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="41" P_CHI2="0.7381844121412521" P_Q="0.0" P_Z="7.167782993376264E-4" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="129" TOTAL_2="129" WEIGHT="100.0" Z="3.3830796918178447">
<NAME>Side-effect Nightmares</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.16399393123121822" CI_START="0.008419861872230067" EFFECT_SIZE="0.08620689655172414" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:36:47 +0100" MODIFIED_BY="[Empty name]" ORDER="477" O_E="0.0" SE="0.03968799186774261" STUDY_ID="STD-Ahmadi-2002" TOTAL_1="58" TOTAL_2="58" VAR="0.0015751366984940037" WEIGHT="56.908993001482834"/>
<DICH_DATA CI_END="0.2196996099550967" CI_START="0.03484584459035783" EFFECT_SIZE="0.12727272727272726" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:36:54 +0100" MODIFIED_BY="[Empty name]" ORDER="478" O_E="0.0" SE="0.04715743932614113" STUDY_ID="STD-Morris-2001" TOTAL_1="55" TOTAL_2="56" VAR="0.002223824083798682" WEIGHT="40.30869348165981"/>
<DICH_DATA CI_END="0.38513236011758206" CI_START="-0.3184656934509154" EFFECT_SIZE="0.033333333333333326" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="7" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:37:00 +0100" MODIFIED_BY="[Empty name]" ORDER="479" O_E="0.0" SE="0.17949259759832045" STUDY_ID="STD-Petrakis-2004" TOTAL_1="16" TOTAL_2="15" VAR="0.03221759259259259" WEIGHT="2.782313516857364"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="8.841532907139516" CI_END="0.0731948272025724" CI_START="-0.03584787894744348" CI_STUDY="95" CI_TOTAL="95" DF="5" EFFECT_MEASURE="RD" EFFECT_SIZE="0.018673474127564454" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="64" I2="43.44872034619119" I2_Q="0.0" ID="CMP-001.42" LOG_CI_END="-1.1355196101541691" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.7287748757269108" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="42" P_CHI2="0.11555438842440302" P_Q="0.0" P_Z="0.5020393403258387" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="6" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0018889455817261238" TOTALS="YES" TOTAL_1="694" TOTAL_2="460" WEIGHT="100.0" Z="0.6712844544763074">
<NAME>Side effect: Pain</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.20209355935309625" CI_START="0.026865716665003328" EFFECT_SIZE="0.11447963800904978" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:38:07 +0100" MODIFIED_BY="[Empty name]" ORDER="480" O_E="0.0" SE="0.04470180168367066" STUDY_ID="STD-Chick-2000" TOTAL_1="85" TOTAL_2="78" VAR="0.001998251073766221" WEIGHT="19.9067588857158"/>
<DICH_DATA CI_END="0.09709242959471158" CI_START="-0.034891472656912545" EFFECT_SIZE="0.031100478468899517" ESTIMABLE="YES" EVENTS_1="91" EVENTS_2="39" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:38:15 +0100" MODIFIED_BY="[Empty name]" ORDER="481" O_E="0.0" SE="0.03366998151310338" STUDY_ID="STD-Krystal-2001" TOTAL_1="418" TOTAL_2="209" VAR="0.0011336676550927237" WEIGHT="25.6008561133965"/>
<DICH_DATA CI_END="0.07157848085241514" CI_START="-0.18268959196352624" EFFECT_SIZE="-0.05555555555555555" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:38:23 +0100" MODIFIED_BY="[Empty name]" ORDER="482" O_E="0.0" SE="0.06486549620849553" STUDY_ID="STD-Lee-2001" TOTAL_1="35" TOTAL_2="18" VAR="0.004207532598374348" WEIGHT="12.69281776728539"/>
<DICH_DATA CI_END="0.03419996629333019" CI_START="-0.11646411723672642" EFFECT_SIZE="-0.041132075471698115" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:38:30 +0100" MODIFIED_BY="[Empty name]" ORDER="483" O_E="0.0" SE="0.0384354214461275" STUDY_ID="STD-O_x0027_Malley-2007" TOTAL_1="53" TOTAL_2="50" VAR="0.0014772816217414376" WEIGHT="22.98760062378916"/>
<DICH_DATA CI_END="0.2688963144665747" CI_START="-0.22748844697175066" EFFECT_SIZE="0.020703933747412" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:38:36 +0100" MODIFIED_BY="[Empty name]" ORDER="484" O_E="0.0" SE="0.1266310925490838" STUDY_ID="STD-Oslin-1997" TOTAL_1="21" TOTAL_2="23" VAR="0.016035433600174627" WEIGHT="4.317108323639091"/>
<DICH_DATA CI_END="0.13950541643474595" CI_START="-0.09072492862986792" EFFECT_SIZE="0.02439024390243902" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:38:43 +0100" MODIFIED_BY="[Empty name]" ORDER="485" O_E="0.0" SE="0.058733310122186286" STUDY_ID="STD-Pettinati-2008a" TOTAL_1="82" TOTAL_2="82" VAR="0.0034496017179089103" WEIGHT="14.494858286174049"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.08044371953082204" CI_END="0.12429509266524674" CI_START="-0.05801734201265738" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.03313887532629468" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-001.43" LOG_CI_END="-0.9055460175407808" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.4796622348386026" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="43" P_CHI2="0.7766970038381176" P_Q="0.0" P_Z="0.4761402956331934" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="50" TOTAL_2="23" WEIGHT="100.0" Z="0.7125241044852607">
<NAME>Side effect: Palpitation</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.32992667741821347" CI_START="-0.19659334408488016" EFFECT_SIZE="0.06666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:39:53 +0100" MODIFIED_BY="[Empty name]" ORDER="486" O_E="0.0" SE="0.13431880015556824" STUDY_ID="STD-Kranzler-1998" TOTAL_1="15" TOTAL_2="5" VAR="0.018041540075231483" WEIGHT="11.989547731523533"/>
<DICH_DATA CI_END="0.12573851237943567" CI_START="-0.06859565523657854" EFFECT_SIZE="0.02857142857142857" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:39:58 +0100" MODIFIED_BY="[Empty name]" ORDER="487" O_E="0.0" SE="0.04957595372897087" STUDY_ID="STD-Lee-2001" TOTAL_1="35" TOTAL_2="18" VAR="0.0024577751881370603" WEIGHT="88.01045226847647"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.067827058282704" CI_END="0.06760670274048183" CI_START="-0.07195326889037706" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.002173283074947617" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" I2="60.53535416660953" I2_Q="0.0" ID="CMP-001.44" LOG_CI_END="-1.1700102446071938" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="44" P_CHI2="0.079347963632045" P_Q="0.0" P_Z="0.9513252276948139" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.002259349175168345" TOTALS="YES" TOTAL_1="166" TOTAL_2="154" WEIGHT="100.0" Z="0.06104266868689931">
<NAME>Side-effect Pruritus</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.08834515370600651" CI_START="-0.04374953768181906" EFFECT_SIZE="0.022297808012093724" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:46:10 +0100" MODIFIED_BY="[Empty name]" ORDER="493" O_E="0.0" SE="0.033698244567188895" STUDY_ID="STD-Baltieri-2008" TOTAL_1="49" TOTAL_2="54" VAR="0.001135571686910076" WEIGHT="37.33669882618965"/>
<DICH_DATA CI_END="1.910064084911095E-4" CI_START="-0.12214222592068623" EFFECT_SIZE="-0.06097560975609756" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:46:18 +0100" MODIFIED_BY="[Empty name]" ORDER="494" O_E="0.0" SE="0.0312080306817182" STUDY_ID="STD-Gastpar-2002" TOTAL_1="82" TOTAL_2="82" VAR="9.739411790310646E-4" WEIGHT="39.20314103604709"/>
<DICH_DATA CI_END="0.1670345656317586" CI_START="-0.05274885134604434" EFFECT_SIZE="0.05714285714285714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:42:32 +0100" MODIFIED_BY="[Empty name]" ORDER="489" O_E="0.0" SE="0.05606822847547876" STUDY_ID="STD-Lee-2001" TOTAL_1="35" TOTAL_2="18" VAR="0.003143646244378487" WEIGHT="23.460160137763268"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.503843336831604" CI_END="0.36109172149906155" CI_START="-0.3211102064550744" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.019990757521993592" ESTIMABLE="YES" EVENTS_1="68" EVENTS_2="65" I2="77.79674102289076" I2_Q="0.0" ID="CMP-001.45" LOG_CI_END="-0.4423824682291946" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.6991707485838143" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="45" P_CHI2="0.033818808881239115" P_Q="0.0" P_Z="0.9085507272347126" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.04874104909993181" TOTALS="YES" TOTAL_1="75" TOTAL_2="79" WEIGHT="100.0" Z="0.11486676645515066">
<NAME>Side effect: Restlessness</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.13684440061965558" CI_START="-0.48684440061965567" EFFECT_SIZE="-0.17500000000000004" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:48:26 +0100" MODIFIED_BY="[Empty name]" ORDER="496" O_E="0.0" SE="0.1591072096627512" STUDY_ID="STD-Petrakis-2004" TOTAL_1="16" TOTAL_2="15" VAR="0.025315104166666665" WEIGHT="40.89861130172999"/>
<DICH_DATA CI_END="0.2530488802039774" CI_START="0.05680281471127692" EFFECT_SIZE="0.15492584745762716" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="53" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:48:36 +0100" MODIFIED_BY="[Empty name]" ORDER="497" O_E="0.0" SE="0.05006369174144638" STUDY_ID="STD-Petrakis-2005" TOTAL_1="59" TOTAL_2="64" VAR="0.002506373230782566" WEIGHT="59.101388698270014"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.607143570208315" CI_END="-1.3467742997895146E-4" CI_START="-0.04517007554746262" CI_STUDY="95" CI_TOTAL="95" DF="8" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.022652376488720788" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="46" I2="16.7286307159191" I2_Q="0.0" ID="CMP-001.46" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="46" P_CHI2="0.293688659039243" P_Q="0.0" P_Z="0.04864541160492301" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="9" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="1.9167405554668235E-4" TOTALS="YES" TOTAL_1="869" TOTAL_2="657" WEIGHT="99.99999999999997" Z="1.9716864483495473">
<NAME>Side effect: Serious adverse events</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.019687629847361422" CI_START="-0.06202348042671232" EFFECT_SIZE="-0.021167925289675447" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:52:17 +0100" MODIFIED_BY="[Empty name]" ORDER="498" O_E="0.0" SE="0.020845054021043384" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="4.34516277140217E-4" WEIGHT="21.078780463602442"/>
<DICH_DATA CI_END="-0.086204682493106" CI_START="-0.4514297261090445" EFFECT_SIZE="-0.26881720430107525" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:52:23 +0100" MODIFIED_BY="[Empty name]" ORDER="499" O_E="0.0" SE="0.09317136602937273" STUDY_ID="STD-Hersh-1998" TOTAL_1="31" TOTAL_2="33" VAR="0.00868090344777935" WEIGHT="1.487654353674492"/>
<DICH_DATA CI_END="0.0475116176775721" CI_START="-0.0475116176775721" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:52:28 +0100" MODIFIED_BY="[Empty name]" ORDER="500" O_E="0.0" SE="0.024241066699356557" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="5.876293147226534E-4" WEIGHT="16.93734308703874"/>
<DICH_DATA CI_END="0.23701444482849598" CI_START="-0.23701444482849598" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:52:34 +0100" MODIFIED_BY="[Empty name]" ORDER="501" O_E="0.0" SE="0.1209279592370246" STUDY_ID="STD-Kranzler-1998" TOTAL_1="15" TOTAL_2="5" VAR="0.01462357132523148" WEIGHT="0.8909287839580851"/>
<DICH_DATA CI_END="0.0043798034876758735" CI_START="-0.052644719438905946" EFFECT_SIZE="-0.024132457975615036" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:52:40 +0100" MODIFIED_BY="[Empty name]" ORDER="502" O_E="0.0" SE="0.014547339485925246" STUDY_ID="STD-Kranzler-2004" TOTAL_1="167" TOTAL_2="166" VAR="2.1162508611875978E-4" WEIGHT="32.7283824523655"/>
<DICH_DATA CI_END="0.16177740255389167" CI_START="-0.08515402593051503" EFFECT_SIZE="0.03831168831168831" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:52:46 +0100" MODIFIED_BY="[Empty name]" ORDER="503" O_E="0.0" SE="0.06299386887518604" STUDY_ID="STD-Morris-2001" TOTAL_1="55" TOTAL_2="56" VAR="0.003968227515864132" WEIGHT="3.1729905923376993"/>
<DICH_DATA CI_END="0.024528157246653644" CI_START="-0.10452815724665365" EFFECT_SIZE="-0.04" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:52:52 +0100" MODIFIED_BY="[Empty name]" ORDER="504" O_E="0.0" SE="0.032923134177792815" STUDY_ID="STD-O_x0027_Malley-2007" TOTAL_1="53" TOTAL_2="50" VAR="0.0010839327640889496" WEIGHT="10.347489796979623"/>
<DICH_DATA CI_END="0.15315646586745435" CI_START="-0.15315646586745435" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:52:58 +0100" MODIFIED_BY="[Empty name]" ORDER="505" O_E="0.0" SE="0.07814248990059665" STUDY_ID="STD-O_x0027_Malley-2008" TOTAL_1="34" TOTAL_2="34" VAR="0.006106248727864848" WEIGHT="2.0958225442051805"/>
<DICH_DATA CI_END="0.031446202953094485" CI_START="-0.09129789786834873" EFFECT_SIZE="-0.02992584745762712" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:53:04 +0100" MODIFIED_BY="[Empty name]" ORDER="506" O_E="0.0" SE="0.031312845998608396" STUDY_ID="STD-Petrakis-2005" TOTAL_1="59" TOTAL_2="64" VAR="9.80494324532566E-4" WEIGHT="11.260607925838217"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7053041640712249" CI_END="0.003306145643696263" CI_START="-0.05723494479776009" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.026964399577031912" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="5" I2="0.0" I2_Q="0.0" ID="CMP-001.47" LOG_CI_END="-2.4806780186228945" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="47" P_CHI2="0.7028217740592807" P_Q="0.0" P_Z="0.08082886307193025" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="185" TOTAL_2="163" WEIGHT="100.0" Z="1.7458969321616435">
<NAME>Side effect: Sexual dysfunction</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.02624965206066554" CI_START="-0.057995683806697285" EFFECT_SIZE="-0.015873015873015872" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:53:53 +0100" MODIFIED_BY="[Empty name]" ORDER="507" O_E="0.0" SE="0.021491552021332863" STUDY_ID="STD-Anton-1999" TOTAL_1="68" TOTAL_2="63" VAR="4.6188680828565667E-4" WEIGHT="51.64267690912823"/>
<DICH_DATA CI_END="0.009745069771144484" CI_START="-0.08291580147846156" EFFECT_SIZE="-0.036585365853658534" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:53:59 +0100" MODIFIED_BY="[Empty name]" ORDER="508" O_E="0.0" SE="0.023638411720955883" STUDY_ID="STD-Gastpar-2002" TOTAL_1="82" TOTAL_2="82" VAR="5.587745086894245E-4" WEIGHT="42.688187878918654"/>
<DICH_DATA CI_END="0.07157848085241514" CI_START="-0.18268959196352624" EFFECT_SIZE="-0.05555555555555555" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:54:04 +0100" MODIFIED_BY="[Empty name]" ORDER="509" O_E="0.0" SE="0.06486549620849553" STUDY_ID="STD-Lee-2001" TOTAL_1="35" TOTAL_2="18" VAR="0.004207532598374348" WEIGHT="5.669135211953119"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.616468582972272" CI_END="0.05425432373440933" CI_START="-0.043643188798032445" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RD" EFFECT_SIZE="0.005305567468188441" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-001.48" LOG_CI_END="-1.265565645513171" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-2.2752681583936063" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="48" P_CHI2="0.6239087211848688" P_Q="0.0" P_Z="0.8317630275365091" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="171" TOTAL_2="142" WEIGHT="100.0" Z="0.21244096782848743">
<NAME>Side effect: Skin rash</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.32992667741821347" CI_START="-0.19659334408488016" EFFECT_SIZE="0.06666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:54:54 +0100" MODIFIED_BY="[Empty name]" ORDER="510" O_E="0.0" SE="0.13431880015556824" STUDY_ID="STD-Kranzler-1998" TOTAL_1="15" TOTAL_2="5" VAR="0.018041540075231483" WEIGHT="3.4571126661014735"/>
<DICH_DATA CI_END="0.07157848085241514" CI_START="-0.18268959196352624" EFFECT_SIZE="-0.05555555555555555" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:54:59 +0100" MODIFIED_BY="[Empty name]" ORDER="511" O_E="0.0" SE="0.06486549620849553" STUDY_ID="STD-Lee-2001" TOTAL_1="35" TOTAL_2="18" VAR="0.004207532598374348" WEIGHT="14.823803559872221"/>
<DICH_DATA CI_END="0.08206117831956843" CI_START="-0.046589480206360875" EFFECT_SIZE="0.01773584905660377" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:55:05 +0100" MODIFIED_BY="[Empty name]" ORDER="512" O_E="0.0" SE="0.032819648611073796" STUDY_ID="STD-O_x0027_Malley-2007" TOTAL_1="53" TOTAL_2="50" VAR="0.0010771293349543583" WEIGHT="57.905429446597495"/>
<DICH_DATA CI_END="0.4868444006196556" CI_START="-0.13684440061965564" EFFECT_SIZE="0.175" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:55:11 +0100" MODIFIED_BY="[Empty name]" ORDER="513" O_E="0.0" SE="0.1591072096627512" STUDY_ID="STD-Petrakis-2004" TOTAL_1="16" TOTAL_2="15" VAR="0.025315104166666665" WEIGHT="2.463811181633893"/>
<DICH_DATA CI_END="0.09026666641272121" CI_START="-0.12160569775175253" EFFECT_SIZE="-0.01566951566951566" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:55:18 +0100" MODIFIED_BY="[Empty name]" ORDER="514" O_E="0.0" SE="0.05405006567357765" STUDY_ID="STD-Pettinati-2008b" TOTAL_1="52" TOTAL_2="54" VAR="0.0029214095993180577" WEIGHT="21.349843145794907"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.5181957624813784" CI_END="0.13929056640443854" CI_START="0.05311780354989411" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RD" EFFECT_SIZE="0.09620418497716632" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="87" I2="0.0" I2_Q="0.0" ID="CMP-001.49" LOG_CI_END="-0.8560782956164461" LOG_CI_START="-1.274759891582109" LOG_EFFECT_SIZE="-1.0168060353118975" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="49" P_CHI2="0.4751170867562745" P_Q="0.0" P_Z="1.2073902798861931E-5" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="484" TOTAL_2="490" WEIGHT="100.00000000000001" Z="4.376249094752834">
<NAME>Side effect: Somnolence</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.20082616539017867" CI_START="0.058073510985225896" EFFECT_SIZE="0.12944983818770228" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="72" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-11 09:14:11 +0100" MODIFIED_BY="[Empty name]" ORDER="1113" O_E="0.0" SE="0.036417162644560686" STUDY_ID="STD-Anton-2006" TOTAL_1="309" TOTAL_2="309" VAR="0.0013262097350803862" WEIGHT="36.43943629413714"/>
<DICH_DATA CI_END="0.3560919028274916" CI_START="-0.006885553621142404" EFFECT_SIZE="0.1746031746031746" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:56:37 +0100" MODIFIED_BY="[Empty name]" ORDER="515" O_E="0.0" SE="0.09259799142018778" STUDY_ID="STD-de-Goes-e-Castro-2004" TOTAL_1="35" TOTAL_2="36" VAR="0.00857438801505317" WEIGHT="5.636126458154758"/>
<DICH_DATA CI_END="0.16284697699965378" CI_START="-0.006954616962536533" EFFECT_SIZE="0.07794618001855862" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:56:43 +0100" MODIFIED_BY="[Empty name]" ORDER="516" O_E="0.0" SE="0.04331752912338278" STUDY_ID="STD-Morley-2006" TOTAL_1="53" TOTAL_2="61" VAR="0.0018764083293551152" WEIGHT="25.754700828222735"/>
<DICH_DATA CI_END="0.1364854061274224" CI_START="-0.02554200990100733" EFFECT_SIZE="0.05547169811320754" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:56:49 +0100" MODIFIED_BY="[Empty name]" ORDER="517" O_E="0.0" SE="0.041334284024217106" STUDY_ID="STD-O_x0027_Malley-2007" TOTAL_1="53" TOTAL_2="50" VAR="0.0017085230357946493" WEIGHT="28.28544546468419"/>
<DICH_DATA CI_END="0.3068524021808205" CI_START="-0.13038181394552634" EFFECT_SIZE="0.08823529411764708" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:56:54 +0100" MODIFIED_BY="[Empty name]" ORDER="518" O_E="0.0" SE="0.11154139044778233" STUDY_ID="STD-O_x0027_Malley-2008" TOTAL_1="34" TOTAL_2="34" VAR="0.012441481783024629" WEIGHT="3.88429095480118"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.448427036826742" CI_END="0.20300148588377492" CI_START="-0.01375216125882138" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RD" EFFECT_SIZE="0.09462466231247676" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="33" I2="18.31490300025117" I2_Q="0.0" ID="CMP-001.50" LOG_CI_END="-0.6925007832258882" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.0239956573580757" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="50" P_CHI2="0.2939889020656452" P_Q="0.0" P_Z="0.0870331148707097" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.001964121067921162" TOTALS="YES" TOTAL_1="110" TOTAL_2="97" WEIGHT="100.0" Z="1.7112600653008565">
<NAME>Side effect: Tremor</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.1670345656317586" CI_START="-0.05274885134604434" EFFECT_SIZE="0.05714285714285714" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:59:34 +0100" MODIFIED_BY="[Empty name]" ORDER="521" O_E="0.0" SE="0.05606822847547876" STUDY_ID="STD-Lee-2001" TOTAL_1="35" TOTAL_2="18" VAR="0.003143646244378487" WEIGHT="59.86121805923674"/>
<DICH_DATA CI_END="0.37963021554008164" CI_START="-0.3212968822067483" EFFECT_SIZE="0.029166666666666674" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:59:40 +0100" MODIFIED_BY="[Empty name]" ORDER="522" O_E="0.0" SE="0.17881121879678744" STUDY_ID="STD-Petrakis-2004" TOTAL_1="16" TOTAL_2="15" VAR="0.03197345196759259" WEIGHT="9.009400069871031"/>
<DICH_DATA CI_END="0.3593881196397602" CI_START="0.011904253241595775" EFFECT_SIZE="0.18564618644067798" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="25" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 14:59:47 +0100" MODIFIED_BY="[Empty name]" ORDER="523" O_E="0.0" SE="0.08864547235027602" STUDY_ID="STD-Petrakis-2005" TOTAL_1="59" TOTAL_2="64" VAR="0.00785801976820355" WEIGHT="31.129381870892228"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="6.912810951186749" CI_END="0.04516255789129406" CI_START="-0.076129539273745" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.015483490691225468" ESTIMABLE="YES" EVENTS_1="116" EVENTS_2="104" I2="42.1364184809176" I2_Q="0.0" ID="CMP-001.51" LOG_CI_END="-1.3452214687263637" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="51" P_CHI2="0.14056828908533414" P_Q="0.0" P_Z="0.6167957606261526" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0018905328062838289" TOTALS="YES" TOTAL_1="716" TOTAL_2="505" WEIGHT="99.99999999999999" Z="0.500396725245349">
<NAME>Side effect: Upper respiratory problems</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.25943653074028633" CI_START="-0.012981025461251627" EFFECT_SIZE="0.12322775263951735" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="17" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 15:00:51 +0100" MODIFIED_BY="[Empty name]" ORDER="524" O_E="0.0" SE="0.06949555153827644" STUDY_ID="STD-Chick-2000" TOTAL_1="85" TOTAL_2="78" VAR="0.004829631683609236" WEIGHT="14.247180730359661"/>
<DICH_DATA CI_END="0.04731272638864033" CI_START="-0.04606755431277708" EFFECT_SIZE="6.225860379316245E-4" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="18" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 15:00:59 +0100" MODIFIED_BY="[Empty name]" ORDER="525" O_E="0.0" SE="0.02382193791263236" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="5.674847259133111E-4" WEIGHT="38.951470756870435"/>
<DICH_DATA CI_END="0.03642374531284431" CI_START="-0.13398472092260041" EFFECT_SIZE="-0.04878048780487805" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 15:01:05 +0100" MODIFIED_BY="[Empty name]" ORDER="526" O_E="0.0" SE="0.043472346323607206" STUDY_ID="STD-Gastpar-2002" TOTAL_1="82" TOTAL_2="82" VAR="0.0018898448948796447" WEIGHT="25.326410637695044"/>
<DICH_DATA CI_END="0.06095579726577641" CI_START="-0.23168750458284962" EFFECT_SIZE="-0.0853658536585366" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="33" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 15:01:19 +0100" MODIFIED_BY="[Empty name]" ORDER="528" O_E="0.0" SE="0.07465527534101622" STUDY_ID="STD-Pettinati-2008a" TOTAL_1="82" TOTAL_2="82" VAR="0.005573410136242945" WEIGHT="12.827455778063552"/>
<DICH_DATA CI_END="0.07241727822571037" CI_START="-0.3031865089949411" EFFECT_SIZE="-0.11538461538461536" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="27" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 15:01:12 +0100" MODIFIED_BY="[Empty name]" ORDER="527" O_E="0.0" SE="0.09581905335592036" STUDY_ID="STD-Pettinati-2008b" TOTAL_1="52" TOTAL_2="54" VAR="0.009181290986024713" WEIGHT="8.647482097011288"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="10.193634033840306" CI_END="0.08895845527545104" CI_START="0.043427791167251296" CI_STUDY="95" CI_TOTAL="95" DF="13" EFFECT_MEASURE="RD" EFFECT_SIZE="0.06619312322135117" ESTIMABLE="YES" EVENTS_1="252" EVENTS_2="130" I2="0.0" I2_Q="0.0" ID="CMP-001.52" LOG_CI_END="-1.0508127670296918" LOG_CI_START="-1.3622322592463234" LOG_EFFECT_SIZE="-1.1791871269069876" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="52" NOTES="&lt;p&gt;Trials that summarized nausea and vomiting in one category:&lt;/p&gt;&lt;p&gt;Anton (1999)&lt;/p&gt;&lt;p&gt;Killeen (2004)&lt;/p&gt;&lt;p&gt;Monti (2001)&lt;/p&gt;" NOTES_MODIFIED="2010-10-08 15:21:54 +0200" NOTES_MODIFIED_BY="Laura Amato" P_CHI2="0.6780287964771403" P_Q="0.0" P_Z="1.2062062399071287E-8" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="14" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1494" TOTAL_2="1252" WEIGHT="100.0" Z="5.698846703828583">
<NAME>Side effect: Vomiting</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.3371918637817937" CI_START="0.05356443873921474" EFFECT_SIZE="0.19537815126050423" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-22 10:37:31 +0200" MODIFIED_BY="[Empty name]" ORDER="640" O_E="0.0" SE="0.07235526450480619" STUDY_ID="STD-Anton-1999" TOTAL_1="68" TOTAL_2="63" VAR="0.005235284301560466" WEIGHT="2.576982833789088"/>
<DICH_DATA CI_END="0.11153708858472075" CI_START="0.011440257693596384" EFFECT_SIZE="0.06148867313915857" ESTIMABLE="YES" EVENTS_1="45" EVENTS_2="26" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-22 10:45:39 +0200" MODIFIED_BY="[Empty name]" ORDER="643" O_E="0.0" SE="0.025535375058081525" STUDY_ID="STD-Anton-2006" TOTAL_1="309" TOTAL_2="309" VAR="6.520553793568919E-4" WEIGHT="20.690325089309024"/>
<DICH_DATA CI_END="0.1473997877474724" CI_START="-0.07650989332816618" EFFECT_SIZE="0.035444947209653105" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-22 10:33:43 +0200" MODIFIED_BY="[Empty name]" ORDER="639" O_E="0.0" SE="0.05712086621024916" STUDY_ID="STD-Chick-2000" TOTAL_1="85" TOTAL_2="78" VAR="0.003262793356609184" WEIGHT="4.1348734966002905"/>
<DICH_DATA CI_END="0.10751345511418404" CI_START="0.018617864422335248" EFFECT_SIZE="0.06306565976825965" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-22 11:37:40 +0200" MODIFIED_BY="[Empty name]" ORDER="1022" O_E="0.0" SE="0.02267786331612363" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="5.142854845847859E-4" WEIGHT="26.232974057238106"/>
<DICH_DATA CI_END="0.08891209488478878" CI_START="-0.0157413631774717" EFFECT_SIZE="0.03658536585365854" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-22 11:40:22 +0200" MODIFIED_BY="[Empty name]" ORDER="1023" O_E="0.0" SE="0.026697801308532606" STUDY_ID="STD-Gastpar-2002" TOTAL_1="82" TOTAL_2="82" VAR="7.127725947098853E-4" WEIGHT="18.927828981160616"/>
<DICH_DATA CI_END="0.3771366914144906" CI_START="-0.13713669141449059" EFFECT_SIZE="0.12" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-22 11:46:01 +0200" MODIFIED_BY="[Empty name]" ORDER="1024" O_E="0.0" SE="0.1311946002287552" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" VAR="0.017212023129182893" WEIGHT="0.7838263796109182"/>
<DICH_DATA CI_END="0.2542530160362445" CI_START="-0.028762819957813116" EFFECT_SIZE="0.11274509803921569" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-22 10:38:02 +0200" MODIFIED_BY="[Empty name]" ORDER="641" O_E="0.0" SE="0.07219924402347451" STUDY_ID="STD-Killeeen-2004" TOTAL_1="51" TOTAL_2="36" VAR="0.005212730837561219" WEIGHT="2.588132438742742"/>
<DICH_DATA CI_END="0.2618707272732839" CI_START="0.03633380043944051" EFFECT_SIZE="0.14910226385636222" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 15:03:48 +0100" MODIFIED_BY="[Empty name]" ORDER="531" O_E="0.0" SE="0.05753598755202899" STUDY_ID="STD-Kranzler-2000" TOTAL_1="61" TOTAL_2="63" VAR="0.0033103898635872347" WEIGHT="4.075422633304984"/>
<DICH_DATA CI_END="0.2613757037123029" CI_START="0.019874296287697116" EFFECT_SIZE="0.140625" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-22 10:37:43 +0200" MODIFIED_BY="[Empty name]" ORDER="642" O_E="0.0" SE="0.06160863396713869" STUDY_ID="STD-Monti-2001" TOTAL_1="64" TOTAL_2="64" VAR="0.003795623779296875" WEIGHT="3.554419130977733"/>
<DICH_DATA CI_END="0.1674470417800349" CI_START="-0.07220894654193964" EFFECT_SIZE="0.047619047619047616" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 15:03:55 +0100" MODIFIED_BY="[Empty name]" ORDER="532" O_E="0.0" SE="0.06113785513722455" STUDY_ID="STD-Oslin-1997" TOTAL_1="21" TOTAL_2="23" VAR="0.0037378373307802542" WEIGHT="3.6093699594761626"/>
<DICH_DATA CI_END="0.14352466148739818" CI_START="-0.06019132815406482" EFFECT_SIZE="0.041666666666666685" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="22" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 15:04:03 +0100" MODIFIED_BY="[Empty name]" ORDER="533" O_E="0.0" SE="0.051969319652898915" STUDY_ID="STD-Oslin-2008" TOTAL_1="120" TOTAL_2="120" VAR="0.0027008101851851854" WEIGHT="4.995255812174659"/>
<DICH_DATA CI_END="0.1719000877159288" CI_START="-0.13217551144474238" EFFECT_SIZE="0.01986228813559321" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 15:04:12 +0100" MODIFIED_BY="[Empty name]" ORDER="534" O_E="0.0" SE="0.07757173130710071" STUDY_ID="STD-Petrakis-2005" TOTAL_1="59" TOTAL_2="64" VAR="0.006017373497981029" WEIGHT="2.242047594295658"/>
<DICH_DATA CI_END="0.22074552810792034" CI_START="-0.025623576888408134" EFFECT_SIZE="0.0975609756097561" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 15:04:27 +0100" MODIFIED_BY="[Empty name]" ORDER="536" O_E="0.0" SE="0.06285041636980489" STUDY_ID="STD-Pettinati-2008a" TOTAL_1="82" TOTAL_2="82" VAR="0.003950174837857838" WEIGHT="3.4153520613388983"/>
<DICH_DATA CI_END="0.20001173983771514" CI_START="-0.10884364866962393" EFFECT_SIZE="0.04558404558404561" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="10" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 15:04:19 +0100" MODIFIED_BY="[Empty name]" ORDER="535" O_E="0.0" SE="0.07879108773006824" STUDY_ID="STD-Pettinati-2008b" TOTAL_1="52" TOTAL_2="54" VAR="0.00620803550568731" WEIGHT="2.173189531981125"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.917293965505242E-4" CI_END="0.28920770450824895" CI_START="0.05324446644373926" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.1712260854759941" ESTIMABLE="YES" EVENTS_1="64" EVENTS_2="50" I2="0.0" I2_Q="0.0" ID="CMP-001.53" LOG_CI_END="-0.5387901415958721" LOG_CI_START="-1.2737255206183091" LOG_EFFECT_SIZE="-0.7664300719293351" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="53" P_CHI2="0.9842091762840666" P_Q="0.0" P_Z="0.004448326234746266" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="92" TOTAL_2="96" WEIGHT="100.0" Z="2.8444851282722006">
<NAME>Side effect: Weakness</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.38676149243249197" CI_START="-0.04072043671401687" EFFECT_SIZE="0.17302052785923755" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 15:05:42 +0100" MODIFIED_BY="[Empty name]" ORDER="537" O_E="0.0" SE="0.10905351642133013" STUDY_ID="STD-Hersh-1998" TOTAL_1="31" TOTAL_2="33" VAR="0.01189266944385732" WEIGHT="30.468647283490462"/>
<DICH_DATA CI_END="0.31192919558854315" CI_START="0.02895032561884689" EFFECT_SIZE="0.17043976060369503" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="44" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 15:05:51 +0100" MODIFIED_BY="[Empty name]" ORDER="538" O_E="0.0" SE="0.07218981374193544" STUDY_ID="STD-Kranzler-2000" TOTAL_1="61" TOTAL_2="63" VAR="0.0052113692080953304" WEIGHT="69.53135271650955"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="11.505192098726072" CI_END="2.23297453011174" CI_START="1.1475701495960662" CI_STUDY="95" CI_TOTAL="95" DF="19" EFFECT_MEASURE="RR" EFFECT_SIZE="1.600779471246597" ESTIMABLE="YES" EVENTS_1="110" EVENTS_2="47" I2="0.0" I2_Q="0.0" ID="CMP-001.54" LOG_CI_END="0.3488837694238739" LOG_CI_START="0.05977924292502689" LOG_EFFECT_SIZE="0.20433150617445037" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="54" NOTES="&lt;p&gt;Anton (1999) S. 1661, 11 &lt;/p&gt;" NOTES_MODIFIED="2010-10-08 15:21:54 +0200" NOTES_MODIFIED_BY="Laura Amato" P_CHI2="0.9056737882371787" P_Q="0.0" P_Z="0.005596988684510509" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="22" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="1812" TOTAL_2="1581" WEIGHT="100.00000000000001" Z="2.770502405193879">
<NAME>Drop-outs due to adverse events</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.500213073180689" CI_START="0.05919552675075067" EFFECT_SIZE="0.9264705882352942" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1613743840161281" LOG_CI_START="-1.2277111105214373" LOG_EFFECT_SIZE="-0.0331683632526546" MODIFIED="2009-03-17 11:37:36 +0100" MODIFIED_BY="[Empty name]" ORDER="222" O_E="0.0" SE="1.4033606456552938" STUDY_ID="STD-Anton-1999" TOTAL_1="68" TOTAL_2="63" VAR="1.969421101774043" WEIGHT="1.4643550861870773"/>
<DICH_DATA CI_END="9.199580617173954" CI_START="0.9783054657077114" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="4" LOG_CI_END="0.9637680295413577" LOG_CI_START="-0.009525520102032807" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2009-03-17 11:38:12 +0100" MODIFIED_BY="[Empty name]" ORDER="202" O_E="0.0" SE="0.5717174489413002" STUDY_ID="STD-Anton-2006" TOTAL_1="309" TOTAL_2="309" VAR="0.32686084142394817" WEIGHT="8.823118103298377"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 11:38:19 +0100" MODIFIED_BY="[Empty name]" ORDER="203" O_E="0.0" SE="0.0" STUDY_ID="STD-Balldin-2003" TOTAL_1="56" TOTAL_2="62" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="2.3539985168466773" CI_START="0.5292342983551908" EFFECT_SIZE="1.1161616161616161" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="11" LOG_CI_END="0.37180618487720907" LOG_CI_START="-0.27635201803004994" LOG_EFFECT_SIZE="0.04772708342357958" MODIFIED="2009-03-17 11:38:27 +0100" MODIFIED_BY="[Empty name]" ORDER="204" O_E="0.0" SE="0.3807313368225733" STUDY_ID="STD-Chick-2000" TOTAL_1="90" TOTAL_2="85" VAR="0.14495635083870378" WEIGHT="19.895173895733574"/>
<DICH_DATA CI_END="65.90289327402995" CI_START="0.13656456572516806" EFFECT_SIZE="3.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.8189044814432243" LOG_CI_START="-0.8646619720038995" LOG_EFFECT_SIZE="0.47712125471966244" MODIFIED="2009-07-10 16:12:27 +0200" MODIFIED_BY="[Empty name]" ORDER="634" O_E="0.0" SE="1.5763402186230246" STUDY_ID="STD-Galarza-1997" TOTAL_1="10" TOTAL_2="10" VAR="2.484848484848485" WEIGHT="1.1606067029084177"/>
<DICH_DATA CI_END="2.761932854593442" CI_START="0.866291598185907" EFFECT_SIZE="1.546815834767642" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="14" LOG_CI_END="0.4412131162288486" LOG_CI_START="-0.062335897628229046" LOG_EFFECT_SIZE="0.18943860930030978" MODIFIED="2009-03-17 11:38:36 +0100" MODIFIED_BY="[Empty name]" ORDER="205" O_E="0.0" SE="0.29578718334746623" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="0.08749005783262762" WEIGHT="32.96296606345909"/>
<DICH_DATA CI_END="5.985800734713489" CI_START="0.3185922089585445" EFFECT_SIZE="1.380952380952381" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.7771222552280631" LOG_CI_START="-0.49676484889798966" LOG_EFFECT_SIZE="0.1401787031650368" MODIFIED="2009-03-17 11:38:47 +0100" MODIFIED_BY="[Empty name]" ORDER="206" O_E="0.0" SE="0.7482875908065082" STUDY_ID="STD-Gastpar-2002" TOTAL_1="84" TOTAL_2="87" VAR="0.5599343185550082" WEIGHT="5.150482318478677"/>
<DICH_DATA CI_END="102.8603434004992" CI_START="0.24304799277851388" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0122479698848665" LOG_CI_START="-0.6143079612128292" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2009-03-17 11:38:55 +0100" MODIFIED_BY="[Empty name]" ORDER="207" O_E="0.0" SE="1.5428519555883335" STUDY_ID="STD-Guardia-2002" TOTAL_1="101" TOTAL_2="101" VAR="2.380392156862745" WEIGHT="1.2115364264297845"/>
<DICH_DATA CI_END="5.5802719108136" CI_START="0.05076789299343497" EFFECT_SIZE="0.532258064516129" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7466553613907669" LOG_CI_START="-1.2944108606314997" LOG_EFFECT_SIZE="-0.27387774962036643" MODIFIED="2009-03-17 11:39:03 +0100" MODIFIED_BY="[Empty name]" ORDER="208" O_E="0.0" SE="1.1989324022566246" STUDY_ID="STD-Hersh-1998" TOTAL_1="31" TOTAL_2="33" VAR="1.4374389051808407" WEIGHT="2.0062987003013926"/>
<DICH_DATA CI_END="21.048031282871733" CI_START="0.06325346674246843" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.3232114805531539" LOG_CI_START="-1.1989156670554648" LOG_EFFECT_SIZE="0.062147906748844434" MODIFIED="2009-03-17 11:39:10 +0100" MODIFIED_BY="[Empty name]" ORDER="209" O_E="0.0" SE="1.4815099712360342" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" VAR="2.194871794871795" WEIGHT="1.3139408934795807"/>
<DICH_DATA CI_END="161.85818338602556" CI_START="0.5004380891067964" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2091346617833825" LOG_CI_START="-0.3006496429047325" LOG_EFFECT_SIZE="0.9542425094393249" MODIFIED="2009-03-17 11:39:18 +0100" MODIFIED_BY="[Empty name]" ORDER="210" O_E="0.0" SE="1.4742597242064726" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="2.1734417344173442" WEIGHT="1.3268963053201428"/>
<DICH_DATA CI_END="4.760834343511767" CI_START="0.5298422855058398" EFFECT_SIZE="1.588235294117647" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.6776830701637814" LOG_CI_START="-0.27585338460235465" LOG_EFFECT_SIZE="0.20091484278071337" MODIFIED="2009-03-17 11:39:25 +0100" MODIFIED_BY="[Empty name]" ORDER="211" O_E="0.0" SE="0.5601120336112039" STUDY_ID="STD-Killeeen-2004" TOTAL_1="51" TOTAL_2="36" VAR="0.3137254901960784" WEIGHT="9.19253263553599"/>
<DICH_DATA CI_END="10.69467252110128" CI_START="0.36929857473870065" EFFECT_SIZE="1.9873417721518987" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0291674906881818" LOG_CI_START="-0.43262236845059726" LOG_EFFECT_SIZE="0.2982725611187923" MODIFIED="2009-03-17 11:39:34 +0100" MODIFIED_BY="[Empty name]" ORDER="212" O_E="0.0" SE="0.858662599234622" STUDY_ID="STD-Kranzler-2004" TOTAL_1="158" TOTAL_2="157" VAR="0.737301459324357" WEIGHT="3.911469007357905"/>
<DICH_DATA CI_END="120.70574812046438" CI_START="0.33785091841841086" EFFECT_SIZE="6.385964912280702" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="2.0817279520986594" LOG_CI_START="-0.4712748961455304" LOG_EFFECT_SIZE="0.8052265279765646" MODIFIED="2009-03-17 11:39:41 +0100" MODIFIED_BY="[Empty name]" ORDER="213" O_E="0.0" SE="1.4996465106265522" STUDY_ID="STD-Latt-2002" TOTAL_1="56" TOTAL_2="51" VAR="2.2489396568343936" WEIGHT="1.2823517956397275"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 11:39:49 +0100" MODIFIED_BY="[Empty name]" ORDER="214" O_E="0.0" SE="0.0" STUDY_ID="STD-Morley-2006" TOTAL_1="53" TOTAL_2="61" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="41.33803806479813" CI_START="0.6047698722617662" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="1" LOG_CI_END="1.6163498608289724" LOG_CI_START="-0.21840985215693492" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2009-03-17 11:39:58 +0100" MODIFIED_BY="[Empty name]" ORDER="215" O_E="0.0" SE="1.0777469376149773" STUDY_ID="STD-O_x0027_Malley-1992" TOTAL_1="52" TOTAL_2="52" VAR="1.1615384615384616" WEIGHT="2.4828551982748808"/>
<DICH_DATA CI_END="15.344261514858012" CI_START="0.06517094348474765" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1859459916443629" LOG_CI_START="-1.1859459916443629" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-03-17 11:40:05 +0100" MODIFIED_BY="[Empty name]" ORDER="216" O_E="0.0" SE="1.393261092038472" STUDY_ID="STD-O_x0027_Malley-2008" TOTAL_1="34" TOTAL_2="34" VAR="1.9411764705882355" WEIGHT="1.4856618400866246"/>
<DICH_DATA CI_END="8.46796373902594" CI_START="0.015615490221016005" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9277789896432341" LOG_CI_START="-1.8064443773037593" LOG_EFFECT_SIZE="-0.43933269383026263" MODIFIED="2009-03-17 11:40:14 +0100" MODIFIED_BY="[Empty name]" ORDER="217" O_E="0.0" SE="1.606096340368614" STUDY_ID="STD-Oslin-1997" TOTAL_1="21" TOTAL_2="23" VAR="2.5795454545454546" WEIGHT="1.1179999957531894"/>
<DICH_DATA CI_END="13.684571710013993" CI_START="0.0642260692277889" EFFECT_SIZE="0.9375" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.1362312097192329" LOG_CI_START="-1.19228865691972" LOG_EFFECT_SIZE="-0.028028723600243537" MODIFIED="2009-03-17 11:40:21 +0100" MODIFIED_BY="[Empty name]" ORDER="218" O_E="0.0" SE="1.3677840960229555" STUDY_ID="STD-Petrakis-2004" TOTAL_1="16" TOTAL_2="15" VAR="1.8708333333333333" WEIGHT="1.5415225695645312"/>
<DICH_DATA CI_END="110.55363202201595" CI_START="0.26539406477333005" EFFECT_SIZE="5.416666666666667" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.0435730150396423" LOG_CI_START="-0.5761087938491805" LOG_EFFECT_SIZE="0.7337321105952308" MODIFIED="2009-03-17 11:40:28 +0100" MODIFIED_BY="[Empty name]" ORDER="219" O_E="0.0" SE="1.5388140621753876" STUDY_ID="STD-Petrakis-2005" TOTAL_1="59" TOTAL_2="64" VAR="2.367948717948718" WEIGHT="1.217902983019514"/>
<DICH_DATA CI_END="100.52959945656309" CI_START="0.24868297630890304" EFFECT_SIZE="5.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="2.002293952184388" LOG_CI_START="-0.6043539435123508" LOG_EFFECT_SIZE="0.6989700043360189" MODIFIED="2009-03-17 11:40:35 +0100" MODIFIED_BY="[Empty name]" ORDER="220" O_E="0.0" SE="1.531157877047447" STUDY_ID="STD-Volpicelli-1992" TOTAL_1="35" TOTAL_2="35" VAR="2.3444444444444446" WEIGHT="1.2301130931299902"/>
<DICH_DATA CI_END="4.143157655157111" CI_START="0.010052553210109411" EFFECT_SIZE="0.20408163265306123" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="2" LOG_CI_END="0.6173314593572066" LOG_CI_START="-1.9977236194142343" LOG_EFFECT_SIZE="-0.6901960800285136" MODIFIED="2009-03-17 11:40:42 +0100" MODIFIED_BY="[Empty name]" ORDER="221" O_E="0.0" SE="1.536096298001754" STUDY_ID="STD-Volpicelli-1997" TOTAL_1="48" TOTAL_2="49" VAR="2.359591836734694" WEIGHT="1.2222163860415316"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="52.90293279526306" CI_END="1.0128526731838023" CI_START="0.8274047604270213" CI_STUDY="95" CI_TOTAL="95" DF="36" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9154447680791628" ESTIMABLE="YES" EVENTS_1="877" EVENTS_2="820" I2="31.950842613354233" I2_Q="0.0" ID="CMP-001.55" LOG_CI_END="0.00554627865100215" LOG_CI_START="-0.08228198474430233" LOG_EFFECT_SIZE="-0.03836785304665009" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="55" NOTES="&lt;p&gt;Results provided by the investigators:&lt;/p&gt;&lt;p&gt;Balldin (2003)&lt;/p&gt;&lt;p&gt;Krystal (2001)&lt;/p&gt;&lt;p&gt;Oslin (1997)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-10-08 15:21:54 +0200" NOTES_MODIFIED_BY="Laura Amato" P_CHI2="0.03430323074631714" P_Q="0.0" P_Z="0.08681857157018312" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="37" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.027044167193603457" TOTALS="YES" TOTAL_1="3011" TOTAL_2="2561" WEIGHT="99.99999999999999" Z="1.7124239334460054">
<NAME>Drop-outs</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.6311701919871983" CI_START="0.20950198003228845" EFFECT_SIZE="0.36363636363636365" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="33" LOG_CI_END="-0.19985351955965688" LOG_CI_START="-0.6788118681008685" LOG_EFFECT_SIZE="-0.43933269383026263" MODIFIED="2009-03-17 11:32:02 +0100" MODIFIED_BY="[Empty name]" ORDER="169" O_E="0.0" SE="0.28134250481517004" STUDY_ID="STD-Ahmadi-2002" TOTAL_1="58" TOTAL_2="58" VAR="0.07915360501567398" WEIGHT="2.5062730780140443"/>
<DICH_DATA CI_END="1.2786825949464924" CI_START="0.27741469808276" EFFECT_SIZE="0.5955882352941176" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="14" LOG_CI_END="0.1067627537275681" LOG_CI_START="-0.5568705327107036" LOG_EFFECT_SIZE="-0.22505388949156777" MODIFIED="2009-03-17 11:32:14 +0100" MODIFIED_BY="[Empty name]" ORDER="201" O_E="0.0" SE="0.3898214774915891" STUDY_ID="STD-Anton-1999" TOTAL_1="68" TOTAL_2="63" VAR="0.15196078431372548" WEIGHT="1.4868896932288644"/>
<DICH_DATA CI_END="2.182354519731503" CI_START="0.5984923334730625" EFFECT_SIZE="1.1428571428571428" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="14" LOG_CI_END="0.3389253023736281" LOG_CI_START="-0.2229414084182546" LOG_EFFECT_SIZE="0.05799194697768673" MODIFIED="2009-03-17 11:32:21 +0100" MODIFIED_BY="[Empty name]" ORDER="170" O_E="0.0" SE="0.3300432872042263" STUDY_ID="STD-Anton-2005" TOTAL_1="80" TOTAL_2="80" VAR="0.10892857142857143" WEIGHT="1.9574557380414028"/>
<DICH_DATA CI_END="1.5495163477734066" CI_START="0.972044179638237" EFFECT_SIZE="1.2272727272727273" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="88" LOG_CI_END="0.19019616251162305" LOG_CI_START="-0.01231399583806086" LOG_EFFECT_SIZE="0.08894108333678108" MODIFIED="2009-03-17 11:32:29 +0100" MODIFIED_BY="[Empty name]" ORDER="171" O_E="0.0" SE="0.11895546945605531" STUDY_ID="STD-Anton-2006" TOTAL_1="309" TOTAL_2="309" VAR="0.01415040371351051" WEIGHT="6.461060561434719"/>
<DICH_DATA CI_END="1.6171400399048677" CI_START="0.4076266285772051" EFFECT_SIZE="0.8119047619047619" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="15" LOG_CI_END="0.20874763024931633" LOG_CI_START="-0.3897374530601218" LOG_EFFECT_SIZE="-0.09049491140540274" MODIFIED="2009-03-17 11:32:38 +0100" MODIFIED_BY="[Empty name]" ORDER="172" O_E="0.0" SE="0.35155310048490573" STUDY_ID="STD-Balldin-2003" TOTAL_1="56" TOTAL_2="62" VAR="0.12358958246055023" WEIGHT="1.7669388038488676"/>
<DICH_DATA CI_END="1.0691871354717837" CI_START="0.4728008390526099" EFFECT_SIZE="0.7109940750493746" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="31" LOG_CI_END="0.02905372465686397" LOG_CI_START="-0.3253217614085372" LOG_EFFECT_SIZE="-0.14813401837583662" MODIFIED="2009-03-17 11:32:46 +0100" MODIFIED_BY="[Empty name]" ORDER="173" O_E="0.0" SE="0.20816191470176382" STUDY_ID="STD-Baltieri-2008" TOTAL_1="49" TOTAL_2="54" VAR="0.0433313827323044" WEIGHT="3.782004086836932"/>
<DICH_DATA CI_END="1.3876157048847735" CI_START="0.28355911005838524" EFFECT_SIZE="0.6272727272727273" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="11" LOG_CI_END="0.14226920649590777" LOG_CI_START="-0.5473563953378472" LOG_EFFECT_SIZE="-0.2025435944209697" MODIFIED="2009-06-10 11:09:14 +0200" MODIFIED_BY="[Empty name]" ORDER="947" O_E="0.0" SE="0.40508949221893226" STUDY_ID="STD-Brown-2009" TOTAL_1="20" TOTAL_2="23" VAR="0.16409749670619236" WEIGHT="1.3924782907232212"/>
<DICH_DATA CI_END="1.3129980783134014" CI_START="0.7947825462029037" EFFECT_SIZE="1.0215419501133787" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="49" LOG_CI_END="0.11826409046229241" LOG_CI_START="-0.09975167876780591" LOG_EFFECT_SIZE="0.009256205847243237" MODIFIED="2009-03-17 11:32:55 +0100" MODIFIED_BY="[Empty name]" ORDER="174" O_E="0.0" SE="0.12806354204122247" STUDY_ID="STD-Chick-2000" TOTAL_1="90" TOTAL_2="85" VAR="0.016400270800143953" WEIGHT="6.126460134470754"/>
<DICH_DATA CI_END="1.6271453778640377" CI_START="0.6501933988604373" EFFECT_SIZE="1.0285714285714285" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="18" LOG_CI_END="0.2114263568603798" LOG_CI_START="-0.18695744402635664" LOG_EFFECT_SIZE="0.012234456417011586" MODIFIED="2009-03-17 11:34:34 +0100" MODIFIED_BY="[Empty name]" ORDER="185" O_E="0.0" SE="0.2340126166724879" STUDY_ID="STD-de-Goes-e-Castro-2004" TOTAL_1="35" TOTAL_2="36" VAR="0.05476190476190476" WEIGHT="3.253555770015905"/>
<DICH_DATA CI_END="3.330510326941122" CI_START="0.4691473217664706" EFFECT_SIZE="1.25" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="4" LOG_CI_END="0.5225107846154843" LOG_CI_START="-0.3286907585993715" LOG_EFFECT_SIZE="0.09691001300805642" MODIFIED="2009-07-10 15:57:56 +0200" MODIFIED_BY="[Empty name]" ORDER="633" O_E="0.0" SE="0.49999999999999994" STUDY_ID="STD-Galarza-1997" TOTAL_1="10" TOTAL_2="10" VAR="0.24999999999999997" WEIGHT="0.9607154704945738"/>
<DICH_DATA CI_END="1.2624898453859135" CI_START="0.8336165646561822" EFFECT_SIZE="1.0258813029897367" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="81" LOG_CI_END="0.1012278936337885" LOG_CI_START="-0.07903366416535294" LOG_EFFECT_SIZE="0.011097114734217806" MODIFIED="2009-03-17 11:33:06 +0100" MODIFIED_BY="[Empty name]" ORDER="175" O_E="0.0" SE="0.10588653136031777" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="0.011211957523519559" WEIGHT="6.957333483233067"/>
<DICH_DATA CI_END="1.317066825690414" CI_START="0.5863545575978442" EFFECT_SIZE="0.8787878787878788" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="33" LOG_CI_END="0.11960781087091056" LOG_CI_START="-0.23183969482877334" LOG_EFFECT_SIZE="-0.05611594197893139" MODIFIED="2009-03-17 11:33:15 +0100" MODIFIED_BY="[Empty name]" ORDER="176" O_E="0.0" SE="0.20644200454120498" STUDY_ID="STD-Gastpar-2002" TOTAL_1="84" TOTAL_2="87" VAR="0.042618301238990894" WEIGHT="3.8207175746394637"/>
<DICH_DATA CI_END="1.3297927239448497" CI_START="0.6820833518830915" EFFECT_SIZE="0.9523809523809523" ESTIMABLE="YES" EVENTS_1="40" EVENTS_2="42" LOG_CI_END="0.12378395234883048" LOG_CI_START="-0.1661625504887067" LOG_EFFECT_SIZE="-0.021189299069938095" MODIFIED="2009-03-17 11:33:24 +0100" MODIFIED_BY="[Empty name]" ORDER="177" O_E="0.0" SE="0.17031601102510593" STUDY_ID="STD-Guardia-2002" TOTAL_1="101" TOTAL_2="101" VAR="0.029007543611504004" WEIGHT="4.7484833845415375"/>
<DICH_DATA CI_END="1.5534224569737856" CI_START="0.45034382462857514" EFFECT_SIZE="0.836405529953917" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.1912895792202786" LOG_CI_START="-0.346455788173075" LOG_EFFECT_SIZE="-0.0775831044763982" MODIFIED="2009-03-17 11:33:33 +0100" MODIFIED_BY="[Empty name]" ORDER="178" O_E="0.0" SE="0.3158742906893548" STUDY_ID="STD-Hersh-1998" TOTAL_1="31" TOTAL_2="33" VAR="0.099776567518503" WEIGHT="2.0987153089546964"/>
<DICH_DATA CI_END="3.115812392578869" CI_START="0.5305393958978397" EFFECT_SIZE="1.2857142857142858" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="7" LOG_CI_END="0.4935713003096956" LOG_CI_START="-0.2752823614595596" LOG_EFFECT_SIZE="0.10914446942506807" MODIFIED="2009-06-12 10:55:52 +0200" MODIFIED_BY="[Empty name]" ORDER="627" O_E="0.0" SE="0.45162844681026676" STUDY_ID="STD-Huang-2005" TOTAL_1="40" TOTAL_2="40" VAR="0.20396825396825397" WEIGHT="1.152148512597495"/>
<DICH_DATA CI_END="10.113070991103987" CI_START="0.2531377464127283" EFFECT_SIZE="1.6" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.0048830558846087" LOG_CI_START="-0.5966430905727592" LOG_EFFECT_SIZE="0.2041199826559248" MODIFIED="2009-03-17 11:33:41 +0100" MODIFIED_BY="[Empty name]" ORDER="179" O_E="0.0" SE="0.9407443861113389" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" VAR="0.885" WEIGHT="0.291828649320972"/>
<DICH_DATA CI_END="0.8831011664811572" CI_START="0.4076543137571331" EFFECT_SIZE="0.6" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="30" LOG_CI_END="-0.05398954157780295" LOG_CI_START="-0.3897079576549099" LOG_EFFECT_SIZE="-0.2218487496163564" MODIFIED="2009-07-22 12:38:00 +0200" MODIFIED_BY="[Empty name]" ORDER="180" O_E="0.0" SE="0.19720265943665385" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.03888888888888888" WEIGHT="4.036831192841607"/>
<DICH_DATA CI_END="2.437258534679475" CI_START="0.8177546847885785" EFFECT_SIZE="1.411764705882353" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="12" LOG_CI_END="0.38690159985741557" LOG_CI_START="-0.08737695919075132" LOG_EFFECT_SIZE="0.14976232033333212" MODIFIED="2009-03-17 11:34:00 +0100" MODIFIED_BY="[Empty name]" ORDER="181" O_E="0.0" SE="0.278593573301624" STUDY_ID="STD-Killeeen-2004" TOTAL_1="51" TOTAL_2="36" VAR="0.07761437908496732" WEIGHT="2.543133140075704"/>
<DICH_DATA CI_END="3.5129450629963324" CI_START="1.1229059510421788" EFFECT_SIZE="1.9861286254728878" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="13" LOG_CI_END="0.5456713581540803" LOG_CI_START="0.05034338346195084" LOG_EFFECT_SIZE="0.29800737080801554" MODIFIED="2009-03-17 11:34:09 +0100" MODIFIED_BY="[Empty name]" ORDER="182" O_E="0.0" SE="0.2909581042471755" STUDY_ID="STD-Kranzler-2000" TOTAL_1="61" TOTAL_2="63" VAR="0.08465661842711024" WEIGHT="2.3827998697962913"/>
<DICH_DATA CI_END="1.198143076877216" CI_START="0.5206796711359201" EFFECT_SIZE="0.7898409607270367" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="39" LOG_CI_END="0.07850868265097573" LOG_CI_START="-0.28342937812580654" LOG_EFFECT_SIZE="-0.1024603477374154" MODIFIED="2009-03-17 11:34:17 +0100" MODIFIED_BY="[Empty name]" ORDER="183" O_E="0.0" SE="0.21260420852257766" STUDY_ID="STD-Kranzler-2004" TOTAL_1="158" TOTAL_2="157" VAR="0.045200549481511684" WEIGHT="3.6841533842551524"/>
<DICH_DATA CI_END="4.465688111420857" CI_START="0.3047931420983279" EFFECT_SIZE="1.1666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="3" LOG_CI_END="0.6498883881893329" LOG_CI_START="-0.5159948089281067" LOG_EFFECT_SIZE="0.06694678963061322" MODIFIED="2009-03-17 11:34:25 +0100" MODIFIED_BY="[Empty name]" ORDER="184" O_E="0.0" SE="0.6848455612016867" STUDY_ID="STD-Krystal-2001" TOTAL_1="418" TOTAL_2="209" VAR="0.46901344269765316" WEIGHT="0.5365518281062689"/>
<DICH_DATA CI_END="2.0295657566436116" CI_START="0.7480299741156662" EFFECT_SIZE="1.2321428571428572" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="17" LOG_CI_END="0.30740312674708964" LOG_CI_START="-0.12608099928497987" LOG_EFFECT_SIZE="0.09066106373105492" MODIFIED="2009-03-17 11:34:42 +0100" MODIFIED_BY="[Empty name]" ORDER="186" O_E="0.0" SE="0.2546307214122682" STUDY_ID="STD-Latt-2002" TOTAL_1="56" TOTAL_2="51" VAR="0.06483680428693216" WEIGHT="2.896798032763122"/>
<DICH_DATA CI_END="1.1126544117767025" CI_START="0.5348489472720098" EFFECT_SIZE="0.7714285714285715" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="14" LOG_CI_END="0.04636029428588053" LOG_CI_START="-0.27176885466845707" LOG_EFFECT_SIZE="-0.11270428019128831" MODIFIED="2009-03-17 11:34:51 +0100" MODIFIED_BY="[Empty name]" ORDER="187" O_E="0.0" SE="0.1868706368604627" STUDY_ID="STD-Lee-2001" TOTAL_1="35" TOTAL_2="18" VAR="0.03492063492063492" WEIGHT="4.295351689213597"/>
<DICH_DATA CI_END="1.5717465673070241" CI_START="0.5523122345186275" EFFECT_SIZE="0.9317160826594789" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="21" LOG_CI_END="0.1963825205245343" LOG_CI_START="-0.257815336415869" LOG_EFFECT_SIZE="-0.030716407945667337" MODIFIED="2009-03-17 11:35:00 +0100" MODIFIED_BY="[Empty name]" ORDER="188" O_E="0.0" SE="0.2667980694824451" STUDY_ID="STD-Morley-2006" TOTAL_1="53" TOTAL_2="61" VAR="0.07118120987955961" WEIGHT="2.7096930076932217"/>
<DICH_DATA CI_END="1.2464045963245154" CI_START="0.4543952720048691" EFFECT_SIZE="0.7525691699604743" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="23" LOG_CI_END="0.09565904186466821" LOG_CI_START="-0.342566196119393" LOG_EFFECT_SIZE="-0.1234535771273624" MODIFIED="2009-03-17 11:35:08 +0100" MODIFIED_BY="[Empty name]" ORDER="189" O_E="0.0" SE="0.2574156740417508" STUDY_ID="STD-Morris-2001" TOTAL_1="55" TOTAL_2="56" VAR="0.0662628292423689" WEIGHT="2.8525258297840566"/>
<DICH_DATA CI_END="1.2253507990445678" CI_START="0.416373892301266" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="21" LOG_CI_END="0.08826043831646174" LOG_CI_START="-0.38051650967293776" LOG_EFFECT_SIZE="-0.146128035678238" MODIFIED="2009-03-17 11:35:17 +0100" MODIFIED_BY="[Empty name]" ORDER="190" O_E="0.0" SE="0.27536189973229014" STUDY_ID="STD-O_x0027_Malley-1992" TOTAL_1="52" TOTAL_2="52" VAR="0.07582417582417582" WEIGHT="2.587390927325214"/>
<DICH_DATA CI_END="1.3561520700863507" CI_START="0.5673902989517273" EFFECT_SIZE="0.8771929824561403" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="23" LOG_CI_END="0.1323083912245538" LOG_CI_START="-0.24611809389749906" LOG_EFFECT_SIZE="-0.05690485133647262" MODIFIED="2009-03-17 11:35:26 +0100" MODIFIED_BY="[Empty name]" ORDER="191" O_E="0.0" SE="0.22228959060200643" STUDY_ID="STD-O_x0027_Malley-2007" TOTAL_1="57" TOTAL_2="50" VAR="0.04941266209000762" WEIGHT="3.4811882722193004"/>
<DICH_DATA CI_END="1.2916457447528251" CI_START="0.2931904714512417" EFFECT_SIZE="0.6153846153846154" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="13" LOG_CI_END="0.11114341753274073" LOG_CI_START="-0.5328501481625271" LOG_EFFECT_SIZE="-0.21085336531489315" MODIFIED="2009-03-17 11:35:33 +0100" MODIFIED_BY="[Empty name]" ORDER="192" O_E="0.0" SE="0.378285008308963" STUDY_ID="STD-O_x0027_Malley-2008" TOTAL_1="34" TOTAL_2="34" VAR="0.1430995475113122" WEIGHT="1.564328238012135"/>
<DICH_DATA CI_END="1.5839895985453274" CI_START="0.13909489357889154" EFFECT_SIZE="0.46938775510204084" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="7" LOG_CI_END="0.19975232541685872" LOG_CI_START="-0.8566888134387003" LOG_EFFECT_SIZE="-0.3284682440109208" MODIFIED="2009-07-22 09:24:47 +0200" MODIFIED_BY="[Empty name]" ORDER="193" O_E="0.0" SE="0.6205587544317325" STUDY_ID="STD-Oslin-1997" TOTAL_1="21" TOTAL_2="23" VAR="0.3850931677018633" WEIGHT="0.6458056451029563"/>
<DICH_DATA CI_END="5.476400216462892" CI_START="0.5592177121740772" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="4" LOG_CI_END="0.7384951789524828" LOG_CI_START="-0.252419081579894" LOG_EFFECT_SIZE="0.24303804868629444" MODIFIED="2009-05-20 14:33:37 +0200" MODIFIED_BY="[Empty name]" ORDER="834" O_E="0.0" SE="0.5820679417414163" STUDY_ID="STD-Oslin-2005" TOTAL_1="37" TOTAL_2="37" VAR="0.3388030888030888" WEIGHT="0.7275184194236147"/>
<DICH_DATA CI_END="2.04836834260165" CI_START="0.7761260645496431" EFFECT_SIZE="1.2608695652173914" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="23" LOG_CI_END="0.31140805522149906" LOG_CI_START="-0.11006773145877258" LOG_EFFECT_SIZE="0.10067016188136323" MODIFIED="2009-03-17 11:35:51 +0100" MODIFIED_BY="[Empty name]" ORDER="194" O_E="0.0" SE="0.24757696343478366" STUDY_ID="STD-Oslin-2008" TOTAL_1="120" TOTAL_2="120" VAR="0.06129435282358821" WEIGHT="3.0129621526530244"/>
<DICH_DATA CI_END="8.783918833890697" CI_START="0.4002342310399982" EFFECT_SIZE="1.875" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="0.9436883141100868" LOG_CI_START="-0.3976857699826114" LOG_EFFECT_SIZE="0.27300127206373764" MODIFIED="2009-03-17 11:35:58 +0100" MODIFIED_BY="[Empty name]" ORDER="195" O_E="0.0" SE="0.7879297769048542" STUDY_ID="STD-Petrakis-2004" TOTAL_1="16" TOTAL_2="15" VAR="0.6208333333333333" WEIGHT="0.4108193558453631"/>
<DICH_DATA CI_END="1.0440083969443834" CI_START="0.33068626289197584" EFFECT_SIZE="0.5875706214689266" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="24" LOG_CI_END="0.018703991704505" LOG_CI_START="-0.48058384583055747" LOG_EFFECT_SIZE="-0.23093992706302624" MODIFIED="2009-03-17 11:36:07 +0100" MODIFIED_BY="[Empty name]" ORDER="196" O_E="0.0" SE="0.29328414728275154" STUDY_ID="STD-Petrakis-2005" TOTAL_1="59" TOTAL_2="64" VAR="0.0860155910473707" WEIGHT="2.354158734939877"/>
<DICH_DATA CI_END="1.7870068999407798" CI_START="0.7860428089164017" EFFECT_SIZE="1.1851851851851851" ESTIMABLE="YES" EVENTS_1="32" EVENTS_2="27" LOG_CI_END="0.25212622939451995" LOG_CI_START="-0.10455380107268264" LOG_EFFECT_SIZE="0.07378621416091864" MODIFIED="2009-03-17 11:36:25 +0100" MODIFIED_BY="[Empty name]" ORDER="198" O_E="0.0" SE="0.20951561549106076" STUDY_ID="STD-Pettinati-2008a" TOTAL_1="82" TOTAL_2="82" VAR="0.04389679313459802" WEIGHT="3.751860930579651"/>
<DICH_DATA CI_END="1.3303581039662282" CI_START="0.4840216123082403" EFFECT_SIZE="0.8024475524475524" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="22" LOG_CI_END="0.1239685594956012" LOG_CI_START="-0.31513524600712717" LOG_EFFECT_SIZE="-0.095583343255763" MODIFIED="2009-03-17 11:36:16 +0100" MODIFIED_BY="[Empty name]" ORDER="197" O_E="0.0" SE="0.25793174895119525" STUDY_ID="STD-Pettinati-2008b" TOTAL_1="52" TOTAL_2="54" VAR="0.06652878711702241" WEIGHT="2.8444182338160466"/>
<DICH_DATA CI_END="1.4836833347638105" CI_START="0.416090768367218" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="14" LOG_CI_END="0.1713412185711402" LOG_CI_START="-0.38081191961116617" LOG_EFFECT_SIZE="-0.104735350520013" MODIFIED="2009-03-17 11:36:36 +0100" MODIFIED_BY="[Empty name]" ORDER="199" O_E="0.0" SE="0.32433748657040123" STUDY_ID="STD-Volpicelli-1992" TOTAL_1="35" TOTAL_2="35" VAR="0.10519480519480519" WEIGHT="2.012724483758241"/>
<DICH_DATA CI_END="1.9705582988027368" CI_START="0.5288352519575794" EFFECT_SIZE="1.0208333333333333" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="13" LOG_CI_END="0.29458928795767286" LOG_CI_START="-0.27667960265182" LOG_EFFECT_SIZE="0.008954842652926412" MODIFIED="2009-03-17 11:36:45 +0100" MODIFIED_BY="[Empty name]" ORDER="200" O_E="0.0" SE="0.3355661741706312" STUDY_ID="STD-Volpicelli-1997" TOTAL_1="48" TOTAL_2="49" VAR="0.1126046572475144" WEIGHT="1.9059280913990453"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.731337943767354" CI_END="0.9925389812426717" CI_START="0.7532029070019691" CI_STUDY="95" CI_TOTAL="95" DF="4" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8646289643452578" ESTIMABLE="YES" EVENTS_1="371" EVENTS_2="407" I2="48.262512528965125" I2_Q="0.0" ID="CMP-001.56" LOG_CI_END="-0.003252427631706767" LOG_CI_START="-0.12308801248373478" LOG_EFFECT_SIZE="-0.0631702200577208" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="56" P_CHI2="0.10193058202080219" P_Q="0.0" P_Z="0.03879508782298771" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="5" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.011232628781445854" TOTALS="YES" TOTAL_1="533" TOTAL_2="528" WEIGHT="100.0" Z="2.066353768982456">
<NAME>Post-treatment: Return to heavy drinking</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0726407394259514" CI_START="0.624941359600841" EFFECT_SIZE="0.8187414500683995" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="43" LOG_CI_END="0.030454287659577396" LOG_CI_START="-0.20416073209043936" LOG_EFFECT_SIZE="-0.08685322221543096" MODIFIED="2009-05-22 13:42:06 +0200" MODIFIED_BY="[Empty name]" ORDER="1202" O_E="0.0" SE="0.13781402396423786" STUDY_ID="STD-Anton-1999" TOTAL_1="68" TOTAL_2="63" VAR="0.01899270520121553" WEIGHT="16.39365137361976"/>
<DICH_DATA CI_END="1.0297509380943026" CI_START="0.8818607026410759" EFFECT_SIZE="0.9529411764705882" ESTIMABLE="YES" EVENTS_1="243" EVENTS_2="255" LOG_CI_END="0.012732196267196174" LOG_CI_START="-0.05460000993848218" LOG_EFFECT_SIZE="-0.02093390683564301" MODIFIED="2009-05-22 13:42:06 +0200" MODIFIED_BY="[Empty name]" ORDER="1203" O_E="0.0" SE="0.03955127122501156" STUDY_ID="STD-Anton-2006" TOTAL_1="309" TOTAL_2="309" VAR="0.0015643030555144272" WEIGHT="38.72049912244218"/>
<DICH_DATA CI_END="0.9155795157895428" CI_START="0.47037319541669764" EFFECT_SIZE="0.65625" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="32" LOG_CI_END="-0.03830393233550677" LOG_CI_START="-0.32755743483646665" LOG_EFFECT_SIZE="-0.18293068358598671" MODIFIED="2009-06-08 09:30:10 +0200" MODIFIED_BY="[Empty name]" ORDER="1204" O_E="0.0" SE="0.16990893919699343" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.028869047619047614" WEIGHT="12.356181397864841"/>
<DICH_DATA CI_END="1.4182834496247427" CI_START="0.7471627632651687" EFFECT_SIZE="1.0294117647058822" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="34" LOG_CI_END="0.15176303501208943" LOG_CI_START="-0.12658478039604856" LOG_EFFECT_SIZE="0.012589127308020467" MODIFIED="2009-06-08 09:30:10 +0200" MODIFIED_BY="[Empty name]" ORDER="1205" O_E="0.0" SE="0.1635028846146481" STUDY_ID="STD-Monti-2001" TOTAL_1="64" TOTAL_2="64" VAR="0.026733193277310927" WEIGHT="13.051306704122464"/>
<DICH_DATA CI_END="0.9987675012335366" CI_START="0.6259743249142843" EFFECT_SIZE="0.7906976744186046" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="43" LOG_CI_END="-5.355975427248796E-4" LOG_CI_START="-0.20344347953193795" LOG_EFFECT_SIZE="-0.10198953853733142" MODIFIED="2009-07-22 15:07:38 +0200" MODIFIED_BY="[Empty name]" ORDER="1206" O_E="0.0" SE="0.11918909429067855" STUDY_ID="STD-O_x0027_Malley-1992" TOTAL_1="52" TOTAL_2="52" VAR="0.01420604019783226" WEIGHT="19.478361401950757"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.683855402808072E-4" CI_END="1.1060842612042867" CI_START="0.7927726528950421" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.936415161176054" ESTIMABLE="YES" EVENTS_1="65" EVENTS_2="70" I2="0.0" I2_Q="0.0" ID="CMP-001.57" LOG_CI_END="0.043788212666832756" LOG_CI_START="-0.1008513394784109" LOG_EFFECT_SIZE="-0.028531563405789058" METHOD="MH" MODIFIED="2010-10-08 15:21:54 +0200" MODIFIED_BY="Laura Amato" NO="57" NOTES="&lt;p&gt;Posttreatment duration: &lt;/p&gt;" NOTES_MODIFIED="2010-10-08 15:21:54 +0200" NOTES_MODIFIED_BY="Laura Amato" P_CHI2="0.9778856580140197" P_Q="0.0" P_Z="0.439377966346605" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="92" TOTAL_2="93" WEIGHT="100.00000000000003" Z="0.773244052108418">
<NAME>Post-treatment: Return to any drinking</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0952488547993489" CI_START="0.7978264681043047" EFFECT_SIZE="0.9347826086956522" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="46" LOG_CI_END="0.03951280774879006" LOG_CI_START="-0.09809155995276507" LOG_EFFECT_SIZE="-0.02928937610198753" MODIFIED="2009-07-22 15:04:08 +0200" MODIFIED_BY="[Empty name]" ORDER="897" O_E="0.0" SE="0.08082948674049907" STUDY_ID="STD-O_x0027_Malley-1992" TOTAL_1="52" TOTAL_2="52" VAR="0.006533405926732516" WEIGHT="65.99362380446335"/>
<DICH_DATA CI_END="1.3749174238070214" CI_START="0.6420871719214511" EFFECT_SIZE="0.9395833333333333" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="24" LOG_CI_END="0.13827661564856839" LOG_CI_START="-0.19240600664382182" LOG_EFFECT_SIZE="-0.027064695497626686" MODIFIED="2009-06-12 13:57:58 +0200" MODIFIED_BY="[Empty name]" ORDER="949" O_E="0.0" SE="0.19424460923993" STUDY_ID="STD-Zi_x00f3__x0142_kowski-2000" TOTAL_1="40" TOTAL_2="41" VAR="0.0377309682187731" WEIGHT="34.00637619553667"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="34.94662278726669" CI_END="0.9802090881898957" CI_START="0.9172065264391196" CI_STUDY="95" CI_TOTAL="95" DF="25" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9481846723938913" ESTIMABLE="YES" EVENTS_1="1823" EVENTS_2="1576" I2="28.46232910062739" I2_Q="0.0" ID="CMP-001.58" LOG_CI_END="-0.008681275163090566" LOG_CI_START="-0.03753286368216424" LOG_EFFECT_SIZE="-0.023107069422627406" METHOD="MH" MODIFIED="2010-10-15 13:53:40 +0200" MODIFIED_BY="Laura Amato" NO="58" NOTES="&lt;p&gt;Results provided by the investigators:&lt;/p&gt;&lt;p&gt;Anton (2006)&lt;/p&gt;&lt;p&gt;Balldin (2003)&lt;/p&gt;&lt;p&gt;Brown (2009)&lt;/p&gt;&lt;p&gt;Guardia (2002)&lt;/p&gt;&lt;p&gt;Killeeen (2004)&lt;/p&gt;&lt;p&gt;Krystal (2001)&lt;/p&gt;&lt;p&gt;Ziolkowski (2000)&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2010-10-15 13:53:40 +0200" NOTES_MODIFIED_BY="Laura Amato" P_CHI2="0.08917348217225873" P_Q="0.0" P_Z="0.0016926673644504175" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="27" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="2561" TOTAL_2="2132" WEIGHT="100.0" Z="3.1394475092195373">
<NAME>Sensitivity analysis: Statistical model</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.05501916081994" CI_START="0.5977359092512923" EFFECT_SIZE="0.7941176470588235" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="42" LOG_CI_END="0.023260347181391996" LOG_CI_START="-0.22349065294792766" LOG_EFFECT_SIZE="-0.10011515288326783" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1269" O_E="0.0" SE="0.1449427589131121" STUDY_ID="STD-Anton-1999" TOTAL_1="68" TOTAL_2="63" VAR="0.021008403361344533" WEIGHT="2.580357370303514"/>
<DICH_DATA CI_END="1.0265471364745902" CI_START="0.8769760963985553" EFFECT_SIZE="0.9488188976377953" ESTIMABLE="YES" EVENTS_1="241" EVENTS_2="254" LOG_CI_END="0.011378895879832901" LOG_CI_START="-0.057012243969972204" LOG_EFFECT_SIZE="-0.022816674045069686" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1251" O_E="0.0" SE="0.040173294089377705" STUDY_ID="STD-Anton-2006" TOTAL_1="309" TOTAL_2="309" VAR="0.0016138935579916298" WEIGHT="15.031304471197323"/>
<DICH_DATA CI_END="1.1028453044442927" CI_START="0.9658597812043965" EFFECT_SIZE="1.0320823244552058" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="59" LOG_CI_END="0.042514598443915884" LOG_CI_START="-0.015085917755609676" LOG_EFFECT_SIZE="0.013714340344153092" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1275" O_E="0.0" SE="0.033834828342754954" STUDY_ID="STD-Balldin-2003" TOTAL_1="56" TOTAL_2="62" VAR="0.0011447956089836939" WEIGHT="3.313988387350591"/>
<DICH_DATA CI_END="1.2602014296051345" CI_START="0.7761796752531707" EFFECT_SIZE="0.989010989010989" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" LOG_CI_END="0.10043996795429373" LOG_CI_START="-0.11003773371783114" LOG_EFFECT_SIZE="-0.004798882881768708" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1273" O_E="0.0" SE="0.12363564384363265" STUDY_ID="STD-Baltieri-2008" TOTAL_1="49" TOTAL_2="54" VAR="0.01528577242862958" WEIGHT="2.1959194896764838"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1254" O_E="0.0" SE="0.0" STUDY_ID="STD-Brown-2009" TOTAL_1="20" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.175392360397191" CI_START="0.8791633993381085" EFFECT_SIZE="1.0165441176470589" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="64" LOG_CI_END="0.07018286363877968" LOG_CI_START="-0.05593040042574289" LOG_EFFECT_SIZE="0.0071262316065183766" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1264" O_E="0.0" SE="0.07407955558222577" STUDY_ID="STD-Chick-2000" TOTAL_1="85" TOTAL_2="79" VAR="0.005487780555260077" WEIGHT="3.925979274213244"/>
<DICH_DATA CI_END="1.0279861075480583" CI_START="0.9474192484596005" EFFECT_SIZE="0.9868808567603748" ESTIMABLE="YES" EVENTS_1="388" EVENTS_2="198" LOG_CI_END="0.011987245538647284" LOG_CI_START="-0.023457796075372458" LOG_EFFECT_SIZE="-0.005735275268362568" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1260" O_E="0.0" SE="0.020820592899860928" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="4.3349708870173923E-4" WEIGHT="15.585532611526906"/>
<DICH_DATA CI_END="1.2720378856867658" CI_START="0.7000395431438031" EFFECT_SIZE="0.9436507936507936" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="45" LOG_CI_END="0.10450004629642128" LOG_CI_START="-0.1548774272941639" LOG_EFFECT_SIZE="-0.02518869049887133" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1257" O_E="0.0" SE="0.15235961192631112" STUDY_ID="STD-Gastpar-2002" TOTAL_1="84" TOTAL_2="87" VAR="0.023213451346336123" WEIGHT="2.616306621592572"/>
<DICH_DATA CI_END="1.2727904259294296" CI_START="0.7568456509936812" EFFECT_SIZE="0.9814814814814815" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="54" LOG_CI_END="0.10475689983961217" LOG_CI_START="-0.120992680283971" LOG_EFFECT_SIZE="-0.00811789022217945" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1268" O_E="0.0" SE="0.13260642084303684" STUDY_ID="STD-Guardia-2002" TOTAL_1="101" TOTAL_2="101" VAR="0.017584462848800594" WEIGHT="3.1956316592309273"/>
<DICH_DATA CI_END="0.8968220243868565" CI_START="0.5506009832031952" EFFECT_SIZE="0.7027027027027027" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="37" LOG_CI_END="-0.047293734766085706" LOG_CI_START="-0.2591630174262683" LOG_EFFECT_SIZE="-0.153228376096177" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1258" O_E="0.0" SE="0.12445306540445474" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.01548856548856549" WEIGHT="2.1895994702137833"/>
<DICH_DATA CI_END="1.4440589007315197" CI_START="0.7041799601497147" EFFECT_SIZE="1.0084033613445378" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="21" LOG_CI_END="0.15958490773568682" LOG_CI_START="-0.15231633842549874" LOG_EFFECT_SIZE="0.0036342846550940556" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1259" O_E="0.0" SE="0.1832123359311492" STUDY_ID="STD-Killeeen-2004" TOTAL_1="51" TOTAL_2="36" VAR="0.033566760037348264" WEIGHT="1.4570121358179322"/>
<DICH_DATA CI_END="1.3812002805549306" CI_START="0.8494424658463556" EFFECT_SIZE="1.0831667333066772" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="41" LOG_CI_END="0.14025665789305944" LOG_CI_START="-0.07086603128772812" LOG_EFFECT_SIZE="0.03469531330266566" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1263" O_E="0.0" SE="0.1240145126989608" STUDY_ID="STD-Kranzler-2000" TOTAL_1="61" TOTAL_2="63" VAR="0.015379599359960708" WEIGHT="2.38717884699419"/>
<DICH_DATA CI_END="1.0019434233433513" CI_START="0.8377036568034879" EFFECT_SIZE="0.9161504623395278" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="141" LOG_CI_END="8.43198952887247E-4" LOG_CI_START="-0.07690958874035127" LOG_EFFECT_SIZE="-0.03803319489373202" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1261" O_E="0.0" SE="0.04567237237351468" STUDY_ID="STD-Kranzler-2004" TOTAL_1="158" TOTAL_2="157" VAR="0.0020859655982249873" WEIGHT="8.370638695396424"/>
<DICH_DATA CI_END="1.0290907543853136" CI_START="0.8059546805466064" EFFECT_SIZE="0.9107142857142857" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="140" LOG_CI_END="0.012453676405537625" LOG_CI_START="-0.09368937822206576" LOG_EFFECT_SIZE="-0.04061785090826406" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1265" O_E="0.0" SE="0.06234895570484846" STUDY_ID="STD-Krystal-2001" TOTAL_1="418" TOTAL_2="209" VAR="0.0038873922774851554" WEIGHT="11.046627957835303"/>
<DICH_DATA CI_END="1.4323366178155366" CI_START="0.5509163459038132" EFFECT_SIZE="0.8883116883116883" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.156045094843362" LOG_CI_START="-0.2589143417480933" LOG_EFFECT_SIZE="-0.051434623452365665" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1267" O_E="0.0" SE="0.2437492271361598" STUDY_ID="STD-Lee-2001" TOTAL_1="35" TOTAL_2="18" VAR="0.05941368572947521" WEIGHT="0.8597611382277477"/>
<DICH_DATA CI_END="1.1997343917933971" CI_START="0.8550434147066528" EFFECT_SIZE="1.0128301886792452" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="50" LOG_CI_END="0.0790851085922953" LOG_CI_START="-0.0680118334720021" LOG_EFFECT_SIZE="0.0055366375601465945" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1256" O_E="0.0" SE="0.08640547191017486" STUDY_ID="STD-Morley-2006" TOTAL_1="53" TOTAL_2="61" VAR="0.007465905576020018" WEIGHT="2.751274820325522"/>
<DICH_DATA CI_END="1.0602926997846036" CI_START="0.7529560979722425" EFFECT_SIZE="0.8935064935064935" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="49" LOG_CI_END="0.025425771259002097" LOG_CI_START="-0.12323034513294324" LOG_EFFECT_SIZE="-0.04890228693697058" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1272" O_E="0.0" SE="0.0873213386282726" STUDY_ID="STD-Morris-2001" TOTAL_1="55" TOTAL_2="56" VAR="0.007625016179833452" WEIGHT="2.8736160565990487"/>
<DICH_DATA CI_END="0.967996988340346" CI_START="0.5215384464108057" EFFECT_SIZE="0.7105263157894737" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="38" LOG_CI_END="-0.014125993878800312" LOG_CI_START="-0.2827136710368454" LOG_EFFECT_SIZE="-0.14841983245782286" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1255" O_E="0.0" SE="0.15776973109308" STUDY_ID="STD-O_x0027_Malley-1992" TOTAL_1="52" TOTAL_2="52" VAR="0.02489128804918278" WEIGHT="2.2487778342736156"/>
<DICH_DATA CI_END="1.3647831039386018" CI_START="0.9374575840490486" EFFECT_SIZE="1.131117266851339" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="38" LOG_CI_END="0.13506363727622298" LOG_CI_START="-0.028048373125761073" LOG_EFFECT_SIZE="0.05350763207523094" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1252" O_E="0.0" SE="0.09581280232759878" STUDY_ID="STD-O_x0027_Malley-2007" TOTAL_1="57" TOTAL_2="50" VAR="0.00918009308986752" WEIGHT="2.3958941411887116"/>
<DICH_DATA CI_END="0.9673244521940851" CI_START="0.5559435374118685" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="30" LOG_CI_END="-0.014427833917195277" LOG_CI_START="-0.25496931387771726" LOG_EFFECT_SIZE="-0.13469857389745624" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1276" O_E="0.0" SE="0.14129525602833978" STUDY_ID="STD-O_x0027_Malley-2008" TOTAL_1="34" TOTAL_2="34" VAR="0.01996434937611409" WEIGHT="1.7753509217949595"/>
<DICH_DATA CI_END="1.9759691717101815" CI_START="0.34147541754166066" EFFECT_SIZE="0.8214285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.2957801646136561" LOG_CI_START="-0.4666405552629088" LOG_EFFECT_SIZE="-0.08543019532462635" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1262" O_E="0.0" SE="0.44784970489892456" STUDY_ID="STD-Oslin-1997" TOTAL_1="21" TOTAL_2="23" VAR="0.2005693581780538" WEIGHT="0.4519075073659897"/>
<DICH_DATA CI_END="1.9346302440652738" CI_START="0.7887561779696548" EFFECT_SIZE="1.2352941176470589" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="17" LOG_CI_END="0.28659797281393634" LOG_CI_START="-0.10305722610264562" LOG_EFFECT_SIZE="0.09177037335564536" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1274" O_E="0.0" SE="0.22888539266794258" STUDY_ID="STD-Oslin-2005" TOTAL_1="37" TOTAL_2="37" VAR="0.052388522976758264" WEIGHT="1.0060321890171438"/>
<DICH_DATA CI_END="1.1249039948236184" CI_START="0.8705411111680323" EFFECT_SIZE="0.9895833333333334" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="96" LOG_CI_END="0.051115459071825776" LOG_CI_START="-0.060210714573267016" LOG_EFFECT_SIZE="-0.004547627750720631" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1270" O_E="0.0" SE="0.06539354547257462" STUDY_ID="STD-Oslin-2008" TOTAL_1="120" TOTAL_2="120" VAR="0.004276315789473684" WEIGHT="5.68112294974387"/>
<DICH_DATA CI_END="1.676839534303586" CI_START="0.6393779397348134" EFFECT_SIZE="1.0354391371340523" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.22449150464493242" LOG_CI_START="-0.19424235213802046" LOG_EFFECT_SIZE="0.015124576253455991" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1266" O_E="0.0" SE="0.24596634024032676" STUDY_ID="STD-Petrakis-2005" TOTAL_1="59" TOTAL_2="64" VAR="0.060499440531220194" WEIGHT="1.2490002691001938"/>
<DICH_DATA CI_END="1.268707555567973" CI_START="0.504450373288339" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" LOG_CI_END="0.10336152623978546" LOG_CI_START="-0.29718155225589826" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1250" O_E="0.0" SE="0.23528098702858008" STUDY_ID="STD-Volpicelli-1992" TOTAL_1="35" TOTAL_2="35" VAR="0.05535714285714287" WEIGHT="1.1835672811966398"/>
<DICH_DATA CI_END="1.1889216075614926" CI_START="0.6239992058329584" EFFECT_SIZE="0.861328125" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="32" LOG_CI_END="0.07515322003009052" LOG_CI_START="-0.20481596304607497" LOG_EFFECT_SIZE="-0.06483137150799222" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1253" O_E="0.0" SE="0.16445528400874684" STUDY_ID="STD-Volpicelli-1997" TOTAL_1="48" TOTAL_2="49" VAR="0.027045540438397585" WEIGHT="1.8741848906371532"/>
<DICH_DATA CI_END="1.3261896420833033" CI_START="0.7922132451204937" EFFECT_SIZE="1.025" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="30" LOG_CI_END="0.12260563162633525" LOG_CI_START="-0.10115790084278914" LOG_EFFECT_SIZE="0.010723865391773066" MODIFIED="2010-01-09 13:48:24 +0100" MODIFIED_BY="[Empty name]" ORDER="1271" O_E="0.0" SE="0.13143980661971333" STUDY_ID="STD-Zi_x00f3__x0142_kowski-2000" TOTAL_1="40" TOTAL_2="41" VAR="0.01727642276422764" WEIGHT="1.7534330091802068"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="52.87306368799738" CI_END="0.9226365726400353" CI_START="0.794964564256122" CI_STUDY="95" CI_TOTAL="95" DF="25" EFFECT_MEASURE="RR" EFFECT_SIZE="0.856424766652359" ESTIMABLE="YES" EVENTS_1="1165" EVENTS_2="1243" I2="52.71694459105988" I2_Q="0.0" ID="CMP-001.59" LOG_CI_END="-0.03496933427040258" LOG_CI_START="-0.09965222969701362" LOG_EFFECT_SIZE="-0.0673107819837081" METHOD="MH" MODIFIED="2010-10-15 13:53:40 +0200" MODIFIED_BY="Laura Amato" NO="59" P_CHI2="9.281733319757013E-4" P_Q="0.0" P_Z="4.51941020159986E-5" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="26" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.01466969672234715" TOTALS="YES" TOTAL_1="2237" TOTAL_2="2009" WEIGHT="100.00000000000001" Z="4.079183765327234">
<NAME>Sensitivity analysis: Funding source</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="16.69604809641102" CI_END="1.0494454835394926" CI_START="0.7765225005058594" DF="6" EFFECT_SIZE="0.902728104704106" ESTIMABLE="YES" EVENTS_1="296" EVENTS_2="333" I2="64.06335220554521" ID="CMP-001.59.01" LOG_CI_END="0.020959882829877406" LOG_CI_START="-0.10984595564185029" LOG_EFFECT_SIZE="-0.044443036405986465" MODIFIED="2010-01-05 16:00:26 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.010467701447159805" P_Z="0.1829101235205027" STUDIES="7" TAU2="0.018465774642340966" TOTAL_1="561" TOTAL_2="560" WEIGHT="28.500545352498957" Z="1.3318480541396192">
<NAME>Industry sponsored</NAME>
<DICH_DATA CI_END="1.1073188942420145" CI_START="0.9243370618651896" EFFECT_SIZE="1.0116995073891626" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="58" LOG_CI_END="0.04427271036871017" LOG_CI_START="-0.0341696333088997" LOG_EFFECT_SIZE="0.005051538529905233" MODIFIED="2010-01-05 15:49:37 +0100" MODIFIED_BY="[Empty name]" ORDER="1166" O_E="0.0" SE="0.04607742097209158" STUDY_ID="STD-Balldin-2003" TOTAL_1="56" TOTAL_2="62" VAR="0.002123128723439345" WEIGHT="8.596671560866428"/>
<DICH_DATA CI_END="1.2388202070168948" CI_START="0.8065030656609786" EFFECT_SIZE="0.9995560488346282" ESTIMABLE="YES" EVENTS_1="57" EVENTS_2="53" LOG_CI_END="0.09300828073734807" LOG_CI_START="-0.09339397744164589" LOG_EFFECT_SIZE="-1.9284835214893506E-4" MODIFIED="2010-01-05 15:49:37 +0100" MODIFIED_BY="[Empty name]" ORDER="1161" O_E="0.0" SE="0.10949360916040024" STUDY_ID="STD-Chick-2000" TOTAL_1="85" TOTAL_2="79" VAR="0.011988850446970482" WEIGHT="5.415239023323041"/>
<DICH_DATA CI_END="1.4024453698131532" CI_START="0.6822551344180127" EFFECT_SIZE="0.9781746031746031" ESTIMABLE="YES" EVENTS_1="34" EVENTS_2="36" LOG_CI_END="0.14688595295794266" LOG_CI_START="-0.16605318729453325" LOG_EFFECT_SIZE="-0.00958361716829529" MODIFIED="2010-01-05 15:49:37 +0100" MODIFIED_BY="[Empty name]" ORDER="1171" O_E="0.0" SE="0.1838220000580317" STUDY_ID="STD-Gastpar-2002" TOTAL_1="84" TOTAL_2="87" VAR="0.033790527705335006" WEIGHT="2.9789875437292044"/>
<DICH_DATA CI_END="0.9172755281341353" CI_START="0.19327379083161578" EFFECT_SIZE="0.42105263157894735" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" LOG_CI_END="-0.037500192819751935" LOG_CI_START="-0.713827035102019" LOG_EFFECT_SIZE="-0.3756636139608854" MODIFIED="2010-01-05 15:49:37 +0100" MODIFIED_BY="[Empty name]" ORDER="1183" O_E="0.0" SE="0.3972777350284667" STUDY_ID="STD-Guardia-2002" TOTAL_1="101" TOTAL_2="101" VAR="0.1578295987493486" WEIGHT="0.8368869249096401"/>
<DICH_DATA CI_END="1.023815555803078" CI_START="0.8238254531845772" EFFECT_SIZE="0.9183927886459532" ESTIMABLE="YES" EVENTS_1="122" EVENTS_2="132" LOG_CI_END="0.010221723913303017" LOG_CI_START="-0.08416479406588406" LOG_EFFECT_SIZE="-0.03697153507629053" MODIFIED="2010-01-05 15:49:37 +0100" MODIFIED_BY="[Empty name]" ORDER="1187" O_E="0.0" SE="0.055443107881773715" STUDY_ID="STD-Kranzler-2004" TOTAL_1="158" TOTAL_2="157" VAR="0.003073938211589999" WEIGHT="8.136010770841201"/>
<DICH_DATA CI_END="1.002895037476627" CI_START="0.409532610219688" EFFECT_SIZE="0.6408730158730159" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="27" LOG_CI_END="0.0012554823423941252" LOG_CI_START="-0.38771151057123887" LOG_EFFECT_SIZE="-0.19322801411442236" MODIFIED="2010-01-05 15:49:37 +0100" MODIFIED_BY="[Empty name]" ORDER="1167" O_E="0.0" SE="0.2284811370551357" STUDY_ID="STD-Latt-2002" TOTAL_1="56" TOTAL_2="51" VAR="0.0522036299900077" WEIGHT="2.158744181478202"/>
<DICH_DATA CI_END="1.3470011349479771" CI_START="0.12523094458737097" EFFECT_SIZE="0.4107142857142857" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="8" LOG_CI_END="0.1293679616483279" LOG_CI_START="-0.902288343625543" LOG_EFFECT_SIZE="-0.38646019098860757" MODIFIED="2010-01-05 15:49:37 +0100" MODIFIED_BY="[Empty name]" ORDER="1168" O_E="0.0" SE="0.606000020498944" STUDY_ID="STD-Oslin-1997" TOTAL_1="21" TOTAL_2="23" VAR="0.3672360248447205" WEIGHT="0.3780053473512439"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="30.485816600039136" CI_END="0.9126039203529563" CI_START="0.7715932549277311" DF="18" EFFECT_SIZE="0.8391418410286461" ESTIMABLE="YES" EVENTS_1="869" EVENTS_2="910" I2="40.95614942465772" ID="CMP-001.59.02" LOG_CI_END="-0.03971766992233333" LOG_CI_START="-0.1126115775036199" LOG_EFFECT_SIZE="-0.0761646237129766" MODIFIED="2010-01-09 18:35:30 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.03298272032814209" P_Z="4.206888053097151E-5" STUDIES="19" TAU2="0.0119109221249344" TOTAL_1="1676" TOTAL_2="1449" WEIGHT="71.49945464750105" Z="4.095813335483827">
<NAME>Non-profit sponsored</NAME>
<DICH_DATA CI_END="0.9108199521780594" CI_START="0.44117433589720834" EFFECT_SIZE="0.6339009287925697" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="38" LOG_CI_END="-0.04056746441402639" LOG_CI_START="-0.3553897593832673" LOG_EFFECT_SIZE="-0.19797861189864682" MODIFIED="2010-01-05 15:53:28 +0100" MODIFIED_BY="[Empty name]" ORDER="1228" O_E="0.0" SE="0.18492817446042564" STUDY_ID="STD-Anton-1999" TOTAL_1="68" TOTAL_2="63" VAR="0.03419842970926562" WEIGHT="2.9541219497827704"/>
<DICH_DATA CI_END="0.9902205910630894" CI_START="0.5197329647541995" EFFECT_SIZE="0.717391304347826" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="46" LOG_CI_END="-0.004268047008677679" LOG_CI_START="-0.28421973659869554" LOG_EFFECT_SIZE="-0.14424389180368663" MODIFIED="2010-01-05 15:53:28 +0100" MODIFIED_BY="[Empty name]" ORDER="1223" O_E="0.0" SE="0.16444500824838956" STUDY_ID="STD-Anton-2005" TOTAL_1="80" TOTAL_2="80" VAR="0.027042160737812914" WEIGHT="3.4609440510835707"/>
<DICH_DATA CI_END="1.0157058857044763" CI_START="0.8259539672896838" EFFECT_SIZE="0.915929203539823" ESTIMABLE="YES" EVENTS_1="207" EVENTS_2="226" LOG_CI_END="0.006767969062773602" LOG_CI_START="-0.08304415644374001" LOG_EFFECT_SIZE="-0.038138093690483175" MODIFIED="2010-01-05 15:53:28 +0100" MODIFIED_BY="[Empty name]" ORDER="1236" O_E="0.0" SE="0.05275608709971741" STUDY_ID="STD-Anton-2006" TOTAL_1="309" TOTAL_2="309" VAR="0.0027832047260729696" WEIGHT="8.271541861565654"/>
<DICH_DATA CI_END="1.0409448319572654" CI_START="0.7516211334361477" EFFECT_SIZE="0.8845315904139434" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="51" LOG_CI_END="0.017427713361236823" LOG_CI_START="-0.12400101728137106" LOG_EFFECT_SIZE="-0.05328665196006713" MODIFIED="2010-01-05 15:53:28 +0100" MODIFIED_BY="[Empty name]" ORDER="1233" O_E="0.0" SE="0.08307593646297537" STUDY_ID="STD-Hein_x00e4_l_x00e4_-2001" TOTAL_1="63" TOTAL_2="58" VAR="0.0069016112192003196" WEIGHT="6.692334341875362"/>
<DICH_DATA CI_END="1.260162826363499" CI_START="0.6963750011818706" EFFECT_SIZE="0.9367741935483871" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="25" LOG_CI_END="0.10042666418299362" LOG_CI_START="-0.1571568277954268" LOG_EFFECT_SIZE="-0.028365081806216576" MODIFIED="2010-01-05 15:53:28 +0100" MODIFIED_BY="[Empty name]" ORDER="1216" O_E="0.0" SE="0.15130581824697328" STUDY_ID="STD-Hersh-1998" TOTAL_1="31" TOTAL_2="33" VAR="0.022893450635386114" WEIGHT="3.843192466316762"/>
<DICH_DATA CI_END="0.9534900594109206" CI_START="0.46612383638171156" EFFECT_SIZE="0.6666666666666666" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="30" LOG_CI_END="-0.02068383032168624" LOG_CI_START="-0.3314986877896763" LOG_EFFECT_SIZE="-0.17609125905568127" MODIFIED="2010-01-05 15:53:28 +0100" MODIFIED_BY="[Empty name]" ORDER="1209" O_E="0.0" SE="0.18257418583505539" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.03333333333333334" WEIGHT="3.007360259736428"/>
<DICH_DATA CI_END="2.176882556831785" CI_START="0.7009801940414653" EFFECT_SIZE="1.2352941176470589" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="12" LOG_CI_END="0.33783499941512735" LOG_CI_START="-0.15429425270383665" LOG_EFFECT_SIZE="0.09177037335564536" MODIFIED="2010-01-05 15:53:28 +0100" MODIFIED_BY="[Empty name]" ORDER="1221" O_E="0.0" SE="0.28907915877376605" STUDY_ID="STD-Killeeen-2004" TOTAL_1="51" TOTAL_2="36" VAR="0.08356676003734825" WEIGHT="1.4695400231049058"/>
<DICH_DATA CI_END="1.3396020845421344" CI_START="0.6539456472103151" EFFECT_SIZE="0.9359631147540983" ESTIMABLE="YES" EVENTS_1="29" EVENTS_2="32" LOG_CI_END="0.12697581466989097" LOG_CI_START="-0.18445834662616148" LOG_EFFECT_SIZE="-0.028741265978135234" MODIFIED="2010-01-05 15:53:28 +0100" MODIFIED_BY="[Empty name]" ORDER="1234" O_E="0.0" SE="0.18293796796926262" STUDY_ID="STD-Kranzler-2000" TOTAL_1="61" TOTAL_2="63" VAR="0.03346630012472296" WEIGHT="2.999052983051991"/>
<DICH_DATA CI_END="1.0362441863164529" CI_START="0.7328270354900073" EFFECT_SIZE="0.8714285714285714" ESTIMABLE="YES" EVENTS_1="183" EVENTS_2="105" LOG_CI_END="0.015462107024900128" LOG_CI_START="-0.13499851703187965" LOG_EFFECT_SIZE="-0.05976820500348979" MODIFIED="2010-01-05 15:53:28 +0100" MODIFIED_BY="[Empty name]" ORDER="1227" O_E="0.0" SE="0.0883813153630534" STUDY_ID="STD-Krystal-2001" TOTAL_1="418" TOTAL_2="209" VAR="0.007811256905303497" WEIGHT="6.4215427569241115"/>
<DICH_DATA CI_END="1.4855732426693047" CI_START="0.4773519432566174" EFFECT_SIZE="0.8421052631578947" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="19" LOG_CI_END="0.1718940685280875" LOG_CI_START="-0.32116130512189595" LOG_EFFECT_SIZE="-0.07463361829690421" MODIFIED="2010-01-05 15:53:28 +0100" MODIFIED_BY="[Empty name]" ORDER="1212" O_E="0.0" SE="0.2896231671454623" STUDY_ID="STD-Monti-2001" TOTAL_1="64" TOTAL_2="64" VAR="0.08388157894736842" WEIGHT="1.4648456243245653"/>
<DICH_DATA CI_END="1.3123382710959026" CI_START="0.8303370936172787" EFFECT_SIZE="1.0438788942518649" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="43" LOG_CI_END="0.11804579413635513" LOG_CI_START="-0.08074556042257375" LOG_EFFECT_SIZE="0.018650116856890674" MODIFIED="2010-01-05 15:53:28 +0100" MODIFIED_BY="[Empty name]" ORDER="1210" O_E="0.0" SE="0.11677102570099017" STUDY_ID="STD-Morley-2006" TOTAL_1="53" TOTAL_2="61" VAR="0.013635472443261305" WEIGHT="5.100213466019171"/>
<DICH_DATA CI_END="0.8920981246228511" CI_START="0.4927392976786826" EFFECT_SIZE="0.6630021141649048" ESTIMABLE="YES" EVENTS_1="28" EVENTS_2="43" LOG_CI_END="-0.04958737360764319" LOG_CI_START="-0.30738279984317834" LOG_EFFECT_SIZE="-0.17848508672541075" MODIFIED="2010-01-05 15:53:28 +0100" MODIFIED_BY="[Empty name]" ORDER="1218" O_E="0.0" SE="0.15143030947869401" STUDY_ID="STD-Morris-2001" TOTAL_1="55" TOTAL_2="56" VAR="0.022931138628813047" WEIGHT="3.8393403653978253"/>
<DICH_DATA CI_END="1.0056817734332681" CI_START="0.49545483408011104" EFFECT_SIZE="0.7058823529411765" ESTIMABLE="YES" EVENTS_1="24" EVENTS_2="34" LOG_CI_END="0.002460579223404905" LOG_CI_START="-0.30499592988470303" LOG_EFFECT_SIZE="-0.15126767533064908" MODIFIED="2010-01-05 15:53:28 +0100" MODIFIED_BY="[Empty name]" ORDER="1214" O_E="0.0" SE="0.1806014753843682" STUDY_ID="STD-O_x0027_Malley-1992" TOTAL_1="52" TOTAL_2="52" VAR="0.03261689291101055" WEIGHT="3.0529248578871564"/>
<DICH_DATA CI_END="1.4041285884489532" CI_START="0.813978011065845" EFFECT_SIZE="1.069078947368421" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="32" LOG_CI_END="0.1474068817942262" LOG_CI_START="-0.08938732705398487" LOG_EFFECT_SIZE="0.029009777370120622" MODIFIED="2010-01-05 15:53:28 +0100" MODIFIED_BY="[Empty name]" ORDER="1213" O_E="0.0" SE="0.13909409042767718" STUDY_ID="STD-O_x0027_Malley-2007" TOTAL_1="57" TOTAL_2="50" VAR="0.019347165991902834" WEIGHT="4.243848298094582"/>
<DICH_DATA CI_END="1.0531862794102325" CI_START="0.586170700135986" EFFECT_SIZE="0.7857142857142857" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="28" LOG_CI_END="0.022505192614775998" LOG_CI_START="-0.23197589365480198" LOG_EFFECT_SIZE="-0.104735350520013" MODIFIED="2010-01-05 15:53:28 +0100" MODIFIED_BY="[Empty name]" ORDER="1231" O_E="0.0" SE="0.14948344977644334" STUDY_ID="STD-O_x0027_Malley-2008" TOTAL_1="34" TOTAL_2="34" VAR="0.022345301757066463" WEIGHT="3.9001056562700103"/>
<DICH_DATA CI_END="0.850023691821018" CI_START="0.31810878049848024" EFFECT_SIZE="0.52" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="25" LOG_CI_END="-0.07056896948130421" LOG_CI_START="-0.4974243432490974" LOG_EFFECT_SIZE="-0.28399665636520083" MODIFIED="2010-01-05 15:53:28 +0100" MODIFIED_BY="[Empty name]" ORDER="1217" O_E="0.0" SE="0.25073695951937935" STUDY_ID="STD-Oslin-2005" TOTAL_1="37" TOTAL_2="37" VAR="0.06286902286902288" WEIGHT="1.8618105341070685"/>
<DICH_DATA CI_END="1.1706677672836119" CI_START="0.7881064372899773" EFFECT_SIZE="0.9605263157894737" ESTIMABLE="YES" EVENTS_1="73" EVENTS_2="76" LOG_CI_END="0.0684336608216132" LOG_CI_START="-0.10341512514228415" LOG_EFFECT_SIZE="-0.017490732160335455" MODIFIED="2010-01-05 15:53:28 +0100" MODIFIED_BY="[Empty name]" ORDER="1226" O_E="0.0" SE="0.10094482754040318" STUDY_ID="STD-Oslin-2008" TOTAL_1="120" TOTAL_2="120" VAR="0.01018985820716174" WEIGHT="5.807119449472734"/>
<DICH_DATA CI_END="0.831382895649233" CI_START="0.213241479331991" EFFECT_SIZE="0.42105263157894735" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="19" LOG_CI_END="-0.08019891464044512" LOG_CI_START="-0.6711283132813257" LOG_EFFECT_SIZE="-0.3756636139608854" MODIFIED="2010-01-05 15:53:28 +0100" MODIFIED_BY="[Empty name]" ORDER="1235" O_E="0.0" SE="0.3471148539093527" STUDY_ID="STD-Volpicelli-1992" TOTAL_1="35" TOTAL_2="35" VAR="0.12048872180451127" WEIGHT="1.0680977663829312"/>
<DICH_DATA CI_END="1.0615484316755095" CI_START="0.41968265344480227" EFFECT_SIZE="0.6674679487179487" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="26" LOG_CI_END="0.0259398130376758" LOG_CI_START="-0.377078980916911" LOG_EFFECT_SIZE="-0.1755695839396176" MODIFIED="2010-01-05 15:53:28 +0100" MODIFIED_BY="[Empty name]" ORDER="1219" O_E="0.0" SE="0.2367352345441289" STUDY_ID="STD-Volpicelli-1997" TOTAL_1="48" TOTAL_2="49" VAR="0.05604357127466372" WEIGHT="2.041517936103437"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="34.94662278726662" CI_END="0.9967288087120282" CI_START="0.9222909594122763" CI_STUDY="95" CI_TOTAL="95" DF="25" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9587877602790265" ESTIMABLE="YES" EVENTS_1="1823" EVENTS_2="1576" I2="28.462329100627247" I2_Q="0.0" ID="CMP-001.60" LOG_CI_END="-0.0014229890312708767" LOG_CI_START="-0.03513204843324812" LOG_EFFECT_SIZE="-0.018277518732259454" METHOD="MH" MODIFIED="2010-10-15 13:53:40 +0200" MODIFIED_BY="Laura Amato" NO="60" P_CHI2="0.0891734821722604" P_Q="0.0" P_Z="0.033549980709127215" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="27" SUBGROUPS="YES" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0020736055819613394" TOTALS="YES" TOTAL_1="2561" TOTAL_2="2132" WEIGHT="100.00000000000003" Z="2.1254392188637286">
<NAME>Outcome selection bias</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_SUBGROUP CHI2="28.266979330533783" CI_END="0.9965163983185884" CI_START="0.8958422066042113" DF="19" EFFECT_SIZE="0.9448393774536524" ESTIMABLE="YES" EVENTS_1="1159" EVENTS_2="1018" I2="32.78376236163183" ID="CMP-001.60.01" LOG_CI_END="-0.0015155503095256623" LOG_CI_START="-0.047768480110240215" LOG_EFFECT_SIZE="-0.02464201520988292" MODIFIED="2010-01-09 21:21:47 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.0784236533330821" P_Z="0.0367611711368402" STUDIES="20" TAU2="0.0034837845915476626" TOTAL_1="1566" TOTAL_2="1351" WEIGHT="65.4870946143041" Z="2.0884066166598863">
<NAME>Reported results</NAME>
<DICH_DATA CI_END="1.05501916081994" CI_START="0.5977359092512923" EFFECT_SIZE="0.7941176470588235" ESTIMABLE="YES" EVENTS_1="36" EVENTS_2="42" LOG_CI_END="0.023260347181391996" LOG_CI_START="-0.22349065294792766" LOG_EFFECT_SIZE="-0.10011515288326783" MODIFIED="2010-01-09 21:21:10 +0100" MODIFIED_BY="[Empty name]" ORDER="2113" O_E="0.0" SE="0.1449427589131121" STUDY_ID="STD-Anton-1999" TOTAL_1="68" TOTAL_2="63" VAR="0.021008403361344533" WEIGHT="1.698614659517794"/>
<DICH_DATA CI_END="1.2602014296051345" CI_START="0.7761796752531707" EFFECT_SIZE="0.989010989010989" ESTIMABLE="YES" EVENTS_1="35" EVENTS_2="39" LOG_CI_END="0.10043996795429373" LOG_CI_START="-0.11003773371783114" LOG_EFFECT_SIZE="-0.004798882881768708" MODIFIED="2010-01-09 21:21:10 +0100" MODIFIED_BY="[Empty name]" ORDER="2116" O_E="0.0" SE="0.12363564384363265" STUDY_ID="STD-Baltieri-2008" TOTAL_1="49" TOTAL_2="54" VAR="0.01528577242862958" WEIGHT="2.258573938438336"/>
<DICH_DATA CI_END="1.175392360397191" CI_START="0.8791633993381085" EFFECT_SIZE="1.0165441176470589" ESTIMABLE="YES" EVENTS_1="70" EVENTS_2="64" LOG_CI_END="0.07018286363877968" LOG_CI_START="-0.05593040042574289" LOG_EFFECT_SIZE="0.0071262316065183766" MODIFIED="2010-01-09 21:21:10 +0100" MODIFIED_BY="[Empty name]" ORDER="2118" O_E="0.0" SE="0.07407955558222577" STUDY_ID="STD-Chick-2000" TOTAL_1="85" TOTAL_2="79" VAR="0.005487780555260077" WEIGHT="5.185218430946015"/>
<DICH_DATA CI_END="1.0279861075480583" CI_START="0.9474192484596005" EFFECT_SIZE="0.9868808567603748" ESTIMABLE="YES" EVENTS_1="388" EVENTS_2="198" LOG_CI_END="0.011987245538647284" LOG_CI_START="-0.023457796075372458" LOG_EFFECT_SIZE="-0.005735275268362568" MODIFIED="2010-01-09 21:21:10 +0100" MODIFIED_BY="[Empty name]" ORDER="2119" O_E="0.0" SE="0.020820592899860928" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="4.3349708870173923E-4" WEIGHT="15.638545330036521"/>
<DICH_DATA CI_END="1.2720378856867658" CI_START="0.7000395431438031" EFFECT_SIZE="0.9436507936507936" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="45" LOG_CI_END="0.10450004629642128" LOG_CI_START="-0.1548774272941639" LOG_EFFECT_SIZE="-0.02518869049887133" MODIFIED="2010-01-09 21:21:10 +0100" MODIFIED_BY="[Empty name]" ORDER="2120" O_E="0.0" SE="0.15235961192631112" STUDY_ID="STD-Gastpar-2002" TOTAL_1="84" TOTAL_2="87" VAR="0.023213451346336123" WEIGHT="1.5504943447311628"/>
<DICH_DATA CI_END="0.8968220243868565" CI_START="0.5506009832031952" EFFECT_SIZE="0.7027027027027027" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="37" LOG_CI_END="-0.047293734766085706" LOG_CI_START="-0.2591630174262683" LOG_EFFECT_SIZE="-0.153228376096177" MODIFIED="2010-01-09 21:21:10 +0100" MODIFIED_BY="[Empty name]" ORDER="2122" O_E="0.0" SE="0.12445306540445474" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.01548856548856549" WEIGHT="2.232493841722044"/>
<DICH_DATA CI_END="1.3812002805549306" CI_START="0.8494424658463556" EFFECT_SIZE="1.0831667333066772" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="41" LOG_CI_END="0.14025665789305944" LOG_CI_START="-0.07086603128772812" LOG_EFFECT_SIZE="0.03469531330266566" MODIFIED="2010-01-09 21:21:10 +0100" MODIFIED_BY="[Empty name]" ORDER="2124" O_E="0.0" SE="0.1240145126989608" STUDY_ID="STD-Kranzler-2000" TOTAL_1="61" TOTAL_2="63" VAR="0.015379599359960708" WEIGHT="2.2464320388540875"/>
<DICH_DATA CI_END="1.0019434233433513" CI_START="0.8377036568034879" EFFECT_SIZE="0.9161504623395278" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="141" LOG_CI_END="8.43198952887247E-4" LOG_CI_START="-0.07690958874035127" LOG_EFFECT_SIZE="-0.03803319489373202" MODIFIED="2010-01-09 21:21:10 +0100" MODIFIED_BY="[Empty name]" ORDER="2125" O_E="0.0" SE="0.04567237237351468" STUDY_ID="STD-Kranzler-2004" TOTAL_1="158" TOTAL_2="157" VAR="0.0020859655982249873" WEIGHT="9.425836718212835"/>
<DICH_DATA CI_END="1.4323366178155366" CI_START="0.5509163459038132" EFFECT_SIZE="0.8883116883116883" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="11" LOG_CI_END="0.156045094843362" LOG_CI_START="-0.2589143417480933" LOG_EFFECT_SIZE="-0.051434623452365665" MODIFIED="2010-01-09 21:21:10 +0100" MODIFIED_BY="[Empty name]" ORDER="2127" O_E="0.0" SE="0.2437492271361598" STUDY_ID="STD-Lee-2001" TOTAL_1="35" TOTAL_2="18" VAR="0.05941368572947521" WEIGHT="0.6376510970963467"/>
<DICH_DATA CI_END="1.1997343917933971" CI_START="0.8550434147066528" EFFECT_SIZE="1.0128301886792452" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="50" LOG_CI_END="0.0790851085922953" LOG_CI_START="-0.0680118334720021" LOG_EFFECT_SIZE="0.0055366375601465945" MODIFIED="2010-01-09 21:21:10 +0100" MODIFIED_BY="[Empty name]" ORDER="2128" O_E="0.0" SE="0.08640547191017486" STUDY_ID="STD-Morley-2006" TOTAL_1="53" TOTAL_2="61" VAR="0.007465905576020018" WEIGHT="4.110005021527415"/>
<DICH_DATA CI_END="1.0602926997846036" CI_START="0.7529560979722425" EFFECT_SIZE="0.8935064935064935" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="49" LOG_CI_END="0.025425771259002097" LOG_CI_START="-0.12323034513294324" LOG_EFFECT_SIZE="-0.04890228693697058" MODIFIED="2010-01-09 21:21:10 +0100" MODIFIED_BY="[Empty name]" ORDER="2129" O_E="0.0" SE="0.0873213386282726" STUDY_ID="STD-Morris-2001" TOTAL_1="55" TOTAL_2="56" VAR="0.007625016179833452" WEIGHT="4.042578391567731"/>
<DICH_DATA CI_END="0.967996988340346" CI_START="0.5215384464108057" EFFECT_SIZE="0.7105263157894737" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="38" LOG_CI_END="-0.014125993878800312" LOG_CI_START="-0.2827136710368454" LOG_EFFECT_SIZE="-0.14841983245782286" MODIFIED="2010-01-09 21:21:10 +0100" MODIFIED_BY="[Empty name]" ORDER="2130" O_E="0.0" SE="0.15776973109308" STUDY_ID="STD-O_x0027_Malley-1992" TOTAL_1="52" TOTAL_2="52" VAR="0.02489128804918278" WEIGHT="1.454017927848826"/>
<DICH_DATA CI_END="1.3647831039386018" CI_START="0.9374575840490486" EFFECT_SIZE="1.131117266851339" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="38" LOG_CI_END="0.13506363727622298" LOG_CI_START="-0.028048373125761073" LOG_EFFECT_SIZE="0.05350763207523094" MODIFIED="2010-01-09 21:21:10 +0100" MODIFIED_BY="[Empty name]" ORDER="2131" O_E="0.0" SE="0.09581280232759878" STUDY_ID="STD-O_x0027_Malley-2007" TOTAL_1="57" TOTAL_2="50" VAR="0.00918009308986752" WEIGHT="3.4839602432547188"/>
<DICH_DATA CI_END="0.9673244521940851" CI_START="0.5559435374118685" EFFECT_SIZE="0.7333333333333333" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="30" LOG_CI_END="-0.014427833917195277" LOG_CI_START="-0.25496931387771726" LOG_EFFECT_SIZE="-0.13469857389745624" MODIFIED="2010-01-09 21:21:10 +0100" MODIFIED_BY="[Empty name]" ORDER="2132" O_E="0.0" SE="0.14129525602833978" STUDY_ID="STD-O_x0027_Malley-2008" TOTAL_1="34" TOTAL_2="34" VAR="0.01996434937611409" WEIGHT="1.7790869813831471"/>
<DICH_DATA CI_END="1.9759691717101815" CI_START="0.34147541754166066" EFFECT_SIZE="0.8214285714285714" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="8" LOG_CI_END="0.2957801646136561" LOG_CI_START="-0.4666405552629088" LOG_EFFECT_SIZE="-0.08543019532462635" MODIFIED="2010-01-09 21:21:10 +0100" MODIFIED_BY="[Empty name]" ORDER="2133" O_E="0.0" SE="0.44784970489892456" STUDY_ID="STD-Oslin-1997" TOTAL_1="21" TOTAL_2="23" VAR="0.2005693581780538" WEIGHT="0.19348038557436686"/>
<DICH_DATA CI_END="1.9346302440652738" CI_START="0.7887561779696548" EFFECT_SIZE="1.2352941176470589" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="17" LOG_CI_END="0.28659797281393634" LOG_CI_START="-0.10305722610264562" LOG_EFFECT_SIZE="0.09177037335564536" MODIFIED="2010-01-09 21:21:10 +0100" MODIFIED_BY="[Empty name]" ORDER="2134" O_E="0.0" SE="0.22888539266794258" STUDY_ID="STD-Oslin-2005" TOTAL_1="37" TOTAL_2="37" VAR="0.052388522976758264" WEIGHT="0.7199027985097529"/>
<DICH_DATA CI_END="1.1249039948236184" CI_START="0.8705411111680323" EFFECT_SIZE="0.9895833333333334" ESTIMABLE="YES" EVENTS_1="95" EVENTS_2="96" LOG_CI_END="0.051115459071825776" LOG_CI_START="-0.060210714573267016" LOG_EFFECT_SIZE="-0.004547627750720631" MODIFIED="2010-01-09 21:21:10 +0100" MODIFIED_BY="[Empty name]" ORDER="2135" O_E="0.0" SE="0.06539354547257462" STUDY_ID="STD-Oslin-2008" TOTAL_1="120" TOTAL_2="120" VAR="0.004276315789473684" WEIGHT="6.174476260224883"/>
<DICH_DATA CI_END="1.676839534303586" CI_START="0.6393779397348134" EFFECT_SIZE="1.0354391371340523" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="22" LOG_CI_END="0.22449150464493242" LOG_CI_START="-0.19424235213802046" LOG_EFFECT_SIZE="0.015124576253455991" MODIFIED="2010-01-09 21:21:10 +0100" MODIFIED_BY="[Empty name]" ORDER="2136" O_E="0.0" SE="0.24596634024032676" STUDY_ID="STD-Petrakis-2005" TOTAL_1="59" TOTAL_2="64" VAR="0.060499440531220194" WEIGHT="0.6265867046220209"/>
<DICH_DATA CI_END="1.268707555567973" CI_START="0.504450373288339" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="20" LOG_CI_END="0.10336152623978546" LOG_CI_START="-0.29718155225589826" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2010-01-09 21:21:10 +0100" MODIFIED_BY="[Empty name]" ORDER="2137" O_E="0.0" SE="0.23528098702858008" STUDY_ID="STD-Volpicelli-1992" TOTAL_1="35" TOTAL_2="35" VAR="0.05535714285714287" WEIGHT="0.6826907158243493"/>
<DICH_DATA CI_END="1.1889216075614926" CI_START="0.6239992058329584" EFFECT_SIZE="0.861328125" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="32" LOG_CI_END="0.07515322003009052" LOG_CI_START="-0.20481596304607497" LOG_EFFECT_SIZE="-0.06483137150799222" MODIFIED="2010-01-09 21:21:10 +0100" MODIFIED_BY="[Empty name]" ORDER="2138" O_E="0.0" SE="0.16445528400874684" STUDY_ID="STD-Volpicelli-1997" TOTAL_1="48" TOTAL_2="49" VAR="0.027045540438397585" WEIGHT="1.3464487844117383"/>
</DICH_SUBGROUP>
<DICH_SUBGROUP CHI2="6.435318550691363" CI_END="1.0384314515839357" CI_START="0.9242968034068502" DF="5" EFFECT_SIZE="0.9797034608779164" ESTIMABLE="YES" EVENTS_1="664" EVENTS_2="558" I2="22.303768483025028" ID="CMP-001.60.02" LOG_CI_END="0.016377833387818893" LOG_CI_START="-0.03418854892722518" LOG_EFFECT_SIZE="-0.008905357769703146" MODIFIED="2010-01-09 21:19:32 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.26613375479884427" P_Z="0.48997587005368826" STUDIES="7" TAU2="0.0011475433455901734" TOTAL_1="995" TOTAL_2="781" WEIGHT="34.51290538569592" Z="0.690347210892691">
<NAME>Subsequently provided results</NAME>
<DICH_DATA CI_END="1.0265471364745902" CI_START="0.8769760963985553" EFFECT_SIZE="0.9488188976377953" ESTIMABLE="YES" EVENTS_1="241" EVENTS_2="254" LOG_CI_END="0.011378895879832901" LOG_CI_START="-0.057012243969972204" LOG_EFFECT_SIZE="-0.022816674045069686" MODIFIED="2010-01-09 21:19:32 +0100" MODIFIED_BY="[Empty name]" ORDER="2079" O_E="0.0" SE="0.040173294089377705" STUDY_ID="STD-Anton-2006" TOTAL_1="309" TOTAL_2="309" VAR="0.0016138935579916298" WEIGHT="10.632528245883263"/>
<DICH_DATA CI_END="1.1028453044442927" CI_START="0.9658597812043965" EFFECT_SIZE="1.0320823244552058" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="59" LOG_CI_END="0.042514598443915884" LOG_CI_START="-0.015085917755609676" LOG_EFFECT_SIZE="0.013714340344153092" MODIFIED="2010-01-09 21:19:32 +0100" MODIFIED_BY="[Empty name]" ORDER="2080" O_E="0.0" SE="0.033834828342754954" STUDY_ID="STD-Balldin-2003" TOTAL_1="56" TOTAL_2="62" VAR="0.0011447956089836939" WEIGHT="12.182272015226145"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-09 21:19:32 +0100" MODIFIED_BY="[Empty name]" ORDER="2081" O_E="0.0" SE="0.0" STUDY_ID="STD-Brown-2009" TOTAL_1="20" TOTAL_2="23" VAR="0.0" WEIGHT="0.0"/>
<DICH_DATA CI_END="1.2727904259294296" CI_START="0.7568456509936812" EFFECT_SIZE="0.9814814814814815" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="54" LOG_CI_END="0.10475689983961217" LOG_CI_START="-0.120992680283971" LOG_EFFECT_SIZE="-0.00811789022217945" MODIFIED="2010-01-09 21:19:32 +0100" MODIFIED_BY="[Empty name]" ORDER="2082" O_E="0.0" SE="0.13260642084303684" STUDY_ID="STD-Guardia-2002" TOTAL_1="101" TOTAL_2="101" VAR="0.017584462848800594" WEIGHT="1.9944705605392241"/>
<DICH_DATA CI_END="1.4440589007315197" CI_START="0.7041799601497147" EFFECT_SIZE="1.0084033613445378" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="21" LOG_CI_END="0.15958490773568682" LOG_CI_START="-0.15231633842549874" LOG_EFFECT_SIZE="0.0036342846550940556" MODIFIED="2010-01-09 21:19:32 +0100" MODIFIED_BY="[Empty name]" ORDER="2083" O_E="0.0" SE="0.1832123359311492" STUDY_ID="STD-Killeeen-2004" TOTAL_1="51" TOTAL_2="36" VAR="0.033566760037348264" WEIGHT="1.1000852006124755"/>
<DICH_DATA CI_END="1.0290907543853136" CI_START="0.8059546805466064" EFFECT_SIZE="0.9107142857142857" ESTIMABLE="YES" EVENTS_1="255" EVENTS_2="140" LOG_CI_END="0.012453676405537625" LOG_CI_START="-0.09368937822206576" LOG_EFFECT_SIZE="-0.04061785090826406" MODIFIED="2010-01-09 21:19:32 +0100" MODIFIED_BY="[Empty name]" ORDER="2084" O_E="0.0" SE="0.06234895570484846" STUDY_ID="STD-Krystal-2001" TOTAL_1="418" TOTAL_2="209" VAR="0.0038873922774851554" WEIGHT="6.577328106247762"/>
<DICH_DATA CI_END="1.3261896420833033" CI_START="0.7922132451204937" EFFECT_SIZE="1.025" ESTIMABLE="YES" EVENTS_1="30" EVENTS_2="30" LOG_CI_END="0.12260563162633525" LOG_CI_START="-0.10115790084278914" LOG_EFFECT_SIZE="0.010723865391773066" MODIFIED="2010-01-09 21:19:32 +0100" MODIFIED_BY="[Empty name]" ORDER="2085" O_E="0.0" SE="0.13143980661971333" STUDY_ID="STD-Zi_x00f3__x0142_kowski-2000" TOTAL_1="40" TOTAL_2="41" VAR="0.01727642276422764" WEIGHT="2.026221257187055"/>
</DICH_SUBGROUP>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2010-10-11 16:50:14 +0200" MODIFIED_BY="Laura Amato" NO="2">
<NAME>Subgroup analysis: NTX injectable</NAME>
<DICH_OUTCOME CHI2="0.04603748347571672" CI_END="1.000610530134588" CI_START="0.8429205253153778" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9183872569331227" ESTIMABLE="YES" EVENTS_1="171" EVENTS_2="186" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="2.650689604243058E-4" LOG_CI_START="-0.074213370860516" LOG_EFFECT_SIZE="-0.03697415095004584" METHOD="MH" MODIFIED="2010-01-13 14:28:59 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.8301078320706304" P_Q="0.0" P_Z="0.05165318396806405" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="242" TOTAL_2="244" WEIGHT="100.00000000000001" Z="1.946012950734829">
<NAME>Return to any drinking</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2720378856867658" CI_START="0.7000395431438031" EFFECT_SIZE="0.9436507936507936" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="45" LOG_CI_END="0.10450004629642128" LOG_CI_START="-0.1548774272941639" LOG_EFFECT_SIZE="-0.02518869049887133" MODIFIED="2009-06-23 18:08:21 +0200" MODIFIED_BY="[Empty name]" ORDER="1899" O_E="0.0" SE="0.15235961192631112" STUDY_ID="STD-Garbutt-2005" TOTAL_1="84" TOTAL_2="87" VAR="0.023213451346336123" WEIGHT="8.24511332729915"/>
<DICH_DATA CI_END="1.0019434233433513" CI_START="0.8377036568034879" EFFECT_SIZE="0.9161504623395278" ESTIMABLE="YES" EVENTS_1="130" EVENTS_2="141" LOG_CI_END="8.43198952887247E-4" LOG_CI_START="-0.07690958874035127" LOG_EFFECT_SIZE="-0.03803319489373202" MODIFIED="2009-06-23 18:08:53 +0200" MODIFIED_BY="[Empty name]" ORDER="1901" O_E="0.0" SE="0.04567237237351468" STUDY_ID="STD-Kranzler-2004" TOTAL_1="158" TOTAL_2="157" VAR="0.0020859655982249873" WEIGHT="91.75488667270086"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.004869909076745581" CI_END="-1.313344014142019" CI_START="-15.770643342851649" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-8.541993678496834" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.02" MODIFIED="2010-01-10 12:12:26 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.9443649982464201" P_Q="1.0" P_Z="0.02055489001727145" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="173" TOTAL_2="162" UNITS="" WEIGHT="100.0" Z="2.3160618847776044">
<NAME>Drinking days</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="25.478359328642412" CI_START="-40.27835932864241" EFFECT_SIZE="-7.399999999999999" ESTIMABLE="YES" MEAN_1="21.0" MEAN_2="28.4" MODIFIED="2009-06-23 18:13:08 +0200" MODIFIED_BY="[Empty name]" ORDER="1904" SD_1="25.5" SD_2="34.5" SE="16.774981371077587" STUDY_ID="STD-Kranzler-1998" TOTAL_1="15" TOTAL_2="5" WEIGHT="4.833860125263869"/>
<CONT_DATA CI_END="-1.1900385206011528" CI_START="-16.00996147939885" EFFECT_SIZE="-8.600000000000001" ESTIMABLE="YES" MEAN_1="37.1" MEAN_2="45.7" MODIFIED="2009-06-23 18:13:35 +0200" MODIFIED_BY="[Empty name]" ORDER="1905" SD_1="33.6" SD_2="33.5" SE="3.7806620620826092" STUDY_ID="STD-Kranzler-2004" TOTAL_1="158" TOTAL_2="157" WEIGHT="95.16613987473613"/>
</CONT_OUTCOME>
<CONT_OUTCOME CHI2="0.5415000840828185" CI_END="2.3549485811122493" CI_START="-8.457943911575232" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="MD" EFFECT_SIZE="-3.0514976652314907" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-002.03" MODIFIED="2010-01-10 13:43:06 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.762807158998881" P_Q="1.0" P_Z="0.26862279734751715" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="190" TOTAL_2="167" UNITS="" WEIGHT="100.0" Z="1.1062397090892164">
<NAME>Heavy drinking days</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="17.861762880995872" CI_START="-45.06176288099587" EFFECT_SIZE="-13.600000000000001" ESTIMABLE="YES" MEAN_1="11.7" MEAN_2="25.3" MODIFIED="2010-01-10 13:42:12 +0100" MODIFIED_BY="[Empty name]" ORDER="1210" SD_1="17.8" SD_2="35.0" SE="16.052214800456664" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" WEIGHT="2.9529607304491248"/>
<CONT_DATA CI_END="7.398917318921166" CI_START="-10.598917318921165" EFFECT_SIZE="-1.5999999999999996" ESTIMABLE="YES" MEAN_1="3.7" MEAN_2="5.3" MODIFIED="2010-01-10 13:42:29 +0100" MODIFIED_BY="[Empty name]" ORDER="1211" SD_1="10.7" SD_2="8.2" SE="4.591368713865906" STUDY_ID="STD-Kranzler-1998" TOTAL_1="15" TOTAL_2="5" WEIGHT="36.0946849596845"/>
<CONT_DATA CI_END="3.5249500765974267" CI_START="-10.324950076597432" EFFECT_SIZE="-3.400000000000002" ESTIMABLE="YES" MEAN_1="26.7" MEAN_2="30.1" MODIFIED="2010-01-10 13:43:06 +0100" MODIFIED_BY="[Empty name]" ORDER="1212" SD_1="30.7" SD_2="31.2" SE="3.533202717611421" STUDY_ID="STD-Kranzler-2004" TOTAL_1="150" TOTAL_2="157" WEIGHT="60.952354309866365"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="6.251878634846597" CI_END="0.25905579310763677" CI_START="-0.013520921275108302" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RD" EFFECT_SIZE="0.12276743591626423" ESTIMABLE="YES" EVENTS_1="33" EVENTS_2="8" I2="68.00961572010628" I2_Q="0.0" ID="CMP-002.04" LOG_CI_END="-0.5866066914040803" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-0.9109168146064647" METHOD="MH" MODIFIED="2010-01-10 14:44:36 +0100" MODIFIED_BY="[Empty name]" NO="4" P_CHI2="0.043895720990109965" P_Q="0.0" P_Z="0.07747649514077544" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.009316569872114799" TOTALS="YES" TOTAL_1="253" TOTAL_2="234" WEIGHT="100.0" Z="1.7655195045922747">
<NAME>Side effect: Abdominal pain</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5167856388460081" CI_START="-0.036785638846008106" EFFECT_SIZE="0.24" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 08:37:55 +0200" MODIFIED_BY="[Empty name]" ORDER="680" O_E="0.0" SE="0.14121975762272057" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" VAR="0.019943019943019943" WEIGHT="16.525442510838996"/>
<DICH_DATA CI_END="0.3090197445065897" CI_START="0.027175935951385843" EFFECT_SIZE="0.16809784022898777" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 08:38:10 +0200" MODIFIED_BY="[Empty name]" ORDER="681" O_E="0.0" SE="0.07190025193788045" STUDY_ID="STD-Kranzler-1998" TOTAL_1="61" TOTAL_2="63" VAR="0.005169646228730682" WEIGHT="33.37846584744228"/>
<DICH_DATA CI_END="0.08978867517076536" CI_START="0.01799575596695919" EFFECT_SIZE="0.05389221556886228" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 08:38:10 +0200" MODIFIED_BY="[Empty name]" ORDER="682" O_E="0.0" SE="0.01831485674484316" STUDY_ID="STD-Kranzler-2004" TOTAL_1="167" TOTAL_2="166" VAR="3.35433977584127E-4" WEIGHT="50.09609164171872"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.03693194305593436" CI_END="0.4249981336571611" CI_START="0.01820293801921824" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.22160053583818967" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-002.05" LOG_CI_END="-0.3716129771124555" LOG_CI_START="-1.7398585096766852" LOG_EFFECT_SIZE="-0.6544291938024183" METHOD="MH" MODIFIED="2010-10-08 15:25:14 +0200" MODIFIED_BY="Laura Amato" NO="5" P_CHI2="0.847603748635567" P_Q="0.0" P_Z="0.03273082295865318" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="40" TOTAL_2="10" WEIGHT="100.0" Z="2.1353697086638763">
<NAME>Side effect: Daytime sleepiness</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.5167856388460081" CI_START="-0.036785638846008106" EFFECT_SIZE="0.24" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 08:44:55 +0200" MODIFIED_BY="[Empty name]" ORDER="685" O_E="0.0" SE="0.14121975762272057" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" VAR="0.019943019943019943" WEIGHT="54.001339595474256"/>
<DICH_DATA CI_END="0.49989776378562273" CI_START="-0.0998977637856227" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 08:45:20 +0200" MODIFIED_BY="[Empty name]" ORDER="686" O_E="0.0" SE="0.15301187478503583" STUDY_ID="STD-Kranzler-1998" TOTAL_1="15" TOTAL_2="5" VAR="0.023412633825231483" WEIGHT="45.99866040452574"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7212414342696944" CI_END="0.10803283472655988" CI_START="0.044081274350630154" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.07605705453859501" ESTIMABLE="YES" EVENTS_1="41" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.06" LOG_CI_END="-0.9664442280935314" LOG_CI_START="-1.3557458589056628" LOG_EFFECT_SIZE="-1.1188604975203378" METHOD="MH" MODIFIED="2010-10-11 16:50:14 +0200" MODIFIED_BY="Laura Amato" NO="6" P_CHI2="0.39573702261509036" P_Q="0.0" P_Z="3.132463799258297E-6" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="440" TOTAL_2="214" WEIGHT="100.0" Z="4.66193746609354">
<NAME>Side effect: Decreased appetite</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.1093061033801852" CI_START="0.04511829276900484" EFFECT_SIZE="0.07721219807459502" ESTIMABLE="YES" EVENTS_1="38" EVENTS_2="3" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 08:46:31 +0200" MODIFIED_BY="[Empty name]" ORDER="687" O_E="0.0" SE="0.016374742372177654" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="2.6813218775519033E-4" WEIGHT="99.2652328825961"/>
<DICH_DATA CI_END="0.2930321759859651" CI_START="-0.4530321759859651" EFFECT_SIZE="-0.08000000000000002" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 08:46:40 +0200" MODIFIED_BY="[Empty name]" ORDER="688" O_E="0.0" SE="0.19032603605392512" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" VAR="0.036224" WEIGHT="0.7347671174039021"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3903972202217144" CI_END="0.11871527378647509" CI_START="0.03816768097941553" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.07844147738294531" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-002.07" LOG_CI_END="-0.9254934015639646" LOG_CI_START="-1.4183042264391343" LOG_EFFECT_SIZE="-1.1054542353354804" METHOD="MH" MODIFIED="2010-10-11 16:50:14 +0200" MODIFIED_BY="Laura Amato" NO="7" P_CHI2="0.5320910486629752" P_Q="0.0" P_Z="1.3484805317595194E-4" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="440" TOTAL_2="214" WEIGHT="100.0" Z="3.817431786768713">
<NAME>Side effect: Dizziness</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.12029800217534456" CI_START="0.03929155221446348" EFFECT_SIZE="0.07979477719490402" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="8" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 08:48:47 +0200" MODIFIED_BY="[Empty name]" ORDER="690" O_E="0.0" SE="0.020665290433867563" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="4.2705422871609815E-4" WEIGHT="98.8703181861118"/>
<DICH_DATA CI_END="0.3389173589085932" CI_START="-0.4189173589085933" EFFECT_SIZE="-0.04000000000000001" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 08:49:00 +0200" MODIFIED_BY="[Empty name]" ORDER="691" O_E="0.0" SE="0.19332873557751315" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" VAR="0.037376" WEIGHT="1.1296818138881954"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.6778874910480905" CI_END="0.09711283933303792" CI_START="0.013049541600471448" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.055081190466754686" ESTIMABLE="YES" EVENTS_1="94" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-002.08" LOG_CI_END="-1.012723348023331" LOG_CI_START="-1.8844047437956104" LOG_EFFECT_SIZE="-1.2589966819308125" METHOD="MH" MODIFIED="2010-10-08 15:25:14 +0200" MODIFIED_BY="Laura Amato" NO="8" P_CHI2="0.4103154613686444" P_Q="0.0" P_Z="0.010214770937543137" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="582" TOTAL_2="375" WEIGHT="100.0" Z="2.5684728639573016">
<NAME>Side effect: Fatigue</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.1269835451758224" CI_START="0.014366544176803428" EFFECT_SIZE="0.0706750446763129" ESTIMABLE="YES" EVENTS_1="75" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 08:50:55 +0200" MODIFIED_BY="[Empty name]" ORDER="693" O_E="0.0" SE="0.02872935469409833" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="8.253758211393098E-4" WEIGHT="55.719207439312044"/>
<DICH_DATA CI_END="0.09862307259647689" CI_START="-0.02770466844093257" EFFECT_SIZE="0.03545920207777216" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="13" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 08:51:04 +0200" MODIFIED_BY="[Empty name]" ORDER="694" O_E="0.0" SE="0.03222705673008957" STUDY_ID="STD-Kranzler-2004" TOTAL_1="167" TOTAL_2="166" VAR="0.0010385831854844113" WEIGHT="44.280792560687956"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.31206257277958876" CI_END="0.07700215782905259" CI_START="-0.02215562917475358" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RD" EFFECT_SIZE="0.027423264327149508" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="68" I2="0.0" I2_Q="0.0" ID="CMP-002.09" LOG_CI_END="-1.1134971044363535" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.5618808502435115" METHOD="MH" MODIFIED="2010-10-08 15:25:14 +0200" MODIFIED_BY="Laura Amato" NO="9" P_CHI2="0.9577441026797338" P_Q="0.0" P_Z="0.2783192994086331" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="622" TOTAL_2="385" WEIGHT="99.99999999999999" Z="1.0841026619053515">
<NAME>Side effect: Headache</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.08785384768117906" CI_START="-0.037309084897988856" EFFECT_SIZE="0.0252723813915951" ESTIMABLE="YES" EVENTS_1="78" EVENTS_2="34" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 08:52:37 +0200" MODIFIED_BY="[Empty name]" ORDER="699" O_E="0.0" SE="0.031929906255022324" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="0.001019518913454514" WEIGHT="62.76278276263781"/>
<DICH_DATA CI_END="0.5154272876744013" CI_START="-0.27542728767440133" EFFECT_SIZE="0.12" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 08:52:50 +0200" MODIFIED_BY="[Empty name]" ORDER="696" O_E="0.0" SE="0.20175232340669588" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" VAR="0.040704000000000004" WEIGHT="1.5720284023080333"/>
<DICH_DATA CI_END="0.32992667741821347" CI_START="-0.19659334408488016" EFFECT_SIZE="0.06666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 08:53:00 +0200" MODIFIED_BY="[Empty name]" ORDER="697" O_E="0.0" SE="0.13431880015556824" STUDY_ID="STD-Kranzler-1998" TOTAL_1="15" TOTAL_2="5" VAR="0.018041540075231483" WEIGHT="3.5466952278310533"/>
<DICH_DATA CI_END="0.11024381481087862" CI_START="-0.06472040380157194" EFFECT_SIZE="0.02276170550465334" ESTIMABLE="YES" EVENTS_1="37" EVENTS_2="33" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 08:53:14 +0200" MODIFIED_BY="[Empty name]" ORDER="698" O_E="0.0" SE="0.04463454940818964" STUDY_ID="STD-Kranzler-2004" TOTAL_1="167" TOTAL_2="166" VAR="0.0019922430008721217" WEIGHT="32.118493607223094"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.15440584841020014" CI_END="0.06876510398576655" CI_START="-0.03847908829678937" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.015143007844488585" ESTIMABLE="YES" EVENTS_1="56" EVENTS_2="25" I2="0.0" I2_Q="0.0" ID="CMP-002.10" LOG_CI_END="-1.162631895938025" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.8197878526746851" METHOD="MH" MODIFIED="2010-10-08 15:25:14 +0200" MODIFIED_BY="Laura Amato" NO="10" P_CHI2="0.6943602103307078" P_Q="0.0" P_Z="0.5799221072368022" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="430" TOTAL_2="214" WEIGHT="100.0" Z="0.5534985039489693">
<NAME>Side effect: Insomnia</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.06768316886787376" CI_START="-0.04185737766478386" EFFECT_SIZE="0.012912895601544946" ESTIMABLE="YES" EVENTS_1="55" EVENTS_2="25" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 08:54:39 +0200" MODIFIED_BY="[Empty name]" ORDER="700" O_E="0.0" SE="0.027944530459921575" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="7.808967826254847E-4" WEIGHT="95.85124504057232"/>
<DICH_DATA CI_END="0.32992667741821347" CI_START="-0.19659334408488016" EFFECT_SIZE="0.06666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 08:54:49 +0200" MODIFIED_BY="[Empty name]" ORDER="701" O_E="0.0" SE="0.13431880015556824" STUDY_ID="STD-Kranzler-1998" TOTAL_1="15" TOTAL_2="5" VAR="0.018041540075231483" WEIGHT="4.148754959427682"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.135461215892837" CI_END="0.14278237228657317" CI_START="-0.027133602426096214" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RD" EFFECT_SIZE="0.05782438493023848" ESTIMABLE="YES" EVENTS_1="174" EVENTS_2="124" I2="41.5826568660313" I2_Q="0.0" ID="CMP-002.11" LOG_CI_END="-0.8453254066440631" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-1.2378889780614342" METHOD="MH" MODIFIED="2010-10-08 15:25:14 +0200" MODIFIED_BY="Laura Amato" NO="11" P_CHI2="0.16214276413052708" P_Q="0.0" P_Z="0.18220479485386554" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0028770193475966834" TOTALS="YES" TOTAL_1="622" TOTAL_2="385" WEIGHT="100.0" Z="1.3339971369154335">
<NAME>Side effect: Injection pain</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.05888605238114977" CI_START="-0.038294595645114726" EFFECT_SIZE="0.010295728368017523" ESTIMABLE="YES" EVENTS_1="42" EVENTS_2="19" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 08:56:09 +0200" MODIFIED_BY="[Empty name]" ORDER="703" O_E="0.0" SE="0.024791437187829227" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="6.14615357838082E-4" WEIGHT="53.812534516716426"/>
<DICH_DATA CI_END="0.42467604254355296" CI_START="-0.10467604254355292" EFFECT_SIZE="0.16" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 08:56:09 +0200" MODIFIED_BY="[Empty name]" ORDER="704" O_E="0.0" SE="0.1350412786312829" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" VAR="0.018236146934371786" WEIGHT="8.899362160873162"/>
<DICH_DATA CI_END="0.42455683077684775" CI_START="-0.5578901641101812" EFFECT_SIZE="-0.06666666666666671" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 08:56:09 +0200" MODIFIED_BY="[Empty name]" ORDER="705" O_E="0.0" SE="0.2506288387532744" STUDY_ID="STD-Kranzler-1998" TOTAL_1="15" TOTAL_2="5" VAR="0.06281481481481482" WEIGHT="2.860229364907656"/>
<DICH_DATA CI_END="0.2156101269708158" CI_START="0.01647990982306627" EFFECT_SIZE="0.11604501839694104" ESTIMABLE="YES" EVENTS_1="123" EVENTS_2="103" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 08:56:09 +0200" MODIFIED_BY="[Empty name]" ORDER="706" O_E="0.0" SE="0.050799458234555145" STUDY_ID="STD-Kranzler-2004" TOTAL_1="167" TOTAL_2="166" VAR="0.0025805849569243127" WEIGHT="34.42787395750275"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="2.0841999798515207" CI_END="0.049164215050885834" CI_START="-0.07559334535042005" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.013214565149767103" ESTIMABLE="YES" EVENTS_1="69" EVENTS_2="47" I2="52.019959232931164" I2_Q="0.0" ID="CMP-002.12" LOG_CI_END="-1.3083508903326315" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-10-08 15:25:14 +0200" MODIFIED_BY="Laura Amato" NO="12" P_CHI2="0.14883022599659312" P_Q="0.0" P_Z="0.6779907799448451" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.001066659891433291" TOTALS="YES" TOTAL_1="582" TOTAL_2="375" WEIGHT="100.00000000000001" Z="0.4152064481156777">
<NAME>Side effect: Nasopharyngitis</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.06928804968836724" CI_START="-0.0387121576032805" EFFECT_SIZE="0.015287946042543368" ESTIMABLE="YES" EVENTS_1="54" EVENTS_2="24" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 09:00:35 +0200" MODIFIED_BY="[Empty name]" ORDER="709" O_E="0.0" SE="0.027551579555425403" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="7.590895359989351E-4" WEIGHT="55.479993413387106"/>
<DICH_DATA CI_END="0.019402864572753434" CI_START="-0.11687057974481894" EFFECT_SIZE="-0.048733857586032756" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 09:00:35 +0200" MODIFIED_BY="[Empty name]" ORDER="710" O_E="0.0" SE="0.034764272556148966" STUDY_ID="STD-Kranzler-2004" TOTAL_1="167" TOTAL_2="166" VAR="0.0012085546463582123" WEIGHT="44.52000658661291"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.875388718426679" CI_END="0.21545949555978572" CI_START="-0.00554263719038324" CI_STUDY="95" CI_TOTAL="95" DF="3" EFFECT_MEASURE="RD" EFFECT_SIZE="0.10495842918470123" ESTIMABLE="YES" EVENTS_1="153" EVENTS_2="41" I2="69.62144898253734" I2_Q="0.0" ID="CMP-002.13" LOG_CI_END="-0.6666343612723216" LOG_CI_START="NaN" LOG_EFFECT_SIZE="-0.9789826776018107" METHOD="MH" MODIFIED="2010-10-08 15:25:14 +0200" MODIFIED_BY="Laura Amato" NO="13" P_CHI2="0.019655655460912747" P_Q="0.0" P_Z="0.06265189066347202" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.00678411105184795" TOTALS="YES" TOTAL_1="622" TOTAL_2="385" WEIGHT="100.0" Z="1.8616538991364544">
<NAME>Side effect: Nausea</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.24244535469068648" CI_START="0.12059148164989111" EFFECT_SIZE="0.1815184181702888" ESTIMABLE="YES" EVENTS_1="121" EVENTS_2="23" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 09:01:14 +0200" MODIFIED_BY="[Empty name]" ORDER="711" O_E="0.0" SE="0.031085742901901043" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="9.663234117630911E-4" WEIGHT="41.011977264368085"/>
<DICH_DATA CI_END="0.5154272876744013" CI_START="-0.27542728767440133" EFFECT_SIZE="0.12" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 09:01:23 +0200" MODIFIED_BY="[Empty name]" ORDER="712" O_E="0.0" SE="0.20175232340669588" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" VAR="0.040704000000000004" WEIGHT="6.693478324786339"/>
<DICH_DATA CI_END="0.32992667741821347" CI_START="-0.19659334408488016" EFFECT_SIZE="0.06666666666666667" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 09:01:33 +0200" MODIFIED_BY="[Empty name]" ORDER="713" O_E="0.0" SE="0.13431880015556824" STUDY_ID="STD-Kranzler-1998" TOTAL_1="15" TOTAL_2="5" VAR="0.018041540075231483" WEIGHT="12.803718234156342"/>
<DICH_DATA CI_END="0.10502086469060119" CI_START="-0.03439104000262773" EFFECT_SIZE="0.03531491234398673" ESTIMABLE="YES" EVENTS_1="23" EVENTS_2="17" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 09:01:41 +0200" MODIFIED_BY="[Empty name]" ORDER="714" O_E="0.0" SE="0.03556491491499136" STUDY_ID="STD-Kranzler-2004" TOTAL_1="167" TOTAL_2="166" VAR="0.0012648631729105745" WEIGHT="39.49082617668923"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.057453137385959856" CI_END="3.301941947616051E-4" CI_START="-0.046206754190528984" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.02293827999788369" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="20" I2="0.0" I2_Q="0.0" ID="CMP-002.14" LOG_CI_END="-3.481230566461365" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-10-08 15:25:14 +0200" MODIFIED_BY="Laura Amato" NO="14" P_CHI2="0.9716821441871512" P_Q="0.0" P_Z="0.05334088708074229" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="597" TOTAL_2="380" WEIGHT="100.0" Z="1.9321508703547887">
<NAME>Side effect: Serious adverse events</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.019687629847361422" CI_START="-0.06202348042671232" EFFECT_SIZE="-0.021167925289675447" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="15" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 09:03:10 +0200" MODIFIED_BY="[Empty name]" ORDER="715" O_E="0.0" SE="0.020845054021043384" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="4.34516277140217E-4" WEIGHT="32.436469622928946"/>
<DICH_DATA CI_END="0.23701444482849598" CI_START="-0.23701444482849598" EFFECT_SIZE="0.0" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 09:03:18 +0200" MODIFIED_BY="[Empty name]" ORDER="716" O_E="0.0" SE="0.1209279592370246" STUDY_ID="STD-Kranzler-1998" TOTAL_1="15" TOTAL_2="5" VAR="0.01462357132523148" WEIGHT="0.9637983575057867"/>
<DICH_DATA CI_END="0.0043798034876758735" CI_START="-0.052644719438905946" EFFECT_SIZE="-0.024132457975615036" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 09:03:30 +0200" MODIFIED_BY="[Empty name]" ORDER="717" O_E="0.0" SE="0.014547339485925246" STUDY_ID="STD-Kranzler-2004" TOTAL_1="167" TOTAL_2="166" VAR="2.1162508611875978E-4" WEIGHT="66.59973201956527"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.18286492292936948" CI_END="0.10851574798389779" CI_START="0.02091919278517229" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.06471747038453504" ESTIMABLE="YES" EVENTS_1="53" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-002.15" LOG_CI_END="-0.9645072317120287" LOG_CI_START="-1.6794550777258461" LOG_EFFECT_SIZE="-1.1889784663572793" METHOD="MH" MODIFIED="2010-10-08 15:25:14 +0200" MODIFIED_BY="Laura Amato" NO="15" P_CHI2="0.6689226503887116" P_Q="0.0" P_Z="0.0037783969355641134" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="440" TOTAL_2="214" WEIGHT="100.0" Z="2.896093592640999">
<NAME>Side effect: Vomiting</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.10751345511418404" CI_START="0.018617864422335248" EFFECT_SIZE="0.06306565976825965" ESTIMABLE="YES" EVENTS_1="50" EVENTS_2="12" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 09:05:18 +0200" MODIFIED_BY="[Empty name]" ORDER="719" O_E="0.0" SE="0.02267786331612363" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="5.142854845847859E-4" WEIGHT="97.0987446072932"/>
<DICH_DATA CI_END="0.3771366914144906" CI_START="-0.13713669141449059" EFFECT_SIZE="0.12" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 09:05:32 +0200" MODIFIED_BY="[Empty name]" ORDER="720" O_E="0.0" SE="0.1311946002287552" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" VAR="0.017212023129182893" WEIGHT="2.901255392706806"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.12112175953055918" CI_END="2.6922909381389983" CI_START="0.9168339057784248" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.5711090402342662" ESTIMABLE="YES" EVENTS_1="49" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-002.16" LOG_CI_END="0.43012198943048213" LOG_CI_START="-0.03770933427263409" LOG_EFFECT_SIZE="0.196206327578924" METHOD="MH" MODIFIED="2010-10-08 15:25:14 +0200" MODIFIED_BY="Laura Amato" NO="16" P_CHI2="0.9412364714737588" P_Q="0.0" P_Z="0.10017621340308407" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="598" TOTAL_2="371" WEIGHT="100.0" Z="1.6439999466029667">
<NAME>Drop-outs due to adverse events</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.761932854593442" CI_START="0.866291598185907" EFFECT_SIZE="1.546815834767642" ESTIMABLE="YES" EVENTS_1="43" EVENTS_2="14" LOG_CI_END="0.4412131162288486" LOG_CI_START="-0.062335897628229046" LOG_EFFECT_SIZE="0.18943860930030978" ORDER="728" O_E="0.0" SE="0.29578718334746623" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="0.08749005783262762" WEIGHT="86.31675275816161"/>
<DICH_DATA CI_END="21.048031282871733" CI_START="0.06325346674246843" EFFECT_SIZE="1.1538461538461537" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.3232114805531539" LOG_CI_START="-1.1989156670554648" LOG_EFFECT_SIZE="0.062147906748844434" ORDER="724" O_E="0.0" SE="1.4815099712360342" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="5" VAR="2.194871794871795" WEIGHT="3.44068282638681"/>
<DICH_DATA CI_END="10.69467252110128" CI_START="0.36929857473870065" EFFECT_SIZE="1.9873417721518987" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.0291674906881818" LOG_CI_START="-0.43262236845059726" LOG_EFFECT_SIZE="0.2982725611187923" ORDER="740" O_E="0.0" SE="0.858662599234622" STUDY_ID="STD-Kranzler-2004" TOTAL_1="158" TOTAL_2="157" VAR="0.737301459324357" WEIGHT="10.242564415451579"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.6953387310953287" CI_END="1.4021890947748124" CI_START="0.6814145893663632" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.977482534999972" ESTIMABLE="YES" EVENTS_1="204" EVENTS_2="121" I2="45.87776262104168" I2_Q="0.0" ID="CMP-002.17" LOG_CI_END="0.1468065851567436" LOG_CI_START="-0.16658857224528187" LOG_EFFECT_SIZE="-0.009890993544269124" METHOD="MH" MODIFIED="2010-10-08 15:25:14 +0200" MODIFIED_BY="Laura Amato" NO="17" P_CHI2="0.1576041412059198" P_Q="0.0" P_Z="0.901540175830275" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.045708877558568416" TOTALS="YES" TOTAL_1="598" TOTAL_2="381" WEIGHT="100.0" Z="0.12371595833701554">
<NAME>Drop-out</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.2624898453859135" CI_START="0.8336165646561822" EFFECT_SIZE="1.0258813029897367" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="81" LOG_CI_END="0.1012278936337885" LOG_CI_START="-0.07903366416535294" LOG_EFFECT_SIZE="0.011097114734217806" MODIFIED="2010-01-10 14:12:44 +0100" MODIFIED_BY="[Empty name]" ORDER="1213" O_E="0.0" SE="0.10588653136031777" STUDY_ID="STD-Garbutt-2005" TOTAL_1="415" TOTAL_2="209" VAR="0.011211957523519559" WEIGHT="59.53721340440331"/>
<DICH_DATA CI_END="34.69045716809552" CI_START="0.6641595954863826" EFFECT_SIZE="4.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="1" LOG_CI_END="1.5402100232284224" LOG_CI_START="-0.17772754847724784" LOG_EFFECT_SIZE="0.6812412373755872" MODIFIED="2010-01-10 14:13:53 +0100" MODIFIED_BY="[Empty name]" ORDER="1214" O_E="0.0" SE="1.0091250335480402" STUDY_ID="STD-Johnson-2004" TOTAL_1="25" TOTAL_2="15" VAR="1.0183333333333333" WEIGHT="3.184937468409705"/>
<DICH_DATA CI_END="1.198143076877216" CI_START="0.5206796711359201" EFFECT_SIZE="0.7898409607270367" ESTIMABLE="YES" EVENTS_1="31" EVENTS_2="39" LOG_CI_END="0.07850868265097573" LOG_CI_START="-0.28342937812580654" LOG_EFFECT_SIZE="-0.1024603477374154" MODIFIED="2010-01-10 14:14:06 +0100" MODIFIED_BY="[Empty name]" ORDER="1215" O_E="0.0" SE="0.21260420852257766" STUDY_ID="STD-Kranzler-2004" TOTAL_1="158" TOTAL_2="157" VAR="0.045200549481511684" WEIGHT="37.27784912718698"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2010-10-08 15:26:20 +0200" MODIFIED_BY="Laura Amato" NO="3">
<NAME>NTX versus ACAM</NAME>
<DICH_OUTCOME CHI2="1.0499459190522744" CI_END="1.0553517363218363" CI_START="0.8732298901522044" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9599816043968006" ESTIMABLE="YES" EVENTS_1="266" EVENTS_2="276" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="0.023397229003142946" LOG_CI_START="-0.058871407060476465" LOG_EFFECT_SIZE="-0.01773708902866676" METHOD="MH" MODIFIED="2010-01-10 17:10:10 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.5915714503709817" P_Q="0.0" P_Z="0.39803542531462444" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="402" TOTAL_2="398" WEIGHT="100.0" Z="0.8451350927924431">
<NAME>Return to heavy drinking</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Acamprosate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0716555834272392" CI_START="0.863552702125261" EFFECT_SIZE="0.9619932821055538" ESTIMABLE="YES" EVENTS_1="207" EVENTS_2="211" LOG_CI_END="0.030055231018386863" LOG_CI_START="-0.06371115254499596" LOG_EFFECT_SIZE="-0.01682796076330453" MODIFIED="2009-05-20 15:20:58 +0200" MODIFIED_BY="[Empty name]" ORDER="843" O_E="0.0" SE="0.05507883785621547" STUDY_ID="STD-Anton-2006" TOTAL_1="309" TOTAL_2="303" VAR="0.003033678379591275" WEIGHT="76.97935394595127"/>
<DICH_DATA CI_END="1.1839416410505663" CI_START="0.5405671849096366" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="25" LOG_CI_END="0.0733302956349148" LOG_CI_START="-0.26715032165102753" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2009-05-20 15:20:58 +0200" MODIFIED_BY="[Empty name]" ORDER="844" O_E="0.0" SE="0.2" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.04" WEIGHT="5.838265043518417"/>
<DICH_DATA CI_END="1.271527983892217" CI_START="0.8051132028336916" EFFECT_SIZE="1.0117924528301887" ESTIMABLE="YES" EVENTS_1="39" EVENTS_2="40" LOG_CI_END="0.10432592260550372" LOG_CI_START="-0.09414305142152052" LOG_EFFECT_SIZE="0.005091435591991627" MODIFIED="2009-05-20 15:20:58 +0200" MODIFIED_BY="[Empty name]" ORDER="845" O_E="0.0" SE="0.11658165778074" STUDY_ID="STD-Morley-2006" TOTAL_1="53" TOTAL_2="55" VAR="0.013591282930905578" WEIGHT="17.182381010530307"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.1347399583361346" CI_END="1.044751331005902" CI_START="0.9053557711206759" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9725593282222946" ESTIMABLE="YES" EVENTS_1="311" EVENTS_2="318" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.019012933104153987" LOG_CI_START="-0.04318072568725605" LOG_EFFECT_SIZE="-0.012083896291551006" METHOD="MH" MODIFIED="2010-01-10 17:10:10 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.5670149010713396" P_Q="0.0" P_Z="0.4462861819614845" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="402" TOTAL_2="398" WEIGHT="100.0" Z="0.7616211036495026">
<NAME>Return to any drinking</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Acamprosate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0503216948317202" CI_START="0.8931006275229678" EFFECT_SIZE="0.9685261817603056" ESTIMABLE="YES" EVENTS_1="241" EVENTS_2="244" LOG_CI_END="0.02132233611060587" LOG_CI_START="-0.049099605483387244" LOG_EFFECT_SIZE="-0.013888634686390674" MODIFIED="2009-06-08 10:43:02 +0200" MODIFIED_BY="[Empty name]" ORDER="610" O_E="0.0" SE="0.04136619708654452" STUDY_ID="STD-Anton-2006" TOTAL_1="309" TOTAL_2="303" VAR="0.0017111622614028443" WEIGHT="77.99669919283696"/>
<DICH_DATA CI_END="1.157485906863749" CI_START="0.6489159882268238" EFFECT_SIZE="0.8666666666666667" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="30" LOG_CI_END="0.06351571190721124" LOG_CI_START="-0.18781152540490018" LOG_EFFECT_SIZE="-0.06214790674884446" MODIFIED="2009-05-20 15:07:11 +0200" MODIFIED_BY="[Empty name]" ORDER="841" O_E="0.0" SE="0.14763086328702338" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.021794871794871787" WEIGHT="6.123688610280142"/>
<DICH_DATA CI_END="1.2420040991669306" CI_START="0.8670629131897021" EFFECT_SIZE="1.0377358490566038" ESTIMABLE="YES" EVENTS_1="44" EVENTS_2="44" LOG_CI_END="0.09412302920822688" LOG_CI_START="-0.06194938942131723" LOG_EFFECT_SIZE="0.016086819893454795" MODIFIED="2009-05-20 15:07:11 +0200" MODIFIED_BY="[Empty name]" ORDER="842" O_E="0.0" SE="0.09167771127392628" STUDY_ID="STD-Morley-2006" TOTAL_1="53" TOTAL_2="55" VAR="0.008404802744425389" WEIGHT="15.879612196882903"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.8238510211722057" CI_END="13.417683677635663" CI_START="-7.4523674783704426" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="2.98265809963261" ESTIMABLE="YES" I2="64.58736695022631" I2_Q="0.0" ID="CMP-003.03" MODIFIED="2010-01-29 11:21:03 +0100" MODIFIED_BY="[Empty name]" NO="3" P_CHI2="0.09287343991393637" P_Q="1.0" P_Z="0.5753298845275775" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="39.78904740968688" TOTALS="YES" TOTAL_1="362" TOTAL_2="358" UNITS="" WEIGHT="100.0" Z="0.560219273999645">
<NAME>Drinking days</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Acamprosate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="3.1198692361256146" CI_START="-5.119869236125615" EFFECT_SIZE="-1.0" ESTIMABLE="YES" MEAN_1="22.1" MEAN_2="23.1" MODIFIED="2009-05-20 15:25:38 +0200" MODIFIED_BY="[Empty name]" ORDER="848" SD_1="26.1" SD_2="25.9" SE="2.102012725041183" STUDY_ID="STD-Anton-2006" TOTAL_1="309" TOTAL_2="303" WEIGHT="64.1201973006071"/>
<CONT_DATA CI_END="22.373420244456376" CI_START="-2.1734202444563824" EFFECT_SIZE="10.099999999999998" ESTIMABLE="YES" MEAN_1="31.2" MEAN_2="21.1" MODIFIED="2010-01-10 19:06:37 +0100" MODIFIED_BY="[Empty name]" ORDER="849" SD_1="34.8" SD_2="30.0" SE="6.262064171213121" STUDY_ID="STD-Morley-2006" TOTAL_1="53" TOTAL_2="55" WEIGHT="35.87980269939289"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.71415901263327" CI_END="-0.20499114400458165" CI_START="-0.3413397787756186" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="-0.2731654613901001" ESTIMABLE="YES" EVENTS_1="115" EVENTS_2="212" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="NaN" LOG_CI_START="NaN" LOG_EFFECT_SIZE="NaN" METHOD="MH" MODIFIED="2010-10-08 15:26:20 +0200" MODIFIED_BY="Laura Amato" NO="4" P_CHI2="0.3980670546302837" P_Q="0.0" P_Z="4.051786639898773E-15" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="362" TOTAL_2="358" WEIGHT="100.0" Z="7.853316126617956">
<NAME>Side-effect: Diarrhea</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Acamprosate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="-0.21156674551789711" CI_START="-0.36333152100778465" EFFECT_SIZE="-0.2874491332628409" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="193" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-22 11:25:37 +0200" MODIFIED_BY="[Empty name]" ORDER="1007" O_E="0.0" SE="0.03871621537104475" STUDY_ID="STD-Anton-2006" TOTAL_1="309" TOTAL_2="303" VAR="0.0014989453326571215" WEIGHT="80.71599784322446"/>
<DICH_DATA CI_END="-0.05813243271086585" CI_START="-0.3686257148019987" EFFECT_SIZE="-0.21337907375643225" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="19" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-22 11:26:58 +0200" MODIFIED_BY="[Empty name]" ORDER="1009" O_E="0.0" SE="0.0792089254037993" STUDY_ID="STD-Morley-2006" TOTAL_1="53" TOTAL_2="55" VAR="0.006274053863624642" WEIGHT="19.28400215677555"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.19442953620342276" CI_END="0.13314180453645086" CI_START="0.02716605412066138" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RD" EFFECT_SIZE="0.08015392932855613" ESTIMABLE="YES" EVENTS_1="113" EVENTS_2="78" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="-0.8756855611374498" LOG_CI_START="-1.565973438434257" LOG_EFFECT_SIZE="-1.0960751826812536" METHOD="MH" MODIFIED="2010-10-08 15:26:20 +0200" MODIFIED_BY="Laura Amato" NO="5" P_CHI2="0.9073611797143534" P_Q="0.0" P_Z="0.0030287303639824283" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="402" TOTAL_2="398" WEIGHT="100.0" Z="2.9648068371673904">
<NAME>Side-effect: Nausea</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Acamprosate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.1601740090055964" CI_START="0.01830014908982483" EFFECT_SIZE="0.08923707904771061" ESTIMABLE="YES" EVENTS_1="101" EVENTS_2="72" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-22 11:29:42 +0200" MODIFIED_BY="[Empty name]" ORDER="1014" O_E="0.0" SE="0.03619297625743495" STUDY_ID="STD-Anton-2006" TOTAL_1="309" TOTAL_2="303" VAR="0.0013099315303712502" WEIGHT="55.79666372968207"/>
<DICH_DATA CI_END="0.17980539735825762" CI_START="-0.029805397358257588" EFFECT_SIZE="0.07500000000000001" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-10 20:33:54 +0100" MODIFIED_BY="[Empty name]" ORDER="1216" O_E="0.0" SE="0.053473124090518596" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.002859375" WEIGHT="25.561463294962174"/>
<DICH_DATA CI_END="0.18275893565887893" CI_START="-0.06269032502423058" EFFECT_SIZE="0.06003430531732418" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-22 11:30:02 +0200" MODIFIED_BY="[Empty name]" ORDER="1016" O_E="0.0" SE="0.06261575789636492" STUDY_ID="STD-Morley-2006" TOTAL_1="53" TOTAL_2="55" VAR="0.0039207331369361855" WEIGHT="18.641872975355756"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.7192752946276761" CI_END="0.1266875950944814" CI_START="0.01481132294619221" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.07074945902033682" ESTIMABLE="YES" EVENTS_1="117" EVENTS_2="94" I2="0.0" I2_Q="0.0" ID="CMP-003.06" LOG_CI_END="-0.8972659079718511" LOG_CI_START="-1.8294061485975581" LOG_EFFECT_SIZE="-1.1502768765864393" METHOD="MH" MODIFIED="2010-10-08 15:26:20 +0200" MODIFIED_BY="Laura Amato" NO="6" P_CHI2="0.3963817527914012" P_Q="0.0" P_Z="0.013177935811232985" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="362" TOTAL_2="358" WEIGHT="100.00000000000001" Z="2.47892406392937">
<NAME>Side-effect: Somnolence</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Acamprosate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.1269664084323465" CI_START="-0.02250936078583418" EFFECT_SIZE="0.05222852382325616" ESTIMABLE="YES" EVENTS_1="112" EVENTS_2="94" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-22 11:31:48 +0200" MODIFIED_BY="[Empty name]" ORDER="1019" O_E="0.0" SE="0.03813227446963987" STUDY_ID="STD-Anton-2006" TOTAL_1="309" TOTAL_2="303" VAR="0.0014540703562279486" WEIGHT="56.01887455605254"/>
<DICH_DATA CI_END="0.17868762894984083" CI_START="0.00999161633317805" EFFECT_SIZE="0.09433962264150944" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-22 11:31:58 +0200" MODIFIED_BY="[Empty name]" ORDER="1020" O_E="0.0" SE="0.043035487883276276" STUDY_ID="STD-Morley-2006" TOTAL_1="53" TOTAL_2="55" VAR="0.0018520532173516193" WEIGHT="43.98112544394748"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="5.334043122070237E-4" CI_END="2.7285826130037134" CI_START="0.6329158935962524" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.3141397576971952" ESTIMABLE="YES" EVENTS_1="16" EVENTS_2="12" I2="0.0" I2_Q="0.0" ID="CMP-003.07" LOG_CI_END="0.4359371074057684" LOG_CI_START="-0.19865399831426284" LOG_EFFECT_SIZE="0.11864155454575279" METHOD="MH" MODIFIED="2010-10-08 15:26:20 +0200" MODIFIED_BY="Laura Amato" NO="7" P_CHI2="0.9815740577066139" P_Q="0.0" P_Z="0.46364391378186387" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="402" TOTAL_2="398" WEIGHT="100.0" Z="0.7328598585247387">
<NAME>Drop-out due to adverse events</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Acamprosate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="3.0577687289073987" CI_START="0.5590377513974865" EFFECT_SIZE="1.307443365695793" ESTIMABLE="YES" EVENTS_1="12" EVENTS_2="9" LOG_CI_END="0.48540463491620583" LOG_CI_START="-0.2525588635446652" LOG_EFFECT_SIZE="0.11642288568577032" MODIFIED="2009-05-20 15:34:56 +0200" MODIFIED_BY="[Empty name]" ORDER="856" O_E="0.0" SE="0.4334834119741476" STUDY_ID="STD-Anton-2006" TOTAL_1="309" TOTAL_2="303" VAR="0.18790786845674856" WEIGHT="73.94659817126762"/>
<DICH_DATA CI_END="5.579155313499883" CI_START="0.31864640395941085" EFFECT_SIZE="1.3333333333333333" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="3" LOG_CI_END="0.74656845154428" LOG_CI_START="-0.49669097832768017" LOG_EFFECT_SIZE="0.12493873660829993" MODIFIED="2009-05-20 15:34:56 +0200" MODIFIED_BY="[Empty name]" ORDER="857" O_E="0.0" SE="0.7302967433402214" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.5333333333333332" WEIGHT="26.053401828732383"/>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="0" EVENTS_2="0" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-05-20 15:34:56 +0200" MODIFIED_BY="[Empty name]" ORDER="858" O_E="0.0" SE="0.0" STUDY_ID="STD-Morley-2006" TOTAL_1="53" TOTAL_2="55" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.6091273451932488" CI_END="1.0953115801925986" CI_START="0.7650015801372051" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9153770204620153" ESTIMABLE="YES" EVENTS_1="143" EVENTS_2="153" I2="0.0" I2_Q="0.0" ID="CMP-003.08" LOG_CI_END="0.039537679276400846" LOG_CI_START="-0.11633766779519274" LOG_EFFECT_SIZE="-0.038399994259395984" METHOD="MH" MODIFIED="2010-10-08 15:26:20 +0200" MODIFIED_BY="Laura Amato" NO="8" P_CHI2="0.4472832350715339" P_Q="0.0" P_Z="0.33420592766607726" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="402" TOTAL_2="398" WEIGHT="100.0" Z="0.9656768330452259">
<NAME>Drop-out</NAME>
<GROUP_LABEL_1>Naltrexone</GROUP_LABEL_1>
<GROUP_LABEL_2>Acamprosate</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1248830352359829" CI_START="0.7409560758391901" EFFECT_SIZE="0.9129561432875795" ESTIMABLE="YES" EVENTS_1="108" EVENTS_2="116" LOG_CI_END="0.051107367076333135" LOG_CI_START="-0.13020753640133" LOG_EFFECT_SIZE="-0.03955008466249843" MODIFIED="2009-05-20 15:33:50 +0200" MODIFIED_BY="[Empty name]" ORDER="853" O_E="0.0" SE="0.1065052718260266" STUDY_ID="STD-Anton-2006" TOTAL_1="309" TOTAL_2="303" VAR="0.011343372926735816" WEIGHT="73.90738916150873"/>
<DICH_DATA CI_END="1.2079005231117947" CI_START="0.5070586184800505" EFFECT_SIZE="0.782608695652174" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="23" LOG_CI_END="0.0820311693492346" LOG_CI_START="-0.2949418311778082" LOG_EFFECT_SIZE="-0.10645533091428679" MODIFIED="2009-05-20 15:33:50 +0200" MODIFIED_BY="[Empty name]" ORDER="854" O_E="0.0" SE="0.2214358065560328" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.04903381642512077" WEIGHT="17.09756935972216"/>
<DICH_DATA CI_END="2.292300484269454" CI_START="0.6926978904529171" EFFECT_SIZE="1.2601078167115902" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="14" LOG_CI_END="0.36027154615163315" LOG_CI_START="-0.15945613496465172" LOG_EFFECT_SIZE="0.10040770559349067" MODIFIED="2009-05-20 15:33:50 +0200" MODIFIED_BY="[Empty name]" ORDER="855" O_E="0.0" SE="0.30529061258121915" STUDY_ID="STD-Morley-2006" TOTAL_1="53" TOTAL_2="55" VAR="0.09320235813021605" WEIGHT="8.995041478769105"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-004" MODIFIED="2010-10-08 15:31:36 +0200" MODIFIED_BY="Laura Amato" NO="4">
<NAME>NTX + ACAM versus PBO</NAME>
<DICH_OUTCOME CHI2="8.096267357246875" CI_END="1.3490292302928903" CI_START="0.3783080470023612" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.7143868794016319" ESTIMABLE="YES" EVENTS_1="227" EVENTS_2="256" I2="87.64862922782667" I2_Q="0.0" ID="CMP-004.01" LOG_CI_END="0.1300213599145841" LOG_CI_START="-0.4221544207174267" LOG_EFFECT_SIZE="-0.14606653040142134" METHOD="MH" MODIFIED="2010-01-11 14:57:38 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.004435679001331683" P_Q="0.0" P_Z="0.2997662630607679" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.18672701164993363" TOTALS="YES" TOTAL_1="345" TOTAL_2="349" WEIGHT="100.0" Z="1.0369347913297964">
<NAME>Return to heavy drinking</NAME>
<GROUP_LABEL_1>NTX + ACAM</GROUP_LABEL_1>
<GROUP_LABEL_2>PBO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0507812730995194" CI_START="0.8595275460703318" EFFECT_SIZE="0.9503554330480197" ESTIMABLE="YES" EVENTS_1="212" EVENTS_2="226" LOG_CI_END="0.02151232423773458" LOG_CI_START="-0.06574020051893598" LOG_EFFECT_SIZE="-0.02211393814060068" MODIFIED="2009-05-20 14:54:14 +0200" MODIFIED_BY="[Empty name]" ORDER="234" O_E="0.0" SE="0.05125256494903154" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="309" VAR="0.0026268254138546968" WEIGHT="55.55917670662249"/>
<DICH_DATA CI_END="0.7750049130173529" CI_START="0.3225786002138575" EFFECT_SIZE="0.5" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="30" LOG_CI_END="-0.11069554434586686" LOG_CI_START="-0.4913644469820954" LOG_EFFECT_SIZE="-0.3010299956639812" MODIFIED="2009-05-20 14:54:14 +0200" MODIFIED_BY="[Empty name]" ORDER="235" O_E="0.0" SE="0.223606797749979" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.05000000000000001" WEIGHT="44.440823293377505"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="14.346895770221755" CI_END="1.38560777107655" CI_START="0.3523636044508283" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.6987401151870496" ESTIMABLE="YES" EVENTS_1="259" EVENTS_2="291" I2="93.02985108405409" I2_Q="0.0" ID="CMP-004.02" LOG_CI_END="0.14164031038790773" LOG_CI_START="-0.4530089561126056" LOG_EFFECT_SIZE="-0.15568432286234896" METHOD="MH" MODIFIED="2010-01-11 14:57:38 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="1.5203166352462105E-4" P_Q="0.0" P_Z="0.3047638500903189" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.22792516310023747" TOTALS="YES" TOTAL_1="345" TOTAL_2="349" WEIGHT="100.0" Z="1.0262710574366658">
<NAME>Return to any drinking</NAME>
<GROUP_LABEL_1>NTX + ACAM</GROUP_LABEL_1>
<GROUP_LABEL_2>PBO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0389266781721378" CI_START="0.8894039084025911" EFFECT_SIZE="0.9612624241641926" ESTIMABLE="YES" EVENTS_1="241" EVENTS_2="254" LOG_CI_END="0.016584898482220792" LOG_CI_START="-0.050900966416262454" LOG_EFFECT_SIZE="-0.017158033967020862" MODIFIED="2009-05-29 10:59:07 +0200" MODIFIED_BY="[Empty name]" ORDER="608" O_E="0.0" SE="0.03964153110178796" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="309" VAR="0.0015714509880940222" WEIGHT="53.16437302812691"/>
<DICH_DATA CI_END="0.6929759451619714" CI_START="0.3415257097829695" EFFECT_SIZE="0.4864864864864865" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="37" LOG_CI_END="-0.1592818405176808" LOG_CI_START="-0.46657659740969704" LOG_EFFECT_SIZE="-0.3129292189636889" MODIFIED="2009-05-20 14:53:56 +0200" MODIFIED_BY="[Empty name]" ORDER="233" O_E="0.0" SE="0.1805064613319495" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.03258258258258258" WEIGHT="46.83562697187308"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.5486814204197937" CI_END="0.273955142370748" CI_START="0.12933662743515717" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.20164588490295257" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="119" I2="0.0" I2_Q="0.0" ID="CMP-004.03" LOG_CI_END="-0.5623205430764" LOG_CI_START="-0.8882784678468997" LOG_EFFECT_SIZE="-0.6954106364492011" METHOD="MH" MODIFIED="2010-10-08 15:30:03 +0200" MODIFIED_BY="Laura Amato" NO="3" P_CHI2="0.4588570601906826" P_Q="0.0" P_Z="4.6115680367956365E-8" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="345" TOTAL_2="349" WEIGHT="100.0" Z="5.4656718362308725">
<NAME>Side effects: Diarrhea</NAME>
<GROUP_LABEL_1>NTX + ACAM</GROUP_LABEL_1>
<GROUP_LABEL_2>PBO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.2686313831998181" CI_START="0.11430670370134384" EFFECT_SIZE="0.19146904345058097" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="108" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="979" O_E="0.0" SE="0.03936926410785291" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="309" VAR="0.0015499389563938752" WEIGHT="87.81668273324426"/>
<DICH_DATA CI_END="0.48216249120543564" CI_START="0.0678375087945644" EFFECT_SIZE="0.275" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="11" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-11 12:09:55 +0100" MODIFIED_BY="[Empty name]" ORDER="1116" O_E="0.0" SE="0.10569709078304852" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.011171875000000001" WEIGHT="12.18331726675573"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.528333732023368E-5" CI_END="0.2630856757404793" CI_START="0.13609412264822418" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.19958989919435174" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="66" I2="0.0" I2_Q="0.0" ID="CMP-004.04" LOG_CI_END="-0.5799027973579324" LOG_CI_START="-0.8661606298044517" LOG_EFFECT_SIZE="-0.6998614411806876" METHOD="MH" MODIFIED="2010-10-08 15:30:03 +0200" MODIFIED_BY="Laura Amato" NO="4" P_CHI2="0.994630844317135" P_Q="0.0" P_Z="7.234788251177444E-10" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="345" TOTAL_2="349" WEIGHT="100.0" Z="6.160866680868509">
<NAME>Side effects: Nausea</NAME>
<GROUP_LABEL_1>NTX + ACAM</GROUP_LABEL_1>
<GROUP_LABEL_2>PBO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.27097388300693404" CI_START="0.12798627403057458" EFFECT_SIZE="0.19948007851875432" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="65" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" ORDER="981" O_E="0.0" SE="0.03647710113660952" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="309" VAR="0.0013305789073304393" WEIGHT="78.87744985371278"/>
<DICH_DATA CI_END="0.33815660865598846" CI_START="0.06184339134401157" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-11 12:27:46 +0100" MODIFIED_BY="[Empty name]" ORDER="1119" O_E="0.0" SE="0.07048936089935842" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.00496875" WEIGHT="21.122550146287224"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4136525773053401" CI_END="10.554865052564912" CI_START="1.3299805442198132" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="3.7467005707391365" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-004.05" LOG_CI_END="1.0234526850808083" LOG_CI_START="0.12384528788454556" LOG_EFFECT_SIZE="0.573648986482677" METHOD="MH" MODIFIED="2010-10-08 15:30:03 +0200" MODIFIED_BY="Laura Amato" NO="5" P_CHI2="0.5201214150457666" P_Q="0.0" P_Z="0.01243320207002867" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="345" TOTAL_2="349" WEIGHT="100.0" Z="2.499604509207168">
<NAME>Drop-out due to adverse events</NAME>
<GROUP_LABEL_1>NTX + ACAM</GROUP_LABEL_1>
<GROUP_LABEL_2>PBO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="9.985303764810133" CI_START="1.0857322072134867" EFFECT_SIZE="3.292622950819672" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="4" LOG_CI_END="0.9993612811620728" LOG_CI_START="0.03572272095177356" LOG_EFFECT_SIZE="0.5175420010569232" MODIFIED="2009-05-20 14:57:52 +0200" MODIFIED_BY="[Empty name]" ORDER="242" O_E="0.0" SE="0.5660460603553338" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="309" VAR="0.3204081424437942" WEIGHT="87.15206775609633"/>
<DICH_DATA CI_END="161.85818338602556" CI_START="0.5004380891067964" EFFECT_SIZE="9.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.2091346617833825" LOG_CI_START="-0.3006496429047325" LOG_EFFECT_SIZE="0.9542425094393249" MODIFIED="2009-05-20 14:57:52 +0200" MODIFIED_BY="[Empty name]" ORDER="243" O_E="0.0" SE="1.4742597242064726" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="2.1734417344173442" WEIGHT="12.84793224390367"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="18.531407777041895" CI_END="2.4903329609909477" CI_START="0.27768392733941555" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8315800845323088" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="118" I2="94.6037558936085" I2_Q="0.0" ID="CMP-004.06" LOG_CI_END="0.3962574167558999" LOG_CI_START="-0.5564492569793439" LOG_EFFECT_SIZE="-0.08009592011172202" METHOD="MH" MODIFIED="2010-10-08 15:30:03 +0200" MODIFIED_BY="Laura Amato" NO="6" P_CHI2="1.6712914632899256E-5" P_Q="0.0" P_Z="0.7417354449751301" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.5932200868674979" TOTALS="YES" TOTAL_1="345" TOTAL_2="349" WEIGHT="100.0" Z="0.3295560387166943">
<NAME>Drop-out</NAME>
<GROUP_LABEL_1>NTX + ACAM</GROUP_LABEL_1>
<GROUP_LABEL_2>PBO</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.7837134289588956" CI_START="1.1425368711092618" EFFECT_SIZE="1.4275707898658718" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="88" LOG_CI_END="0.25132508198021336" LOG_CI_START="0.05787022420001712" LOG_EFFECT_SIZE="0.15459765309011525" MODIFIED="2009-05-20 14:57:35 +0200" MODIFIED_BY="[Empty name]" ORDER="240" O_E="0.0" SE="0.11363634107707754" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="309" VAR="0.0129132180133859" WEIGHT="51.668454521883575"/>
<DICH_DATA CI_END="0.7382418844012765" CI_START="0.2949951531866799" EFFECT_SIZE="0.4666666666666667" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="30" LOG_CI_END="-0.13180131859805616" LOG_CI_START="-0.5301851194847926" LOG_EFFECT_SIZE="-0.3309932190414244" MODIFIED="2009-05-20 14:57:35 +0200" MODIFIED_BY="[Empty name]" ORDER="241" O_E="0.0" SE="0.23401261667248788" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.054761904761904755" WEIGHT="48.331545478116425"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-005" MODIFIED="2010-10-08 15:31:36 +0200" MODIFIED_BY="Laura Amato" NO="5">
<NAME>NTX + ACAM versus NTX</NAME>
<DICH_OUTCOME CHI2="1.5513353115434387" CI_END="1.259416567491236" CI_START="0.7479516954118547" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9705579616307562" ESTIMABLE="YES" EVENTS_1="227" EVENTS_2="227" I2="35.539403212250086" I2_Q="0.0" ID="CMP-005.01" LOG_CI_END="0.10016940210142343" LOG_CI_START="-0.12612644905196482" LOG_EFFECT_SIZE="-0.012978523475270705" METHOD="MH" MODIFIED="2010-01-11 12:23:48 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.2129389056170462" P_Q="0.0" P_Z="0.8221225936475537" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.019213933939363558" TOTALS="YES" TOTAL_1="345" TOTAL_2="349" WEIGHT="100.0" Z="0.22481577505189124">
<NAME>Return to heavy drinking</NAME>
<GROUP_LABEL_1>NTX + ACAM</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.155850941209699" CI_START="0.9314219752281783" EFFECT_SIZE="1.0375861249703018" ESTIMABLE="YES" EVENTS_1="212" EVENTS_2="207" LOG_CI_END="0.06290183098410035" LOG_CI_START="-0.030853519884335334" LOG_EFFECT_SIZE="0.016024155549882506" MODIFIED="2009-07-24 17:46:42 +0200" MODIFIED_BY="[Empty name]" ORDER="754" O_E="0.0" SE="0.055072357196590795" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="309" VAR="0.003032964527188886" WEIGHT="79.42530932707619"/>
<DICH_DATA CI_END="1.2440577950744771" CI_START="0.4521494115683953" EFFECT_SIZE="0.75" ESTIMABLE="YES" EVENTS_1="15" EVENTS_2="20" LOG_CI_END="0.09484055680084613" LOG_CI_START="-0.34471803001744594" LOG_EFFECT_SIZE="-0.12493873660829995" MODIFIED="2010-01-11 12:23:48 +0100" MODIFIED_BY="[Empty name]" ORDER="1117" O_E="0.0" SE="0.25819888974716115" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.06666666666666668" WEIGHT="20.574690672923804"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="3.327585551932606" CI_END="1.2750725885657166" CI_START="0.6112875712915571" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8828567414279487" ESTIMABLE="YES" EVENTS_1="259" EVENTS_2="267" I2="69.94818061344158" I2_Q="0.0" ID="CMP-005.02" LOG_CI_END="0.1055349094101194" LOG_CI_START="-0.21375443420264054" LOG_EFFECT_SIZE="-0.05410976239626054" METHOD="MH" MODIFIED="2010-01-11 12:24:00 +0100" MODIFIED_BY="[Empty name]" NO="2" P_CHI2="0.06812688935521527" P_Q="0.0" P_Z="0.506493394985577" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.05330277368906047" TOTALS="YES" TOTAL_1="345" TOTAL_2="349" WEIGHT="100.0" Z="0.6643077047839951">
<NAME>Return to any drinking</NAME>
<GROUP_LABEL_1>NTX + ACAM</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.1005490266743596" CI_START="0.9326267890794135" EFFECT_SIZE="1.0131147540983607" ESTIMABLE="YES" EVENTS_1="241" EVENTS_2="241" LOG_CI_END="0.041609394040553256" LOG_CI_START="-0.03029211388445562" LOG_EFFECT_SIZE="0.005658640078048829" MODIFIED="2009-07-24 17:45:01 +0200" MODIFIED_BY="[Empty name]" ORDER="752" O_E="0.0" SE="0.04223530167335461" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="309" VAR="0.001783820707439271" WEIGHT="63.85547329391069"/>
<DICH_DATA CI_END="1.0444397185601513" CI_START="0.4588967006053199" EFFECT_SIZE="0.6923076923076923" ESTIMABLE="YES" EVENTS_1="18" EVENTS_2="26" LOG_CI_END="0.018883379067711405" LOG_CI_START="-0.33828506480273524" LOG_EFFECT_SIZE="-0.1597008428675119" MODIFIED="2010-01-11 12:24:00 +0100" MODIFIED_BY="[Empty name]" ORDER="1118" O_E="0.0" SE="0.20980251194181165" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.04401709401709402" WEIGHT="36.14452670608931"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="9.849490064792917" CI_END="0.6543649368023086" CI_START="0.0955698094908996" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.37496737314660405" ESTIMABLE="YES" EVENTS_1="187" EVENTS_2="93" I2="89.84719012434452" I2_Q="0.0" ID="CMP-005.03" LOG_CI_END="-0.1841799797542862" LOG_CI_START="-1.0196792797141014" LOG_EFFECT_SIZE="-0.4260065196825287" METHOD="MH" MODIFIED="2010-10-08 15:29:57 +0200" MODIFIED_BY="Laura Amato" NO="3" P_CHI2="0.001698794906957568" P_Q="0.0" P_Z="0.00852887708179227" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.03667097083865173" TOTALS="YES" TOTAL_1="345" TOTAL_2="349" WEIGHT="100.0" Z="2.630382803375353">
<NAME>Side effects: Diarrhea</NAME>
<GROUP_LABEL_1>NTX + ACAM</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.3189256116634039" CI_START="0.16757234578791985" EFFECT_SIZE="0.24324897872566187" ESTIMABLE="YES" EVENTS_1="165" EVENTS_2="92" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-26 10:04:25 +0200" MODIFIED_BY="[Empty name]" ORDER="738" O_E="0.0" SE="0.03861123649958348" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="309" VAR="0.0014908275840267674" WEIGHT="53.25007383285072"/>
<DICH_DATA CI_END="0.6865856287604358" CI_START="0.3634143712395642" EFFECT_SIZE="0.525" ESTIMABLE="YES" EVENTS_1="22" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-11 12:30:19 +0100" MODIFIED_BY="[Empty name]" ORDER="1120" O_E="0.0" SE="0.08244316223920574" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.006796875" WEIGHT="46.74992616714928"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.22474662962592407" CI_END="0.15939409002378319" CI_START="0.022145863073602598" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.09076997654869289" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="105" I2="0.0" I2_Q="0.0" ID="CMP-005.04" LOG_CI_END="-0.7975277853090517" LOG_CI_START="-1.6547073896262738" LOG_EFFECT_SIZE="-1.0420577767587884" METHOD="MH" MODIFIED="2010-10-08 15:29:57 +0200" MODIFIED_BY="Laura Amato" NO="4" P_CHI2="0.6354468024089275" P_Q="0.0" P_Z="0.009528977646033304" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="345" TOTAL_2="349" WEIGHT="100.0" Z="2.5924689719680103">
<NAME>Side effects: Nausea</NAME>
<GROUP_LABEL_1>NTX + ACAM</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.1590123778496203" CI_START="0.0069380704500242585" EFFECT_SIZE="0.08297522414982228" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="101" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-26 10:35:46 +0200" MODIFIED_BY="[Empty name]" ORDER="741" O_E="0.0" SE="0.038795179043885186" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="309" VAR="0.0015050659170471085" WEIGHT="81.4520072000868"/>
<DICH_DATA CI_END="0.2843412749196681" CI_START="-0.03434127491966807" EFFECT_SIZE="0.125" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="4" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2010-01-29 11:23:47 +0100" MODIFIED_BY="[Empty name]" ORDER="1121" O_E="0.0" SE="0.0812980627075455" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.006609375000000001" WEIGHT="18.5479927999132"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.014358878004717949" CI_END="2.0809952525907685" CI_START="0.5520574689884142" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.071834395847682" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-005.05" LOG_CI_END="0.31827108944950083" LOG_CI_START="-0.25801571001460527" LOG_EFFECT_SIZE="0.030127689717447767" METHOD="MH" MODIFIED="2010-10-08 15:29:57 +0200" MODIFIED_BY="Laura Amato" NO="5" P_CHI2="0.9046189791474137" P_Q="0.0" P_Z="0.8376269249136603" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="345" TOTAL_2="349" WEIGHT="100.00000000000001" Z="0.20492986075164557">
<NAME>Drop-out due to adverse events</NAME>
<GROUP_LABEL_1>NTX + ACAM</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="2.366877915295778" CI_START="0.5089388865016793" EFFECT_SIZE="1.0975409836065573" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="12" LOG_CI_END="0.374175857387992" LOG_CI_START="-0.2933343647134705" LOG_EFFECT_SIZE="0.040420746337260706" MODIFIED="2009-07-24 17:57:17 +0200" MODIFIED_BY="[Empty name]" ORDER="760" O_E="0.0" SE="0.3920988086912884" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="309" VAR="0.15374147577712755" WEIGHT="74.535213838136"/>
<DICH_DATA CI_END="3.723945821594102" CI_START="0.26853237074537567" EFFECT_SIZE="1.0" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="4" LOG_CI_END="0.5710033539543428" LOG_CI_START="-0.5710033539543428" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 17:57:23 +0200" MODIFIED_BY="[Empty name]" ORDER="761" O_E="0.0" SE="0.6708203932499369" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.44999999999999996" WEIGHT="25.464786161864016"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.8453334901386553" CI_END="1.4801945277476878" CI_START="0.7204344336157642" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RR" EFFECT_SIZE="1.03265827176228" ESTIMABLE="YES" EVENTS_1="138" EVENTS_2="126" I2="45.80925315971686" I2_Q="0.0" ID="CMP-005.06" LOG_CI_END="0.17031879429752786" LOG_CI_START="-0.1424055379791882" LOG_EFFECT_SIZE="0.013956628159169848" METHOD="MH" MODIFIED="2010-10-08 15:29:57 +0200" MODIFIED_BY="Laura Amato" NO="6" P_CHI2="0.17432729280817982" P_Q="0.0" P_Z="0.8611243111103007" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.037107167979367715" TOTALS="YES" TOTAL_1="345" TOTAL_2="349" WEIGHT="100.0" Z="0.1749431413823322">
<NAME>Drop-out</NAME>
<GROUP_LABEL_1>NTX + ACAM</GROUP_LABEL_1>
<GROUP_LABEL_2>NTX</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.426107382668869" CI_START="0.9487699289338868" EFFECT_SIZE="1.1632058287795992" ESTIMABLE="YES" EVENTS_1="124" EVENTS_2="108" LOG_CI_END="0.154152228141875" LOG_CI_START="-0.02283908863520673" LOG_EFFECT_SIZE="0.06565656975333416" MODIFIED="2009-07-24 17:53:40 +0200" MODIFIED_BY="[Empty name]" ORDER="758" O_E="0.0" SE="0.10396557559600579" STUDY_ID="STD-Anton-2006" TOTAL_1="305" TOTAL_2="309" VAR="0.010808840909008795" WEIGHT="70.42355020475635"/>
<DICH_DATA CI_END="1.3397693136156186" CI_START="0.45152420305283675" EFFECT_SIZE="0.7777777777777778" ESTIMABLE="YES" EVENTS_1="14" EVENTS_2="18" LOG_CI_END="0.12703002638833524" LOG_CI_START="-0.34531896523847133" LOG_EFFECT_SIZE="-0.10914446942506803" MODIFIED="2010-01-11 15:44:59 +0100" MODIFIED_BY="[Empty name]" ORDER="1122" O_E="0.0" SE="0.2774601358468041" STUDY_ID="STD-Kiefer-2003" TOTAL_1="40" TOTAL_2="40" VAR="0.07698412698412699" WEIGHT="29.57644979524364"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-006" MODIFIED="2010-10-11 12:08:39 +0200" MODIFIED_BY="Laura Amato" NO="6">
<NAME>NMF versus PBO</NAME>
<DICH_OUTCOME CHI2="3.099019765387621" CI_END="1.0848878331203795" CI_START="0.6735559595271151" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.8548290270087289" ESTIMABLE="YES" EVENTS_1="193" EVENTS_2="82" I2="35.46346421092145" I2_Q="0.0" ID="CMP-006.01" LOG_CI_END="0.03538483866838777" LOG_CI_START="-0.17162631693541872" LOG_EFFECT_SIZE="-0.06812073913351542" METHOD="MH" MODIFIED="2010-01-11 17:51:03 +0100" MODIFIED_BY="[Empty name]" NO="1" P_CHI2="0.21235212202810105" P_Q="0.0" P_Z="0.19707749526018867" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.018796708355326867" TOTALS="YES" TOTAL_1="286" TOTAL_2="110" WEIGHT="99.99999999999999" Z="1.2899227088753422">
<NAME>Return to heavy drinking</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.0597729290892959" CI_START="0.8216119124373633" EFFECT_SIZE="0.9331248914365121" ESTIMABLE="YES" EVENTS_1="158" EVENTS_2="57" LOG_CI_END="0.02521282167265388" LOG_CI_START="-0.08533327258956624" LOG_EFFECT_SIZE="-0.030060225458456206" MODIFIED="2009-06-23 17:48:00 +0200" MODIFIED_BY="[Empty name]" ORDER="224" O_E="0.0" SE="0.06493532298162003" STUDY_ID="STD-Anton-2004" TOTAL_1="202" TOTAL_2="68" VAR="0.00421659617072731" WEIGHT="64.251566294374"/>
<DICH_DATA CI_END="1.6561856484947366" CI_START="0.48907560618955226" EFFECT_SIZE="0.9" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="5" LOG_CI_END="0.21910901698860555" LOG_CI_START="-0.3106239981099558" LOG_EFFECT_SIZE="-0.045757490560675115" MODIFIED="2009-05-20 14:36:18 +0200" MODIFIED_BY="[Empty name]" ORDER="835" O_E="0.0" SE="0.3111677952896103" STUDY_ID="STD-Mason-1994" TOTAL_1="14" TOTAL_2="7" VAR="0.09682539682539684" WEIGHT="12.788565465895905"/>
<DICH_DATA CI_END="0.9878455023024338" CI_START="0.4276984599466745" EFFECT_SIZE="0.65" ESTIMABLE="YES" EVENTS_1="26" EVENTS_2="20" LOG_CI_END="-0.005310973169684686" LOG_CI_START="-0.36886231354460414" LOG_EFFECT_SIZE="-0.18708664335714442" MODIFIED="2009-05-20 14:36:32 +0200" MODIFIED_BY="[Empty name]" ORDER="225" O_E="0.0" SE="0.21355185694438625" STUDY_ID="STD-Mason-1999" TOTAL_1="70" TOTAL_2="35" VAR="0.04560439560439561" WEIGHT="22.95986823973008"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="2.063192367458103" CI_END="24.370663509229793" CI_START="-32.685187318753606" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="MD" EFFECT_SIZE="-4.157261904761905" ESTIMABLE="YES" I2="51.53142209264659" I2_Q="0.0" ID="CMP-006.02" MODIFIED="2010-10-11 12:08:38 +0200" MODIFIED_BY="Laura Amato" NO="2" P_CHI2="0.15089380516454376" P_Q="1.0" P_Z="0.7751708606853654" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="222.70850000000007" TOTALS="YES" TOTAL_1="84" TOTAL_2="42" UNITS="" WEIGHT="100.0" Z="0.28561781094805583">
<NAME>Consumed amount per drinking day</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<CONT_DATA CI_END="44.802810683859306" CI_START="-19.602810683859303" EFFECT_SIZE="12.600000000000001" ESTIMABLE="YES" MEAN_1="54.6" MEAN_2="42.0" MODIFIED="2009-05-20 14:51:26 +0200" MODIFIED_BY="[Empty name]" ORDER="838" SD_1="41.3" SD_2="32.2" SE="16.430307361702035" STUDY_ID="STD-Mason-1994" TOTAL_1="14" TOTAL_2="7" WEIGHT="43.002510528020736"/>
<CONT_DATA CI_END="7.123445963689605" CI_START="-40.72344596368961" EFFECT_SIZE="-16.800000000000004" ESTIMABLE="YES" MEAN_1="57.4" MEAN_2="74.2" MODIFIED="2009-05-20 14:51:26 +0200" MODIFIED_BY="[Empty name]" ORDER="228" SD_1="46.2" SD_2="64.4" SE="12.206064066684233" STUDY_ID="STD-Mason-1999" TOTAL_1="70" TOTAL_2="35" WEIGHT="56.997489471979264"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.7721687657799189" CI_END="0.1946794541027127" CI_START="0.054759444879348945" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.12471944949103082" ESTIMABLE="YES" EVENTS_1="58" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-006.03" LOG_CI_END="-0.7106798802244627" LOG_CI_START="-1.2615409631504935" LOG_EFFECT_SIZE="-0.9040658147814918" METHOD="MH" MODIFIED="2010-10-11 12:08:39 +0200" MODIFIED_BY="Laura Amato" NO="3" P_CHI2="0.37954700268157826" P_Q="0.0" P_Z="4.7570414708338066E-4" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="272" TOTAL_2="103" WEIGHT="100.0" Z="3.494076801894113">
<NAME>Side effect: Insomnia</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.23877466635423172" CI_START="0.060002270162949345" EFFECT_SIZE="0.14938846825859053" ESTIMABLE="YES" EVENTS_1="48" EVENTS_2="6" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 14:58:21 +0200" MODIFIED_BY="[Empty name]" ORDER="748" O_E="0.0" SE="0.04560604113172901" STUDY_ID="STD-Anton-2004" TOTAL_1="202" TOTAL_2="68" VAR="0.002079910987708958" WEIGHT="61.257423681262196"/>
<DICH_DATA CI_END="0.19811150860496202" CI_START="-0.026682937176390586" EFFECT_SIZE="0.08571428571428572" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="2" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 14:58:30 +0200" MODIFIED_BY="[Empty name]" ORDER="749" O_E="0.0" SE="0.05734657563978279" STUDY_ID="STD-Mason-1999" TOTAL_1="70" TOTAL_2="35" VAR="0.0032886297376093295" WEIGHT="38.74257631873781"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="4.528333732023368E-5" CI_END="0.2630856757404793" CI_START="0.13609412264822418" CI_STUDY="95" CI_TOTAL="95" DF="1" EFFECT_MEASURE="RD" EFFECT_SIZE="0.19958989919435174" ESTIMABLE="YES" EVENTS_1="134" EVENTS_2="66" I2="0.0" I2_Q="0.0" ID="CMP-006.04" LOG_CI_END="-0.5799027973579324" LOG_CI_START="-0.8661606298044517" LOG_EFFECT_SIZE="-0.6998614411806876" METHOD="MH" MODIFIED="2010-10-11 12:08:39 +0200" MODIFIED_BY="Laura Amato" NO="4" P_CHI2="0.994630844317135" P_Q="0.0" P_Z="7.234788251177444E-10" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="345" TOTAL_2="349" WEIGHT="100.0" Z="6.160866680868509">
<NAME>Side effect: Nausea</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.27097388300693404" CI_START="0.12798627403057458" EFFECT_SIZE="0.19948007851875432" ESTIMABLE="YES" EVENTS_1="125" EVENTS_2="65" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 14:59:53 +0200" MODIFIED_BY="[Empty name]" ORDER="750" O_E="0.0" SE="0.03647710113660952" STUDY_ID="STD-Anton-2004" TOTAL_1="305" TOTAL_2="309" VAR="0.0013305789073304393" WEIGHT="78.87744985371278"/>
<DICH_DATA CI_END="0.33815660865598846" CI_START="0.06184339134401157" EFFECT_SIZE="0.2" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="1" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-24 14:59:53 +0200" MODIFIED_BY="[Empty name]" ORDER="751" O_E="0.0" SE="0.07048936089935842" STUDY_ID="STD-Mason-1999" TOTAL_1="40" TOTAL_2="40" VAR="0.00496875" WEIGHT="21.122550146287224"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.3843909151890973" CI_END="1.2500427929508864" CI_START="0.6750534902372982" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="0.9186107719417818" ESTIMABLE="YES" EVENTS_1="84" EVENTS_2="36" I2="0.0" I2_Q="0.0" ID="CMP-006.05" LOG_CI_END="0.09692488054751497" LOG_CI_START="-0.17066181295490956" LOG_EFFECT_SIZE="-0.0368684662036973" METHOD="MH" MODIFIED="2010-10-11 12:08:39 +0200" MODIFIED_BY="Laura Amato" NO="5" P_CHI2="0.8251456311491169" P_Q="0.0" P_Z="0.5891328182869923" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="YES" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="286" TOTAL_2="110" WEIGHT="100.0" Z="0.5400931188218752">
<NAME>Drop-out</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="1.4163255377081057" CI_START="0.5764812027044856" EFFECT_SIZE="0.9035956227201668" ESTIMABLE="YES" EVENTS_1="51" EVENTS_2="19" LOG_CI_END="0.1511630859676373" LOG_CI_START="-0.23921484915819738" LOG_EFFECT_SIZE="-0.04402588159528002" MODIFIED="2009-05-20 14:52:21 +0200" MODIFIED_BY="[Empty name]" ORDER="229" O_E="0.0" SE="0.22930993149485956" STUDY_ID="STD-Anton-2004" TOTAL_1="202" TOTAL_2="68" VAR="0.052583044682177185" WEIGHT="46.98492101432465"/>
<DICH_DATA CI_END="1.535736527021474" CI_START="0.41673815054804064" EFFECT_SIZE="0.8" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="5" LOG_CI_END="0.18631671395357718" LOG_CI_START="-0.38013673996968994" LOG_EFFECT_SIZE="-0.09691001300805639" MODIFIED="2009-05-20 14:52:21 +0200" MODIFIED_BY="[Empty name]" ORDER="839" O_E="0.0" SE="0.3327375628243462" STUDY_ID="STD-Mason-1994" TOTAL_1="14" TOTAL_2="7" VAR="0.11071428571428571" WEIGHT="22.31518891302399"/>
<DICH_DATA CI_END="1.8163535763462217" CI_START="0.5973888886915791" EFFECT_SIZE="1.0416666666666667" ESTIMABLE="YES" EVENTS_1="25" EVENTS_2="12" LOG_CI_END="0.2592003933641884" LOG_CI_START="-0.2237428594433251" LOG_EFFECT_SIZE="0.017728766960431616" MODIFIED="2009-05-20 14:52:21 +0200" MODIFIED_BY="[Empty name]" ORDER="230" O_E="0.0" SE="0.28368325730679006" STUDY_ID="STD-Mason-1999" TOTAL_1="70" TOTAL_2="35" VAR="0.08047619047619047" WEIGHT="30.69989007265135"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="7.33923671556889" CI_END="9.24323550551592" CI_START="0.22159811155803194" CI_STUDY="95" CI_TOTAL="95" DF="2" EFFECT_MEASURE="RR" EFFECT_SIZE="1.4311825644230294" ESTIMABLE="YES" EVENTS_1="27" EVENTS_2="6" I2="72.74920979510914" I2_Q="0.0" ID="CMP-006.06" LOG_CI_END="0.9658240184312852" LOG_CI_START="-0.654433944951824" LOG_EFFECT_SIZE="0.1556950367397306" METHOD="MH" MODIFIED="2010-10-11 12:08:39 +0200" MODIFIED_BY="Laura Amato" NO="6" P_CHI2="0.025486266338873964" P_Q="0.0" P_Z="0.7064139240756683" Q="0.0" RANDOM="YES" SCALE="100.0" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="1.876380903486143" TOTALS="YES" TOTAL_1="286" TOTAL_2="110" WEIGHT="100.0" Z="0.37667664221114927">
<NAME>Drop-out due to adverse events</NAME>
<GROUP_LABEL_1>Experimental</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours experimental</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.683809253414397" CI_START="0.8508538148696745" EFFECT_SIZE="3.5346534653465347" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="2" LOG_CI_END="1.1668387342678233" LOG_CI_START="-0.07014504960872199" LOG_EFFECT_SIZE="0.5483468423295507" MODIFIED="2009-05-20 14:53:10 +0200" MODIFIED_BY="[Empty name]" ORDER="231" O_E="0.0" SE="0.7266103978175661" STUDY_ID="STD-Anton-2004" TOTAL_1="202" TOTAL_2="68" VAR="0.5279626702166016" WEIGHT="37.67445739523118"/>
<DICH_DATA CI_END="1.2334744515205174" CI_START="0.11400722554622031" EFFECT_SIZE="0.375" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="4" LOG_CI_END="0.0911301585451966" LOG_CI_START="-0.9430676230897589" LOG_EFFECT_SIZE="-0.42596873227228116" MODIFIED="2009-05-20 14:53:10 +0200" MODIFIED_BY="[Empty name]" ORDER="840" O_E="0.0" SE="0.6074928962939559" STUDY_ID="STD-Mason-1994" TOTAL_1="14" TOTAL_2="7" VAR="0.369047619047619" WEIGHT="40.3407806670007"/>
<DICH_DATA CI_END="66.8650106624499" CI_START="0.18840198141189946" EFFECT_SIZE="3.5492957746478875" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="0" LOG_CI_END="1.825198918196055" LOG_CI_START="-0.7249145340711176" LOG_EFFECT_SIZE="0.5501421920624688" MODIFIED="2009-05-20 14:53:10 +0200" MODIFIED_BY="[Empty name]" ORDER="232" O_E="0.0" SE="1.4979492651269115" STUDY_ID="STD-Mason-1999" TOTAL_1="70" TOTAL_2="35" VAR="2.2438520008942544" WEIGHT="21.984761937768113"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2010-10-15 14:24:38 +0200" MODIFIED_BY="Laura Amato">
<FIGURE FILENAME="Flow Diagram Opioid-antagonists for alcohol-dependence.jpg" FILE_TYPE="JPG" ID="FIG-01" MODIFIED="2010-01-25 11:52:52 +0100" MODIFIED_BY="[Empty name]" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="OTHER">
<CAPTION/>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2010-01-31 22:18:37 +0100" MODIFIED_BY="[Empty name]" NO="2" REF_ID="CMP-001.01" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 NTX versus PBO, outcome: 1.1 Return to heavy drinking.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2010-01-28 18:26:07 +0100" MODIFIED_BY="[Empty name]" NO="3" REF_ID="CMP-001.02" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 NTX versus PBO, outcome: 1.2 Return to any drinking.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2010-01-28 18:26:08 +0100" MODIFIED_BY="[Empty name]" NO="4" REF_ID="CMP-001.03" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 NTX versus PBO, outcome: 1.3 Drinking days.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2010-01-28 18:26:08 +0100" MODIFIED_BY="[Empty name]" NO="5" REF_ID="CMP-001.04" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 NTX versus PBO, outcome: 1.4 Heavy drinking days.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2010-01-28 18:26:08 +0100" MODIFIED_BY="[Empty name]" NO="6" REF_ID="CMP-001.05" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 NTX versus PBO, outcome: 1.5 Consumed amount per drinking day.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2010-01-28 18:26:08 +0100" MODIFIED_BY="[Empty name]" NO="7" REF_ID="CMP-001.06" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 NTX versus PBO, outcome: 1.6 GGT.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2010-10-15 13:53:41 +0200" MODIFIED_BY="Laura Amato" NO="8" REF_ID="CMP-001.59" SETTINGS="SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;SHOW_EFFECT_SIZE_COLUMN:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 NTX versus PBO, outcome: 1.93 Sensitivity analysis: Funding source.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Funnel plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2010-10-05 16:06:11 +0200" MODIFIED_BY="[Empty name]" NO="9" REF_ID="CMP-001.01" SETTINGS="DISTINGUISH_SUBGROUPS:YES;SHOW_STUDY_NAMES:NO;SHOW_CI_LINES:YES;SHOW_EFFECT_ESTIMATE:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FUNNEL_PLOT">
<CAPTION>
<P>Funnel plot of comparison: 1 NTX versus PBO, outcome: 1.1 Return to heavy drinking.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2010-10-15 14:24:38 +0200" MODIFIED_BY="Laura Amato" NO="10" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-11" MODIFIED="2010-10-15 14:24:38 +0200" MODIFIED_BY="Laura Amato" NO="11" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Risk of bias summary: review authors' judgements about each risk of bias item for each included study.</P>
</CAPTION>
<FILE>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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK MODIFIED="2008-07-31 13:32:11 +0200" MODIFIED_BY="[Empty name]"/>
<APPENDICES MODIFIED="2010-10-06 10:56:56 +0200" MODIFIED_BY="[Empty name]">
<APPENDIX ID="APP-01" MODIFIED="2010-07-12 16:34:55 +0200" MODIFIED_BY="[Empty name]" NO="1">
<TITLE MODIFIED="2009-07-18 15:15:50 +0200" MODIFIED_BY="[Empty name]">Search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2010-07-12 16:34:55 +0200" MODIFIED_BY="[Empty name]">
<P>
<B>Search strategy for CENTRAL </B>
</P>
<OL>
<LI>Alcohol-Related Disorders[mesh]</LI>
<LI>((alcohol) NEAR/2 (dependen* or disorder* or drink* or misuse or abuse* or consumption))</LI>
<LI>alcoholism [mesh]</LI>
<LI>alcohol*</LI>
<LI>exp drinking behaviour [mesh]</LI>
<LI>#1 or #2 or #3 or #4 or #5</LI>
<LI>naltrexone [mesh]</LI>
<LI>naltrexone or nalmefene or vivitrol or revia</LI>
<LI>opioid near/2 antagonist</LI>
<LI>#7 or #8 or #9</LI>
<LI>#6 AND #10</LI>
</OL>
<P>
<B>Search strategy for PubMed </B>
</P>
<OL>
<LI>Alcohol-Related Disorders[mesh]</LI>
<LI>((alcohol) AND (dependen* or disorder* or drink* or misuse or abuse* or consumption))</LI>
<LI>alcoholism [mesh]</LI>
<LI>alcohol*</LI>
<LI>exp drinking behaviour</LI>
<LI>#1 OR #2 OR #3 OR #4 OR #5</LI>
<LI>naltrexone [mesh]</LI>
<LI>Narcotic Antagonists [mesh]</LI>
<LI>naltrexone [tiab]</LI>
<LI>ReVia [tiab]</LI>
<LI>Vivitrol [tiab]</LI>
<LI>Nalmefene [substance name]</LI>
<LI>nalmefene [tiab]</LI>
<LI>(opioid AND antagonist) [tiab]</LI>
<LI>#7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR OR 14</LI>
<LI>randomized controlled trial[pt]</LI>
<LI>controlled clinical trial[pt]</LI>
<LI>random*[tiab]</LI>
<LI>placebo[tiab]</LI>
<LI>drug therapy[mesh]</LI>
<LI>trial[tiab]</LI>
<LI>groups[tiab]</LI>
<LI>#16 OR #17 OR #18 OR #9 OR #20 OR #21 OR #22 </LI>
<LI>animals [mesh]</LI>
<LI>humans [mesh]</LI>
<LI>animals NOT (24 and 25)</LI>
<LI>23 NOT 26</LI>
<LI>6 AND 15 AND 27</LI>
</OL>
<P>  </P>
<P>
<B>Search strategy for EMBASE (Host: OVID)</B>
</P>
<OL>
<LI>exp alcoholism</LI>
<LI>exp drinking behaviour</LI>
<LI>((alcohol) AND (abuse* OR dependen* OR disorder*or drink*o disorder* or consumption))</LI>
<LI>alcohol*</LI>
<LI>1 or 2 or 3 or 4</LI>
<LI>exp naltrexone</LI>
<LI>exp Narcotic Antagonists</LI>
<LI>(ReVia or Vivitrol or naltrexone or nalmefene).ti,ab</LI>
<LI>(opioid ADJ2 antagonist).ti,ab</LI>
<LI>6 OR 7 OR 8 OR 9</LI>
<LI>random*.ti,ab</LI>
<LI>placebo. ti,ab</LI>
<LI>(control* or prospective* or volunteer*).ti,ab</LI>
<LI>(singl* or doubl* or trebl* or tripl*) ADJ2 (blind* or mask*)).ti,ab</LI>
<LI>crossover*.ti,ab</LI>
<LI>exp randomized controlled trial/</LI>
<LI>clinical-trial/</LI>
<LI>exp double blind procedure/</LI>
<LI>exp single blind procedure/</LI>
<LI>exp crossover procedure/</LI>
<LI>exp Latin square design/</LI>
<LI>exp placebos/</LI>
<LI>exp multicenter study/</LI>
<LI>11 OR 12 OR 13 OR 14 OR 15 OR 16 OR 17 OR 18 OR 19 OR 20 OR 21 OR 22 OR 23</LI>
<LI>5 AND 10 AND 24</LI>
<LI>limit 25 to human</LI>
</OL>
<P>
<B>Search strategy for CINAHL (Host: EBSCO)</B>
</P>
<OL>
<LI>MH alcohol-related disorders</LI>
<LI>TX (((alcohol) and (abuse* OR dependen* OR disorder*or drink* or consumption or intoxication))</LI>
<LI>alcohol*</LI>
<LI>1 OR 2 OR 3</LI>
<LI>MH naltrexone</LI>
<LI>TW naltrexone OR ReVia OR Vivitrol OR nalmefene</LI>
<LI>TW (opioid AND antagonist)</LI>
<LI>5 OR 6 OR 7</LI>
<LI>MH Random Assignment/</LI>
<LI>MH Clinical Trials/</LI>
<LI>TW random*</LI>
<LI>TW placebo*</LI>
<LI>TW group*</LI>
<LI>TW (singl* or doubl* or tripl* or trebl*) and (mask* or blind*)</LI>
<LI>MH crossover design</LI>
<LI>TW (crossover* or allocate* or assign*)</LI>
<LI>9 OR 10 OR 11 OR 12 OR 13 OR 14 OR 15 OR 16</LI>
<LI>4 AND 8 AND 17</LI>
</OL>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2010-03-08 15:55:16 +0100" MODIFIED_BY="[Empty name]" NO="2">
<TITLE MODIFIED="2009-05-26 11:03:30 +0200" MODIFIED_BY="[Empty name]">Abbreviations</TITLE>
<APPENDIX_BODY MODIFIED="2010-01-29 11:18:26 +0100" MODIFIED_BY="[Empty name]">
<P>
<B>Term (abbreviation)</B>
</P>
<P>Acamprosate (ACAM)</P>
<P>Acceptable Quality Level (AQL)</P>
<P>Alcohol Dependence Scale (ADS)</P>
<P>Alcoholics Anonymous (AA)</P>
<P>Addiction Severity Index (ASI)</P>
<P>Aspartate aminotransferase (AspAT)</P>
<P>Blood alcohol concentration (BAC)</P>
<P>Carbohydrate-deficient transferrin (CDT)</P>
<P>Cognitive behavioural therapy (CBT)</P>
<P>Case report form (CRF)</P>
<P>Cognitive Behavioral Intervention (CBI)</P>
<P>Combined behavioral intervention (CBI)</P>
<P>Clinical Trials Registry Platform Search Portal (ClinicalTrials.gov)</P>
<P>Cochrane Drugs and Alcohol Group (CDAG)</P>
<P>Confidence interval (CI)</P>
<P>Contingency management (CM)</P>
<P>Cumulative abstinence duration (CAD)</P>
<P>Diagnostic and Statistical Manual of Mental Disorders (DSM)</P>
<P>Electronic microchip system (EMS)</P>
<P>Food and Drug Administration (FDA)</P>
<P>Gamma-glutamyltransferase (GGT)</P>
<P>Glutamat-Pyruvat-Transaminase (GPT)</P>
<P>Good Clinical Practice (GCP)</P>
<P>Hopkins symptom checklist (HSCL)</P>
<P>Individual patient database (IPD)</P>
<P>Intention-to-treat (ITT)</P>
<P>International Statistical Classification of Diseases (ICD)</P>
<P>International Unit (IU)</P>
<P>Mean corpuscular volume (MCV)</P>
<P>Mean difference (MD)</P>
<P>Medial management (MM)</P>
<P>Meta-analysis based on literature (MAL)</P>
<P>
<I>Meta</I>Register of Controlled Trials (<I>m</I>RCT)</P>
<P>Microelective events monitoring system (MEMS)</P>
<P>Motivational Enhancement (ME)</P>
<P>Naltrexone (NTX)</P>
<P>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</P>
<P>Number needed to treat for an additional beneficial outcome (NNTB)</P>
<P>Number needed to treat for an additional harmful outcome (NNTH)</P>
<P>Ondansetrone (ONDAN)</P>
<P>Placebo (PBO)</P>
<P>Randomized controlled trial (RCT)</P>
<P>Risk benefit (RB)</P>
<P>Risk difference (RD)</P>
<P>Risk ratio (RR)</P>
<P>Systematic Assessment for Treatment Emergent Effects (SAFTEE)</P>
<P>Standard deviation (SD)</P>
<P>Standard error (SE)</P>
<P>Standard drink unit (SDU)</P>
<P>Weighted mean difference (WMD)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2010-10-06 10:56:56 +0200" MODIFIED_BY="[Empty name]" NO="3">
<TITLE MODIFIED="2010-07-21 14:56:07 +0200" MODIFIED_BY="[Empty name]">Criteria for risk of bias</TITLE>
<APPENDIX_BODY MODIFIED="2010-10-06 10:56:56 +0200" MODIFIED_BY="[Empty name]">
<TABLE COLS="4" ROWS="25">
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
<P>
<B>Item</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
<P>
<B>Judgment</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>
<B> </B>
</P>
<P>
<B>Description</B>
</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Sequence generation</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Was the method of randomization adequate?</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Methods used for sequence generation are based on a random process, in which every study participant has an equal chance to be assigned to each of the treatment conditions (e.g. random number table, computer random number generator, coin tossing, shuffling cards or envelopes, throwing dice)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Methods used for sequence generation permit any prediction of assignment in advance (e.g. date of birth, date of admission, hospital or clinic record number)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Insufficient information about the sequence generation process to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Allocation concealment</B>
</P>
</TD>
<TD VALIGN="TOP">
<P> Was the treatment allocation concealed?</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Randomization and drug preparation were a) undertaken centralized and remote from the patient recruitment centre(s) AND allocation codes were protected against identification by the use of sealed randomization envelopes</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Methods for allocation were used that allow unconcealment such as an open random allocation schedule, assignment envelopes without appropriate safeguards, alternation or rotation</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Blinding</B>
</P>
<P>(all outcomes)</P>
</TD>
<TD VALIGN="TOP">
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P> </P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Patients and research staff were included in the blinding procedures; AND active medication and placebo were of identical appearance</P>
<P>The integrity of blinding was checked and confirmed at the end of the treatment</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Participants, providers and outcome assessor were not blinded or incompletely blinding OR placebo with a different appearance to the active medication was used</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Blinding </B>
</P>
<P>(subjective outcomes)</P>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Yes</P>
<P> </P>
<P> </P>
</TD>
<TD>
<P>Knowledge of the allocated interventions was adequately prevented during the study (see criteria "Blinding (all outcomes)")</P>
<P>Objective measures were used for a validity check of patient-reported drinking outcomes</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Participants, providers and outcome assessor were not blinded or incompletely blinding OR placebo with a different appearance to the active medication was used</P>
<P>No objective measures were used for a validity check of patient-reported drinking outcomes</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Insufficient information to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Handling of incomplete outcome data</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Were incomplete outcome data adequately addressed?</P>
<P>For all outcomes except retention in treatment or drop out</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
<P> </P>
<P> </P>
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>All randomized patients (intention-to-treat analysis) or at least those who have received at least one dose of treatment (treatment received analysis) were analyzed in the group they were allocated to by randomization AND drop-outs or lost to follow-ups were adequately handled, considering the potential association between absence from a study visit and a patient's drinking status, either by generally assigning missing participants to the relapse category (substitution by "worst case") or by analyzing the pattern of missingness (e.g. pattern-mixture analyses)</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>Patients who have received treatment were excluded from the analysis OR drop-outs or lost to follow-ups were handled in a way which does not consider the potential association between absence from a study visit and a patient's drinking status</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P> </P>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>Insufficient reporting of attrition/exclusions to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Selective reporting</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Are reports of the study free of suggestion or selective outcome reporting?</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>All outcomes listed in the protocol or the methods section of the publication were adequately reported in the results section</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD>
<P>One or more outcomes listed in the study protocol or the methods section of the publication were not adequately reported in the results section</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Outcomes are not explicitly stated in the study protocol or the methods section of the trial publication</P>
</TD>
</TR>
<TR>
<TD>
<P>
<B>Other bias:</B> <B>Equivalence of baseline characteristics </B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Equivalence between groups at baseline?</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Baseline equivalence in potentially effect-determining baseline characteristics (age AND gender AND (baseline drinking OR treatment / drinking history))</P>
<P>If differences between groups at baseline became evident, these were controlled in the statistical analyses</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>No</P>
</TD>
<TD>
<P>Differences between groups in one or more of the potentially effect-determining baseline characteristics became evident and were not controlled in the statistical analyses</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD>
<P>Unclear</P>
</TD>
<TD>
<P>Insufficient reporting of baseline equivalence to permit judgement of &#8216;Yes&#8217; or &#8216;No&#8217;</P>
</TD>
</TR>
<TR>
<TD VALIGN="TOP">
<P>
<B>Susceptability to bias effects</B>
</P>
</TD>
<TD VALIGN="TOP">
<P>Was the susceptibility to bias reduced by objective measures?</P>
</TD>
<TD VALIGN="TOP">
<P>Yes</P>
</TD>
<TD VALIGN="TOP">
<P>Objective outcomes including either laboratory indicators or collateral reports were used as a validity check for patient-reported drinking data</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P>No</P>
</TD>
<TD VALIGN="TOP">
<P>The validity of patient-reported drinking data was not checked by either laboratory indicators or by collateral reports</P>
</TD>
</TR>
<TR>
<TD>
<P/>
</TD>
<TD>
<P/>
</TD>
<TD VALIGN="TOP">
<P>Unclear</P>
</TD>
<TD VALIGN="TOP">
<P>It is unclear whether objective outcomes were used as a validity check</P>
</TD>
</TR>
</TABLE>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS MODIFIED="2008-07-31 13:32:11 +0200" MODIFIED_BY="[Empty name]"/>
</COCHRANE_REVIEW>